toolName,toolType,_pmid,_doi,_publicationTitle,_year,_confidence,_usageType,nf_specific,completeness_score,priority,strainNomenclature,animalModelGeneticDisorder,animalModelOfManifestation,targetAntigen,hostOrganism,clonality,organ,cellLineGeneticDisorder,cellLineManifestation,cellLineCategory,insertName,vectorType,vectorBackbone,promoter,softwareName,softwareType,softwareVersion,sourceRepository,modelType,derivationSource,cellTypes,organoidType,modelSystemType,patientDiagnosis,hostStrain,tumorType,assessmentName,assessmentType,targetPopulation,diseaseSpecific,numberOfItems,_context,filter_reason
Matrigel spheroids,advanced_cellular_models,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,spheroid,cell line,,,,,,,,,,,,NF1-deficient MUT-45 spheroids grow larger than NF1-EV spheroids when grown in Matrigel,Publication title lacks 3D/organoid/spheroid terminology
primary cultures derived from plexiform neurofibromas,advanced_cellular_models,PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,other,patient tissue,"Schwann cells, fibroblasts",,,,,,,,,,,Primary cultures containing tumor and nontumor stromal cells were utilized in a novel strategy to test drug responses...four primary cultures derived from plexiform neurofibromas,Publication title lacks 3D/organoid/spheroid terminology
oviductal organoids,advanced_cellular_models,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,organoid,primary cell,oviductal epithelial cells,oviductal organoid,,,,,,,,,,establish organoid-based tumor progression models of HG-SOC from murine oviductal and OSE tissues,Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
OSE organoids,advanced_cellular_models,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,organoid,primary cell,ovarian surface epithelium,OSE organoid,,,,,,,,,,establish organoid-based tumor progression models of HG-SOC from murine oviductal and OSE tissues,Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
neurofibromaspheres,advanced_cellular_models,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,spheroid,iPSC,"Schwann cells, fibroblasts",,,,,,,,,,,neurofibromaspheres were obtained by 3D culture of differentiating pNF iPSC-derived Schwann cells (SC) with pNF patient-derived NF1 fibroblasts,Publication title lacks 3D/organoid/spheroid terminology
S462 spheres,advanced_cellular_models,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,cell line,MPNST cells,,,,,,,,,,,The culture of S462 spheres followed the protocol in [22],Publication title lacks 3D/organoid/spheroid terminology
optic glioma neurospheres,advanced_cellular_models,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,primary cell,Neural stem cells,neurosphere,,,,,,,,,,"Optic chiasm was microdissected from 3-month-old Nf1 flox/flox, Nf1 +/− and Nf1 +/− GFAP CKO mice to generate primary optic nerve neurospheres",Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
hiMGL cells,advanced_cellular_models,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,other,iPSC,Microglia-like cells,,,,,,,,,,,"hiMGL cells were generated from hiPSCs as previously described (McQuade et al., 2018) with minor modifications",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
3D tumor spheroid model,advanced_cellular_models,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,cell line,"sNF96.2-luciferase cells, primary tumor cells",,,,,,,,,,,Their anti-tumor efficacy was further evaluated using a 3D tumor spheroid model,Publication title lacks 3D/organoid/spheroid terminology
neurosphere cultures,advanced_cellular_models,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,primary cell,neural stem/progenitor cells,,,,,,,,,,,"We established and maintained neurosphere cultures as described (31) with some modifications. Briefly, we dissected out the lateral walls of the lateral ventricle or whole brain tumor",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
neurofibroma spheres,advanced_cellular_models,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,spheroid,patient tissue,Schwann cells,,,,,,,,,,,"For mouse or human neurofibroma spheres, we chopped tissue into 1–3 mm³ pieces",Publication title lacks 3D/organoid/spheroid terminology
embryonic mouse spheres,advanced_cellular_models,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,primary cell,DRG cells,,,,,,,,,,,"Embryonic mouse spheres, dissociated from E12.5 DRG with 0.25% Trypsin 20 min. at 37°C",Publication title lacks 3D/organoid/spheroid terminology
neurofibromasphere model,advanced_cellular_models,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,spheroid,iPSC,"Schwann cells, fibroblasts",,,,,,,,,,,induced pluripotent stem cell-derived 3D neurofibromasphere model,Publication title lacks 3D/organoid/spheroid terminology
3D microtissues,advanced_cellular_models,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,patient tissue,,,,,,,,,,,,Selected PDX were harvested for assembly into 3D microtissues,Publication title lacks 3D/organoid/spheroid terminology
BioCoat Matrigel invasion chambers (Becton Dickinson),advanced_cellular_models,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,other,other,,,,,,,,,,,,In vitro invasion of MM cell from Nf2+/−;p16/p19+/− wild-type mice were measured using 24-well BioCoat Matrigel invasion chambers (Becton Dickinson),Publication title lacks 3D/organoid/spheroid terminology
NF1 patient-derived induced pluripotent stem cells (iPSCs),advanced_cellular_models,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,other,patient tissue,pluripotent stem cells,,,,,,,,,,,the availability of NF1 patient-derived induced pluripotent stem cells (iPSCs) provides new opportunities to define the critical factors,Publication title lacks 3D/organoid/spheroid terminology
growth factor-reduced Matrigel,advanced_cellular_models,PMID:30713041,10.1016/j.stemcr.2019.01.001,Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.,,0.8,Experimental Usage,False,0.33,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,iPSC established lines were grown on dishes coated with growth factor-reduced Matrigel (BD Biosciences) in mTESR1 medium,Publication title lacks 3D/organoid/spheroid terminology
3D spheres,advanced_cellular_models,PMID:30713041,10.1016/j.stemcr.2019.01.001,Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,iPSC,Schwann cells,,,,,,,,,,,"iPSC-derived NF1(-/-) SCs exhibited a continuous high proliferation rate, poor myelination ability, and a tendency to form 3D spheres",Publication title lacks 3D/organoid/spheroid terminology
skin-derived precursors (SKPs),advanced_cellular_models,PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,primary cell,stem/progenitor cells,,,,,,,,,,,we identify a population of stem/progenitor cells residing in the dermis termed skin-derived precursors (SKPs),Publication title lacks 3D/organoid/spheroid terminology
DRG sphere cultures,advanced_cellular_models,PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,primary cell,dorsal root ganglion progenitors,,,,,,,,,,,We characterize a peripheral nervous system embryonic dorsal root ganglion progenitor population using in vitro clonal sphere-formation assays,Publication title lacks 3D/organoid/spheroid terminology
neurofibroma spheres,advanced_cellular_models,PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,spheroid,patient tissue,glial-like progenitors,,,,,,,,,,,Neurofibroma spheres contain glial-like progenitors that differentiate into neurons and SM/Fb-like cells in vitro,Publication title lacks 3D/organoid/spheroid terminology
retinal organoids,advanced_cellular_models,PMID:33816648,10.1016/j.omtm.2021.03.004,Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,organoid,iPSC,,retinal organoid,,,,,,,,,,"For organoid seeding, miPSCs/mESCs were collected with trypsin-EDTA as single-cell suspension, washed through single centrifugation",Publication title lacks NF-specific terms: Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and gl
B6N-Tyrc-Brd/BrdCrCrl,animal_models,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,Experimental Usage,False,1.00,Medium,B6N-Tyrc-Brd/BrdCrCrl,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,injecting 1 × 10 5 cells into the medial flank 4-week-old male B6N-Tyrc-Brd/BrdCrCrl mice (Charles Rivers),Wildtype/control with no known disease: B6N-Tyrc-Brd/BrdCrCrl
"athymic nude mice (Charles River, Stock No. 490)",animal_models,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,1.00,Medium,"athymic nude mice (Charles River, Stock No. 490)",No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"8-week-old athymic nude mice (Charles River, Stock No. 490) underwent surgery to implant pNF progenitor cells","Wildtype/control with no known disease: athymic nude mice (Charles River, Stock No. 490)"
K14Cre,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,K14Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"K14Cre (Dassule et al. 2000), K14CreERT (Vasioukhin et al. 1999), TyrCreERT2 (Bosenberg et al. 2006)... mice were purchased from the Jackson Laboratory",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
K14CreERT,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,K14CreERT,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"K14Cre (Dassule et al. 2000), K14CreERT (Vasioukhin et al. 1999), TyrCreERT2 (Bosenberg et al. 2006)... mice were purchased from the Jackson Laboratory",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
TyrCreERT2,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,TyrCreERT2,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"K14Cre (Dassule et al. 2000), K14CreERT (Vasioukhin et al. 1999), TyrCreERT2 (Bosenberg et al. 2006)... mice were purchased from the Jackson Laboratory",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
R26-rtTA,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,R26-rtTA,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"R26-rtTA (Belteki et al. 2005), and tetO-DTA (Lee et al. 1998) mice were purchased from the Jackson Laboratory",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
tetO-DTA,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,tetO-DTA,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"R26-rtTA (Belteki et al. 2005), and tetO-DTA (Lee et al. 1998) mice were purchased from the Jackson Laboratory",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
K14-Scf,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,K14-Scf,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,K14-Scf (Kunisada et al. 1998a) was kindly provided by Dr. John Harris (University of Massachusetts Medical School),Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
Krox20Cre,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,Krox20Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Krox20Cre (Voiculescu et al. 2000), DhhCre (Skucas et al. 2013), PLPCreERT2 (Leone et al. 2003)... were described previously",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
DhhCre,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,DhhCre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Krox20Cre (Voiculescu et al. 2000), DhhCre (Skucas et al. 2013), PLPCreERT2 (Leone et al. 2003)... were described previously",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
PLPCreERT2,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,PLPCreERT2,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Krox20Cre (Voiculescu et al. 2000), DhhCre (Skucas et al. 2013), PLPCreERT2 (Leone et al. 2003)... were described previously",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
CMVCreERT,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,CMVCreERT,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CMVCreERT (Hayashi and McMahon 2002), R26-LacZ, and R26-YFP were described previously",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
R26-LacZ,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,R26-LacZ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CMVCreERT (Hayashi and McMahon 2002), R26-LacZ, and R26-YFP were described previously",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
R26-YFP,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,R26-YFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CMVCreERT (Hayashi and McMahon 2002), R26-LacZ, and R26-YFP were described previously",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
Long Evans,animal_models,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,1.00,Medium,Long Evans,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Twenty-seven female Long Evans rats (age 12 weeks, approximate weight 200 g, Charles River. Wilmington, MA) were used in the experiments.",Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
Myf5 Cre,animal_models,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,False,1.00,Medium,Myf5 Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mouse lines used in this study were described before: Myf5 Cre,Wildtype/control with no known disease: Myf5 Cre
Lbx1 Cre,animal_models,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,False,1.00,Medium,Lbx1 Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse lines used in this study were described before: Myf5 Cre, Lbx1 Cre",Wildtype/control with no known disease: Lbx1 Cre
Rosa26 mTmG,animal_models,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,False,1.00,Medium,Rosa26 mTmG,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse lines used in this study were described before: Myf5 Cre, Lbx1 Cre, Nf1 flox, and Rosa26 mTmG",Wildtype/control with no known disease: Rosa26 mTmG
NOD.CB17-Prkdc/NCrCrl,animal_models,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,False,1.00,Medium,NOD.CB17-Prkdc/NCrCrl,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Female NOD SCID (NOD.CB17-Prkdc/NCrCrl) mice from Charles River Laboratories were housed in barrier facilities designed for immune-compromised animals.,Wildtype/control with no known disease: NOD.CB17-Prkdc/NCrCrl
Balb/c,animal_models,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.9,Experimental Usage,False,1.00,Medium,Balb/c,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Initial range-finding studies employed female Balb/c mice (Taconic Laboratories).,Wildtype/control with no known disease: Balb/c
FVB/C57BL/6,animal_models,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,FVB/C57BL/6,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Syngeneic immune-competent FVB/C57BL/6 mice, both male and female, 10–12 weeks old, are used for implantation of the mouse NF2 −/− Schwann cell line.",Wildtype/control with no known disease: FVB/C57BL/6
nude mice (nu/nu),animal_models,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,nude mice (nu/nu),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"When using human VS cell lines, such as the established human HEI-193 cell line or other immortalized human VS cell lines, immune-deficient mice (e.g., nude mice (nu/nu) or NOD SCID mice) should be used.",Wildtype/control with no known disease: nude mice (nu/nu)
NOD SCID,animal_models,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,NOD SCID,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"When using human VS cell lines, such as the established human HEI-193 cell line or other immortalized human VS cell lines, immune-deficient mice (e.g., nude mice (nu/nu) or NOD SCID mice) should be used.",Wildtype/control with no known disease: NOD SCID
Nu/Nu,animal_models,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,1.00,Medium,Nu/Nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"3 × 10^6 p53−/−; Myc; Cas9 cells were injected into flanks of 6-8-week old, female, NCI Nu/Nu mice (Taconic)",Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
p53 flox/flox,animal_models,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,p53 flox/flox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p53 mice were crossed with Albumin-Cre mice (Jackson Laboratories) flox/flox,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
Albumin-Cre,animal_models,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,Albumin-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p53 mice were crossed with Albumin-Cre mice (Jackson Laboratories) flox/flox,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
Kras LSL-G12D/+,animal_models,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,Kras LSL-G12D/+,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Kras G12D;shp53 mouse cholangiocarcinoma was generated as in using Kras LSL-G12D/+ liver progenitor cells,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
K14 Cre,animal_models,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,1.00,Medium,K14 Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"K14 Cre mice were available from the Jackson Laboratory (Bar Harbor, ME). All mice were maintained on a mix C57bl/6 background.",Wildtype/control with no known disease: K14 Cre
zebrafish,animal_models,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.9,Experimental Usage,False,1.00,Medium,zebrafish,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RNA transcripts were injected into zebrafish embryos at the single-cell stage. GFP signals in the zebrafish embryos indicated synthetic RNA expression,Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
Nf1 flox/flox,animal_models,PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,,0.9,Experimental Usage,False,1.00,Medium,Nf1 flox/flox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,littermate control Nf1 flox/flox (CTL) mice were maintained on an inbred C57BL/6 background,Wildtype/control with no known disease: Nf1 flox/flox
Col2.3Cre,animal_models,PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.85,Experimental Usage,False,1.00,Medium,Col2.3Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Col2.3Cre transgenic mice were generated as described elsewhere. In this model, the 2.3 α1(I) Collagen promoter is used to selectively drive Cre expression",Wildtype/control with no known disease: Col2.3Cre
ROSA26,animal_models,PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.85,Experimental Usage,False,1.00,Medium,ROSA26,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Col2.3Cre transgenic mice were crossed with ROSA26 reporter mice. LacZ staining was performed to assess Cre recombination,Wildtype/control with no known disease: ROSA26
p53floxE2–10,animal_models,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.85,Experimental Usage,False,1.00,Medium,p53floxE2–10,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The floxed p53 alleles (p53floxE2–10) and (p53LSLR172H) have been described previously,Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
p53LSLR172H,animal_models,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.85,Experimental Usage,False,1.00,Medium,p53LSLR172H,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The floxed p53 alleles (p53floxE2–10) and (p53LSLR172H) have been described previously,Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
hGFAP-cre+; p53floxE2–10/floxE2–10,animal_models,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,False,1.00,Medium,hGFAP-cre+; p53floxE2–10/floxE2–10,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"p53 null CKO (p53ΔE2–10 CKO, hGFAP-cre+; p53floxE2–10/floxE2–10) and p53R172H CKO",Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
hGFAP-cre+; p53LSLR172H/floxE2–10,animal_models,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,False,1.00,Medium,hGFAP-cre+; p53LSLR172H/floxE2–10,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p53R172H CKO (hGFAP-cre+; p53LSLR172H/floxE2–10) mice analyzed in this study,Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
C57BL/6,animal_models,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,1.00,Medium,C57BL/6,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Wild-type C57BL/6 and B6J.129(B6N)-Gt(ROSA)26Sor (JAX stock #026175) tm1(CAG-cas9*,-EGFP)Fezh/J mice strains were used",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
"B6J.129(B6N)-Gt(ROSA)26Sor tm1(CAG-cas9*,-EGFP)Fezh/J",animal_models,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,Experimental Usage,False,1.00,Medium,"B6J.129(B6N)-Gt(ROSA)26Sor tm1(CAG-cas9*,-EGFP)Fezh/J",No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"B6J.129(B6N)-Gt(ROSA)26Sor (JAX stock #026175) tm1(CAG-cas9*,-EGFP)Fezh/J mice strains were used for derivation of wild-type and Cas9/GFP-expressing organoids",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,animal_models,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,Experimental Usage,False,1.00,Medium,NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NOD scid gamma (NSG; NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ mice were used. Transplantation experiments were performed,Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
1016 tuba1a:GFP,animal_models,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,1.00,Medium,1016 tuba1a:GFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1016 tuba1a:GFP, gfap:GFP, hsp70:DN-MAML-GFP, gfap:mCherry and tp1:mCherry, fish were previously described",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
gfap:GFP,animal_models,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,1.00,Medium,gfap:GFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1016 tuba1a:GFP, gfap:GFP, hsp70:DN-MAML-GFP, gfap:mCherry and tp1:mCherry, fish were previously described",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
hsp70:DN-MAML-GFP,animal_models,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,1.00,Medium,hsp70:DN-MAML-GFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1016 tuba1a:GFP, gfap:GFP, hsp70:DN-MAML-GFP, gfap:mCherry and tp1:mCherry, fish were previously described",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
gfap:mCherry,animal_models,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,1.00,Medium,gfap:mCherry,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1016 tuba1a:GFP, gfap:GFP, hsp70:DN-MAML-GFP, gfap:mCherry and tp1:mCherry, fish were previously described",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
tp1:mCherry,animal_models,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,1.00,Medium,tp1:mCherry,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1016 tuba1a:GFP, gfap:GFP, hsp70:DN-MAML-GFP, gfap:mCherry and tp1:mCherry, fish were previously described",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
athymic nude mice,animal_models,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.85,Experimental Usage,False,1.00,Medium,athymic nude mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Athymic nude mice were purchased from Charles River Laboratories (stock no. 553).,Wildtype/control with no known disease: athymic nude mice
C57Bl/6,animal_models,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.85,Experimental Usage,False,1.00,Medium,C57Bl/6,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For subcutaneous CT26 tumour implantation, LPS and CLP experiments, female C57Bl/6 and BALB/C mice of 6–8 weeks were purchased from Harlan Laboratories.",Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
BALB/C,animal_models,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.85,Experimental Usage,False,1.00,Medium,BALB/C,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For subcutaneous CT26 tumour implantation, LPS and CLP experiments, female C57Bl/6 and BALB/C mice of 6–8 weeks were purchased from Harlan Laboratories.",Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
"NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ",animal_models,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,1.00,Medium,"NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ",No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For the CART19 treatment, NSG-SGM3 (NSGS) mice (stock number 013062) were purchased from the Jackson Laboratory.",Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
LysMcre Thfl/fl,animal_models,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,1.00,Medium,LysMcre Thfl/fl,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"LysMcre mice were purchased from Jackson Laboratory (stock number 004781), in which a nuclear-localized Cre recombinase was inserted into the first coding exon of the lysozyme 2 (Lyz2 or LysM) gene",Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
NSG,animal_models,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Experimental Usage,False,1.00,Medium,NSG,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"150,000 cells in 3 µl were implanted in the sciatic nerve of NSG mice (female, 6–10 weeks old)",Wildtype/control with no known disease: NSG
CB17 SCID,animal_models,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,Experimental Usage,False,1.00,Medium,CB17 SCID,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"subcutaneously injected into both flanks of 6- to 8-week-old female CB17 SCID mice (Taconic, RRID: MSR_TAC:cb17sc)",Wildtype/control with no known disease: CB17 SCID
y [1] M{w[+mC] = nos‐Cas9.P}ZH‐2A w[*],animal_models,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,False,1.00,Medium,y [1] M{w[+mC] = nos‐Cas9.P}ZH‐2A w[*],No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,germline source of Cas9: y [1] M{w[+mC] = nos‐Cas9.P}ZH‐2A w[*] (Bloomington Stock #54591),Wildtype/control with no known disease: y [1] M{w[+mC] = nos‐Cas9.P}ZH‐2A w[*]
Crl:NU(NCr)‐Foxn1nu,animal_models,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,Experimental Usage,False,1.00,Medium,Crl:NU(NCr)‐Foxn1nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,subcutaneously into the right flank of male CD‐1 nude mice (Athymic Nude Mice obtained from Charles River (Crl:NU(NCr)‐Foxn1nu)),Wildtype/control with no known disease: Crl:NU(NCr)‐Foxn1nu
C57BL/6J,animal_models,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,False,1.00,Medium,C57BL/6J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Toxicity studies were performed using CD‐1 mice and C57BL/6J Inbred Mice (JAX® Mice Strain),Wildtype/control with no known disease: C57BL/6J
FVB,animal_models,PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.85,Experimental Usage,False,1.00,Medium,FVB,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"WT FVB mice were obtained from Jackson Labs (Bar Harbor, ME)",Wildtype/control with no known disease: FVB
nu/nu,animal_models,PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,0.9,Experimental Usage,False,1.00,Medium,nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"implanted in 1 µl culture medium into the sciatic nerve of athymic mice (nu/nu, 5-week-old females; Cox 7 breeding facility, MGH)",Wildtype/control with no known disease: nu/nu
Rosa26-LSL-Cas9 knockin,animal_models,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.95,Experimental Usage,False,1.00,Medium,Rosa26-LSL-Cas9 knockin,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Twenty mice of Rosa26‐LSL‐Cas9 knockin were purchased from Jackson Laboratory (Strain #:024857, USA) and successfully bred in our lab.",Wildtype/control with no known disease: Rosa26-LSL-Cas9 knockin
Nf1Prx1-/-,animal_models,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.95,Experimental Usage,True,1.00,High,Nf1Prx1-/-,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,...two mouse models of genetic muscle disease: a type 1 neurofibromatosis (NF1) limb-mesenchyme knockout (Nf1Prx1-/-) and a muscular dystrophy mouse (mdx)...,Publication title lacks NF-specific terms: Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse
mdx,animal_models,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.9,Experimental Usage,False,1.00,Medium,mdx,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,...two mouse models of genetic muscle disease: a type 1 neurofibromatosis (NF1) limb-mesenchyme knockout (Nf1Prx1-/-) and a muscular dystrophy mouse (mdx)...,Publication title lacks NF-specific terms: Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse
C57BL/6,animal_models,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.85,Experimental Usage,False,1.00,Medium,C57BL/6,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C57BL/6 mice (B6) and mice (NF1) were bred in-house at the Transgenic Facility at The Children's Hospital at Westmead...,Publication title lacks NF-specific terms: Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse
Nf1flox/flox,animal_models,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,...the NF1 mice bred from the Prx1-Cre transgenic mice and the Nf1flox/flox mice...,Publication title lacks NF-specific terms: Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse
Prx1-Cre,animal_models,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.9,Experimental Usage,False,1.00,Medium,Prx1-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,...the NF1 mice bred from the Prx1-Cre transgenic mice and the Nf1flox/flox mice...,Publication title lacks NF-specific terms: Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse
B10 mdx,animal_models,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.9,Experimental Usage,False,1.00,Medium,B10 mdx,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The mdx mice (B10 mdx) were sourced from Australian Bioresources (ABR, Moss Vale). As these mice are on a C57BL/10 background...",Publication title lacks NF-specific terms: Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse
C57BL/6J,animal_models,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.9,Experimental Usage,True,1.00,High,C57BL/6J,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C57BL/6J mice in which one allele of the NF1 gene has been targeted were generated as described elsewhere,Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
Nf1 (+/-),animal_models,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.95,Experimental Usage,True,1.00,High,Nf1 (+/-),Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,male and female Nf1 (+/-) mice were mated for 12–16 hours,Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
Nf1 (-/-),animal_models,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.95,Experimental Usage,True,1.00,High,Nf1 (-/-),Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"In order to obtain Nf1 (-/-) embryos, male and female Nf1 (+/-) mice were mated",Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
NG2-EYFP mice,animal_models,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,1.00,Medium,NG2-EYFP mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NG2-EYFP mice, which carry a YFP fluorescent protein gene instead of a NG2 gene, are healthy and fertile and do not show any obvious phenotype",Wildtype/control with no known disease: NG2-EYFP mice
C57Bl6/J,animal_models,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.85,Experimental Usage,False,1.00,Medium,C57Bl6/J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mice for cell cultures were obtained from breedings of C57Bl6/J mice (Janvier Labs, France)",Wildtype/control with no known disease: C57Bl6/J
nu/nu,animal_models,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,1.00,Medium,nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,injected subcutaneously into the right flanks of 6 to 8-week-old female athymic nude (nu/nu) mice (Harlan),Wildtype/control with no known disease: nu/nu
NOD/SCID,animal_models,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,1.00,Medium,NOD/SCID,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Four-month-old male NOD/SCID mice were anesthetized with isofluorane and orthotopically implanted with 1 mm3 piece of explant tumour,Wildtype/control with no known disease: NOD/SCID
Lats1/2-mut,animal_models,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,1.00,Medium,Lats1/2-mut,No known disease,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mouse MPNST mice (Lats1/2-mut) were generated by crossing floxed Lats1Lats2 mice with Dhh-Cre mice (JAX 012929) to obtain Lats1/2-mut offspring,Wildtype/control with no known disease: Lats1/2-mut
CAG-tdTomato (stock no. 007909),animal_models,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,False,1.00,Medium,CAG-tdTomato (stock no. 007909),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The reporter mice CAG-tdTomato (stock no. 007909), CAG-CAT-EGFP (ccGFP) (stock no. 024636) C57/Bl6;FVBN obtained from The Jackson Laboratory",Wildtype/control with no known disease: CAG-tdTomato (stock no. 007909)
CAG-CAT-EGFP (stock no. 024636),animal_models,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,False,1.00,Medium,CAG-CAT-EGFP (stock no. 024636),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The reporter mice CAG-tdTomato (stock no. 007909), CAG-CAT-EGFP (ccGFP) (stock no. 024636) C57/Bl6;FVBN obtained from The Jackson Laboratory",Wildtype/control with no known disease: CAG-CAT-EGFP (stock no. 024636)
NBSGW (JAX 026622),animal_models,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,False,1.00,Medium,NBSGW (JAX 026622),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Female immunodeficient NBSGW (JAX 026622) mice of 6 to 8 weeks were used for allograft transplantations,Wildtype/control with no known disease: NBSGW (JAX 026622)
NCR nude,animal_models,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,False,1.00,Medium,NCR nude,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Female athymic NCR nude mice of 6 to 8 weeks were used for xenograft transplantations,Wildtype/control with no known disease: NCR nude
PLPCre-ERT2,animal_models,PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.85,Experimental Usage,False,1.00,Medium,PLPCre-ERT2,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For conditional ablation of NF1, we used a tamoxifen-inducible Cre line, the PLPCre-ERT2 transgenic mice",Wildtype/control with no known disease: PLPCre-ERT2
ROSA26R,animal_models,PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.85,Experimental Usage,False,1.00,Medium,ROSA26R,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The LacZ reporter mice, ROSA26R, were obtained from the Jackson Laboratories",Wildtype/control with no known disease: ROSA26R
Thy1::ChR2-YFP (line 20),animal_models,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.85,Experimental Usage,False,1.00,Medium,Thy1::ChR2-YFP (line 20),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Thy1::ChR2-YFP (line 20) and Nlgn3KO mice were acquired from the Jackson Laboratory (012350 and 008394, respectively)",Wildtype/control with no known disease: Thy1::ChR2-YFP (line 20)
Nlgn3KO,animal_models,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.85,Experimental Usage,False,1.00,Medium,Nlgn3KO,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Thy1::ChR2-YFP (line 20) and Nlgn3KO mice were acquired from the Jackson Laboratory (012350 and 008394, respectively)",Wildtype/control with no known disease: Nlgn3KO
C57BL/6J,animal_models,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,Experimental Usage,False,1.00,Medium,C57BL/6J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wildtype C57BL/6J and Nf1 mice littermates were housed and bred in the Indiana University Laboratory Animal Research Center,Wildtype/control with no known disease: C57BL/6J
NOD-Rag1 null IL2rg,animal_models,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,False,1.00,Medium,NOD-Rag1 null IL2rg,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Immunodeficient NOD-Rag1 null IL2rg mice (The Jackson Laboratory) received approximately 3 million cells via subcutaneous flank injection,Wildtype/control with no known disease: NOD-Rag1 null IL2rg
NOD-SCID-Prkdc scid,animal_models,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,False,1.00,Medium,NOD-SCID-Prkdc scid,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,non-obese diabetic severe combined immune deficiency spontaneous male mice (NOD-SCID-Prkdc scid) received 5 × 10^6 cells,Wildtype/control with no known disease: NOD-SCID-Prkdc scid
Nf1 flox/flox,animal_models,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,True,1.00,High,Nf1 flox/flox,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Optic chiasm was microdissected from 3-month-old Nf1 flox/flox, Nf1 +/− and Nf1 +/− GFAP CKO mice to generate primary optic nerve neurospheres",Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
Nf1 +/−,animal_models,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,True,1.00,High,Nf1 +/−,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Optic chiasm was microdissected from 3-month-old Nf1 flox/flox, Nf1 +/− and Nf1 +/− GFAP CKO mice",Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
Nf1 +/− GFAP CKO,animal_models,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,True,1.00,High,Nf1 +/− GFAP CKO,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Optic chiasm was microdissected from 3-month-old Nf1 flox/flox, Nf1 +/− and Nf1 +/− GFAP CKO mice",Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
B6.Cg/NTac-Foxn1nu NE10,animal_models,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,False,1.00,Medium,B6.Cg/NTac-Foxn1nu NE10,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Athymic (B6.Cg/NTac-Foxn1nu NE10) mice were purchased from Taconic Laboratories,Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
Foxn1 nu/nu,animal_models,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,Foxn1 nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.5 million cells in serum-free DMEM with 33% Matrigel Basement Membrane (BD Biosciences) were injected into the back flanks of athymic Foxn1 nu/nu mice (Charles Rivers Laboratory),"Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
Balb/c,animal_models,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,1.00,Medium,Balb/c,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CT26 and 4T1 subcutaneous grafts in Balb/c mice,Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
Fbxw11tm1a(KOMP)Wtsi,animal_models,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,Experimental Usage,False,1.00,Medium,Fbxw11tm1a(KOMP)Wtsi,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Fbxw11 heterozygous (Fbxw11+/–, C57BL/6NTac) mice were from Knockout Mouse Project (KOMP)",Wildtype/control with no known disease: Fbxw11tm1a(KOMP)Wtsi
Fbxw11fl/fl,animal_models,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,Experimental Usage,False,1.00,Medium,Fbxw11fl/fl,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fbxw11fl/fl (exon 4 targeted) mice were generated from the Fbxw11tm1a(KOMP)Wtsi strain by FLP-FRT recombination,Wildtype/control with no known disease: Fbxw11fl/fl
p19 knockout,animal_models,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.9,Experimental Usage,False,1.00,Medium,p19 knockout,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mice with the p19 mutation were a kind gift from Dr. Martine Roussel at St. Jude's Children's Research Hospital,Wildtype/control with no known disease: p19 knockout
Mx1-Cre,animal_models,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.9,Experimental Usage,False,1.00,Medium,Mx1-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mx1-Cre, Nf1 flox, and Nf1 fcr (Nf1 knockout) mice have been described previously",Wildtype/control with no known disease: Mx1-Cre
C57BL/6J,animal_models,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.85,Experimental Usage,False,1.00,Medium,C57BL/6J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Recipient C57BL/6J × 129/Sv F1 mice were sublethally irradiated,Wildtype/control with no known disease: C57BL/6J
129/Sv,animal_models,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.85,Experimental Usage,False,1.00,Medium,129/Sv,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,recipient animals were generated by crossing 129/Sv mice to C57BL/6J mice,Wildtype/control with no known disease: 129/Sv
Wisconsin Miniature SwineTM,animal_models,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.95,Development,False,1.00,Medium,Wisconsin Miniature SwineTM,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The Wisconsin Miniature SwineTM (WMSTM) was developed to address these shortcomings. The WMSTM porcine model grows slower, reaching and maintaining human sizes at adulthood.","Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
WMSTM-WT,animal_models,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,False,1.00,Medium,WMSTM-WT,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The WMSTM-WT and WMSTM-FH lines are housed at the University of Wisconsin Swine Research and Teaching Center,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
WMSTM-FH,animal_models,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,False,1.00,Medium,WMSTM-FH,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The WMSTM-WT and WMSTM-FH lines are housed at the University of Wisconsin Swine Research and Teaching Center,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
Lats1 lox/lox Lats2 lox/lox,animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,Lats1 lox/lox Lats2 lox/lox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Lats1 mice ( lox/lox Lats2 lox/lox Heallen et al., 2011 ), on a mixed C57/Bl6;129Sv;FVBN background, were crossed with Dhh -Cre",Wildtype/control with no known disease: Lats1 lox/lox Lats2 lox/lox
Dhh-Cre,animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,Dhh-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"were crossed with Dhh -Cre ( Jaegle et al., 2003 ) mice or Plp1 -CreERT (Stock 005975) mice, both on a C57/Bl6 background",Wildtype/control with no known disease: Dhh-Cre
Plp1-CreERT (Stock 005975),animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,Plp1-CreERT (Stock 005975),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Plp1 -CreERT (Stock 005975) mice, both on a C57/Bl6 background to obtain Lats1 ;Cre lox/+ Lats2 lox/+ +/− mice",Wildtype/control with no known disease: Plp1-CreERT (Stock 005975)
CAG-tdTomato (Stock 007909),animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,CAG-tdTomato (Stock 007909),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The reporter mice CAG-tdTomato (Stock 007909), CAG-CATEGFP (ccGFP) (Stock 024636) were obtained from the Jackson Laboratory",Wildtype/control with no known disease: CAG-tdTomato (Stock 007909)
CAG-CATEGFP (Stock 024636),animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,CAG-CATEGFP (Stock 024636),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CAG-CATEGFP (ccGFP) (Stock 024636) were obtained from the Jackson Laboratory,Wildtype/control with no known disease: CAG-CATEGFP (Stock 024636)
Taz lox/lox Yap1 lox/lox,animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,Taz lox/lox Yap1 lox/lox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Taz ( lox/lox Yap1 lox/lox Deng et al., 2017 ) mice, on a mixed C57/Bl6;129Sv;FVBN background",Wildtype/control with no known disease: Taz lox/lox Yap1 lox/lox
Nf1+/-,animal_models,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,True,1.00,High,Nf1+/-,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1+/- mice were obtained from Tyler Jacks (Massachusetts Institute of Technology, Cambridge, MA, USA) and backcrossed 13 generations into the C57BL/6J strain.",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
Nf1flox/flox,animal_models,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1flox/flox mice were obtained from Luis Parada (University of Texas Southwestern Medical Center, Dallas, TX, USA) and maintained on C57BL/6J background.",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
Tie2cre,animal_models,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,Experimental Usage,False,1.00,Medium,Tie2cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tie2cre (4128) and VE-cadherin cre (VEcre, 6137) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA)",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
VE-cadherin cre,animal_models,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,Experimental Usage,False,1.00,Medium,VE-cadherin cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tie2cre (4128) and VE-cadherin cre (VEcre, 6137) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA)",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
standardised femoral rat fracture model,animal_models,PMID:26822862,10.1038/srep20010,Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study.,,0.75,Citation Only,False,1.00,Low,standardised femoral rat fracture model,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The geometrical domain of the computational model is deduced from the real callus geometry at three weeks post-fracture in a standardised femoral rat fracture model,Wildtype/control with no known disease: standardised femoral rat fracture model
MacGreen (Csf1r-eGFP),animal_models,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,False,1.00,Medium,MacGreen (Csf1r-eGFP),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,bred onto a wild type or MacGreen (Csf1r-eGFP; [ 58 ] C57/BL6 background,Wildtype/control with no known disease: MacGreen (Csf1r-eGFP)
CX3CR1-CreER,animal_models,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,False,1.00,Medium,CX3CR1-CreER,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CX3CR1-CreER [ 71 ] were intercrossed with Nf1 flox/flox,Wildtype/control with no known disease: CX3CR1-CreER
R26R-EYFP,animal_models,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,False,1.00,Medium,R26R-EYFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,intercrossed with Nf1 flox/flox [ 1 ] and R26R-EYFP mice [ 63 ],Wildtype/control with no known disease: R26R-EYFP
hGFAP-Cre,animal_models,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,False,1.00,Medium,hGFAP-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hGFAP-Cre +/+ were intercrossed with Nf1 flox/flox,Wildtype/control with no known disease: hGFAP-Cre
BALB/c nude,animal_models,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.85,Experimental Usage,False,1.00,Medium,BALB/c nude,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RT4-D6P2T or HEI-193 cells were subcutaneously inoculated into the back of 4-week-old BALB/c nude mice (male),Wildtype/control with no known disease: BALB/c nude
Rabl6m/m C57Bl/6N,animal_models,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,1.00,Medium,Rabl6m/m C57Bl/6N,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mouse embryonic fibroblasts (MEFs) from wildtype and Rabl6m/m C57Bl/6N mice were isolated,Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
NRG,animal_models,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,False,1.00,Medium,NRG,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nonobese diabetic Rag gamma (NRG; no. 007799) female mice were purchased from the Jackson Laboratory,Wildtype/control with no known disease: NRG
Nf1 P1,animal_models,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Experimental Usage,True,1.00,High,Nf1 P1,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Nf1 P1 mutation was backcrossed six generations into the w CS10 genetic background and w CS10 flies were used as controls.,Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
w CS10,animal_models,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,1.00,Medium,w CS10,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Nf1 P1 mutation was backcrossed six generations into the w CS10 genetic background and w CS10 flies were used as controls.,Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
Cnp-Cre; R26-lsl-SB11; T2/Onc15,animal_models,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,Cnp-Cre; R26-lsl-SB11; T2/Onc15,No known disease,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Triple transgenic mice (Cnp-Cre; R26-lsl-SB11; T2/Onc15) undergo insertional mutagenesis in Schwann cells.,Wildtype/control with no known disease: Cnp-Cre; R26-lsl-SB11; T2/Onc15
Postn-Cre,animal_models,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.9,Experimental Usage,False,1.00,Medium,Postn-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Postn-Cre transgenic and conditional Nf2flox/flox knocking alleles were obtained,Wildtype/control with no known disease: Postn-Cre
JAX:002019,animal_models,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,Experimental Usage,False,1.00,Medium,JAX:002019,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NF1-proficient and NF1-deficient engineered clones were injected into the flanks of 6- to 7-week-old athymic nude mice (RRID: JAX:002019),Wildtype/control with no known disease: JAX:002019
JAX:007799,animal_models,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,Experimental Usage,False,1.00,Medium,JAX:007799,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"S462-TY cells (1.0 × 106) in 50% Matrigel (BD Biosciences) were injected subcutaneously into the flank of 6- to 7-week-old NOD-Rag1 null IL2rg null, NOD rag gamma, NOD-RG (NRG) mice (RRID: JAX:007799)",Wildtype/control with no known disease: JAX:007799
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ,animal_models,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,False,1.00,Medium,NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For the patient-derived xenograft (PDX) MPNST model, tumor tissue was implanted subcutaneously directly into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice",Wildtype/control with no known disease: NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
Balb/cAnNRj-Foxn1nu/Foxn1nu,animal_models,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.95,Experimental Usage,False,1.00,Medium,Balb/cAnNRj-Foxn1nu/Foxn1nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Balb/c Nude (Balb/cAnNRj-Foxn1nu/Foxn1nu, Janvier), Foxn1 (Nu/Nu) Nude (Crl:NU-Foxn1nu, Charles River)",Wildtype/control with no known disease: Balb/cAnNRj-Foxn1nu/Foxn1nu
Crl:NU-Foxn1nu,animal_models,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.95,Experimental Usage,False,1.00,Medium,Crl:NU-Foxn1nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Foxn1 (Nu/Nu) Nude (Crl:NU-Foxn1nu, Charles River), SHO ® (SCID Hairless Outbred, Crl:SHO-PrkdcscidHrhr, Charles River)",Wildtype/control with no known disease: Crl:NU-Foxn1nu
Crl:SHO-PrkdcscidHrhr,animal_models,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.95,Experimental Usage,False,1.00,Medium,Crl:SHO-PrkdcscidHrhr,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"SHO ® (SCID Hairless Outbred, Crl:SHO-PrkdcscidHrhr, Charles River) and Shorn (ShrN NOD SCID, NOD.Cg-PrkdcscidHrhr/NCrHsd, Harlan)",Wildtype/control with no known disease: Crl:SHO-PrkdcscidHrhr
NOD.Cg-PrkdcscidHrhr/NCrHsd,animal_models,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.95,Experimental Usage,False,1.00,Medium,NOD.Cg-PrkdcscidHrhr/NCrHsd,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Shorn (ShrN NOD SCID, NOD.Cg-PrkdcscidHrhr/NCrHsd, Harlan) mice were scheduled for xenotransplantations",Wildtype/control with no known disease: NOD.Cg-PrkdcscidHrhr/NCrHsd
Mut3,animal_models,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.85,Experimental Usage,True,1.00,High,Mut3,Neurofibromatosis type 1,astrocytomas,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"To generate Mut3 to Mut6 mice (see Fig. 1A for genetic configurations), we crossed Mut3 (8) or Mut4 males with wild-type (wt), loxP-Pten (Pten f hereafter; ref. 27)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
Mut4,animal_models,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.85,Experimental Usage,True,1.00,High,Mut4,Neurofibromatosis type 1,astrocytomas,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"To generate Mut3 to Mut6 mice (see Fig. 1A for genetic configurations), we crossed Mut3 (8) or Mut4 males with wild-type (wt), loxP-Pten (Pten f hereafter; ref. 27)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
loxP-Pten (Pten f),animal_models,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.9,Experimental Usage,False,1.00,Medium,loxP-Pten (Pten f),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"we crossed Mut3 (8) or Mut4 males with wild-type (wt), loxP-Pten (Pten f hereafter; ref. 27), p53 f (28), or p53 f ; Pten f females",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
p53 f,animal_models,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.9,Experimental Usage,False,1.00,Medium,p53 f,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"we crossed Mut3 (8) or Mut4 males with wild-type (wt), loxP-Pten (Pten f hereafter; ref. 27), p53 f (28), or p53 f ; Pten f females",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
athymic nude,animal_models,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,1.00,Medium,athymic nude,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"using athymic nude six-week-old male mice, in which no tumor was engrafted",Wildtype/control with no known disease: athymic nude
athymic Ncr Nu/Nu,animal_models,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,Experimental Usage,False,1.00,Medium,athymic Ncr Nu/Nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Xenografts were developed in male athymic Ncr Nu/Nu mice (National Cancer Institute, NIH, Bethesda, MD)",Wildtype/control with no known disease: athymic Ncr Nu/Nu
nude mice,animal_models,PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.8,Experimental Usage,False,1.00,Medium,nude mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1×10 6 FC-1801 cells were suspended in Ca/Mg-free PBS and injected subcutaneously into the right flank of nude mice.,Wildtype/control with no known disease: nude mice
BALB/c nu/nu,animal_models,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,Experimental Usage,False,1.00,Medium,BALB/c nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2×10^6 cells were injected subcutaneously into flanks of 5-week old nude mice (BALB/c nu/nu),Wildtype/control with no known disease: BALB/c nu/nu
#002019,animal_models,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,1.00,Medium,#002019,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Athymic nude (# 002019) and NOD scid gamma (NSG, # 005557) female mice were purchased from the Jackson Laboratory",Wildtype/control with no known disease: #002019
#005557,animal_models,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,1.00,Medium,#005557,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Athymic nude (# 002019) and NOD scid gamma (NSG, # 005557) female mice were purchased from the Jackson Laboratory",Wildtype/control with no known disease: #005557
athymic female nude mice,animal_models,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.85,Experimental Usage,False,1.00,Medium,athymic female nude mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"We injected 5×10^5 mouse sphere cells/injection subcutaneously into athymic female nude mice (Harlan, Indianapolis, IN)",Wildtype/control with no known disease: athymic female nude mice
Wnt-1-Cre+,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,1.00,Medium,Wnt-1-Cre+,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For conditional deletion of Nf1 we used Wnt-1-Cre (+ Danielian et al., 1998)",Wildtype/control with no known disease: Wnt-1-Cre+
3.9Periostin-Cre+,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,1.00,Medium,3.9Periostin-Cre+,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"3.9Periostin-Cre (+ Lindsley et al., 2007)",Wildtype/control with no known disease: 3.9Periostin-Cre+
P0a-Cre+,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,1.00,Medium,P0a-Cre+,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"P0a-Cre (+ Giovannini et al., 2000) mice",Wildtype/control with no known disease: P0a-Cre+
Ink4a-/-,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,1.00,Medium,Ink4a-/-,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Compound mutant mice were generated by mating Nf1 mice with +/− Ink4a mice (−/− Sharpless et al., 2001)",Wildtype/control with no known disease: Ink4a-/-
Ink4aArf-/-,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,1.00,Medium,Ink4aArf-/-,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Ink4aArf mice (−/− Serrano et al., 1996)",Wildtype/control with no known disease: Ink4aArf-/-
"Mx1-Cre, Nf1 flox/flox",animal_models,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.95,Experimental Usage,True,1.00,High,"Mx1-Cre, Nf1 flox/flox",Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mx1-Cre, Nf1 flox/flox mice (129SV × C57BL/6 J) were generated and somatic Nf1 inactivation was induced as described elsewhere","Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
C57BL/6JOlaHsd,animal_models,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,C57BL/6JOlaHsd,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Experimental mice were obtained by crossing Nf1 mice (in C57BL/6JOlaHsd background),Wildtype/control with no known disease: C57BL/6JOlaHsd
129T2/SvEmsJ,animal_models,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,129T2/SvEmsJ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"with 129T2/SvEmsJ (Jackson Laboratories, Bar Harbor, ME, USA)",Wildtype/control with no known disease: 129T2/SvEmsJ
G12V H-Ras,animal_models,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,G12V H-Ras,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,+/− H-Ras mice in C57BL/6JOlaHsd background were obtained by crossing heterozygous G12V H-Ras mice,Wildtype/control with no known disease: G12V H-Ras
NOD scid gamma,animal_models,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,False,1.00,Medium,NOD scid gamma,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NOD scid gamma (NSG) female and male mice were purchased from Johns Hopkins University Animal Resources Core,Wildtype/control with no known disease: NOD scid gamma
Tg(4xhre-tata:eGFP)ia,animal_models,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.85,Experimental Usage,False,1.00,Medium,Tg(4xhre-tata:eGFP)ia,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The male Zebrafish reporter line for HIF1α Tg(4xhre-tata:eGFP)ia was outcrossed with female wild-type Zebrafish,Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
Tg(ptf1a:Gal4)/UAS:eGFPKRAS G12D,animal_models,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.85,Experimental Usage,False,1.00,Medium,Tg(ptf1a:Gal4)/UAS:eGFPKRAS G12D,No known disease,pancreatic adenocarcinoma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"generating the final transgenic line Tg(ptf1a:Gal4)/UAS:eGFPKRAS G12D, as described",Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
nu/nu Balb/c,animal_models,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.9,Experimental Usage,False,1.00,Medium,nu/nu Balb/c,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Athymic nude mice (female, nu/nu Balb/c, 6 weeks, 20 g) were obtained from Charles River Laboratories (Sulzfeld, Germany).",Wildtype/control with no known disease: nu/nu Balb/c
Nf1flox/flox,animal_models,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1flox/flox Nf1flox/null; GFAP-Cre (OPG-1), Nf1flox/R681*; GFAP-Cre (OPG-2), Nf1flox/null; Ptenflox/wt; GFAP-Cre (OPG-3), and Nf1flox/null; Olig2-Cre (OPG-4) mice",Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
Nf1flox/null; GFAP-Cre,animal_models,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/null; GFAP-Cre,Neurofibromatosis type 1,Optic glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1flox/null; GFAP-Cre (OPG-1), Nf1flox/R681*; GFAP-Cre (OPG-2), Nf1flox/null; Ptenflox/wt; GFAP-Cre (OPG-3), and Nf1flox/null; Olig2-Cre (OPG-4) mice",Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
Nf1flox/R681*; GFAP-Cre,animal_models,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/R681*; GFAP-Cre,Neurofibromatosis type 1,Optic glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1flox/null; GFAP-Cre (OPG-1), Nf1flox/R681*; GFAP-Cre (OPG-2), Nf1flox/null; Ptenflox/wt; GFAP-Cre (OPG-3), and Nf1flox/null; Olig2-Cre (OPG-4) mice",Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
Nf1flox/null; Ptenflox/wt; GFAP-Cre,animal_models,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/null; Ptenflox/wt; GFAP-Cre,Neurofibromatosis type 1,Optic glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1flox/null; GFAP-Cre (OPG-1), Nf1flox/R681*; GFAP-Cre (OPG-2), Nf1flox/null; Ptenflox/wt; GFAP-Cre (OPG-3), and Nf1flox/null; Olig2-Cre (OPG-4) mice",Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
Nf1flox/null; Olig2-Cre,animal_models,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/null; Olig2-Cre,Neurofibromatosis type 1,Optic glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1flox/null; GFAP-Cre (OPG-1), Nf1flox/R681*; GFAP-Cre (OPG-2), Nf1flox/null; Ptenflox/wt; GFAP-Cre (OPG-3), and Nf1flox/null; Olig2-Cre (OPG-4) mice",Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
Prss56Cre/Cre,animal_models,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,Prss56Cre/Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The following mouse lines were used and genotyped as described in the original publications: Prss56Cre/Cre, R26tdTom/tdTom; Prss56Cre/Cre",Wildtype/control with no known disease: Prss56Cre/Cre
R26tdTom/tdTom,animal_models,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,R26tdTom/tdTom,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The following mouse lines were used and genotyped as described in the original publications: Prss56Cre/Cre, R26tdTom/tdTom; Prss56Cre/Cre",Wildtype/control with no known disease: R26tdTom/tdTom
B6D2F1,animal_models,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,B6D2F1,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf1+/−; and B6D2F1 (https://janvier-labs.com/en/fiche_produit/b6d2f1-mouse/),Wildtype/control with no known disease: B6D2F1
cis Nf1+/−;P53+/−,animal_models,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,cis Nf1+/−;P53+/−,Neurofibromatosis type 1,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cisMPNST cells were derived from spontaneous MPNSTs arising in cis Nf1+/−;P53+/− mice,Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
nude,animal_models,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,False,1.00,Medium,nude,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Experiments were performed in 8-week-old nude female mice (Charles River, Wilmington, MA)",Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
p16 Ink4a*/*,animal_models,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.9,Experimental Usage,False,1.00,Medium,p16 Ink4a*/*,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf2 flox2/flox2 mice (4) on the FVB/N background were bred to p16 Ink4a*/* mice (11) on a FVB/N/129Ola mixed background,Wildtype/control with no known disease: p16 Ink4a*/*
nu/nu,animal_models,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,False,1.00,Medium,nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Athymic nu/nu mice were anesthetized in isoflurane and injected s.c. with 10^6 STS26T cells in the left flank,Wildtype/control with no known disease: nu/nu
NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,animal_models,PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.95,Experimental Usage,False,1.00,Medium,NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"6- to 8-week-old NSG (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ, strain #:005557, Jackson Laboratory or Johns Hopkins Oncology Animal Facility) and SCID female mice were used for in vivo efficacy studies",Wildtype/control with no known disease: NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ
C.B-17/IcrHsd-Prkdc scid,animal_models,PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.9,Experimental Usage,False,1.00,Medium,C.B-17/IcrHsd-Prkdc scid,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NSG and SCID (C.B-17/IcrHsd-Prkdc scid , Envigo) female mice were used for in vivo efficacy studies",Wildtype/control with no known disease: C.B-17/IcrHsd-Prkdc scid
"B6-Olig2tm2(TVA,cre)Rth/J",animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.95,Experimental Usage,False,1.00,Medium,"B6-Olig2tm2(TVA,cre)Rth/J",No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Olig2-Cre mice (B6-Olig2 tm2 (TVA, cre)Rth /J; Jackson Laboratory; [ 20 ])","Wildtype/control with no known disease: B6-Olig2tm2(TVA,cre)Rth/J"
GFAP-Cre,animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,Experimental Usage,False,1.00,Medium,GFAP-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Olig2-Cre mice (B6-Olig2 tm2 (TVA, cre)Rth /J; Jackson Laboratory; [ 20 ]) and GFAP-Cre mice [ 32 ]",Wildtype/control with no known disease: GFAP-Cre
B6.Cg-Gt(ROSA)26Sortm(CAGZsGreen1)Hze+/J,animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.95,Experimental Usage,False,1.00,Medium,B6.Cg-Gt(ROSA)26Sortm(CAGZsGreen1)Hze+/J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rosa-GREEN mice (B6.Cg- Gt(ROSA)26Sor tm(CAGZsGreen1)Hze+ / J; Jackson Laboratory),Wildtype/control with no known disease: B6.Cg-Gt(ROSA)26Sortm(CAGZsGreen1)Hze+/J
Eed f/f,animal_models,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.85,Experimental Usage,False,1.00,Medium,Eed f/f,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Eed-isogenic mouse MPNST cells were generated as follows: Eed f/f mice (67, 68) were bred with PLP-CreERT:: Nf1 f/f ; Cdkn2a f/f mice",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
PLP-CreERT:: Nf1 f/f ; Cdkn2a f/f,animal_models,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,Experimental Usage,True,1.00,High,PLP-CreERT:: Nf1 f/f ; Cdkn2a f/f,Neurofibromatosis type 1,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Eed f/f mice (67, 68) were bred with PLP-CreERT:: Nf1 f/f ; Cdkn2a f/f mice",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
CB-17 SCID,animal_models,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,False,1.00,Medium,CB-17 SCID,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Eed-isogenic cells were infected with sgRNA lentiviruses for additional knockout of Cdkn2b followed by subcutaneous implantation into CB-17 SCID mice (Taconic, RRID:IMSR_TAC:cb17sc)",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
Plp-Cre,animal_models,PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.9,Experimental Usage,False,1.00,Medium,Plp-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Inducible Plp-Cre (66) and Nf1 fl/+ (67) mice were maintained on a pure C57BL/6 background,Publication title lacks NF-specific terms: Brain-wide structural and functional disruption in mice with oligodendrocyte-spe
Nf1 fl/+,animal_models,PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.95,Experimental Usage,True,1.00,High,Nf1 fl/+,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Inducible Plp-Cre (66) and Nf1 fl/+ (67) mice were maintained on a pure C57BL/6 background,Publication title lacks NF-specific terms: Brain-wide structural and functional disruption in mice with oligodendrocyte-spe
NU/NU,animal_models,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,1.00,Medium,NU/NU,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Subcutaneous allografts were performed by implanting 5 million JW18.2 or JW23.3 MPNST allografts cells into the flanks of 5–6-week-old female NU/NU mice (Harlan Sprague Dawley),Wildtype/control with no known disease: NU/NU
Postn-cre,animal_models,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,Experimental Usage,False,1.00,Medium,Postn-cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Periostin-cre (Postn-cre) were crossed with floxed Nf2 gene (Postn-cre;Nf2) as previously described.,Wildtype/control with no known disease: Postn-cre
Rosa26 LSL-Neurod1 (R26ND1),animal_models,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,Experimental Usage,False,1.00,Medium,Rosa26 LSL-Neurod1 (R26ND1),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rosa26 (LSL-Neurod1 R26ND1) line that induces Neurod1 expression via cre-mediated excision of a stop codon,Wildtype/control with no known disease: Rosa26 LSL-Neurod1 (R26ND1)
tg(Atoh1-cre)8,animal_models,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,Experimental Usage,False,1.00,Medium,tg(Atoh1-cre)8,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,we used the following mouse lines: tg(Atoh1-cre)8; R26smo and tg(Neurod1-cre)29 to generate fast and slow growing medulloblastoma,Wildtype/control with no known disease: tg(Atoh1-cre)8
tg(Neurod1-cre)29,animal_models,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,Experimental Usage,False,1.00,Medium,tg(Neurod1-cre)29,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,we used the following mouse lines: tg(Atoh1-cre)8; R26smo and tg(Neurod1-cre)29 to generate fast and slow growing medulloblastoma,Wildtype/control with no known disease: tg(Neurod1-cre)29
R26LacZ,animal_models,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.8,Experimental Usage,False,1.00,Medium,R26LacZ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,we used the widely available R26LacZ reporter mice to verify that the Postn-cre effectively and exclusively recombines,Wildtype/control with no known disease: R26LacZ
1016 tuba1a:GFP,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,1016 tuba1a:GFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) 1016 tuba1a:GFP Fausett and Goldman, 2006",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
gfap:GFP,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,gfap:GFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) gfap:GFP Kassen et al., 2007",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
tp1:mCherry,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,tp1:mCherry,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) tp1:mCherry Parsons et al., 2009",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
zop:nsfb-EGFP,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,zop:nsfb-EGFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) zop:nsfb-EGFP Montgomery et al., 2010",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
hsp70:ca-Alk5,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,hsp70:ca-Alk5,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) hsp70:ca-Alk5 Zhou et al., 2011",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
hsp70:tgfb1b,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Development,False,1.00,Medium,hsp70:tgfb1b,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) hsp70:tgfb1b This paper; Figure 5 tgfb1b expressed under the hsp70 promoter",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
hsp70:tgfb3,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Development,False,1.00,Medium,hsp70:tgfb3,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) hsp70:tgfb3 This paper; Figure 4 tgfb3 expressed under the hsp70 promoter",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
Long-Evans,animal_models,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.95,Experimental Usage,False,1.00,Medium,Long-Evans,No known disease,Optic Pathway Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Twenty-four domestic rats of the Long-Evans strain (age 4 weeks with approximate weight of 150 g) were used as control and test recipients,Publication title lacks NF-specific terms: C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of
NPcis (Stock #008191),animal_models,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,Experimental Usage,True,1.00,High,NPcis (Stock #008191),Neurofibromatosis type 1,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NPcis (Stock #008191), Nf1 (#017640), fl Trp53 (#008462), fl Plp-CreER (#005975), and T Nestin-Cre (#003771) were obtained from The Jackson Laboratory.",Publication title lacks NF-specific terms: A genetic mouse model with postnatal
Nf1 (#017640),animal_models,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,Experimental Usage,True,1.00,High,Nf1 (#017640),Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NPcis (Stock #008191), Nf1 (#017640), fl Trp53 (#008462), fl Plp-CreER (#005975), and T Nestin-Cre (#003771) were obtained from The Jackson Laboratory.",Publication title lacks NF-specific terms: A genetic mouse model with postnatal
fl Trp53 (#008462),animal_models,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,Experimental Usage,False,1.00,Medium,fl Trp53 (#008462),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NPcis (Stock #008191), Nf1 (#017640), fl Trp53 (#008462), fl Plp-CreER (#005975), and T Nestin-Cre (#003771) were obtained from The Jackson Laboratory.",Publication title lacks NF-specific terms: A genetic mouse model with postnatal
fl Plp-CreER (#005975),animal_models,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,Experimental Usage,False,1.00,Medium,fl Plp-CreER (#005975),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NPcis (Stock #008191), Nf1 (#017640), fl Trp53 (#008462), fl Plp-CreER (#005975), and T Nestin-Cre (#003771) were obtained from The Jackson Laboratory.",Publication title lacks NF-specific terms: A genetic mouse model with postnatal
T Nestin-Cre (#003771),animal_models,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,Experimental Usage,False,1.00,Medium,T Nestin-Cre (#003771),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NPcis (Stock #008191), Nf1 (#017640), fl Trp53 (#008462), fl Plp-CreER (#005975), and T Nestin-Cre (#003771) were obtained from The Jackson Laboratory.",Publication title lacks NF-specific terms: A genetic mouse model with postnatal
SCID,animal_models,PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.9,Experimental Usage,False,1.00,Medium,SCID,No known disease,Immunodeficiency for xenograft studies,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mice with severe combined immunodeficiency (SCID) were used as recipients of human neurofibroma xenotransplants,Wildtype/control with no known disease: SCID
Nf1 flox/flox,animal_models,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,False,1.00,Medium,Nf1 flox/flox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,control littermate Nf1 flox/flox (WT) mice were maintained on an inbred C57BL/6 background,Wildtype/control with no known disease: Nf1 flox/flox
Tg(HOTCre:Cas9),animal_models,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,Experimental Usage,False,1.00,Medium,Tg(HOTCre:Cas9),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Transgenic lines used in this study were the ABWT (Zebrafish International Resource Center), Tg(HOTCre:Cas9) (a kind gift from Dr Wenbiao Chen, Vanderbilt University School of Medicine)",Wildtype/control with no known disease: Tg(HOTCre:Cas9)
Tg(-7.2kb-sox10:mRFP),animal_models,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,Experimental Usage,False,1.00,Medium,Tg(-7.2kb-sox10:mRFP),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Transgenic lines used in this study were the ABWT (Zebrafish International Resource Center), Tg(HOTCre:Cas9) (a kind gift from Dr Wenbiao Chen, Vanderbilt University School of Medicine, Nashville, TN, USA), Tg(−7.2kb-sox10:mRFP)",Wildtype/control with no known disease: Tg(-7.2kb-sox10:mRFP)
ABWT,animal_models,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.85,Experimental Usage,False,1.00,Medium,ABWT,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Transgenic lines used in this study were the ABWT (Zebrafish International Resource Center),Wildtype/control with no known disease: ABWT
NOD-Rag1 null IL2rg (NRG),animal_models,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,False,1.00,Medium,NOD-Rag1 null IL2rg (NRG),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tumor tissue was implanted dorsally into 5- to 6-week-old NOD- Rag1 null IL2rg (NRG) mice.,Wildtype/control with no known disease: NOD-Rag1 null IL2rg (NRG)
Nf1flox/flox,animal_models,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,Nf1flox/flox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1 +/- GFAP CKO ( Nf1 flox/mut ;GFAP-Cre,  Nf1 -CKO) and littermate control ( Nf1 flox/flox ; CTL) mice were maintained on an inbred C57BL/6 background",Wildtype/control with no known disease: Nf1flox/flox
FVB/N.129-Cdkn2atm1Rdp,animal_models,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,1.00,Medium,FVB/N.129-Cdkn2atm1Rdp,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"p16/p19+/− (01XB2, FVB/N.129-Cdkn2atm1Rdp) mice, obtained from the Mouse Models of Human Cancers Consortium, were crossed to Nf2 mice",Wildtype/control with no known disease: FVB/N.129-Cdkn2atm1Rdp
SCID mice,animal_models,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,Experimental Usage,False,1.00,Medium,SCID mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5 × 106 or 1.0 × 106 murine MM cells were injected into the tail vein of recipient SCID mice,Wildtype/control with no known disease: SCID mice
BALB/c,animal_models,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,False,1.00,Medium,BALB/c,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The anti-p55 mouse monoclonal antibody was generated by immunizing BALB/c mice with the recombinant SH3-GUK segment,Wildtype/control with no known disease: BALB/c
Sprague‒Dawley,animal_models,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,1.00,Medium,Sprague‒Dawley,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NSCs were obtained from the fetal brains of embryonic Day 14 pregnant Sprague‒Dawley rats (Experimental Animal Center of Southern Medical University, Guangzhou, China)",Wildtype/control with no known disease: Sprague‒Dawley
R26 LacZR,animal_models,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,R26 LacZR,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The R26 LacZR allele was introduced to the control, Nf1 hGFAP CKO, Nf1 Math1 CKO, Nf1 L7 CKO and Nf1 NcreER CKO mice as a reporter",Wildtype/control with no known disease: R26 LacZR
Fmr1 KO,animal_models,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,Experimental Usage,False,1.00,Medium,Fmr1 KO,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Generation of the Fmr1 KO (Mientjes et al., 2006)...Calyces from both Tsc1(+/-) and from Fmr1 knock-out (KO) mice showed increased volume",Wildtype/control with no known disease: Fmr1 KO
H-ras G12V,animal_models,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,Experimental Usage,False,1.00,Medium,H-ras G12V,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Generation of the...H-ras mice (G12V Schuhmacher et al., 2008) has been described previously",Wildtype/control with no known disease: H-ras G12V
Tsc1 (+/-),animal_models,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,Experimental Usage,False,1.00,Medium,Tsc1 (+/-),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tsc1 animals were obtained by crossing the +/- Tsc1 line (f/+ Meikle et al., 2005)...Calyces from both Tsc1(+/-) and from Fmr1 knock-out (KO) mice showed increased volume",Wildtype/control with no known disease: Tsc1 (+/-)
CAGG-Cre,animal_models,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.8,Experimental Usage,False,1.00,Medium,CAGG-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tsc1 animals were obtained by crossing the +/- Tsc1 line (f/+ Meikle et al., 2005) once with CAGG-Cre mice to obtain germ-line deletion",Wildtype/control with no known disease: CAGG-Cre
NSG,animal_models,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,False,1.00,Medium,NSG,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tumor tissue was implanted s.c. into the flank of 5- to 6-week-old NSG mice (The Jackson Laboratory).,Wildtype/control with no known disease: NSG
C57BL/6N,animal_models,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,False,1.00,Medium,C57BL/6N,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,viral injection into the left sciatic nerve of wild-type C57BL/6N mice,Wildtype/control with no known disease: C57BL/6N
NOD scid gamma,animal_models,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,False,1.00,Medium,NOD scid gamma,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,injected into the left sciatic nerve of immunodeficient (NOD scid gamma) mice,Wildtype/control with no known disease: NOD scid gamma
NOD RAG1/2−/− IL2Rγ−/−,animal_models,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,False,1.00,Medium,NOD RAG1/2−/− IL2Rγ−/−,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,implanted subcutaneously with Matrigel in immunodeficient NRG (NOD RAG1/2−/− IL2Rγ−/−) mice,Wildtype/control with no known disease: NOD RAG1/2−/− IL2Rγ−/−
NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,animal_models,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,Experimental Usage,False,1.00,Medium,NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) male mice (6–8 weeks of age) were obtained from the on-site breeding colony,Wildtype/control with no known disease: NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ
Nf2 flox2/flox2,animal_models,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,Experimental Usage,True,1.00,High,Nf2 flox2/flox2,Neurofibromatosis type 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Schwann cells purified from sciatic nerve of Nf2 flox2/flox2 mice, as described previously",Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
Tsc1flox/flox,animal_models,PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,0.9,Experimental Usage,False,1.00,Medium,Tsc1flox/flox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The floxed Tsc1 (Tsc1flox/flox), P0-Cre (line A), Rosa 26 transgenic mice were described previously",Publication title lacks NF-specific terms: Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone
P0-Cre (line A),animal_models,PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,0.9,Experimental Usage,False,1.00,Medium,P0-Cre (line A),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tsc1flox/flox mice were mated with P0-Cre mice to generate Tsc1flox/flox;P0-Cre mice,Publication title lacks NF-specific terms: Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone
Rosa26,animal_models,PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,0.9,Experimental Usage,False,1.00,Medium,Rosa26,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tsc1flox/flox mice were bred with Rosa 26 reporter mice to generate Tsc1flox/flox;Rosa/Rosa mice,Publication title lacks NF-specific terms: Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone
B6-Nf1−/+;Trp53−/+cis,animal_models,PMID:18188004,10.4161/epi.3.1.5469,Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows balanced expression from the maternal and paternal chromosomes and strain-specific variation in expression levels.,,0.9,Experimental Usage,True,1.00,High,B6-Nf1−/+;Trp53−/+cis,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"To generate B6 paternal F1 hybrids on a B6XA background, we crossed B6- Nf1 − /+;Trp53 − /+cis  males to wild-type A/J females.",Publication title lacks NF-specific terms: Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows
129S4-Nf1−/+;Trp53−/+cis,animal_models,PMID:18188004,10.4161/epi.3.1.5469,Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows balanced expression from the maternal and paternal chromosomes and strain-specific variation in expression levels.,,0.9,Experimental Usage,True,1.00,High,129S4-Nf1−/+;Trp53−/+cis,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"To generate B6X129S4 F1 hybrids, 129S4- Nf1 − /+;Trp53 − /+cis  mice were crossed to wild-type B6.",Publication title lacks NF-specific terms: Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows
A/J,animal_models,PMID:18188004,10.4161/epi.3.1.5469,Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows balanced expression from the maternal and paternal chromosomes and strain-specific variation in expression levels.,,0.85,Experimental Usage,False,1.00,Medium,A/J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,we crossed B6- Nf1 − /+;Trp53 − /+cis  males to wild-type A/J females. We purchased wild-type A/J from Jackson Laboratory,Publication title lacks NF-specific terms: Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows
athymic nude mice,animal_models,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,1.00,Medium,athymic nude mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Female athymic nude mice (≥ 8-week old) obtained from The Jackson Laboratory (Bar Harbor, ME) were used for tumor studies",Wildtype/control with no known disease: athymic nude mice
PeriCre,animal_models,PMID:21980365,10.1371/journal.pone.0024917,The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,PeriCre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.9kb (peri-EGFP/Cre PeriCre) transgenic mice were generated as described elsewhere,Wildtype/control with no known disease: PeriCre
Col2.3Cre,animal_models,PMID:21980365,10.1371/journal.pone.0024917,The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,Col2.3Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Col2.3Cre transgenic mice were generated as described elsewhere,Wildtype/control with no known disease: Col2.3Cre
ROSA26,animal_models,PMID:21980365,10.1371/journal.pone.0024917,The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,ROSA26,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,adult PeriCre transgenic mice were crossed with ROSA26 reporter mice,Wildtype/control with no known disease: ROSA26
C57BL/6-TgN(ACTbEGFP) 1Osb,animal_models,PMID:21980365,10.1371/journal.pone.0024917,The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,C57BL/6-TgN(ACTbEGFP) 1Osb,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The C57BL/6-TgN(ACTbEGFP) 1Osb transgenic mouse line was obtained from Jackson Laboratory, Bar Harbor, Maine",Wildtype/control with no known disease: C57BL/6-TgN(ACTbEGFP) 1Osb
C57Bl6 TgMISIIR-TAg-low,animal_models,PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,0.9,Experimental Usage,False,1.00,Medium,C57Bl6 TgMISIIR-TAg-low,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Female C57Bl6 TgMISIIR-TAg-low mice were housed in pathogen-free conditions,Wildtype/control with no known disease: C57Bl6 TgMISIIR-TAg-low
C57BL/6J,animal_models,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.9,Experimental Usage,False,1.00,Medium,C57BL/6J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Female C57BL/6J (6–8 weeks of age) mice were purchased from the The Jackson Laboratory (stock no. 000664),Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
NSG,animal_models,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.85,Experimental Usage,False,1.00,Medium,NSG,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,female NSG (6–8 weeks of age) mice were purchased from the MSK animal core facility,Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
CD11b-TK,animal_models,PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,0.9,Experimental Usage,False,1.00,Medium,CD11b-TK,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"we used CD11b-TK mice, in which resident brain microglia (CD11b+, CD68+, Iba1+, CD45low cells) can be ablated at specific times after ganciclovir administration",Wildtype/control with no known disease: CD11b-TK
Cx3cr1+/GFP,animal_models,PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,0.9,Experimental Usage,False,1.00,Medium,Cx3cr1+/GFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"( Cx3cr1+/GFP 23 ),  , wild type (WT) and  Nf1 +/- ;Cx3cr1+/GFP  mice were all maintained on a C57BL/6 background",Wildtype/control with no known disease: Cx3cr1+/GFP
Nf1+/−,animal_models,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.95,Experimental Usage,True,1.00,High,Nf1+/−,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Studies with Nf1 +/− mice were performed in 129T2/SvEmsJ-C57BL/6 F1 hybrids generated. WT littermates were used as controls.,Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
Nf1floxed/+ synapsin 1-Cre,animal_models,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.9,Experimental Usage,True,1.00,High,Nf1floxed/+ synapsin 1-Cre,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The mice with Cre-mediated deletions of the Nf1 gene (Nf1; Dlx5/6+/− Nf1 syn I+/− Nf1; CamkII +/− Nf1) were F1 progeny from a cross between the GFAP+/− Nf1 and the cell-type specific Cre mice (floxed/+ synapsin 1-Cre,Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
GFAP-Cre,animal_models,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.9,Experimental Usage,False,1.00,Medium,GFAP-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"cell-type specific Cre mice (floxed/+ synapsin 1-Cre, GFAP-Cre, αCaMKII-Cre, and Dlx5/6-Cre",Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
αCaMKII-Cre,animal_models,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.9,Experimental Usage,False,1.00,Medium,αCaMKII-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"cell-type specific Cre mice (floxed/+ synapsin 1-Cre, GFAP-Cre, αCaMKII-Cre, and Dlx5/6-Cre",Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
Dlx5/6-Cre,animal_models,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.9,Experimental Usage,False,1.00,Medium,Dlx5/6-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"cell-type specific Cre mice (floxed/+ synapsin 1-Cre, GFAP-Cre, αCaMKII-Cre, and Dlx5/6-Cre",Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
C57Bl/6J,animal_models,PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,0.85,Experimental Usage,False,1.00,Medium,C57Bl/6J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"We generated SV40-immortalized cell lines derived from wild-type (WT) and neurofibromatosis 2 (merlin) heterozygote (Nf2+/-) mice, both on a commonly used genetic background, C57Bl/6J.",Wildtype/control with no known disease: C57Bl/6J
B6.129S7-Rag1tmMom,animal_models,PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,0.9,Experimental Usage,False,1.00,Medium,B6.129S7-Rag1tmMom,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1 × 10^6 glioma cells were injected into each immunocompromised B6.129S7-Rag1tmMom (Rag1, Jackson Laboratories) mouse",Publication title lacks NF-specific terms: Merlin is a potent inhibitor of glioma growth.
Nude mice,animal_models,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.9,Experimental Usage,False,1.00,Medium,Nude mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1 × 10^6 cells were sciatic nerve transplanted in Nude mice (Charles River, Wilmington, MA, USA)",Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
TetO-YAP,animal_models,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,1.00,Medium,TetO-YAP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The TetO-YAP line (Camargo et al., 2007) was provided by Thijn R. Brummelkamp and Fernando D. Camargo",Wildtype/control with no known disease: TetO-YAP
Sox10-rtTA,animal_models,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,1.00,Medium,Sox10-rtTA,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Sox10-rtTA line (Ludwig et al., 2004) was a gift from Michael Wegner",Wildtype/control with no known disease: Sox10-rtTA
Wnt1-Cre,animal_models,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,1.00,Medium,Wnt1-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wnt1-Cre (Stock No: 007807) and Axin2-rtTA (Stock No: 016997) lines were obtained from the Jackson Laboratory,Wildtype/control with no known disease: Wnt1-Cre
Axin2-rtTA,animal_models,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,1.00,Medium,Axin2-rtTA,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wnt1-Cre (Stock No: 007807) and Axin2-rtTA (Stock No: 016997) lines were obtained from the Jackson Laboratory,Wildtype/control with no known disease: Axin2-rtTA
Yap Flox/Flox,animal_models,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,1.00,Medium,Yap Flox/Flox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The Yap line (Flox/Flox Xin et al., 2011) was provided by Eric N. Olson",Wildtype/control with no known disease: Yap Flox/Flox
Ella-Cre,animal_models,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,1.00,Medium,Ella-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"An Nf2 allele was generated by breeding Δ Nf2 mice with the Flox/Flox Ella-Cre line (Stock No: 003724, Jackson Laboratory)",Wildtype/control with no known disease: Ella-Cre
C57BL6,animal_models,PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,0.8,Experimental Usage,False,1.00,Medium,C57BL6,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"5- to 6-week-old C57BL6 mice (Taconic; RRID:IMSR_TAC:b6) were implanted with 400,000 JW23.3 cells",Wildtype/control with no known disease: C57BL6
NOD-Rag1null IL2rgnull,animal_models,PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,NOD-Rag1null IL2rgnull,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"6- to 10-week-old immunodeficient NOD-Rag1null IL2rgnull (NRG) mice (strain #007799, Jackson Laboratories; RRID:IMSR_JAX:007799)",Wildtype/control with no known disease: NOD-Rag1null IL2rgnull
nu/nu,animal_models,PMID:28065690,10.1016/j.biochi.2017.01.001,Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Female 6–7 weeks old nu/nu immunodeficient mice were injected subcutaneously with 10^7 S462TY cells,Wildtype/control with no known disease: nu/nu
CMV-CreERT,animal_models,PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,CMV-CreERT,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For conditional ablation of Nf1, we used a tamoxifen-inducible Cre line, the CMV-CreERT transgenic mice",Wildtype/control with no known disease: CMV-CreERT
ROSA26,animal_models,PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,ROSA26,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The LacZ reporter mice, ROSA26 (Soriano, 1999), were obtained from the Jackson Laboratories",Wildtype/control with no known disease: ROSA26
AB strain,animal_models,PMID:33279959,10.1093/brain/awaa404,"Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish.",,0.9,Experimental Usage,False,1.00,Medium,AB strain,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The wild-type zebrafish line (AB strain) and Tg(gfap:GFP) transgenic fish were obtained from the China Zebrafish Resource Center,Wildtype/control with no known disease: AB strain
Tg(gfap:GFP),animal_models,PMID:33279959,10.1093/brain/awaa404,"Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish.",,0.95,Experimental Usage,False,1.00,Medium,Tg(gfap:GFP),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The wild-type zebrafish line (AB strain) and Tg(gfap:GFP) transgenic fish (Bernardos and Raymond, 2006) were obtained",Wildtype/control with no known disease: Tg(gfap:GFP)
athymic nu/nu,animal_models,PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,0.85,Experimental Usage,False,1.00,Medium,athymic nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,We anaesthetized athymic nu/nu mice in isoflurane and subcutaneously injected 1–4.5 × 10 5 mouse or human sphere cells,Wildtype/control with no known disease: athymic nu/nu
NSG-SCID,animal_models,PMID:32245042,10.3390/genes11030331,Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.,,0.85,Experimental Usage,False,1.00,Medium,NSG-SCID,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,15–25 mg portions of each tumor were transplanted into the flank of NSG-SCID mice using a 10 gauge trochar,Wildtype/control with no known disease: NSG-SCID
#005557,animal_models,PMID:37616542,10.1158/1535-7163.MCT-23-0258,"Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.",,0.85,Experimental Usage,False,1.00,Medium,#005557,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NSG mice (#005557) were obtained from Jackson Labs and bred in house,Wildtype/control with no known disease: #005557
C57BL/6,animal_models,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.8,Experimental Usage,False,1.00,Medium,C57BL/6,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wild-type murine Schwann cell cultures were prepared from the sciatic nerves of adult C57BL/6 mice,Wildtype/control with no known disease: C57BL/6
Tg(Thy1-eGFP)M,animal_models,PMID:33816648,10.1016/j.omtm.2021.03.004,Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas.,,0.85,Experimental Usage,False,1.00,Medium,Tg(Thy1-eGFP)M,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mouse iPSCs originally derived from Tg(Thy1-eGFP)M mouse fibroblasts by overexpression of the Oct4-Sox2-Klf4-CMyc cassette,Publication title lacks NF-specific terms: Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and gl
C57BL/6,animal_models,PMID:33816648,10.1016/j.omtm.2021.03.004,Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas.,,0.9,Experimental Usage,False,1.00,Medium,C57BL/6,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cells were delivered intravitreally into 35 eyes of adult C57BL/6 mice,Publication title lacks NF-specific terms: Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and gl
AB,animal_models,PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,0.85,Experimental Usage,False,1.00,Medium,AB,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"AB and Tg(UAS-E1b:nfsB-mCherry) c264 strains were acquired from the Zebrafish International Resource Center (ZIRC, Eugene, OR, USA).",Publication title lacks NF-specific terms: Activation of Sonic hedgehog signaling in neural progenitor cells promotes gliom
Tg(UAS-E1b:nfsB-mCherry) c264,animal_models,PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,0.9,Experimental Usage,False,1.00,Medium,Tg(UAS-E1b:nfsB-mCherry) c264,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"AB and Tg(UAS-E1b:nfsB-mCherry) c264 strains were acquired from the Zebrafish International Resource Center (ZIRC, Eugene, OR, USA).",Publication title lacks NF-specific terms: Activation of Sonic hedgehog signaling in neural progenitor cells promotes gliom
nonobese diabetic/severe combined immunodeficient,animal_models,PMID:18931645,10.1097/MAO.0b013e31818b6cea,Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice.,,0.9,Experimental Usage,False,1.00,Medium,nonobese diabetic/severe combined immunodeficient,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Female nonobese diabetic/severe combined immunodeficient (SCID) mice (Jackson Laboratories, Bar Harbor, MN, USA), 6 to 8 weeks of age, were used for schwannoma xenograft experiments.",Wildtype/control with no known disease: nonobese diabetic/severe combined immunodeficient
031956,animal_models,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.9,Experimental Usage,False,1.00,Medium,031956,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"FAK flox mice were purchased through the Jackson Laboratory (strain #: 031956, RRID:IMSR_JAX:031956)",Wildtype/control with no known disease: 031956
Df27352,animal_models,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.8,Experimental Usage,False,1.00,Medium,Df27352,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bloomington line Df27352 was used as an SIFa deficiency allele (2R:60C2;60D14) tested in transheterozygotes with SIFa CRISPR alleles.,Wildtype/control with no known disease: Df27352
CaLexA,animal_models,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.75,Experimental Usage,False,1.00,Low,CaLexA,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CaLexA flies were a gift from J. Wang.,Wildtype/control with no known disease: CaLexA
UAS-RedStinger,animal_models,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.8,Experimental Usage,False,1.00,Medium,UAS-RedStinger,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UAS-RedStinger flies were obtained from the Bloomington Drosophila Stock Center.,Wildtype/control with no known disease: UAS-RedStinger
Prx1Cre,animal_models,PMID:18671844,10.1186/1741-7015-6-21,Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin.,,0.9,Experimental Usage,False,1.00,Medium,Prx1Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Nf1flox and Prx1Cre lines were maintained by continuous backcrossing to wild-type C57BL/6J mice,Wildtype/control with no known disease: Prx1Cre
C57BL/6-TgN(ACTbEGFP)1Osb,animal_models,PMID:18984156,10.1016/j.cell.2008.08.041,Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.,,0.95,Experimental Usage,False,1.00,Medium,C57BL/6-TgN(ACTbEGFP)1Osb,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The C57BL/6-TgN(ACTbEGFP)1Osb mice were obtained from Jackson Laboratory, Bar Harbor, ME.",Wildtype/control with no known disease: C57BL/6-TgN(ACTbEGFP)1Osb
tyrosine hydroxylase,antibodies,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,tyrosine hydroxylase,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-tyrosine hydroxylase (Rabbit polyclonal) EMD Millipore Cat#: AB152 RRID: AB_390204 IHC (1:1000),Antibody target not in NF pathway/tumor biology gene list: tyrosine hydroxylase
tyrosine hydroxylase,antibodies,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,tyrosine hydroxylase,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-tyrosine hydroxylase (mouse monoclonal) ImmunoStar Cat#: 22941 RRID: AB_572268 IHC (1:1000),Antibody target not in NF pathway/tumor biology gene list: tyrosine hydroxylase
GFP,antibodies,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,GFP,Mouse,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-GFP (mouse polyclonal) Aves Cat#: GFP-1020 RRID: AB_10000240 IHC (1:1000),Generic reporter/tag/housekeeping antibody: gfp
chicken IgY,antibodies,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.85,Experimental Usage,False,0.67,Low,,,,chicken IgY,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,Alexa Fluor 488-conjugated donkey anti-chicken IgY F(ab')two fragment Jackson ImmunoResearch Cat#: 703-546-155,Secondary antibody (not an NF-specific research tool)
mouse IgG,antibodies,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.85,Experimental Usage,False,0.67,Low,,,,mouse IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,Alexa Fluor 647-conjugated donkey anti-mouse IgG Fab fragment Jackson ImmunoResearch Cat#: 711-607-003,Secondary antibody (not an NF-specific research tool)
TRIM23,antibodies,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,False,1.00,Medium,,,,TRIM23,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemical stain for TRIM23 (ThermoFisher, PA5-34624, 1:150, rabbit polyclonal)",Antibody target not in NF pathway/tumor biology gene list: TRIM23
H3K27me3,antibodies,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,False,1.00,Medium,,,,H3K27me3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemistry for histone 3 lysine trimethylation (H3K27 me3) was performed using rabbit monoclonal antibodies (C36B11, 1:50 dilution; Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: H3K27me3
Cleaved-caspase 3,antibodies,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,Experimental Usage,False,0.33,Low,,,,Cleaved-caspase 3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemical staining for Cleaved-caspase 3 at 1:500 (Cell Signaling Technology, Danvers, MA)",Antibody target not in NF pathway/tumor biology gene list: Cleaved-caspase 3
Ki67,antibodies,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,Experimental Usage,False,0.33,Low,,,,Ki67,,,,,,,,,,,,,,,,,,,,,,,,,,,,prediluted Ki67 (790–4286; Ventana),Antibody target not in NF pathway/tumor biology gene list: Ki67
GFAP,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,0.33,Low,,,,GFAP,,,,,,,,,,,,,,,,,,,,,,,,,,,,"serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2",Antibody target not in NF pathway/tumor biology gene list: GFAP
Iba1,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,0.33,Low,,,,Iba1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2",Antibody target not in NF pathway/tumor biology gene list: Iba1
Ki67,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,0.33,Low,,,,Ki67,,,,,,,,,,,,,,,,,,,,,,,,,,,,"serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2",Antibody target not in NF pathway/tumor biology gene list: Ki67
SOX10,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,0.33,Low,,,,SOX10,,,,,,,,,,,,,,,,,,,,,,,,,,,,"serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2",Antibody target not in NF pathway/tumor biology gene list: SOX10
Rbpms,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,0.33,Low,,,,Rbpms,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary RGCs, hippocampal neurons, DRG neurons, sh NF1 Schwann cells, and hiPSC-sensory neurons were immunostained with appropriate primary (RGCs: Rbpms, Tuj-1",Antibody target not in NF pathway/tumor biology gene list: Rbpms
Tuj-1,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,0.33,Low,,,,Tuj-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary RGCs, hippocampal neurons, DRG neurons, sh NF1 Schwann cells, and hiPSC-sensory neurons were immunostained with appropriate primary (RGCs: Rbpms, Tuj-1",Antibody target not in NF pathway/tumor biology gene list: Tuj-1
Peripherin,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,0.33,Low,,,,Peripherin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"DRG neurons: Peripherin, ISL1, Tuj-1",Antibody target not in NF pathway/tumor biology gene list: Peripherin
ISL1,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,0.33,Low,,,,ISL1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"DRG neurons: Peripherin, ISL1, Tuj-1",Antibody target not in NF pathway/tumor biology gene list: ISL1
P-cadherin,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,False,0.33,Low,,,,P-cadherin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in this study were P-cadherin (R&D Systems, AF761), DCT (PEP8h; gift from Dr. Vincent Hearing)",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
DCT,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,False,0.67,Low,,,,DCT,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"DCT (PEP8h; gift from Dr. Vincent Hearing, National Institutes of Health)",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
K14,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,False,0.67,Low,,,,K14,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"K14 (biotin-labeled, Thermo, clone LL002), LacZ (Abcam, ab9361), GFP/YFP (Aves, 1020)",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
LacZ,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,False,0.33,Low,,,,LacZ,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"K14 (biotin-labeled, Thermo, clone LL002), LacZ (Abcam, ab9361), GFP/YFP (Aves, 1020)",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
GFP/YFP,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,False,0.33,Low,,,,GFP/YFP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"LacZ (Abcam, ab9361), GFP/YFP (Aves, 1020), Krox20 (Covance, PRB-236P)",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
Krox20,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,False,0.33,Low,,,,Krox20,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GFP/YFP (Aves, 1020), Krox20 (Covance, PRB-236P), and KIT (Cell Signaling, 3074)",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
KIT,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,False,0.33,Low,,,,KIT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Krox20 (Covance, PRB-236P), and KIT (Cell Signaling, 3074). For immunofluorescent staining",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
pERα S118,antibodies,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,False,0.33,Low,,,,pERα S118,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pERα S118 (Sigma, Cat# SAB450399)",Antibody target not in NF pathway/tumor biology gene list: pERα S118
pERK T202/Y204,antibodies,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,False,0.33,Low,,,,pERK T202/Y204,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pERK T202/Y204 (Cell Signaling Technology, Cat#9101L)",Antibody target not in NF pathway/tumor biology gene list: pERK T202/Y204
pAKT S473,antibodies,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,False,0.33,Low,,,,pAKT S473,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pAKT S473 (Cell Signaling Technology, Cat#9271L)",Antibody target not in NF pathway/tumor biology gene list: pAKT S473
β-tubulin,antibodies,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,False,0.33,Low,,,,β-tubulin,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"β-tubulin (Cell Signaling Technology, Cat#2146, primary 1:500, secondary 1:2000)",Generic reporter/tag/housekeeping antibody: β-tubulin
Brn3a,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,0.33,Low,,,,Brn3a,,,,,,,,,,,,,,,,,,,,,,,,,,,,labeled overnight at room temperature with the following conjugated primary antibodies: Brn3a-FITC,Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
RBPMS,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,0.33,Low,,,,RBPMS,,,,,,,,,,,,,,,,,,,,,,,,,,,,"labeled overnight at room temperature with the following conjugated primary antibodies: Brn3a-FITC, RBPMS-APC",Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
Thy1.1,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,0.33,Low,,,,Thy1.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,Thy1.1-APC (ganglion cell marker),Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
Caspase9,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,0.33,Low,,,,Caspase9,,,,,,,,,,,,,,,,,,,,,,,,,,,,Caspase9-FITC (apoptosis marker),Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
Ki67,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,0.33,Low,,,,Ki67,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ki67-FITC (proliferation marker),Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
Cmyc,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,0.33,Low,,,,Cmyc,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Cmyc-FITC, Oct4-APC (stemness markers)",Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
Oct4,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,0.33,Low,,,,Oct4,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Cmyc-FITC, Oct4-APC (stemness markers)",Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
NeuN,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,0.33,Low,,,,NeuN,,,,,,,,,,,,,,,,,,,,,,,,,,,,NeuN-APC (neuronal marker),Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
CD45,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,0.33,Low,,,,CD45,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Every 5th section was stained with CD45-PE, IBA1-FITC (immune cell marker)",Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
IBA1,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,0.33,Low,,,,IBA1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CD45-PE, IBA1-FITC (immune cell marker)",Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
GFAP,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,0.33,Low,,,,GFAP,,,,,,,,,,,,,,,,,,,,,,,,,,,,Every 6th section was stained with GFAP-PE (Muller cells marker),Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
STEM121,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,0.33,Low,,,,STEM121,,,,,,,,,,,,,,,,,,,,,,,,,,,,STEM121-FITC (human cell marker),Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
HLA-DR,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,False,0.33,Low,,,,HLA-DR,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"stained with anti-HLA-DR Percp-cy5.5 (eBioscience, 0.015 µg/test, San Diego, CA, USA)",Antibody target not in NF pathway/tumor biology gene list: HLA-DR
CD33,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,False,0.33,Low,,,,CD33,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-CD33 APC (eBioscience, 0.125 µg/test)",Antibody target not in NF pathway/tumor biology gene list: CD33
CD11b,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,False,0.33,Low,,,,CD11b,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-CD11b FITC antibodies (eBioscience, 0.5 µg/test)",Antibody target not in NF pathway/tumor biology gene list: CD11b
CD9,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,False,0.33,Low,,,,CD9,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"primary antibodies against CD9 (Proteintech, 60232-1-Ig, Wuhan, China)",Antibody target not in NF pathway/tumor biology gene list: CD9
CD81,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,False,0.33,Low,,,,CD81,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD81 (Proteintech, 66866-1-Ig)",Antibody target not in NF pathway/tumor biology gene list: CD81
TOMM20,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,False,0.67,Low,,,,TOMM20,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"TOMM20 (Proteintech, 11802-1-AP)",Antibody target not in NF pathway/tumor biology gene list: TOMM20
HSP90,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,False,0.67,Low,,,,HSP90,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"HSP90 (Proteintech, 13171-1-AP)",Antibody target not in NF pathway/tumor biology gene list: HSP90
AKT,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,False,0.33,Low,,,,AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AKT (CST, #9272S, Danvers, MA, USA)",Antibody target not in NF pathway/tumor biology gene list: AKT
p-AKT,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,False,0.33,Low,,,,p-AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-AKT (CST, #4051S)",Antibody target not in NF pathway/tumor biology gene list: p-AKT
ERK,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,False,0.33,Low,,,,ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ERK (CST, #4695)",Antibody target not in NF pathway/tumor biology gene list: ERK
p-ERK,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,False,0.33,Low,,,,p-ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-ERK (CST, #9101S)",Antibody target not in NF pathway/tumor biology gene list: p-ERK
Erk1/2,antibodies,PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.85,Experimental Usage,False,0.33,Low,,,,Erk1/2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blot analyses were performed using anti-total and anti-phospho Erk1/2 (Cell Signaling, Danvers, MA, USA) antibodies",Antibody target not in NF pathway/tumor biology gene list: Erk1/2
phospho-Erk1/2,antibodies,PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.85,Experimental Usage,False,0.33,Low,,,,phospho-Erk1/2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blot analyses were performed using anti-total and anti-phospho Erk1/2 (Cell Signaling, Danvers, MA, USA) antibodies",Antibody target not in NF pathway/tumor biology gene list: phospho-Erk1/2
FLAG,antibodies,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,False,0.67,Low,,,,FLAG,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies (Cell Signaling Technology) used for Western blotting were FLAG (rabbit, 14793)",Generic reporter/tag/housekeeping antibody: flag
V5,antibodies,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,False,0.67,Low,,,,V5,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies (Cell Signaling Technology) used for Western blotting were V5 (rabbit, 13202)",Generic reporter/tag/housekeeping antibody: v5
HA,antibodies,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,False,0.67,Low,,,,HA,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies (Cell Signaling Technology) used for Western blotting were HA (rabbit, 3724)",Generic reporter/tag/housekeeping antibody: ha
pEGFR,antibodies,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,False,0.33,Low,,,,pEGFR,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Western blots to verify protein expression levels were run on Tris acetate or Bolt gels and probed with a series of antibodies: pEGFR (Cell Signaling 3777),Antibody target not in NF pathway/tumor biology gene list: pEGFR
vinculin,antibodies,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,False,0.33,Low,,,,vinculin,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,vinculin (Cell Signaling 19301),Generic reporter/tag/housekeeping antibody: vinculin
KRAS,antibodies,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,False,0.67,Low,,,,KRAS,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,KRAS (Sigma/Novus Biologicals WH0003845M1/H0003845M1),Antibody target not in NF pathway/tumor biology gene list: KRAS
collagen IV,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.33,Low,,,,collagen IV,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The primary antibodies and dilutions used were goat anti-collagen IV (Millipore AB769; 1:500),Antibody target not in NF pathway/tumor biology gene list: collagen IV
MyHC type 1,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,1.00,Medium,,,,MyHC type 1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-MyHC type 1 (DSHB BA-D5; 1:500),Antibody target not in NF pathway/tumor biology gene list: MyHC type 1
MyHC type 2A,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,1.00,Medium,,,,MyHC type 2A,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-MyHC type 2A (DSHB SC-71; 1:200),Antibody target not in NF pathway/tumor biology gene list: MyHC type 2A
laminin,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,laminin,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-laminin (Sigma-Aldrich L9393; 1:500),Antibody target not in NF pathway/tumor biology gene list: laminin
Pax7,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,1.00,Medium,,,,Pax7,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-Pax7 (DSHB Pax7; 1:10),Antibody target not in NF pathway/tumor biology gene list: Pax7
myosin heavy chain,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,myosin heavy chain,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-myosin heavy chain (Sigma-Aldrich 05-716; 1:1000),Antibody target not in NF pathway/tumor biology gene list: myosin heavy chain
beta III tubulin,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.33,Low,,,,beta III tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-beta III tubulin antibody (Sigma-Aldrich AB9354; 1:500),Antibody target not in NF pathway/tumor biology gene list: beta III tubulin
perilipin A/B,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.33,Low,,,,perilipin A/B,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-perilipin A/B antibody (Sigma-Aldrich p1873; 1:250),Antibody target not in NF pathway/tumor biology gene list: perilipin A/B
PPARG,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,PPARG,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies used were rabbit anti-PPARG (Cell Signaling Technology 2443),Antibody target not in NF pathway/tumor biology gene list: PPARG
phosphor (pThr172) AMPKa,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,phosphor (pThr172) AMPKa,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-phosphor (pThr172) AMPKa (Cell Signaling Technology 2535),Antibody target not in NF pathway/tumor biology gene list: phosphor (pThr172) AMPKa
AMPKα,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,AMPKα,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-AMPKα (Cell Signaling Technology 2532),Antibody target not in NF pathway/tumor biology gene list: AMPKα
β-actin,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,β-actin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-β-actin (Cell Signaling Technology 58169),Generic reporter/tag/housekeeping antibody: β-actin
β-tubulin,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,β-tubulin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-β-tubulin (Sigma-Aldrich T8328),Generic reporter/tag/housekeeping antibody: β-tubulin
phosphor (s235/236) S6,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,phosphor (s235/236) S6,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-phosphor (s235/236) S6 (Cell Signaling Technology 4858),Antibody target not in NF pathway/tumor biology gene list: phosphor (s235/236) S6
MyHC type 2B,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,1.00,Medium,,,,MyHC type 2B,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-MyHC type 2B (DSHB BF-F3),Antibody target not in NF pathway/tumor biology gene list: MyHC type 2B
phosphor (Ser473) AKT,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,phosphor (Ser473) AKT,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-phosphor (Ser473) AKT (Cell Signaling, #9271; 1:1000)",Antibody target not in NF pathway/tumor biology gene list: phosphor (Ser473) AKT
phospho (Ser1101) IRS-1,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,phospho (Ser1101) IRS-1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-phospho (Ser1101) IRS-1 (Cell Signaling, #2385; 1:1000)",Antibody target not in NF pathway/tumor biology gene list: phospho (Ser1101) IRS-1
phospho (Ser636/639) IRS-1,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,phospho (Ser636/639) IRS-1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-phospho (Ser636/639) IRS-1 (Cell Signaling, #2388; 1:1000)",Antibody target not in NF pathway/tumor biology gene list: phospho (Ser636/639) IRS-1
DIG-Fab,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.33,Low,,,,DIG-Fab,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with anti-DIG-Fab antibody coupled to alkaline phosphatase (Roche, 11093274910)",Generic reporter/tag/housekeeping antibody: dig-fab
RAS,antibodies,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,False,1.00,Medium,,,,RAS,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"N-, K-, and H-RAS were detected with a 1:100 dilution of murine monoclonal pan-RAS antibody (BD Biosciences, San Diego, CA, USA, product #610002).",Antibody target not in NF pathway/tumor biology gene list: RAS
N-RAS,antibodies,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,False,1.00,Medium,,,,N-RAS,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"N-RAS was detected with a 1:400 dilution of a rabbit polyclonal N-RAS antibody (Santa Cruz, CA, USA, product #sc-519).",Antibody target not in NF pathway/tumor biology gene list: N-RAS
RAB5A,antibodies,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,False,1.00,Medium,,,,RAB5A,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"RAB5A was detected with a 1:250 dilution of a rabbit polyclonal RAB5A antibody (Santa Cruz, Santa Cruz, CA, USA, product #sc-309).",Antibody target not in NF pathway/tumor biology gene list: RAB5A
RAP1A,antibodies,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,False,0.67,Low,,,,RAP1A,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Non-prenylated RAP1A was detected with a 1:250 dilution of a goat polyclonal RAP1A antibody (Santa Cruz, product #1482).",Antibody target not in NF pathway/tumor biology gene list: RAP1A
GAPDH,antibodies,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,False,1.00,Medium,,,,GAPDH,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"GAPDH was detected with a 1:1000 dilution of rabbit polyclonal antibody to GAPDH (Cell Signaling, Boston, MA, USA, product #2118).",Generic reporter/tag/housekeeping antibody: gapdh
β-actin,antibodies,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,False,1.00,Medium,,,,β-actin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"β-actin was detected with a 1:25,000 dilution of murine monoclonal antibody to β-actin (Sigma, St. Louis, MI, USA, product #A5441).",Generic reporter/tag/housekeeping antibody: β-actin
H3K27me3,antibodies,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,0.33,Low,,,,H3K27me3,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10)",Antibody target not in NF pathway/tumor biology gene list: H3K27me3
MYF-4,antibodies,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,0.33,Low,,,,MYF-4,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10)",Antibody target not in NF pathway/tumor biology gene list: MYF-4
S100,antibodies,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,0.33,Low,,,,S100,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10)",Antibody target not in NF pathway/tumor biology gene list: S100
Sox10,antibodies,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,0.33,Low,,,,Sox10,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10)",Antibody target not in NF pathway/tumor biology gene list: Sox10
HMB45,antibodies,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,0.33,Low,,,,HMB45,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Additional IHC (HMB45 and Melan-A) was performed to exclude melanoma,Antibody target not in NF pathway/tumor biology gene list: HMB45
Melan-A,antibodies,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,0.33,Low,,,,Melan-A,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Additional IHC (HMB45 and Melan-A) was performed to exclude melanoma,Antibody target not in NF pathway/tumor biology gene list: Melan-A
S100,antibodies,PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.9,Experimental Usage,False,0.67,Low,,,,S100,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cells were incubated with 2 µg/mL rabbit anti-human S100 antibody (DAKO, Glostrup, Denmark)",Antibody target not in NF pathway/tumor biology gene list: S100
CD90,antibodies,PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.85,Experimental Usage,False,0.33,Low,,,,CD90,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cells were incubated with 2 µg/mL anti-human CD90 antibody (Dianova, Hamburg, Germany)",Antibody target not in NF pathway/tumor biology gene list: CD90
rabbit IgG,antibodies,PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.85,Experimental Usage,False,0.67,Low,,,,rabbit IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,10 µg/mL secondary fluorescein isothiocyanate (FITC)-conjugated anti-rabbit antibody (DAKO),Secondary antibody (not an NF-specific research tool)
mouse IgG,antibodies,PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.85,Experimental Usage,False,0.67,Low,,,,mouse IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,2 µg/mL secondary FITC-conjugated goat anti-mouse IgG (DAKO),Secondary antibody (not an NF-specific research tool)
s-100b,antibodies,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.85,Experimental Usage,False,0.33,Low,,,,s-100b,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Schwann cells were incubated with antibody against s-100b (Sigma) as the primary overnight at 1:400 ratio,Publication title lacks NF-specific terms: Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon na
rabbit IgG,antibodies,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.85,Experimental Usage,False,0.67,Low,,,,rabbit IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"treated with anti-rabbit IgG as secondary (Alexa Fluro 594, Invitrogen) for 2 hours at 1:1000 ratio",Publication title lacks NF-specific terms: Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon na
HMGA2,antibodies,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,0.33,Low,,,,HMGA2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam)",Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
beta-Catenin,antibodies,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,0.33,Low,,,,beta-Catenin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam)",Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
CK19,antibodies,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,0.33,Low,,,,CK19,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam)",Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
SOX9,antibodies,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,0.33,Low,,,,SOX9,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"1:1000 anti-Sox9 (Millipore); 1:10,000 anti-Hsp90 (BD Biosciences)",Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
HSP90,antibodies,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,0.33,Low,,,,HSP90,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"1:1000 anti-Sox9 (Millipore); 1:10,000 anti-Hsp90 (BD Biosciences)",Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
p-ERK,antibodies,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,0.33,Low,,,,p-ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,1:1000 anti-pErk (Cell Signaling),Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
Flag,antibodies,PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.9,Experimental Usage,False,0.67,Low,,,,Flag,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse anti-Flag (Sigma-Aldrich) was used at 1∶20,000",Generic reporter/tag/housekeeping antibody: flag
Ki67,antibodies,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,Experimental Usage,False,1.00,Medium,,,,Ki67,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,...followed by a 12-min incubation with the CONFIRM anti-Ki67 (clone 30-9) rabbit monoclonal primary antibody (Roche)...,Antibody target not in NF pathway/tumor biology gene list: Ki67
collagen XV,antibodies,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,Experimental Usage,False,0.67,Low,,,,collagen XV,,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...followed by an incubation with polyclonal anti-collagen XV (Sigma-Aldrich, HPA017913, 1:1000)...",Antibody target not in NF pathway/tumor biology gene list: collagen XV
collagen XVIII,antibodies,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,Experimental Usage,False,0.67,Low,,,,collagen XVIII,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...or in-house monoclonal anti-collagen XVIII (ref. [ 46 ], DB144-N2, 7 µg/ml) primary antibody...",Antibody target not in NF pathway/tumor biology gene list: collagen XVIII
K1,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,0.33,Low,,,,K1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"K1 (BioLegend, 905601, 1:100)",Antibody target not in NF pathway/tumor biology gene list: K1
H3K27Me3,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,0.33,Low,,,,H3K27Me3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"H3K27Me3 (Cell Signaling, 9733 S, 1:500)",Antibody target not in NF pathway/tumor biology gene list: H3K27Me3
S100,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,0.33,Low,,,,S100,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"S100 (DAKO, Z0311, 1:5000)",Antibody target not in NF pathway/tumor biology gene list: S100
LUMICAN,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,0.33,Low,,,,LUMICAN,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"LUMICAN (Santa Cruz; sc-166871, 1:200)",Antibody target not in NF pathway/tumor biology gene list: LUMICAN
CD3,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,0.33,Low,,,,CD3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,precoated with indicated doses of anti-CD3 Ab (eBioscience; cat. no. 16-0031-86),Antibody target not in NF pathway/tumor biology gene list: CD3
CD28,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,0.67,Low,,,,CD28,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,anti-CD28 mAb (eBioscience; cat. no. 16-0281-85),Antibody target not in NF pathway/tumor biology gene list: CD28
CD69,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,0.67,Low,,,,CD69,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,FITC-anti-CD69 mAb (eBioscience; cat. no. 11-0691-85; 1:100),Antibody target not in NF pathway/tumor biology gene list: CD69
CD4,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,0.33,Low,,,,CD4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD4 [eBioscience; cat. no. 17-0042-83; 1:100],Antibody target not in NF pathway/tumor biology gene list: CD4
CD8,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,0.33,Low,,,,CD8,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD8 [Lifetech; cat. no. A15836; 1:100],Antibody target not in NF pathway/tumor biology gene list: CD8
FoxP3,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,0.33,Low,,,,FoxP3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,FoxP3 [eBioscience; cat. no. 12-57773-80; 1:100],Antibody target not in NF pathway/tumor biology gene list: FoxP3
B220,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,0.33,Low,,,,B220,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,B220 [eBioscience; cat. no. 11-0452-85; 1:100],Antibody target not in NF pathway/tumor biology gene list: B220
CD45,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,0.33,Low,,,,CD45,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD45 [eBioscience; cat. no. 25-0451-82; 1:100],Antibody target not in NF pathway/tumor biology gene list: CD45
MIA,antibodies,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,MIA,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"stained with monoclonal anti-human MIA antibody (R&D Systems, McKinley Place NE, Minneapolis) diluted at 1:40",Antibody target not in NF pathway/tumor biology gene list: MIA
GFAP,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,GFAP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunofluorescence staining was performed using the following primary antibodies: GFAP (Sigma; St. Louis, MO)",Antibody target not in NF pathway/tumor biology gene list: GFAP
AQP4,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,AQP4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",Antibody target not in NF pathway/tumor biology gene list: AQP4
NG2,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,NG2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",Antibody target not in NF pathway/tumor biology gene list: NG2
O4,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,O4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",Antibody target not in NF pathway/tumor biology gene list: O4
LHX2,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,LHX2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",Antibody target not in NF pathway/tumor biology gene list: LHX2
APC,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,APC,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"APC (Calbiochem; San Diego, CA)",Antibody target not in NF pathway/tumor biology gene list: APC
FOXG1,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,FOXG1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FOXG1, FOXP2 (Abcam; Cambridge, MA)",Antibody target not in NF pathway/tumor biology gene list: FOXG1
FOXP2,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,FOXP2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FOXG1, FOXP2 (Abcam; Cambridge, MA)",Antibody target not in NF pathway/tumor biology gene list: FOXP2
HOXB3,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,HOXB3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HOXB3 (Santa Cruz Biotechnology; Santa Cruz, CA)",Antibody target not in NF pathway/tumor biology gene list: HOXB3
GLAST,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.85,Experimental Usage,False,0.33,Low,,,,GLAST,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,GLAST (a gift from Dr. Watanabe; (Shibata et al. 1997)),Antibody target not in NF pathway/tumor biology gene list: GLAST
GFAP,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,GFAP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemical staining was performed using GFAP (Zymed, San Francisco, CA)",Antibody target not in NF pathway/tumor biology gene list: GFAP
Ki-67,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,Ki-67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki-67 (BD Pharmingen, San Diego, CA) antibodies followed by Vectastain ABC development",Antibody target not in NF pathway/tumor biology gene list: Ki-67
α-tubulin,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,α-tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"α-tubulin (Sigma, St. Louis, MO) was employed for normalization and densitometric analysis",Generic reporter/tag/housekeeping antibody: α-tubulin
DDK tag,antibodies,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,0.33,Low,,,,DDK tag,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The expression of the DDK-tagged transcript was validated by Western blot using anti-DDK antibodies,Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
Merlin,antibodies,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,True,0.67,Medium,,,,Merlin,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-Merlin monoclonal antibody 4B5 was made by W. Ip,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
GFP,antibodies,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,0.33,Low,,,,GFP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Horseradish peroxidase (HRP) conjugated an antibody specific for GFP (cat. no. 600–103-215) was from Rockland,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
RFP,antibodies,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,0.33,Low,,,,RFP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,specific for RFP (cat no. ab34767) was from Abcam,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
YAP1,antibodies,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.85,Experimental Usage,False,0.33,Low,,,,YAP1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibody specific for YAP1 was from Cell Signaling Inc.,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
HA,antibodies,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,False,0.67,Low,,,,HA,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc)",Generic reporter/tag/housekeeping antibody: ha
HA,antibodies,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,False,0.67,Low,,,,HA,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc)",Generic reporter/tag/housekeeping antibody: ha
myc,antibodies,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.9,Experimental Usage,False,1.00,Medium,,,,myc,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc)",Antibody target not in NF pathway/tumor biology gene list: myc
V5,antibodies,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,False,0.67,Low,,,,V5,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Invitrogen (mouse anti-V5), Sigma-Aldrich (St. Louis, U.S.A.) (mouse and rabbit anti-FLAG)",Generic reporter/tag/housekeeping antibody: v5
FLAG,antibodies,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,False,0.67,Low,,,,FLAG,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Sigma-Aldrich (St. Louis, U.S.A.) (mouse and rabbit anti-FLAG), and LI-COR Biosciences",Generic reporter/tag/housekeeping antibody: flag
FLAG,antibodies,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,False,0.67,Low,,,,FLAG,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Sigma-Aldrich (St. Louis, U.S.A.) (mouse and rabbit anti-FLAG), and LI-COR Biosciences",Generic reporter/tag/housekeeping antibody: flag
rabbit,antibodies,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,False,0.67,Low,,,,rabbit,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"LI-COR Biosciences (Lincoln, U.S.A.) (goat anti-rabbit 680 nm and goat anti-mouse 800 nm conjugates)",Secondary antibody (not an NF-specific research tool)
mouse,antibodies,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,False,0.67,Low,,,,mouse,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"LI-COR Biosciences (Lincoln, U.S.A.) (goat anti-rabbit 680 nm and goat anti-mouse 800 nm conjugates)",Secondary antibody (not an NF-specific research tool)
phosphorylated ERK Thr202/Tyr204,antibodies,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,phosphorylated ERK Thr202/Tyr204,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)",Antibody target not in NF pathway/tumor biology gene list: phosphorylated ERK Thr202/Tyr204
phosphorylated Akt Ser473,antibodies,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,phosphorylated Akt Ser473,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)",Antibody target not in NF pathway/tumor biology gene list: phosphorylated Akt Ser473
phosphorylated S6 Ser235/236,antibodies,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,phosphorylated S6 Ser235/236,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)",Antibody target not in NF pathway/tumor biology gene list: phosphorylated S6 Ser235/236
γH2AX Ser139,antibodies,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,γH2AX Ser139,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Coverslips were permeabilized and probed with anti-γH2AX Ser139 antibody (Millipore), followed by anti-rabbit AlexaFluor 488 secondary antibody",Antibody target not in NF pathway/tumor biology gene list: γH2AX Ser139
rabbit IgG,antibodies,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.67,Low,,,,rabbit IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,followed by anti-rabbit AlexaFluor 488 secondary antibody (Molecular Probes),Secondary antibody (not an NF-specific research tool)
HIF-1α,antibodies,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,False,0.33,Low,,,,HIF-1α,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HIF-1α, BECLIN1, BIM, BCL-xL, β-tubulin, Ferritin HC and transferrin receptor-1 (TfR1/CD71; Santa Cruz Biotechnology Inc., Santa Cruz, CA)",Antibody target not in NF pathway/tumor biology gene list: HIF-1α
BNIP3,antibodies,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,False,0.33,Low,,,,BNIP3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"BNIP3 (Sigma, St. Louis, MO)",Antibody target not in NF pathway/tumor biology gene list: BNIP3
BECLIN1,antibodies,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,False,0.33,Low,,,,BECLIN1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HIF-1α, BECLIN1, BIM, BCL-xL, β-tubulin, Ferritin HC and transferrin receptor-1 (TfR1/CD71; Santa Cruz Biotechnology Inc., Santa Cruz, CA)",Antibody target not in NF pathway/tumor biology gene list: BECLIN1
LC3,antibodies,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,False,0.33,Low,,,,LC3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"LC3 (Abgent, San Diego, CA)",Antibody target not in NF pathway/tumor biology gene list: LC3
GAPDH,antibodies,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GAPDH, BCL-2 and PUMA (Cell Signaling, Danvers, MA)",Generic reporter/tag/housekeeping antibody: gapdh
p53,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,Experimental Usage,False,0.67,Low,,,,p53,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-p53 (NCL-p53-CM5p, 1:1000, Leica Biosystems)",Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
Ki67,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,Experimental Usage,False,1.00,Medium,,,,Ki67,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-Ki67 (550609, 1:500, BD Pharmingen)",Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
Olig2,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,Experimental Usage,False,0.67,Low,,,,Olig2,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-Olig2 (AB9610, 1:2000, EMD Millipore)",Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
Olig2,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,False,0.33,Low,,,,Olig2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Guinea pig anti-Olig2 (1:10000, a kind gift of home-made antibody from Dr. B. Novitch)",Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
GFAP,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,Experimental Usage,False,1.00,Medium,,,,GFAP,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-GFAP (556330, 1:2000, BD Pharmingen)",Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
Pten,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,Experimental Usage,False,0.67,Low,,,,Pten,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-Pten (9559S, 1:1000, Cell Signaling)",Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
p-S6,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,Experimental Usage,False,0.67,Low,,,,p-S6,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-p-S6 (5364S, 1:2000, Cell Signaling)",Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
BrdU,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,Experimental Usage,False,0.33,Low,,,,BrdU,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rat anti-BrdU (ab6326, 1:500, Abcam)",Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
p-Erk,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,Experimental Usage,False,0.67,Low,,,,p-Erk,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-p-Erk (9101S, 1:2000, Cell Signaling)",Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
PAX8,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,0.33,Low,,,,PAX8,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"PAX8 Proteintech, 10336-1-AP 1:2000 Overnight, RT Citrate buffer, pH 6.0",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
Ac-alpha-Tubulin,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,0.33,Low,,,,Ac-alpha-Tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Ac-alpha-Tubulin Santa Cruz, sc-23950 1:2000 Overnight, RT Citrate buffer, pH 6.0",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
KI67,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,0.33,Low,,,,KI67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"KI67 Monosan, MONX10283 1:2000 Overnight, RT Citrate buffer, pH 6.0",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
Cytokeratin-8,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,0.33,Low,,,,Cytokeratin-8,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cytokeratin-8 Santa Cruz, sc-101459 1:50 Overnight, RT Citrate buffer, pH 6.0",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
GFP,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,0.33,Low,,,,GFP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GFP Life Technologies, A11122 1:1000 Overnight, RT Citrate buffer, pH 6.0",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
Cleaved Caspase-3,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,0.33,Low,,,,Cleaved Caspase-3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cleaved Caspase-3 (D175) Cell Signaling Technology, #9661L 1:500 Overnight, RT Citrate buffer, pH 6.0",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
γH2A.X,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,1.00,Medium,,,,γH2A.X,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-γH2A.X primary antibody (1:500, Millipore, clone JBW301)",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
p53,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,0.33,Low,,,,p53,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"probed with antibodies directed against p53 (sc-6243, 1:250, Santa Cruz Biotechnology)",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
GAPDH,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GAPDH (LN2100751, 1:1000, Labned)",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
ABCC1,antibodies,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.95,Experimental Usage,False,0.33,Low,,,,ABCC1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,incubated in primary antibodies against ABCC1 (Abcam ab24102) and S100 (Dako Z0311) at 1:50 and 1:400 dilution,Antibody target not in NF pathway/tumor biology gene list: ABCC1
S100,antibodies,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.95,Experimental Usage,False,0.33,Low,,,,S100,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,incubated in primary antibodies against ABCC1 (Abcam ab24102) and S100 (Dako Z0311) at 1:50 and 1:400 dilution,Antibody target not in NF pathway/tumor biology gene list: S100
GFP,antibodies,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,Experimental Usage,False,0.67,Low,,,,GFP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies used in this study: Rabbit anti-GFP, Thermo Fisher, Cat. # A6455 (1/1000)",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
mCherry,antibodies,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,Experimental Usage,False,0.67,Low,,,,mCherry,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse anti-mCherry, Abcam, Cat. # ab125096 (1:500)",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
glutamine synthetase,antibodies,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,Experimental Usage,False,1.00,Medium,,,,glutamine synthetase,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-glutamine synthetase (GS), Sigma-Aldrich, Cat. #MAB302 (1/500)",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
Mouse IgG,antibodies,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,Experimental Usage,False,0.67,Low,,,,Mouse IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"Alexa Flour 555 Donkey anti Mouse-IgG (H+L), Thermo Fisher Cat. # A31570 (1:500)",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
Rabbit IgG,antibodies,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,Experimental Usage,False,0.67,Low,,,,Rabbit IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"Alexa flour 555 Donkey anti Rabbit IgG (H+L), Thermo Fisher, Cat # A31572 (1:500)",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
Mouse IgG,antibodies,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,Experimental Usage,False,0.67,Low,,,,Mouse IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,Alexa Flour 488 donkey anti mouse Thermo Fisher Cat. # A21202 (1:500),Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
Rabbit IgG,antibodies,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,Experimental Usage,False,0.67,Low,,,,Rabbit IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,Alexa Flour 488 goat anti rabbit Thermo Fisher Cat. # A11008 (1:500),Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
β-actin,antibodies,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.9,Experimental Usage,False,1.00,Medium,,,,β-actin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies used in western blot analysis were: mouse anti-β-actin, mouse anti-α-tubulin, and mouse anti-α-smooth muscle actin (α-SMA), all from Sigma-Aldrich",Generic reporter/tag/housekeeping antibody: β-actin
NHE1,antibodies,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.9,Experimental Usage,False,1.00,Medium,,,,NHE1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-NHE1 (clone 54), anti-Poly-ADP Ribose Polymerase (PARP), anti-cleaved PARP (Asp214) and anti-pSer807/811-Rb, all from Santa Cruz Biotechnology",Antibody target not in NF pathway/tumor biology gene list: NHE1
ERBB3 Y1197,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,ERBB3 Y1197,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing ERRB3 Y1197, ERBB3, EPHA2 S897... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: ERBB3 Y1197
ERBB3,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,ERBB3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing ERRB3 Y1197, ERBB3, EPHA2 S897... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: ERBB3
EPHA2 S897,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,EPHA2 S897,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing ERRB3 Y1197, ERBB3, EPHA2 S897... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: EPHA2 S897
NDRG1 T346,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,NDRG1 T346,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... NDRG1 T346, Akt S473... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: NDRG1 T346
Akt S473,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,Akt S473,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... NDRG1 T346, Akt S473, Akt T308... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: Akt S473
Akt T308,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,Akt T308,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... Akt S473, Akt T308, Akt... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: Akt T308
Akt,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,Akt,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... Akt T308, Akt, p70S6K T389... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: Akt
p70S6K T389,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,p70S6K T389,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... Akt, p70S6K T389, p70S6K... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: p70S6K T389
p70S6K,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,p70S6K,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... p70S6K T389, p70S6K, ribosomal S6 S240/244... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: p70S6K
ribosomal S6 S240/244,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,ribosomal S6 S240/244,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... p70S6K, ribosomal S6 S240/244, S6... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: ribosomal S6 S240/244
S6,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,S6,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... ribosomal S6 S240/244, S6, IGF1R Y1135/36/IR Y1150/51... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: S6
IGF1R Y1135/36/IR Y1150/51,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,IGF1R Y1135/36/IR Y1150/51,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... S6, IGF1R Y1135/36/IR Y1150/51, IGF1R... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: IGF1R Y1135/36/IR Y1150/51
IGF1R,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,IGF1R,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... IGF1R Y1135/36/IR Y1150/51, IGF1R, FOXO1/3a T24/T32... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: IGF1R
FOXO1/3a T24/T32,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,FOXO1/3a T24/T32,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... IGF1R, FOXO1/3a T24/T32, and FOXO3 were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: FOXO1/3a T24/T32
FOXO3,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,FOXO3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... FOXO1/3a T24/T32, and FOXO3 were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: FOXO3
EPHA2,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,EPHA2,,,,,,,,,,,,,,,,,,,,,,,,,,,,Other antibodies included EPHA2 (Santa Cruz),Antibody target not in NF pathway/tumor biology gene list: EPHA2
secreted form of NRG1,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,secreted form of NRG1,,,,,,,,,,,,,,,,,,,,,,,,,,,,Other antibodies included... secreted form of NRG1 (R&D Systems),Antibody target not in NF pathway/tumor biology gene list: secreted form of NRG1
NDRG1,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,NDRG1,,,,,,,,,,,,,,,,,,,,,,,,,,,,Other antibodies included... NDRG1 (Abcam),Antibody target not in NF pathway/tumor biology gene list: NDRG1
GAPDH,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,GAPDH,,,,,,,,,,,,,,,,,,,,,,,,,,,,Other antibodies included... and GAPDH (EMD Millipore),Generic reporter/tag/housekeeping antibody: gapdh
STING,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,STING,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"STING (13647S, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: STING
TBK1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,TBK1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"TBK1 (3504T, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: TBK1
p-TBK1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,p-TBK1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-TBK1 (s172) (5483T, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: p-TBK1
IRF3,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,IRF3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"IRF3 (MA5-32348, Invitrogen, Thermo Fisher Scientific)",Antibody target not in NF pathway/tumor biology gene list: IRF3
p-IRF3,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,p-IRF3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-IRF3 (4947S, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: p-IRF3
NF-κB,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,NF-κB,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"NF-κB (ab16502, Abcam)",Antibody target not in NF pathway/tumor biology gene list: NF-κB
p-NF-κB,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,p-NF-κB,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p–NF-κB (3033S, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: p-NF-κB
PD-L1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,PD-L1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"PD-L1 (ab213480, Abcam, 66248-1-Ig, Proteintech)",Antibody target not in NF pathway/tumor biology gene list: PD-L1
GAPDH,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GAPDH (SC-32233, Santa Cruz Biotechnology)",Generic reporter/tag/housekeeping antibody: gapdh
vinculin,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,vinculin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"vinculin (4650S, Cell Signaling Technology)",Generic reporter/tag/housekeeping antibody: vinculin
Foxp3,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,Foxp3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Foxp3 (ab215206, Abcam)",Antibody target not in NF pathway/tumor biology gene list: Foxp3
CTLA-4,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.67,Low,,,,CTLA-4,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"CTLA-4 (BE0164, Bio X Cell)",Antibody target not in NF pathway/tumor biology gene list: CTLA-4
CD20,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,CD20,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD20 (BS-0080R, Bioss)",Antibody target not in NF pathway/tumor biology gene list: CD20
CD3,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,CD3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD3 (ab16669, Abcam)",Antibody target not in NF pathway/tumor biology gene list: CD3
CD4,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,CD4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD4 (ab183685, Abcam)",Antibody target not in NF pathway/tumor biology gene list: CD4
CD8α,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.85,Experimental Usage,False,0.33,Low,,,,CD8α,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD8α (PA5-81344),Antibody target not in NF pathway/tumor biology gene list: CD8α
Iba1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,Iba1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Iba1 (019-19741, Thermo Fisher Scientific)",Antibody target not in NF pathway/tumor biology gene list: Iba1
iNOS,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,iNOS,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"iNOS (ab15323, Abcam)",Antibody target not in NF pathway/tumor biology gene list: iNOS
mannose receptor,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,mannose receptor,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"mannose receptor (ab64693, Abcam)",Antibody target not in NF pathway/tumor biology gene list: mannose receptor
p-H3,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,p-H3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-H3 (ser10) (9701s, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: p-H3
cleaved caspase 3,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,cleaved caspase 3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cleaved caspase 3 (9661S, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: cleaved caspase 3
cleaved PARP,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,cleaved PARP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cleaved PARP (9488S, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: cleaved PARP
PD-1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,PD-1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti–PD-1 (ab214421, Abcam; 66220-1-Ig, Proteintech) antibodies",Antibody target not in NF pathway/tumor biology gene list: PD-1
PD-1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,1.00,Medium,,,,PD-1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"250 μg mouse monoclonal anti–PD-1 antibody (BE0146, Bio X Cell)",Antibody target not in NF pathway/tumor biology gene list: PD-1
PD-L1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,1.00,Medium,,,,PD-L1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"100 μg mouse monoclonal anti–PD-L1 antibody (BE0146, Bio X Cell)",Antibody target not in NF pathway/tumor biology gene list: PD-L1
CTLA-4,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,1.00,Medium,,,,CTLA-4,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"300 μg mouse monoclonal anti–CTLA-4 antibody (BE0164, Bio X Cell)",Antibody target not in NF pathway/tumor biology gene list: CTLA-4
CD3,antibodies,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,Experimental Usage,False,0.67,Low,,,,CD3,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-mCD3 (145–2C11) and anti-mIL6 receptor (15A7) antibodies were purchased from BioXcell.,Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
IL6 receptor,antibodies,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,Experimental Usage,False,0.67,Low,,,,IL6 receptor,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-mCD3 (145–2C11) and anti-mIL6 receptor (15A7) antibodies were purchased from BioXcell.,Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
TNFα,antibodies,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,Experimental Usage,False,0.33,Low,,,,TNFα,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-mTNFα antibody (R023) was purchased from Sino Biological,Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
IL3,antibodies,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,Experimental Usage,False,0.67,Low,,,,IL3,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,anti-mIL3 antibody (MP2–8F8) was purchased from BD Biosciences.,Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
CD11b,antibodies,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,Experimental Usage,False,0.33,Low,,,,CD11b,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibody, anti-CD11b (1:8000 dilution; catalogue number ab133357, Abcam) was applied at 36 °C for 40 min.",Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
phospho-ERK1/2,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,False,1.00,Medium,,,,phospho-ERK1/2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-phospho-ERK1/2 (p44/42 MAPK) (Thr202/Tyr204) antibody (#9101),Antibody target not in NF pathway/tumor biology gene list: phospho-ERK1/2
ERK1/2,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,False,1.00,Medium,,,,ERK1/2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,anti-ERK1/2 (p44/42 MAPK) antibody (#9102),Antibody target not in NF pathway/tumor biology gene list: ERK1/2
GFP,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,False,1.00,Medium,,,,GFP,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-GFP antibody (#2555) were purchased from Cell Signaling Technologies,Generic reporter/tag/housekeeping antibody: gfp
GFP,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,False,0.67,Low,,,,GFP,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Goat anti-GFP antibody (600-101-215) was purchased from Rockland Immunochemicals,Generic reporter/tag/housekeeping antibody: gfp
βIII-tubulin,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,False,1.00,Medium,,,,βIII-tubulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,The mouse anti-βIII-tubulin antibody Tuj1 was obtained from R&D system,Antibody target not in NF pathway/tumor biology gene list: βIII-tubulin
NGFR,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,False,1.00,Medium,,,,NGFR,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-NGFR (p75) antibody (AB-N07) was purchased from Advanced Targeting System,Antibody target not in NF pathway/tumor biology gene list: NGFR
S100B,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,False,1.00,Medium,,,,S100B,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-S100B antibody (Z0311) was purchased from DAKO,Antibody target not in NF pathway/tumor biology gene list: S100B
βActin,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,False,1.00,Medium,,,,βActin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"The anti-βActin (C-11, SC-1615HRP) HRP antibody was purchased from Santa Cruz Biotechnology",Antibody target not in NF pathway/tumor biology gene list: βActin
HA,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,False,1.00,Medium,,,,HA,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-HA antibody (26183) was purchased from Invitrogen,Generic reporter/tag/housekeeping antibody: ha
Human Nuclear Antigen,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,False,1.00,Medium,,,,Human Nuclear Antigen,Rabbit,Recombinant,,,,,,,,,,,,,,,,,,,,,,,,,,Human Nuclear Antigen (HNA) recombinant rabbit Monoclonal Antibody (235-1 R) was purchased from ThermoFisher,Generic reporter/tag/housekeeping antibody: human nuclear antigen
actin,antibodies,PMID:34945792,10.3390/jpm11121320,Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C.,,0.9,Experimental Usage,False,0.33,Low,,,,actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,actin (Cell Signaling cat# 4967 1:1000),Generic reporter/tag/housekeeping antibody: actin
p-ERK,antibodies,PMID:34945792,10.3390/jpm11121320,Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C.,,0.9,Experimental Usage,False,0.33,Low,,,,p-ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,p-ERK (Cell Signaling cat# 9101 1:1000),Antibody target not in NF pathway/tumor biology gene list: p-ERK
ERK,antibodies,PMID:34945792,10.3390/jpm11121320,Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C.,,0.9,Experimental Usage,False,0.33,Low,,,,ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,total ERK (Cell Signaling cat# 9102 1:1000),Antibody target not in NF pathway/tumor biology gene list: ERK
p-AKT,antibodies,PMID:34945792,10.3390/jpm11121320,Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C.,,0.9,Experimental Usage,False,0.33,Low,,,,p-AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,p-AKT (Cell Signaling cat# 4060L 1:1000),Antibody target not in NF pathway/tumor biology gene list: p-AKT
AKT,antibodies,PMID:34945792,10.3390/jpm11121320,Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C.,,0.9,Experimental Usage,False,0.33,Low,,,,AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,total AKT (Cell Signaling cat# 4691L 1:1000),Antibody target not in NF pathway/tumor biology gene list: AKT
pS6,antibodies,PMID:34945792,10.3390/jpm11121320,Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C.,,0.9,Experimental Usage,False,0.33,Low,,,,pS6,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,pS6 (Cell Signaling cat# 2215S 1:1000),Antibody target not in NF pathway/tumor biology gene list: pS6
S6,antibodies,PMID:34945792,10.3390/jpm11121320,Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C.,,0.9,Experimental Usage,False,0.33,Low,,,,S6,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,total S6 (Cell Signaling cat# 2217L 1:1000),Antibody target not in NF pathway/tumor biology gene list: S6
phospho-ERK,antibodies,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,phospho-ERK,Mouse,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐phospho‐ERK (mouse, Sigma M8159, 1 : 2500)",Antibody target not in NF pathway/tumor biology gene list: phospho-ERK
ERK,antibodies,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,ERK,Rabbit,,,,,,,,,,,,,,,,,,,,,,,,,,,"total ERK (rabbit, CST 9102, Danvers, MA USA, 1 : 1000)",Antibody target not in NF pathway/tumor biology gene list: ERK
β-tubulin,antibodies,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,β-tubulin,Mouse,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐β‐tubulin (mouse, Developmental Studies Hybridoma Bank E7, Iowa City, IA USA, 1 : 10 000)",Generic reporter/tag/housekeeping antibody: β-tubulin
GAPDH,antibodies,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,GAPDH,Rabbit,,,,,,,,,,,,,,,,,,,,,,,,,,,"GAPDH (rabbit, Proteintech 10 494‐1‐AP, San Diego, CA USA, 1 : 15 000)",Generic reporter/tag/housekeeping antibody: gapdh
PARP,antibodies,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,PARP,Rabbit,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐PARP (rabbit, Cell Signaling 952, 1 : 1000)",Antibody target not in NF pathway/tumor biology gene list: PARP
LC3B,antibodies,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,LC3B,Rabbit,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐LC3B (rabbit, Cell Signaling 2775, 1 : 1000; CST Danvers, MA USA)",Antibody target not in NF pathway/tumor biology gene list: LC3B
p44/42 MAPK (ERK1/2),antibodies,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,False,0.67,Low,,,,p44/42 MAPK (ERK1/2),Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs",Antibody target not in NF pathway/tumor biology gene list: p44/42 MAPK (ERK1/2)
p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2),antibodies,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,False,0.67,Low,,,,p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2),Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs",Antibody target not in NF pathway/tumor biology gene list: p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2)
phosphatidylinositol 3-kinase (PI3K),antibodies,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,False,0.67,Low,,,,phosphatidylinositol 3-kinase (PI3K),Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs",Antibody target not in NF pathway/tumor biology gene list: phosphatidylinositol 3-kinase (PI3K)
rabbit IgG,antibodies,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,rabbit IgG,,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs",Secondary antibody (not an NF-specific research tool)
ATRX,antibodies,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,Experimental Usage,False,0.33,Low,,,,ATRX,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Primary ATRX antibody was from Sigma-Aldrich (HPA001906) and was used at 1:200 dilution,Antibody target not in NF pathway/tumor biology gene list: ATRX
CD3,antibodies,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,Experimental Usage,False,0.33,Low,,,,CD3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies were incubated at 4 °C overnight: CD3 (Dako, A0452, 1:200)",Antibody target not in NF pathway/tumor biology gene list: CD3
CD8,antibodies,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,Experimental Usage,False,0.67,Low,,,,CD8,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"CD8 (Leica NCL-L-CD8–4B11, 1:200)",Antibody target not in NF pathway/tumor biology gene list: CD8
GZMB,antibodies,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,Experimental Usage,False,0.33,Low,,,,GZMB,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GZMB (Leica, PA0291, ready to use)",Antibody target not in NF pathway/tumor biology gene list: GZMB
CD20,antibodies,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,Experimental Usage,False,0.67,Low,,,,CD20,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"CD20 (Leica, NCL-L-CD20-L26, 1:200)",Antibody target not in NF pathway/tumor biology gene list: CD20
CD68,antibodies,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,Experimental Usage,False,0.33,Low,,,,CD68,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD68 (Sigma, HPA048982, 1:2,000)",Antibody target not in NF pathway/tumor biology gene list: CD68
S100,antibodies,PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,0.85,Experimental Usage,False,0.33,Low,,,,S100,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"S100 (1:400, Dako, Glostrun Denman, Carpinteria, CA) was visualized using fluorescent immunohistochemistry",Antibody target not in NF pathway/tumor biology gene list: S100
"indoleamine 2,3-dioxygenase",antibodies,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,Experimental Usage,False,1.00,Medium,,,,"indoleamine 2,3-dioxygenase",Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"The slides were incubated in their prospective antibodies for 30 min: indoleamine 2,3-dioxygenase rabbit monoclonal (1:100, Abcam, Cambridge, UK)","Antibody target not in NF pathway/tumor biology gene list: indoleamine 2,3-dioxygenase"
AHR,antibodies,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,Experimental Usage,False,1.00,Medium,,,,AHR,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"AHR antibody mouse monoclonal (1:50, Santa Cruz, Dallas, TX, USA)",Antibody target not in NF pathway/tumor biology gene list: AHR
TDO2,antibodies,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,Experimental Usage,False,1.00,Medium,,,,TDO2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"antibody-TDO2, rabbit/IgG polyclonal (1:100, Proteintech, Rosemont, IL, USA)",Antibody target not in NF pathway/tumor biology gene list: TDO2
HDAC1,antibodies,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,False,0.33,Low,,,,HDAC1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: HDAC1
PDLIM2,antibodies,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,False,0.33,Low,,,,PDLIM2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: PDLIM2
PDLIM2,antibodies,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,False,0.33,Low,,,,PDLIM2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,PDLIM2 (1:500) from Santa Cruz Biotechnology and GAPDH (1:50.000) from Millipore,Antibody target not in NF pathway/tumor biology gene list: PDLIM2
GAPDH,antibodies,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,PDLIM2 (1:500) from Santa Cruz Biotechnology and GAPDH (1:50.000) from Millipore,Generic reporter/tag/housekeeping antibody: gapdh
EMA,antibodies,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.85,Experimental Usage,False,0.33,Low,,,,EMA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam.",Antibody target not in NF pathway/tumor biology gene list: EMA
vimentin,antibodies,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.85,Experimental Usage,False,0.33,Low,,,,vimentin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam.",Antibody target not in NF pathway/tumor biology gene list: vimentin
Ki-67,antibodies,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.85,Experimental Usage,False,0.33,Low,,,,Ki-67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam.",Antibody target not in NF pathway/tumor biology gene list: Ki-67
CD31,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,False,0.33,Low,,,,CD31,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD31 (ab28364, 1:50, Abcam) and AXL (ab227871, 1:500, Abcam)",Antibody target not in NF pathway/tumor biology gene list: CD31
AXL,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,False,0.33,Low,,,,AXL,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD31 (ab28364, 1:50, Abcam) and AXL (ab227871, 1:500, Abcam)",Antibody target not in NF pathway/tumor biology gene list: AXL
pAXL,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,False,0.33,Low,,,,pAXL,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pAXL (Cat#5724, 1:1000, Cell Signaling Technology), AXL (Cat#ab215205, 1:1000, Abcam)",Antibody target not in NF pathway/tumor biology gene list: pAXL
AXL,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,False,0.33,Low,,,,AXL,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pAXL (Cat#5724, 1:1000, Cell Signaling Technology), AXL (Cat#ab215205, 1:1000, Abcam)",Antibody target not in NF pathway/tumor biology gene list: AXL
pAKT,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,False,0.33,Low,,,,pAKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pAKT (Cat #9271, 1:1000, Cell Signaling Technology), pGSK-3β (Cat#9323, 1:1000, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: pAKT
pGSK-3β,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,False,0.33,Low,,,,pGSK-3β,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pAKT (Cat #9271, 1:1000, Cell Signaling Technology), pGSK-3β (Cat#9323, 1:1000, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: pGSK-3β
pMEK1/2,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,False,0.33,Low,,,,pMEK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pMEK1/2 (Cat#9121, 1:1000, Cell Signaling Technology), and GAPDH (#CST-5174, 1:1000, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: pMEK1/2
GAPDH,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pMEK1/2 (Cat#9121, 1:1000, Cell Signaling Technology), and GAPDH (#CST-5174, 1:1000, Cell Signaling Technology)",Generic reporter/tag/housekeeping antibody: gapdh
CalbindinD-28K,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,CalbindinD-28K,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-CalbindinD-28K (rabbit polyclonal, 1:2000 Swant CB-38a, Marly, Switzerland",Antibody target not in NF pathway/tumor biology gene list: CalbindinD-28K
CalbindinD-28K,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,CalbindinD-28K,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse monoclonal 1:1000 Sigma-Aldrich (clone CB-955), Munich, Germany",Antibody target not in NF pathway/tumor biology gene list: CalbindinD-28K
Olig2,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,Olig2,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-Olig2 (mouse monoclonal antibody, 1:500; Millipore (AB9610), Darmstadt, Germany)",Antibody target not in NF pathway/tumor biology gene list: Olig2
MBP,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,MBP,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-MBP (mouse monoclonal antibody, 1:500; Chemikon (MAB384), Schwalbach, Germany)",Antibody target not in NF pathway/tumor biology gene list: MBP
GFP,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,0.33,Low,,,,GFP,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-GFP (A11122, 1:500, Thermo Fisher, Schwerte, Germany)",Generic reporter/tag/housekeeping antibody: gfp
Ki67,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,0.33,Low,,,,Ki67,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti Ki67 (15580, 1:500, Abcam, Cambridge, UK)",Antibody target not in NF pathway/tumor biology gene list: Ki67
phospho-Histone H3,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-Histone H3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti phospho-Histone H3 (pH3-Ser10, 06–570, 1:1000, Millipore, Darmstadt, Germany)",Antibody target not in NF pathway/tumor biology gene list: phospho-Histone H3
cyclophilin B,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,0.33,Low,,,,cyclophilin B,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-phospho S518-Merlin 1:1000, and anti-cyclophilin B 1:4000, Abcam, Cambridge, UK",Antibody target not in NF pathway/tumor biology gene list: cyclophilin B
MAF,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,0.33,Low,,,,MAF,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)",Antibody target not in NF pathway/tumor biology gene list: MAF
pS6,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,0.33,Low,,,,pS6,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)",Antibody target not in NF pathway/tumor biology gene list: pS6
pERK,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,0.33,Low,,,,pERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)",Antibody target not in NF pathway/tumor biology gene list: pERK
DEPTOR,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,0.33,Low,,,,DEPTOR,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)",Antibody target not in NF pathway/tumor biology gene list: DEPTOR
SOX9,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,0.33,Low,,,,SOX9,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Membranes were probed with antibodies for MAF (Imgenex), SOX9 (Santa Cruz), S100β (Dako)",Antibody target not in NF pathway/tumor biology gene list: SOX9
S100β,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,0.33,Low,,,,S100β,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore)",Antibody target not in NF pathway/tumor biology gene list: S100β
MBP,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,0.33,Low,,,,MBP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore)",Antibody target not in NF pathway/tumor biology gene list: MBP
BLBP,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,0.33,Low,,,,BLBP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore)",Antibody target not in NF pathway/tumor biology gene list: BLBP
cleaved-caspase 3,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,0.33,Low,,,,cleaved-caspase 3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Membranes were probed with antibodies for MAF (Imgenex), SOX9 (Santa Cruz), S100β (Dako), MBP (Chemicon), BLBP (Millipore), DEPTOR (Novus), cleaved-caspase 3",Antibody target not in NF pathway/tumor biology gene list: cleaved-caspase 3
β-ACTIN,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,0.33,Low,,,,β-ACTIN,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p473AKT, AKT, and β-ACTIN (Cell Signaling) as a loading control",Generic reporter/tag/housekeeping antibody: β-actin
S100,antibodies,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,Experimental Usage,False,0.33,Low,,,,S100,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Immunohistochemical analysis showed scattered S100 positivity in tumor cell nuclei,Antibody target not in NF pathway/tumor biology gene list: S100
CD34,antibodies,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,Experimental Usage,False,0.33,Low,,,,CD34,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,strong and diffuse CD34 positivity in the tumor cell cytoplasm,Antibody target not in NF pathway/tumor biology gene list: CD34
RHAMM,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,0.33,Low,,,,RHAMM,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies were sourced as follows: RHAMM (Epitomics),Antibody target not in NF pathway/tumor biology gene list: RHAMM
TPX2,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,0.33,Low,,,,TPX2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,TPX2 (Novus),Antibody target not in NF pathway/tumor biology gene list: TPX2
nestin,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,0.33,Low,,,,nestin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,nestin (Covance),Antibody target not in NF pathway/tumor biology gene list: nestin
Tuj1,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,0.33,Low,,,,Tuj1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Tuj1 (Covance),Antibody target not in NF pathway/tumor biology gene list: Tuj1
β-actin,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,0.33,Low,,,,β-actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,β-actin (Sigma),Generic reporter/tag/housekeeping antibody: β-actin
AURKA,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,0.33,Low,,,,AURKA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AURKA, phospho (p)-AURKA (Thr288), p-histone H3 (Ser10), and caspase 9 (Cell Signalling)",Antibody target not in NF pathway/tumor biology gene list: AURKA
phospho-AURKA (Thr288),antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,0.33,Low,,,,phospho-AURKA (Thr288),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,phospho (p)-AURKA (Thr288),Antibody target not in NF pathway/tumor biology gene list: phospho-AURKA (Thr288)
p-histone H3 (Ser10),antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,0.33,Low,,,,p-histone H3 (Ser10),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,p-histone H3 (Ser10),Antibody target not in NF pathway/tumor biology gene list: p-histone H3 (Ser10)
caspase 9,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,0.33,Low,,,,caspase 9,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,caspase 9 (Cell Signalling),Antibody target not in NF pathway/tumor biology gene list: caspase 9
p-RHAMM (Thr703),antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.9,Experimental Usage,False,0.67,Low,,,,p-RHAMM (Thr703),Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,The p-RHAMM (Thr703) polyclonal antibody is characterized in [11],Antibody target not in NF pathway/tumor biology gene list: p-RHAMM (Thr703)
PDGFRβ,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,PDGFRβ,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"we used antibodies to PDGFRβ (rabbit; Abcam, ab32570), α-SMA (mouse; Sigma-Aldrich, clone 1A4, A2547)",Antibody target not in NF pathway/tumor biology gene list: PDGFRβ
α-SMA,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,1.00,Medium,,,,α-SMA,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"α-SMA (mouse; Sigma-Aldrich, clone 1A4, A2547), IBA1 (rabbit; Wako Chemicals, 019-19741)",Antibody target not in NF pathway/tumor biology gene list: α-SMA
IBA1,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,IBA1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"IBA1 (rabbit; Wako Chemicals, 019-19741), CD3 (rat; Bio-Rad, MCA1477)",Antibody target not in NF pathway/tumor biology gene list: IBA1
CD3,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.33,Low,,,,CD3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD3 (rat; Bio-Rad, MCA1477), GLUT1 (rabbit; Abcam, ab652)",Antibody target not in NF pathway/tumor biology gene list: CD3
GLUT1,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,GLUT1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GLUT1 (rabbit; Abcam, ab652), cleaved caspase-3 (rabbit; Cell Signaling Technology, #9661)",Antibody target not in NF pathway/tumor biology gene list: GLUT1
cleaved caspase-3,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,cleaved caspase-3,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cleaved caspase-3 (rabbit; Cell Signaling Technology, #9661), BrdU (rat; Abcam, ab6326)",Antibody target not in NF pathway/tumor biology gene list: cleaved caspase-3
BrdU,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.33,Low,,,,BrdU,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"BrdU (rat; Abcam, ab6326), VEGFA (rabbit; ABclonal, A0280)",Generic reporter/tag/housekeeping antibody: brdu
VEGFA,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,VEGFA,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"VEGFA (rabbit; ABclonal, A0280), ALDH1A1 (rabbit; Proteintech, 15910-1-AP)",Antibody target not in NF pathway/tumor biology gene list: VEGFA
ALDH1A1,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,ALDH1A1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ALDH1A1 (rabbit; Proteintech, 15910-1-AP), ZEB1 (rabbit; ABclonal, A5600)",Antibody target not in NF pathway/tumor biology gene list: ALDH1A1
ZEB1,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,ZEB1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ZEB1 (rabbit; ABclonal, A5600), IGFBP2 (rabbit; Cell Signaling Technology, #3922)",Antibody target not in NF pathway/tumor biology gene list: ZEB1
IGFBP2,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,IGFBP2,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"IGFBP2 (rabbit; Cell Signaling Technology, #3922), Nestin (mouse; Millipore, MAB353)",Antibody target not in NF pathway/tumor biology gene list: IGFBP2
Nestin,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,1.00,Medium,,,,Nestin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Nestin (mouse; Millipore, MAB353), EYA4 (rabbit; Thermo Fisher Scientific, PA5-52113)",Antibody target not in NF pathway/tumor biology gene list: Nestin
EYA4,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,EYA4,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"EYA4 (rabbit; Thermo Fisher Scientific, PA5-52113), SOX2 (goat; Santa Cruz Biotechnology, sc-17320)",Antibody target not in NF pathway/tumor biology gene list: EYA4
SOX2,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.33,Low,,,,SOX2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"SOX2 (goat; Santa Cruz Biotechnology, sc-17320), and YAP/TAZ (rabbit; Cell Signaling Technology, #8418)",Antibody target not in NF pathway/tumor biology gene list: SOX2
YAP/TAZ,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,YAP/TAZ,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"YAP/TAZ (rabbit; Cell Signaling Technology, #8418). Secondary antibodies conjugated to Alexa Fluor 488",Antibody target not in NF pathway/tumor biology gene list: YAP/TAZ
GAP43,antibodies,PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.9,Experimental Usage,False,0.67,Low,,,,GAP43,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GAP43 (rabbit, 1:1000, Abcam)",Antibody target not in NF pathway/tumor biology gene list: GAP43
S100β,antibodies,PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.9,Experimental Usage,False,0.67,Low,,,,S100β,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"S100β (rabbit, 1:5000, DAKO)",Antibody target not in NF pathway/tumor biology gene list: S100β
p75 NGFR,antibodies,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.33,Low,,,,p75 NGFR,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Schwann cells were isolated from contaminating fibroblasts via p75 NGFR antibody-mediated magnetic cell selection,Antibody target not in NF pathway/tumor biology gene list: p75 NGFR
Ki67,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,False,1.00,Medium,,,,Ki67,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"using mouse anti-Ki67 (1:2,000, BD Biosciences 556003 lot 8239549)",Antibody target not in NF pathway/tumor biology gene list: Ki67
CD8,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD8,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-CD8 (1:500, Cell Signaling Technology 98941T lot 5)",Antibody target not in NF pathway/tumor biology gene list: CD8
PDGFRα,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,PDGFRα,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"goat anti-PDGFRα (1:2,000, R&D Systems AF1062 RRID: AB_2236897)",Antibody target not in NF pathway/tumor biology gene list: PDGFRα
S100β,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,S100β,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-S100β (1:2,000, Abcam ab52642 lot GR3215095-1)",Antibody target not in NF pathway/tumor biology gene list: S100β
IBA1,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,IBA1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-IBA1 (1:1,000, Abcam ab178846 lot GR3185035-4)",Antibody target not in NF pathway/tumor biology gene list: IBA1
BRN3A,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,False,1.00,Medium,,,,BRN3A,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-BRN3A (1:200, Santa Cruz Biotechnology sc-8429 lot H1718)",Antibody target not in NF pathway/tumor biology gene list: BRN3A
NLGN3,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,NLGN3,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-NLGN3, 1:500, Novus NBP1-90080 lot B118108",Antibody target not in NF pathway/tumor biology gene list: NLGN3
β-actin,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,β-actin,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-β-actin, 1:10,000, Cell Signaling 4970 lot 15",Generic reporter/tag/housekeeping antibody: β-actin
ADAM10,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,ADAM10,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-ADAM10, 1:250, Abcam ab124695 lot GR3244660-5",Antibody target not in NF pathway/tumor biology gene list: ADAM10
cleaved caspase-3,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,False,1.00,Medium,,,,cleaved caspase-3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-cleaved caspase-3, 1:500, R&D Systems MAB835 lot KHK051810A",Antibody target not in NF pathway/tumor biology gene list: cleaved caspase-3
caspase-3,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,caspase-3,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-caspase-3, 1:1,000, Cell Signaling 9662 lot 19",Antibody target not in NF pathway/tumor biology gene list: caspase-3
tau 1,antibodies,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,Experimental Usage,False,0.33,Low,,,,tau 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Additionally, axons were identified by immunolabeling with tau 1 antibodies (not shown)",Antibody target not in NF pathway/tumor biology gene list: tau 1
B-Actin,antibodies,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,False,0.33,Low,,,,B-Actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies for B-Actin(1:1000, Cat #8457S, Cell Signaling Technologies)",Generic reporter/tag/housekeeping antibody: b-actin
Vinculin,antibodies,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,False,0.33,Low,,,,Vinculin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Vinculin(1:30000, Cat #V9264, Sigma Aldrich)",Generic reporter/tag/housekeeping antibody: vinculin
PTCH1,antibodies,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,False,0.33,Low,,,,PTCH1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"PTCH1(1:500,Cat#MAB41051, R&D systems)",Antibody target not in NF pathway/tumor biology gene list: PTCH1
APC,antibodies,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,False,0.33,Low,,,,APC,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"APC(1:500, Cat #15270, Abcam)",Antibody target not in NF pathway/tumor biology gene list: APC
Tuj-1,antibodies,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,Experimental Usage,False,0.33,Low,,,,Tuj-1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte)",Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
O4,antibodies,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,Experimental Usage,False,0.33,Low,,,,O4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte)",Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
GFAP,antibodies,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,Experimental Usage,False,0.33,Low,,,,GFAP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte)",Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
β-catenin,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,False,0.33,Low,,,,β-catenin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Sections were then incubated overnight at 4°C in a humidified chamber with primary antibody (β-catenin, 1:100, Cell Signaling)","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
activated β-catenin,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,False,0.33,Low,,,,activated β-catenin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
β-catenin,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,False,0.33,Low,,,,β-catenin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
GSK3B,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,False,0.33,Low,,,,GSK3B,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
AXIN1,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,False,0.33,Low,,,,AXIN1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
GAPDH,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
CCND1,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,False,0.67,Low,,,,CCND1,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemistry for CCND1 (SP4) monoclonal antibody (Neomarkers, Thermo Scientific, 1:50) and β-catenin (6B3) monoclonal antibody (Cell Signaling; 1:200)","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
β-catenin,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,False,0.67,Low,,,,β-catenin,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemistry for CCND1 (SP4) monoclonal antibody (Neomarkers, Thermo Scientific, 1:50) and β-catenin (6B3) monoclonal antibody (Cell Signaling; 1:200)","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
HK2,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,False,0.67,Low,,,,HK2,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"primary goat polyclonal anti‐HK2 (sc‐6521, Santa Cruz) and rabbit monoclonal anti‐MPP2",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
MPP2,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,False,1.00,Medium,,,,MPP2,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit monoclonal anti‐MPP2 (ab92536, Abcam) antibodies",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
GAPDH,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐GAPDH (#2118, Cell Signaling), ATP5A (ab14748, Abcam)",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
ATP5A,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,False,0.33,Low,,,,ATP5A,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ATP5A (ab14748, Abcam), anti‐UQCRC2 (ab14745, Abcam)",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
UQCRC2,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,False,0.33,Low,,,,UQCRC2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐UQCRC2 (ab14745, Abcam), rabbit monoclonal anti‐MMP2 (ab92536, Abcam)",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
MMP9,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,False,1.00,Medium,,,,MMP9,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit monoclonal anti‐MMP9 (ab137867, Abcam) rabbit polyclonal, and TOM20",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
TOM20,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,False,0.33,Low,,,,TOM20,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"TOM20 (sc‐11415, Santa Cruz) antibodies",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
HK2,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,False,1.00,Medium,,,,HK2,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies (rabbit monoclonal anti‐HK2, H.738.7, Thermo Scientific; mouse monoclonal anti‐TOM20",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
TOM20,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,False,1.00,Medium,,,,TOM20,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse monoclonal anti‐TOM20, sc‐17764, Santa Cruz) were diluted 1:150",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
beta-Actin,antibodies,PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.33,Low,,,,beta-Actin,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Anti-beta-Actin antibody (Santa Cruz Biotechnologies, sc4778, 1/10,000) was used to verify equal protein loading",Generic reporter/tag/housekeeping antibody: beta-actin
vinculin,antibodies,PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.33,Low,,,,vinculin,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-vinculin (abcam, ab129002, 1/1000) was used to verify equal protein loading",Generic reporter/tag/housekeeping antibody: vinculin
Flag,antibodies,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,0.33,Low,,,,Flag,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Flag (F7425, MilliporeSigma)",Generic reporter/tag/housekeeping antibody: flag
GFP,antibodies,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,0.33,Low,,,,GFP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GFP (ab1218, Abcam, Western blotting and Invitrogen, IP)",Generic reporter/tag/housekeeping antibody: gfp
FBXW11/bTrCP2,antibodies,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,0.33,Low,,,,FBXW11/bTrCP2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FBXW11/bTrCP2 (GTX33193, GeneTex and PA5-109715, Invitrogen, Thermo Fisher Scientific)",Antibody target not in NF pathway/tumor biology gene list: FBXW11/bTrCP2
ERK1/2,antibodies,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,0.33,Low,,,,ERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ERK1/2 (9102, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: ERK1/2
pERK Thr202/Tyr204,antibodies,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,0.33,Low,,,,pERK Thr202/Tyr204,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-pERK Thr202/Tyr204 (4377, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: pERK Thr202/Tyr204
TRAP1,antibodies,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,TRAP1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse monoclonal anti-human TRAP1 (sc-73604),Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
ATP50/OSCP,antibodies,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,ATP50/OSCP,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse monoclonal anti ATP50/OSCP (ab110276) antibodies,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
ATPB,antibodies,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,ATPB,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse monoclonal anti-ATPB (ab14730),Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
SDHA,antibodies,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,SDHA,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,anti SDHA (sc-166947),Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
Cyclophilin,antibodies,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,Cyclophilin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse monoclonal anti-Cyclophilin (ab110324) antibodies,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
GFAP,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,GFAP,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"glial fibrillary acidic protein (GFAP, DAKO, polyclonal, 1:3,000 dilution, no antigen retrieval)",Antibody target not in NF pathway/tumor biology gene list: GFAP
OLIG2,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,OLIG2,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"OLIG2 (Immuno Bio Labs, polyclonal, 1:200 dilution, ER1 antigen retrieval)",Antibody target not in NF pathway/tumor biology gene list: OLIG2
SOX10,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,SOX10,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"SOX10 (Cell Marque, clone EP268, dilution 1:250, ER2 antigen retrieval)",Antibody target not in NF pathway/tumor biology gene list: SOX10
synaptophysin,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,synaptophysin,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"synaptophysin (Cell Marque, polyclonal, 1:100 dilution, ER2 antigen retrieval)",Antibody target not in NF pathway/tumor biology gene list: synaptophysin
p16,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,p16,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"p16 (MTM Labs, clone E6H4, undiluted, ER1 antigen retrieval)",Antibody target not in NF pathway/tumor biology gene list: p16
ATRX,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,ATRX,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"ATRX (Sigma, polyclonal, 1:100 dilution)",Antibody target not in NF pathway/tumor biology gene list: ATRX
p53,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,p53,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"p53 (Biocare, clone DO-7, 1:100 dilution, ER2 antigen retrieval)",Antibody target not in NF pathway/tumor biology gene list: p53
histone H3 K27M mutant protein,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,histone H3 K27M mutant protein,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"histone H3 K27M mutant protein (RevMAb Biosciences, clone RM192, 1:600 dilution)",Antibody target not in NF pathway/tumor biology gene list: histone H3 K27M mutant protein
histone H3 lysine 27 trimethylation,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,histone H3 lysine 27 trimethylation,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"histone H3 lysine 27 trimethylation (Cell Signaling, cat #9733, clone C36B11, 1:50 dilution, ER2 antigen retrieval)",Antibody target not in NF pathway/tumor biology gene list: histone H3 lysine 27 trimethylation
Ki-67,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,Ki-67,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki-67 (Dako, clone Mib1, 1:50 dilution, ER2 antigen retrieval)",Antibody target not in NF pathway/tumor biology gene list: Ki-67
CD16/CD32,antibodies,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.9,Experimental Usage,False,0.33,Low,,,,CD16/CD32,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Blocking antibody (anti-CD16/CD32) was added to the cell suspensions and incubated 15 min,Antibody target not in NF pathway/tumor biology gene list: CD16/CD32
MMP2,antibodies,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,Experimental Usage,False,1.00,Medium,,,,MMP2,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse monoclonal (CA-4001) matrix metalloproteinase (MMP)2...dilution 1 : 1000; incubation overnight at 4 °C, Abcam",Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
MMP9,antibodies,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,Experimental Usage,False,1.00,Medium,,,,MMP9,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit monoclonal (EP1254) MMP9 (dilution 1 : 1000; incubation overnight at 4 °C, Abcam",Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
MMP3,antibodies,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.85,Experimental Usage,False,0.33,Low,,,,MMP3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"MMP3 (dilution 1 : 50; incubation overnight at 4 °C, Santa Cruz Biotechnology, Inc.)",Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
GAPDH,antibodies,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,Experimental Usage,False,1.00,Medium,,,,GAPDH,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,GAPDH mouse mAb (6C5) (dilution 1 : 5000; incubation 1 h at room temperature; Advanced Immunochemical Inc.),Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
CD45,antibodies,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,Experimental Usage,False,0.67,Low,,,,CD45,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Tumors were stained first with CD45-Vioblue direct antibody conjugate (clone REA747, Miltenyi Biotec) for 30 min at 4 °C.",Antibody target not in NF pathway/tumor biology gene list: CD45
CD24,antibodies,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,Experimental Usage,False,0.67,Low,,,,CD24,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"CD45 negative cells were stained with calcein AM (Life Technologies) for viability and CD24-APC (human antibody, clone REA832, Miltenyi Biotec)",Antibody target not in NF pathway/tumor biology gene list: CD24
CD44,antibodies,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,Experimental Usage,False,0.67,Low,,,,CD44,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"CD24-APC (human antibody, clone REA832, Miltenyi Biotec) and CD44-VioBlue (human antibody, clone REA690, Miltenyi Biotec)",Antibody target not in NF pathway/tumor biology gene list: CD44
HLA Class I ABC,antibodies,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,Experimental Usage,False,0.33,Low,,,,HLA Class I ABC,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HLA-B (anti-HLA Class I ABC antibody, ab225636, Abcam, Cambridge, UK) for MHC I",Antibody target not in NF pathway/tumor biology gene list: HLA Class I ABC
MHC Class II,antibodies,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,Experimental Usage,False,0.33,Low,,,,MHC Class II,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"DPB1 (anti-MHC Class II antibody, ab55152, Abcam, Cambridge, UK) for MHC II",Antibody target not in NF pathway/tumor biology gene list: MHC Class II
SOX10,antibodies,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,False,0.33,Low,,,,SOX10,,,,,,,,,,,,,,,,,,,,,,,,,,,,"labeled with primary antibodies including SOX10 to mark schwannoma cells (API 3099, Biocare; labeling validated in schwannoma and melanoma)",Antibody target not in NF pathway/tumor biology gene list: SOX10
Pericentrin,antibodies,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,False,0.33,Low,,,,Pericentrin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Pericentrin (PA5-54109, Thermo Fisher Scientific; labeling validated by Pericentrin knockdown) and γTubulin (T5192, Sigma; labeling validated in human and chicken cells) to mark centrosomes",Antibody target not in NF pathway/tumor biology gene list: Pericentrin
γTubulin,antibodies,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,False,0.33,Low,,,,γTubulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Pericentrin (PA5-54109, Thermo Fisher Scientific; labeling validated by Pericentrin knockdown) and γTubulin (T5192, Sigma; labeling validated in human and chicken cells) to mark centrosomes",Antibody target not in NF pathway/tumor biology gene list: γTubulin
Acetylated Tubulin,antibodies,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,False,0.33,Low,,,,Acetylated Tubulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"and Acetylated Tubulin to mark cilia (T6793, Sigma; labeling validated in vertebrate and invertebrate organisms)",Generic reporter/tag/housekeeping antibody: acetylated tubulin
CD3,antibodies,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,False,0.33,Low,,,,CD3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"slides were subjected to antigen retrieval and labeled with CD3 (A0452, Agilent Technologies, Santa Clara, CA; labeling validated by over-expression)",Antibody target not in NF pathway/tumor biology gene list: CD3
CD68,antibodies,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,False,0.33,Low,,,,CD68,,,,,,,,,,,,,,,,,,,,,,,,,,,,"or CD68 (M0814, Agilent Technologies; labeling validated using human B-cell lymphoma) primary antibodies",Antibody target not in NF pathway/tumor biology gene list: CD68
CD13,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD13,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...incubated for 30 min in ice and in the dark with the following mouse anti-human monoclonal antibodies directly conjugated with fluorochromes: CD13/FITC (22A5, Caltag Medsystems, UK)...",Antibody target not in NF pathway/tumor biology gene list: CD13
CD14,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD14,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...mouse anti-human monoclonal antibodies directly conjugated with fluorochromes: CD13/FITC (22A5, Caltag Medsystems, UK), CD14/PE (M5E2, BD Biosciences, CA, USA)...",Antibody target not in NF pathway/tumor biology gene list: CD14
CD34,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD34,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD14/PE (M5E2, BD Biosciences, CA, USA), CD34/FITC (581, BD Biosciences), CD45/ALexa405 (HI30, Caltag Medsystems)...",Antibody target not in NF pathway/tumor biology gene list: CD34
CD45,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD45,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD34/FITC (581, BD Biosciences), CD45/ALexa405 (HI30, Caltag Medsystems), CD90/PECy5 (5E10, BioLegend, CA, USA)...",Antibody target not in NF pathway/tumor biology gene list: CD45
CD90,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD90,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD45/ALexa405 (HI30, Caltag Medsystems), CD90/PECy5 (5E10, BioLegend, CA, USA), CD105/APC (45A5A3, BioLegend)...",Antibody target not in NF pathway/tumor biology gene list: CD90
CD105,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD105,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD90/PECy5 (5E10, BioLegend, CA, USA), CD105/APC (45A5A3, BioLegend), CD146/PE (P1H12, BD Biosciences)...",Antibody target not in NF pathway/tumor biology gene list: CD105
CD146,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD146,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD105/APC (45A5A3, BioLegend), CD146/PE (P1H12, BD Biosciences), CD271/APC (C401457, BD Biosciences)...",Antibody target not in NF pathway/tumor biology gene list: CD146
CD271,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD271,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD146/PE (P1H12, BD Biosciences), CD271/APC (C401457, BD Biosciences). Unstained cells were used as controls...",Antibody target not in NF pathway/tumor biology gene list: CD271
Ki-67,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,False,1.00,Medium,,,,Ki-67,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...Expression of Ki-67 was evaluated immunohistochemically using mouse monoclonal antibody anti-Ki-67 (1:80; M7240; Dako Corporation, CA, USA)...",Antibody target not in NF pathway/tumor biology gene list: Ki-67
OCT3/4,antibodies,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,False,0.33,Low,,,,OCT3/4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4)",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
NANOG,antibodies,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,False,0.33,Low,,,,NANOG,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4)",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
TRA-1-60,antibodies,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,False,0.33,Low,,,,TRA-1-60,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4)",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
SSEA-4,antibodies,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,False,0.33,Low,,,,SSEA-4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4)",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
IBA1,antibodies,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,False,0.33,Low,,,,IBA1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Cells were next stained with anti-IBA1 antibody (Table S1) in TBS containing 5% donkey serum overnight,Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
MKK3,antibodies,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,False,0.33,Low,,,,MKK3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,incubated at 4 °C overnight in primary antibody; MKK3 (Cell Signaling #5674),Antibody target not in NF pathway/tumor biology gene list: MKK3
p38,antibodies,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,False,0.33,Low,,,,p38,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,p38 (Cell Signaling #9219),Antibody target not in NF pathway/tumor biology gene list: p38
phospho-p38,antibodies,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-p38,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,phospho-p38 (Cell Signaling # 4511),Antibody target not in NF pathway/tumor biology gene list: phospho-p38
phospho-ERK1/2,antibodies,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-ERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,phospho-ERK1/2 (Cell Signaling #9101),Antibody target not in NF pathway/tumor biology gene list: phospho-ERK1/2
β-Actin,antibodies,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,False,0.33,Low,,,,β-Actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,β-Actin (Cell Signaling #3700),Generic reporter/tag/housekeeping antibody: β-actin
TAZ,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,TAZ,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"we used antibodies to TAZ (Rabbit; Proteintech 23306-1), YAP (Rabbit; Cell Signaling Technology, #4912)",Antibody target not in NF pathway/tumor biology gene list: TAZ
YAP,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,YAP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"YAP (Rabbit; Cell Signaling Technology, #4912), TAZ/YAP (Rabbit; Cell Signaling Technology, #8418)",Antibody target not in NF pathway/tumor biology gene list: YAP
TAZ/YAP,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,TAZ/YAP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"TAZ/YAP (Rabbit; Cell Signaling Technology, #8418), Sox10 (Goat, Santa Cruz Biotechnology, sc-17342",Antibody target not in NF pathway/tumor biology gene list: TAZ/YAP
Sox10,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,0.33,Low,,,,Sox10,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Sox10 (Goat, Santa Cruz Biotechnology, sc-17342; Rabbit, Abcam ab180862), Krox20 (Rabbit; Covance, PRB-236P)",Antibody target not in NF pathway/tumor biology gene list: Sox10
Sox10,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,Sox10,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Sox10 (Goat, Santa Cruz Biotechnology, sc-17342; Rabbit, Abcam ab180862), Krox20 (Rabbit; Covance, PRB-236P)",Antibody target not in NF pathway/tumor biology gene list: Sox10
Krox20,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,Krox20,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Krox20 (Rabbit; Covance, PRB-236P), MBP (Goat; Santa Cruz Biotechnology, sc-13914)",Antibody target not in NF pathway/tumor biology gene list: Krox20
Ki67,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,Ki67,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki67 (Rabbit; Thermo Fisher Scientific, RM-9106), BrdU (Rat; Abcam, ab6326)",Antibody target not in NF pathway/tumor biology gene list: Ki67
BrdU,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,0.33,Low,,,,BrdU,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"BrdU (Rat; Abcam, ab6326), α-SMA (Mouse; Sigma, clone 1A4, A2547)",Generic reporter/tag/housekeeping antibody: brdu
TEAD1,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,TEAD1,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"TEAD1 (Mouse, Santa Cruz Biotechnology sc-393976), neurofibromin (Rabbit, Santa Cruz Biotechnology sc-67)",Antibody target not in NF pathway/tumor biology gene list: TEAD1
TEAD1,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,TEAD1,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The antibodies used were as follows: TEAD1 (Mouse, BD Biosciences, 610922), H3K4me1 (Rabbit, Abcam, 8895)",Antibody target not in NF pathway/tumor biology gene list: TEAD1
neurofibromin,antibodies,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,True,0.33,Medium,,,,neurofibromin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-neurofibromin (#A300; Bethyl Laboratories, Montgomery, TX, USA)",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
phospho-Akt,antibodies,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-Akt,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
Akt,antibodies,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,False,0.33,Low,,,,Akt,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
phospho-Erk,antibodies,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-Erk,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
Erk,antibodies,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,False,0.33,Low,,,,Erk,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
CD31,antibodies,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,False,0.33,Low,,,,CD31,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-phospho-endothelial nitric oxide synthase (eNOS) (612392) and FITC-anti-CD31 (BD Laboratories, San Jose, CA, USA)",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
GAPDH,antibodies,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"and anti-GAPDH (Novus, Littleton, CO, USA)",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
S100 B,antibodies,PMID:34646065,10.1155/2021/9386823,Survival and ,,0.85,Experimental Usage,False,0.33,Low,,,,S100 B,,,,,,,,,,,,,,,,,,,,,,,,,,,,immunohistochemical S100 B data from a pathology service...An S100 B immunonegative tumor phenotype was associated with a significantly worse outcome,Publication title lacks NF-specific terms: Survival and
Iba-1,antibodies,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,Experimental Usage,False,0.67,Low,,,,Iba-1,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"goat monoclonal Iba-1 antibody targeting microglia (1:300; Abcam, Cambridge, UK)",Antibody target not in NF pathway/tumor biology gene list: Iba-1
GFP,antibodies,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,False,0.67,Low,,,,GFP,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"chicken polyclonal GFP antibody targeting eYFP (1:250; Abcam, Cambridge, UK)",Generic reporter/tag/housekeeping antibody: gfp
NeuN,antibodies,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,False,0.67,Low,,,,NeuN,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-NeuN targeting neurons (1:00; Synaptic Systems),Antibody target not in NF pathway/tumor biology gene list: NeuN
goat IgG,antibodies,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.85,Experimental Usage,False,0.67,Low,,,,goat IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"donkey anti-goat IgG conjugated with Cy5 or Alexa488 fluorophores (both 1:200; Dianova, Hamburg, Germany)",Secondary antibody (not an NF-specific research tool)
goat IgG,antibodies,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.85,Experimental Usage,False,0.67,Low,,,,goat IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"donkey anti-goat IgG conjugated with Cy5 or Alexa488 fluorophores (both 1:200; Dianova, Hamburg, Germany)",Secondary antibody (not an NF-specific research tool)
chicken IgY,antibodies,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.85,Experimental Usage,False,0.67,Low,,,,chicken IgY,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,donkey anti-chicken IgY conjugated with Alexa488 or Cy5 (both 1:200; Dianova),Secondary antibody (not an NF-specific research tool)
chicken IgY,antibodies,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.85,Experimental Usage,False,0.67,Low,,,,chicken IgY,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,donkey anti-chicken IgY conjugated with Alexa488 or Cy5 (both 1:200; Dianova),Secondary antibody (not an NF-specific research tool)
mouse IgG,antibodies,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.85,Experimental Usage,False,0.67,Low,,,,mouse IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,NeuN with donkey anti-mouse IgG (H + L) conjugated with Cy3 (1:200; Dianova),Secondary antibody (not an NF-specific research tool)
CD11b,antibodies,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,False,0.33,Low,,,,CD11b,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with anti-mouse CD11b antibodies coupled to magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany)",Antibody target not in NF pathway/tumor biology gene list: CD11b
pERK,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,pERK,,,,,,,,,,,,,,,,,,,,,,,,,,,,The following antibodies were purchased from Cell signaling Technologies: pERK (Catalogue # 4370),Antibody target not in NF pathway/tumor biology gene list: pERK
ERK,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,ERK,,,,,,,,,,,,,,,,,,,,,,,,,,,,total ERK (Catalogue # 9102),Antibody target not in NF pathway/tumor biology gene list: ERK
pAKT,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,pAKT,,,,,,,,,,,,,,,,,,,,,,,,,,,,pAKT (Catalogue # 4060),Antibody target not in NF pathway/tumor biology gene list: pAKT
AKT,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,AKT,,,,,,,,,,,,,,,,,,,,,,,,,,,,total AKT (Catalogue # 4691),Antibody target not in NF pathway/tumor biology gene list: AKT
Ubiquitin,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,Ubiquitin,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ubiquitin (Catalogue # 4289),Antibody target not in NF pathway/tumor biology gene list: Ubiquitin
MYC,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,MYC,,,,,,,,,,,,,,,,,,,,,,,,,,,,MYC (Catalogue # 18583),Antibody target not in NF pathway/tumor biology gene list: MYC
pCHEK1 S296,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,pCHEK1 S296,,,,,,,,,,,,,,,,,,,,,,,,,,,,pCHEK1 S296 (Catalogue # 90178),Antibody target not in NF pathway/tumor biology gene list: pCHEK1 S296
BMI1,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,BMI1,,,,,,,,,,,,,,,,,,,,,,,,,,,,BMI1 (Catalogue # 5856),Antibody target not in NF pathway/tumor biology gene list: BMI1
H3K27Ac,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,H3K27Ac,,,,,,,,,,,,,,,,,,,,,,,,,,,,H3K27Ac (Catalogue # 8173),Antibody target not in NF pathway/tumor biology gene list: H3K27Ac
H3,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,H3,,,,,,,,,,,,,,,,,,,,,,,,,,,,total H3 (Catalogue # 14269),Antibody target not in NF pathway/tumor biology gene list: H3
CDK9,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,CDK9,,,,,,,,,,,,,,,,,,,,,,,,,,,,CDK9 (Catalogue # 2316),Antibody target not in NF pathway/tumor biology gene list: CDK9
Vinculin,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,Vinculin,,,,,,,,,,,,,,,,,,,,,,,,,,,,Vinculin (Catalogue # 4650),Generic reporter/tag/housekeeping antibody: vinculin
CPNase,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,CPNase,,,,,,,,,,,,,,,,,,,,,,,,,,,,CPNase (Catalogue # 5664),Antibody target not in NF pathway/tumor biology gene list: CPNase
MAG,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,MAG,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAG (Catalogue # 9043),Antibody target not in NF pathway/tumor biology gene list: MAG
Beta-Actin,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,Beta-Actin,,,,,,,,,,,,,,,,,,,,,,,,,,,,Beta-Actin (Catalogue # NB600-501) was purchased from Novus,Generic reporter/tag/housekeeping antibody: beta-actin
pS2 RNApol II,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,pS2 RNApol II,,,,,,,,,,,,,,,,,,,,,,,,,,,,pS2 RNApol II (Catalogue # 04-1571-1) from EMD Millipore,Antibody target not in NF pathway/tumor biology gene list: pS2 RNApol II
SOX2,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,SOX2,,,,,,,,,,,,,,,,,,,,,,,,,,,,SOX2 (Catalogue # MAB2018) from R&D systems,Antibody target not in NF pathway/tumor biology gene list: SOX2
NG2,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,NG2,,,,,,,,,,,,,,,,,,,,,,,,,,,,NG2 (Catalogue # PA5-17199) from Invitrogen,Antibody target not in NF pathway/tumor biology gene list: NG2
EGFR,antibodies,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,EGFR,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used were: monoclonal anti-EGFR (1:250; Capralogics, Hardwick, MA)",Antibody target not in NF pathway/tumor biology gene list: EGFR
ErbB2,antibodies,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,ErbB2,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"polyclonal anti-ErbB2 (1:250; Santa Cruz Biotechnology, Santa Cruz, CA)",Antibody target not in NF pathway/tumor biology gene list: ErbB2
ErbB3,antibodies,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,ErbB3,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,polyclonal anti-ErbB3 (1:250; Santa Cruz),Antibody target not in NF pathway/tumor biology gene list: ErbB3
actin,antibodies,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,actin,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"monoclonal anti-actin (BD Biosciences, San Jose, CA)",Generic reporter/tag/housekeeping antibody: actin
MPM-2,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,False,0.33,Low,,,,MPM-2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cells were labeled with MPM-2 antibody (Upstate Biotechnology, Lake Placid, NY)",Antibody target not in NF pathway/tumor biology gene list: MPM-2
Ras,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,False,0.33,Low,,,,Ras,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Detection of Ras was done by immunoblotting using the supplied pan-Ras antibody,Antibody target not in NF pathway/tumor biology gene list: Ras
Cyclin D1,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,False,0.33,Low,,,,Cyclin D1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",Antibody target not in NF pathway/tumor biology gene list: Cyclin D1
ERK,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,False,0.33,Low,,,,ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",Antibody target not in NF pathway/tumor biology gene list: ERK
phospho-ERK,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,False,0.33,Low,,,,phospho-ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",Antibody target not in NF pathway/tumor biology gene list: phospho-ERK
B-Raf,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,False,0.33,Low,,,,B-Raf,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",Antibody target not in NF pathway/tumor biology gene list: B-Raf
phospho-MEK1/2,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,False,0.33,Low,,,,phospho-MEK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-MEK1/2 [Ser217/221] and phospho Rb[S807/S811] (Cell Signaling Technology, Beverly, MA)",Antibody target not in NF pathway/tumor biology gene list: phospho-MEK1/2
phospho-Rb,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,False,0.33,Low,,,,phospho-Rb,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-MEK1/2 [Ser217/221] and phospho Rb[S807/S811] (Cell Signaling Technology, Beverly, MA)",Antibody target not in NF pathway/tumor biology gene list: phospho-Rb
p53,antibodies,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,False,0.33,Low,,,,p53,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p53 (# P6874, Sigma-Aldrich; # 2524, Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: p53
MDM2,antibodies,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,False,0.33,Low,,,,MDM2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"MDM2 (# M43084 and # SAB4300601, Sigma-Aldrich)",Antibody target not in NF pathway/tumor biology gene list: MDM2
cyclinD1,antibodies,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,False,0.33,Low,,,,cyclinD1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cyclinD1 (# C7464, Sigma-Aldrich)",Antibody target not in NF pathway/tumor biology gene list: cyclinD1
caspase-3,antibodies,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,False,0.33,Low,,,,caspase-3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"caspase-3 (# 9662, Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: caspase-3
β-actin,antibodies,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.85,Experimental Usage,False,0.33,Low,,,,β-actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The β-actin antibody (# AA128, Beyotime) was used to ensure equal loading of total protein",Generic reporter/tag/housekeeping antibody: β-actin
CXCL12,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.67,Low,,,,CXCL12,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,All antibodies used in this study were purchased from Peprotech (goat anti-CXCL12,Antibody target not in NF pathway/tumor biology gene list: CXCL12
CXCL12,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,False,1.00,Medium,,,,CXCL12,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,purchased from Peprotech (goat anti-CXCL12 and rabbit anti CXCL12),Antibody target not in NF pathway/tumor biology gene list: CXCL12
GFAP,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,GFAP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Invitrogen (Rat anti-GFAP),Antibody target not in NF pathway/tumor biology gene list: GFAP
Endoglin,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.67,Low,,,,Endoglin,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,R&D (Goat anti-Endoglin),Antibody target not in NF pathway/tumor biology gene list: Endoglin
IBA-1,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,False,1.00,Medium,,,,IBA-1,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Wako (rabbit anti-IBA-1),Antibody target not in NF pathway/tumor biology gene list: IBA-1
p-PKA substrate,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,p-PKA substrate,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT)",Antibody target not in NF pathway/tumor biology gene list: p-PKA substrate
AKT,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT)",Antibody target not in NF pathway/tumor biology gene list: AKT
pS473-AKT,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,pS473-AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT)",Antibody target not in NF pathway/tumor biology gene list: pS473-AKT
CXCR4,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,CXCR4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Leinco (pan-CXCR4),Antibody target not in NF pathway/tumor biology gene list: CXCR4
CNPase,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,False,1.00,Medium,,,,CNPase,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Sigma (mouse anti-CNPase),Antibody target not in NF pathway/tumor biology gene list: CNPase
phosphorylated CXCR4,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,phosphorylated CXCR4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibody directed against phosphorylated CXCR4 (pCXCR4) was developed in our lab,Antibody target not in NF pathway/tumor biology gene list: phosphorylated CXCR4
Olig2,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,False,1.00,Medium,,,,Olig2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,The rabbit anti Olig2 antibody (DF-308) was a gift from Dr. Charles Stiles,Antibody target not in NF pathway/tumor biology gene list: Olig2
GAPDH,antibodies,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies against GAPDH (cat. no. 5174S)...were obtained from Cell Signaling Technology,Generic reporter/tag/housekeeping antibody: gapdh
phosphorylated PKA,antibodies,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,Experimental Usage,False,0.33,Low,,,,phosphorylated PKA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,phosphorylated PKA (cat. no. 5661S)...were obtained from Cell Signaling Technology,Antibody target not in NF pathway/tumor biology gene list: phosphorylated PKA
PKA,antibodies,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,Experimental Usage,False,0.33,Low,,,,PKA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,PKA (cat. no. 4782S)...were obtained from Cell Signaling Technology,Antibody target not in NF pathway/tumor biology gene list: PKA
phosphorylated CREB,antibodies,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,Experimental Usage,False,0.33,Low,,,,phosphorylated CREB,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,phosphorylated CREB (cat. no. 9198S)...were obtained from Cell Signaling Technology,Antibody target not in NF pathway/tumor biology gene list: phosphorylated CREB
CREB,antibodies,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,Experimental Usage,False,0.33,Low,,,,CREB,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CREB (cat. no. 9197T) were obtained from Cell Signaling Technology,Antibody target not in NF pathway/tumor biology gene list: CREB
P-glycoprotein,antibodies,PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.9,Experimental Usage,False,0.33,Low,,,,P-glycoprotein,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Anti-P-glycoprotein primary antibody and Cy3-conjugated secondary antibody were purchased from Abcam (Cambridge, UK; ab170904) and Jackson ImmunoResearch",Antibody target not in NF pathway/tumor biology gene list: P-glycoprotein
S100,antibodies,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.33,Low,,,,S100,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"primary antibody (S100 (Santa Cruz 1:100), Ki67 (Novocastra 1:200))",Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
Ki67,antibodies,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.33,Low,,,,Ki67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"primary antibody (S100 (Santa Cruz 1:100), Ki67 (Novocastra 1:200))",Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
p-AKT S473,antibodies,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.33,Low,,,,p-AKT S473,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The primary antibodies used in this study were: p-AKT S473 (Cell Signaling 1:100),Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
p-4EBP,antibodies,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.33,Low,,,,p-4EBP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,p-4EBP (Cell Signaling 1:500),Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
p-ERK,antibodies,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.33,Low,,,,p-ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,p-ERK (Cell Signaling 1:1000),Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
GAPDH,antibodies,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,GAPDH (Cell Signaling 1:2000),Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
FLAG,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.9,Experimental Usage,False,1.00,Medium,,,,FLAG,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Supernatants from cleared lysates were incubated with Anti-FLAG M2 affinity gel (Sigma) to immunoprecipitated FLAG-tagged protein complexes,Generic reporter/tag/housekeeping antibody: flag
FLAG,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.9,Experimental Usage,False,1.00,Medium,,,,FLAG,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Primary antibodies used were FLAG-M2 and KRAS (Sigma),Generic reporter/tag/housekeeping antibody: flag
KRAS,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,False,0.33,Low,,,,KRAS,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Primary antibodies used were FLAG-M2 and KRAS (Sigma),Antibody target not in NF pathway/tumor biology gene list: KRAS
HA,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,False,0.33,Low,,,,HA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HA, HSP70, and Ubiquitin (Cell Signaling)",Generic reporter/tag/housekeeping antibody: ha
HSP70,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,False,0.33,Low,,,,HSP70,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HA, HSP70, and Ubiquitin (Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: HSP70
Ubiquitin,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,False,0.33,Low,,,,Ubiquitin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HA, HSP70, and Ubiquitin (Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: Ubiquitin
RAS,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,False,0.33,Low,,,,RAS,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,pan-RAS (Abcam),Antibody target not in NF pathway/tumor biology gene list: RAS
GST,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,False,0.33,Low,,,,GST,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,GST and Vinculin (Bethyl Laboratories),Generic reporter/tag/housekeeping antibody: gst
Vinculin,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,False,0.33,Low,,,,Vinculin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,GST and Vinculin (Bethyl Laboratories),Generic reporter/tag/housekeeping antibody: vinculin
RASA1,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,False,0.33,Low,,,,RASA1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,RASA1 (Santa Cruz Biotechnology),Antibody target not in NF pathway/tumor biology gene list: RASA1
p-RB1-S807/811,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.95,Experimental Usage,False,0.33,Low,,,,p-RB1-S807/811,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-RB1-S807/811 (1:1000, no. 8516) and RB1 (no. 9309 and no. 9313, 1:500) from Cell Signaling Technology",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
RB1,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,0.33,Low,,,,RB1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-RB1-S807/811 (1:1000, no. 8516) and RB1 (no. 9309 and no. 9313, 1:500) from Cell Signaling Technology",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
RB1,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,0.33,Low,,,,RB1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-RB1-S807/811 (1:1000, no. 8516) and RB1 (no. 9309 and no. 9313, 1:500) from Cell Signaling Technology",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
p16,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,0.33,Low,,,,p16,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"human p16 (ab108349, 1:1000) and GAPDH (1:5000, no. Ab8245) from Abcam",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
GAPDH,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"human p16 (ab108349, 1:1000) and GAPDH (1:5000, no. Ab8245) from Abcam",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
p16,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,0.33,Low,,,,p16,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse p16 (sc-1207, 1:200) from Santa Cruz Biotechnology",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
Secondary antibody,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.85,Experimental Usage,False,0.67,Low,,,,Secondary antibody,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"HRP-coupled secondary antibodies (nos. NA934 and NA935, 1:2000) from Sigma",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
Secondary antibody,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.85,Experimental Usage,False,0.67,Low,,,,Secondary antibody,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"HRP-coupled secondary antibodies (nos. NA934 and NA935, 1:2000) from Sigma",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
RABL6A,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,0.67,Low,,,,RABL6A,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,RABL6A antibodies (monoclonal and polyclonal) were produced in the Quelle laboratory,Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
Secondary antibody,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.85,Experimental Usage,False,0.67,Low,,,,Secondary antibody,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"secondary fluorescent-conjugated antibodies (Alexa Fluor 488 and 647, 1:5000)",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
Secondary antibody,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.85,Experimental Usage,False,0.67,Low,,,,Secondary antibody,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"secondary fluorescent-conjugated antibodies (Alexa Fluor 488 and 647, 1:5000)",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
Nf1,antibodies,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Experimental Usage,True,1.00,High,,,,Nf1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Immunoprecipitations were performed using 400 µg of total protein in 1 ml IP buffer incubated with 200 μl of mAb21 anti-Nf1 monoclonal antibody supernatant,Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
phospho-ERK,antibodies,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Experimental Usage,False,0.67,Low,,,,phospho-ERK,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used for immunoblotting were: anti-Nf1 (mouse, mAb21, 1:10), anti-phospho-ERK (mouse, Sigma M8159, 1:2500)",Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
ERK,antibodies,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Experimental Usage,False,0.67,Low,,,,ERK,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"total ERK (rabbit, CST 9102, 1:1000)",Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
β-tubulin,antibodies,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Experimental Usage,False,1.00,Medium,,,,β-tubulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-β-tubulin (mouse, Developmental Studies Hybridoma Bank E7, 1:10,000)",Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
GFP,antibodies,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Experimental Usage,False,0.67,Low,,,,GFP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used were: rabbit anti-GFP (Invitrogen, A11122, 1:4000)",Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
nc82,antibodies,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Experimental Usage,False,0.67,Low,,,,nc82,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The following antibodies were used: rabbit anti-GFP (1:1000, Invitrogen), mouse anti-nc82 (1:50, DSHB)",Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
FOXR2,antibodies,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,False,0.33,Low,,,,FOXR2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemistry (IHC) for FOXR2 (1:100, SIGMA) was performed",Antibody target not in NF pathway/tumor biology gene list: FOXR2
GAPDH,antibodies,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,probed with antibodies against FOXR2 (SIGMA) and GAPDH (Cell Signaling Tech.),Generic reporter/tag/housekeeping antibody: gapdh
CNPase,antibodies,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,False,0.33,Low,,,,CNPase,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Immunofluorescence on tissue sections and cell lines with antibodies probing FOXR2 (SIGMA) and CNPase (Santa Cruz),Antibody target not in NF pathway/tumor biology gene list: CNPase
Nuclear Pore Complex Proteins,antibodies,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,0.33,Low,,,,Nuclear Pore Complex Proteins,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Nuclei were then stained with 1–1.5ug (depending on pellet size) of TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody's (B0451, B0452, B0453, or B0457)",Antibody target not in NF pathway/tumor biology gene list: Nuclear Pore Complex Proteins
Nuclear Pore Complex Proteins,antibodies,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,0.33,Low,,,,Nuclear Pore Complex Proteins,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Nuclei were then stained with 1–1.5ug (depending on pellet size) of TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody's (B0451, B0452, B0453, or B0457)",Antibody target not in NF pathway/tumor biology gene list: Nuclear Pore Complex Proteins
Nuclear Pore Complex Proteins,antibodies,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,0.33,Low,,,,Nuclear Pore Complex Proteins,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Nuclei were then stained with 1–1.5ug (depending on pellet size) of TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody's (B0451, B0452, B0453, or B0457)",Antibody target not in NF pathway/tumor biology gene list: Nuclear Pore Complex Proteins
Nuclear Pore Complex Proteins,antibodies,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,0.33,Low,,,,Nuclear Pore Complex Proteins,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Nuclei were then stained with 1–1.5ug (depending on pellet size) of TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody's (B0451, B0452, B0453, or B0457)",Antibody target not in NF pathway/tumor biology gene list: Nuclear Pore Complex Proteins
CD11b,antibodies,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.95,Experimental Usage,False,0.33,Low,,,,CD11b,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD11b at 1:100 dilution (abcam Cat # ab52478) for myeloid cells,Antibody target not in NF pathway/tumor biology gene list: CD11b
SOX10,antibodies,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.95,Experimental Usage,False,0.33,Low,,,,SOX10,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,SOX10 at 1:500 dilution (abcam Cat # ab155279) for Schwann cells,Antibody target not in NF pathway/tumor biology gene list: SOX10
Rabbit IgG,antibodies,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,Experimental Usage,False,0.67,Low,,,,Rabbit IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"treated with secondary antibody Goat anti-Rabbit, Alexa Fluor™ 488 1:2000",Secondary antibody (not an NF-specific research tool)
Rabbit IgG,antibodies,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,Experimental Usage,False,0.67,Low,,,,Rabbit IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"Goat anti-Rabbit, Alexa Fluor™ 594 1:2000 for 1 h at room temperature",Secondary antibody (not an NF-specific research tool)
HER1,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.67,Low,,,,HER1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human HER1 (Abcam, ab52894)",Antibody target not in NF pathway/tumor biology gene list: HER1
HER2,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.67,Low,,,,HER2,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human HER2 (ZSGB-BIO, ZA-0023)",Antibody target not in NF pathway/tumor biology gene list: HER2
VEGFR2,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.67,Low,,,,VEGFR2,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human VEGFR2 (CST, 9698S)",Antibody target not in NF pathway/tumor biology gene list: VEGFR2
B7H3,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.67,Low,,,,B7H3,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human B7H3 (CST, #14058)",Antibody target not in NF pathway/tumor biology gene list: B7H3
CD171,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.67,Low,,,,CD171,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human CD171 (Abcam, ab208155)",Antibody target not in NF pathway/tumor biology gene list: CD171
EGFRvIII,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.67,Low,,,,EGFRvIII,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human EGFRvIII (ZSGB-BIO, ZA-0643)",Antibody target not in NF pathway/tumor biology gene list: EGFRvIII
TGFβ1,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.67,Low,,,,TGFβ1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human TGFβ1 (Abcam, ab215715)",Antibody target not in NF pathway/tumor biology gene list: TGFβ1
PDL1,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.67,Low,,,,PDL1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human PDL1 (Genetex, GTX104763)",Antibody target not in NF pathway/tumor biology gene list: PDL1
S100,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.67,Low,,,,S100,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human S100 (ZSGB-BIO, ZA-0225)",Antibody target not in NF pathway/tumor biology gene list: S100
S100β,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.33,Low,,,,S100β,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"S100β- Alexa Fluor 647 (Abcam, ab196175)",Antibody target not in NF pathway/tumor biology gene list: S100β
HER1,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,False,0.33,Low,,,,HER1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HER1-PE (352904), CD4-PE (317410), CD8a-APC (301014)",Antibody target not in NF pathway/tumor biology gene list: HER1
CD4,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,False,0.33,Low,,,,CD4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HER1-PE (352904), CD4-PE (317410), CD8a-APC (301014)",Antibody target not in NF pathway/tumor biology gene list: CD4
CD8a,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,False,0.33,Low,,,,CD8a,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD4-PE (317410), CD8a-APC (301014), CD45RO-PE (304206)",Antibody target not in NF pathway/tumor biology gene list: CD8a
CD45RO,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,False,0.33,Low,,,,CD45RO,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD8a-APC (301014), CD45RO-PE (304206), and CCR7-Percp (353242)",Antibody target not in NF pathway/tumor biology gene list: CD45RO
CCR7,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,False,0.33,Low,,,,CCR7,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD45RO-PE (304206), and CCR7-Percp (353242) (all from BioLegend)",Antibody target not in NF pathway/tumor biology gene list: CCR7
β-actin,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,False,0.67,Low,,,,β-actin,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies used in western blotting targeting β-actin (#13E5),Generic reporter/tag/housekeeping antibody: β-actin
MEK1/2,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.85,Experimental Usage,False,0.33,Low,,,,MEK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies used in western blotting targeting...MEK1/2,Antibody target not in NF pathway/tumor biology gene list: MEK1/2
phospho-MEK1/2,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,False,0.67,Low,,,,phospho-MEK1/2,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,phospho-MEK1/2 (#41G9),Antibody target not in NF pathway/tumor biology gene list: phospho-MEK1/2
phospho-ERK,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,False,0.67,Low,,,,phospho-ERK,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,phospho-ERK (#D13.14.4E),Antibody target not in NF pathway/tumor biology gene list: phospho-ERK
MMP1,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,False,0.67,Low,,,,MMP1,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,MMP1 (#E9S9N),Antibody target not in NF pathway/tumor biology gene list: MMP1
AHR,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,False,0.33,Low,,,,AHR,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody for Aryl hydrocarbon receptor (AHR, #H-211)",Antibody target not in NF pathway/tumor biology gene list: AHR
collagen I,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,False,0.67,Low,,,,collagen I,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,collagen I (#EPR7785),Antibody target not in NF pathway/tumor biology gene list: collagen I
S100 protein,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.85,Experimental Usage,False,0.33,Low,,,,S100 protein,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-S100 protein antibody (Nichirei Biosciences Inc.),Antibody target not in NF pathway/tumor biology gene list: S100 protein
CD31,antibodies,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.9,Experimental Usage,False,0.33,Low,,,,CD31,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Anti-CD31 (Abcam, ab7388) for vasculature",Antibody target not in NF pathway/tumor biology gene list: CD31
S100B,antibodies,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.9,Experimental Usage,False,0.33,Low,,,,S100B,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Anti-S100B (Atlas Antibodies, HPA015768-100UL) antibodies for S100B protein",Antibody target not in NF pathway/tumor biology gene list: S100B
rabbit IgG,antibodies,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,False,0.67,Low,,,,rabbit IgG,,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-rabbit IgG, and horseradish peroxidase–linked secondary 7074 (RRID: AB_2099233)",Secondary antibody (not an NF-specific research tool)
β-actin,antibodies,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,β-actin,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,β-Actin was probed as a loading control using β-actin (13E5) rabbit mAb #4970 (RRID: AB_2223172),Generic reporter/tag/housekeeping antibody: β-actin
S100,antibodies,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,False,1.00,Medium,,,,S100,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"antibodies against S100 (monoclonal, mouse, 10 μg/mL, Ventana S100-4C4.9) to demonstrate human Schwann cell origin",Antibody target not in NF pathway/tumor biology gene list: S100
Ki67,antibodies,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,False,1.00,Medium,,,,Ki67,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-Ki67 (monoclonal, mouse, 0.4 μg/mL, Ventana Ki-67-30.9) to evaluate proliferation fraction",Antibody target not in NF pathway/tumor biology gene list: Ki67
CD34,antibodies,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD34,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-CD34 (monoclonal, mouse, 0.8 μg/mL, Ventana QBEnd/10) to demonstrate vessel and stem cell formation",Antibody target not in NF pathway/tumor biology gene list: CD34
p53,antibodies,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,False,1.00,Medium,,,,p53,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-p53 (monoclonal, mouse, Ventana Bp-53-11), anti-p16 (monoclonal, mouse, 1 μg/mL, Ventana 725-4713)",Antibody target not in NF pathway/tumor biology gene list: p53
p16,antibodies,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,False,1.00,Medium,,,,p16,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-p16 (monoclonal, mouse, 1 μg/mL, Ventana 725-4713), anti-vimentin (vimentin, monoclonal, mouse, 2.5 μg/mL, Ventana V9",Antibody target not in NF pathway/tumor biology gene list: p16
vimentin,antibodies,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,False,1.00,Medium,,,,vimentin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-vimentin (vimentin, monoclonal, mouse, 2.5 μg/mL, Ventana V9 and anti-actin (monoclonal, mouse, 0.02 μg/mL, Cell Margue 1A4)",Antibody target not in NF pathway/tumor biology gene list: vimentin
actin,antibodies,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,False,1.00,Medium,,,,actin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-actin (monoclonal, mouse, 0.02 μg/mL, Cell Margue 1A4). Staining was visualized using the ultraView™ Universal Alkaline Phosphatase Red Detection Kit",Generic reporter/tag/housekeeping antibody: actin
Ki67 antigen,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,False,0.33,Low,,,,Ki67 antigen,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used for immunohistochemistry were against Ki67 antigen (Novocastra), glial fibrillary acidic protein (Gfap; Sigma)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
glial fibrillary acidic protein,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,False,0.33,Low,,,,glial fibrillary acidic protein,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used for immunohistochemistry were against Ki67 antigen (Novocastra), glial fibrillary acidic protein (Gfap; Sigma), Pten (NeoMarkers)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
Pten,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,False,0.33,Low,,,,Pten,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"glial fibrillary acidic protein (Gfap; Sigma), Pten (NeoMarkers), nestin (BD Bioscience)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
nestin,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,False,0.33,Low,,,,nestin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Pten (NeoMarkers), nestin (BD Bioscience), phosphorylated Akt (p-Akt; Cell Signaling)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
phosphorylated Akt,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,False,0.33,Low,,,,phosphorylated Akt,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"nestin (BD Bioscience), phosphorylated Akt (p-Akt; Cell Signaling), BrdUrd (DAKO)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
BrdUrd,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,False,0.33,Low,,,,BrdUrd,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"phosphorylated Akt (p-Akt; Cell Signaling), BrdUrd (DAKO), Olig2 (Chemicon)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
Olig2,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,False,0.33,Low,,,,Olig2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"BrdUrd (DAKO), Olig2 (Chemicon), or doublecortin (Santa Cruz)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
doublecortin,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,False,0.33,Low,,,,doublecortin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Olig2 (Chemicon), or doublecortin (Santa Cruz). We used microwave antigen retrieval for all antibodies, except for doublecortin antibody",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
β3-tubulin,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,False,0.33,Low,,,,β3-tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used were against β3-tubulin (TuJ1; Covance), Gfap (Dako), CNPase (Chemicon), or nestin",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
Gfap,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,False,0.33,Low,,,,Gfap,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"β3-tubulin (TuJ1; Covance), Gfap (Dako), CNPase (Chemicon), or nestin",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
CNPase,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,False,0.33,Low,,,,CNPase,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Gfap (Dako), CNPase (Chemicon), or nestin",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
Pten,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,False,0.33,Low,,,,Pten,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used were against Pten (Cell Signaling), p-Akt, Akt, or β-actin (Sigma)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
β-actin,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,False,0.33,Low,,,,β-actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used were against Pten (Cell Signaling), p-Akt, Akt, or β-actin (Sigma)",Publication title lacks NF-specific terms: Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
S100A10,antibodies,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,Experimental Usage,False,0.67,Low,,,,S100A10,,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,optic nerve sections were incubated with polyclonal anti-S100A10 antibodies (1:1000; R&D Systems),Antibody target not in NF pathway/tumor biology gene list: S100A10
secondary antibody,antibodies,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.8,Experimental Usage,False,0.67,Low,,,,secondary antibody,,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"followed by horseradish peroxidase-conjugated secondary antibodies (Vector Laboratories, Burlingame, CA, USA)",Secondary antibody (not an NF-specific research tool)
Cdk1,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,Cdk1,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against Cdk1 (77055S), phospho-Cdk1 Tyr15 (9111T)... were purchased from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: Cdk1
phospho-Cdk1 Tyr15,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,phospho-Cdk1 Tyr15,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against Cdk1 (77055S), phospho-Cdk1 Tyr15 (9111T)... were purchased from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: phospho-Cdk1 Tyr15
Caspase-3,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,Caspase-3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... Caspase-3 (9662S), Cleaved Caspase-3 (9661S)... were purchased from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: Caspase-3
Cleaved Caspase-3,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,Cleaved Caspase-3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... Caspase-3 (9662S), Cleaved Caspase-3 (9661S)... were purchased from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: Cleaved Caspase-3
Histone H3,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,Histone H3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... Histone H3 (9715S), Acetyl-Histone H3 Lys18 (9675S)... were purchased from Cell Signaling Technology",Generic reporter/tag/housekeeping antibody: histone h3
Acetyl-Histone H3 Lys18,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,Acetyl-Histone H3 Lys18,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... Histone H3 (9715S), Acetyl-Histone H3 Lys18 (9675S)... were purchased from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: Acetyl-Histone H3 Lys18
SAPK/JNK,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,SAPK/JNK,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... SAPK/JNK (9252T), phospho-SAPK/JNK Thr183/Tyr185 (4668T)... were purchased from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: SAPK/JNK
phospho-SAPK/JNK Thr183/Tyr185,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,phospho-SAPK/JNK Thr183/Tyr185,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... SAPK/JNK (9252T), phospho-SAPK/JNK Thr183/Tyr185 (4668T)... were purchased from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: phospho-SAPK/JNK Thr183/Tyr185
p70S6 Kinase,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,p70S6 Kinase,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... p70S6 Kinase (9202S), and phospho-p70 Thr389 S6 Kinase (9234S) were purchased from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: p70S6 Kinase
phospho-p70 Thr389 S6 Kinase,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,phospho-p70 Thr389 S6 Kinase,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... p70S6 Kinase (9202S), and phospho-p70 Thr389 S6 Kinase (9234S) were purchased from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: phospho-p70 Thr389 S6 Kinase
BrdU,antibodies,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,Experimental Usage,False,1.00,Medium,,,,BrdU,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse monoclonal anti-BrdU (1:800, Sigma-Aldrich, St. Louis, MO)",Generic reporter/tag/housekeeping antibody: brdu
S100,antibodies,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,Experimental Usage,False,1.00,Medium,,,,S100,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-S100 (1:800, Sigma-Aldrich, St. Louis, MO)",Antibody target not in NF pathway/tumor biology gene list: S100
mouse IgG,antibodies,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.85,Experimental Usage,False,0.67,Low,,,,mouse IgG,,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"secondary antibodies (anti-mouse Alexa Fluor 568 and anti-rabbit Alexa Fluor 488, 1:800 each, Invitrogen)",Secondary antibody (not an NF-specific research tool)
rabbit IgG,antibodies,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.85,Experimental Usage,False,0.67,Low,,,,rabbit IgG,,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"secondary antibodies (anti-mouse Alexa Fluor 568 and anti-rabbit Alexa Fluor 488, 1:800 each, Invitrogen)",Secondary antibody (not an NF-specific research tool)
phospho-S6 (Ser240/244),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-S6 (Ser240/244),,,,,,,,,,,,,,,,,,,,,,,,,,,,"co-incubation with AlexaFlour488 conjugated-pS6 (Ser240/244) antibody (Cell Signaling Technology; Beverly, MA)",Antibody target not in NF pathway/tumor biology gene list: phospho-S6 (Ser240/244)
phospho-S6 (S240/244),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-S6 (S240/244),,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies for phospho-S6 (S240/244), S6, phospho-p70 S6K (T389)",Antibody target not in NF pathway/tumor biology gene list: phospho-S6 (S240/244)
S6,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,S6,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies for phospho-S6 (S240/244), S6, phospho-p70 S6K (T389)",Antibody target not in NF pathway/tumor biology gene list: S6
phospho-p70 S6K (T389),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-p70 S6K (T389),,,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-p70 S6K (T389), p70 S6K, phospho-Akt (S473)",Antibody target not in NF pathway/tumor biology gene list: phospho-p70 S6K (T389)
p70 S6K,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,p70 S6K,,,,,,,,,,,,,,,,,,,,,,,,,,,,"p70 S6K, phospho-Akt (S473), Akt",Antibody target not in NF pathway/tumor biology gene list: p70 S6K
phospho-Akt (S473),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-Akt (S473),,,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-Akt (S473), Akt, phospho-NDRG1 (T346)",Antibody target not in NF pathway/tumor biology gene list: phospho-Akt (S473)
Akt,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,Akt,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Akt, phospho-NDRG1 (T346), SGK1",Antibody target not in NF pathway/tumor biology gene list: Akt
phospho-NDRG1 (T346),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-NDRG1 (T346),,,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-NDRG1 (T346), SGK1, phospho-PAK1 (S144)",Antibody target not in NF pathway/tumor biology gene list: phospho-NDRG1 (T346)
SGK1,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,SGK1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"SGK1, phospho-PAK1 (S144), PAK1",Antibody target not in NF pathway/tumor biology gene list: SGK1
phospho-PAK1 (S144),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-PAK1 (S144),,,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-PAK1 (S144), PAK1, and 4EBP1",Antibody target not in NF pathway/tumor biology gene list: phospho-PAK1 (S144)
PAK1,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,PAK1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"PAK1, and 4EBP1 were from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: PAK1
4EBP1,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,4EBP1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"PAK1, and 4EBP1 were from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: 4EBP1
NDRG1,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,NDRG1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NDRG1 (Abcam; Cambridge, MA)",Antibody target not in NF pathway/tumor biology gene list: NDRG1
Rac1,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,Rac1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Rac1 (BD Biosciences; San Jose, CA)",Antibody target not in NF pathway/tumor biology gene list: Rac1
GAPDH,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,GAPDH,,,,,,,,,,,,,,,,,,,,,,,,,,,,GAPDH (EMD Millipore),Generic reporter/tag/housekeeping antibody: gapdh
Rheb,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.67,Low,,,,Rheb,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Rheb (3M6 monoclonal; a generous gift from Richard Lamb, University of Liverpool, U.K.)",Antibody target not in NF pathway/tumor biology gene list: Rheb
S100,antibodies,PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.85,Experimental Usage,False,0.33,Low,,,,S100,,,,,,,,,,,,,,,,,,,,,,,,,,,,They were all S100-positive by immunostaining. The MPNSTs all arose from plexiform neurofibromas and showed very weak S100 immunostaining,Antibody target not in NF pathway/tumor biology gene list: S100
tubulin,antibodies,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,Experimental Usage,False,1.00,Medium,,,,tubulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-tubulin B-1-2-5 (Santa Cruz, mouse, 2% milk, 1:10000, 1 h, RT)",Generic reporter/tag/housekeeping antibody: tubulin
EGFR,antibodies,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,Experimental Usage,False,1.00,Medium,,,,EGFR,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-EGFR D38B1 #4267 (Cell Signaling, rabbit, 2% milk, 1:1000–1:2000, 1 h, RT)",Antibody target not in NF pathway/tumor biology gene list: EGFR
p-ERK,antibodies,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,Experimental Usage,False,0.67,Low,,,,p-ERK,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-ERK ½ (p44/42 MAPK) #9101 (Cell Signaling, rabbit, 2% BSA, 1:2000, overnight, 4 °C)",Antibody target not in NF pathway/tumor biology gene list: p-ERK
rabbit IgG,antibodies,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,Experimental Usage,False,0.67,Low,,,,rabbit IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,secondary antibodies goat anti-rabbit HRP 1:20000 or goat anti-mouse HRP 1:10000 (Jackson Immunoresearch Laboratories Inc.),Secondary antibody (not an NF-specific research tool)
mouse IgG,antibodies,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,Experimental Usage,False,0.67,Low,,,,mouse IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,secondary antibodies goat anti-rabbit HRP 1:20000 or goat anti-mouse HRP 1:10000 (Jackson Immunoresearch Laboratories Inc.),Secondary antibody (not an NF-specific research tool)
Pak1,antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,0.33,Low,,,,Pak1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include Pak1; Pak2; Mek1/2... (Cell Signaling Technology),Antibody target not in NF pathway/tumor biology gene list: Pak1
Pak2,antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,0.33,Low,,,,Pak2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include Pak1; Pak2; Mek1/2... (Cell Signaling Technology),Antibody target not in NF pathway/tumor biology gene list: Pak2
Mek1/2,antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,0.33,Low,,,,Mek1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include Pak1; Pak2; Mek1/2... (Cell Signaling Technology),Antibody target not in NF pathway/tumor biology gene list: Mek1/2
phospho-MEK1 (Ser298),antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,Experimental Usage,False,0.33,Low,,,,phospho-MEK1 (Ser298),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... phospho-MEK1 (Ser298)... (Cell Signaling Technology),Antibody target not in NF pathway/tumor biology gene list: phospho-MEK1 (Ser298)
Erk1/2,antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,0.33,Low,,,,Erk1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... Erk1/2... (Cell Signaling Technology),Antibody target not in NF pathway/tumor biology gene list: Erk1/2
phospho-Erk1/2 (Thr202/Tyr204),antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,Experimental Usage,False,0.33,Low,,,,phospho-Erk1/2 (Thr202/Tyr204),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... phospho-Erk1/2 (Thr202/Tyr204)... (Cell Signaling Technology),Antibody target not in NF pathway/tumor biology gene list: phospho-Erk1/2 (Thr202/Tyr204)
Akt,antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,0.33,Low,,,,Akt,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... Akt... (Cell Signaling Technology),Antibody target not in NF pathway/tumor biology gene list: Akt
phospho-Akt (Thr308),antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,Experimental Usage,False,0.33,Low,,,,phospho-Akt (Thr308),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... phospho-Akt (Thr308)... (Cell Signaling Technology),Antibody target not in NF pathway/tumor biology gene list: phospho-Akt (Thr308)
phospho-Pak1–3 (Ser141),antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,Experimental Usage,False,0.33,Low,,,,phospho-Pak1–3 (Ser141),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... phospho-Pak1–3 (Ser141; Invitrogen),Antibody target not in NF pathway/tumor biology gene list: phospho-Pak1–3 (Ser141)
GST,antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,0.33,Low,,,,GST,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... GST (Santa Cruz Biotechnology),Generic reporter/tag/housekeeping antibody: gst
β-actin,antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,0.33,Low,,,,β-actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... β-actin (Sigma),Generic reporter/tag/housekeeping antibody: β-actin
DUSP6,antibodies,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,DUSP6,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies against DUSP6 (# ab76310) were from Abcam,Antibody target not in NF pathway/tumor biology gene list: DUSP6
cyclin D1,antibodies,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,cyclin D1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies against cyclin D1 (sc-718 and sc-8396) were from Santa Cruz Biotechnology,Antibody target not in NF pathway/tumor biology gene list: cyclin D1
cyclin D1,antibodies,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,cyclin D1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies against cyclin D1 (sc-718 and sc-8396) were from Santa Cruz Biotechnology,Antibody target not in NF pathway/tumor biology gene list: cyclin D1
Ki-67,antibodies,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,Ki-67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibody, anti-Ki-67 (1:200 dilution; # Ab16667, lot number GR3185488–1, Abcam)",Antibody target not in NF pathway/tumor biology gene list: Ki-67
panendothelial cell antigen,antibodies,PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.9,Experimental Usage,False,0.33,Low,,,,panendothelial cell antigen,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"panendothelial cell antigen (550563, BD Pharmingen, USA) and anti-ratAlexa555 (A11081, Invitrogen, USA)",Antibody target not in NF pathway/tumor biology gene list: panendothelial cell antigen
rat,antibodies,PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.85,Experimental Usage,False,0.67,Low,,,,rat,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"panendothelial cell antigen (550563, BD Pharmingen, USA) and anti-ratAlexa555 (A11081, Invitrogen, USA)",Secondary antibody (not an NF-specific research tool)
S100β,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,S100β,,,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated overnight at 4°C with antibody: anti-S100β, Dako, Carpinteria, CA",Antibody target not in NF pathway/tumor biology gene list: S100β
Ki67,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,Ki67,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki67 (Novacastra Leica Microsystems, Buffalo Grove, IL)",Antibody target not in NF pathway/tumor biology gene list: Ki67
P-Stat3 (Y705),antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,P-Stat3 (Y705),,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA)",Antibody target not in NF pathway/tumor biology gene list: P-Stat3 (Y705)
cleaved caspase 3,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,cleaved caspase 3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA)",Antibody target not in NF pathway/tumor biology gene list: cleaved caspase 3
β-catenin,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,β-catenin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA)",Antibody target not in NF pathway/tumor biology gene list: β-catenin
P-Jak2,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,P-Jak2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",Antibody target not in NF pathway/tumor biology gene list: P-Jak2
Jak2,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,Jak2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",Antibody target not in NF pathway/tumor biology gene list: Jak2
P-Stat3,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,P-Stat3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",Antibody target not in NF pathway/tumor biology gene list: P-Stat3
Stat3,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,Stat3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",Antibody target not in NF pathway/tumor biology gene list: Stat3
P-β-catenin,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,P-β-catenin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",Antibody target not in NF pathway/tumor biology gene list: P-β-catenin
P-GSK3β,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,P-GSK3β,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",Antibody target not in NF pathway/tumor biology gene list: P-GSK3β
GSK3β,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,GSK3β,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",Antibody target not in NF pathway/tumor biology gene list: GSK3β
β-actin,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,β-actin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",Generic reporter/tag/housekeeping antibody: β-actin
CD16/32,antibodies,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,False,0.33,Low,,,,CD16/32,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse Fc receptor was blocked by TruStain FcX™ (anti-mouse CD16/32) antibody (BioLegend, Cat# 101320)",Antibody target not in NF pathway/tumor biology gene list: CD16/32
CD31,antibodies,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,False,0.33,Low,,,,CD31,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 102410)",Antibody target not in NF pathway/tumor biology gene list: CD31
Ter119,antibodies,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,False,0.33,Low,,,,Ter119,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 116208)",Antibody target not in NF pathway/tumor biology gene list: Ter119
CD45,antibodies,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,False,0.33,Low,,,,CD45,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 103112)",Antibody target not in NF pathway/tumor biology gene list: CD45
p75,antibodies,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.95,Experimental Usage,False,0.33,Low,,,,p75,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,cell suspensions were stained with antibodies against p75 (Ab 1554; Chemicon),Antibody target not in NF pathway/tumor biology gene list: p75
α4 integrin,antibodies,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,0.33,Low,,,,α4 integrin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"antibodies against p75 (Ab 1554; Chemicon) and α 4 integrin (Becton-Dickinson, San Jose, CA)",Antibody target not in NF pathway/tumor biology gene list: α4 integrin
BrdU,antibodies,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,0.33,Low,,,,BrdU,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,cells were stained for BrdU using a flow-cytometry kit (BD Pharmingen; cat#559619),Generic reporter/tag/housekeeping antibody: brdu
"Lineage markers (CD3e, CD11b, CD45R/B220, Ly6G/Ly6C, TER-119)",antibodies,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.9,Experimental Usage,False,0.33,Low,,,,"Lineage markers (CD3e, CD11b, CD45R/B220, Ly6G/Ly6C, TER-119)",,,,,,,,,,,,,,,,,,,,,,,,,,,,"Total BM cells were labeled with biotin-conjugated α-Lin Abs, consisting of α-CD3e, α-CD11b, α-CD45R/B220, α-Ly6G/Ly6C, and α-TER-119 Abs","Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
Ki67,antibodies,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.85,Experimental Usage,False,0.33,Low,,,,Ki67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"immunostaining with Ki67 (BD PharMingen, Pasadena CA) antibodies was performed as previously described",Antibody target not in NF pathway/tumor biology gene list: Ki67
phospho-histone-H3 (Ser 10),antibodies,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.85,Experimental Usage,False,0.33,Low,,,,phospho-histone-H3 (Ser 10),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary phospho-histone-H3 (Ser 10) antibody was purchased from Abcam, Inc.",Antibody target not in NF pathway/tumor biology gene list: phospho-histone-H3 (Ser 10)
"Various (phospho-S6, phospho-4EBP1, phospho-STAT3, AKT, etc.)",antibodies,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.8,Experimental Usage,False,0.33,Low,,,,"Various (phospho-S6, phospho-4EBP1, phospho-STAT3, AKT, etc.)",Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"All antibodies were purchased from Cell Signaling Technology (Beverly, MD) and used at a 1:1,000 dilution","Antibody target not in NF pathway/tumor biology gene list: Various (phospho-S6, phospho-4EBP1, phospho-STAT3, AKT, etc.)"
α-tubulin,antibodies,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.85,Experimental Usage,False,0.33,Low,,,,α-tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"using α-tubulin (Sigma, St. Louis MO), β-actin or non-phospho-STAT3, AKT, S6, and 4EBP1 antibodies for normalization",Generic reporter/tag/housekeeping antibody: α-tubulin
ERK,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,False,0.33,Low,,,,ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: ERK
phospho-ERK,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: phospho-ERK
phospho-MEK,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-MEK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: phospho-MEK
cleaved PARP,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,False,0.33,Low,,,,cleaved PARP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: cleaved PARP
RAD51,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,False,0.33,Low,,,,RAD51,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: RAD51
BRCA2,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,False,0.33,Low,,,,BRCA2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: BRCA2
GAPDH,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",Generic reporter/tag/housekeeping antibody: gapdh
MGMT,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,Experimental Usage,False,0.33,Low,,,,MGMT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,MGMT (sc-166528) was obtained from Santa Cruz Biotechnology,Antibody target not in NF pathway/tumor biology gene list: MGMT
RAD51,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,Experimental Usage,False,0.33,Low,,,,RAD51,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with RAD51(1:500 no. ab133534 Abcam) or yH2AX (1:200 no. 05–636, Millipore) antibody",Antibody target not in NF pathway/tumor biology gene list: RAD51
yH2AX,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,Experimental Usage,False,0.33,Low,,,,yH2AX,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with RAD51(1:500 no. ab133534 Abcam) or yH2AX (1:200 no. 05–636, Millipore) antibody",Antibody target not in NF pathway/tumor biology gene list: yH2AX
p-AKT,antibodies,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,Experimental Usage,False,0.33,Low,,,,p-AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
AKT,antibodies,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,Experimental Usage,False,0.33,Low,,,,AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
β-Actin,antibodies,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,Experimental Usage,False,0.33,Low,,,,β-Actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
Ago2,antibodies,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,Experimental Usage,False,0.33,Low,,,,Ago2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Bound RNA and protein of interest is immunoprecipitated using the Ago2 antibody (Cell Signaling Technology, Beverly, MA, USA) at a dilution of 1:50",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
TRAP1,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,TRAP1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Mouse monoclonal anti-rodent TRAP1 was from Becton Dickinson (Cat. #612344),Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
TRAP1,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,TRAP1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse monoclonal anti-human TRAP1 was from Santa Cruz (Cat. #sc-73604),Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
β actin,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,β actin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse monoclonal anti-β actin was from Santa Cruz (Cat. #sc-47778),Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
citrate synthetase,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,citrate synthetase,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit polyclonal anti-citrate synthetase was from Abcam (Cat. #ab96600),Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
HIF1α,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,HIF1α,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit polyclonal anti-HIF1α was from Novus Biologicals (Cat. #NB100-449),Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
HIF1α,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,HIF1α,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit polyclonal anti-HIF1α was from GeneTex (Cat. #GTX131826),Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
phospho-ERK1/2,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,phospho-ERK1/2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit polyclonal anti-phospho-ERK1/2 was from Cell Signaling (Cat. #9101),Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
GLUT1,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,GLUT1,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit polyclonal anti-glucose transporter GLUT1 was from Abcam (Cat. #ab652),Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
Etv5,antibodies,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,Etv5,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Rabbit anti-Etv5 antibody (Novus Biologicals) was diluted at 1:100 for immunohistochemistry,Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
podoplanin,antibodies,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,Experimental Usage,False,0.67,Low,,,,podoplanin,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"podoplanin (clone D2-40, Dako, 1:200), phospho-ERK (#9101, Cell Signaling, 1:250)",Antibody target not in NF pathway/tumor biology gene list: podoplanin
phospho-ERK,antibodies,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"podoplanin (clone D2-40, Dako, 1:200), phospho-ERK (#9101, Cell Signaling, 1:250)",Antibody target not in NF pathway/tumor biology gene list: phospho-ERK
ERK1/2,antibodies,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.9,Experimental Usage,False,0.33,Low,,,,ERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-ERK1/2 (p44/42 MAPK (Erk1/2); Cell Signaling Technology; 1:1000),Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
phospho-ERK1/2,antibodies,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-ERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-phopho ERK1/2 (Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204); Cell Signaling Technology; 1:1000),Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
GAPDH,antibodies,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-GAPDH; Santa Cruz Biotechnology Inc.; 1:3000,Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
rabbit IgG,antibodies,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,Experimental Usage,False,0.67,Low,,,,rabbit IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,anti-rabbit IgG HRP (Santa Cruz Biotechnology Inc.; 1:25000),Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
mouse IgG,antibodies,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,Experimental Usage,False,0.67,Low,,,,mouse IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,anti-mouse IgG HRP (Santa Cruz Biotechnology Inc.; 1:50000),Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
CD11b,antibodies,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,Experimental Usage,False,0.67,Low,,,,CD11b,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-mouse monoclonal antibodies against CD11b (8G12/HPCA-2, Becton–Dickinson; San Jose, CA) bound to allophycocyanin (APC)",Antibody target not in NF pathway/tumor biology gene list: CD11b
p75/NGFR,antibodies,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,Experimental Usage,False,0.33,Low,,,,p75/NGFR,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-p75/NGFR (C40-1457, Becton–Dickinson) bound to phycoerythrin (PE)",Antibody target not in NF pathway/tumor biology gene list: p75/NGFR
F4/80,antibodies,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.85,Experimental Usage,False,0.33,Low,,,,F4/80,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-F4/80 bound to Cy5.5 on ice in a solution containing phosphate-buffered saline,Antibody target not in NF pathway/tumor biology gene list: F4/80
CSF1,antibodies,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,Experimental Usage,False,0.67,Low,,,,CSF1,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,50 ng/mL Anti-CSF1 (R&D Systems MAB4161) in the same medium,Antibody target not in NF pathway/tumor biology gene list: CSF1
tomato,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,tomato,Rat,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rat anti-tomato (1:1000; Kerafast #EST203),Generic reporter/tag/housekeeping antibody: tomato
RFP,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,RFP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-RFP (1:1000; Rockland #600-401-379),Generic reporter/tag/housekeeping antibody: rfp
CD45,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,CD45,Goat,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,goat anti-CD45 (1:100; Bio-Techne #AF114),Antibody target not in NF pathway/tumor biology gene list: CD45
PDGFRα,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,PDGFRα,Goat,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,goat anti-PDGFRα (1:100; R&D system #AF1062),Antibody target not in NF pathway/tumor biology gene list: PDGFRα
Ki67,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,Ki67,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-Ki67 (1:200; Abcam #ab15580),Antibody target not in NF pathway/tumor biology gene list: Ki67
P-ERK,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,P-ERK,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-P-ERK (1:250; Cell Signaling #9101),Antibody target not in NF pathway/tumor biology gene list: P-ERK
cKIT,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,cKIT,Goat,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,goat anti-cKIT (1:100; R&D system #AF1356),Antibody target not in NF pathway/tumor biology gene list: cKIT
F4/80,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,F4/80,Rat,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rat anti-F4/80 (1:400; Abcam #ab6640),Antibody target not in NF pathway/tumor biology gene list: F4/80
MBP,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,MBP,Rat,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rat anti-MBP (1:200; Chemicon Millipore #MAB386),Antibody target not in NF pathway/tumor biology gene list: MBP
POSTN,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,POSTN,Goat,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,goat anti-POSTN (1:400; BioTechne #AF2955),Antibody target not in NF pathway/tumor biology gene list: POSTN
TNC,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,TNC,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-TNC (1:100; Abcam #ab108930),Antibody target not in NF pathway/tumor biology gene list: TNC
PGP9.5,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,PGP9.5,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-PGP9.5 (1:100; Abcam #ab108986),Antibody target not in NF pathway/tumor biology gene list: PGP9.5
nestin,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,nestin,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-nestin (1:100; Abcam # ab221660),Antibody target not in NF pathway/tumor biology gene list: nestin
Aqp1,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,Aqp1,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse A488-anti-Aqp1 (1:100; Santa Cruz Biotech #sc-25287),Antibody target not in NF pathway/tumor biology gene list: Aqp1
S100β,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,S100β,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-S100β (1:300; Abcam #ab218516),Antibody target not in NF pathway/tumor biology gene list: S100β
S-100β,antibodies,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.85,Experimental Usage,False,0.33,Low,,,,S-100β,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,We assessed the purity of Schwann cell cultures by immunofluorescent staining with an S-100β antibody,Antibody target not in NF pathway/tumor biology gene list: S-100β
SOX9,antibodies,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,False,0.33,Low,,,,SOX9,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"probed membranes with anti-SOX9 (Santa Cruz Biotechnology, Santa Cruz, CA; 1:700)",Antibody target not in NF pathway/tumor biology gene list: SOX9
β-actin,antibodies,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,False,0.33,Low,,,,β-actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"then re-probed with anti-β-actin (Cell Signaling Technology, Inc. #4967) as a loading control",Generic reporter/tag/housekeeping antibody: β-actin
SOX9,antibodies,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,False,0.67,Low,,,,SOX9,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"We performed SOX9 immunohistochemistry on formalin-fixed, paraffin-embedded sections with polyclonal anti-SOX9 antibody (Abcam, Cambridge, UK)",Antibody target not in NF pathway/tumor biology gene list: SOX9
beta-actin,antibodies,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Experimental Usage,False,0.33,Low,,,,beta-actin,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,beta-actin (Cell Signaling cat# 3700 1:10000),Generic reporter/tag/housekeeping antibody: beta-actin
p-ERK,antibodies,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Experimental Usage,False,0.33,Low,,,,p-ERK,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,p-ERK (Cell Signaling cat# 9101 1:1000),Antibody target not in NF pathway/tumor biology gene list: p-ERK
ERK,antibodies,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Experimental Usage,False,0.33,Low,,,,ERK,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,total ERK (Cell Signaling cat# 9102 1:1000),Antibody target not in NF pathway/tumor biology gene list: ERK
HIF1α,antibodies,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,False,1.00,Medium,,,,HIF1α,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"IHC was performed using a primary rabbit polyclonal anti HIF1α antibody (Novus Biologicals, Centennials, CO, USA)",Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
KIF11,antibodies,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,KIF11,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,incubated with anti-KIF11 antibody (Proteintech),Antibody target not in NF pathway/tumor biology gene list: KIF11
KIF15,antibodies,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,KIF15,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-KIF15 antibody (Proteintech),Antibody target not in NF pathway/tumor biology gene list: KIF15
Ki67,antibodies,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,Ki67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Ki67 (Ventana Medical Systems),Antibody target not in NF pathway/tumor biology gene list: Ki67
α-tubulin,antibodies,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,α-tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-α-tubulin (Sigma-Aldrich),Generic reporter/tag/housekeeping antibody: α-tubulin
α-tubulin,antibodies,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,α-tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-α-tubulin-Alexa488 antibody (Life Technologies),Generic reporter/tag/housekeeping antibody: α-tubulin
PGDS,antibodies,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.9,Experimental Usage,False,1.00,Medium,,,,PGDS,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"PGDS immunohistochemistry was carried out on adjacent paraffin sections using affinity‐purified rabbit polyclonal antibodies (1:500; Santa Cruz, CA, USA sc‐14825)",Antibody target not in NF pathway/tumor biology gene list: PGDS
phospho-AKT (S473),antibodies,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-AKT (S473),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: phospho-AKT (S473)
AKT,antibodies,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: AKT
phospho-S6K (T389),antibodies,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,phospho-S6K (T389),Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: phospho-S6K (T389)
S6K1,antibodies,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,S6K1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Total S6K1 antibody was used as previously described,Antibody target not in NF pathway/tumor biology gene list: S6K1
CD31,antibodies,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,CD31,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Sections were incubated with rat anti-CD31 antibodies (BD bioscience) at 1:40 dilution for 60 min at room temperature,Antibody target not in NF pathway/tumor biology gene list: CD31
Mib1,antibodies,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,Mib1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"For Mib1 detection, paraffin sections were treated with TRS or antigen retrieval followed by a prediluted Mib1 antibody (DAKO)",Antibody target not in NF pathway/tumor biology gene list: Mib1
CXCL12,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,False,0.33,Low,,,,CXCL12,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies were obtained from Peprotech (CXCL12),Antibody target not in NF pathway/tumor biology gene list: CXCL12
mCherry,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,False,0.33,Low,,,,mCherry,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Clontech (Dsred (mCherry)),Generic reporter/tag/housekeeping antibody: mcherry
GFAP,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,False,0.33,Low,,,,GFAP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Invitrogen (GFAP),Antibody target not in NF pathway/tumor biology gene list: GFAP
PDE4A,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,False,0.33,Low,,,,PDE4A,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Abcam (PDE4A & 58kD Golgi marker),Antibody target not in NF pathway/tumor biology gene list: PDE4A
LCA,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,False,0.33,Low,,,,LCA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Pharmingen (LCA),Antibody target not in NF pathway/tumor biology gene list: LCA
IBA-1,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,False,0.33,Low,,,,IBA-1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Wako (IBA-1),Antibody target not in NF pathway/tumor biology gene list: IBA-1
phosphorylated protein kinase A substrate,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,False,0.33,Low,,,,phosphorylated protein kinase A substrate,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Cell Signaling (phosphorylated protein kinase A (pPKA) substrate),Antibody target not in NF pathway/tumor biology gene list: phosphorylated protein kinase A substrate
CNPase,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,False,0.33,Low,,,,CNPase,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Sigma (CNPase),Antibody target not in NF pathway/tumor biology gene list: CNPase
phosphorylated CXCR4,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,False,0.33,Low,,,,phosphorylated CXCR4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibody directed against phosphorylated CXCR4 (pCXCR4) was developed in our lab and previously described,Antibody target not in NF pathway/tumor biology gene list: phosphorylated CXCR4
Olig2,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.85,Experimental Usage,False,0.33,Low,,,,Olig2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibody directed against Olig2 (DF-308) was a gift of Dr. Charles Stiles (Dana Farber Cancer Institute),Antibody target not in NF pathway/tumor biology gene list: Olig2
Ly6G,antibodies,PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.9,Experimental Usage,False,0.33,Low,,,,Ly6G,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Depletion of neutrophils via anti-Ly6G antibody or bone marrow suppression using hydroxyurea significantly improved tumor clearance.,Publication title lacks NF-specific terms: Neutrophil depletion enhanced the
p75,antibodies,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.95,Experimental Usage,False,0.33,Low,,,,p75,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated for 30 minutes on ice with unconjugated primary antibody p75 (1:1,000, Ab3125, Abcam)",Antibody target not in NF pathway/tumor biology gene list: p75
S100B,antibodies,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.95,Experimental Usage,False,0.33,Low,,,,S100B,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with primary antibodies, p75 (1:100, Ab3125, Abcam), S100B (1:1,000, Z0311, Dako)",Antibody target not in NF pathway/tumor biology gene list: S100B
MPZ,antibodies,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.95,Experimental Usage,False,0.33,Low,,,,MPZ,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"MPZ (1:100, Ab183868, Abcam), overnight at 4ºC",Antibody target not in NF pathway/tumor biology gene list: MPZ
CD31,antibodies,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,False,0.33,Low,,,,CD31,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD31 (3528S, 1:100, Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: CD31
Survivin,antibodies,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,False,0.33,Low,,,,Survivin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Survivin (MA5–15077, 1:200, Invitrogen)",Antibody target not in NF pathway/tumor biology gene list: Survivin
CENPF,antibodies,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,False,0.33,Low,,,,CENPF,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CENPF (PA5–84637, 1:200, Invitrogen)",Antibody target not in NF pathway/tumor biology gene list: CENPF
H3K27me3,antibodies,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,False,0.33,Low,,,,H3K27me3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"H3K27me3 (9733S, 1:100, Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: H3K27me3
CENPF,antibodies,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,False,0.33,Low,,,,CENPF,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CENPF (ab223847, 1:1000 dilution, Abcam)",Antibody target not in NF pathway/tumor biology gene list: CENPF
Vinculin,antibodies,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,False,0.33,Low,,,,Vinculin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Vinculin (ab219649, 1:1000 dilution, Abcam)",Generic reporter/tag/housekeeping antibody: vinculin
secondary antibody,antibodies,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.8,Experimental Usage,False,0.67,Low,,,,secondary antibody,,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"followed by either Alexa-Fluor-tagged secondary antibodies (Invitrogen, Grand Island, NY)",Secondary antibody (not an NF-specific research tool)
secondary antibody,antibodies,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.8,Experimental Usage,False,0.67,Low,,,,secondary antibody,,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,or biotinylated secondary antibodies and Vectastain Elite ABC development,Secondary antibody (not an NF-specific research tool)
CD34,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,False,0.33,Low,,,,CD34,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD34 Santa Cruz Biotechnology CAT#SC-74499; RRID: AB_1120394,Antibody target not in NF pathway/tumor biology gene list: CD34
CD56,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,False,0.67,Low,,,,CD56,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD56 Biocare Medical CAT#CM164A,Antibody target not in NF pathway/tumor biology gene list: CD56
CD117/c-kit,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,False,0.67,Low,,,,CD117/c-kit,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD117/c-kit Biocare Medical CAT#CME296AK; RRID: AB_10581782,Antibody target not in NF pathway/tumor biology gene list: CD117/c-kit
NGFR,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,False,0.67,Low,,,,NGFR,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,NGFR Biocare Medical CAT#ACI369A,Antibody target not in NF pathway/tumor biology gene list: NGFR
PanCytokeratin,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,False,0.67,Low,,,,PanCytokeratin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,PanCytokeratin Biocare Medical CAT#CM011A; RRID: AB_2811020,Antibody target not in NF pathway/tumor biology gene list: PanCytokeratin
SOX2,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,False,0.67,Low,,,,SOX2,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,SOX2 Biocare Medical CAT#ACI3109A,Antibody target not in NF pathway/tumor biology gene list: SOX2
SOX10,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,False,0.67,Low,,,,SOX10,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,SOX10 Biocare Medical CAT#ACI3099A,Antibody target not in NF pathway/tumor biology gene list: SOX10
S100,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,False,0.67,Low,,,,S100,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,S100 Biocare Medical CAT#ACI3237A,Antibody target not in NF pathway/tumor biology gene list: S100
c-Kit,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,False,0.67,Low,,,,c-Kit,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,APC Anti-c-Kit antibody [YB5.B8] (ab95678),Antibody target not in NF pathway/tumor biology gene list: c-Kit
S100A11,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,False,0.67,Low,,,,S100A11,Unknown,Recombinant,,,,,,,,,,,,,,,,,,,,,,,,,,Recombinant PE Anti-S100A11 antibody [EPR11172] (ab211996),Antibody target not in NF pathway/tumor biology gene list: S100A11
CD34,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,False,0.67,Low,,,,CD34,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,FITC Anti-CD34 antibody [4H11[APG]] (ab18227),Antibody target not in NF pathway/tumor biology gene list: CD34
H3K27me3,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.67,Low,,,,H3K27me3,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"H3K27me3 (Cell Signaling Technology, #9733, clone C36B11, 1:50 dilution)",Antibody target not in NF pathway/tumor biology gene list: H3K27me3
SOX10,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.67,Low,,,,SOX10,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"SOX10 (Cell Marque, #383R-1, clone EP268, 1:50 dilution)",Antibody target not in NF pathway/tumor biology gene list: SOX10
S100B,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.33,Low,,,,S100B,,,,,,,,,,,,,,,,,,,,,,,,,,,,"S100B (Ventana, #760-2523, 1:2 dilution)",Antibody target not in NF pathway/tumor biology gene list: S100B
pERK,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.33,Low,,,,pERK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"pERK (Cell Signaling Technologies, #4370, 1:1000 dilution)",Antibody target not in NF pathway/tumor biology gene list: pERK
ERK,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.33,Low,,,,ERK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"total ERK (Cell Signaling Technologies, #4695, 1:1000 dilution)",Antibody target not in NF pathway/tumor biology gene list: ERK
beta tubulin,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.33,Low,,,,beta tubulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"beta tubulin (Developmental Hybridoma Studies Bank, #E7, 1:10,000 dilution)",Generic reporter/tag/housekeeping antibody: beta tubulin
pAKT,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.33,Low,,,,pAKT,,,,,,,,,,,,,,,,,,,,,,,,,,,,"pAKT (Cell Signaling Technologies, #4060, 1:1000 dilution)",Antibody target not in NF pathway/tumor biology gene list: pAKT
AKT,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.33,Low,,,,AKT,,,,,,,,,,,,,,,,,,,,,,,,,,,,"total AKT (Cell Signaling Technologies, # 4685, 1:1000 dilution)",Antibody target not in NF pathway/tumor biology gene list: AKT
pMEK,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.33,Low,,,,pMEK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"pMEK (Cell Signaling Technologies, #9121, 1:1000 dilution)",Antibody target not in NF pathway/tumor biology gene list: pMEK
MEK,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.33,Low,,,,MEK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"total MEK (Cell Signaling Technologies, #8727, 1:1000 dilution)",Antibody target not in NF pathway/tumor biology gene list: MEK
pPAK,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.33,Low,,,,pPAK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"pPAK (Cell Signaling Technologies, #2601, 1:1000 dilution)",Antibody target not in NF pathway/tumor biology gene list: pPAK
Caspase-3,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.33,Low,,,,Caspase-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Caspase-3 (Cell Signaling Technologies, #9662, 1:1000 dilution)",Antibody target not in NF pathway/tumor biology gene list: Caspase-3
Caspase-7,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.33,Low,,,,Caspase-7,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Caspase-7 (Cell Signaling Technologies, #9492, 1:1,000 dilution)",Antibody target not in NF pathway/tumor biology gene list: Caspase-7
ALDH1A1,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,0.33,Low,,,,ALDH1A1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,ALDH1A1 (1:200; ab52492; Abcam),Antibody target not in NF pathway/tumor biology gene list: ALDH1A1
YAP,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,0.33,Low,,,,YAP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,YAP (1:100; #14074; CST),Antibody target not in NF pathway/tumor biology gene list: YAP
TAZ,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,0.33,Low,,,,TAZ,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,TAZ (1:100; sc-48805; Santa Cruz),Antibody target not in NF pathway/tumor biology gene list: TAZ
Ki67,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,0.33,Low,,,,Ki67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Ki67 (1:100; ab15580; Abcam),Antibody target not in NF pathway/tumor biology gene list: Ki67
Neurofilament,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,0.33,Low,,,,Neurofilament,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Neurofilament (1:1000; ab4680; Abcam),Antibody target not in NF pathway/tumor biology gene list: Neurofilament
S100,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,0.33,Low,,,,S100,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,S100 (pre-diluted; GA504; Dako),Antibody target not in NF pathway/tumor biology gene list: S100
Pan-TEAD,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,0.33,Low,,,,Pan-TEAD,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Pan-TEAD (1:1000; #13295; CST),Antibody target not in NF pathway/tumor biology gene list: Pan-TEAD
GAPDH,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,GAPDH (1:5000; AB2302; Merck),Generic reporter/tag/housekeeping antibody: gapdh
CTGF,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,0.33,Low,,,,CTGF,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CTGF (1:500, ab6992, Abcam)",Antibody target not in NF pathway/tumor biology gene list: CTGF
EGFR,antibodies,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,Experimental Usage,False,0.67,Low,,,,EGFR,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Rabbit anti-EGFR, Notch1 (Cell Signaling), and rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution",Antibody target not in NF pathway/tumor biology gene list: EGFR
Notch1,antibodies,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,Experimental Usage,False,0.67,Low,,,,Notch1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Rabbit anti-EGFR, Notch1 (Cell Signaling), and rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution",Antibody target not in NF pathway/tumor biology gene list: Notch1
"Na+,K+-ATPase",antibodies,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.85,Experimental Usage,False,0.67,Low,,,,"Na+,K+-ATPase",Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling)","Antibody target not in NF pathway/tumor biology gene list: Na+,K+-ATPase"
GAPDH,antibodies,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.85,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling)",Generic reporter/tag/housekeeping antibody: gapdh
PARP,antibodies,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.85,Experimental Usage,False,0.33,Low,,,,PARP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: PARP
Actin,antibodies,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,False,0.33,Low,,,,Actin,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,An actin immunocytochemistry assay was performed to study the cytoskeletal organization after PMO treatment using Phalloidin (Molecular Probes),Generic reporter/tag/housekeeping antibody: actin
FLAG,antibodies,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.95,Experimental Usage,False,1.00,Medium,,,,FLAG,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Flag expression was assessed by western blot (Monoclonal ANTI-FLAG M2 antibody, Sigma-Aldrich, St. Louis, MO)",Generic reporter/tag/housekeeping antibody: flag
NeuroD1,antibodies,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.95,Experimental Usage,False,0.33,Low,,,,NeuroD1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used were anti-NeuroD1 (Abcam, ab109224) and anti-β-actin (Sigma, A5316)",Antibody target not in NF pathway/tumor biology gene list: NeuroD1
β-actin,antibodies,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.95,Experimental Usage,False,0.33,Low,,,,β-actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used were anti-NeuroD1 (Abcam, ab109224) and anti-β-actin (Sigma, A5316)",Generic reporter/tag/housekeeping antibody: β-actin
Ras,antibodies,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.9,Experimental Usage,False,1.00,Medium,,,,Ras,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Ras was detected with a 1:250 dilution of anti-pan Ras monoclonal antibody (BD Transduction Laboratories, San Jose, CA)",Antibody target not in NF pathway/tumor biology gene list: Ras
Caspase-3,antibodies,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.9,Experimental Usage,False,0.67,Low,,,,Caspase-3,,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Caspase-3 was detected with a 1:1000 dilution of anti-Caspase-3 polycolonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)",Antibody target not in NF pathway/tumor biology gene list: Caspase-3
Phospho-Rb Ser 780,antibodies,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.9,Experimental Usage,False,0.67,Low,,,,Phospho-Rb Ser 780,,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Retinoblastoma protein (pRb) phosphorylated Serine 780 was detected with a 1:1000 dilution of anti-Phospho-Rb Ser 780 polyclonal antibody (Cell Signaling Technology, Danvers, MA)",Antibody target not in NF pathway/tumor biology gene list: Phospho-Rb Ser 780
β-Tubulin,antibodies,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.9,Experimental Usage,False,1.00,Medium,,,,β-Tubulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"β-Tubulin was immunoblotted with a 1:2000 dilution of the E7 monoclonal antibody (Developmental Studies Hybridoma Bank, Iowa City, IA)",Generic reporter/tag/housekeeping antibody: β-tubulin
pSmad3,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,pSmad3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-pSmad3, rabbit monoclonal Abcam Cat. # ab52903 RRID: AB_882596 1/200 dilution",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
Zpr-1,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,Zpr-1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody Zpr-1, mouse monoclonal Zebrafish International Resource Center Cat. # zpr-1 RRID: AB_10013803",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
Zn-5,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,Zn-5,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody Zn-5, mouse monoclonal Zebrafish International Resource Center Cat. # zn-5 RRID: AB_10013770",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
HuC/D,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,HuC/D,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-HuC/D, rabbit polyclonal Abcam Cat. # ab210554 RRID: AB_210554 1/500 dilution",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
PKC β1,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,PKC β1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-PKC β1, mouse monoclonal Santa Cruz Biotechnology Cat. # SC-8049 RRID: AB_628143",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
glutamine synthetase,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,glutamine synthetase,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-glutamine synthetase (GS), mouse monoclonal Sigma-Aldrich Cat. # MAB302 RRID: AB_2110656",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
SOX9,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,SOX9,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-SOX9, rabbit polyclonal Millipore Sigma Cat. # AB5535 RRID: AB_2239761 1/500 dilution",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
BrdU,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,BrdU,Rat,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-BrdU, rat monoclonal Thermo Fisher Cat. # MA 182088 RRID: AB_927214 1/500 dilution",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
BrdU,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,BrdU,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-BrdU, mouse monoclonal Thermo Fisher Cat. # B35128 RRID: AB_2536432 Clone MoBu-1",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
S100,antibodies,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,False,0.33,Low,,,,S100,,,,,,,,,,,,,,,,,,,,,,,,,,,,incubated with primary antibodies overnight at 4°C: S100-fluorescein isothiocyanate (FITC) (major protein expressed by C6 cells),Publication title lacks NF-specific terms: C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of
β-tubulin III,antibodies,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,False,0.33,Low,,,,β-tubulin III,,,,,,,,,,,,,,,,,,,,,,,,,,,,β-tubulin III-FITC (neurofibroma presence),Publication title lacks NF-specific terms: C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of
Ki67,antibodies,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,False,0.33,Low,,,,Ki67,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ki67-FITC (proliferation marker),Publication title lacks NF-specific terms: C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of
Vimentin,antibodies,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,False,0.33,Low,,,,Vimentin,,,,,,,,,,,,,,,,,,,,,,,,,,,,Vimentin-antigen presenting cell (APC) (expressed by C6 cells),Publication title lacks NF-specific terms: C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of
Foxp3,antibodies,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,False,0.33,Low,,,,Foxp3,,,,,,,,,,,,,,,,,,,,,,,,,,,,Foxp3-APC and CD45 (immune response markers),Publication title lacks NF-specific terms: C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of
CD45,antibodies,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,False,0.33,Low,,,,CD45,,,,,,,,,,,,,,,,,,,,,,,,,,,,Foxp3-APC and CD45 (immune response markers),Publication title lacks NF-specific terms: C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of
GFAP,antibodies,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,False,0.33,Low,,,,GFAP,,,,,,,,,,,,,,,,,,,,,,,,,,,,"labeled overnight at room temperature with the following conjugated primary antibodies: S100-FITC, Vimentin-FTIC, CD45-APC, Ki67-APC, and GFAP-APC",Publication title lacks NF-specific terms: C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of
S-100,antibodies,PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.85,Experimental Usage,False,0.67,Low,,,,S-100,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Human S-100 A and B protein was detected using rabbit antiserum (Dako Corp, Carpinteria, Calif)",Antibody target not in NF pathway/tumor biology gene list: S-100
rabbit IgG,antibodies,PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.8,Experimental Usage,False,0.67,Low,,,,rabbit IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,The rabbit anti-S-100 antibodies were detected using affinity purified biotinylated F(ab')2 swine anti-rabbit IgG (Dako),Secondary antibody (not an NF-specific research tool)
biotin,antibodies,PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.8,Experimental Usage,False,0.67,Low,,,,biotin,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,followed by horseradish peroxidase-conjugated streptavidin (Dako),Secondary antibody (not an NF-specific research tool)
Gal α 1-3Gal,antibodies,PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.85,Experimental Usage,False,0.33,Low,,,,Gal α 1-3Gal,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Fluorescein-conjugated IB4 (Vector Laboratories, Burlingame, Calif) diluted in PBS",Antibody target not in NF pathway/tumor biology gene list: Gal α 1-3Gal
DARPP32,antibodies,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,False,0.33,Low,,,,DARPP32,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: DARPP32
p-MAPK,antibodies,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,False,0.33,Low,,,,p-MAPK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: p-MAPK
total MAPK,antibodies,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,False,0.33,Low,,,,total MAPK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: total MAPK
p-DARPP32,antibodies,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,False,0.33,Low,,,,p-DARPP32,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,total MAPK (Cell Signaling) and p-DARPP32 (Abcam) antibodies,Antibody target not in NF pathway/tumor biology gene list: p-DARPP32
Cy3/Cy5,antibodies,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,Cy3/Cy5,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with a monoclonal anti-Cy3/Cy5 antibody (ab52060, Abcam, 1:2500) for 1 h at room temperature",Generic reporter/tag/housekeeping antibody: cy3/cy5
ATRX,antibodies,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.95,Experimental Usage,False,1.00,Medium,,,,ATRX,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"using an ATRX antibody (Rabbit polyclonal, 1:200 dilution, catalog# HPA001906 Sigma-Aldrich)",Antibody target not in NF pathway/tumor biology gene list: ATRX
DAXX,antibodies,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.95,Experimental Usage,False,1.00,Medium,,,,DAXX,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemistry for DAXX (Rabbit polyclonal, 1:100 dilution, catalog# HPA008736, Atlas Antibodies) was performed manually",Antibody target not in NF pathway/tumor biology gene list: DAXX
H3K27me3,antibodies,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.95,Experimental Usage,False,1.00,Medium,,,,H3K27me3,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"using a mouse monoclonal antibody (Abcam, Cat# ab6002, Cambridge, MA) at 1:1600 dilution",Antibody target not in NF pathway/tumor biology gene list: H3K27me3
phospho-ERK1/2,antibodies,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.95,Experimental Usage,False,0.33,Low,,,,phospho-ERK1/2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The cells were labeled with Alexa Fluor 647-conjugated anti-phospho-ERK1/2 primary antibody (Cell Signaling Technology, MA, USA)",Antibody target not in NF pathway/tumor biology gene list: phospho-ERK1/2
pH3,antibodies,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.8,Experimental Usage,False,0.33,Low,,,,pH3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The embryos were incubated in anti-pH3 antibody overnight at 4°C,Antibody target not in NF pathway/tumor biology gene list: pH3
Unknown,antibodies,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.85,Experimental Usage,False,0.33,Low,,,,Unknown,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"The next day, the samples were washed in PBS–Triton-X100 (4×30 min) at room temperature and incubated in a secondary antibody (Thermo Fisher Scientific, A21202) for 4 h at room temperature",Secondary antibody (not an NF-specific research tool)
Sox10,antibodies,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.85,Experimental Usage,False,0.33,Low,,,,Sox10,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-Sox10 antibody staining on HCR-processed sections was performed according to Kamenev et al. (2021),Antibody target not in NF pathway/tumor biology gene list: Sox10
"HLA-A,B,C",antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,False,0.33,Low,,,,"HLA-A,B,C",,,,,,,,,,,,,,,,,,,,,,,,,,,,"following Biolegend antibodies and stains: anti-human HLA-A,B,C (311405)","Antibody target not in NF pathway/tumor biology gene list: HLA-A,B,C"
H-2,antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,False,0.33,Low,,,,H-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-mouse H-2 (125505), Mouse IgG1, κ Isotype Ctrl (FC) Antibody",Antibody target not in NF pathway/tumor biology gene list: H-2
human nuclei,antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,False,0.33,Low,,,,human nuclei,,,,,,,,,,,,,,,,,,,,,,,,,,,,"using the following antibodies: human nuclei (ab254080, Abcam)",Generic reporter/tag/housekeeping antibody: human nuclei
Ki-67,antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,False,0.33,Low,,,,Ki-67,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki-67 (RM9106S1, Fisher Scientific), S-100 b (sc-393919, Santa Cruz Biotechnology)",Antibody target not in NF pathway/tumor biology gene list: Ki-67
S-100 b,antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,False,0.33,Low,,,,S-100 b,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki-67 (RM9106S1, Fisher Scientific), S-100 b (sc-393919, Santa Cruz Biotechnology)",Antibody target not in NF pathway/tumor biology gene list: S-100 b
H3K27me3,antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,False,0.33,Low,,,,H3K27me3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"H3K27me3 (9733, Cell Signaling Technologies), pERK (4370, Cell Signaling Technologies)",Antibody target not in NF pathway/tumor biology gene list: H3K27me3
pERK,antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,False,0.33,Low,,,,pERK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"H3K27me3 (9733, Cell Signaling Technologies), pERK (4370, Cell Signaling Technologies)",Antibody target not in NF pathway/tumor biology gene list: pERK
FAP,antibodies,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,Experimental Usage,False,0.67,Low,,,,FAP,Unknown,Recombinant,,,,,,,,,,,,,,,,,,,,,,,,,,"A recombinant anti-FAP antibody (clone ab207178, Abcam, Cambridge, UK) was applied at a dilution of 1:250",Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
LAMA2,antibodies,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,Experimental Usage,False,0.33,Low,,,,LAMA2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"primary antibodies for LAMA2 (Abnova (Catalog #: H00003908-M01), 1:1000)",Antibody target not in NF pathway/tumor biology gene list: LAMA2
SLC22A3,antibodies,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,Experimental Usage,False,0.33,Low,,,,SLC22A3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"SLC22A3 (Novus Biologicals (Catalog #: NBP1-83976), 1:750)",Antibody target not in NF pathway/tumor biology gene list: SLC22A3
PRRX1,antibodies,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,Experimental Usage,False,0.33,Low,,,,PRRX1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"PRRX1 (Thermo Fisher Scientific (Catalog#: MA5-26580), 1:200)",Antibody target not in NF pathway/tumor biology gene list: PRRX1
SOX10,antibodies,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,Experimental Usage,False,0.33,Low,,,,SOX10,,,,,,,,,,,,,,,,,,,,,,,,,,,,"SOX10 (Roche (Catalog#: 760-4968), pre-diluted kit)",Antibody target not in NF pathway/tumor biology gene list: SOX10
Phospho-p44/42 ERK1/2,antibodies,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.95,Experimental Usage,False,1.00,Medium,,,,Phospho-p44/42 ERK1/2,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Primary antibodies against Phospho-p44/42 ERK1/2 (p-ERK) (Cell Signaling Technologies #4370S) and p44/42 ERK1/2 (ERK) (Cell Signaling Technologies #4695S) were used at 1:100 dilution,Antibody target not in NF pathway/tumor biology gene list: Phospho-p44/42 ERK1/2
p44/42 ERK1/2,antibodies,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.95,Experimental Usage,False,1.00,Medium,,,,p44/42 ERK1/2,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Primary antibodies against Phospho-p44/42 ERK1/2 (p-ERK) (Cell Signaling Technologies #4370S) and p44/42 ERK1/2 (ERK) (Cell Signaling Technologies #4695S) were used at 1:100 dilution,Antibody target not in NF pathway/tumor biology gene list: p44/42 ERK1/2
phosphor-p44/p42 MAPK (ERK1/2),antibodies,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.95,Experimental Usage,False,1.00,Medium,,,,phosphor-p44/p42 MAPK (ERK1/2),Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemical staining for phosphor-p44/p42 MAPK (ERK1/2) (Thr202/Tyr204) (Cell Signaling Technology Catalog #4370, Rabbit mAb, 1:100 dilution)",Antibody target not in NF pathway/tumor biology gene list: phosphor-p44/p42 MAPK (ERK1/2)
pDARPP32,antibodies,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,Experimental Usage,False,0.33,Low,,,,pDARPP32,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using pDARPP32 (1:500, Cell Signaling), DARPP32 (1:1000, Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: pDARPP32
DARPP32,antibodies,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,Experimental Usage,False,0.33,Low,,,,DARPP32,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using pDARPP32 (1:500, Cell Signaling), DARPP32 (1:1000, Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: DARPP32
pERK1/2,antibodies,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,Experimental Usage,False,0.33,Low,,,,pERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pERK1/2 (1:1000, Cell Signaling), and ERK1/2 (1:1000, Cell Signaling) primary antibodies",Antibody target not in NF pathway/tumor biology gene list: pERK1/2
ERK1/2,antibodies,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,Experimental Usage,False,0.33,Low,,,,ERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pERK1/2 (1:1000, Cell Signaling), and ERK1/2 (1:1000, Cell Signaling) primary antibodies",Antibody target not in NF pathway/tumor biology gene list: ERK1/2
KRAS,antibodies,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,False,1.00,Medium,,,,KRAS,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"KRAS (Sigma; WH0003845M1, clone 3B10-2F2; does not detect proteins with E162L mutation)",Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
EGFP,antibodies,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,False,1.00,Medium,,,,EGFP,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"EGFP (Thermo Fisher Scientific; 11575712, clone F56-6A1.2.3)",Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
p-ERK1/2,antibodies,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,False,1.00,Medium,,,,p-ERK1/2,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"p-ERK1/2 (CST 4370, clone D13.14.4E)",Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
ERK1/2,antibodies,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,False,1.00,Medium,,,,ERK1/2,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"ERK1/2 (CST 9107, clone 3A7)",Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
Phospho-ERK1/2,antibodies,PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.9,Experimental Usage,False,0.33,Low,,,,Phospho-ERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"using an anti-Phospho-ERK1/2 antibody (Cell Signaling cat#9101, dilution 1:1000)",Antibody target not in NF pathway/tumor biology gene list: Phospho-ERK1/2
ERK1/2,antibodies,PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.9,Experimental Usage,False,0.33,Low,,,,ERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ananti-ERK1/2 antibody (Cell Signaling cat#9102, dilution 1:1000)",Antibody target not in NF pathway/tumor biology gene list: ERK1/2
c-Met,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,1.00,Medium,,,,c-Met,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,overnight incubation in a 1:250 dilution of total c-met rabbit polyclonal antibody (Santa Cruz),Antibody target not in NF pathway/tumor biology gene list: c-Met
phosphorylated c-Met,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,1.00,Medium,,,,phosphorylated c-Met,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"1:50 dilution of phosphorylated c-met (phosphorylated tyrosine sites pY1230, pY1234, and pY1236) rabbit polyclonal antibody (Invitrogen)",Antibody target not in NF pathway/tumor biology gene list: phosphorylated c-Met
Ki67,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,1.00,Medium,,,,Ki67,Rat,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Other slides were stained in a 1:100 dilution of Ki67 rat monoclonal antibody (Dako),Antibody target not in NF pathway/tumor biology gene list: Ki67
pan-cytokeratin,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,Experimental Usage,False,0.33,Low,,,,pan-cytokeratin,,,,,,,,,,,,,,,,,,,,,,,,,,,,Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma),Antibody target not in NF pathway/tumor biology gene list: pan-cytokeratin
cytokeratin 8,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,Experimental Usage,False,0.33,Low,,,,cytokeratin 8,,,,,,,,,,,,,,,,,,,,,,,,,,,,Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma),Antibody target not in NF pathway/tumor biology gene list: cytokeratin 8
mesothelin,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,Experimental Usage,False,0.33,Low,,,,mesothelin,,,,,,,,,,,,,,,,,,,,,,,,,,,,Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma) or mesothelin (Santa Cruz),Antibody target not in NF pathway/tumor biology gene list: mesothelin
Sox2,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,Experimental Usage,False,0.33,Low,,,,Sox2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin",Antibody target not in NF pathway/tumor biology gene list: Sox2
Nanog,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,Experimental Usage,False,0.33,Low,,,,Nanog,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin",Antibody target not in NF pathway/tumor biology gene list: Nanog
Oct 3/4,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,Experimental Usage,False,0.33,Low,,,,Oct 3/4,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin",Antibody target not in NF pathway/tumor biology gene list: Oct 3/4
beta-catenin,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,Experimental Usage,False,0.33,Low,,,,beta-catenin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin",Antibody target not in NF pathway/tumor biology gene list: beta-catenin
phospho P-Met,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho P-Met,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: phospho P-Met
Akt,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,0.33,Low,,,,Akt,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: Akt
P-Akt,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,0.33,Low,,,,P-Akt,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: P-Akt
MAPK,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,0.33,Low,,,,MAPK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: MAPK
c-Met,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,0.33,Low,,,,c-Met,,,,,,,,,,,,,,,,,,,,,,,,,,,,"and against c-Met, P-Erk and β-actin (1:1,000), from Santa Cruz",Antibody target not in NF pathway/tumor biology gene list: c-Met
P-Erk,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,0.33,Low,,,,P-Erk,,,,,,,,,,,,,,,,,,,,,,,,,,,,"and against c-Met, P-Erk and β-actin (1:1,000), from Santa Cruz",Antibody target not in NF pathway/tumor biology gene list: P-Erk
β-actin,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,0.33,Low,,,,β-actin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"and against c-Met, P-Erk and β-actin (1:1,000), from Santa Cruz",Generic reporter/tag/housekeeping antibody: β-actin
p53,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,0.33,Low,,,,p53,,,,,,,,,,,,,,,,,,,,,,,,,,,,"and p53 (1:500, NCL-p53-505, Novocastra) were used",Antibody target not in NF pathway/tumor biology gene list: p53
CD24,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,0.33,Low,,,,CD24,,,,,,,,,,,,,,,,,,,,,,,,,,,,1 × 106 MM cells were incubated with or without 10 μL of anti-CD24 FITC-labeled antibody (BD Biosciences),Antibody target not in NF pathway/tumor biology gene list: CD24
p55/MPP1,antibodies,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.9,Development,False,1.00,Medium,,,,p55/MPP1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,The anti-p55 mouse monoclonal antibody was generated by immunizing BALB/c mice with the recombinant SH3-GUK segment of human erythrocyte p55 protein. The clone 2G4 was selected,Antibody target not in NF pathway/tumor biology gene list: p55/MPP1
S100,antibodies,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,False,0.67,Low,,,,S100,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The following primary antibodies were used: rabbit anti-NF2 (Santa Cruz); mouse anti-p55 monoclonal (this study); mouse anti-S100 (SIGMA),Antibody target not in NF pathway/tumor biology gene list: S100
GFAP,antibodies,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,False,0.67,Low,,,,GFAP,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-GFAP (Chemicon) and rabbit anti-GFAP (SIGMA),Antibody target not in NF pathway/tumor biology gene list: GFAP
GFAP,antibodies,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,False,1.00,Medium,,,,GFAP,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-GFAP (Chemicon) and rabbit anti-GFAP (SIGMA),Antibody target not in NF pathway/tumor biology gene list: GFAP
NF-H,antibodies,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,False,1.00,Medium,,,,NF-H,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-NF-H (Chemicon); and mouse anti-Caspr,Antibody target not in NF pathway/tumor biology gene list: NF-H
Caspr,antibodies,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,False,0.67,Low,,,,Caspr,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"and mouse anti-Caspr, kindly provided by Dr. Elior Peles, The Weizmann Institute of Science, Rehovot, Israel",Antibody target not in NF pathway/tumor biology gene list: Caspr
CD3,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,False,0.33,Low,,,,CD3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",Antibody target not in NF pathway/tumor biology gene list: CD3
CD8,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,False,0.33,Low,,,,CD8,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",Antibody target not in NF pathway/tumor biology gene list: CD8
CD11c,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,False,0.33,Low,,,,CD11c,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",Antibody target not in NF pathway/tumor biology gene list: CD11c
CD19,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,False,0.33,Low,,,,CD19,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",Antibody target not in NF pathway/tumor biology gene list: CD19
CD163,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,False,0.33,Low,,,,CD163,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",Antibody target not in NF pathway/tumor biology gene list: CD163
CSF1R,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,False,0.33,Low,,,,CSF1R,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",Antibody target not in NF pathway/tumor biology gene list: CSF1R
FOXP3,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,False,0.33,Low,,,,FOXP3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",Antibody target not in NF pathway/tumor biology gene list: FOXP3
PD-L1,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,False,0.33,Low,,,,PD-L1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3, human leukocyte antigen (HLA)-class I, and PD-L1",Antibody target not in NF pathway/tumor biology gene list: PD-L1
H3K27me3,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.95,Experimental Usage,False,0.67,Low,,,,H3K27me3,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"IHC for H3K27me3 (Cell Signaling Technology, #9733, clone C36B11, 1:100 dilution) was performed on FFPE whole slide tissue sections",Antibody target not in NF pathway/tumor biology gene list: H3K27me3
ColIA,antibodies,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,Experimental Usage,False,0.67,Low,,,,ColIA,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Fibroblasts were stained for 30 min at 4°C with 1 µg/ml of FITC-conjugated anti-ColIA monoclonal antibody (Pharmingen, San Diego, CA, USA)",Antibody target not in NF pathway/tumor biology gene list: ColIA
ColIA,antibodies,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,Experimental Usage,False,0.33,Low,,,,ColIA,,,,,,,,,,,,,,,,,,,,,,,,,,,,"All tissues were sectioned (5 µm thickness), mounted onto slides and stained with PE-conjugated anti-ColIA antibody and counterstained with DAPI",Antibody target not in NF pathway/tumor biology gene list: ColIA
Abl,antibodies,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,Experimental Usage,False,0.33,Low,,,,Abl,,,,,,,,,,,,,,,,,,,,,,,,,,,,"equivalent protein (500 µg) was incubated overnight at 4°C with anti-Abl (K12; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)",Antibody target not in NF pathway/tumor biology gene list: Abl
Flag,antibodies,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,Experimental Usage,False,0.33,Low,,,,Flag,,,,,,,,,,,,,,,,,,,,,,,,,,,,"equivalent protein (500 µg) was incubated overnight at 4°C with anti-Abl (K12; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) or anti-Flag (Sigma-Aldrich)",Generic reporter/tag/housekeeping antibody: flag
c-abl,antibodies,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,Experimental Usage,False,0.33,Low,,,,c-abl,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Total c-abl protein was detected using an antibody from BD Biosciences (Cat. no. 554148, San Jose, CA, USA)",Antibody target not in NF pathway/tumor biology gene list: c-abl
TGF-β,antibodies,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,Experimental Usage,False,0.33,Low,,,,TGF-β,,,,,,,,,,,,,,,,,,,,,,,,,,,,"TGF-β neutralizing antibodies were obtained from R&D Systems, Inc. (Cat. no. AF-101-NA) and utilized as suggested by the manufacturer",Antibody target not in NF pathway/tumor biology gene list: TGF-β
Nestin,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,Nestin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Anti-Nestin antibody primary IF CST (Danvers, USA)",Antibody target not in NF pathway/tumor biology gene list: Nestin
SOX2,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,SOX2,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-SOX2 antibody primary IF CST,Antibody target not in NF pathway/tumor biology gene list: SOX2
MAP2,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,MAP2,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-MAP2 antibody primary IF and WB CST,Antibody target not in NF pathway/tumor biology gene list: MAP2
β3-Tubulin,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,β3-Tubulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-β3-Tubulin antibody primary IF and WB CST,Antibody target not in NF pathway/tumor biology gene list: β3-Tubulin
GFAP,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,GFAP,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-GFAP antibody primary IF and WB CST,Antibody target not in NF pathway/tumor biology gene list: GFAP
NF-200,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,NF-200,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-NF-200 antibody primary IF and WB CST,Antibody target not in NF pathway/tumor biology gene list: NF-200
NeuN,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,NeuN,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-NeuN antibody primary IF and WB CST,Antibody target not in NF pathway/tumor biology gene list: NeuN
cleaved caspase-3,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,cleaved caspase-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-cleaved caspase-3 antibody primary IF and WB CST,Antibody target not in NF pathway/tumor biology gene list: cleaved caspase-3
P-mTOR,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,P-mTOR,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-P-mTOR antibody primary WB CST,Antibody target not in NF pathway/tumor biology gene list: P-mTOR
Rictor,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,Rictor,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-Rictor antibody primary WB CST,Antibody target not in NF pathway/tumor biology gene list: Rictor
GAPDH,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,GAPDH,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-GAPDH antibody primary WB CST,Generic reporter/tag/housekeeping antibody: gapdh
Bcl-2,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,Bcl-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-Bcl-2 antibody primary IF and WB CST,Antibody target not in NF pathway/tumor biology gene list: Bcl-2
CNPase,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,CNPase,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-CNPase antibody primary IF and WB CST,Antibody target not in NF pathway/tumor biology gene list: CNPase
myelin basic protein,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,myelin basic protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-myelin basic protein (MBP) antibody primary IF and WB CST,Antibody target not in NF pathway/tumor biology gene list: myelin basic protein
cleaved caspase-3,antibodies,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,Experimental Usage,False,0.33,Low,,,,cleaved caspase-3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cleaved caspase-3+ cells (1∶500 dilution; Cell Signaling Technology, Beverly MA)",Antibody target not in NF pathway/tumor biology gene list: cleaved caspase-3
pErbB2,antibodies,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,Experimental Usage,False,0.33,Low,,,,pErbB2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,stained with pErbB2 (1∶50 dilution) as previously described [14],Antibody target not in NF pathway/tumor biology gene list: pErbB2
BLBP,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,BLBP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"BLBP (1:2000, rabbit, a kind gift from Dr. Todd Anthony)",Antibody target not in NF pathway/tumor biology gene list: BLBP
Calbindin,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,Calbindin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Calbindin (1:1000, mouse, Sigma-Aldrich)",Antibody target not in NF pathway/tumor biology gene list: Calbindin
GFAP,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,GFAP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GFAP (1:2000, rabbit, DAKO, Carpinteria, CA)",Antibody target not in NF pathway/tumor biology gene list: GFAP
BrdU,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.33,Low,,,,BrdU,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"BrdU (1:1000, rat, Abcam, Cambridge, MA)",Generic reporter/tag/housekeeping antibody: brdu
NeuN,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,NeuN,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"NeuN (1:400, mouse, Millipore, Billerica, MA)",Antibody target not in NF pathway/tumor biology gene list: NeuN
GABARα6,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,GABARα6,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GABARα6 (1:500, rabbit, Millipore)",Antibody target not in NF pathway/tumor biology gene list: GABARα6
Ki-67,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,Ki-67,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki-67 (1:500, mouse, BD Pharmingen)",Antibody target not in NF pathway/tumor biology gene list: Ki-67
Tbr2,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,Tbr2,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Tbr2 (1:1000, rabbit, Abcam)",Antibody target not in NF pathway/tumor biology gene list: Tbr2
Calretinin,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,Calretinin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Calretinin (1:1000, mouse, Millipore)",Antibody target not in NF pathway/tumor biology gene list: Calretinin
MAP2,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,MAP2,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"MAP2 (1:1000, mouse, Sigma-Aldrich)",Antibody target not in NF pathway/tumor biology gene list: MAP2
P27,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,P27,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"P27 (1:250, rabbit, Santa Cruz Biotechnology, Dallas, TX)",Antibody target not in NF pathway/tumor biology gene list: P27
β-gal,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,β-gal,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"β-gal (1:1000, rabbit, 5 prime-3 prime, Gaithersburg, MD)",Generic reporter/tag/housekeeping antibody: β-gal
p-Erk,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,p-Erk,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-Erk (1:200, rabbit, Cell Signaling, Beverly, MA)",Antibody target not in NF pathway/tumor biology gene list: p-Erk
p-S6,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,p-S6,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-S6 (1:1000, rabbit, Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: p-S6
BIM,antibodies,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,Experimental Usage,False,0.67,Low,,,,BIM,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies: anti-human C-terminal BIM (goat, Bio-RAD, Hercules, CA, USA, AHP2074; 1:1000)",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
BIM,antibodies,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,Experimental Usage,False,1.00,Medium,,,,BIM,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-human N-terminal BIM (C34C5) (rabbit, Cell Signaling, #2933; 1:1000)",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
b-tubulin,antibodies,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,Experimental Usage,False,1.00,Medium,,,,b-tubulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-b-tubulin (mouse, Developmental Studies Hybridoma Bank E7, Iowa City, IA USA, 1:10,000)",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
S100,antibodies,PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,Experimental Usage,False,1.00,Medium,,,,S100,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"S100 mouse monoclonal primary antibody (Cell Signaling Technology, Danvers, USA) diluted 1:1000",Antibody target not in NF pathway/tumor biology gene list: S100
Mouse IgG,antibodies,PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,Experimental Usage,False,0.67,Low,,,,Mouse IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"secondary antibody (1:1000, Anti-Mouse IgG (H+L), F(ab')2 Fragment Alexa Fluor 488 Conjugate, Cell Signaling Technology)",Secondary antibody (not an NF-specific research tool)
S100,antibodies,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,False,0.33,Low,,,,S100,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"IHC was performed using the Avidin/Biotin blocking kit (Vector Labs, SP-2001) staining with antibodies against S100 (1:250 dilution; catalog ab41548, Abcam)",Antibody target not in NF pathway/tumor biology gene list: S100
KI-67,antibodies,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,False,0.33,Low,,,,KI-67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"staining with antibodies against S100 (1:250 dilution; catalog ab41548, Abcam), KI-67 (prediluted; catalog 790-4286, Ventana)",Antibody target not in NF pathway/tumor biology gene list: KI-67
COL4A,antibodies,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,False,0.33,Low,,,,COL4A,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"KI-67 (prediluted; catalog 790-4286, Ventana), and COL4A (1:1000 dilution; catalog ab6586, Abcam)",Antibody target not in NF pathway/tumor biology gene list: COL4A
histone H3 (tri methyl K27),antibodies,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,False,0.33,Low,,,,histone H3 (tri methyl K27),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunolabeling for anti-histone H3 (tri methyl K27) (1:200 dilution; catalog ab6002, Abcam)",Antibody target not in NF pathway/tumor biology gene list: histone H3 (tri methyl K27)
XBP1,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,XBP1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The sheared chromatin was immunoprecipitated with 5 μg of anti-XBP1 antibodies (Cell Signaling Technology, Danvers, MA, USA)",Antibody target not in NF pathway/tumor biology gene list: XBP1
GAPDH,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in the study include anti-GAPDH (Proteintech Group Inc., Rosemont, IL, USA)",Generic reporter/tag/housekeeping antibody: gapdh
α-tubulin,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,α-tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-α-tubulin (Proteintech Group Inc., Rosemont, IL, USA)",Generic reporter/tag/housekeeping antibody: α-tubulin
XBP1u,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,XBP1u,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-XBP1u (Abcepta, Reservoir Victoria, Australia)",Antibody target not in NF pathway/tumor biology gene list: XBP1u
XBP1s,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,XBP1s,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-XBP1s (Cell Signaling),Antibody target not in NF pathway/tumor biology gene list: XBP1s
Parkin,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,Parkin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-Parkin (Cell Signaling, Danvers, MA, USA)",Antibody target not in NF pathway/tumor biology gene list: Parkin
PINK1,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,PINK1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-PINK1 (Genetex, Hsinchu, Taiwan)",Antibody target not in NF pathway/tumor biology gene list: PINK1
LC3B,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,LC3B,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-LC3B (Cell Signaling, Danvers, MA, USA)",Antibody target not in NF pathway/tumor biology gene list: LC3B
GLUT1,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,GLUT1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-GLUT1 (Proteintech Group Inc., Rosemont, IL, USA) antibodies",Antibody target not in NF pathway/tumor biology gene list: GLUT1
ATP5H,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,ATP5H,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"the primary antibodies, anti-ATP5H (Thermo Fisher Scientific, Waltham, MA, USA)",Antibody target not in NF pathway/tumor biology gene list: ATP5H
LC3,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,LC3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-LC3 antibodies (Cell Signaling, Danvers, MA, USA)",Antibody target not in NF pathway/tumor biology gene list: LC3
Ki67,antibodies,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,Experimental Usage,False,1.00,Medium,,,,Ki67,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"proliferation marker protein Ki-67 (antigen Ki67, monoclonal mouse anti-human Ki67 antigen, clone MIB1, M7240, DAKO)",Antibody target not in NF pathway/tumor biology gene list: Ki67
p21,antibodies,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,Experimental Usage,False,1.00,Medium,,,,p21,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"cyclin-dependent kinase inhibitor p21 (p21, monoclonal mouse anti-human p21 WAF1/Cip1 , M7202, DAKO)",Antibody target not in NF pathway/tumor biology gene list: p21
p53,antibodies,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,Experimental Usage,False,1.00,Medium,,,,p53,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"tumor protein p53 (p53, monoclonal mouse anti-human p53 M7001, DAKO)",Antibody target not in NF pathway/tumor biology gene list: p53
bcl2,antibodies,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,Experimental Usage,False,1.00,Medium,,,,bcl2,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"B-cell lymphoma 2 (bcl2, monoclonal mouse anti-human bcl2 oncoprotein, M887, DAKO)",Antibody target not in NF pathway/tumor biology gene list: bcl2
bcl6,antibodies,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,Experimental Usage,False,1.00,Medium,,,,bcl6,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"B-cell lymphoma 6 (bcl6, monoclonal mouse anti-human bcl6 protein, M7211, DAKO)",Antibody target not in NF pathway/tumor biology gene list: bcl6
cyclin D1,antibodies,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,Experimental Usage,False,1.00,Medium,,,,cyclin D1,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"cyclin D1 (monoclonal rabbit anti-human cyclin D1, M3642, DAKO)",Antibody target not in NF pathway/tumor biology gene list: cyclin D1
phospho-RB1 S807/811,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,False,0.33,Low,,,,phospho-RB1 S807/811,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with phospho-RB1 S807/811 antibody (Cell Signaling Technology, no. 8516, 1:1600)",Antibody target not in NF pathway/tumor biology gene list: phospho-RB1 S807/811
kappa light chain,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,False,1.00,Medium,,,,kappa light chain,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"kappa light chain to identify plasma cells (rabbit monoclonal antibody, Sigma Aldrich, clone RM103, SAB5600201, 1:400)",Antibody target not in NF pathway/tumor biology gene list: kappa light chain
B220,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,False,0.67,Low,,,,B220,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"B220 to identify B cells (RRID: AB_323211, rat anti-mouse monoclonal, Serotec Company, Catalog #MCA1258G, 1:1200)",Antibody target not in NF pathway/tumor biology gene list: B220
CD3,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,False,1.00,Medium,,,,CD3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"CD3 to identify T cells (rabbit monoclonal, NeoMarkers Company, #RM-9107-S, 1:200)",Antibody target not in NF pathway/tumor biology gene list: CD3
SIAH,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,False,1.00,Medium,,,,SIAH,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Immunostaining for SIAH (24E6H3 mouse monoclonal antibody),Antibody target not in NF pathway/tumor biology gene list: SIAH
RABL6A,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,False,0.33,Low,,,,RABL6A,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Immunostaining for SIAH (24E6H3 mouse monoclonal antibody) and RABL6A was conducted,Antibody target not in NF pathway/tumor biology gene list: RABL6A
PD-L1,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,False,0.33,Low,,,,PD-L1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,bi-weekly intraperitoneal injections of 10 mg/kg anti-PDL1 antibody (BioXCell BE0101),Antibody target not in NF pathway/tumor biology gene list: PD-L1
Ref-1,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,Experimental Usage,False,1.00,Medium,,,,Ref-1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"stained for Ref-1 (mouse Ref-1 antibody, 1:200 dilution, Novus Biologicals, 13B8E5C2)",Antibody target not in NF pathway/tumor biology gene list: Ref-1
p-STAT3,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,Experimental Usage,False,1.00,Medium,,,,p-STAT3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"p-STAT3 (Y705) (rabbit monoclonal 1:25 dilution, Cell Signaling, D3A7)",Antibody target not in NF pathway/tumor biology gene list: p-STAT3
HIF1-α,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,0.67,Low,,,,HIF1-α,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HIF1-α (rabbit, GTX127309, GeneTex, Irvine, CA, USA)",Antibody target not in NF pathway/tumor biology gene list: HIF1-α
STAT3,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,1.00,Medium,,,,STAT3,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"STAT3 (mouse, 124H6), Cleaved PARP (poly-ADP ribose polymerase, rabbit, D64E10), total PARP (rabbit, #9542) (Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: STAT3
Cleaved PARP,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,1.00,Medium,,,,Cleaved PARP,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Cleaved PARP (poly-ADP ribose polymerase, rabbit, D64E10)",Antibody target not in NF pathway/tumor biology gene list: Cleaved PARP
PARP,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,0.67,Low,,,,PARP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"total PARP (rabbit, #9542) (Cell Signaling, Danvers, MA, USA)",Antibody target not in NF pathway/tumor biology gene list: PARP
Vinculin,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,0.67,Low,,,,Vinculin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Vinculin (mouse, V284, Sigma, St. Louis, MO, USA)",Generic reporter/tag/housekeeping antibody: vinculin
Actin,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,1.00,Medium,,,,Actin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Actin (mouse, ACTN05(C4), NeoMarkers) at 1:1000 dilution",Generic reporter/tag/housekeeping antibody: actin
merlin,antibodies,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,Experimental Usage,True,0.33,Medium,,,,merlin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The absence of merlin in schwannoma cells was confirmed regularly by Western blot (1:2000, Cat. No. 12888, Cell Signaling Technology)",Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
Ki-67,antibodies,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,Ki-67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cells were stained with antibodies specific for Ki-67 (1:800 dilution, Cat. no. 9449, Cell Signaling)",Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
nitrated Hsp90,antibodies,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.95,Experimental Usage,False,0.33,Low,,,,nitrated Hsp90,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,in-house developed antibodies specific for Hsp90 nitrated at Tyr 33 or Tyr 56 (dilution 1:200),Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
TSC1,antibodies,PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,0.95,Experimental Usage,False,0.67,Low,,,,TSC1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Membranes were incubated with rabbit anti-TSC1 antibody (Cell signaling, #4906)",Publication title lacks NF-specific terms: Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone
p-S6,antibodies,PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,0.95,Experimental Usage,False,0.67,Low,,,,p-S6,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-p-S6 antibody (Cell Signaling, #5364)",Publication title lacks NF-specific terms: Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone
S6,antibodies,PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,0.95,Experimental Usage,False,0.67,Low,,,,S6,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-S6 antibody (Cell signaling #2217),Publication title lacks NF-specific terms: Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone
Vinculin,antibodies,PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,0.95,Experimental Usage,False,0.67,Low,,,,Vinculin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-Vinculin antibody (Sigma-aldrich V4505),Publication title lacks NF-specific terms: Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone
Osterix,antibodies,PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,0.9,Experimental Usage,False,0.33,Low,,,,Osterix,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Sections were then incubated with primary antibodies (anti-p-S6 and anti-Osterix) overnight at 4°C,Publication title lacks NF-specific terms: Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone
Ki67,antibodies,PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,0.95,Experimental Usage,False,0.33,Low,,,,Ki67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"sections were incubated with primary antibody (Ki67, Spring, M306) overnight at 4°C",Publication title lacks NF-specific terms: Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone
S100 protein,antibodies,PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,0.9,Experimental Usage,False,1.00,Medium,,,,S100 protein,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunostaining with S100 protein (rabbit polyclonal, Dako, Carpenteria, Calif, USA) and KIT (rabbit polyclonal, Dako) was performed when necessary to confirm diagnosis.",Antibody target not in NF pathway/tumor biology gene list: S100 protein
KIT,antibodies,PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,0.9,Experimental Usage,False,1.00,Medium,,,,KIT,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunostaining with S100 protein (rabbit polyclonal, Dako, Carpenteria, Calif, USA) and KIT (rabbit polyclonal, Dako) was performed when necessary to confirm diagnosis.",Antibody target not in NF pathway/tumor biology gene list: KIT
EGFR,antibodies,PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,0.95,Experimental Usage,False,1.00,Medium,,,,EGFR,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"For mouse monoclonal anti-EGFR (31G7, Zymed, South San Francisco, Calif, USA, final dilution 1/10), P53 (DO-7, Novocastra, Newcastle upon Tyne, UK, final dilution 1/50)",Antibody target not in NF pathway/tumor biology gene list: EGFR
p53,antibodies,PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,0.95,Experimental Usage,False,1.00,Medium,,,,p53,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"For mouse monoclonal anti-EGFR (31G7, Zymed, South San Francisco, Calif, USA, final dilution 1/10), P53 (DO-7, Novocastra, Newcastle upon Tyne, UK, final dilution 1/50)",Antibody target not in NF pathway/tumor biology gene list: p53
Ki-67,antibodies,PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,0.9,Experimental Usage,False,1.00,Medium,,,,Ki-67,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"and anti-Ki-67 (Mib1 Dako, final dilution 1/50), staining was revealed with LSAB kit (Dako).",Antibody target not in NF pathway/tumor biology gene list: Ki-67
Survivin,antibodies,PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,0.95,Experimental Usage,False,1.00,Medium,,,,Survivin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"For anti-Survivin (12C4, Dako, final dilution 1/100) staining was revealed with CSAII (Dako), according to manufacturer's instruction.",Antibody target not in NF pathway/tumor biology gene list: Survivin
Aurora kinase A,antibodies,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.95,Experimental Usage,False,0.67,Low,,,,Aurora kinase A,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"membranes were probed with several different antibodies including anti-AurkA antibodies (Cell Signalling Technology Inc., #3092)",Antibody target not in NF pathway/tumor biology gene list: Aurora kinase A
Aurora kinase B,antibodies,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.95,Experimental Usage,False,0.67,Low,,,,Aurora kinase B,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-AurkB antibody (Cell Signalling Technology Inc., #3094)",Antibody target not in NF pathway/tumor biology gene list: Aurora kinase B
Histone 3,antibodies,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.95,Experimental Usage,False,0.67,Low,,,,Histone 3,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-Histone 3 (Cell Signalling Technology Inc., #9715)",Antibody target not in NF pathway/tumor biology gene list: Histone 3
phospho-Histone 3,antibodies,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.95,Experimental Usage,False,0.67,Low,,,,phospho-Histone 3,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-p-Histone 3 (Cell Signalling Technology Inc., #9701)",Antibody target not in NF pathway/tumor biology gene list: phospho-Histone 3
PARP,antibodies,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.95,Experimental Usage,False,0.67,Low,,,,PARP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-PARP (Cell Signalling Technology Inc., #9542)",Antibody target not in NF pathway/tumor biology gene list: PARP
β-actin,antibodies,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.95,Experimental Usage,False,1.00,Medium,,,,β-actin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"stripped and re-probed with anti-β-actin antibodies (Cell Signaling Technology, Inc. #4967) as a loading control",Generic reporter/tag/housekeeping antibody: β-actin
S100β,antibodies,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.9,Experimental Usage,False,0.33,Low,,,,S100β,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Schwann cells were labeled with anti-S100β antibodies (Dako, Carpenteria, CA)",Antibody target not in NF pathway/tumor biology gene list: S100β
HA tag,antibodies,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.9,Experimental Usage,False,0.33,Low,,,,HA tag,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"expression of the HA-tagged CNP-HRAS12V transgene was detected with anti-HA antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)",Generic reporter/tag/housekeeping antibody: ha tag
cleaved caspase-3,antibodies,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.95,Experimental Usage,False,0.67,Low,,,,cleaved caspase-3,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Sections were incubated overnight in primary antibody; rabbit cleaved caspase-3 (1:8000, Cell Signaling, #9661)",Antibody target not in NF pathway/tumor biology gene list: cleaved caspase-3
Ki-67,antibodies,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.95,Experimental Usage,False,0.67,Low,,,,Ki-67,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Rabbit Ki-67 (1:5000 NCL-Ki67-P; Novocastra),Antibody target not in NF pathway/tumor biology gene list: Ki-67
cyclin B1,antibodies,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.95,Experimental Usage,False,0.67,Low,,,,cyclin B1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit cyclinB1 (1:500, Cell Signaling, #4138)",Antibody target not in NF pathway/tumor biology gene list: cyclin B1
BRD4,antibodies,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,BRD4,,,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies Used: BRD4 (Bethyl Labs),Antibody target not in NF pathway/tumor biology gene list: BRD4
GAPDH,antibodies,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,GAPDH,,,,,,,,,,,,,,,,,,,,,,,,,,,,"GAPDH, BRD3, BRD2 (Santa Cruz Biotechnology)",Generic reporter/tag/housekeeping antibody: gapdh
BRD3,antibodies,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,BRD3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"GAPDH, BRD3, BRD2 (Santa Cruz Biotechnology)",Antibody target not in NF pathway/tumor biology gene list: BRD3
BRD2,antibodies,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,BRD2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"GAPDH, BRD3, BRD2 (Santa Cruz Biotechnology)",Antibody target not in NF pathway/tumor biology gene list: BRD2
Alpha/Beta Tubulin,antibodies,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,Alpha/Beta Tubulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Alpha/Beta Tubulin (a,b-Tubulin), Bim, Cleaved-Caspase 3, Cleaved-PARP, Histone 3 (Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: Alpha/Beta Tubulin
Bim,antibodies,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,Bim,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Alpha/Beta Tubulin (a,b-Tubulin), Bim, Cleaved-Caspase 3, Cleaved-PARP, Histone 3 (Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: Bim
Cleaved-Caspase 3,antibodies,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,Cleaved-Caspase 3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Alpha/Beta Tubulin (a,b-Tubulin), Bim, Cleaved-Caspase 3, Cleaved-PARP, Histone 3 (Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: Cleaved-Caspase 3
Cleaved-PARP,antibodies,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,Cleaved-PARP,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Alpha/Beta Tubulin (a,b-Tubulin), Bim, Cleaved-Caspase 3, Cleaved-PARP, Histone 3 (Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: Cleaved-PARP
Histone 3,antibodies,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,Histone 3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Alpha/Beta Tubulin (a,b-Tubulin), Bim, Cleaved-Caspase 3, Cleaved-PARP, Histone 3 (Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: Histone 3
S100B,antibodies,PMID:26657314,10.1371/journal.pone.0144620,Immortalized Human Schwann Cell Lines Derived From Tumors of Schwannomatosis Patients.,,0.85,Experimental Usage,False,0.33,Low,,,,S100B,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The schwannomatosis cell lines were stained with S100B antibodies to confirm Schwann cell identity.,Antibody target not in NF pathway/tumor biology gene list: S100B
S100,antibodies,PMID:32193437,10.1038/s41598-020-61251-4,Longitudinal phenotype development in a minipig model of neurofibromatosis type 1.,,0.8,Experimental Usage,False,0.33,Low,,,,S100,,,,,,,,,,,,,,,,,,,,,,,,,,,,stained for hematoxylin and eosin (HE) or Masson's Trichrome (MT) stains. S100 immunohistochemistry was performed as detailed previously,Antibody target not in NF pathway/tumor biology gene list: S100
pY397 FAK,antibodies,PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,0.9,Experimental Usage,False,0.67,Low,,,,pY397 FAK,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-pY397 FAK (141-9) was from Life Technologies.,Antibody target not in NF pathway/tumor biology gene list: pY397 FAK
FAK,antibodies,PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,0.9,Experimental Usage,False,0.67,Low,,,,FAK,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-FAK (4.47) and GAPDH (clone 374) were from Millipore,Antibody target not in NF pathway/tumor biology gene list: FAK
GAPDH,antibodies,PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,0.9,Experimental Usage,False,0.67,Low,,,,GAPDH,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-FAK (4.47) and GAPDH (clone 374) were from Millipore,Generic reporter/tag/housekeeping antibody: gapdh
actin,antibodies,PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,0.9,Experimental Usage,False,0.67,Low,,,,actin,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,anti-actin (AC-74) was from Sigma,Generic reporter/tag/housekeeping antibody: actin
HGF,antibodies,PMID:20739432,10.1158/1078-0432.CCR-10-0613,Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.,,0.8,Experimental Usage,False,0.33,Low,,,,HGF,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HGF (10 ng/mL), or anti-HGF antibody (0.5 μg/mL) in triplicate",Antibody target not in NF pathway/tumor biology gene list: HGF
β-actin,antibodies,PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,0.9,Experimental Usage,False,0.67,Low,,,,β-actin,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"monoclonal anti-β-actin antibody (Sigma cat# AC-74, dilution 1: 5000)",Generic reporter/tag/housekeeping antibody: β-actin
Phospho-Smad1/5,antibodies,PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,0.9,Experimental Usage,False,0.33,Low,,,,Phospho-Smad1/5,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-Phospho-Smad1/5 antibody (Cell Signaling cat#9516S, dilution 1:1000)",Antibody target not in NF pathway/tumor biology gene list: Phospho-Smad1/5
Smad1+Smad5,antibodies,PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,0.9,Experimental Usage,False,0.33,Low,,,,Smad1+Smad5,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-Smad1+Smad5 antibody (Abcam cat# ab75273, dilution 1:1000)",Antibody target not in NF pathway/tumor biology gene list: Smad1+Smad5
ENPP1/PC-1,antibodies,PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,0.9,Experimental Usage,False,0.33,Low,,,,ENPP1/PC-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti ENPP1/PC-1 (Aviva Systems Biology, cat# OAEB02445, dilution 1:500)",Antibody target not in NF pathway/tumor biology gene list: ENPP1/PC-1
ANK,antibodies,PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,0.9,Experimental Usage,False,0.33,Low,,,,ANK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-ANK (Origen, cat# TA325111, dilution 1:1000)",Antibody target not in NF pathway/tumor biology gene list: ANK
SPI1,antibodies,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.95,Experimental Usage,False,0.33,Low,,,,SPI1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"IHC of SPI1 (#CST-2258, Cell Signaling Technology, RRID:AB_2186909, 1:200 dilution)",Antibody target not in NF pathway/tumor biology gene list: SPI1
ETV4,antibodies,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.95,Experimental Usage,False,0.33,Low,,,,ETV4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ETV4 (#10684-1-AP, proteintech, RRID:AB_2100984, 1:200 dilution)",Antibody target not in NF pathway/tumor biology gene list: ETV4
CDK6,antibodies,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.95,Experimental Usage,False,0.33,Low,,,,CDK6,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CDK6 (#14052-1-AP, proteintech, RRID:AB_10642144, 1:200 dilution)",Antibody target not in NF pathway/tumor biology gene list: CDK6
pRSK1,antibodies,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.95,Experimental Usage,False,0.33,Low,,,,pRSK1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pRSK1 (#CST-11989, Cell Signaling Technology, RRID:AB_2687613, 1:300 dilution)",Antibody target not in NF pathway/tumor biology gene list: pRSK1
CDK4,antibodies,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.95,Experimental Usage,False,0.33,Low,,,,CDK4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"IHC of human CDK4 (#BS-0633R, Bioss, RRID:AB_10856091, 1:400 dilution)",Antibody target not in NF pathway/tumor biology gene list: CDK4
phospho-Rb,antibodies,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.95,Experimental Usage,False,0.33,Low,,,,phospho-Rb,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-Rb (S807/811) (#CST-8516, Cell Signaling Technology, RRID:AB_11178658, 1:100 dilution)",Antibody target not in NF pathway/tumor biology gene list: phospho-Rb
CSF1R,antibodies,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.95,Experimental Usage,False,0.33,Low,,,,CSF1R,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CSF1R (#CST-3152, Cell Signaling Technology, RRID:AB_2085233, 1:100 dilution)",Antibody target not in NF pathway/tumor biology gene list: CSF1R
Ki67,antibodies,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.95,Experimental Usage,False,0.33,Low,,,,Ki67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki67 (#ab16667, Abcam, RRID:AB_302459, 1:200 dilution)",Antibody target not in NF pathway/tumor biology gene list: Ki67
γ-H2AX,antibodies,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,γ-H2AX,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Alexa Fluor 488 pre-conjugated anti-γ-H2AX (N1-431) mouse monoclonal (1:50 for 30 min; cat. no 560445, BD Biosciences)",Antibody target not in NF pathway/tumor biology gene list: γ-H2AX
cleaved caspase 3,antibodies,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,cleaved caspase 3,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-cleaved caspase 3 (Asp175) rabbit polyclonal (1:200; cat. no 9661, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: cleaved caspase 3
SQSTM1/p62,antibodies,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,SQSTM1/p62,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-SQSTM1/p62 (D-3) mouse monoclonal (1:500; cat. no sc-28359, Santa Cruz Biotechnology)",Antibody target not in NF pathway/tumor biology gene list: SQSTM1/p62
8-hydroxyguanosine,antibodies,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.9,Experimental Usage,False,0.67,Low,,,,8-hydroxyguanosine,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-8-hydroxyguanosine goat polyclonal (1:200; cat. no DR1001, Millipore)",Antibody target not in NF pathway/tumor biology gene list: 8-hydroxyguanosine
BNIP3L/Nix,antibodies,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,BNIP3L/Nix,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-BNIP3L/Nix (D4R4B) rabbit monoclonal (1:200, overnight at 4°C; cat. no 12396, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: BNIP3L/Nix
Tom20,antibodies,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,Tom20,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-Tom20 (FL-145) rabbit polyclonal (1:200; cat. no sc-11415, Santa Cruz Biotechnology)",Antibody target not in NF pathway/tumor biology gene list: Tom20
LAMP1,antibodies,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,LAMP1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-LAMP1 (D4O1S) mouse monoclonal (1:100, overnight at 4°C; cat. no 15665, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: LAMP1
FLAG,antibodies,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,FLAG,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-FLAG (M2) mouse monoclonal (1:500 for 2 h at 37°C; cat. no F1804, Sigma-Aldrich)",Generic reporter/tag/housekeeping antibody: flag
PARP,antibodies,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,PARP,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-PARP (46D11) rabbit monoclonal (cat. no 9532, Cell Signaling Technology, 1:5000, overnight at 4°C)",Antibody target not in NF pathway/tumor biology gene list: PARP
LC3BI/II,antibodies,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,LC3BI/II,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-LC3BI/II rabbit polyclonal (cat. no #2775, Cell Signaling, 1:1000, overnight at 4°C)",Antibody target not in NF pathway/tumor biology gene list: LC3BI/II
C17orf59/BORCS6,antibodies,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,C17orf59/BORCS6,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-C17orf59/BORCS6 rabbit polyclonal (cat. no PA566346, Invitrogen, 1:1000, overnight at 4°C)",Antibody target not in NF pathway/tumor biology gene list: C17orf59/BORCS6
GAPDH,antibodies,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,GAPDH,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-GAPDH (14C10) rabbit monoclonal (cat. no 2118, Cell Signaling Technology, 1:2500, 1 h at RT)",Generic reporter/tag/housekeeping antibody: gapdh
α-tubulin,antibodies,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,α-tubulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-α-tubulin (B-1-2-5) mouse monoclonal (cat. no sc-23948, Santa Cruz Biotehcnology, 1:10,000, 1 h at RT)",Generic reporter/tag/housekeeping antibody: α-tubulin
CD45,antibodies,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.9,Experimental Usage,False,0.33,Low,,,,CD45,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"IHC of CD45 (Cell Signaling Technology [CST], catalog 70257, 1:100) was performed",Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
H3K27me3,antibodies,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.9,Experimental Usage,False,0.33,Low,,,,H3K27me3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"IHC stainings for H3K27me3 (MilliporeSigma, catalog 07-449, 1:500, protocol no. 313)",Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
Ki67,antibodies,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.9,Experimental Usage,False,0.33,Low,,,,Ki67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki67 (Abcam, catalog ab15580, 1:500, protocol no. 312)",Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
S100B,antibodies,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.9,Experimental Usage,False,0.33,Low,,,,S100B,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"S100B (Abcam, catalog ab52642, 1:2000, protocol no. 313)",Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
NF1,antibodies,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.95,Experimental Usage,True,0.33,Medium,,,,NF1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-NF1 (1:2000, Bethyl Laboratories, catalog A300-140A)",Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
SUZ12,antibodies,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.9,Experimental Usage,True,0.33,Medium,,,,SUZ12,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-SUZ12 (1:1000, CST, catalog 3737)",Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
Iba1,antibodies,PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,0.95,Experimental Usage,False,1.00,Medium,,,,Iba1,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"sections were incubated overnight with rabbit anti-Iba1 (1:3000; Wako, Richmond, VA)",Antibody target not in NF pathway/tumor biology gene list: Iba1
Ki67,antibodies,PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,0.95,Experimental Usage,False,1.00,Medium,,,,Ki67,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-Ki67 (1:500; BD Biosciences, San Jose, CA)",Antibody target not in NF pathway/tumor biology gene list: Ki67
CD34,antibodies,PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,0.95,Experimental Usage,False,1.00,Medium,,,,CD34,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,or rat anti-CD34 (1:50; BD Biosciences),Antibody target not in NF pathway/tumor biology gene list: CD34
CD11b,antibodies,PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,0.95,Experimental Usage,False,1.00,Medium,,,,CD11b,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rat anti-CD11b (M1/70, 1:10; BD Biosciences)",Antibody target not in NF pathway/tumor biology gene list: CD11b
CD45,antibodies,PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,0.95,Experimental Usage,False,0.67,Low,,,,CD45,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"cell surface staining was performed with anti-CD45-APC (30-F11, BD Biosciences)",Antibody target not in NF pathway/tumor biology gene list: CD45
CD11b,antibodies,PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,0.95,Experimental Usage,False,0.67,Low,,,,CD11b,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,anti-CD11b-PerCP-Cy5.5 antibodies,Antibody target not in NF pathway/tumor biology gene list: CD11b
CD68,antibodies,PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,0.95,Experimental Usage,False,0.67,Low,,,,CD68,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"then stained with CD68-R-PE (FA-11, AbD Serotec, Oxford, UK)",Antibody target not in NF pathway/tumor biology gene list: CD68
NF1,antibodies,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.95,Experimental Usage,True,0.33,Medium,,,,NF1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The primary antibodies used were against NF1 (1:300; Santa Cruz Biotechnology),Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
phospho-ERK p42/p44,antibodies,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.95,Experimental Usage,False,0.33,Low,,,,phospho-ERK p42/p44,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-ERK p42/p44 and total ERK p42/p44 (1:1,000; NEB)",Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
total ERK p42/p44,antibodies,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.95,Experimental Usage,False,0.33,Low,,,,total ERK p42/p44,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-ERK p42/p44 and total ERK p42/p44 (1:1,000; NEB)",Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
β-actin,antibodies,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.95,Experimental Usage,False,0.33,Low,,,,β-actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"β-actin (1:5,000; Sigma)",Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
synapsin I,antibodies,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.95,Experimental Usage,False,0.33,Low,,,,synapsin I,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,synapsin I (1:1000; NEB),Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
phospho-synapsin I,antibodies,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.85,Experimental Usage,False,0.33,Low,,,,phospho-synapsin I,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-synapsin I is a gift from P. Greengard (Rockefeller University, New York, NY)",Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
phospho-Thr202/Tyr204 ERK p42/p44,antibodies,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.95,Experimental Usage,False,0.33,Low,,,,phospho-Thr202/Tyr204 ERK p42/p44,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The primary antibodies used were against phospho-Thr202/Tyr204 ERK p42/p44 (New England Biolabs),Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
GAD65/67,antibodies,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.95,Experimental Usage,False,0.33,Low,,,,GAD65/67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,GAD65/67 (Chemicon),Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
mesothelin,antibodies,PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,0.9,Experimental Usage,False,1.00,Medium,,,,mesothelin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated overnight at 4°C with antibodies recognizing mesothelin (dilution 1:2,000; Santa Cruz Biotechnology, Santa Cruz, CA, clone B-3)",Antibody target not in NF pathway/tumor biology gene list: mesothelin
SV40 large T-antigen,antibodies,PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,0.9,Experimental Usage,False,1.00,Medium,,,,SV40 large T-antigen,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"SV40 large T-antigen (1:2000; Santa Cruz Biotechnology, Pab101)",Antibody target not in NF pathway/tumor biology gene list: SV40 large T-antigen
β-actin,antibodies,PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,0.85,Experimental Usage,False,1.00,Medium,,,,β-actin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"β-actin (1:20,000; Sigma-Aldrich, clone ac-74)",Generic reporter/tag/housekeeping antibody: β-actin
wide spectrum cytokeratin,antibodies,PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,0.85,Experimental Usage,False,0.33,Low,,,,wide spectrum cytokeratin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies used were anti-wide spectrum cytokeratin and anti-vimentin (Abcam Ab9377, 1:100",Antibody target not in NF pathway/tumor biology gene list: wide spectrum cytokeratin
vimentin,antibodies,PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,0.85,Experimental Usage,False,0.33,Low,,,,vimentin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-vimentin (Abcam Ab9377, 1:100 and Ab92547, 1:500, respectively)",Antibody target not in NF pathway/tumor biology gene list: vimentin
pan-cytokeratin,antibodies,PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,0.9,Experimental Usage,False,1.00,Medium,,,,pan-cytokeratin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse monoclonal anti-pan-cytokeratin, clone Lu-5 (BMA Biomedicals, Augst, Switzerland, T-1302; 1:500)",Antibody target not in NF pathway/tumor biology gene list: pan-cytokeratin
desmin,antibodies,PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,0.85,Experimental Usage,False,1.00,Medium,,,,desmin,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit polyclonal anti-desmin (Sigma D8281; 1:500),Antibody target not in NF pathway/tumor biology gene list: desmin
α-tubulin,antibodies,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.95,Experimental Usage,False,0.33,Low,,,,α-tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cells were incubated with α-tubulin (Invitrogen, 1:1000) and NGFR (Advance Targeting systems, 1:100) antibodies",Generic reporter/tag/housekeeping antibody: α-tubulin
NGFR,antibodies,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.95,Experimental Usage,False,0.33,Low,,,,NGFR,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cells were incubated with α-tubulin (Invitrogen, 1:1000) and NGFR (Advance Targeting systems, 1:100) antibodies",Antibody target not in NF pathway/tumor biology gene list: NGFR
P-ERK 1/2,antibodies,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.95,Experimental Usage,False,0.33,Low,,,,P-ERK 1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,All antibodies used were diluted in 3% non-fat dry milk and include P-ERK 1/2 (Cell Signalling diluted 1:2000),Antibody target not in NF pathway/tumor biology gene list: P-ERK 1/2
ERK 1/2,antibodies,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.95,Experimental Usage,False,0.33,Low,,,,ERK 1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ERK 1/2 (Millipore diluted 1:1000), P-PKA α/β (Invitrogen diluted 1ug/ml)",Antibody target not in NF pathway/tumor biology gene list: ERK 1/2
P-PKA α/β,antibodies,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.95,Experimental Usage,False,0.33,Low,,,,P-PKA α/β,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"P-PKA α/β (Invitrogen diluted 1ug/ml), PKA α/β (Termo Fisher Scientific diluted 1:500)",Antibody target not in NF pathway/tumor biology gene list: P-PKA α/β
PKA α/β,antibodies,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.95,Experimental Usage,False,0.33,Low,,,,PKA α/β,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,PKA α/β (Termo Fisher Scientific diluted 1:500) NF1 c-terminal (Bethyl diluted 1:1000),Antibody target not in NF pathway/tumor biology gene list: PKA α/β
α-Tubulin,antibodies,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.95,Experimental Usage,False,0.33,Low,,,,α-Tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,NF1 n-terminal (Santa Cruz diluted 1:500) and α-Tubulin (Sigma Aldrich 1:1000),Generic reporter/tag/housekeeping antibody: α-tubulin
rabbit IgG,antibodies,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.95,Experimental Usage,False,0.67,Low,,,,rabbit IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,Secondary antibody Alexa Fluor 568 goat anti-rabbit IgG (H + L) (Invitrogen) was used at 1:1000,Secondary antibody (not an NF-specific research tool)
Annexin-V,antibodies,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.95,Experimental Usage,False,0.33,Low,,,,Annexin-V,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The analysis of apoptotic cells was performed using Annexin-V-Alexa 568 antibody (Roche, Life technologies)",Antibody target not in NF pathway/tumor biology gene list: Annexin-V
merlin,antibodies,PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,0.9,Experimental Usage,True,0.33,Medium,,,,merlin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Anti-v5 epitope (Invitrogen), anti-merlin (Santa Cruz), anti–mammalian sterile 20-like 1/2 (MST1/2; Bethyl Laboratories)",Publication title lacks NF-specific terms: Merlin is a potent inhibitor of glioma growth.
v5 epitope,antibodies,PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,0.9,Experimental Usage,False,0.33,Low,,,,v5 epitope,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Anti-v5 epitope (Invitrogen), anti-merlin (Santa Cruz), anti–mammalian sterile 20-like 1/2",Publication title lacks NF-specific terms: Merlin is a potent inhibitor of glioma growth.
MST1/2,antibodies,PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,0.9,Experimental Usage,False,0.33,Low,,,,MST1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-merlin (Santa Cruz), anti–mammalian sterile 20-like 1/2 (MST1/2; Bethyl Laboratories), anti-Lats2",Publication title lacks NF-specific terms: Merlin is a potent inhibitor of glioma growth.
Lats2,antibodies,PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,0.9,Experimental Usage,False,0.33,Low,,,,Lats2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti–mammalian sterile 20-like 1/2 (MST1/2; Bethyl Laboratories), anti-Lats2 (Bethyl Laboratories), anti–Yes-associated protein",Publication title lacks NF-specific terms: Merlin is a potent inhibitor of glioma growth.
S100,antibodies,PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,0.95,Experimental Usage,False,0.33,Low,,,,S100,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"S100 (1:4000; Agilent Dako, Santa Clara, CA, USA; GA50461-2)",Antibody target not in NF pathway/tumor biology gene list: S100
CD34,antibodies,PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,0.95,Experimental Usage,False,0.67,Low,,,,CD34,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD34 (1:400; Bioss, Woburn, MA, USA; bs-8996R)",Antibody target not in NF pathway/tumor biology gene list: CD34
Sox10,antibodies,PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,0.95,Experimental Usage,False,0.33,Low,,,,Sox10,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Sox10 (1:100; Abcam, Cambridge, UK; ab227680)",Antibody target not in NF pathway/tumor biology gene list: Sox10
CD117,antibodies,PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,0.95,Experimental Usage,False,0.33,Low,,,,CD117,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD117 (1:100, Cell Signaling; 37805S)",Antibody target not in NF pathway/tumor biology gene list: CD117
GFAP,antibodies,PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,0.95,Experimental Usage,False,0.33,Low,,,,GFAP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GFAP (1:200, Abcam; ab16997)",Antibody target not in NF pathway/tumor biology gene list: GFAP
AIF1,antibodies,PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,0.95,Experimental Usage,False,0.33,Low,,,,AIF1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AIF1 (1:500, LSBio; LS-B2645)",Antibody target not in NF pathway/tumor biology gene list: AIF1
SMA,antibodies,PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,0.95,Experimental Usage,False,0.33,Low,,,,SMA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"SMA (1:250, LSBio; LS-B3933)",Antibody target not in NF pathway/tumor biology gene list: SMA
NF1,antibodies,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.95,Experimental Usage,True,0.33,Medium,,,,NF1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"NF1 (A300-140A, 1:1000, Bethyl Laboratories, Montgomery, TX, USA)",Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
ATRX,antibodies,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.95,Experimental Usage,False,0.33,Low,,,,ATRX,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ATRX (#10321, 1:500, Cell Signaling Technology, Danvers, MA, USA)",Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
α-tubulin,antibodies,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.9,Experimental Usage,False,0.33,Low,,,,α-tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"α-tubulin (#3873, 1:5000, Cell Signaling Technology)",Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
β-actin,antibodies,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.9,Experimental Usage,False,0.33,Low,,,,β-actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"β-actin (sc-47778, 1:5000, Santa Cruz Biotechnology, Dallas, TX, USA)",Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
pERK1/2,antibodies,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.95,Experimental Usage,False,0.33,Low,,,,pERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pERK1/2 (#4370, 1:1000, Cell Signaling Technology)",Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
Erk1/2,antibodies,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.95,Experimental Usage,False,0.33,Low,,,,Erk1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Erk1/2 (#9102, 1:1000, Cell Signaling Technology)",Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
γH2AX,antibodies,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.95,Experimental Usage,False,0.33,Low,,,,γH2AX,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"γH2AX (#9718, 1:1000, Cell Signaling Technology)",Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
mouse IgG,antibodies,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.9,Experimental Usage,False,0.67,Low,,,,mouse IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-mouse IgG HRP-linked (#7076, 1:5000, Cell Signaling Technology)",Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
rabbit IgG,antibodies,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.9,Experimental Usage,False,0.67,Low,,,,rabbit IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-rabbit IgG HRP-linked (#7074, 1:5000, Cell Signaling Technology)",Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
SMA,antibodies,PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,0.95,Experimental Usage,False,0.67,Low,,,,SMA,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with primary antibodies [rabbit anti-SMA (Novus, NB600-531)",Antibody target not in NF pathway/tumor biology gene list: SMA
COL11A1,antibodies,PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,0.95,Experimental Usage,False,0.67,Low,,,,COL11A1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-COL11A1 (ThermoScientific; PA5-68410),Antibody target not in NF pathway/tumor biology gene list: COL11A1
FAP,antibodies,PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,0.95,Experimental Usage,False,0.67,Low,,,,FAP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-FAP (Abcam; ab53066),Antibody target not in NF pathway/tumor biology gene list: FAP
collagen VI,antibodies,PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,0.95,Experimental Usage,False,0.67,Low,,,,collagen VI,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-collagen VI (Abcam; ab6588),Antibody target not in NF pathway/tumor biology gene list: collagen VI
S100β,antibodies,PMID:30713041,10.1016/j.stemcr.2019.01.001,Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.,,0.85,Experimental Usage,False,0.33,Low,,,,S100β,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,SC purity was assessed by performing S100β staining as described previously,Antibody target not in NF pathway/tumor biology gene list: S100β
Blbp,antibodies,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,0.67,Low,,,,Blbp,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Blbp (Millipore, ABN14; rabbit, 1:500)",Antibody target not in NF pathway/tumor biology gene list: Blbp
BrdU,antibodies,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,0.33,Low,,,,BrdU,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"BrdU (Abcam, ab6326; rat, 1:100)",Generic reporter/tag/housekeeping antibody: brdu
Isl1/2,antibodies,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,1.00,Medium,,,,Isl1/2,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Isl1/2 (Developmental Studies Hybridoma Bank, Clone # 39.4D5; mouse, 1:500)",Antibody target not in NF pathway/tumor biology gene list: Isl1/2
Ki67,antibodies,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,0.67,Low,,,,Ki67,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki67 (Vector Laboratories, VP-RM04; rabbit, 1:250)",Antibody target not in NF pathway/tumor biology gene list: Ki67
p75,antibodies,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,0.67,Low,,,,p75,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p75 (Promega, G3231; rabbit, 1:2000)",Antibody target not in NF pathway/tumor biology gene list: p75
S100β,antibodies,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,0.67,Low,,,,S100β,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"S100β (Sigma, S2532; mouse, 1:100 and amplification with Invitrogen TSA kit)",Antibody target not in NF pathway/tumor biology gene list: S100β
Sox10,antibodies,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,0.33,Low,,,,Sox10,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Sox10 (Santa Cruz, sc-17342; goat, 1:250)",Antibody target not in NF pathway/tumor biology gene list: Sox10
TrkA,antibodies,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,0.67,Low,,,,TrkA,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"TrkA (provided by Louis Reichardt, University of California, San Francisco, CA; rabbit, 1:1000)",Antibody target not in NF pathway/tumor biology gene list: TrkA
Tuj1,antibodies,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,0.67,Low,,,,Tuj1,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Tuj1 (Covance, MMS-435P; mouse, 1:1000)",Antibody target not in NF pathway/tumor biology gene list: Tuj1
Yap/Taz,antibodies,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,0.67,Low,,,,Yap/Taz,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Yap/Taz (Cell Signaling, 8418; rabbit, 1:200 and amplification with Invitrogen TSA kit)",Antibody target not in NF pathway/tumor biology gene list: Yap/Taz
pYap,antibodies,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,0.67,Low,,,,pYap,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pYap (Cell Signaling, 4911; rabbit, 1:200)",Antibody target not in NF pathway/tumor biology gene list: pYap
GAPDH,antibodies,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.9,Experimental Usage,False,0.67,Low,,,,GAPDH,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GAPDH (Sigma, G8795, mouse; 1:10,000)",Generic reporter/tag/housekeeping antibody: gapdh
phospho-ERK,antibodies,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.95,Experimental Usage,False,1.00,Medium,,,,phospho-ERK,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"pERK (Cell Signaling Technologies, #4370, 1:1,000 dilution)","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
ERK,antibodies,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.95,Experimental Usage,False,1.00,Medium,,,,ERK,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"total ERK (Cell Signaling Technologies, #4695, 1:1,000 dilution)","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
phospho-AKT,antibodies,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.95,Experimental Usage,False,1.00,Medium,,,,phospho-AKT,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"pAKT (Cell Signaling Technologies, #4060, 1:1,000 dilution)","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
AKT,antibodies,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.95,Experimental Usage,False,1.00,Medium,,,,AKT,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"total AKT (Cell Signaling Technologies, # 4685, 1:1,000 dilution)","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
phospho-MEK,antibodies,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.95,Experimental Usage,False,1.00,Medium,,,,phospho-MEK,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"pMEK (Cell Signaling Technologies, #9121, 1:1,000 dilution)","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
MEK,antibodies,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.95,Experimental Usage,False,1.00,Medium,,,,MEK,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"total MEK (Cell Signaling Technologies, #8727, 1:1,000 dilution)","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
neurofibromin,antibodies,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.95,Experimental Usage,True,1.00,High,,,,neurofibromin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"neurofibromin (Millipore, #3668175, 1:1000 dilution)","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
SHP2,antibodies,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.95,Experimental Usage,False,1.00,Medium,,,,SHP2,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"SHP2 (Cell Signaling Technologies, #3397, 1:1,000 dilution)","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
SOS2,antibodies,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.9,Experimental Usage,False,1.00,Medium,,,,SOS2,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"SOS2 (Santa Cruz, sc-393667)","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
PGP 9.5,antibodies,PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,0.9,Experimental Usage,False,1.00,Medium,,,,PGP 9.5,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"The samples were then incubated with polyclonal rabbit anti-PGP 9.5 (Dako #Z5116, Glostrup, Denmark, antibody dilution 1:200)",Antibody target not in NF pathway/tumor biology gene list: PGP 9.5
rabbit,antibodies,PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,0.85,Experimental Usage,False,0.67,Low,,,,rabbit,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,"Bound antibody was visualized with anti-rabbit secondary antibody (Histofine Max PO Multi, #414152 F, Nichirei Biosciences Inc., Tokyo, Japan)",Secondary antibody (not an NF-specific research tool)
TYK2,antibodies,PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,TYK2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with TYK2 primary antibody (ab223733, 1:100; Abcam; RRID:AB_2928057) overnight",Antibody target not in NF pathway/tumor biology gene list: TYK2
STAT3,antibodies,PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,STAT3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Primary antibodies included total STAT3 (4904S; RRID:AB_331269),Antibody target not in NF pathway/tumor biology gene list: STAT3
pSTAT3,antibodies,PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,pSTAT3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,pSTAT3 (Tyr705; 9145S; RRID:AB_2491009),Antibody target not in NF pathway/tumor biology gene list: pSTAT3
ERK1/2,antibodies,PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,ERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,total p44/42 ERK1/2 (4695S; RRID:AB_390779),Antibody target not in NF pathway/tumor biology gene list: ERK1/2
pERK1/2,antibodies,PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,pERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,pERK1/2 (Thr202/Tyr204; 4370S; RRID:AB_2315112),Antibody target not in NF pathway/tumor biology gene list: pERK1/2
TYK2,antibodies,PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,TYK2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,TYK2 (A2128; Abclonal; RRID:AB_2764147),Antibody target not in NF pathway/tumor biology gene list: TYK2
β-TubulinIII,antibodies,PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,0.9,Experimental Usage,False,0.67,Low,,,,β-TubulinIII,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"β-TubulinIII (rabbit, 1:2000, Sigma)",Antibody target not in NF pathway/tumor biology gene list: β-TubulinIII
GAP43,antibodies,PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,0.9,Experimental Usage,False,0.67,Low,,,,GAP43,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GAP43 (rabbit, 1:1000, Abcam)",Antibody target not in NF pathway/tumor biology gene list: GAP43
GFAP,antibodies,PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,0.9,Experimental Usage,False,0.67,Low,,,,GFAP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GFAP (rabbit, 1:2000, DAKO)",Antibody target not in NF pathway/tumor biology gene list: GFAP
nestin,antibodies,PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,0.9,Experimental Usage,False,0.67,Low,,,,nestin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"nestin (mouse, 1:200, Chemicon)",Antibody target not in NF pathway/tumor biology gene list: nestin
S100β,antibodies,PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,0.9,Experimental Usage,False,0.67,Low,,,,S100β,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"S100β(rabbit, 1:5000, DAKO)",Antibody target not in NF pathway/tumor biology gene list: S100β
Dhh,antibodies,PMID:19427294,10.1016/j.stem.2009.03.017,Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.,,0.85,Experimental Usage,False,0.33,Low,,,,Dhh,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Western blotting on lysates of SKPs and 3T3 cells with Dhh antibody (Santa Cruz Biotechnology),Antibody target not in NF pathway/tumor biology gene list: Dhh
Ki67,antibodies,PMID:23099891,10.1007/s00401-012-1056-7,Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.,,0.95,Experimental Usage,False,0.67,Low,,,,Ki67,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"...We used rabbit anti-Ki67 (Novocastra; 1:5,000 for 3,3′ diamino benzidine (DAB), and 1:1,000 for fluorescence)...",Antibody target not in NF pathway/tumor biology gene list: Ki67
Iba1,antibodies,PMID:23099891,10.1007/s00401-012-1056-7,Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.,,0.95,Experimental Usage,False,0.67,Low,,,,Iba1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"...rabbit anti-Iba1 (Wako Chemicals, Richmond, VA, 1:2,000)...",Antibody target not in NF pathway/tumor biology gene list: Iba1
CD163,antibodies,PMID:23099891,10.1007/s00401-012-1056-7,Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.,,0.95,Experimental Usage,False,0.33,Low,,,,CD163,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"...goat anti-CD163 (Santa Cruz SC18796, 1:2,000)...",Antibody target not in NF pathway/tumor biology gene list: CD163
cleaved caspase 3,antibodies,PMID:23099891,10.1007/s00401-012-1056-7,Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.,,0.95,Experimental Usage,False,0.67,Low,,,,cleaved caspase 3,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"...rabbit anti-cleaved caspase 3 (cell signaling, 1:5,000)...",Antibody target not in NF pathway/tumor biology gene list: cleaved caspase 3
CNPase,antibodies,PMID:23099891,10.1007/s00401-012-1056-7,Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.,,0.95,Experimental Usage,False,1.00,Medium,,,,CNPase,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,...mouse anti-CNPase (1:750; Millipore MAB226)...,Antibody target not in NF pathway/tumor biology gene list: CNPase
GFP,antibodies,PMID:23099891,10.1007/s00401-012-1056-7,Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.,,0.95,Experimental Usage,False,0.33,Low,,,,GFP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"...chicken anti-GFP (Millipore, 1:2,000)...",Generic reporter/tag/housekeeping antibody: gfp
CD11b,antibodies,PMID:23099891,10.1007/s00401-012-1056-7,Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.,,0.95,Experimental Usage,False,1.00,Medium,,,,CD11b,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...mouse anti-human monoclonal antibodies against CD11b (8G12/HPCA-2, Becton–Dickinson; San Jose, CA) bound to allophycocyanin (APC)...",Antibody target not in NF pathway/tumor biology gene list: CD11b
p75/NGFR,antibodies,PMID:23099891,10.1007/s00401-012-1056-7,Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.,,0.95,Experimental Usage,False,0.33,Low,,,,p75/NGFR,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"...p75/NGFR (C40-1457, Becton–Dickinson) bound to phycoerythrin (PE)...",Antibody target not in NF pathway/tumor biology gene list: p75/NGFR
pKit,antibodies,PMID:23099891,10.1007/s00401-012-1056-7,Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,pKit,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"...Primary antibodies recognizing pKit, Kit, and β-actin (Cell Signaling, Danvers, MA)...",Antibody target not in NF pathway/tumor biology gene list: pKit
Kit,antibodies,PMID:23099891,10.1007/s00401-012-1056-7,Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,Kit,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"...Primary antibodies recognizing pKit, Kit, and β-actin (Cell Signaling, Danvers, MA)...",Antibody target not in NF pathway/tumor biology gene list: Kit
β-actin,antibodies,PMID:23099891,10.1007/s00401-012-1056-7,Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,β-actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"...Primary antibodies recognizing pKit, Kit, and β-actin (Cell Signaling, Danvers, MA)...",Generic reporter/tag/housekeeping antibody: β-actin
EGFR,antibodies,PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,0.9,Experimental Usage,False,0.67,Low,,,,EGFR,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies were: goat anti-EGFR (Santa Cruz, SC-03-G, 1:10)",Antibody target not in NF pathway/tumor biology gene list: EGFR
P75,antibodies,PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,0.9,Experimental Usage,False,1.00,Medium,,,,P75,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies were: goat anti-EGFR (Santa Cruz, SC-03-G, 1:10), rabbit anti-P75 (Chemicon 1:400)",Antibody target not in NF pathway/tumor biology gene list: P75
β-Tubulin,antibodies,PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,0.9,Experimental Usage,False,1.00,Medium,,,,β-Tubulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-β-Tubulin (Chemicon 1:200),Generic reporter/tag/housekeeping antibody: β-tubulin
S100β,antibodies,PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,0.9,Experimental Usage,False,1.00,Medium,,,,S100β,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-S100β (DAKO 1:2000),Antibody target not in NF pathway/tumor biology gene list: S100β
SMA,antibodies,PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,0.9,Experimental Usage,False,1.00,Medium,,,,SMA,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-SMA (Sigma 1:500),Antibody target not in NF pathway/tumor biology gene list: SMA
NF-M,antibodies,PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,0.9,Experimental Usage,False,1.00,Medium,,,,NF-M,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-NF-M (Chemicon, 1:200)",Antibody target not in NF pathway/tumor biology gene list: NF-M
CD34,antibodies,PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD34,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-human monoclonal antibodies against CD34 (8G12/HPCA-2, Becton-Dickinson; San Jose, CA) bound to allophycocyanin (APC)",Antibody target not in NF pathway/tumor biology gene list: CD34
p75/NGFR,antibodies,PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,0.9,Experimental Usage,False,1.00,Medium,,,,p75/NGFR,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"p75/NGFR (C40–1457, Becton-Dickinson) bound to phycoerythrin (PE)",Antibody target not in NF pathway/tumor biology gene list: p75/NGFR
EGFR,antibodies,PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,0.9,Experimental Usage,False,1.00,Medium,,,,EGFR,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"EGFR (EGFR1, Research Diagnostics Inc; Flanders, NJ) bound to FITC",Antibody target not in NF pathway/tumor biology gene list: EGFR
EGFR,antibodies,PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,0.85,Experimental Usage,False,1.00,Medium,,,,EGFR,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,The monoclonal antibody Cetuximab was also used at 5 μg/ml (ImClone),Antibody target not in NF pathway/tumor biology gene list: EGFR
S100,antibodies,PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,0.85,Experimental Usage,False,0.33,Low,,,,S100,,,,,,,,,,,,,,,,,,,,,,,,,,,,"S100 (Agilent Technologies, GA-50461-2)",Antibody target not in NF pathway/tumor biology gene list: S100
desmin,antibodies,PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,0.85,Experimental Usage,False,0.33,Low,,,,desmin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"desmin (abcam, ab15200)",Antibody target not in NF pathway/tumor biology gene list: desmin
SMA,antibodies,PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,0.85,Experimental Usage,False,0.33,Low,,,,SMA,,,,,,,,,,,,,,,,,,,,,,,,,,,,"SMA (GeneTex, GTX100034)",Antibody target not in NF pathway/tumor biology gene list: SMA
p53,antibodies,PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,0.85,Experimental Usage,False,0.33,Low,,,,p53,,,,,,,,,,,,,,,,,,,,,,,,,,,,"p53 (Santa Cruz, sc-126)",Antibody target not in NF pathway/tumor biology gene list: p53
Iba1,antibodies,PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,0.85,Experimental Usage,False,0.33,Low,,,,Iba1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Iba1 (Fujifilm, 019–19741)",Antibody target not in NF pathway/tumor biology gene list: Iba1
HLA-A/B/C,antibodies,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.95,Experimental Usage,False,1.00,Medium,,,,HLA-A/B/C,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Cell suspensions were stained with 1:100 dilutions of Phycoerythrin-conjugated anti-human HLA-A/B/C antibody (W6/32) (eBioscience, catalog number 12-9983-42)",Antibody target not in NF pathway/tumor biology gene list: HLA-A/B/C
β-2-microglobulin,antibodies,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.95,Experimental Usage,False,1.00,Medium,,,,β-2-microglobulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Phycoerythrin-conjugated anti-human β-2-microglobulin antibody (2M2) (Biolegend, catalog number 316306)",Antibody target not in NF pathway/tumor biology gene list: β-2-microglobulin
PD-L1,antibodies,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.95,Experimental Usage,False,1.00,Medium,,,,PD-L1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Phycoerythrin -Cyanine 7-conjugated anti-human PD-L1 antibody (29E.2A3) (Biolegend, catalog number 329717)",Antibody target not in NF pathway/tumor biology gene list: PD-L1
CTLA-4,antibodies,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.95,Experimental Usage,False,1.00,Medium,,,,CTLA-4,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Allophycocyanin-conjugated anti-human CTLA-4 antibody (L3D10) (Biolegend, catalog number 349907)",Antibody target not in NF pathway/tumor biology gene list: CTLA-4
HLA Class 1 ABC,antibodies,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.95,Experimental Usage,False,1.00,Medium,,,,HLA Class 1 ABC,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"An antibody to HLA Class 1 ABC (clone EMR8-5, Abcam Inc, catalog number ab70328) was used at a dilution factor of 1:6000",Antibody target not in NF pathway/tumor biology gene list: HLA Class 1 ABC
β-2-Microglobulin,antibodies,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.9,Experimental Usage,False,1.00,Medium,,,,β-2-Microglobulin,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"β-2-Microglobulin antibody (HPA006361, rabbit polyclonal, Sigma-Aldrich, catalog number HPA006361) was used at a dilution of 1:6000",Antibody target not in NF pathway/tumor biology gene list: β-2-Microglobulin
PD-L1,antibodies,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.95,Experimental Usage,False,1.00,Medium,,,,PD-L1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"An antibody to PD-L1 (clone B55, Sino Biological Inc., catalog number 10084-H08H) was used at a dilution factor of 1:200",Antibody target not in NF pathway/tumor biology gene list: PD-L1
CD4,antibodies,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.95,Experimental Usage,False,1.00,Medium,,,,CD4,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies to CD4 (clone SP35, Cell Marque, catalog number 104R-18) and CD8 (clone 4B11, Leica Microsystems, catalog number PA0183)",Antibody target not in NF pathway/tumor biology gene list: CD4
CD8,antibodies,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.95,Experimental Usage,False,1.00,Medium,,,,CD8,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies to CD4 (clone SP35, Cell Marque, catalog number 104R-18) and CD8 (clone 4B11, Leica Microsystems, catalog number PA0183)",Antibody target not in NF pathway/tumor biology gene list: CD8
CD56,antibodies,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.95,Experimental Usage,False,1.00,Medium,,,,CD56,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies to CD56 (clone 1B6, Leica Microsystems, catalog number NCL-L-CD56-1B6) and CD45RO (clone UCHL1, Leica Microsystems, catalog number PA0146)",Antibody target not in NF pathway/tumor biology gene list: CD56
CD45RO,antibodies,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.95,Experimental Usage,False,1.00,Medium,,,,CD45RO,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies to CD56 (clone 1B6, Leica Microsystems, catalog number NCL-L-CD56-1B6) and CD45RO (clone UCHL1, Leica Microsystems, catalog number PA0146)",Antibody target not in NF pathway/tumor biology gene list: CD45RO
FOXP3,antibodies,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.95,Experimental Usage,False,1.00,Medium,,,,FOXP3,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"An antibody to FOXP3 (clone 236A/E7, Abcam Inc., catalog number ab20034) was used at a dilution factor of 1:100",Antibody target not in NF pathway/tumor biology gene list: FOXP3
Tom20,antibodies,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.9,Experimental Usage,False,0.33,Low,,,,Tom20,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-Tom20 FL-145 (Santa Cruz, 1:200, RT, 1 hour)",Antibody target not in NF pathway/tumor biology gene list: Tom20
Tid1,antibodies,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.9,Experimental Usage,False,0.33,Low,,,,Tid1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-Tid1 Ab-2 RS13 (Neomarkers, 1:200 4°C, overnight)",Antibody target not in NF pathway/tumor biology gene list: Tid1
p-H2AX Ser139,antibodies,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.9,Experimental Usage,False,0.33,Low,,,,p-H2AX Ser139,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-p-H2AX Ser139-488 N1-431 (BD, 1:100, 4°C, 30 minutes, no secondary)",Antibody target not in NF pathway/tumor biology gene list: p-H2AX Ser139
LC3BI/II,antibodies,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.9,Experimental Usage,False,0.33,Low,,,,LC3BI/II,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-LC3BI/II #2775 (Cell Signaling, 1:1000, overnight)",Antibody target not in NF pathway/tumor biology gene list: LC3BI/II
p62/SQSTM-1,antibodies,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.9,Experimental Usage,False,0.67,Low,,,,p62/SQSTM-1,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-p62/SQSTM-1 D-3 (Santa Cruz, 1:1000, 1 h)",Antibody target not in NF pathway/tumor biology gene list: p62/SQSTM-1
alpha-tubulin,antibodies,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.9,Experimental Usage,False,0.67,Low,,,,alpha-tubulin,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-alpha-tubulin B-1-2-5 (Santa Cruz, 1:10000, 1 h)",Generic reporter/tag/housekeeping antibody: alpha-tubulin
K63 polyubiquitin,antibodies,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.9,Experimental Usage,False,0.33,Low,,,,K63 polyubiquitin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-K63 polyubiquitin #5921 (Cell Signaling, 1:1000, 1 h)",Antibody target not in NF pathway/tumor biology gene list: K63 polyubiquitin
pK48 polyubiquitin,antibodies,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.9,Experimental Usage,False,0.33,Low,,,,pK48 polyubiquitin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-pK48 polyubiquitin #8081 (Cell Signaling, 1:2000, 1 h)",Antibody target not in NF pathway/tumor biology gene list: pK48 polyubiquitin
GAPDH,antibodies,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.9,Experimental Usage,False,0.33,Low,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-GAPDH ab9485-100 (Abcam, 1:1000, overnight)",Generic reporter/tag/housekeeping antibody: gapdh
RIP,antibodies,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.85,Experimental Usage,False,0.33,Low,,,,RIP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-RIP (BD Transduction Laboratories, 1:1000, overnight)",Antibody target not in NF pathway/tumor biology gene list: RIP
Ki67,antibodies,PMID:37616542,10.1158/1535-7163.MCT-23-0258,"Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.",,0.9,Experimental Usage,False,0.33,Low,,,,Ki67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubation with 1°C anti-Ki67 (Abcam ab16667; 1:200, overnight, 4°C)",Antibody target not in NF pathway/tumor biology gene list: Ki67
phospho-Erk 1/2,antibodies,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,phospho-Erk 1/2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing phospho-Erk 1/2 (#9101), Erk2 (#9108), Akt phosphorylated at Ser473 (#9271)",Antibody target not in NF pathway/tumor biology gene list: phospho-Erk 1/2
Erk2,antibodies,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,Erk2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing phospho-Erk 1/2 (#9101), Erk2 (#9108), Akt phosphorylated at Ser473 (#9271)",Antibody target not in NF pathway/tumor biology gene list: Erk2
Akt phosphorylated at Ser473,antibodies,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,Akt phosphorylated at Ser473,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Erk2 (#9108), Akt phosphorylated at Ser473 (#9271), Akt (#9272), SAPK/JNK phosphorylated on Thr183/Tyr185 (#9251)",Antibody target not in NF pathway/tumor biology gene list: Akt phosphorylated at Ser473
Akt,antibodies,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,Akt,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Akt phosphorylated at Ser473 (#9271), Akt (#9272), SAPK/JNK phosphorylated on Thr183/Tyr185 (#9251)",Antibody target not in NF pathway/tumor biology gene list: Akt
SAPK/JNK phosphorylated on Thr183/Tyr185,antibodies,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,SAPK/JNK phosphorylated on Thr183/Tyr185,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Akt (#9272), SAPK/JNK phosphorylated on Thr183/Tyr185 (#9251), SAPK/JNK (#9252)",Antibody target not in NF pathway/tumor biology gene list: SAPK/JNK phosphorylated on Thr183/Tyr185
SAPK/JNK,antibodies,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,SAPK/JNK,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"SAPK/JNK phosphorylated on Thr183/Tyr185 (#9251), SAPK/JNK (#9252) or Src family members phosphorylated at Tyr416 (#2101)",Antibody target not in NF pathway/tumor biology gene list: SAPK/JNK
Src family members phosphorylated at Tyr416,antibodies,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,Src family members phosphorylated at Tyr416,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,SAPK/JNK (#9252) or Src family members phosphorylated at Tyr416 (#2101) or Tyr527 (#2105),Antibody target not in NF pathway/tumor biology gene list: Src family members phosphorylated at Tyr416
Src family members phosphorylated at Tyr527,antibodies,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,Src family members phosphorylated at Tyr527,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Src family members phosphorylated at Tyr416 (#2101) or Tyr527 (#2105) were from Cell Signaling Technology,Antibody target not in NF pathway/tumor biology gene list: Src family members phosphorylated at Tyr527
FAK,antibodies,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,FAK,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Rabbit polyclonal antibodies recognizing FAK (sc-932), erbB2 (sc-284), erbB4 (sc-283)",Antibody target not in NF pathway/tumor biology gene list: FAK
erbB2,antibodies,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,erbB2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Rabbit polyclonal antibodies recognizing FAK (sc-932), erbB2 (sc-284), erbB4 (sc-283)",Antibody target not in NF pathway/tumor biology gene list: erbB2
erbB4,antibodies,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,erbB4,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"erbB2 (sc-284), erbB4 (sc-283) and NRG-1 transmembrane precursors with an ""a"" variant carboxy terminus (sc-348)",Antibody target not in NF pathway/tumor biology gene list: erbB4
NRG-1 transmembrane precursors,antibodies,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,NRG-1 transmembrane precursors,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"erbB4 (sc-283) and NRG-1 transmembrane precursors with an ""a"" variant carboxy terminus (sc-348) and a goat polyclonal anti-β 1 integrin (sc-6622)",Antibody target not in NF pathway/tumor biology gene list: NRG-1 transmembrane precursors
β1 integrin,antibodies,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,0.67,Low,,,,β1 integrin,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,and a goat polyclonal anti-β 1 integrin (sc-6622) antibody were obtained from Santa Cruz Biotechnology,Antibody target not in NF pathway/tumor biology gene list: β1 integrin
erbB3,antibodies,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,erbB3,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Mouse monoclonal antibodies recognizing erbB3 (clone RTJ.1; #554208) or erbB4 (HFR1; sc-53280),Antibody target not in NF pathway/tumor biology gene list: erbB3
erbB4,antibodies,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,erbB4,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Mouse monoclonal antibodies recognizing erbB3 (clone RTJ.1; #554208) or erbB4 (HFR1; sc-53280),Antibody target not in NF pathway/tumor biology gene list: erbB4
GAPDH,antibodies,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,GAPDH,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-GAPDH monoclonal antibody (clone 6C5) was purchased from Fitzgerald Antibodies and Antigens,Generic reporter/tag/housekeeping antibody: gapdh
RBPMS,antibodies,PMID:33816648,10.1016/j.omtm.2021.03.004,Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas.,,0.9,Experimental Usage,False,0.33,Low,,,,RBPMS,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cells derived on D1 were additionally stained with RBPMS antibody (Abcam ab194213, 1:200)",Publication title lacks NF-specific terms: Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and gl
L1CAM,antibodies,PMID:33816648,10.1016/j.omtm.2021.03.004,Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas.,,0.9,Experimental Usage,False,0.33,Low,,,,L1CAM,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"RGCs were isolated using magnetic beads (Invitrogen CELLection pan mouse immunoglobulin G [IgG] kit) and the L1cam (CD171) antibody (Biolegend 826701, 1:100)",Publication title lacks NF-specific terms: Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and gl
Mdm2,antibodies,PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,0.95,Experimental Usage,False,1.00,Medium,,,,Mdm2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit polyclonal antibodies of Mdm2 (Anaspec, , Fremont, CA, USA, 55470, 1:200; Blocking peptide 55470P)",Publication title lacks NF-specific terms: Activation of Sonic hedgehog signaling in neural progenitor cells promotes gliom
Pax2,antibodies,PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,0.95,Experimental Usage,False,1.00,Medium,,,,Pax2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Pax2 (Covance, Nashville, TN, USA, PRB-276P, 1:1000)",Publication title lacks NF-specific terms: Activation of Sonic hedgehog signaling in neural progenitor cells promotes gliom
S100,antibodies,PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,0.95,Experimental Usage,False,1.00,Medium,,,,S100,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"S100 (Dako, Glostrup, Denmark, Z0311, 1:2000)",Publication title lacks NF-specific terms: Activation of Sonic hedgehog signaling in neural progenitor cells promotes gliom
Sox2,antibodies,PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,0.95,Experimental Usage,False,1.00,Medium,,,,Sox2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Sox2 (Millipore, Billerica, MA, USA, AB5603, 1:500)",Publication title lacks NF-specific terms: Activation of Sonic hedgehog signaling in neural progenitor cells promotes gliom
GFAP,antibodies,PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,0.95,Experimental Usage,False,1.00,Medium,,,,GFAP,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"GFAP (Dako, Z0034, 1:1000)",Publication title lacks NF-specific terms: Activation of Sonic hedgehog signaling in neural progenitor cells promotes gliom
BLBP,antibodies,PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,0.95,Experimental Usage,False,1.00,Medium,,,,BLBP,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"BLBP (Millipore, ABN14, 1:200)",Publication title lacks NF-specific terms: Activation of Sonic hedgehog signaling in neural progenitor cells promotes gliom
phospho-Histone 3,antibodies,PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,0.95,Experimental Usage,False,1.00,Medium,,,,phospho-Histone 3,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-Histone 3 (Ser10) (Cell Signaling, 9701, 1:100)",Publication title lacks NF-specific terms: Activation of Sonic hedgehog signaling in neural progenitor cells promotes gliom
active Caspase 3,antibodies,PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,0.95,Experimental Usage,False,1.00,Medium,,,,active Caspase 3,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"active Caspase 3 (Cell Signaling, 9661, 1:200)",Publication title lacks NF-specific terms: Activation of Sonic hedgehog signaling in neural progenitor cells promotes gliom
GFAP,antibodies,PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,0.95,Experimental Usage,False,1.00,Medium,,,,GFAP,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse monoclonal antibodies of GFAP (Sigma, St Louis, MO, USA, G6171, 1:400)",Publication title lacks NF-specific terms: Activation of Sonic hedgehog signaling in neural progenitor cells promotes gliom
F4/80,antibodies,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.95,Experimental Usage,False,0.33,Low,,,,F4/80,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"F4/80: #70076, Cell Signaling Technology (1:100)",Antibody target not in NF pathway/tumor biology gene list: F4/80
IL-6,antibodies,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.95,Experimental Usage,False,0.33,Low,,,,IL-6,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"IL-6: #bs0782R, Bioss (1:100)",Antibody target not in NF pathway/tumor biology gene list: IL-6
MET,antibodies,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.95,Experimental Usage,False,0.33,Low,,,,MET,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"MET: #ab216574 or #ab51067, Abcam (1:100)",Antibody target not in NF pathway/tumor biology gene list: MET
SOX10,antibodies,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.95,Experimental Usage,False,0.33,Low,,,,SOX10,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"SOX10: #ab180862, Abcam (1:100)",Antibody target not in NF pathway/tumor biology gene list: SOX10
NLRP3,antibodies,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.95,Experimental Usage,False,0.33,Low,,,,NLRP3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"NLRP3: #CAB12694, Assay Genie (1:1000 dilution)",Antibody target not in NF pathway/tumor biology gene list: NLRP3
CD68,antibodies,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.95,Experimental Usage,False,0.33,Low,,,,CD68,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD68, Cell Signaling Technology (1:100)",Antibody target not in NF pathway/tumor biology gene list: CD68
pERK,antibodies,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.95,Experimental Usage,False,0.33,Low,,,,pERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunoblots were carried out using antibodies specific to pERK (#9101, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: pERK
ERK,antibodies,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.95,Experimental Usage,False,0.33,Low,,,,ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"total ERK (#9102, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: ERK
phosphorylated FAK Y397,antibodies,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.95,Experimental Usage,False,0.33,Low,,,,phosphorylated FAK Y397,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"phosphorylated FAK Y397 (pFAK 397, #700255, Invitrogen)",Antibody target not in NF pathway/tumor biology gene list: phosphorylated FAK Y397
vinculin,antibodies,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.95,Experimental Usage,False,0.33,Low,,,,vinculin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"or vinculin (#CP74, MilliporeSigma)",Generic reporter/tag/housekeeping antibody: vinculin
GFP,antibodies,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.95,Experimental Usage,False,1.00,Medium,,,,GFP,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-GFP 1:1,000 (Molecular Probes A-11122)",Generic reporter/tag/housekeeping antibody: gfp
DH44,antibodies,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.85,Experimental Usage,False,1.00,Medium,,,,DH44,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-DH44 1:500 (Johnson et al., 2005)",Antibody target not in NF pathway/tumor biology gene list: DH44
PER,antibodies,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.85,Experimental Usage,False,0.67,Low,,,,PER,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"guinea pig anti-PER 1:1,000 (I. Edery)",Antibody target not in NF pathway/tumor biology gene list: PER
PDF,antibodies,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.9,Experimental Usage,False,1.00,Medium,,,,PDF,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-PDF 1:500 (Developmental Studies Hybridoma Bank PDFC7; generated by J. Blau),Antibody target not in NF pathway/tumor biology gene list: PDF
SIFa,antibodies,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.85,Experimental Usage,False,1.00,Medium,,,,SIFa,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-SIFa 1:4,000 (gift from J. Veenstra)",Antibody target not in NF pathway/tumor biology gene list: SIFa
rabbit IgG,antibodies,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.9,Experimental Usage,False,0.67,Low,,,,rabbit IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,Alexa Fluor 488 goat anti-rabbit 1:500 (Molecular Probes A-11008),Secondary antibody (not an NF-specific research tool)
guinea pig IgG,antibodies,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.9,Experimental Usage,False,0.67,Low,,,,guinea pig IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,fluorescein isothiocyanate (FITC) anti-guinea pig 1:500 (Jackson Laboratory 106-095-003),Secondary antibody (not an NF-specific research tool)
mouse IgG,antibodies,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.9,Experimental Usage,False,0.67,Low,,,,mouse IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,Cy5 donkey anti-mouse 1:400 (Jackson Laboratory 715-175-151),Secondary antibody (not an NF-specific research tool)
rabbit IgG,antibodies,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.9,Experimental Usage,False,0.67,Low,,,,rabbit IgG,Unknown,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,Alexa Fluor 633 goat anti-rabbit (Molecular Probes A-21070),Secondary antibody (not an NF-specific research tool)
lacZ,antibodies,PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,0.9,Experimental Usage,False,0.67,Low,,,,lacZ,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"double immunofluorescence with anti-lacZ (rabbit, 1:200, 5′ and 3′) and anti-NeuN",Generic reporter/tag/housekeeping antibody: lacz
NeuN,antibodies,PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,0.9,Experimental Usage,False,0.67,Low,,,,NeuN,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-lacZ (rabbit, 1:200, 5′ and 3′) and anti-NeuN (mouse, 1:200, Chemicon)",Antibody target not in NF pathway/tumor biology gene list: NeuN
GFAP,antibodies,PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,0.9,Experimental Usage,False,0.67,Low,,,,GFAP,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-lacZ and anti-GFAP (mouse, 1:100, Pharmingen)",Antibody target not in NF pathway/tumor biology gene list: GFAP
BrdU,antibodies,PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,0.9,Experimental Usage,False,0.33,Low,,,,BrdU,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The dilution of BrdU antibody was 1:50 (Becton Dickinson),Generic reporter/tag/housekeeping antibody: brdu
GFAP,antibodies,PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,0.9,Experimental Usage,False,0.67,Low,,,,GFAP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GFAP (rabbit, 1:2000, DAKO), nestin (mouse, 1:200, Chemicon)",Antibody target not in NF pathway/tumor biology gene list: GFAP
nestin,antibodies,PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,0.9,Experimental Usage,False,0.67,Low,,,,nestin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GFAP (rabbit, 1:2000, DAKO), nestin (mouse, 1:200, Chemicon)",Antibody target not in NF pathway/tumor biology gene list: nestin
BLBP,antibodies,PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,0.85,Experimental Usage,False,0.67,Low,,,,BLBP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"BLBP (rabbit, 1:1000, a gift from N. Heintz)",Antibody target not in NF pathway/tumor biology gene list: BLBP
PAX2,antibodies,PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,0.85,Experimental Usage,False,0.67,Low,,,,PAX2,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"PAX2 (rabbit, 1:1000, a gift from G. Dressler)",Antibody target not in NF pathway/tumor biology gene list: PAX2
P-erk,antibodies,PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,0.9,Experimental Usage,False,0.67,Low,,,,P-erk,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"P-erk (rabbit, 1:200, Cell Signaling), Cre (mouse, 1:1000, BABCO)",Antibody target not in NF pathway/tumor biology gene list: P-erk
Cre,antibodies,PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,0.9,Experimental Usage,False,0.67,Low,,,,Cre,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"P-erk (rabbit, 1:200, Cell Signaling), Cre (mouse, 1:1000, BABCO)",Antibody target not in NF pathway/tumor biology gene list: Cre
Ki-67,antibodies,PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,0.9,Experimental Usage,False,0.67,Low,,,,Ki-67,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki-67 (Rabbit, 1:1000, Novocastra Labs)",Antibody target not in NF pathway/tumor biology gene list: Ki-67
EGFR,antibodies,PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,0.9,Experimental Usage,False,1.00,Medium,,,,EGFR,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies were rabbit polyclonal IgG anti-EGFR at 1:1,000 (Cell Signaling Technology, Danvers, MA)",Antibody target not in NF pathway/tumor biology gene list: EGFR
phospho-Tyr1068 EGFR,antibodies,PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,0.9,Experimental Usage,False,1.00,Medium,,,,phospho-Tyr1068 EGFR,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit immunoaffinity purified IgG anti-phospho-Tyr1068 of EGFR at 1:1000 (Cell Signaling Technology),Antibody target not in NF pathway/tumor biology gene list: phospho-Tyr1068 EGFR
MAP Kinase,antibodies,PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,0.85,Experimental Usage,False,0.33,Low,,,,MAP Kinase,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-MAP Kinase at 1:2,000 (Upstate Cell Signaling Solutions, Charlottesville, VA)",Antibody target not in NF pathway/tumor biology gene list: MAP Kinase
MAP Kinase activated,antibodies,PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,0.9,Experimental Usage,False,1.00,Medium,,,,MAP Kinase activated,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"monoclonal IgG isotype anti-MAP Kinase activated, clone MAPK-YT at 1:2,000 (Sigma-Aldrich, St. Louis, MO)",Antibody target not in NF pathway/tumor biology gene list: MAP Kinase activated
ErbB2,antibodies,PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,0.9,Experimental Usage,False,1.00,Medium,,,,ErbB2,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse monoclonal anti-ErbB2 (LabVision, Freemont, CA) at 1:1000",Antibody target not in NF pathway/tumor biology gene list: ErbB2
pTyr1221/1222 ErbB2,antibodies,PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,0.9,Experimental Usage,False,1.00,Medium,,,,pTyr1221/1222 ErbB2,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit monoclonal and polyclonal anti-pTyr1221/1222 of ErbB2 (Cell Signaling Technology) at 1:500,Antibody target not in NF pathway/tumor biology gene list: pTyr1221/1222 ErbB2
Cyclin D1,antibodies,PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,0.9,Experimental Usage,False,1.00,Medium,,,,Cyclin D1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse monoclonal anti-Cyclin D1 (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:1000",Antibody target not in NF pathway/tumor biology gene list: Cyclin D1
β-tubulin,antibodies,PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,0.9,Experimental Usage,False,1.00,Medium,,,,β-tubulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse monoclonal IgG anti-β-tubulin ""E7"" at 1:2,000 (developed by Michael Klymkowsky and obtained from the Developmental Studies Hybridoma Bank)",Generic reporter/tag/housekeeping antibody: β-tubulin
ATRX,antibodies,PMID:29796169,10.18632/oncotarget.25195,Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST.,,0.95,Experimental Usage,False,1.00,Medium,,,,ATRX,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemical stain for ATRX (Sigma, HPA001906, 1:300, rabbit polyclonal) was performed with appropriate positive and negative controls.",Antibody target not in NF pathway/tumor biology gene list: ATRX
phospho-p42/44 (pERK1/2),antibodies,PMID:18671844,10.1186/1741-7015-6-21,Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin.,,0.95,Experimental Usage,False,0.33,Low,,,,phospho-p42/44 (pERK1/2),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,membranes were probed with the following antibodies: phospho-p42/44 (pERK1/2) #9102 Cell Signaling (diluted 1:1000),Antibody target not in NF pathway/tumor biology gene list: phospho-p42/44 (pERK1/2)
p44 (ERK1),antibodies,PMID:18671844,10.1186/1741-7015-6-21,Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin.,,0.95,Experimental Usage,False,0.33,Low,,,,p44 (ERK1),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,p44 (ERK1) #4372 Cell Signaling (diluted 1:1000),Antibody target not in NF pathway/tumor biology gene list: p44 (ERK1)
CD117,antibodies,PMID:18984156,10.1016/j.cell.2008.08.041,Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.,,0.8,Experimental Usage,False,0.33,Low,,,,CD117,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Ganglia were minced, digested by collagenase V, and the single cell suspension was admixed with anti CD117, CD31, or Col1A and FcεRI antibodies.",Antibody target not in NF pathway/tumor biology gene list: CD117
CD31,antibodies,PMID:18984156,10.1016/j.cell.2008.08.041,Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.,,0.8,Experimental Usage,False,0.33,Low,,,,CD31,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Ganglia were minced, digested by collagenase V, and the single cell suspension was admixed with anti CD117, CD31, or Col1A and FcεRI antibodies.",Antibody target not in NF pathway/tumor biology gene list: CD31
Col1A,antibodies,PMID:18984156,10.1016/j.cell.2008.08.041,Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.,,0.8,Experimental Usage,False,0.33,Low,,,,Col1A,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Ganglia were minced, digested by collagenase V, and the single cell suspension was admixed with anti CD117, CD31, or Col1A and FcεRI antibodies.",Antibody target not in NF pathway/tumor biology gene list: Col1A
FcεRI,antibodies,PMID:18984156,10.1016/j.cell.2008.08.041,Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.,,0.8,Experimental Usage,False,0.33,Low,,,,FcεRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Ganglia were minced, digested by collagenase V, and the single cell suspension was admixed with anti CD117, CD31, or Col1A and FcεRI antibodies.",Antibody target not in NF pathway/tumor biology gene list: FcεRI
BrdU,antibodies,PMID:18984156,10.1016/j.cell.2008.08.041,Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.,,0.85,Experimental Usage,False,0.33,Low,,,,BrdU,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Cell proliferation in tumors was evaluated by utilizing a BrdU in situ detection kit (BD PharMingen, San Jose, CA).",Generic reporter/tag/housekeeping antibody: brdu
human retinal ganglion cells (hRGC),cell_lines,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Eye,,,,,,,,,,,,,,,,,,,,,,,,,"Human retinal ganglion cells (hRGC), gifted from Dr. Donald Zack laboratory, were described in previous studies, being Brn3b-TdTomato positive",Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
Primary Schwannoma Cells,cell_lines,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,Schwannoma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Primary cells were isolated using the methods described by Rosenbaum et al. Schwannoma tissues were dissected,Generic cell line name: Primary Schwannoma Cells
ipNF 95.11b,cell_lines,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized NF1 patient derived Schwann cell (NF SC, NF-/-) line, ipNF 95.11b and Wild type Schwann cell (WT SC, NF+/+) line, ipn 02.8 were utilized for all experiments",Publication title lacks NF-specific terms: Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon na
ipn 02.8,cell_lines,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Wild type Schwann cell (WT SC, NF+/+) line, ipn 02.8 were utilized for all experiments. The cells were extracted from human patients diagnosed with Plexiform Neurofibroma",Publication title lacks NF-specific terms: Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon na
p53−/− mouse embryonic liver progenitor cells,cell_lines,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Liver,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,We performed a genome-wide CRISPR/Cas9-based knockout screen of P53-null mouse embryonic liver progenitor cells that overexpressed MYC,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
293fs cells,cell_lines,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,293fs cells were used to package lentivirus encoding individual sgRNA and Cas9,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
HEK-293T cells,cell_lines,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"mutant transcripts were expressed in HEK-293T cells. The phosphorylation level of ELK1, which is a downstream substrate of the RAS/MAPK pathway",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
HEK 293T,cell_lines,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"HEK 293T and immortalized mouse Nf2 Schwann cells, a gift from D. Lallemand...were maintained in Dulbecco's minimum essential medium",Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
immortalized mouse Nf2 Schwann cells,cell_lines,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"immortalized mouse Nf2 Schwann cells, a gift from D. Lallemand (Centre National de la Recherche Scientifique, Institut Curie, Paris, France) (flox2/flox2)",Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
HEK293 cells,cell_lines,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.95,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,HEK293 cells (6 × 10 5 ) were transfected with 1 µg of the wild type or the mutated minigene,Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
HEK 293T,cell_lines,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"To study hey1 promoter activity, we transfected HEK 293T cells plated in 24 well tissue culture plates",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
CT26,cell_lines,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Colon,,Colon cancer,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,The colon cancer cell line CT26 was injected subcutaneously into the right flank of 6–8-week-old female BALB/C mice,Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
U937,cell_lines,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Blood,,Leukemia,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human U937 cells were cultured in RPMI 1640 medium with 5% FBS and antibiotics, and were differentiated to M1 macrophage-like cells",Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
Raji,cell_lines,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Blood,,Burkitt's lymphoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Raji, a human Burkitt's lymphoma cell line, was purchased from Sigma.",Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
Eμ-ALL,cell_lines,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Blood,,B-cell acute lymphoblastic leukemia,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The Eμ-ALL cell line was derived from a lymphoid malignancy in an Eμ-myc transgenic mouse and upon intravenous injection, can develop B-ALL in C57Bl/6 mice",Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
Human CD19scFv-CD28–4–1BB-CD3ζ CAR-T cells (PM-CAR1003),cell_lines,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Human CD19scFv-CD28–4–1BB-CD3ζ CAR-T cells (PM-CAR1003) were purchased from Promab Biotechnologies,Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
Epstein-Barr virus-transformed cell lines,cell_lines,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Blood,Neurofibromatosis Type 1,,Hybrid cell line,,,,,,,,,,,,,,,,,,,,,,"Hybrid cell lines harboring only the chromosome 17 with the deletion were established for patients 659, 619, 1106, DA-77 and ASB4-55 using Epstein-Barr virus-transformed cell lines",Publication title lacks NF-specific terms: SVA retrotransposon insertion-associated deletion represents a novel mutational 
TVZ NSCs,cell_lines,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,Brain,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,TVZ NSCs were established from the third ventricle of 3-month-old Nf1 flox/flox and Nf1+/− mice,Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
iHSC1λ,cell_lines,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Cultured immortalized Schwann cells (iHSC1λ and iHSC2λ) were both derived from a patient's normal sciatic nerve, are NF1 wild-type, and were immortalized by hTERT and CDK4","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
iHSC2λ,cell_lines,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Cultured immortalized Schwann cells (iHSC1λ and iHSC2λ) were both derived from a patient's normal sciatic nerve, are NF1 wild-type, and were immortalized by hTERT and CDK4","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
S462,cell_lines,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 ( 45 ), S462-TY ( 35 ), ST8814 ( 46 ), T265 ( 47 ), and STS-26T ( 36 ))","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
S462-TY,cell_lines,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 ( 45 ), S462-TY ( 35 ), ST8814 ( 46 ), T265 ( 47 ), and STS-26T ( 36 ))","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
ST8814,cell_lines,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 ( 45 ), S462-TY ( 35 ), ST8814 ( 46 ), T265 ( 47 ), and STS-26T ( 36 ))","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
T265,cell_lines,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 ( 45 ), S462-TY ( 35 ), ST8814 ( 46 ), T265 ( 47 ), and STS-26T ( 36 ))","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
STS-26T,cell_lines,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 ( 45 ), S462-TY ( 35 ), ST8814 ( 46 ), T265 ( 47 ), and STS-26T ( 36 ))","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
HeLa cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Cervix,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human cervix carcinoma HeLa cells, human breast cancer MDA‐MB‐231 cells, human malignant peripheral nerve sheath tumor S462 cells",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
MDA-MB-231 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Breast,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"human breast cancer MDA‐MB‐231 cells, human malignant peripheral nerve sheath tumor S462 cells",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
S462 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"human malignant peripheral nerve sheath tumor S462 cells, human plexiform neurofibroma PN 04.4 cells",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
PN 04.4 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"human plexiform neurofibroma PN 04.4 cells, mouse breast cancer 4T1 cells",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
4T1 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Breast,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,mouse breast cancer 4T1 cells and mouse colorectal carcinoma CT26 cells,Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
CT26 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Colon,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"mouse colorectal carcinoma CT26 cells, mouse macrophage RAW 264.7 cells",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
RAW 264.7 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"mouse macrophage RAW 264.7 cells and, mouse myoblast C2C12 cells",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
C2C12 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Muscle,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,mouse myoblast C2C12 cells were cultured in DMEM medium,Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
COLO 741 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Colon,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,colorectal carcinoma COLO 741 cells and B‐CLL MEC1 cells were cultured in RPMI 1640 medium,Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
MEC1 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,B‐CLL MEC1 cells were cultured in RPMI 1640 medium,Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
U87 glioblastoma cells,cell_lines,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Experiments were performed on human U87 glioblastoma cells (ATCC),Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
sMPNST cells,cell_lines,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"mouse malignant peripheral nerve sheath tumor cells (sMPNST cells, kindly provided by Lu Q. Le, UTSW, Dallas, TX)",Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
sNF96.2,cell_lines,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The human MPNST cell line sNF96.2, was kindly provided by Dr Abhijit Guha...We confirmed the reported germline mutation in exon 21 (3683delC)",Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
HEK293T,cell_lines,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"compared with HEK293T cells, which are neurofibromin 1 wildtype (WT)",Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
HT1080,cell_lines,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Connective tissue,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,compared with HT1080 WT for neurofibromin 1,Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
CTL BJFF.6 hiPSCs,cell_lines,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Skin,,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,The original CTL BJFF.6 hiPSCs were generated from commercially available human foreskin fibroblasts,Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
human endothelial colony forming cells (ECFC),cell_lines,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Pooled human endothelial colony forming cells (ECFC, endothelial outgrowth cells) were purchased from the Angio BioCore at Indiana University",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
human microvascular endothelial cells (HMVEC),cell_lines,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Human microvascular endothelial cells (HMVEC) were purchased from Lonza (Allendale, NJ, USA)",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
293FT packaging cells,cell_lines,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"To generate lentiviral supernatant, 293FT packaging cells were plated onto tissue culture plates",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
iHSC1λ,cell_lines,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Cultured immortalized Schwann cells (iHSC1λ and iHSC2λ) were both derived from a patient's normal sciatic nerve, are NF1 wild-type, and were immortalized by hTERT and CDK4 R24C",Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
iHSC2λ,cell_lines,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Cultured immortalized Schwann cells (iHSC1λ and iHSC2λ) were both derived from a patient's normal sciatic nerve, are NF1 wild-type, and were immortalized by hTERT and CDK4 R24C",Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
S462,cell_lines,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 [ 34 ], S462-TY [ 35 ], ST8814 [ 36 ], T265 [ 37 ], and STS-26T [ 38 ])",Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
S462-TY,cell_lines,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 [ 34 ], S462-TY [ 35 ], ST8814 [ 36 ], T265 [ 37 ], and STS-26T [ 38 ])",Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
ST8814,cell_lines,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 [ 34 ], S462-TY [ 35 ], ST8814 [ 36 ], T265 [ 37 ], and STS-26T [ 38 ])",Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
T265,cell_lines,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 [ 34 ], S462-TY [ 35 ], ST8814 [ 36 ], T265 [ 37 ], and STS-26T [ 38 ])",Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
STS-26T,cell_lines,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 [ 34 ], S462-TY [ 35 ], ST8814 [ 36 ], T265 [ 37 ], and STS-26T [ 38 ])",Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
Primary human Schwann cells (NHSC),cell_lines,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Primary human Schwann cells (NHSC) isolated from human spinal nerve were purchased from ScienCell Research Laboratories (Cat. #1700),Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
Mouse embryonic fibroblasts (MEFs),cell_lines,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Embryonic tissue,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Mouse embryonic fibroblasts (MEFs) from wildtype and Rabl6m/m C57Bl/6N mice were isolated and cultured,Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
BY4743 background diploid yeast deletion strains,cell_lines,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Yeast,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Diploid yeast deletion strains used for growth analyses were of the BY4743 background (MATa/MATα, his3∆1/his3∆1, leu2∆0/leu2∆0...)","Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
Y258 background haploid yeast MORF strain,cell_lines,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Yeast,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"The haploid yeast MORF (Movable ORF) strain for RAS1 overexpression was of the Y258 background (MATa, pep 4-3, his 4-580...)","Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
MethoCult® M3434,cell_lines,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.8,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Colony forming unit granulocyte/macrophage (CFU-GM) progenitors were grown in MethoCult® (StemCell Technologies, Cat #03434)","Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
M059J,cell_lines,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Brain,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Primary normal human astrocytes (M059J) and 4 glioma cell lines (U87, U118, U251, and A172) were commercially procured from Shanghai Cell Bank",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
U87,cell_lines,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"4 glioma cell lines (U87, U118, U251, and A172) were commercially procured from Shanghai Cell Bank of the Chinese Academy of Sciences",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
U118,cell_lines,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"4 glioma cell lines (U87, U118, U251, and A172) were commercially procured from Shanghai Cell Bank of the Chinese Academy of Sciences",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
U251,cell_lines,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"4 glioma cell lines (U87, U118, U251, and A172) were commercially procured from Shanghai Cell Bank of the Chinese Academy of Sciences",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
A172,cell_lines,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"4 glioma cell lines (U87, U118, U251, and A172) were commercially procured from Shanghai Cell Bank of the Chinese Academy of Sciences",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
U87,cell_lines,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Experiments were performed on human U87 and U251 glioblastoma cells,Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
U251,cell_lines,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Experiments were performed on human U87 and U251 glioblastoma cells,Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
MiaPaCa-2,cell_lines,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Pancreas,,Pancreatic carcinoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,human pancreatic carcinoma cells (MiaPaCa-2 and PANC1),Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
PANC1,cell_lines,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Pancreas,,Pancreatic carcinoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,human pancreatic carcinoma cells (MiaPaCa-2 and PANC1),Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
BxPc3,cell_lines,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Pancreas,,Pancreatic adenocarcinoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,human pancreatic adenocarcinoma cells (BxPc3),Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
ipNF95.6,cell_lines,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,human ipNF95.6 plexiform neurofibroma cells (kindly provided by Dr. Margaret R. Wallace),Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
HEK 293T,cell_lines,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,"co-transfected with the packaging plasmids psPAX (Addgene #12260) and pMD2.G (Addgene, #12259) into the human embryonic kidney (HEK) 293T cells",Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
Wild-type and Nf1-/- primary astrocytes,cell_lines,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,Brain,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Wild-type and Nf1-/- primary astrocytes were generated and maintained as previously described,Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
Sf21 insect cells,cell_lines,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Insect ovary,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Sf21 insect cells (Life Technologies, Carlsbad, CA, USA)...Sf21 cells were infected with saturating amounts",Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
E. coli DH10Multibac cells,cell_lines,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Bacterial,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,E. coli DH10Multibac cells containing the modified baculoviral genome,Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
Nf1−/− MEFs,cell_lines,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,,,,,,,Embryonic tissue,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Mouse embryonic fibroblasts (MEFs) were derived from both wild type mice and syngenic neurofibromin 1 (Nf1)-knockout animals (Nf1+/+ and Nf1−/− MEFs, respectively)",Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
sMPNST cells,cell_lines,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,sMPNST cells were established from Nf1- and p53-deficient skin precursors (SKP),Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
cisMPNST cells,cell_lines,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,cisMPNST cells were derived from spontaneous MPNSTs arising in cis Nf1+/−;P53+/− mice,Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
ipNF 04.4 cells,cell_lines,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Human plexiform neurofibroma ipNF 04.4 cells were generated and provided by Dr. Margaret R. Wallace,Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
GL261,cell_lines,PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The mouse GL261 glioma cell line was obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ), Germany, and was authenticated by DSMZ.",Publication title lacks NF-specific terms: Neutrophil depletion enhanced the
GL261-luc,cell_lines,PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,GL261-luc cells were generated by infection of lentivirus carrying luciferase as described.,Publication title lacks NF-specific terms: Neutrophil depletion enhanced the
"M14 (ST88-14, RRID:CVCL_8916)",cell_lines,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1 patient-derived human MPNST cell lines M14 (ST88-14, RRID:CVCL_8916) and M10 (MPNST1) were kind gifts provided by Jonathan A. Fletcher",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
M10 (MPNST1),cell_lines,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1 patient-derived human MPNST cell lines M14 (ST88-14, RRID:CVCL_8916) and M10 (MPNST1) were kind gifts provided by Jonathan A. Fletcher",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
M1,cell_lines,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1 patient-derived human MPNST cell lines M1, M3, M4, and M6 were kind gifts developed by William L. Gerald and Xiaoliang L. Xu at Memorial Sloan Kettering Cancer Center",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
M3,cell_lines,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1 patient-derived human MPNST cell lines M1, M3, M4, and M6 were kind gifts developed by William L. Gerald and Xiaoliang L. Xu at Memorial Sloan Kettering Cancer Center",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
M4,cell_lines,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1 patient-derived human MPNST cell lines M1, M3, M4, and M6 were kind gifts developed by William L. Gerald and Xiaoliang L. Xu at Memorial Sloan Kettering Cancer Center",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
M6,cell_lines,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1 patient-derived human MPNST cell lines M1, M3, M4, and M6 were kind gifts developed by William L. Gerald and Xiaoliang L. Xu at Memorial Sloan Kettering Cancer Center",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
"HEK-293T cells (ATCC; cat. #CRL-3216, RRID:CVCL_0063)",cell_lines,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,"All MPNST cell lines (human and mouse) and HEK-293T cells (ATCC; cat. #CRL-3216, RRID:CVCL_0063) were cultured in DMEM:F-12 (1:1) high-glucose media",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
C6 cells,cell_lines,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,C6 rat glioma cells were injected into the optic nerve of Long-Evans rats and allowed to proliferate for 2 weeks,Publication title lacks NF-specific terms: C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of
MOLM-13,cell_lines,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,Acute myeloid leukemia,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Early-passage MOLM-13 cells (DSMZ) were cultured in RPMI media,Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
293T lenti-X cells,cell_lines,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,293T lenti-X cells (Takara Bio) with TransIT-LT1,Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
BL21 (DE3) E.coli,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Bacteria,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Proteins were expressed in BL21 (DE3) E.coli and purified using Amersham HiTrap glutathione columns,Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
H929,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"H929, U266B1, U2932, MCF7, and HT229 cell lines were selected based on historic demonstrations of their dependences on corresponding BCL-2-family members",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
U266B1,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"H929, U266B1, U2932, MCF7, and HT229 cell lines were selected based on historic demonstrations of their dependences on corresponding BCL-2-family members",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
U2932,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"H929, U266B1, U2932, MCF7, and HT229 cell lines were selected based on historic demonstrations of their dependences on corresponding BCL-2-family members",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
MCF7,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Breast,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"H929, U266B1, U2932, MCF7, and HT229 cell lines were selected based on historic demonstrations of their dependences on corresponding BCL-2-family members",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
HT229,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Colon,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"H929, U266B1, U2932, MCF7, and HT229 cell lines were selected based on historic demonstrations of their dependences on corresponding BCL-2-family members",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
HCC1937,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Breast,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Except for MCF7, HT229, and HCC1937 (gifts from Dr. Bora Limb, MD Anderson Cancer Research Center, Houston, TX, USA), all cell lines were purchased from the American Type Culture Collection",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
"normal human Schwann cells (Cat. No. 1700, ScienCell Research Laboratories)",cell_lines,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Low passage normal human Schwann cells (Cat. No. 1700, ScienCell Research Laboratories, Carlsbad, CA, USA) were cultured on CellBIND dishes",Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
Mouse merlin-null schwannoma cells,cell_lines,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,Schwannoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Mouse merlin-null schwannoma cells were generated in the laboratory of Dr. Cristina Fernandez-Valle by deleting the sequence coding for exon 2 in the Nf2 gene,Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
sNF96.2,cell_lines,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,HEK-293T and sNF96.2 cell lines were purchased from the American Type Culture Collection (ATCC),Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
M3,cell_lines,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The human MPNST cell line M3 (NF1, –/– CDKN2A/B) was a gift and derived from an NF1-associated MPNST",Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
SKP605,cell_lines,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The murine MPNST cell line, SKP605 (–/– Nf1, –/– Cdkn2a/b), was generated in-house from skin-derived precursors",Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
Primary Schwann cells,cell_lines,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Primary Schwann cells previously isolated from an NF1 patient nerve biopsy, were thawed and cultured on Poly-L-Lysine",Generic cell line name: Primary Schwann cells
M089J,cell_lines,PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human glioma cells, M089J, U138MG, DBRG05MG, LN229, M059K, Hs683, LN18, LN229, and A172 cells were obtained from American Type Culture Collection",Publication title lacks NF-specific terms: Merlin is a potent inhibitor of glioma growth.
U87MG,cell_lines,PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"SF126, SF210, U118MG, and U87MG and rat glioma cell 9L were obtained from University of California-San Francisco and National Cancer Institute",Publication title lacks NF-specific terms: Merlin is a potent inhibitor of glioma growth.
U251,cell_lines,PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"SNB19, U373MG, SF763, U251, SF268, SF539, U343MG, SF188, SF295, SF797, SNB75",Publication title lacks NF-specific terms: Merlin is a potent inhibitor of glioma growth.
U251,cell_lines,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.9,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,U251 was purchased from the American Type Culture Collection (ATCC) and originally derived from an adult glioblastoma patient,Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
SF188,cell_lines,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.9,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,High-grade glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"SF188 was kindly provided by Dr. Chris Jones (Institute of Cancer Research, Sutton, UK) and is derived from a pediatric high-grade glioma",Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
JHH-NF1-GBM1,cell_lines,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.95,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,an NF1-associated ATRX mutant glioblastoma cell line (JHH-NF1-GBM1),Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
JHH-CRC65,cell_lines,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.9,Experimental Usage,True,1.00,High,,,,,,,Soft tissue,Neurofibromatosis Type 1,Sarcoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,an NF1-derived sarcoma cell line (JHH-CRC65),Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
ST88-14,cell_lines,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"two NF1-deficient MPNST cell lines (ST88-14, NF90.8)",Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
NF90.8,cell_lines,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"two NF1-deficient MPNST cell lines (ST88-14, NF90.8)",Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
U2OS,cell_lines,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Bone,,Osteosarcoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,The known ALT-positive osteosarcoma cell line U2OS served as a positive control,Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
Human schwannomas cells,cell_lines,PMID:26549023,10.1038/onc.2015.404,"The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.",,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,Schwannoma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Human schwannomas cells were provided by NF2 patients after informed consent. Schwann cells from healthy nerve donors were used in this research.,"Publication title lacks NF-specific terms: The scaffold protein KSR1, a novel therapeutic target for the treatment of Merli"
HEK293T,cell_lines,PMID:26549023,10.1038/onc.2015.404,"The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.",,0.9,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,HEK293T cells were cultured under standard conditions.,"Publication title lacks NF-specific terms: The scaffold protein KSR1, a novel therapeutic target for the treatment of Merli"
iPN cells,cell_lines,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,,,,,,,,,,,,,,,,,,,,,,,IPN cells were stably transduced to generate parental iPN dCas9-KRAB-BFP cells,"Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
NF95.11b,cell_lines,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Patient-derived iPN, neurofibroma (NF95.11b), or human MPNST (JH002-2, ST88-14) cell lines","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
JH002-2,cell_lines,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Patient-derived iPN, neurofibroma (NF95.11b), or human MPNST (JH002-2, ST88-14) cell lines","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
ST88-14,cell_lines,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Patient-derived iPN, neurofibroma (NF95.11b), or human MPNST (JH002-2, ST88-14) cell lines","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
JW18.2,cell_lines,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Mouse MPNST cell lines (JW18.2, JW23.3) were a gift from Angie Hirbe","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
JW23.3,cell_lines,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Mouse MPNST cell lines (JW18.2, JW23.3) were a gift from Angie Hirbe","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
MSTO-211H,cell_lines,PMID:24848258,10.1126/scitranslmed.3008639,Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Lung,,Malignant pleural mesothelioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MSTO-211H, MDA-MB-468 and MDA-MB-231 s.c. xenograft experiments are described in detail",Publication title lacks NF-specific terms: Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relatio
MDA-MB-468,cell_lines,PMID:24848258,10.1126/scitranslmed.3008639,Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Breast,,Breast adenocarcinoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MSTO-211H, MDA-MB-468 and MDA-MB-231 s.c. xenograft experiments are described in detail",Publication title lacks NF-specific terms: Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relatio
MDA-MB-231,cell_lines,PMID:24848258,10.1126/scitranslmed.3008639,Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Breast,,Breast adenocarcinoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MSTO-211H, MDA-MB-468 and MDA-MB-231 s.c. xenograft experiments are described in detail",Publication title lacks NF-specific terms: Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relatio
Rx-GFP-EF1a-mCherry mESC cell line,cell_lines,PMID:33816648,10.1016/j.omtm.2021.03.004,Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Brain,,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,The Rx-GFP-EF1a-mCherry mESC cell line was generated by lentiviral transduction of Rx-GFP mESCs (RIKEN),Publication title lacks NF-specific terms: Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and gl
Survey of Well-being of Young Children (SWYC),clinical_assessment_tools,PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Survey of Well-being of Young Children (SWYC),questionnaire,pediatric,No,,"...developmental delay assessed with the Survey of Well-being of Young Children...SWYC surveys conducted on the same days, which assess developmental milestones...","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Survey of Well-being of Young Children (SWYC)"
Centers for Disease Control (CDC) growth charts,clinical_assessment_tools,PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Centers for Disease Control (CDC) growth charts,scale,pediatric,No,,...We used the LMS method from Centers for Disease Control (CDC) growth charts on head circumference to compute Z scores...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Centers for Disease Control (CDC) growth charts"
Apple Watch Ultra model 2,clinical_assessment_tools,PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Apple Watch Ultra model 2,performance test,pediatric,No,,An assessment of sleep parameters...with an Apple Watch Ultra model 2 (application: Sleep++) was performed in all the patients,"Hardware device, not a clinical assessment instrument"
National Institute of Health diagnostic criteria for NF1,clinical_assessment_tools,PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,National Institute of Health diagnostic criteria for NF1,structured interview,all ages,Yes,,"Participants were children aged 12–17 years meeting the National Institute of Health (National Institutes of Health Consensus Development Conference, 1988) diagnostic criteria for NF1.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: National Institute of Health diagnostic criteria for NF1"
P300 event-related potential,clinical_assessment_tools,PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,P300 event-related potential,biomarker assay,pediatric,No,,The aim of this study was to investigate P300 event-related potential (ERP) associated with WM in NF1...EEG was recorded during a WM nback task.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: P300 event-related potential"
WM nback task,clinical_assessment_tools,PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,WM nback task,performance test,pediatric,No,,EEG was recorded during a WM nback task. The NF1 group showed poorer performance on measures of WM as compared to the control group.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: WM nback task"
P.L.E.A.S.E.® device,clinical_assessment_tools,PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,P.L.E.A.S.E.® device,other,adult,Yes,,"cNFs were laser-porated using the P.L.E.A.S.E.® device with the following user-defined settings: density of 10%, 5 pulses per pore, repetition rate of 300 Hz","Assessment name not in title and 'tool' not in title — likely generic usage, not development: P.L.E.A.S.E.® device"
Dermlite DL3,clinical_assessment_tools,PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Dermlite DL3,other,adult,Yes,,"visual and dermatoscopy observations (using the Dermlite DL3 [3Gen, San Jan Capistrano, CA, USA]) noting color and presence of necrosis","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Dermlite DL3"
NIH Consensus Development Conference NF1 diagnostic criteria,clinical_assessment_tools,PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NIH Consensus Development Conference NF1 diagnostic criteria,structured interview,all ages,Yes,,"patients with a clinical diagnosis of NF1 according to the NIH Consensus Development Conference NF1 diagnostic criteria (NIH, 1998)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: NIH Consensus Development Conference NF1 diagnostic criteria"
Olympus BX-51 microscope,clinical_assessment_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Olympus BX-51 microscope,performance test,clinician-rated,No,,Images of the hematoxylin-eosin sections were taken (20X magnification) using an Olympus BX-51 microscope using an Olympus DP71 digital camera,"Hardware device, not a clinical assessment instrument"
Olympus DP71 digital camera,clinical_assessment_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Olympus DP71 digital camera,performance test,clinician-rated,No,,Images of the hematoxylin-eosin sections were taken (20X magnification) using an Olympus BX-51 microscope using an Olympus DP71 digital camera,"Hardware device, not a clinical assessment instrument"
Numerical Rating Scale-11,clinical_assessment_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Numerical Rating Scale-11,scale,all ages,Yes,1.0,The Numerical Rating Scale-11 is a self-report measure of pain intensity that was adapted to assess PN-related pain for NF1 clinical trials. Patients were asked to choose their most important tumor pain and rate it from 0 (no pain) to 10 (worst pain) in the past week.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Numerical Rating Scale-11"
Brief Pain Inventory Pain Interference subscale,clinical_assessment_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brief Pain Inventory Pain Interference subscale,scale,all ages,No,7.0,The Brief Pain Inventory Pain Interference subscale assesses the impact of pain on daily functioning in seven areas from 0 (does not interfere) to 10 (completely interfered) in the past week; it yields a mean total score.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Brief Pain Inventory Pain Interference subscale"
Pediatric Quality of Life Inventory NF1 module,clinical_assessment_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Pediatric Quality of Life Inventory NF1 module,questionnaire,pediatric,Yes,16.0,The Pediatric Quality of Life Inventory NF1 module is a disease-specific health-related quality-of-life (QOL) measure assessing 16 domains. Responses on a five-point Likert scale are transformed to a scale of 0-100 (higher scores = better QOL); it produces mean domain and total scores.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Pediatric Quality of Life Inventory NF1 module"
EQ-5D-5L,clinical_assessment_tools,PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,EQ-5D-5L,questionnaire,adult,No,5.0,"The EQ-5D-5L is a brief and generic health status measure that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression","Assessment name not in title and 'tool' not in title — likely generic usage, not development: EQ-5D-5L"
SF-36,clinical_assessment_tools,PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,SF-36,questionnaire,adult,No,36.0,"The 36-item Short Form Survey (SF-36) is a generic health-related QoL measure. It comprises eight domains of health: physical function, limitations because of physical problems","Assessment name not in title and 'tool' not in title — likely generic usage, not development: SF-36"
World Health Organization Quality of Life Brief Version (WHOQOL-BREF),clinical_assessment_tools,PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,World Health Organization Quality of Life Brief Version (WHOQOL-BREF),questionnaire,adult,No,26.0,The 2 primary outcomes were the physical health and psychological QOL domain scores of the World Health Organization Quality of Life Brief Version (WHOQOL-BREF),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: World Health Organization Quality of Life Brief Version (WHOQOL-BREF)"
Perceived Stress Scale,clinical_assessment_tools,PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Perceived Stress Scale,scale,adult,No,,Perceived Stress Scale score of 6 or higher,Generic psychological scale (not NF-specific)
Relaxation Response Resiliency Program for NF (3RP-NF),clinical_assessment_tools,PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Relaxation Response Resiliency Program for NF (3RP-NF),structured interview,adult,Yes,,"mind-body skills training program, the Relaxation Response Resiliency Program for NF (3RP-NF)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Relaxation Response Resiliency Program for NF (3RP-NF)"
Health Enhancement Program for NF (HEP-NF),clinical_assessment_tools,PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Health Enhancement Program for NF (HEP-NF),structured interview,adult,Yes,,health education program (Health Enhancement Program for NF; HEP-NF),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Health Enhancement Program for NF (HEP-NF)"
DPOAE,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,DPOAE,performance test,all ages,No,,We measure hearing function by DPOAE and ABR tests,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: DPOAE"
ABR,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,ABR,performance test,all ages,No,,We measure hearing function by DPOAE and ABR tests,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: ABR"
hind-limb clasping test,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,hind-limb clasping test,performance test,all ages,No,,"cerebellar ataxia using behavior tests, including hind-limb clasping, and ledge and gait tests","Assessment name not in title and 'tool' not in title — likely generic usage, not development: hind-limb clasping test"
ledge test,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,ledge test,performance test,all ages,No,,"In the CPA model, we found that the ledge test, which evaluates coordination, is the most sensitive test","Assessment name not in title and 'tool' not in title — likely generic usage, not development: ledge test"
gait test,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,gait test,performance test,all ages,No,,"cerebellar ataxia using behavior tests, including hind-limb clasping, and ledge and gait tests","Generic physical performance test, not a validated clinical instrument"
rotarod assay,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,rotarod assay,performance test,all ages,No,,"Balance, motor strength, and coordination can be assayed by rotarod assay","Assessment name not in title and 'tool' not in title — likely generic usage, not development: rotarod assay"
Dermus SkinScanner,clinical_assessment_tools,PMID:41598414,10.3390/jcm15020475,Dermoscopy-Guided High-Frequency Ultrasound Imaging of Subcentimeter Cutaneous and Subcutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Dermus SkinScanner,biomarker assay,all ages,Yes,,"measurements were performed at the Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, using a portable DG-HFUS device (Dermus SkinScanner, Dermus Ltd., Budapest, Hungary)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Dermus SkinScanner"
MIA ELISA kit,clinical_assessment_tools,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,MIA ELISA kit,biomarker assay,all ages,Yes,,"The MIA ELISA kit was purchased from (Roche Diagnostics, Indianapolis, IN, USA) and the measurements were conducted",Lab assay/kit misclassified as clinical assessment tool
Wechsler Abbreviated Scale of Intelligence (WASI),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Abbreviated Scale of Intelligence (WASI),performance test,all ages,No,,"Full‐Scale IQ of at least 70, as determined by the Wechsler Abbreviated Scale of Intelligence (WASI 15 )","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wechsler Abbreviated Scale of Intelligence (WASI)"
Brief Visuospatial Memory Test – Revised (BVMT),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brief Visuospatial Memory Test – Revised (BVMT),performance test,all ages,No,,"the Brief Visuospatial Memory Test – Revised (BVMT, Immediate and Delayed 19 ; nonverbal declarative memory)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Brief Visuospatial Memory Test – Revised (BVMT)"
Letter‐Number Sequencing task (LNS),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Letter‐Number Sequencing task (LNS),performance test,all ages,No,,the Letter‐Number Sequencing task (LNS 20 ; working memory),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Letter‐Number Sequencing task (LNS)"
Digit Cancellation,clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Digit Cancellation,performance test,all ages,No,,Digit Cancellation (attention/inhibitory control) 21,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Digit Cancellation"
Hopkins Verbal Learning Test (HVLT),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Hopkins Verbal Learning Test (HVLT),performance test,all ages,No,,Hopkins Verbal Learning Test (HVLT; verbal declarative memory 22 ),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Hopkins Verbal Learning Test (HVLT)"
WISC‐III Object Assembly,clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WISC‐III Object Assembly,performance test,pediatric,No,,WISC‐III Object Assembly (visuoconstructive ability) 23,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: WISC‐III Object Assembly"
Achenbach Child Behavior Checklist (CBCL),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Achenbach Child Behavior Checklist (CBCL),questionnaire,pediatric,No,,Achenbach Child Behavior Checklist (CBCL; self‐ and parent‐report),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Achenbach Child Behavior Checklist (CBCL)"
Young Adult Self Report (YASR),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Young Adult Self Report (YASR),questionnaire,adult,No,,"Young Adult Self Report (YASR) 24 ,  25","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Young Adult Self Report (YASR)"
Neuropsychological Assessment Battery (NAB) Mazes,clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Neuropsychological Assessment Battery (NAB) Mazes,performance test,all ages,No,,the Neuropsychological Assessment Battery (NAB) Mazes 26,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Neuropsychological Assessment Battery (NAB) Mazes"
Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency,clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency,performance test,all ages,No,,Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency (category and letter fluency) 27,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency"
Behavior Rating Inventory of Executive Function (BRIEF),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Behavior Rating Inventory of Executive Function (BRIEF),questionnaire,all ages,No,,Behavior Rating Inventory of Executive Function (BRIEF; General Executive Composite (GEC) score) 28,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Behavior Rating Inventory of Executive Function (BRIEF)"
Spatial capacity working memory (SCAP) task,clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Spatial capacity working memory (SCAP) task,performance test,all ages,No,,"A spatial working memory functional MRI paradigm, designed to be analogous to the behavioral tasks used in the mouse model","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Spatial capacity working memory (SCAP) task"
Hannover classification system,clinical_assessment_tools,PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Hannover classification system,scale,all ages,Yes,,Tumor size was classified by the Hannover and Koos classification systems,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Hannover classification system"
Koos classification system,clinical_assessment_tools,PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Koos classification system,scale,all ages,Yes,,Tumor size was classified by the Hannover and Koos classification systems,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Koos classification system"
RECIST guidelines,clinical_assessment_tools,PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,RECIST guidelines,scale,all ages,No,,"the maximum linear (tumor) diameter (MLD) in axial and coronal (medial to lateral and caudal to rostral/cranial, in total four measurements per MRI) planes were measured according to the RECIST guidelines","Assessment name not in title and 'tool' not in title — likely generic usage, not development: RECIST guidelines"
Tinnitus Functional Index,clinical_assessment_tools,PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Tinnitus Functional Index,questionnaire,adult,No,,The Tinnitus Functional Index was identified as the most highly rated measure for the assessment of tinnitus in populations with neurofibromatosis type 2,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Tinnitus Functional Index"
Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE),clinical_assessment_tools,PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE),scale,clinician-rated,No,,The remaining 16 PROMs were submitted to a formal group review process using the Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE) form,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE)"
Client Oriented Scale of Improvement-Tinnitus,clinical_assessment_tools,PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,0.85,Citation Only,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Client Oriented Scale of Improvement-Tinnitus,scale,adult,Yes,,One measure was excluded (i.e. the Client Oriented Scale of Improvement-Tinnitus) because while it would be very useful for clinical settings,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Client Oriented Scale of Improvement-Tinnitus"
Brief Symptom Inventory 18 (BSI-18),clinical_assessment_tools,PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brief Symptom Inventory 18 (BSI-18),questionnaire,adult,No,18.0,Emotional and behavioral problems were measured using the Brief Symptom Inventory 18 (BSI-18) for adult respondents,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Brief Symptom Inventory 18 (BSI-18)"
Behavior Problem Index (BPI),clinical_assessment_tools,PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Behavior Problem Index (BPI),questionnaire,pediatric,No,,Emotional and behavioral problems were measured using...the Behavior Problem Index (BPI) for adolescents (<18 years of age),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Behavior Problem Index (BPI)"
CCSS Neurocognitive Questionnaire,clinical_assessment_tools,PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CCSS Neurocognitive Questionnaire,questionnaire,adult,No,,"Neurocognitive outcomes were assessed for adult respondents with the CCSS Neurocognitive Questionnaire, which includes subscales measuring task efficiency, emotional regulation, organization, and memory","Assessment name not in title and 'tool' not in title — likely generic usage, not development: CCSS Neurocognitive Questionnaire"
"Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)",clinical_assessment_tools,PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)",scale,all ages,No,,"Chronic health conditions were classified and severity-graded according to the Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)"
RAS-G-LISA assay,clinical_assessment_tools,PMID:34945792,10.3390/jpm11121320,Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,RAS-G-LISA assay,biomarker assay,all ages,No,,The RAS-G-LISA assay was obtained from Cytoskeleton Inc. and was performed according to the manufacturer's instructions.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: RAS-G-LISA assay"
Children's Tumor Foundation NF Registry,clinical_assessment_tools,PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Children's Tumor Foundation NF Registry,other,all ages,Yes,,The survey link was distributed via email to 1160 adolescent caregivers in the Children's Tumor Foundation NF Registry,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Children's Tumor Foundation NF Registry"
5-point Likert-type scales,clinical_assessment_tools,PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,5-point Likert-type scales,scale,pediatric,Yes,,Survey questions used 5-point Likert-type scales to measure ordered scale responses,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: 5-point Likert-type scales"
PEERS® intervention,clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PEERS® intervention,structured interview,pediatric,No,14.0,The PEERS® intervention was administered by certified PEERS® providers...according to the PEERS® manual and the CARD telehealth manual,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: PEERS® intervention"
Kaufman Brief Intelligence Test– Second Edition (KBIT-2),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Kaufman Brief Intelligence Test– Second Edition (KBIT-2),performance test,pediatric,No,,The KBIT-2 is a brief measure of cognitive abilities including verbal reasoning and nonverbal reasoning...administered at the adolescent intake appointment,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Kaufman Brief Intelligence Test– Second Edition (KBIT-2)"
Wechsler Individual Achievement Test– Third Edition (WIAT-III) Word Reading subtest,clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Individual Achievement Test– Third Edition (WIAT-III) Word Reading subtest,performance test,pediatric,No,,The WIAT-III Word Reading subtest examines the ability to accurately read words...administered at the adolescent intake appointment,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wechsler Individual Achievement Test– Third Edition (WIAT-III) Word Reading subtest"
Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version– Attention Deficit/Hyperactivity Disorder module (KSADS-ADHD),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version– Attention Deficit/Hyperactivity Disorder module (KSADS-ADHD),structured interview,caregiver,No,,The KSADS is a semi-structured caregiver interview to assess psychopathology...administered at the pre-test appointment to a caregiver,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version– Attention Deficit/Hyperactivity Disorder module (KSADS-ADHD)"
Social Communication Questionnaire (SCQ),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Social Communication Questionnaire (SCQ),questionnaire,caregiver,No,40.0,The SCQ is a caregiver-report questionnaire that examines ASD symptomatology...has 40 items that are rated as 'Yes' or 'No',"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Social Communication Questionnaire (SCQ)"
Social Skills Improvement System Social-Emotional Learning (SSIS-SEL),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Social Skills Improvement System Social-Emotional Learning (SSIS-SEL),questionnaire,all ages,No,51.0,The SSIS-SEL is a caregiver and self-report questionnaire measure examining social-emotional skills...Parent (51 items) and Student (46 items) forms,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Social Skills Improvement System Social-Emotional Learning (SSIS-SEL)"
Social Responsiveness Scale– Second Edition (SRS-2),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Social Responsiveness Scale– Second Edition (SRS-2),questionnaire,caregiver,No,65.0,The SRS-2 is a caregiver-report questionnaire of social impairment...includes 65 items that are rated on a 4-point scale,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Social Responsiveness Scale– Second Edition (SRS-2)"
Friendship Qualities Scale (FQS),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Friendship Qualities Scale (FQS),questionnaire,pediatric,No,23.0,The FQS is a self-report questionnaire examining the friendship qualities...rate 23 items using a 5-point scale,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Friendship Qualities Scale (FQS)"
Quality of Socialization Questionnaire (QSQ),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Quality of Socialization Questionnaire (QSQ),questionnaire,all ages,No,,The QSQ is a caregiver and self-report questionnaire to gather information about the adolescent's get-togethers with peers,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Quality of Socialization Questionnaire (QSQ)"
Test of Adolescent Social Skills Knowledge (TASSK),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Test of Adolescent Social Skills Knowledge (TASSK),questionnaire,pediatric,No,30.0,The TASSK is a self-report 30-item questionnaire that measures knowledge of specific social skills taught as part of the PEERS® intervention,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Test of Adolescent Social Skills Knowledge (TASSK)"
Pain Interference Index (PII),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Interference Index (PII),questionnaire,pediatric,No,6.0,The original PII measure is a six-item self-report questionnaire that assesses pain interference using the past 2 weeks as a recall period,Publication title lacks NF-specific terms: Development and validation of the English Pain Interference Index and Pain Inter
Pain Interference Index-Parent report (PII-P),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Interference Index-Parent report (PII-P),questionnaire,caregiver,No,6.0,"The six-item PII-P is formatted and scored in the same manner as the self-report PII, with total scores ranging from 0 to 6",Publication title lacks NF-specific terms: Development and validation of the English Pain Interference Index and Pain Inter
Modified Brief Pain Inventory (MBPI),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Modified Brief Pain Inventory (MBPI),questionnaire,pediatric,No,12.0,"The MBPI, adapted from the adult Brief Pain Inventory, is a 12-item self-report questionnaire that measures pain interference",Publication title lacks NF-specific terms: Development and validation of the English Pain Interference Index and Pain Inter
Faces Pain Scale-Revised (FPS-R),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Faces Pain Scale-Revised (FPS-R),scale,pediatric,No,1.0,The FPS-R is a one-item tool designed to provide an overall indicator of pain intensity at the time of the assessment,Publication title lacks NF-specific terms: Development and validation of the English Pain Interference Index and Pain Inter
Pain Rating Scale (PRS),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Rating Scale (PRS),scale,pediatric,No,2.0,The PRS is a two-item visual analogue scale (VAS) developed by the authors that assesses pain intensity,Publication title lacks NF-specific terms: Development and validation of the English Pain Interference Index and Pain Inter
Pain Rating Scale-Parent version (PRS-P),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Rating Scale-Parent version (PRS-P),scale,caregiver,No,2.0,The Pain Rating Scale-Parent version (PRS-P) is similar to the VAS self-report PRS in terms of item content and format,Publication title lacks NF-specific terms: Development and validation of the English Pain Interference Index and Pain Inter
NF Disease Severity Scale,clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NF Disease Severity Scale,scale,clinician-rated,Yes,,"the NF Disease Severity Scale, adapted by our group from Ablon, asks the medical professional to rate the patient's symptoms as mild, moderate, or severe",Publication title lacks NF-specific terms: Development and validation of the English Pain Interference Index and Pain Inter
NF1 Disease Complications Scale,clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NF1 Disease Complications Scale,scale,clinician-rated,Yes,18.0,"the NF1 Disease Complications Scale, is a checklist designed by a multi-disciplinary team of medical experts in NF1 at the National Institutes of Health",Publication title lacks NF-specific terms: Development and validation of the English Pain Interference Index and Pain Inter
Hematoxylin and eosin (H&E),clinical_assessment_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Hematoxylin and eosin (H&E),biomarker assay,clinician-rated,No,,Hematoxylin and eosin (H&E)-stained tissue sections from each tumor were reviewed by a board-certified pathologist,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Hematoxylin and eosin (H&E)"
immunohistochemical staining,clinical_assessment_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,immunohistochemical staining,biomarker assay,clinician-rated,Yes,,Patients from our institutional cohort with adequate tumor samples for immunohistochemical staining of DLK1,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: immunohistochemical staining"
NRS-11,clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NRS-11,scale,all ages,No,11.0,Numerical Rating Scale-11 (NRS-11): The NRS-11 is a self-report 11-point numeric scale that assesses pain intensity,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NRS-11"
BPI-PI Scale,clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,BPI-PI Scale,questionnaire,all ages,No,7.0,Brief Pain Inventory (BPI)-Pain Interference (PI) Scale: The BPI-PI Scale is a 7-item self-report questionnaire that measures the extent to which pain interferes with daily functioning,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: BPI-PI Scale"
PedsQL NF1 Module,clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL NF1 Module,questionnaire,all ages,Yes,74.0,PedsQL™ NF1 Module: This scale is a self-report measure assessing NF1 disease-specific QOL. Participants who were ages 21 years and older completed the 74-item self-report adult questionnaire,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL NF1 Module"
"Human AXL DuoSet ELISA kit (R&D Systems, DY154)",clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Human AXL DuoSet ELISA kit (R&D Systems, DY154)",biomarker assay,all ages,No,,"Levels of circulating sAXL were measured in human plasma using the Human AXL DuoSet ELISA kit (R&D Systems, DY154)",Lab assay/kit misclassified as clinical assessment tool
"Mouse AXL DuoSet ELISA kit (R&D Systems, DY854)",clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse AXL DuoSet ELISA kit (R&D Systems, DY854)",biomarker assay,all ages,No,,"Levels of circulating sAXL were measured in mouse plasma using the Mouse AXL DuoSet ELISA kit (R&D Systems, DY854)",Lab assay/kit misclassified as clinical assessment tool
FragEL DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21),clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,FragEL DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21),biomarker assay,all ages,No,,The FragEL™ DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21) was used according to manufacturer's instructions,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: FragEL DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21)"
"Caspase 3/7 Glo activity (#G8093, Promega)",clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Caspase 3/7 Glo activity (#G8093, Promega)",biomarker assay,all ages,No,,"Caspase 3/7 Glo activity (#G8093, Promega) was measured by luminescence after 24 hours of treatment",Lab assay/kit misclassified as clinical assessment tool
RECIST 1.1,clinical_assessment_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,RECIST 1.1,scale,adult,No,,radiographic tumor burden was quantified by sum of the longest tumor diameters (SLD) per RECIST 1.1 criteria,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: RECIST 1.1"
3-chamber social preference task,clinical_assessment_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,3-chamber social preference task,performance test,all ages,No,,The 3-chamber SP task occurred over 2 days as described previously,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: 3-chamber social preference task"
Open field test,clinical_assessment_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Open field test,performance test,all ages,No,,"mice were placed in the dark in an open chamber (40 × 40 cm, 30 cm height) for 60 minutes while activity was recorded","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Open field test"
Delay discounting task,clinical_assessment_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Delay discounting task,performance test,all ages,No,,mice were trained to identify which side of a T maze had a large reward (4 Cocoa Krispies) compared with the small reward (1 Cocoa Krispie),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Delay discounting task"
Cliff avoidance reaction test,clinical_assessment_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Cliff avoidance reaction test,performance test,all ages,No,,"a round, plastic platform (diameter, 20 cm; thickness, 2 cm) supported by a plastic rod (height, 50 cm) was used to assess the CAR","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Cliff avoidance reaction test"
PedsQL™ NF1 Module,clinical_assessment_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ NF1 Module,questionnaire,adult,Yes,74.0,"The objective of this study was to develop an NF1 HRQOL instrument as a module of PedsQL™ and to test for its initial feasibility, internal consistency reliability and validity in adults with NF1.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL™ NF1 Module"
PedsQL™ 4.0 Generic Core Scales,clinical_assessment_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.85,Citation Only,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ 4.0 Generic Core Scales,scale,all ages,No,,"The NF1 HRQOL format, instructions, and Likert response scale are similar to the PedsQL™ 4.0 Generic Core Scales and other PedsQL™ Disease-Specific Modules.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL™ 4.0 Generic Core Scales"
PedsQL™ Arthritis Module,clinical_assessment_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,Citation Only,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ Arthritis Module,questionnaire,all ages,Yes,,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL™ Arthritis Module"
PedsQL™ Cancer Module,clinical_assessment_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,Citation Only,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ Cancer Module,questionnaire,all ages,Yes,,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL™ Cancer Module"
PedsQL™ Cerebral Palsy Module,clinical_assessment_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,Citation Only,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ Cerebral Palsy Module,questionnaire,all ages,Yes,,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL™ Cerebral Palsy Module"
PedsQL™ Family Impact Module,clinical_assessment_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,Citation Only,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ Family Impact Module,questionnaire,caregiver,No,,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL™ Family Impact Module"
Life Events Checklist (LEC),clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Life Events Checklist (LEC),questionnaire,adult,No,22.0,"Participants completed the Life Events Checklist, adapted from Elliott-DeSorbo et al. [ 30 ], to document stressful events in the past three months. The score is the number of stressful events endorsed (range 0–22).","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Life Events Checklist (LEC)"
Rating of Overall Stress Scale (ROSS),clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rating of Overall Stress Scale (ROSS),scale,adult,No,,Participants rated their stress in the past month from 0 (not stressed) to 10 (very stressed). This measure was adapted from Leidy et al. [ 31 ].,Generic psychological scale (not NF-specific)
PROMIS depression short form,clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PROMIS depression short form,questionnaire,adult,No,8.0,"The following PROMIS self-report short forms were administered: depression (8 items) [ 32 ], pain interference (6 items) [ 33 ], and cognitive function (8 items) [ 34 ].","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PROMIS depression short form"
PROMIS pain interference short form,clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PROMIS pain interference short form,questionnaire,adult,No,6.0,"The following PROMIS self-report short forms were administered: depression (8 items) [ 32 ], pain interference (6 items) [ 33 ], and cognitive function (8 items) [ 34 ].","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PROMIS pain interference short form"
PROMIS cognitive function short form,clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PROMIS cognitive function short form,questionnaire,adult,No,8.0,"The following PROMIS self-report short forms were administered: depression (8 items) [ 32 ], pain interference (6 items) [ 33 ], and cognitive function (8 items) [ 34 ].","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PROMIS cognitive function short form"
MEMS Cap,clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,MEMS Cap,performance test,adult,No,,"Participants' study drug bottles were fitted with a MEMS TM cap at baseline. Having been given instructions to take the drug 12 h apart, adherence was defined as opening the bottle 11–13 h since their last dose.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: MEMS Cap"
Barriers to Adherence Questionnaire,clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Barriers to Adherence Questionnaire,questionnaire,adult,Yes,16.0,The barriers to adherence measure was created by the study team; participants were asked to think of times they missed a dose of their study drug in the past month and marked which of 16 possible reasons caused them to miss a dose.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Barriers to Adherence Questionnaire"
EuroQol (EQ 5D),clinical_assessment_tools,PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,EuroQol (EQ 5D),questionnaire,adult,No,5.0,"The EuroQol (EQ 5D) contains a global health score and covers Mobility, Self-care, Usual Activities, Pain/Discomfort, Anxiety and Depression","Assessment name not in title and 'tool' not in title — likely generic usage, not development: EuroQol (EQ 5D)"
Riccardi NF severity grade classification,clinical_assessment_tools,PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Riccardi NF severity grade classification,scale,adult,Yes,4.0,Disease severity was determined using the Riccardi NF severity grade classification 1 to 4. Grades 1 and 2 were amalgamated to ensure adequate numbers in each group,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Riccardi NF severity grade classification"
NIH Consensus Development Conference 1987 diagnostic criteria,clinical_assessment_tools,PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NIH Consensus Development Conference 1987 diagnostic criteria,structured interview,all ages,Yes,,Adults (18 years or older) who fulfilled the diagnostic criteria for NF1 (NIH Consensus Development Conference 1987) and attended the National NF1 service,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NIH Consensus Development Conference 1987 diagnostic criteria"
Impact of Pediatric Illness Scale,clinical_assessment_tools,PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Impact of Pediatric Illness Scale,scale,pediatric,No,,"...response of three or higher on a pain interference item (1–5 scales) from a self-report or parent-report QOL measure (Impact of Pediatric Illness Scale [ Wolters et al., 2010 ])","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Impact of Pediatric Illness Scale"
Pain Management Inventory,clinical_assessment_tools,PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.8,Development,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Management Inventory,scale,pediatric,Yes,,...two scales developed by the authors for the current study assessed pain management techniques used by the patients (Pain Management Inventory),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Pain Management Inventory"
Post-Treatment Questionnaire,clinical_assessment_tools,PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.8,Development,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Post-Treatment Questionnaire,questionnaire,pediatric,Yes,,...treatment adherence and study satisfaction (Post-Treatment Questionnaire). Details on these measures are in Table I,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Post-Treatment Questionnaire"
visual analogue scale,clinical_assessment_tools,PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,visual analogue scale,scale,adult,No,,The inclusion criteria for the pain group were an average pain score of ≥ 3 on the visual analogue 0–10 scale over the previous 10 weeks,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: visual analogue scale"
NeuroConn DC-STIMULATOR MR,clinical_assessment_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NeuroConn DC-STIMULATOR MR,performance test,pediatric,No,,AtDCS was delivered via a NeuroConn DC-STIMULATOR MR with the anode placed over F3 position in the international 10–20 system,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NeuroConn DC-STIMULATOR MR"
Vineland Adaptive Behaviour Scale—third edition,clinical_assessment_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Vineland Adaptive Behaviour Scale—third edition,scale,caregiver,No,,Parent-rated Vineland Adaptive Behaviour Scale—third edition was administered to the parents to assess child adaptive behaviour,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Vineland Adaptive Behaviour Scale—third edition"
Conners 3 rating scale,clinical_assessment_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Conners 3 rating scale,scale,caregiver,No,27.0,Conners 3 rating scale was used as a standardized measure for parent reported ADHD symptoms. It consists of 27 items each rated on a 4-point Likert scale,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Conners 3 rating scale"
Wechsler Adult and Children Intelligence Scales,clinical_assessment_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Adult and Children Intelligence Scales,performance test,all ages,No,,"All participants completed the age-appropriate digit-span subtest of the Wechsler Adult and Children Intelligence Scales (Wechsler, 2002, 2004)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wechsler Adult and Children Intelligence Scales"
Corsi block-tapping task,clinical_assessment_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Corsi block-tapping task,performance test,all ages,No,,"All participants completed...the Corsi block-tapping task (Kessels et al., 2000, 2008). Both are span tasks where the examiner presents a growing sequence","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Corsi block-tapping task"
Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III),clinical_assessment_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III),performance test,all ages,No,,General intellectual functioning was assessed by the third version of the Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III for adults and children,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III)"
School Achievement Test,clinical_assessment_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,School Achievement Test,performance test,pediatric,No,,"We adopted the arithmetic subtest from the School Achievement Test (Stein, 1994), as an objective measure of school performance","Assessment name not in title and 'tool' not in title — likely generic usage, not development: School Achievement Test"
Brazilian Criterion for Economic Classification (CCEB),clinical_assessment_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brazilian Criterion for Economic Classification (CCEB),questionnaire,adult,No,10.0,Socioeconomic status (SES) was assessed using the Brazilian Criterion for Economic Classification (CCEB) according to the criteria established,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Brazilian Criterion for Economic Classification (CCEB)"
Ki-67/MIB-1 index,clinical_assessment_tools,PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,Ki-67/MIB-1 index,biomarker assay,adult,No,,"the meningioma recurrence score (MRS) generated by our machine learning algorithm revealed multiple predictive factors of recurrence, including age, female gender, and various histopathologic features, including the Ki-67/MIB-1 index.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Ki-67/MIB-1 index"
Rey complex figure test,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rey complex figure test,performance test,pediatric,No,,Rey complex figure test (CFT) (delayed recall; assessing nonverbal long-term memory),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Rey complex figure test"
cancellation test,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,cancellation test,performance test,pediatric,No,,performance on the cancellation test (speed; assessing attention),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: cancellation test"
prism adaptation task,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,prism adaptation task,performance test,pediatric,No,,performance on a prism adaptation task (measurement of adaptation of the angle of hand movements in response to prism glass distortion),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: prism adaptation task"
Stroop color word test,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Stroop color word test,performance test,pediatric,No,,the Stroop color word test,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Stroop color word test"
Wechsler Intelligence Scale for Children–Revised,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Intelligence Scale for Children–Revised,scale,pediatric,No,,"assessed at baseline using the Wechsler Intelligence Scale for Children–Revised, Dutch version","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wechsler Intelligence Scale for Children–Revised"
Beery developmental test of visual-motor integration,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Beery developmental test of visual-motor integration,performance test,pediatric,No,,the Beery developmental test of visual-motor integration,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Beery developmental test of visual-motor integration"
judgment of line orientation task,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,judgment of line orientation task,performance test,pediatric,No,,and the judgment of line orientation task,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: judgment of line orientation task"
Numerical Rating Scale (NRS-11),clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Numerical Rating Scale (NRS-11),scale,pediatric,No,11.0,Children rated tumor pain intensity on a scale from 0 (no pain) to 10 (worst pain imaginable)...pain intensity (11-point Numerical Rating Scale [NRS-11]),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Numerical Rating Scale (NRS-11)"
Pain Interference Index,clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Interference Index,scale,pediatric,No,,"interference of pain in daily functioning (Pain Interference Index)...Scores on the Pain Interference Index range from 0 to 6, with higher scores indicating greater pain interference","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Pain Interference Index"
Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales,clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales,questionnaire,pediatric,No,,"health-related quality of life (Pediatric Quality of Life Inventory [PedsQL] Generic Core Scales)...PedsQL scores range from 0 to 100, with higher scores indicating better health-related quality of life","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales"
Global Impression of Change scale,clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Global Impression of Change scale,scale,pediatric,No,7.0,perceived changes with treatment (Global Impression of Change scale)...Scores on the Global Impression of Change scale range from 1 (very much improved) to 7 (very much worse),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Global Impression of Change scale"
Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility short form,clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility short form,questionnaire,pediatric,No,,children and parents also completed the Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility and Upper Extremity short forms to assess physical functioning,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility short form"
Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity short form,clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity short form,questionnaire,pediatric,No,,children and parents also completed the Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility and Upper Extremity short forms to assess physical functioning,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity short form"
"NCI Common Terminology Criteria for Adverse Events, version 4.0",clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"NCI Common Terminology Criteria for Adverse Events, version 4.0",scale,all ages,No,,"Adverse events were graded with the use of the NCI Common Terminology Criteria for Adverse Events, version 4.0","Assessment name not in title and 'tool' not in title — likely generic usage, not development: NCI Common Terminology Criteria for Adverse Events, version 4.0"
volumetric magnetic resonance imaging analysis,clinical_assessment_tools,PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,volumetric magnetic resonance imaging analysis,biomarker assay,pediatric,Yes,,Response to treatment was monitored by using volumetric magnetic resonance imaging analysis to measure the change in size of the plexiform neurofibroma,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: volumetric magnetic resonance imaging analysis"
Responsibility for Medication Questionnaire,clinical_assessment_tools,PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Responsibility for Medication Questionnaire,questionnaire,pediatric,No,,Adherence to the dosing schedule was assessed by administration of the Responsibility for Medication Questionnaire,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Responsibility for Medication Questionnaire"
"National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0",clinical_assessment_tools,PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0",scale,all ages,No,,"Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0","Assessment name not in title and 'tool' not in title — likely generic usage, not development: National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0"
Response Evaluation Criteria In Solid Tumors (RECIST),clinical_assessment_tools,PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.85,Citation Only,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Response Evaluation Criteria In Solid Tumors (RECIST),scale,all ages,No,,The use of standard response criteria (Response Evaluation Criteria In Solid Tumors [RECIST] and World Health Organization [WHO] criteria),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Response Evaluation Criteria In Solid Tumors (RECIST)"
World Health Organization (WHO) criteria,clinical_assessment_tools,PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.85,Citation Only,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,World Health Organization (WHO) criteria,scale,all ages,No,,The use of standard response criteria (Response Evaluation Criteria In Solid Tumors [RECIST] and World Health Organization [WHO] criteria),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: World Health Organization (WHO) criteria"
CNC-word test,clinical_assessment_tools,PMID:35723774,10.1007/s10072-022-06203-8,A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CNC-word test,performance test,pediatric,No,,Speech perception ability in background noise was evaluated in device-active and inactive conditions using the CNC-word test.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: CNC-word test"
LIFE-R Questionnaire,clinical_assessment_tools,PMID:35723774,10.1007/s10072-022-06203-8,A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,LIFE-R Questionnaire,questionnaire,pediatric,No,,Listening and communication ratings (LIFE-R Questionnaire) were obtained at baseline and at the end of each treatment phase.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: LIFE-R Questionnaire"
Rex Gauge durometer,clinical_assessment_tools,PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Rex Gauge durometer,performance test,all ages,Yes,,One was the Rex Gauge durometer (REX) produced by Rex Gauge LLC...used to measure cNF stiffness,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Rex Gauge durometer"
Delfin SkinFibroMeter,clinical_assessment_tools,PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Delfin SkinFibroMeter,performance test,all ages,Yes,,"the other was the SkinFibroMeter (DEFLIN) made by Delfin Technologies...measure tissue induration, assessing tissue stiffness in quantitative units","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Delfin SkinFibroMeter"
Vectra H1,clinical_assessment_tools,PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Vectra H1,performance test,adult,Yes,,"Images of up to eight cNFs from each participant were captured and analysed using each 3D imaging system: Vectra H1 (Canfield Scientific Inc, Fairfield, NJ, USA)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Vectra H1"
LifeViz Micro,clinical_assessment_tools,PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,LifeViz Micro,performance test,adult,Yes,,"Images of up to eight cNFs from each participant were captured and analysed using each 3D imaging system: LifeViz Micro (QuantifiCare, Biot, France)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: LifeViz Micro"
Cherry Imaging,clinical_assessment_tools,PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Cherry Imaging,performance test,adult,Yes,,"Images of up to eight cNFs from each participant were captured and analysed using each 3D imaging system: Cherry Imaging (Yokneam, Israel)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Cherry Imaging"
compound motor action potential (CMAP),clinical_assessment_tools,PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,compound motor action potential (CMAP),biomarker assay,all ages,No,,"When significantly reduced, the compound motor action potential (CMAP) – correlating with the number of functional axons – is an indicator for axonal damage.",Publication title lacks NF-specific terms: A neuronal function of the tumor suppressor protein merlin.
nerve conduction velocity,clinical_assessment_tools,PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,nerve conduction velocity,performance test,all ages,No,,"By measuring nerve properties as conduction velocity or potential amplitudes of the signal, it is possible to characterize the origin of peripheral nerve diseases.",Publication title lacks NF-specific terms: A neuronal function of the tumor suppressor protein merlin.
electrophysiological measurements,clinical_assessment_tools,PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,electrophysiological measurements,performance test,all ages,No,,Electrophysiological measurements are an indispensable tool for investigating the functional integrity of peripheral nerves in both the clinical and laboratory environment.,Publication title lacks NF-specific terms: A neuronal function of the tumor suppressor protein merlin.
Morris water maze,clinical_assessment_tools,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Morris water maze,performance test,all ages,No,,The water maze task was performed as previously described. Before performing the water maze task,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Morris water maze"
Rotarod,clinical_assessment_tools,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rotarod,performance test,all ages,No,,"Motor learning was assessed with the accelerating rotarod (Ugo Basile, Comerio Varese, Italy)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Rotarod"
EGI 128-electrode Hydrocel Sensor Net,clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,EGI 128-electrode Hydrocel Sensor Net,biomarker assay,pediatric,No,,"We recorded EEG data with an EGI (Philips Neuro, Oregon, USA) 128-electrode Hydrocel Sensor Net, with the vertex electrode...","Assessment name not in title and 'tool' not in title — likely generic usage, not development: EGI 128-electrode Hydrocel Sensor Net"
Mullen Scales of Early Learning (MSEL),clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Mullen Scales of Early Learning (MSEL),scale,pediatric,No,,The Mullen Scales of Early Learning (MSEL) is a standardised measure that assesses developmental ability across five domains...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Mullen Scales of Early Learning (MSEL)"
Autism Observation Score for Infants (AOSI),clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Autism Observation Score for Infants (AOSI),structured interview,pediatric,Yes,,The Autism Observation Score for Infants (AOSI) is a standardised research assessment that examines ASD traits in infants...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Autism Observation Score for Infants (AOSI)"
Infant Behaviour Questionnaire-Revised (IBQ-R),clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Infant Behaviour Questionnaire-Revised (IBQ-R),questionnaire,caregiver,No,191.0,The IBQ-R is a parent-report questionnaire consisting of 191 items and 14 scales that relate to different aspects of infant temperament...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Infant Behaviour Questionnaire-Revised (IBQ-R)"
MacArthur Bates Communicative Development Inventory (CDI),clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,MacArthur Bates Communicative Development Inventory (CDI),questionnaire,caregiver,No,800.0,Parents completed the MacArthur Bates Communicative Development Inventory (CDI) long form measures early language abilities...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: MacArthur Bates Communicative Development Inventory (CDI)"
NIH consensus criteria,clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NIH consensus criteria,structured interview,all ages,Yes,,All participants had their diagnosis confirmed via molecular testing of cord blood samples or clinical diagnosis based on NIH consensus criteria,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NIH consensus criteria"
"International Classification of Diseases, 10th Revision (ICD-10)",clinical_assessment_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"International Classification of Diseases, 10th Revision (ICD-10)",scale,all ages,No,,"a strong positive COVID-19 diagnostic code from the International Classification of Diseases, 10th Revision (ICD-10)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: International Classification of Diseases, 10th Revision (ICD-10)"
Systematized Nomenclature of Medicine (SNOMED),clinical_assessment_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Systematized Nomenclature of Medicine (SNOMED),scale,all ages,No,,"diagnostic code from the International Classification of Diseases, 10th Revision (ICD-10) or Systematized Nomenclature of Medicine (SNOMED) tables","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Systematized Nomenclature of Medicine (SNOMED)"
Logical Observation Identifiers Names and Codes (LOINC),clinical_assessment_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Logical Observation Identifiers Names and Codes (LOINC),scale,all ages,No,,"NF1-relevant diagnosis codes from SNOMED, ICD-9/10, Logical Observation Identifiers Names and Codes (LOINC), and Nebraska Lexicon","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Logical Observation Identifiers Names and Codes (LOINC)"
Nebraska Lexicon,clinical_assessment_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Nebraska Lexicon,scale,all ages,No,,"NF1-relevant diagnosis codes from SNOMED, ICD-9/10, Logical Observation Identifiers Names and Codes (LOINC), and Nebraska Lexicon","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Nebraska Lexicon"
NFTI-QOL,clinical_assessment_tools,PMID:24619350,10.1007/s00415-014-7303-1,Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NFTI-QOL,questionnaire,adult,Yes,8.0,The disease-focused NF2 impact on quality of life (NFTI-QOL) patient questionnaire was assessed as an outcome measure for treatment in a multi-centre study.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NFTI-QOL"
"mouse cytokine array (panel A, R&D system)",clinical_assessment_tools,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse cytokine array (panel A, R&D system)",biomarker assay,all ages,No,,"Mouse cytokine protein expressions were quantified using mouse cytokine array (panel A, R&D system, Minneapolis, MN)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: mouse cytokine array (panel A, R&D system)"
NIH Consensus Conference criteria,clinical_assessment_tools,PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NIH Consensus Conference criteria,scale,all ages,Yes,,"...ages ≤ 25 years with a diagnosis of NF1, as defined by the NIH Consensus Conference criteria [19]...","Assessment name not in title and 'tool' not in title — likely generic usage, not development: NIH Consensus Conference criteria"
Lansky performance status,clinical_assessment_tools,PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Lansky performance status,scale,pediatric,No,,...Exclusion criteria included Lansky or Karnofsky performance statuses of less than 60...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Lansky performance status"
Karnofsky performance status,clinical_assessment_tools,PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Karnofsky performance status,scale,adult,No,,...Exclusion criteria included Lansky or Karnofsky performance statuses of less than 60...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Karnofsky performance status"
National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,clinical_assessment_tools,PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,scale,all ages,No,,...Adverse events (AE) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0"
Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS),clinical_assessment_tools,PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS),scale,all ages,Yes,,...Analysis of functional responses for the cohort of participants with airway involvement were guided by the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) sleep and pulmonary outcomes recommendations...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS)"
Perceived Stress Scale (PSS),clinical_assessment_tools,PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Perceived Stress Scale (PSS),scale,adult,No,10.0,The PSS is the most widely used psychological instrument for measuring the perception of stress. Composed of 10 items rated from never to often,Generic psychological scale (not NF-specific)
Autism Diagnostic Interview Revised (ADI-R),clinical_assessment_tools,PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Autism Diagnostic Interview Revised (ADI-R),structured interview,pediatric,No,87.0,meeting ASD cut-off on the Autism Diagnostic Interview Revised (ADI-R)...Autism Diagnostic Interview-Revised (ADI-R) was used for detailed parent interviews,Publication title lacks NF-specific terms: Autism Spectrum Disorder Symptom Profile Across the RASopathies.
Autism Diagnostic Observation Schedule-2 (ADOS-2),clinical_assessment_tools,PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Autism Diagnostic Observation Schedule-2 (ADOS-2),structured interview,pediatric,No,4.0,scoring above the ASD cut-off on the Autism Diagnostic Observation Schedule-2 (ADOS-2)...The Autism Diagnostic Observation Schedule–second edition (ADOS-2) was used to measure current autism clinical profile,Publication title lacks NF-specific terms: Autism Spectrum Disorder Symptom Profile Across the RASopathies.
Wechsler Abbreviated Scale of Intelligence-II (WASI-II),clinical_assessment_tools,PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Abbreviated Scale of Intelligence-II (WASI-II),performance test,pediatric,No,,"The Wechsler Abbreviated Scale of Intelligence-II (WASI-II) was used to measure verbal intellectual functioning (VIQ), based on two subscales called Similarities and Vocabulary",Publication title lacks NF-specific terms: Autism Spectrum Disorder Symptom Profile Across the RASopathies.
"Conners Parent Rating Scale (3rd edition, short form)",clinical_assessment_tools,PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Conners Parent Rating Scale (3rd edition, short form)",scale,caregiver,No,,"Conners Parent Rating Scale (3rd edition, short form) measured ADHD symptomatology. The two domains, inattention and hyperactivity, were used in the study and presented in T-score",Publication title lacks NF-specific terms: Autism Spectrum Disorder Symptom Profile Across the RASopathies.
Magnetom Avanto,clinical_assessment_tools,PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Magnetom Avanto,biomarker assay,all ages,Yes,,"All MRI sequences were performed on a 1.5 T scanner (Magnetom Avanto, Siemens Healthineers, Erlangen, Germany)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Magnetom Avanto"
Wechsler Abbreviated Scale of Intelligence (WASI),clinical_assessment_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Abbreviated Scale of Intelligence (WASI),scale,adult,No,,"Full-Scale IQ ≥ 70 (as determined by the Wechsler Abbreviated Scale of Intelligence [WASI]; Wechsler, 2011)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wechsler Abbreviated Scale of Intelligence (WASI)"
"Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV)",clinical_assessment_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV)",scale,adult,No,,"same measures from the Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV; Wechsler, 2014) for the healthy controls","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV)"
University of Maryland Letter–Number Sequencing (LNS) task,clinical_assessment_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,University of Maryland Letter–Number Sequencing (LNS) task,performance test,adult,No,,"Working memory capacity was measured behaviorally using the University of Maryland Letter–Number Sequencing (LNS) task (Gold et al., 1997)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: University of Maryland Letter–Number Sequencing (LNS) task"
Spatial capacity working memory (SCAP) task,clinical_assessment_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Spatial capacity working memory (SCAP) task,performance test,adult,No,,"Participants viewed a visual array presenting 1, 3, 5, or 7 circles on the screen followed by a probe circle","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Spatial capacity working memory (SCAP) task"
Vineland Adaptive Behaviour Scale (VABS-III),clinical_assessment_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Vineland Adaptive Behaviour Scale (VABS-III),scale,caregiver,No,,parent-reported Adaptive Behaviour Composite (ABC) scores on the Vineland Adaptive Behaviour Scale (VABS-III),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Vineland Adaptive Behaviour Scale (VABS-III)"
adaptive auditory n-back task,clinical_assessment_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,adaptive auditory n-back task,performance test,pediatric,No,,"performance on an adaptive auditory n-back task, and performance on a non-adaptive visual n-back task performed during EEG","Assessment name not in title and 'tool' not in title — likely generic usage, not development: adaptive auditory n-back task"
non-adaptive visual n-back task,clinical_assessment_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,non-adaptive visual n-back task,performance test,pediatric,No,,"performance on an adaptive auditory n-back task, and performance on a non-adaptive visual n-back task performed during EEG","Assessment name not in title and 'tool' not in title — likely generic usage, not development: non-adaptive visual n-back task"
Brief Pain Inventory Short Form (BPI-SF),clinical_assessment_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brief Pain Inventory Short Form (BPI-SF),questionnaire,adult,No,,responses to the Brief Pain Inventory Short Form (BPI-SF) [ 8 ]...a pain severity aggregate score of ≥3 on the BPI-SF [ 8 ] for pain experienced in the previous 2 weeks,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Brief Pain Inventory Short Form (BPI-SF)"
Patient Health Questionnaire (PHQ),clinical_assessment_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Patient Health Questionnaire (PHQ),questionnaire,adult,No,,responses to...Patient Health Questionnaire (PHQ) [ 19 ]...evidence of moderate to severe depression or anxiety on the PHQ or GAD-7,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Patient Health Questionnaire (PHQ)"
Structured Clinical Interview for DSM Self Report version (SCID-SR),clinical_assessment_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Structured Clinical Interview for DSM Self Report version (SCID-SR),structured interview,adult,No,,Structured Clinical Interview for DSM Self Report version (SCID-SR) [ 20 ]...evidence of psychosis or schizophrenia on the SCID-SR [ 20 ],"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Structured Clinical Interview for DSM Self Report version (SCID-SR)"
Generalized Anxiety Disorder 7 Item version (GAD-7),clinical_assessment_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Generalized Anxiety Disorder 7 Item version (GAD-7),scale,adult,No,7.0,Generalized Anxiety Disorder 7 Item version (GAD-7) [ 21 ]...evidence of moderate to severe depression or anxiety on the PHQ or GAD-7,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Generalized Anxiety Disorder 7 Item version (GAD-7)"
PHQ-9,clinical_assessment_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PHQ-9,questionnaire,adult,No,9.0,The PHQ-9 and GAD-7 are copyrighted by Pfizer Inc. and are freely available for research and clinical use,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: PHQ-9"
Social Responsiveness Scale 2nd Edition,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Social Responsiveness Scale 2nd Edition,scale,caregiver,No,65.0,Children with NF1 that screen at risk for ASD on the parent-rated Social Responsiveness Scale 2nd Edition will be invited back to complete...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Social Responsiveness Scale 2nd Edition"
Autism Diagnostic Observation Scale 2nd Edition,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Autism Diagnostic Observation Scale 2nd Edition,structured interview,pediatric,Yes,,complete the Autism Diagnostic Observation Scale 2nd Edition and Autism Diagnostic Interview-Revised to determine whether they fulfil ASD diagnostic criteria,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Autism Diagnostic Observation Scale 2nd Edition"
Autism Diagnostic Interview-Revised,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Autism Diagnostic Interview-Revised,structured interview,caregiver,Yes,95.0,complete the Autism Diagnostic Observation Scale 2nd Edition and Autism Diagnostic Interview-Revised to determine whether they fulfil ASD diagnostic criteria,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Autism Diagnostic Interview-Revised"
WPPSI-IV,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WPPSI-IV,performance test,pediatric,No,,WPPSI-IV 10 subtests providing 5 indices and full scale IQ Y,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: WPPSI-IV"
WISC-V,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WISC-V,performance test,pediatric,No,,WISC-V 10 subtests providing 5 indices and full scale IQ S,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: WISC-V"
TEA-Ch Sky Search,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,TEA-Ch Sky Search,performance test,pediatric,No,,TEA-Ch Sky Search Assessing the ability to selectively attend to and identify 20 visual targets among distractors S,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: TEA-Ch Sky Search"
TEA-Ch Score!,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,TEA-Ch Score!,performance test,pediatric,No,,TEA-Ch Score! 10 trials assessing the ability to sustain attention by mentally counting aurally administered tones S,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: TEA-Ch Score!"
Shape School,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Shape School,performance test,pediatric,No,60.0,"Shape School 4 conditions (each with 15 items) assessing inhibition, task-switching and working memory abilities","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Shape School"
NEPSY-II Inhibition,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NEPSY-II Inhibition,performance test,pediatric,No,6.0,NESPY-II Inhibition 6 items assessing the ability to inhibit automatic responses in favour of novel responses,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NEPSY-II Inhibition"
Tower of Hanoi,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Tower of Hanoi,performance test,pediatric,No,6.0,"Tower of Hanoi 6 items assessing set shifting, response inhibition, working memory and the ability to hold a set of rules in mind","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Tower of Hanoi"
TEA-Ch Creature Counting,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,TEA-Ch Creature Counting,performance test,pediatric,No,,TEA-Ch Creature Counting 7 trials assessing the ability to accurately switch and redirect attention to count up/down S,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: TEA-Ch Creature Counting"
WIAT-II Abbreviated,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WIAT-II Abbreviated,performance test,pediatric,No,,"WIAT-II Abbreviated 3 subtests assessing numerical operations, spelling and single word reading S","Assessment name not in title and 'tool' not in title — likely generic usage, not development: WIAT-II Abbreviated"
NEPSY-II Affect Recognition,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NEPSY-II Affect Recognition,performance test,pediatric,No,36.0,NEPSY-II Affect Recognition 36 items assessing the ability to match facial expressions from photographs of children's faces,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NEPSY-II Affect Recognition"
Benton Facial Recognition Test,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Benton Facial Recognition Test,performance test,pediatric,No,13.0,Benton Facial Recognition Test 13 items assessing the ability to recognise a target face from a selection of distractors S,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Benton Facial Recognition Test"
NEPSY-II ToM,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NEPSY-II ToM,performance test,pediatric,No,21.0,"NEPSY-II ToM 21 items assessing the ability to comprehend the perspectives, intentions and beliefs of another person","Assessment name not in title and 'tool' not in title — likely generic usage, not development: NEPSY-II ToM"
Reading the Mind in the Eyes Test-Child,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Reading the Mind in the Eyes Test-Child,performance test,pediatric,No,28.0,Reading the Mind in the Eyes Test-Child 28 items assessing the ability to determine a person's thoughts or feelings based on a picture of only their eyes,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Reading the Mind in the Eyes Test-Child"
Faux Pas Task,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Faux Pas Task,performance test,pediatric,No,20.0,Faux Pas Task 20 short stories assessing the ability to identify a social faux pas S,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Faux Pas Task"
Strange Stories,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Strange Stories,performance test,pediatric,No,14.0,"Strange Stories 14 short stories assessing the ability to attribute mental states (eg, desires, beliefs or intentions)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Strange Stories"
CELF-Preschool-2,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CELF-Preschool-2,performance test,pediatric,No,,"CELF-Preschool-2 2 subtests assessing knowledge of grammatical rules in a sentence completion task and the ability to name objects, people and activities Y","Assessment name not in title and 'tool' not in title — likely generic usage, not development: CELF-Preschool-2"
CELF-4 Formulated Sentences,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CELF-4 Formulated Sentences,performance test,pediatric,No,28.0,CELF-4 Formulated Sentences 28 items assessing the ability to formulate semantically and grammatically correct spoken sentences,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: CELF-4 Formulated Sentences"
NEPSY-II Comprehension of Instructions,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NEPSY-II Comprehension of Instructions,performance test,pediatric,No,33.0,NEPSY-II Comprehension of Instructions 33 items assessing the ability to comprehend and follow multistep instructions of increasing complexity,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NEPSY-II Comprehension of Instructions"
SRS-2,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,SRS-2,scale,caregiver,Yes,65.0,"SRS-2 65 items assessing the presence and severity of ASD symptoms including social awareness, social cognition, social communication","Assessment name not in title and 'tool' not in title — likely generic usage, not development: SRS-2"
CADS,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CADS,scale,caregiver,No,26.0,CADS 26 items assessing ADHD symptoms of impulsivity/hyperactivity and inattention Y,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: CADS"
Conners 3,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Conners 3,scale,caregiver,No,110.0,Conners 3 110 items assessing ADHD symptom and comorbid disorders including oppositional defiant and conduct problems,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Conners 3"
BRIEF-Preschool,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,BRIEF-Preschool,scale,caregiver,No,63.0,"BRIEF-Preschool 63 items assessing executive functions within the home environment, including working memory, mental set shifting","Assessment name not in title and 'tool' not in title — likely generic usage, not development: BRIEF-Preschool"
BRIEF,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,BRIEF,scale,caregiver,No,86.0,"BRIEF 86 items assessing executive functions in the home environment, including working memory, mental set shifting, response inhibition","Assessment name not in title and 'tool' not in title — likely generic usage, not development: BRIEF"
ABAS-3: 0–5 years,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,ABAS-3: 0–5 years,scale,caregiver,No,241.0,"ABAS-3: 0–5 years 241 items assessing adaptive functioning skills, including communication, community use, preacademics","Assessment name not in title and 'tool' not in title — likely generic usage, not development: ABAS-3: 0–5 years"
ABAS-3: 5–21 years,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,ABAS-3: 5–21 years,scale,caregiver,No,232.0,"ABAS-3: 5–21 years 232 items assessing adaptive functioning skills, including communication, community use, functional academics","Assessment name not in title and 'tool' not in title — likely generic usage, not development: ABAS-3: 5–21 years"
SSIS Rating Scale,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,SSIS Rating Scale,scale,caregiver,No,79.0,"SSIS Rating Scale 79 items assessing social skills, problem behaviours and academic competence Y, S","Assessment name not in title and 'tool' not in title — likely generic usage, not development: SSIS Rating Scale"
Sensory Profile 2,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Sensory Profile 2,scale,caregiver,No,86.0,"Sensory Profile 2 86 items assessing sensory processing, including auditory, visual, taste/smell, movement, body position, touch","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Sensory Profile 2"
CBCL: 1.5–5 years,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CBCL: 1.5–5 years,scale,caregiver,No,100.0,"CBCL: 1.5–5 years 100 items assessing internalising and externalising problems, emotional reactivity, anxiety/depression","Assessment name not in title and 'tool' not in title — likely generic usage, not development: CBCL: 1.5–5 years"
CBCL: 6–18 years,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CBCL: 6–18 years,scale,caregiver,No,113.0,"CBCL: 6–18 years 113 items assessing internalising and externalising problems, emotional reactivity, anxiety/depression","Assessment name not in title and 'tool' not in title — likely generic usage, not development: CBCL: 6–18 years"
CCC-2,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CCC-2,scale,caregiver,No,70.0,"CCC-2 70 items assessing speech, syntax, semantics, coherence, inappropriate initiation, stereotyped language, use of context","Assessment name not in title and 'tool' not in title — likely generic usage, not development: CCC-2"
3-Tesla Siemens MAGNETOM Prisma MRI scanner,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,3-Tesla Siemens MAGNETOM Prisma MRI scanner,biomarker assay,pediatric,No,,Neuroimaging data will be obtained on a 3-Tesla Siemens MAGNETOM Prisma MRI scanner with a 64-channel head coil,"Hardware device, not a clinical assessment instrument"
MEGA-PRESS,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,MEGA-PRESS,biomarker assay,pediatric,No,,"acquire two GABA-edited magnetic resonance spectra using the localised spectroscopy sequence MEGA-PRESS, developed by CMRR","Assessment name not in title and 'tool' not in title — likely generic usage, not development: MEGA-PRESS"
n-back task,clinical_assessment_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,n-back task,performance test,pediatric,No,24.0,Verbal and visuospatial working memory was assessed using the n-back task. The task was programmed in-house using E-Prime software.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: n-back task"
Corsi block task,clinical_assessment_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Corsi block task,performance test,pediatric,No,,Memory span was assessed using a computerized Corsi block task on the Psychology Experiment Building Language (PEBL),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Corsi block task"
Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV),clinical_assessment_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV),performance test,pediatric,No,,Auditory working memory was assessed using the digit span forward and back task of the Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV)"
Vineland Adaptive Behavior Scale—third edition,clinical_assessment_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Vineland Adaptive Behavior Scale—third edition,scale,caregiver,No,,Parent-rated Vineland Adaptive Behavior Scale—third edition (Hill et al. 2017) was administered to the parents to assess child adaptive behavior,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Vineland Adaptive Behavior Scale—third edition"
Conners 3 rating scale,clinical_assessment_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Conners 3 rating scale,scale,caregiver,No,27.0,Conners 3 rating scale(Conners et al. 2011) was used as a standardized measure for parent reported ADHD symptoms. It consists of 27 items each rated on a 4-point Likert scale,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Conners 3 rating scale"
Nottingham Health Profile (NHP),clinical_assessment_tools,PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Nottingham Health Profile (NHP),questionnaire,adult,No,38.0,The Nottingham Health Profile (NHP) questionnaire was used as comparator questionnaire to evaluate convergent validity...consists of 38 items that cover six subsections,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Nottingham Health Profile (NHP)"
Rotarod,clinical_assessment_tools,PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rotarod,performance test,all ages,No,,Gross motor coordination function was evaluated using the Rotarod (Med Associates),Publication title lacks NF-specific terms: Brain-wide structural and functional disruption in mice with oligodendrocyte-spe
WAIS-III,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WAIS-III,performance test,adult,No,,General intellectual functioning was assessed by the third version of the Brazilian Wechsler Intelligence Scales (WAIS-III for adults and WISC-III for children),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: WAIS-III"
WISC-III,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WISC-III,performance test,pediatric,No,,General intellectual functioning was assessed by the third version of the Brazilian Wechsler Intelligence Scales (WAIS-III for adults and WISC-III for children),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: WISC-III"
Nine-Hole Peg Test,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Nine-Hole Peg Test,performance test,all ages,No,,The Nine-Hole Peg Test was performed as a measure of finger dexterity. It measures the time (in seconds) needed to complete the test,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Nine-Hole Peg Test"
Rey-Osterrieth Complex Figure Test,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rey-Osterrieth Complex Figure Test,performance test,all ages,No,,The Rey-Osterrieth Complex Figure Test was implemented as a measure of the visuospatial cognitive domain,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Rey-Osterrieth Complex Figure Test"
Rey Auditory-Verbal Learning Test (RAVLT),clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rey Auditory-Verbal Learning Test (RAVLT),performance test,all ages,No,,Immediate (A6) and delayed recalls (A7) of the Brazilian-Portuguese version of the Rey Auditory-Verbal Learning Test (RAVLT) were taken as measures of verbal episodic memory,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Rey Auditory-Verbal Learning Test (RAVLT)"
Category Fluency Test,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Category Fluency Test,performance test,all ages,No,,"Assessment of this cognitive domain was performed by a Category Fluency Test (""animals"")","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Category Fluency Test"
Lexical Fluency Test,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Lexical Fluency Test,performance test,all ages,No,,"and by Lexical Fluency Test letters (F, A, and S)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Lexical Fluency Test"
Five Digits Test (FDT),clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Five Digits Test (FDT),performance test,all ages,No,,The Five Digits Test (FDT) is a numeric-Stroop paradigm designed to assess attentional processes,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Five Digits Test (FDT)"
Corsi block-tapping task,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Corsi block-tapping task,performance test,all ages,No,,"For working memory evaluation, we used the Digit Span according to the WAIS-III or WISC-III, and the Corsi block-tapping task","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Corsi block-tapping task"
Tower of London Test,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Tower of London Test,performance test,all ages,No,,The Tower of London Test was used as a measure of Planning Skills,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Tower of London Test"
GE Discovery 690,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,GE Discovery 690,biomarker assay,all ages,No,,"Resting-state 18F-FDG PET/CT brain images were acquired in a GE Discovery 690 (GE Healthcare, Millwalke, EUA) scanner","Assessment name not in title and 'tool' not in title — likely generic usage, not development: GE Discovery 690"
UK NF2 Genetic Severity Score,clinical_assessment_tools,PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,UK NF2 Genetic Severity Score,scale,all ages,Yes,3.0,We have assessed NF2 clinical phenotype in 142 patients in relation to the UK NF2 Genetic Severity Score to validate its use as a clinical and research tool,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: UK NF2 Genetic Severity Score"
8-item NF2 disease-specific quality of life score,clinical_assessment_tools,PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,8-item NF2 disease-specific quality of life score,questionnaire,all ages,Yes,8.0,"Quality of life was assessed using the 8-item NF2 disease-specific quality of life score (0–24), with good internal reliability (Cronbach's α=0.87)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: 8-item NF2 disease-specific quality of life score"
hearing grade score,clinical_assessment_tools,PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,hearing grade score,scale,all ages,Yes,6.0,"Hearing grade was assigned based on a score of 1–6, as used within the English NF2 service to indicate suitability for a hearing implant","Assessment name not in title and 'tool' not in title — likely generic usage, not development: hearing grade score"
Manchester NF2 diagnostic criteria,clinical_assessment_tools,PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Manchester NF2 diagnostic criteria,structured interview,all ages,Yes,,all patients known to the Oxford NF2 centre who met the Manchester NF2 diagnostic criteria and consented to genetic testing were analysed,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Manchester NF2 diagnostic criteria"
Noldus Cat-Walk XT system,clinical_assessment_tools,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Noldus Cat-Walk XT system,performance test,all ages,No,,Gait was analyzed using the Noldus Cat-Walk XT system as before,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Noldus Cat-Walk XT system"
64-channel Neuroscan system,clinical_assessment_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,64-channel Neuroscan system,biomarker assay,pediatric,No,,"EEG signal was recorded from six parieto-occipital channels (PO3, POZ, PO4, O1, OZ and O2) using a 64-channel Neuroscan system","Hardware device, not a clinical assessment instrument"
Wechsler Intelligence Scale for Children (WISC-III),clinical_assessment_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Intelligence Scale for Children (WISC-III),performance test,pediatric,No,,"We administered the Portuguese adapted version of the Wechsler Intelligence Scale for Children (WISC-III), in all participants with NF1","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wechsler Intelligence Scale for Children (WISC-III)"
Diamond Digital color monitor (Mitsubishi Electric Australia),clinical_assessment_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,Diamond Digital color monitor (Mitsubishi Electric Australia),performance test,pediatric,No,,"The stimuli were presented in a CRT monitor (Diamond Digital color monitor, Mitsubishi Electric Australia, Rydalmere, NSW, Australia)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Diamond Digital color monitor (Mitsubishi Electric Australia)"
Manchester Criteria,clinical_assessment_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Manchester Criteria,scale,all ages,Yes,,"patients who fitted Manchester Criteria for NF2 disease (Table S1 ) (Evans et al., 1992 ; Smith et al., 2017 ) were considered to have phenotypic specificity","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Manchester Criteria"
MC-780MA Tanita Tokyo body composition analyzer,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,MC-780MA Tanita Tokyo body composition analyzer,performance test,pediatric,No,,Body fat was measured using the MC‐780MA Tanita Tokyo body composition analyzer. The MC‐780MA body composition analyzer divides the human body into five sections,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: MC-780MA Tanita Tokyo body composition analyzer"
Citec hand-held dynamometer,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Citec hand-held dynamometer,performance test,pediatric,No,,"Maximal isometric strength of three muscle groups involved in prime movements, including grip strength, ankle dorsiflexion, and plantarflexion were tested using hand‐held dynamometry","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Citec hand-held dynamometer"
Handwriting Speed Test,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Handwriting Speed Test,performance test,pediatric,No,,"Fine motor endurance was evaluated by the Handwriting Speed Test (Wallen et al., 1996) that gives a raw score in letters per minute","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Handwriting Speed Test"
6-minute-walk test,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,6-minute-walk test,performance test,pediatric,No,,"gross motor endurance by the 6MWT, which was completed barefoot on a point‐to‐point, 25‐m long, flat, straight, hard surfaced track","Assessment name not in title and 'tool' not in title — likely generic usage, not development: 6-minute-walk test"
PedsQL Generic 4.0,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL Generic 4.0,questionnaire,caregiver,No,,"Quality of life was assessed by parent reported questionnaires, including the Pediatric Quality of Life (PedsQL™) Generic 4.0 and Neuromuscular (3.0) modules","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL Generic 4.0"
PedsQL Neuromuscular 3.0,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL Neuromuscular 3.0,questionnaire,caregiver,Yes,,"Quality of life was assessed by parent reported questionnaires, including the Pediatric Quality of Life (PedsQL™) Generic 4.0 and Neuromuscular (3.0) modules","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL Neuromuscular 3.0"
CBCL/6-18,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CBCL/6-18,questionnaire,caregiver,No,113.0,"The Child Behavior Checklist for ages 6–18 or CBCL/6‐18 (©ASEBA 2020). The CBCL/6‐18 (©ASEBA 2020) consists of 113 questions, scored on a 3‐point Likert scale","Assessment name not in title and 'tool' not in title — likely generic usage, not development: CBCL/6-18"
Wechsler Intelligence Scale,clinical_assessment_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Intelligence Scale,scale,pediatric,No,,Participants completed age-appropriate versions of the Wechsler Intelligence Scale,Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
A Developmental NEuroPSYchological Assessment (NEPSY-II),clinical_assessment_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,A Developmental NEuroPSYchological Assessment (NEPSY-II),performance test,pediatric,No,,select subtests from A Developmental NEuroPSYchological Assessment (NEPSY-II),Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
Tanner staging,clinical_assessment_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Tanner staging,scale,pediatric,No,,Pubertal status was assessed by an experienced physician using Tanner staging,Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
Numeric Rating Scale-11,clinical_assessment_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Numeric Rating Scale-11,scale,all ages,No,1.0,provided feedback about existing pain measures (Numeric Rating Scale-11 and Pain Interference Index) assessing these domains,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Numeric Rating Scale-11"
Pain Interference Index,clinical_assessment_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Interference Index,questionnaire,all ages,No,6.0,provided feedback about existing pain measures (Numeric Rating Scale-11 and Pain Interference Index) assessing these domains,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Pain Interference Index"
NRS-11,clinical_assessment_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NRS-11,scale,all ages,No,1.0,"The self-report NRS-11 has been used in numerous studies, including as a primary outcome measure, to assess pain intensity","Assessment name not in title and 'tool' not in title — likely generic usage, not development: NRS-11"
PII,clinical_assessment_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PII,questionnaire,all ages,No,6.0,The PII is a 6-item questionnaire developed to assess the extent to which pain interferes with six different aspects of daily functioning,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: PII"
PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF),clinical_assessment_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF),scale,all ages,Yes,,"the measures' instructions, items, and formatting were modified to create the PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF)"
Pain Interference Index for plexiform neurofibromas (PII-pNF),clinical_assessment_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Interference Index for plexiform neurofibromas (PII-pNF),questionnaire,all ages,Yes,,"the measures' instructions, items, and formatting were modified to create the PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF) and the Pain Interference Index for plexiform neurofibromas (PII-pNF)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Pain Interference Index for plexiform neurofibromas (PII-pNF)"
PedsQL 4.0 Generic Core Scales,clinical_assessment_tools,PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL 4.0 Generic Core Scales,questionnaire,pediatric,No,23.0,"QOL was assessed with the PedsQL 4.0 Generic Core Scales at baseline and prior to cycles 4, 8, 12, 18, and 24. This 23-item questionnaire yields subscale scores...","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL 4.0 Generic Core Scales"
Quantikine™ human VEGF immunoassay kit,clinical_assessment_tools,PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Quantikine™ human VEGF immunoassay kit,biomarker assay,pediatric,No,,"Plasma VEGF and soluble VEGFR2 (sVEGFR2) were quantified at baseline and at steady-state on day 28 ± 1 of cycle 1 using commercial available human VEGF and sVEGFR2 immunoassay kits (Quantikine™, R&D Systems, Minneapolis, MN)",Lab assay/kit misclassified as clinical assessment tool
Quantikine™ human sVEGFR2 immunoassay kit,clinical_assessment_tools,PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Quantikine™ human sVEGFR2 immunoassay kit,biomarker assay,pediatric,No,,"Plasma VEGF and soluble VEGFR2 (sVEGFR2) were quantified at baseline and at steady-state on day 28 ± 1 of cycle 1 using commercial available human VEGF and sVEGFR2 immunoassay kits (Quantikine™, R&D Systems, Minneapolis, MN)",Lab assay/kit misclassified as clinical assessment tool
HPLC/MS/MS method,clinical_assessment_tools,PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,HPLC/MS/MS method,biomarker assay,pediatric,No,,Sorafenib plasma concentrations were measured using a validated HPLC/MS/MS method,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: HPLC/MS/MS method"
H-score,clinical_assessment_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,H-score,scale,all ages,No,,We used the H-score for quantification of FAP immunohistochemistry: 1 × percentage of weak staining) + (2 × percentage of moderate staining) + (3 × percentage of strong staining). The H score ranges from 0 to 300,Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
SF-36,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,SF-36,questionnaire,adult,No,36.0,"Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: SF-36"
EQ-5D-5L,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,EQ-5D-5L,questionnaire,adult,No,5.0,"Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: EQ-5D-5L"
PROMIS pain interference short form 8a,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PROMIS pain interference short form 8a,questionnaire,adult,No,8.0,"Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PROMIS pain interference short form 8a"
PedsQL NF1 adult module,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL NF1 adult module,questionnaire,adult,Yes,74.0,disease-specific questionnaires (PedsQL NF1 module and the NFTI-QOL for NF2),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: PedsQL NF1 adult module"
NFTI-QOL,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NFTI-QOL,questionnaire,adult,Yes,8.0,disease-specific questionnaires (PedsQL NF1 module and the NFTI-QOL for NF2),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NFTI-QOL"
Ablon visibility index,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Ablon visibility index,scale,clinician-rated,Yes,,clinicians also rated the disease visibility using the Ablon visibility index,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Ablon visibility index"
House and Brackmann facial nerve scale,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,House and Brackmann facial nerve scale,scale,clinician-rated,No,6.0,physicians also completed the House and Brackmann facial nerve scale that rates facial nerve impairments from 1—normal symmetric function to 6—indicating complete paralysis,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: House and Brackmann facial nerve scale"
Ras activation assay (Millipore),clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Ras activation assay (Millipore),biomarker assay,all ages,No,,"Ras activation (Millipore), cAMP (New East Biosciences), TUNEL (Roche Diagnostics), and dopamine (Rocky Mountain Diagnostics) measurements","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Ras activation assay (Millipore)"
cAMP assay (New East Biosciences),clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,cAMP assay (New East Biosciences),biomarker assay,all ages,No,,"Ras activation (Millipore), cAMP (New East Biosciences), TUNEL (Roche Diagnostics), and dopamine (Rocky Mountain Diagnostics) measurements","Assessment name not in title and 'tool' not in title — likely generic usage, not development: cAMP assay (New East Biosciences)"
TUNEL assay (Roche Diagnostics),clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,TUNEL assay (Roche Diagnostics),biomarker assay,all ages,No,,"Ras activation (Millipore), cAMP (New East Biosciences), TUNEL (Roche Diagnostics), and dopamine (Rocky Mountain Diagnostics) measurements","Assessment name not in title and 'tool' not in title — likely generic usage, not development: TUNEL assay (Roche Diagnostics)"
dopamine assay (Rocky Mountain Diagnostics),clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,dopamine assay (Rocky Mountain Diagnostics),biomarker assay,all ages,No,,"Ras activation (Millipore), cAMP (New East Biosciences), TUNEL (Roche Diagnostics), and dopamine (Rocky Mountain Diagnostics) measurements","Assessment name not in title and 'tool' not in title — likely generic usage, not development: dopamine assay (Rocky Mountain Diagnostics)"
Morris Water Maze,clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Morris Water Maze,performance test,all ages,No,,Morris Water Maze testing for spatial learning and memory was conducted as previously described,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Morris Water Maze"
virtual optokinetic system (VOS),clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,virtual optokinetic system (VOS),performance test,all ages,No,,Visual acuity (n=20 mice per group) was assessed using the virtual optokinetic system (VOS) under photopic conditions,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: virtual optokinetic system (VOS)"
Cogstate,clinical_assessment_tools,PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Cogstate,performance test,all ages,No,,Performance tasks (Cogstate) and observer-reported functioning (BRIEF) were the primary outcomes...computerized assessment battery (Cogstate) targeting neurocognitive processes,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Cogstate"
BRIEF,clinical_assessment_tools,PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,BRIEF,questionnaire,caregiver,No,,observer-reported functioning (BRIEF) were the primary outcomes...Behavior Rating Inventory of Executive Function; BRIEF,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: BRIEF"
Behavior Rating Inventory of Executive Function,clinical_assessment_tools,PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Behavior Rating Inventory of Executive Function,questionnaire,caregiver,No,,a consistent parent completed a questionnaire of executive functioning (Behavior Rating Inventory of Executive Function; BRIEF),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Behavior Rating Inventory of Executive Function"
Wood's lamp,clinical_assessment_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wood's lamp,other,all ages,Yes,,"A Wood's lamp, which makes CALMs more visible, was used for CALM counting in CALM1, but not in CALM2.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wood's lamp"
Wechsler Intelligence Scales,clinical_assessment_tools,PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Intelligence Scales,scale,pediatric,No,,We administered age-appropriate versions of the Wechsler Intelligence Scales to measure global cognitive ability,Publication title lacks NF-specific terms: Influences of RASopathies on Neuroanatomical Variation in Children.
BBB open-field locomotor test,clinical_assessment_tools,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,BBB open-field locomotor test,scale,all ages,No,22.0,"The 22-point (0–21) Basso, Beattie, and Bresnahan (BBB) open-field locomotor test was used to assess hindlimb locomotor function","Generic physical performance test, not a validated clinical instrument"
Rotarod apparatus,clinical_assessment_tools,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rotarod apparatus,performance test,all ages,No,,Motor function and motor learning were evaluated by rotarod apparatus,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Rotarod apparatus"
Distress Thermometer (DT),clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Distress Thermometer (DT),scale,all ages,No,,The Distress Thermometer (DT) was designed as a brief screening tool to assess for distress in adult cancer patients...the adapted pediatric DT was used in this study for all ages.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Distress Thermometer (DT)"
Children's Depression Inventory (CDI-S),clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Children's Depression Inventory (CDI-S),questionnaire,pediatric,No,10.0,"The CDI–S (Kovacs, 1992) is a 10-item self-report measure for depression in children, ages 7 to 17 years.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Children's Depression Inventory (CDI-S)"
Children's Depression Inventory Parent Version (CDI-P),clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Children's Depression Inventory Parent Version (CDI-P),questionnaire,caregiver,No,,"The CDI Parent Version (CDI-P) is derived directly from the CDI, is scored identically and has similar psychometric properties...completed by caregivers of all patients, ages 7–21.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Children's Depression Inventory Parent Version (CDI-P)"
Brief Symptom Inventory 18 (BSI-18),clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brief Symptom Inventory 18 (BSI-18),questionnaire,adult,No,18.0,"The BSI-18 (Derogatis et al., 2004) is an 18-item self-report measure to screen for psychological distress and psychiatric disorders in individuals in the community or hospital settings.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Brief Symptom Inventory 18 (BSI-18)"
Lansky Score,clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Lansky Score,scale,pediatric,No,,Medical providers completed a Lansky score for patients 17 years and younger...These scores indicate the disease severity and functional capabilities of the patient,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Lansky Score"
Karnofsky Score,clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Karnofsky Score,scale,adult,No,,a Karnofsky score for patients 18 years and older. These scores indicate the disease severity and functional capabilities of the patient...range from 0–100 in increments of 10,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Karnofsky Score"
Distress Thermometer Acceptability and Feasibility Scales,clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.8,Development,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Distress Thermometer Acceptability and Feasibility Scales,scale,all ages,Yes,,"Patients, primary caregivers, and the child's primary medical provider rated on a scale of 1–4 how easy or difficult the DT was to complete...The DT Acceptability and Feasibility Scales were developed by the study investigators","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Distress Thermometer Acceptability and Feasibility Scales"
Nottingham Health Profile,clinical_assessment_tools,PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Nottingham Health Profile,questionnaire,adult,No,,"The comparator measure used in the UK was the Nottingham Health Profile (NHP; Hunt et al., 1981)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Nottingham Health Profile"
Short Form-36,clinical_assessment_tools,PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Short Form-36,questionnaire,adult,No,36.0,"the Short Form‐36 (SF‐36; Ware & Sherbourne, 1992) was used in the US","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Short Form-36"
NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3,clinical_assessment_tools,PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3,scale,all ages,No,,Adverse events were graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3"
Impact of Pediatric Illness (IPI) Scale,clinical_assessment_tools,PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Impact of Pediatric Illness (IPI) Scale,scale,pediatric,No,43.0,QOL was assessed using the Impact of Pediatric Illness (IPI) Scale for children 6–18 years of age,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Impact of Pediatric Illness (IPI) Scale"
STIR MRI,clinical_assessment_tools,PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,STIR MRI,biomarker assay,all ages,Yes,,STIR MRI of up to three clinically relevant index PN was performed for volumetric analysis,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: STIR MRI"
NFTI-QOL,clinical_assessment_tools,PMID:36604703,10.1186/s13023-022-02607-z,The German version of the neurofibromatosis 2 impact on quality of life questionnaire correlates with severity of depression and physician-reported disease severity.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NFTI-QOL,questionnaire,adult,Yes,8.0,The NFTI-QOL questionnaire has produced useful results in English-speaking cohorts. The aim of this study was to produce and validate a German version of the NFTI-QOL,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NFTI-QOL"
NFTI-QOL-D,clinical_assessment_tools,PMID:36604703,10.1186/s13023-022-02607-z,The German version of the neurofibromatosis 2 impact on quality of life questionnaire correlates with severity of depression and physician-reported disease severity.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NFTI-QOL-D,questionnaire,adult,Yes,8.0,The aim of this study was to produce and validate a German version of the NFTI-QOL (NFTI-QOL-D) and to correlate QOL scores with a depression score,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NFTI-QOL-D"
PHQ-9,clinical_assessment_tools,PMID:36604703,10.1186/s13023-022-02607-z,The German version of the neurofibromatosis 2 impact on quality of life questionnaire correlates with severity of depression and physician-reported disease severity.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PHQ-9,questionnaire,adult,No,9.0,"An online survey was created including the NFTI-QOL-D and the German version of the PHQ-9 questionnaire (9-item patient health questionnaire, a tool for the assessment of depression)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PHQ-9"
Disease severity score,clinical_assessment_tools,PMID:36604703,10.1186/s13023-022-02607-z,The German version of the neurofibromatosis 2 impact on quality of life questionnaire correlates with severity of depression and physician-reported disease severity.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Disease severity score,scale,clinician-rated,Yes,7.0,The utilised clinician-reported disease severity score is based on the presence or absence of 7 symptoms with major impact on the patient's life,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Disease severity score"
PROMIS Pediatric Stigma (PPS),clinical_assessment_tools,PMID:38170419,10.1007/s11136-023-03574-z,Development of the PROMIS pediatric stigma and extension to the PROMIS pediatric stigma: skin item banks.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PROMIS Pediatric Stigma (PPS),scale,pediatric,No,18.0,To develop the PROMIS Pediatric Stigma (PPS) and Skin (PPS-Skin) by constructing a common metric for measuring stigma in children with various conditions,Publication title lacks NF-specific terms: Development of the PROMIS pediatric stigma and extension to the PROMIS pediatric
PROMIS Pediatric Stigma: Skin (PPS-Skin),clinical_assessment_tools,PMID:38170419,10.1007/s11136-023-03574-z,Development of the PROMIS pediatric stigma and extension to the PROMIS pediatric stigma: skin item banks.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PROMIS Pediatric Stigma: Skin (PPS-Skin),scale,pediatric,Yes,24.0,The PPS-Skin (18 cores items + 6 skin items) was developed by calibrating 6 skin items onto the common metric as the PPS,Publication title lacks NF-specific terms: Development of the PROMIS pediatric stigma and extension to the PROMIS pediatric
Neuro-QoL Pediatric Stigma,clinical_assessment_tools,PMID:38170419,10.1007/s11136-023-03574-z,Development of the PROMIS pediatric stigma and extension to the PROMIS pediatric stigma: skin item banks.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Neuro-QoL Pediatric Stigma,scale,pediatric,Yes,18.0,"Children with epilepsy, pNF and MD (sample-1) completed the original 18-item Neuro-QoL Stigma",Publication title lacks NF-specific terms: Development of the PROMIS pediatric stigma and extension to the PROMIS pediatric
Profound Sonalleve V2,clinical_assessment_tools,PMID:34604751,10.1093/noajnl/vdab116,Feasibility of magnetic resonance-guided high-intensity focused ultrasound treatment targeting distinct nodular lesions in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Profound Sonalleve V2,other,all ages,No,,"we will be basing criteria for treatment on the clinical MR-HIFU system available at CNH (Profound Sonalleve V2; Profound Medical Inc., Mississauga, Ontario, Canada)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Profound Sonalleve V2"
NCT03820778,clinical_assessment_tools,PMID:34604751,10.1093/noajnl/vdab116,Feasibility of magnetic resonance-guided high-intensity focused ultrasound treatment targeting distinct nodular lesions in neurofibromatosis type 1.,,0.75,Experimental Usage,True,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,NCT03820778,other,pediatric,Yes,,Patients from CNH were enrolled on clinical trial NCT03820778 evaluating the use of whole-body MRI for identifying ANNUBP in patients with NF1.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NCT03820778"
NCT00924196,clinical_assessment_tools,PMID:34604751,10.1093/noajnl/vdab116,Feasibility of magnetic resonance-guided high-intensity focused ultrasound treatment targeting distinct nodular lesions in neurofibromatosis type 1.,,0.75,Experimental Usage,True,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,NCT00924196,other,all ages,Yes,,"Patients from NCI were enrolled on clinical trial NCT00924196, a natural history study of patients with NF1.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: NCT00924196"
ADM detection kit,clinical_assessment_tools,PMID:20739432,10.1158/1078-0432.CCR-10-0613,Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,ADM detection kit,biomarker assay,all ages,Yes,,We conducted ELISA assays on serum-free conditioned medium and human serum using an ADM detection kit (Phoenix Pharmaceuticals),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: ADM detection kit"
Human HGF ELISA kit,clinical_assessment_tools,PMID:20739432,10.1158/1078-0432.CCR-10-0613,Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Human HGF ELISA kit,biomarker assay,all ages,Yes,,We conducted ELISA assays on serum-free conditioned medium and human serum using an ADM detection kit (Phoenix Pharmaceuticals) and Human HGF ELISA kit (R&D Systems),Lab assay/kit misclassified as clinical assessment tool
Sony Cyber-shot DSC-W30,clinical_assessment_tools,PMID:25475340,10.1186/s13023-014-0202-9,Validity and interexaminer reliability of a new method to quantify skin neurofibromas of neurofibromatosis 1 using paper frames.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Sony Cyber-shot DSC-W30,other,adult,Yes,,"two photographs were taken from each paper frame, using a digital camera (Sony Cyber-shot DSC-W30, Tokyo, Japan)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Sony Cyber-shot DSC-W30"
Paper frames method,clinical_assessment_tools,PMID:25475340,10.1186/s13023-014-0202-9,Validity and interexaminer reliability of a new method to quantify skin neurofibromas of neurofibromatosis 1 using paper frames.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Paper frames method,performance test,adult,Yes,,"The quantification technique uses paper frames, with a central square measuring 100 cm2, which are placed in three specific areas of the body","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Paper frames method"
needs-based model of QoL,clinical_assessment_tools,PMID:30800298,10.1177/2050312119829680,A qualitative study of the impact of plexiform neurofibromas on need fulfilment in adults with neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,needs-based model of QoL,other,adult,No,,"Theoretical thematic analysis, guided by the needs-based model of QoL, was performed on the transcripts.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: needs-based model of QoL"
"25OH-Vitamin-D ELISA Assay kit (Eagle Biosciences, cat# VID31-K01)",clinical_assessment_tools,PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"25OH-Vitamin-D ELISA Assay kit (Eagle Biosciences, cat# VID31-K01)",biomarker assay,all ages,No,,"Vitamin D concentration in mouse serum was determined using a 25OH-Vitamin-D ELISA Assay kit (Eagle Biosciences, cat# VID31-K01)",Lab assay/kit misclassified as clinical assessment tool
"Phosphate Assay kit (BioVision, cat # k410–500)",clinical_assessment_tools,PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Phosphate Assay kit (BioVision, cat # k410–500)",biomarker assay,all ages,No,,"phosphate concentration in mouse serum was determined using a Phosphate Assay kit (BioVision, cat # k410–500)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Phosphate Assay kit (BioVision, cat # k410–500)"
"Calcium Assay kit (BioVision, cat# k380–250)",clinical_assessment_tools,PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Calcium Assay kit (BioVision, cat# k380–250)",biomarker assay,all ages,No,,"calcium concentration in mouse serum was determined using a Calcium Assay kit (BioVision, cat# k380–250)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Calcium Assay kit (BioVision, cat# k380–250)"
RECIST criteria,clinical_assessment_tools,PMID:19430883,10.1007/s11060-009-9867-7,Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.,,0.85,Citation Only,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,RECIST criteria,scale,adult,No,,"Tumor response has historically been measured in relation to linear dimension, as in the 2000 RECIST criteria","Assessment name not in title and 'tool' not in title — likely generic usage, not development: RECIST criteria"
WHO criteria,clinical_assessment_tools,PMID:19430883,10.1007/s11060-009-9867-7,Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.,,0.8,Citation Only,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WHO criteria,scale,adult,No,,"bidimensional area, as in the 1979 WHO criteria","Assessment name not in title and 'tool' not in title — likely generic usage, not development: WHO criteria"
Macdonald criteria,clinical_assessment_tools,PMID:19430883,10.1007/s11060-009-9867-7,Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.,,0.85,Citation Only,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Macdonald criteria,scale,adult,Yes,,"the 1990 'Macdonald' criteria for malignant glioma, which also incorporated steroid dose and neurological condition","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Macdonald criteria"
CID-W22,clinical_assessment_tools,PMID:19430883,10.1007/s11060-009-9867-7,Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CID-W22,performance test,all ages,No,50.0,Word recognition is measured using 50-item CID-W22 (Central Institute for the Deaf; Ira Hirsh recording) monosyllable wordlists and ranges from 0% to 100%,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: CID-W22"
NU#6,clinical_assessment_tools,PMID:19430883,10.1007/s11060-009-9867-7,Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.,,0.85,Citation Only,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NU#6,performance test,all ages,No,,Other standardized monosyllable recorded lists may be used including NU#6,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: NU#6"
CNC,clinical_assessment_tools,PMID:19430883,10.1007/s11060-009-9867-7,Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.,,0.85,Citation Only,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CNC,performance test,all ages,No,,"Other standardized monosyllable recorded lists may be used including NU#6, CNC","Assessment name not in title and 'tool' not in title — likely generic usage, not development: CNC"
American Academy of Otolaryngology (AAO) pure-tone average,clinical_assessment_tools,PMID:19430883,10.1007/s11060-009-9867-7,Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,American Academy of Otolaryngology (AAO) pure-tone average,performance test,all ages,No,,"The pure-tone average is calculated as the average of thresholds at 500, 1000, 2000 and 3000 Hz as recommended by the American Academy of Otolaryngology (AAO)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: American Academy of Otolaryngology (AAO) pure-tone average"
Morris water maze,clinical_assessment_tools,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Morris water maze,performance test,all ages,No,,The Morris water maze apparatus and procedures were previously described,Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
contextual fear conditioning,clinical_assessment_tools,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,contextual fear conditioning,performance test,all ages,No,,The contextual fear conditioning apparatus was previously described,Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
Measure of Current Status-A (MOCS-A),clinical_assessment_tools,PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Measure of Current Status-A (MOCS-A),scale,adult,No,13.0,We used the Measure of Current Status-A (MOCS-A) to measure adaptive coping. It is comprised of 13 items with four subscales: relaxation – the ability to employ relaxation on command...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Measure of Current Status-A (MOCS-A)"
Cognitive and Affective Mindfulness Scale-Revised (CAMS-R),clinical_assessment_tools,PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Cognitive and Affective Mindfulness Scale-Revised (CAMS-R),scale,adult,No,12.0,We used the Cognitive and Affective Mindfulness Scale-Revised (CAMS-R) to measure dispositional mindfulness. It is comprised of 12-items rated on a scale from 1 to 4...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)"
Gratitude Questionnaire-6 (GQ-6),clinical_assessment_tools,PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Gratitude Questionnaire-6 (GQ-6),questionnaire,adult,No,6.0,We used the Gratitude Questionnaire (GQ-6) to measure gratitude in daily life. It is a 6-item measure rated on a scale from 1 to 7...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Gratitude Questionnaire-6 (GQ-6)"
Life Orientation Test Optimism Scale (LOT),clinical_assessment_tools,PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Life Orientation Test Optimism Scale (LOT),scale,adult,No,8.0,We used the Life Orientation Test Optimism Scale (LOT) to measure optimism. It is an 8-item measure rated on a scale from 0 to 4...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Life Orientation Test Optimism Scale (LOT)"
Medical Outcomes Study Social Support Survey (MOS),clinical_assessment_tools,PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Medical Outcomes Study Social Support Survey (MOS),questionnaire,adult,No,19.0,We used the Medical Outcomes Study Social Support Survey (MOS) to measure perceived availability of social support. It is a 19-item measure with four domains...,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Medical Outcomes Study Social Support Survey (MOS)"
Patient Stress Scale-4 items,clinical_assessment_tools,PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Patient Stress Scale-4 items,scale,adult,No,4.0,score of 6 or higher on the Patient Stress Scale-4 items,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Patient Stress Scale-4 items"
3RP-NF (Relaxation Response Resiliency Program - Neurofibromatosis),clinical_assessment_tools,PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,0.9,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,3RP-NF (Relaxation Response Resiliency Program - Neurofibromatosis),structured interview,adult,Yes,,"3RP-NF program is a comprehensive, multimodal treatment aimed at improving QoL and resilience with NF-specific medical symptoms and NF-related stress.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: 3RP-NF (Relaxation Response Resiliency Program - Neurofibromatosis)"
HEP-NF (Health Education Program - Neurofibromatosis),clinical_assessment_tools,PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,0.85,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,HEP-NF (Health Education Program - Neurofibromatosis),other,adult,Yes,,The HEP-NF program was adapted from the original HEP and NF-specific materials gathered from the Children's Tumor Foundation website.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: HEP-NF (Health Education Program - Neurofibromatosis)"
Magnetic Resonance Fingerprinting,clinical_assessment_tools,PMID:31416081,10.1159/000501696,Magnetic Resonance Fingerprinting to Characterize Childhood and Young Adult Brain Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Magnetic Resonance Fingerprinting,biomarker assay,pediatric,No,,"Magnetic resonance fingerprinting (MRF) allows rapid, simultaneous mapping of T1 and T2 relaxation times and may be an important diagnostic tool",Publication title lacks NF-specific terms: Magnetic Resonance Fingerprinting to Characterize Childhood and Young Adult Brai
Hospital Depression and Anxiety Score (HADS),clinical_assessment_tools,PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Depression and Anxiety Score (HADS),scale,adult,No,,The Hospital Depression and Anxiety Score (HADS) was used to screen for anxiety and depression,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Hospital Depression and Anxiety Score (HADS)"
PainDETECT questionnaire,clinical_assessment_tools,PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PainDETECT questionnaire,questionnaire,adult,Yes,,"Pain perception was assessed by the PainDETECT questionnaire, which provides high sensitivity, specificity, and positive predictive value to detect neuropathic pain","Assessment name not in title and 'tool' not in title — likely generic usage, not development: PainDETECT questionnaire"
Freiburger Persönlichkeitsinventar (FPI),clinical_assessment_tools,PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Freiburger Persönlichkeitsinventar (FPI),questionnaire,adult,No,,"In order to examine stable traits of patients' personality the multidimensional ""Freiburger Persönlichkeitsinventar"" (FPI) was used","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Freiburger Persönlichkeitsinventar (FPI)"
Symptom Checklist-90-R (SCL-90-R),clinical_assessment_tools,PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Symptom Checklist-90-R (SCL-90-R),questionnaire,adult,No,90.0,"By means of the Symptom Checklist-90-R (SCL-90-R), the patients' subjective strain through physical and psychological disorders were measured","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Symptom Checklist-90-R (SCL-90-R)"
SF-36 health survey,clinical_assessment_tools,PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,SF-36 health survey,questionnaire,adult,No,36.0,The German Version of the SF-36 health survey was utilized to assess health-related quality of life,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: SF-36 health survey"
Nihon Kohden Neuropack X1,clinical_assessment_tools,PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Nihon Kohden Neuropack X1,performance test,adult,No,,"Conventional electrodiagnostic testing was performed using a Nihon Kohden Neuropack X1 (Rosbach v.d.H., Germany)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Nihon Kohden Neuropack X1"
alamarBlue fluorescent assay,clinical_assessment_tools,PMID:28065690,10.1016/j.biochi.2017.01.001,Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,alamarBlue fluorescent assay,biomarker assay,all ages,No,,"Cell viability was evaluated seventy-two hours after addition of drugs using alamarBlue fluorescent assay (Life Technologies, USA)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: alamarBlue fluorescent assay"
Aldefluor assay,clinical_assessment_tools,PMID:24848258,10.1126/scitranslmed.3008639,Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,Aldefluor assay,biomarker assay,adult,No,,"Furthermore, we validated aldehyde dehydrogenase as a marker of cancer stem cells (CSCs) in MPM",Publication title lacks NF-specific terms: Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relatio
Patient-Reported Outcomes Rating and Acceptance Tool for Endpoints,clinical_assessment_tools,PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Patient-Reported Outcomes Rating and Acceptance Tool for Endpoints,scale,clinician-rated,Yes,,Our revised Patient-Reported Outcome Rating and Acceptance Tool for Endpoints then was used to evaluate each published patient-reported outcome measures in five domains,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Patient-Reported Outcomes Rating and Acceptance Tool for Endpoints"
FACE-Q Craniofacial Module-Appearance Distress scale,clinical_assessment_tools,PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,FACE-Q Craniofacial Module-Appearance Distress scale,scale,all ages,No,,The FACE-Q Craniofacial Module-Appearance Distress scale was the top-rated measure for potential use in neurofibromatosis 1 clinical trials,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: FACE-Q Craniofacial Module-Appearance Distress scale"
Perceived Stigma Questionnaire,clinical_assessment_tools,PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Perceived Stigma Questionnaire,questionnaire,adult,No,,"yielded 49 manuscripts describing seven instruments: the Perceived Stigma Questionnaire, Social Comfort Questionnaire, Body Esteem Scale","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Perceived Stigma Questionnaire"
Social Comfort Questionnaire,clinical_assessment_tools,PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Social Comfort Questionnaire,questionnaire,adult,No,,"yielded 49 manuscripts describing seven instruments: the Perceived Stigma Questionnaire, Social Comfort Questionnaire, Body Esteem Scale","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Social Comfort Questionnaire"
Body Esteem Scale for Adolescents and Adults,clinical_assessment_tools,PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Body Esteem Scale for Adolescents and Adults,scale,all ages,No,,"Body Esteem Scale for Adolescents and Adults, Subjective Happiness Scale, Derriford Appearance Scale","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Body Esteem Scale for Adolescents and Adults"
Subjective Happiness Scale,clinical_assessment_tools,PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Subjective Happiness Scale,scale,adult,No,,"Body Esteem Scale for Adolescents and Adults, Subjective Happiness Scale, Derriford Appearance Scale","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Subjective Happiness Scale"
Derriford Appearance Scale,clinical_assessment_tools,PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Derriford Appearance Scale,scale,adult,No,,"Subjective Happiness Scale, Derriford Appearance Scale, The Self-Description Questionnaire I and Skindex","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Derriford Appearance Scale"
The Self-Description Questionnaire I,clinical_assessment_tools,PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,The Self-Description Questionnaire I,questionnaire,pediatric,No,,"Derriford Appearance Scale, The Self-Description Questionnaire I and Skindex","Assessment name not in title and 'tool' not in title — likely generic usage, not development: The Self-Description Questionnaire I"
Skindex,clinical_assessment_tools,PMID:38140900,10.1177/17407745231205577,Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Skindex,scale,adult,Yes,,The Self-Description Questionnaire I and Skindex. In reviewing the measures retrieved,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Skindex"
Edinburgh Handedness Inventory,clinical_assessment_tools,PMID:29566645,10.1186/s11689-018-9230-4,"Oscillatory motor patterning is impaired in neurofibromatosis type 1: a behavioural, EEG and fMRI study.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Edinburgh Handedness Inventory,questionnaire,adult,No,,All the participants but one were right-handed as assessed by the Edinburgh Handedness Inventory [29],"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Edinburgh Handedness Inventory"
Wechsler Adult Intelligence Scale-3rd edition (WAIS-III),clinical_assessment_tools,PMID:29566645,10.1186/s11689-018-9230-4,"Oscillatory motor patterning is impaired in neurofibromatosis type 1: a behavioural, EEG and fMRI study.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Adult Intelligence Scale-3rd edition (WAIS-III),performance test,adult,No,,Intellectual function was assessed by using the Portuguese-adapted version of the Wechsler Adult Intelligence Scale-3rd edition (WAIS-III),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Wechsler Adult Intelligence Scale-3rd edition (WAIS-III)"
Stroop Colour and Word Test,clinical_assessment_tools,PMID:29566645,10.1186/s11689-018-9230-4,"Oscillatory motor patterning is impaired in neurofibromatosis type 1: a behavioural, EEG and fMRI study.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Stroop Colour and Word Test,performance test,adult,No,,All the participants performed the standard Stroop Colour and Word Test [31] composed by two congruent conditions [word (W) and colour (C)] and one incongruent (interference) condition,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Stroop Colour and Word Test"
Lumina LP-400,clinical_assessment_tools,PMID:29566645,10.1186/s11689-018-9230-4,"Oscillatory motor patterning is impaired in neurofibromatosis type 1: a behavioural, EEG and fMRI study.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Lumina LP-400,performance test,adult,No,,"Behavioural data (tapping timings) were recorded using the MRI-compatible response box Lumina LP-400 (Cedrus Corporation, San Pedro, CA, USA)","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Lumina LP-400"
Wechsler Abbreviated Scale of Intelligence 2nd Edition,clinical_assessment_tools,PMID:39665502,10.1002/hbm.70087,Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Application of Advanced Diffusion-Weighted Imaging in Children With Rasopathies.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Abbreviated Scale of Intelligence 2nd Edition,performance test,pediatric,No,,"A full‐scale IQ ≥ 70, acquired using the Wechsler Abbreviated Scale of Intelligence 2nd Edition, was required to maximize study compliance",Publication title lacks NF-specific terms: Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Applica
Tanner staging,clinical_assessment_tools,PMID:39665502,10.1002/hbm.70087,Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Application of Advanced Diffusion-Weighted Imaging in Children With Rasopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Tanner staging,scale,pediatric,No,,"Pubertal status was determined using Tanner staging (Marshall and Tanner 1970, 1969)",Publication title lacks NF-specific terms: Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Applica
NF Registry,clinical_assessment_tools,PMID:28644838,10.1371/journal.pone.0178639,"Characterization and utilization of an international neurofibromatosis web-based, patient-entered registry: An observational study.",,0.9,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NF Registry,questionnaire,all ages,Yes,,"...web-based patient-entered database, the NF Registry, to inform patients of research opportunities...demographic information and details regarding manifestations of NF were solicited...","Assessment name not in title and 'tool' not in title — likely generic usage, not development: NF Registry"
Japanese Orthopaedic Association,clinical_assessment_tools,PMID:41695895,10.22603/ssrr.2025-0061,Outcomes of Surgical Intervention of Dystrophic Cervical Kyphosis in Patients with Neurofibromatosis Type 1: A Systematic Review.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Japanese Orthopaedic Association,scale,adult,No,,"All surgical approaches resulted in significant functional improvements, as reflected by increased Japanese Orthopaedic Association/modified Japanese Orthopaedic Association scores","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Japanese Orthopaedic Association"
modified Japanese Orthopaedic Association,clinical_assessment_tools,PMID:41695895,10.22603/ssrr.2025-0061,Outcomes of Surgical Intervention of Dystrophic Cervical Kyphosis in Patients with Neurofibromatosis Type 1: A Systematic Review.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,modified Japanese Orthopaedic Association,scale,adult,No,,"All surgical approaches resulted in significant functional improvements, as reflected by increased Japanese Orthopaedic Association/modified Japanese Orthopaedic Association scores","Assessment name not in title and 'tool' not in title — likely generic usage, not development: modified Japanese Orthopaedic Association"
Visual Analog Scale,clinical_assessment_tools,PMID:41695895,10.22603/ssrr.2025-0061,Outcomes of Surgical Intervention of Dystrophic Cervical Kyphosis in Patients with Neurofibromatosis Type 1: A Systematic Review.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Visual Analog Scale,scale,all ages,No,1.0,"All surgical approaches resulted in significant functional improvements, as reflected by increased Japanese Orthopaedic Association/modified Japanese Orthopaedic Association scores, decreased Visual Analog Scale scores","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Visual Analog Scale"
Neck Disability Index,clinical_assessment_tools,PMID:41695895,10.22603/ssrr.2025-0061,Outcomes of Surgical Intervention of Dystrophic Cervical Kyphosis in Patients with Neurofibromatosis Type 1: A Systematic Review.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Neck Disability Index,questionnaire,adult,No,10.0,"All surgical approaches resulted in significant functional improvements, as reflected by increased Japanese Orthopaedic Association/modified Japanese Orthopaedic Association scores, decreased Visual Analog Scale scores, and reduced Neck Disability Index scores","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Neck Disability Index"
Joanna Briggs Institute critical appraisal tool,clinical_assessment_tools,PMID:41695895,10.22603/ssrr.2025-0061,Outcomes of Surgical Intervention of Dystrophic Cervical Kyphosis in Patients with Neurofibromatosis Type 1: A Systematic Review.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Joanna Briggs Institute critical appraisal tool,scale,clinician-rated,No,,"Two independent authors assessed the methodological quality of the full text using the Joanna Briggs Institute critical appraisal tool, which evaluates the quality of observational studies and case series","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Joanna Briggs Institute critical appraisal tool"
"Social Responsiveness Scale, second edition (SRS-2)",clinical_assessment_tools,PMID:27760236,10.1001/jamapsychiatry.2016.2600,Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT).,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Social Responsiveness Scale, second edition (SRS-2)",scale,all ages,No,65.0,"The Social Responsiveness Scale, second edition (SRS-2) is an extensively validated, 65-item quantitative trait measure designed to ascertain the presence and severity of social communicative and repetitive behaviors that characterize ASD.","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Social Responsiveness Scale, second edition (SRS-2)"
"Conners, third edition",clinical_assessment_tools,PMID:27760236,10.1001/jamapsychiatry.2016.2600,Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Conners, third edition",scale,pediatric,No,,"Four versions of the Conners ADHD rating scales were used across sites: Conners, third edition","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Conners, third edition"
Conners Adult ADHD Rating Scale,clinical_assessment_tools,PMID:27760236,10.1001/jamapsychiatry.2016.2600,Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Conners Adult ADHD Rating Scale,scale,adult,No,,"Four versions of the Conners ADHD rating scales were used across sites: Conners, third edition, Conners Adult ADHD Rating Scale","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Conners Adult ADHD Rating Scale"
Conners Parent Rating Scale–Revised,clinical_assessment_tools,PMID:27760236,10.1001/jamapsychiatry.2016.2600,Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Conners Parent Rating Scale–Revised,scale,caregiver,No,,"Conners Parent Rating Scale–Revised, and Conners ADHD/DSM-IV Scales","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Conners Parent Rating Scale–Revised"
Conners ADHD/DSM-IV Scales,clinical_assessment_tools,PMID:27760236,10.1001/jamapsychiatry.2016.2600,Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Conners ADHD/DSM-IV Scales,scale,all ages,No,,"Conners Parent Rating Scale–Revised, and Conners ADHD/DSM-IV Scales","Assessment name not in title and 'tool' not in title — likely generic usage, not development: Conners ADHD/DSM-IV Scales"
METRA Serum PYD EIA Kit,clinical_assessment_tools,PMID:18671844,10.1186/1741-7015-6-21,Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,METRA Serum PYD EIA Kit,biomarker assay,all ages,No,,Serum deoxypyridinoline (D-PYD) was measured with a METRA Serum PYD EIA Kit (Osteomedical GmbH),"Assessment name not in title and 'tool' not in title — likely generic usage, not development: METRA Serum PYD EIA Kit"
Fluorodeoxyglucose ([18F] FDG) PET,clinical_assessment_tools,PMID:18984156,10.1016/j.cell.2008.08.041,Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Fluorodeoxyglucose ([18F] FDG) PET,biomarker assay,all ages,Yes,,Fluorodeoxyglucose ([18F] FDG) PET and X-ray CT imaging was employed to identify neurofibromas.,"Assessment name not in title and 'tool' not in title — likely generic usage, not development: Fluorodeoxyglucose ([18F] FDG) PET"
Matlab,computational_tools,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Matlab,Analysis Software,,,,,,,,,,,,,,,,"Statistical analysis was performed using Matlab (MathWorks, Inc) and GraphPad Prism 7",Generic bioinformatics/stats tool: Matlab
GraphPad Prism 7,computational_tools,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism 7,Analysis Software,7,,,,,,,,,,,,,,,"Statistical analysis was performed using Matlab (MathWorks, Inc) and GraphPad Prism 7 (GraphPad Software, Inc)",Generic bioinformatics/stats tool: GraphPad Prism 7
ABET II Software for Operant Control,computational_tools,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ABET II Software for Operant Control,Analysis Software,,,,,,,,,,,,,,,,ABET II Software for Operant Control Lafayette Instrument Company Model 89501,No version and no repository URL (confidence < 0.9 — unidentifiable)
Fiber Photometry Trace Processing,computational_tools,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Fiber Photometry Trace Processing,Analysis Software,,https://github.com/GradinaruLab/dLight1/blob/master/FP_Session_Processing2.m,,,,,,,,,,,,,,Fiber Photometry Trace Processing Gradinaru Lab FP_Session_Processing_2.m https://github.com/GradinaruLab/dLight1/blob/master/FP_Session_Processing2.m,Software name not in publication title — likely generic usage: Fiber Photometry Trace Processing
Novoalign tool v3.02.06,computational_tools,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Novoalign tool v3.02.06,Analysis Software,v3.02.06,,,,,,,,,,,,,,,Sequence reads were mapped to the human reference genome (GRCh37/hg19) using Novoalign tool v3.02.06,Software name not in publication title — likely generic usage: Novoalign tool v3.02.06
PICARD tools v2.4.1,computational_tools,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,PICARD tools v2.4.1,Analysis Software,v2.4.1,,,,,,,,,,,,,,,followed by marking and removing PCR duplicates by PICARD tools v2.4.1,Software name not in publication title — likely generic usage: PICARD tools v2.4.1
Genome Analysis Toolkit (GATK) v3.6-0,computational_tools,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Genome Analysis Toolkit (GATK) v3.6-0,Analysis Software,v3.6-0,,,,,,,,,,,,,,,Local realignment around insertions/deletions was achieved by Genome Analysis Toolkit (GATK) v3.6-0,Software name not in publication title — likely generic usage: Genome Analysis Toolkit (GATK) v3.6-0
Mutect v1.1.4,computational_tools,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Mutect v1.1.4,Analysis Software,v1.1.4,,,,,,,,,,,,,,,Somatic single-nucleotide variants were identified using Mutect v1.1.4,Software name not in publication title — likely generic usage: Mutect v1.1.4
CNVkit,computational_tools,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CNVkit,Analysis Software,,,,,,,,,,,,,,,,Copy Number Variants were detected and plotted using CNVkit,Generic bioinformatics/stats tool: CNVkit
SciClone,computational_tools,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SciClone,Analysis Software,,,,,,,,,,,,,,,,Clonality was addressed using SciClone,Software name not in publication title — likely generic usage: SciClone
Simple Western system,computational_tools,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Simple Western system,Analysis Software,,,,,,,,,,,,,,,,Protein separation and detection were performed using an automated capillary electrophoresis system (Simple Western system and Compass software; ProteinSimple),No version and no repository URL (confidence < 0.9 — unidentifiable)
Incucyte FLR imaging system,computational_tools,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Incucyte FLR imaging system,Analysis Software,,,,,,,,,,,,,,,,"Cells were imaged every hour for 48 hours using the Incucyte FLR imaging system (Essen Bioscience, Ann Arbor, MI)",No version and no repository URL (confidence < 0.9 — unidentifiable)
LMSz,computational_tools,PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LMSz,Analysis Software,,,,,,,,,,,,,,,,...we implemented a recently described method called 'LMSz' to construct NF1-specific head circumference growth charts...,Software name not in publication title — likely generic usage: LMSz
GAMLSS,computational_tools,PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GAMLSS,Package/Library,,,,,,,,,,,,,,,,"...we fit generalized additive models for location, scale, and space (GAMLSS) with the normal distribution family...",No version and no repository URL (confidence < 0.9 — unidentifiable)
gamlssTools,computational_tools,PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,gamlssTools,Package/Library,,https://github.com/BGDlab/gamlssTools,,,,,,,,,,,,,,...GAMLSS model visualization was performed using customized R functions (https://github.com/BGDlab/gamlssTools)...,Software name not in publication title — likely generic usage: gamlssTools
AXION Biosystems 48-well MEA plates,computational_tools,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AXION Biosystems 48-well MEA plates,Analysis Software,,,,,,,,,,,,,,,,"Primary hippocampal (300,000 cells/well), RGC (300,000 cells/well), or DRG neurons (150,000 cells/well) from each of the strains assayed were plated on AXION Biosystems 48-well MEA plates",No version and no repository URL (confidence < 0.9 — unidentifiable)
AXION Biosystems integrated studio (AxIS) version 2.5.1,computational_tools,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,AXION Biosystems integrated studio (AxIS) version 2.5.1,Analysis Software,2.5.1,,,,,,,,,,,,,,,All neurons were recorded for 3 min at a 4.5 standard deviation threshold level and 5000 Hz as a digital filter using AXION Biosystems integrated studio (AxIS) version 2.5.1 software,Software name not in publication title — likely generic usage: AXION Biosystems integrated studio (AxIS) version 2.5.1
Offline sorter x64 version 4,computational_tools,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Offline sorter x64 version 4,Analysis Software,4,,,,,,,,,,,,,,,Representative traces of action potentials were extracted using the AXION Biosystems neural metric tool and Offline sorter x64 version 4 software,Software name not in publication title — likely generic usage: Offline sorter x64 version 4
ImageJ 1.53a,computational_tools,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ 1.53a,Analysis Software,1.53a,,,,,,,,,,,,,,,"Images were acquired using Image Studio Lite Version 5.2 software, and LAS AF Lite 3.2.0 software and analyzed using ImageJ 1.53a software",Generic tool (versioned): ImageJ 1.53a
"Partek Flow software, version 10.0",computational_tools,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"Partek Flow software, version 10.0",Analysis Software,10.0,,,,,,,,,,,,,,,"The analysis for this paper was generated using Partek Flow software, version 10.0 using publicly available datasets","Software name not in publication title — likely generic usage: Partek Flow software, version 10.0"
STAR version 2.7.8a,computational_tools,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR version 2.7.8a,Analysis Software,2.7.8a,,,,,,,,,,,,,,,RNA-seq reads were aligned to the Ensembl release 100 top-level assembly with STAR version 2.7.8a,Software name not in publication title — likely generic usage: STAR version 2.7.8a
GraphPad Prism,computational_tools,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism,Analysis Software,"v5, v_8.2.1, and v_9.3.1",,,,,,,,,,,,,,,"All statistical tests were performed using GraphPad Prism software (versions v5, v_8.2.1, and v_9.3.1)",Generic bioinformatics/stats tool: GraphPad Prism
Sleep++,computational_tools,PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Sleep++,Analysis Software,,,,,,,,,,,,,,,,Apple Watch Ultra model 2 (application: Sleep++) was performed in all the patients with a total of three different measurements,No version and no repository URL (confidence < 0.9 — unidentifiable)
ALF-express automated DNA sequencer,computational_tools,PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ALF-express automated DNA sequencer,Analysis Software,,,,,,,,,,,,,,,,using the Thermo Sequenase fluorescent labelled primer cycle sequencing kit (Amersham Biosciences) and analysed on an ALF-express automated DNA sequencer (Amersham Biosciences).,No version and no repository URL (confidence < 0.9 — unidentifiable)
Splice Site Prediction by Neural Network (SSPNN),computational_tools,PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Splice Site Prediction by Neural Network (SSPNN),Web Application,,,,,,,,,,,,,,,,"The sequence environment of all donor- and acceptor sites was analysed using Splice Site Prediction by Neural Network (SSPNN, URL address:",Software name not in publication title — likely generic usage: Splice Site Prediction by Neural Network (SSPNN)
mfold computer program version 3.0,computational_tools,PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,mfold computer program version 3.0,Analysis Software,3.0,,,,,,,,,,,,,,,The mfold computer program version 3.0 was used to predict the RNA secondary structure and to calculate the folding free energy,Software name not in publication title — likely generic usage: mfold computer program version 3.0
ImageJ,computational_tools,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,The quantification of HF melanin density and DCT immunofluorescence staining intensity was performed with ImageJ software (National Institutes of Health),Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
Prism7 (GraphPad),computational_tools,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Prism7 (GraphPad),Analysis Software,7,,,,,,,,,,,,,,,"Data statistical analyses were performed by unpaired two-tailed Student's t-test (Prism7, GraphPad)",Publication title lacks NF-specific terms: Identification of hair shaft progenitors that create a niche for hair pigmentati
IncuCyte,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,IncuCyte,Analysis Software,,,,,,,,,,,,,,,,IncuCyte proliferation analysis was used to measure the effect of NF1 deficiency on cell proliferation,No version and no repository URL (confidence < 0.9 — unidentifiable)
Agilent Seahorse XF-96,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Agilent Seahorse XF-96,Analysis Software,,,,,,,,,,,,,,,,We measured cellular energetics using Agilent Seahorse XF-96 Glyco Stress Test and Mito Stress Test assays,Software name not in publication title — likely generic usage: Agilent Seahorse XF-96
STAR v2.7.8a,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR v2.7.8a,Analysis Software,v2.7.8a,,,,,,,,,,,,,,,GENCODE was used to map FASTQ files to GRCh38 (release 33 with STAR v2.7.8a basic two-pass mode),Software name not in publication title — likely generic usage: STAR v2.7.8a
iDEP 9.1,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,iDEP 9.1,Analysis Software,9.1,,,,,,,,,,,,,,,principal component analysis was computed using iDEP 9.1,Software name not in publication title — likely generic usage: iDEP 9.1
Trim Galore v0.6.0,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Trim Galore v0.6.0,Analysis Software,v0.6.0,,,,,,,,,,,,,,,Trim Galore v0.6.0 was used to trim sequencing adapters from demultiplexed FASTQ files,Software name not in publication title — likely generic usage: Trim Galore v0.6.0
LipidSearch v5.0,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,LipidSearch v5.0,Analysis Software,v5.0,,,,,,,,,,,,,,,"Lipid identifications were assigned using LipidSearch (v5.0, Thermo Fisher Scientific)",Software name not in publication title — likely generic usage: LipidSearch v5.0
Compound Discoverer v3.2,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Compound Discoverer v3.2,Analysis Software,v3.2,,,,,,,,,,,,,,,"Data was analyzed using Compound Discoverer (v 3.2, Thermo Fisher Scientific)",Software name not in publication title — likely generic usage: Compound Discoverer v3.2
SynergyFinder R package,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SynergyFinder R package,Package/Library,,,,,,,,,,,,,,,,Synergy was calculated using the SynergyFinder R package,Software name not in publication title — likely generic usage: SynergyFinder R package
CEAS R Package,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CEAS R Package,Package/Library,,,,,,,,,,,,,,,,"ATP metrics were calculated following Mookerjee et al., 2017 and using the CEAS R Package",Software name not in publication title — likely generic usage: CEAS R Package
FactoMineR R package,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FactoMineR R package,Package/Library,,,,,,,,,,,,,,,,PCA analysis was performed using the FactoMineR R package,Software name not in publication title — likely generic usage: FactoMineR R package
ImageJ,computational_tools,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,"ImageJ (Fiji, NIH) was used to track the center of n = 15–17 particles for each sample",Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
MATLAB,computational_tools,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MATLAB,Analysis Software,,,,,,,,,,,,,,,,"A MATLAB program was then used to track the particles, calculate the instantaneous mean square displacement",Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
MACSQuant flow cytometer,computational_tools,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MACSQuant flow cytometer,Analysis Software,,,,,,,,,,,,,,,,"The phenotype of hRGC was analyzed using flow cytometry with the MACSQuant flow cytometer (Miltenyi, San Diego)",Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
Leica SP8 confocal microscope,computational_tools,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Leica SP8 confocal microscope,Analysis Software,,,,,,,,,,,,,,,,Digital images were obtained with an epifluorescence confocal microscope (Leica SP8) using 63x-oil objective,Publication title lacks NF-specific terms: A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for 
FlowJo software,computational_tools,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FlowJo software,Analysis Software,X10.0.7,,,,,,,,,,,,,,,data were processed with FlowJo software (version X10.0.7),Software name not in publication title — likely generic usage: FlowJo software
SpectraMax M5 microplate reader,computational_tools,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SpectraMax M5 microplate reader,Analysis Software,,,,,,,,,,,,,,,,"measured at 450 nm using the SpectraMax M5 microplate reader (Molecular Devices, San Jose, CA, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Orbitrap Fusion Lumos mass spectrometer,computational_tools,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Orbitrap Fusion Lumos mass spectrometer,Analysis Software,,,,,,,,,,,,,,,,"An Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific Inc., Waltham, MA, USA)",Software name not in publication title — likely generic usage: Orbitrap Fusion Lumos mass spectrometer
ImageJ software,computational_tools,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ software,Analysis Software,1.51,,,,,,,,,,,,,,,The Image J software (version 1.51) was used to analyze the relative density,Generic bioinformatics/stats tool: ImageJ software
STRING database,computational_tools,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STRING database,Database,11.0,https://cn.string-db.org/,,,,,,,,,,,,,,We used the STRING database (version 11.0) (https://cn.string-db.org/),Generic bioinformatics/stats tool: STRING database
Cytoscape,computational_tools,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cytoscape,Analysis Software,3.7.2,,,,,,,,,,,,,,,Cytoscape (version 3.7.2) was used to construct the network,Generic bioinformatics/stats tool: Cytoscape
GraphPad Prism,computational_tools,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism,Analysis Software,9.5.0,,,,,,,,,,,,,,,analyses were performed using GraphPad Prism (version 9.5.0),Generic bioinformatics/stats tool: GraphPad Prism
Scanco µCT 40,computational_tools,PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Scanco µCT 40,Analysis Software,,,,,,,,,,,,,,,,"evaluated using an ex vivo µCT imaging system (Scanco µCT 40, Scanco Medical, Bassersdorf, Switzerland)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Dynamight 8841,computational_tools,PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Dynamight 8841,Analysis Software,,,,,,,,,,,,,,,,"positioned on the bottom two supports such that callus was directly below the top loading point at the end of the actuator (Dynamight 8841, Instron)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Bioquant Analysis System,computational_tools,PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bioquant Analysis System,Analysis Software,,,,,,,,,,,,,,,,"Histomorphometric measurements were performed using the Bioquant Analysis System (Nashville, TN, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
SEDFIT 16.1,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SEDFIT 16.1,Analysis Software,16.1,,,,,,,,,,,,,,,Time-corrected data were analyzed in SEDFIT 16.1 in terms of a continuous c(s) distribution of sedimenting species,Software name not in publication title — likely generic usage: SEDFIT 16.1
SEDNTERP,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SEDNTERP,Analysis Software,,,,,,,,,,,,,,,,Protein partial specific volumes were calculated based on their composition in SEDNTERP,No version and no repository URL (confidence < 0.9 — unidentifiable)
SEDPHAT 14.0,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SEDPHAT 14.0,Analysis Software,14.0,,,,,,,,,,,,,,,Data were analyzed globally in terms of a single noninteracting species in SEDPHAT 14.0 to obtain the molar mass,Software name not in publication title — likely generic usage: SEDPHAT 14.0
EMAN2 e2boxer,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,EMAN2 e2boxer,Analysis Software,,,,,,,,,,,,,,,,Negatively-stained neurofibromin particles were autopicked using EMAN2 e2boxer using a box size of 326 pixels,Software name not in publication title — likely generic usage: EMAN2 e2boxer
Sphire,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Sphire,Package/Library,,,,,,,,,,,,,,,,Reference-free 2D classification was carried out using the Iterative Stable Alignment and Clustering (ISAC) procedure implemented in a Sphire package,Software name not in publication title — likely generic usage: Sphire
Chimera,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Chimera,Analysis Software,,,,,,,,,,,,,,,,All further analyses and visualizations were performed using Chimera,No version and no repository URL (confidence < 0.9 — unidentifiable)
Relion,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Relion,Analysis Software,,,,,,,,,,,,,,,,Full-length NF1 dimer data were low-pass filtered to 60 Å and used as a reference in Relion for refinement of the model,No version and no repository URL (confidence < 0.9 — unidentifiable)
MantidPlot,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MantidPlot,Analysis Software,,,,,,,,,,,,,,,,Data reduction followed standard procedures using MantidPlot,No version and no repository URL (confidence < 0.9 — unidentifiable)
ATSAS,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ATSAS,Package/Library,,,,,,,,,,,,,,,,The reduced SAXS and SANS data were analyzed using the ATSAS tools PRIMUS and GNOM for Guinier and P(r) analysis,Software name not in publication title — likely generic usage: ATSAS
DAMMIF,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DAMMIF,Analysis Software,,,,,,,,,,,,,,,,The DAMMIF program within ATSAS was used to generate ab initio shape reconstruction models,No version and no repository URL (confidence < 0.9 — unidentifiable)
EM2DAM,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,EM2DAM,Analysis Software,,,,,,,,,,,,,,,,A theoretical SAXS curve was generated from the final negatively-stained EM model of neurofibromin holoprotein using the ATSAS tool EM2DAM,No version and no repository URL (confidence < 0.9 — unidentifiable)
MULCh,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MULCh,Analysis Software,,,,,,,,,,,,,,,,"Using the contrast module of MULCh, the NF1 sequence was used to calculate Δρ in H2O buffer",No version and no repository URL (confidence < 0.9 — unidentifiable)
STAR 2.4.2a,computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR 2.4.2a,Analysis Software,2.4.2a,,,,,,,,,,,,,,,Mapping was performed using STAR 2.4.2a software with mouse genome (mm9),Software name not in publication title — likely generic usage: STAR 2.4.2a
DESeq2,computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2,Analysis Software,,,,,,,,,,,,,,,,Differential expression analysis was performed with DESeq2 using default settings,Generic bioinformatics/stats tool: DESeq2
GSEA software 4.0.1,computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GSEA software 4.0.1,Analysis Software,4.0.1,,,,,,,,,,,,,,,Gene set enrichment analysis (GSEA) was performed with the entire gene list using GSEA software 4.0.1 desktop (Broad Institute),Software name not in publication title — likely generic usage: GSEA software 4.0.1
DAVID 6.8,computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DAVID 6.8,Web Application,6.8,,,,,,,,,,,,,,,KEGG and gene ontology (GO) enrichment analysis was performed using the Signature Database (MSigDB) and DAVID 6.8,Software name not in publication title — likely generic usage: DAVID 6.8
MaxQuant (v1.5.3.30),computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MaxQuant (v1.5.3.30),Analysis Software,v1.5.3.30,,,,,,,,,,,,,,,Five micrograms of each SCX fraction and a non-fractioned sample were used for proteome profiling and analysed by MaxQuant (v1.5.3.30),Software name not in publication title — likely generic usage: MaxQuant (v1.5.3.30)
ZEN imaging software,computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ZEN imaging software,Analysis Software,,,,,,,,,,,,,,,,Imaging was performed on a LSM700 confocal microscope (Zeiss) with ZEN imaging software (Zeiss),No version and no repository URL (confidence < 0.9 — unidentifiable)
AxioVision 4.6 software,computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,AxioVision 4.6 software,Analysis Software,4.6,,,,,,,,,,,,,,,Imaging was performed using a Zeiss Stereo Discovery V12 and the AxioVision 4.6 software (Zeiss),Software name not in publication title — likely generic usage: AxioVision 4.6 software
FUSION FX software,computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FUSION FX software,Analysis Software,,,,,,,,,,,,,,,,Images were acquired using a Fusion FX spectra gel documentation system (Vilber) with FUSION FX software,No version and no repository URL (confidence < 0.9 — unidentifiable)
ImageJ,computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,Blots images were analysed with ImageJ grey value analysis tool,Generic bioinformatics/stats tool: ImageJ
DatLab software,computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DatLab software,Analysis Software,,,,,,,,,,,,,,,,DatLab software (OROBOROS INSTRUMENTS) was used for data acquisition and analysis,No version and no repository URL (confidence < 0.9 — unidentifiable)
DP Controller software,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DP Controller software,Analysis Software,,,,,,,,,,,,,,,,"Images of the hematoxylin-eosin sections were taken (20X magnification) using an Olympus BX-51 microscope using an Olympus DP71 digital camera, and DP Controller software",No version and no repository URL (confidence < 0.9 — unidentifiable)
CNVkit,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CNVkit,Analysis Software,,,,,,,,,,,,,,,,"Whole exome sequencing (WES), RNA sequencing (RNA-Seq), and copy number analysis (CNVkit) were performed on each sample",Generic bioinformatics/stats tool: CNVkit
Illumina HiSeq4000,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina HiSeq4000,Other,,,,,,,,,,,,,,,,"Exome libraries were captured with an IDT exome reagent, then pooled with a WGS library for sequencing on an Illumina HiSeq4000 with at least 1000x coverage",Sequencing hardware or generic assay protocol: Illumina HiSeq4000
BWA-MEM,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BWA-MEM,Analysis Software,,,,,,,,,,,,,,,,Genomic data were aligned against reference sequence hg38 via BWA-MEM with Base Quality Score Recalibration (BQSR),Software name not in publication title — likely generic usage: BWA-MEM
manta,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,manta,Analysis Software,,,,,,,,,,,,,,,,Structural variants (SVs) and large indels were detected using manta,Software name not in publication title — likely generic usage: manta
VarScan2,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VarScan2,Analysis Software,,,,,,,,,,,,,,,,"SNVs and small indels were detected using VarScan2, Strelka2, MuTect2, and Pindel",Generic bioinformatics/stats tool: VarScan2
Strelka2,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Strelka2,Analysis Software,,,,,,,,,,,,,,,,"SNVs and small indels were detected using VarScan2, Strelka2, MuTect2, and Pindel",Generic bioinformatics/stats tool: Strelka2
MuTect2,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MuTect2,Analysis Software,,,,,,,,,,,,,,,,"SNVs and small indels were detected using VarScan2, Strelka2, MuTect2, and Pindel",Generic bioinformatics/stats tool: MuTect2
Pindel,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Pindel,Analysis Software,,,,,,,,,,,,,,,,"SNVs and small indels were detected using VarScan2, Strelka2, MuTect2, and Pindel",Software name not in publication title — likely generic usage: Pindel
VEP,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,VEP,Analysis Software,version 95,,,,,,,,,,,,,,,"which includes best-practice variant filtering and annotation with VEP (Variant Effect Predictor, version 95)",Generic bioinformatics/stats tool: VEP
GenVisR,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GenVisR,Analysis Software,,,,,,,,,,,,,,,,Waterfall somatic variant plots were created with GenVisR by including somatic variants that occurred in each area,Software name not in publication title — likely generic usage: GenVisR
COSMIC,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,COSMIC,Database,,,,,,,,,,,,,,,,These variants were not reported as a somatic variant in COSMIC (Catalogue Of Somatic Mutations In Cancer) and ClinVar archive,Software name not in publication title — likely generic usage: COSMIC
ClinVar,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ClinVar,Database,,,,,,,,,,,,,,,,These variants were not reported as a somatic variant in COSMIC (Catalogue Of Somatic Mutations In Cancer) and ClinVar archive,Software name not in publication title — likely generic usage: ClinVar
SIFT,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SIFT,Analysis Software,,,,,,,,,,,,,,,,"In order to predict clinical significance and predictions of the functional effects of these variants, each variant was reviewed on SIFT and Polyphen",Software name not in publication title — likely generic usage: SIFT
Polyphen,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Polyphen,Analysis Software,,,,,,,,,,,,,,,,"In order to predict clinical significance and predictions of the functional effects of these variants, each variant was reviewed on SIFT and Polyphen",Software name not in publication title — likely generic usage: Polyphen
SciClone,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SciClone,Analysis Software,,,,,,,,,,,,,,,,SciClone and ClonEvol were utilized to attempt to perform a phylogeny inference,Software name not in publication title — likely generic usage: SciClone
ClonEvol,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ClonEvol,Analysis Software,,,,,,,,,,,,,,,,SciClone and ClonEvol were utilized to attempt to perform a phylogeny inference,Software name not in publication title — likely generic usage: ClonEvol
Partek Flow,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Partek Flow,Analysis Software,,,,,,,,,,,,,,,,Pre/post quality control and full expectation-maximization (EM) quantification were run via Partek Flow,Software name not in publication title — likely generic usage: Partek Flow
edgeR,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,edgeR,Package/Library,,,,,,,,,,,,,,,,Gene counts and transcript counts were normalized by CPM (counts per million) by using edgeR package,Generic bioinformatics/stats tool: edgeR
gplots,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,gplots,Package/Library,,,,,,,,,,,,,,,,Heatmap visualizations were created using gplots R package,Software name not in publication title — likely generic usage: gplots
PantherDB,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PantherDB,Database,,,,,,,,,,,,,,,,PantherDB was utilized to discover GO terms and pathways that may be affected by these genes,Software name not in publication title — likely generic usage: PantherDB
CompuSyn software Version 1.0,computational_tools,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CompuSyn software Version 1.0,Analysis Software,1.0,,,,,,,,,,,,,,,"Drug–drug interactions were analyzed with CompuSyn software Version 1.0 (Informer Technologies, Los Angeles, CA, USA; software is available at https://www.compusyn.software.informer.com",Software name not in publication title — likely generic usage: CompuSyn software Version 1.0
IBM SPSS Statistics software version 29.0.1.0,computational_tools,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,IBM SPSS Statistics software version 29.0.1.0,Analysis Software,29.0.1.0,,,,,,,,,,,,,,,"In vivo S462TY sciatic nerve tumor xenograft data were analyzed using IBM SPSS Statistics software version 29.0.1.0 (IBM, Armonk, NY, USA).",Software name not in publication title — likely generic usage: IBM SPSS Statistics software version 29.0.1.0
SPIN (Signal Processing in MR Version SVN Revision 1895),computational_tools,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPIN (Signal Processing in MR Version SVN Revision 1895),Analysis Software,SVN Revision 1895,http://mrc.wayne.edu,,,,,,,,,,,,,,Internally developed MR software SPIN (Signal Processing in MR (Version SVN Revision 1895); http://mrc.wayne.edu (accessed on 15 December 2023)) was used for tumor volume measurement.,Software name not in publication title — likely generic usage: SPIN (Signal Processing in MR Version SVN Revision 1895)
Illumina NovaSeq6000,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina NovaSeq6000,Other,,,,,,,,,,,,,,,,which were sequenced on the Illumina NovaSeq6000 sequencing machine using S4 flow cells,Sequencing hardware or generic assay protocol: Illumina NovaSeq6000
BWA-MEM,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BWA-MEM,Analysis Software,0.7.17-r1188,,,,,,,,,,,,,,,Raw sequencing reads were mapped to the GRCh38 build of the human reference genome using BWA-MEM (46) version 0.7.17-r1188,Software name not in publication title — likely generic usage: BWA-MEM
GATK,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GATK,Analysis Software,4.1.8.0,,,,,,,,,,,,,,,"Aligned reads in BAM format were processed following the Genome Analysis Toolkit (GATK, version 4.1.8.0) Best Practices workflow",Generic bioinformatics/stats tool: GATK
NGSCheckMate,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NGSCheckMate,Analysis Software,,,,,,,,,,,,,,,,NGSCheckMate was utilized using default options to verify that sequencing data from tumor–normal pairs corresponded to the same individual,No version and no repository URL (confidence < 0.9 — unidentifiable)
Strelka2,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Strelka2,Analysis Software,2.9.2,,,,,,,,,,,,,,,"The germline short variant discovery workflow from GATK (version 4.1.8.0; ref. 47), Strelka2 (version 2.9.2; ref. 51)",Generic bioinformatics/stats tool: Strelka2
VarDict,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,VarDict,Analysis Software,1.8.2,,,,,,,,,,,,,,,and VarDict (version 1.8.2; ref. 52) were used to detect germline SNVs and INDELs in the WGS data,Software name not in publication title — likely generic usage: VarDict
Annovar,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Annovar,Analysis Software,2018Apr16,,,,,,,,,,,,,,,Annovar (version 2018Apr16) was used to annotate all variants (53),Generic bioinformatics/stats tool: Annovar
BamSnap,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BamSnap,Analysis Software,,,,,,,,,,,,,,,,All variants were also manually curated through visual inspection of raw sequencing reads using BamSnap (54),No version and no repository URL (confidence < 0.9 — unidentifiable)
Manta,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Manta,Analysis Software,1.6.0,,,,,,,,,,,,,,,we called SVs in all matched normal samples using Manta (version 1.6.0; ref. 55),Software name not in publication title — likely generic usage: Manta
LUMPY,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,LUMPY,Analysis Software,0.2.13,,,,,,,,,,,,,,,"LUMPY (version 0.2.13; ref. 56), SvABA (version 1.1.3; ref. 57), and Delly (version 0.8.3; refs. 57, 58)",Generic bioinformatics/stats tool: LUMPY
SvABA,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SvABA,Analysis Software,1.1.3,,,,,,,,,,,,,,,"LUMPY (version 0.2.13; ref. 56), SvABA (version 1.1.3; ref. 57), and Delly (version 0.8.3; refs. 57, 58)",Software name not in publication title — likely generic usage: SvABA
Delly,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Delly,Analysis Software,0.8.3,,,,,,,,,,,,,,,"LUMPY (version 0.2.13; ref. 56), SvABA (version 1.1.3; ref. 57), and Delly (version 0.8.3; refs. 57, 58)",Generic bioinformatics/stats tool: Delly
mosdepth,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,mosdepth,Analysis Software,,,,,,,,,,,,,,,,"In addition, we computed the sequencing coverage at 500-bp windows using mosdepth (59)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Mutect2,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Mutect2,Analysis Software,,,,,,,,,,,,,,,,"Somatic SNVs were detected using Mutect2 (GATK version 4.1.8.0), MuSE (version v1.0rc; ref. 60)",Generic bioinformatics/stats tool: Mutect2
MuSE,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MuSE,Analysis Software,v1.0rc,,,,,,,,,,,,,,,"Somatic SNVs were detected using Mutect2 (GATK version 4.1.8.0), MuSE (version v1.0rc; ref. 60)",Software name not in publication title — likely generic usage: MuSE
dNdScv,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,dNdScv,Package/Library,,,,,,,,,,,,,,,,"To identify driver genes, we used the R package dNdScv (61)",No version and no repository URL (confidence < 0.9 — unidentifiable)
NMF,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NMF,Package/Library,,,,,,,,,,,,,,,,Mutational signatures were extracted de novo using nonnegative matrix factorization (NMF) as implemented in the R package NMF (62),No version and no repository URL (confidence < 0.9 — unidentifiable)
MutationalPatterns,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MutationalPatterns,Package/Library,,,,,,,,,,,,,,,,assigned to existing ones using a cosine similarity cutoff of 0.85 using the R package MutationalPatterns (64),No version and no repository URL (confidence < 0.9 — unidentifiable)
MSIprofiler,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MSIprofiler,Analysis Software,,https://github.com/parklab/MSIprofiler,,,,,,,,,,,,,,Mutations at microsatellite loci were detected using MSIprofiler (https://github.com/parklab/MSIprofiler),Software name not in publication title — likely generic usage: MSIprofiler
FACETS,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FACETS,Analysis Software,0.12.1,,,,,,,,,,,,,,,"For WGS data, the software packages FACETS (version 0.12.1) and ascatNGS (version 2.5.1) were used to detect somatic copy-number alterations",Software name not in publication title — likely generic usage: FACETS
ascatNGS,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ascatNGS,Analysis Software,2.5.1,,,,,,,,,,,,,,,"For WGS data, the software packages FACETS (version 0.12.1) and ascatNGS (version 2.5.1) were used to detect somatic copy-number alterations",Software name not in publication title — likely generic usage: ascatNGS
ASCAT,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ASCAT,Analysis Software,,,,,,,,,,,,,,,,"LogR and BAF values were calculated for all tumor samples with a corresponding retained normal sample. Tumor LogR values were corrected for GC content, and copy-number profiles were generated using ASCAT (68)",No version and no repository URL (confidence < 0.9 — unidentifiable)
sigProfilerExtractor,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,sigProfilerExtractor,Analysis Software,,,,,,,,,,,,,,,,"For WGS data, NMF as implemented in sigProfilerExtractor was used to extract de novo copy-number signatures",No version and no repository URL (confidence < 0.9 — unidentifiable)
sigProfilerSingleSample,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,sigProfilerSingleSample,Analysis Software,,,,,,,,,,,,,,,,"In each case, the de novo signatures were decomposed into previously identified pan-cancer copy-number signatures (27) using the function sigProfilerSingleSample",No version and no repository URL (confidence < 0.9 — unidentifiable)
ShatterSeek,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ShatterSeek,Analysis Software,0.7,,,,,,,,,,,,,,,Chromothripsis events were detected using ShatterSeek (version 0.7) using recommended cutoff values (72),Software name not in publication title — likely generic usage: ShatterSeek
STAR,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR,Analysis Software,2.7.4a,,,,,,,,,,,,,,,Sequencing reads were mapped to the transcriptome using the STAR aligner (version 2.7.4a; ref. 74),Generic bioinformatics/stats tool: STAR
HTSeq,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HTSeq,Analysis Software,0.6.1p1,,,,,,,,,,,,,,,Gene-expression counts were generated using HTSeq (v.0.6.1p1; ref. 75),Generic bioinformatics/stats tool: HTSeq
DESeq2,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2,Package/Library,,,,,,,,,,,,,,,,Differential expression analysis was performed using DESeq2 (76),Generic bioinformatics/stats tool: DESeq2
ARRIBA,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ARRIBA,Analysis Software,2.1.0,,,,,,,,,,,,,,,Gene fusions were detected using ARRIBA (version 2.1.0; ref. 77),Generic bioinformatics/stats tool: ARRIBA
TopHat-fusion,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,TopHat-fusion,Analysis Software,2.1.0,,,,,,,,,,,,,,,"TopHat-fusion (version 2.1.0; ref. 78), EricScript (version 0.5.5; ref. 79), and STAR-Fusion (version 1.10.1; ref. 80)",Software name not in publication title — likely generic usage: TopHat-fusion
EricScript,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,EricScript,Analysis Software,0.5.5,,,,,,,,,,,,,,,"TopHat-fusion (version 2.1.0; ref. 78), EricScript (version 0.5.5; ref. 79), and STAR-Fusion (version 1.10.1; ref. 80)",Software name not in publication title — likely generic usage: EricScript
STAR-Fusion,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR-Fusion,Analysis Software,1.10.1,,,,,,,,,,,,,,,"TopHat-fusion (version 2.1.0; ref. 78), EricScript (version 0.5.5; ref. 79), and STAR-Fusion (version 1.10.1; ref. 80)",Generic bioinformatics/stats tool: STAR-Fusion
consensusTME,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,consensusTME,Analysis Software,,,,,,,,,,,,,,,,Immune infiltration was estimated using consensusTME using the sarcoma cell-type–specific genes derived from TCGA (81),No version and no repository URL (confidence < 0.9 — unidentifiable)
minfi,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,minfi,Package/Library,1.34.0,,,,,,,,,,,,,,,Raw Methylation EPIC data were uniformly processed using the R package minfi (version 1.34.0; ref. 86),Software name not in publication title — likely generic usage: minfi
ConsensusClusterPlus,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ConsensusClusterPlus,Package/Library,,,,,,,,,,,,,,,,We performed clustering of each data type separately using ConsensusClusterPlus (89),No version and no repository URL (confidence < 0.9 — unidentifiable)
coca,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,coca,Package/Library,,,,,,,,,,,,,,,,"COCA, as implemented in the R package coca (91), was run on the same datasets used for ConsensusClusterPlus clustering",No version and no repository URL (confidence < 0.9 — unidentifiable)
IchorCNA,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,IchorCNA,Analysis Software,,,,,,,,,,,,,,,,IchorCNA (92) was used to estimate the tumor fraction in cfDNA and genome-wide copy-number profiles,No version and no repository URL (confidence < 0.9 — unidentifiable)
survival,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,survival,Package/Library,2.30,,,,,,,,,,,,,,,Survival analysis was performed using the Cox proportional-hazards model as implemented in the R package survival (version 2.30; ref. 93),Software name not in publication title — likely generic usage: survival
phangorn,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,phangorn,Package/Library,,,,,,,,,,,,,,,,we used the parsimony ratchet method (pratchet) as implemented in the R package phangorn (94),No version and no repository URL (confidence < 0.9 — unidentifiable)
MesKit,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MesKit,Package/Library,,,,,,,,,,,,,,,,we used the maximum parsimony and neighbor-joining algorithms as implemented in the R package MesKit (95),No version and no repository URL (confidence < 0.9 — unidentifiable)
Bruker minispec LF90 TD‐NMR analyzer,computational_tools,PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bruker minispec LF90 TD‐NMR analyzer,Analysis Software,,,,,,,,,,,,,,,,"Total body fat and lean tissue were assessed using a Bruker minispec LF90 TD‐NMR analyzer, which was calibrated prior to each use",No version and no repository URL (confidence < 0.9 — unidentifiable)
Comprehensive Lab Animal Monitoring System (CLAMS),computational_tools,PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Comprehensive Lab Animal Monitoring System (CLAMS),Analysis Software,,,,,,,,,,,,,,,,Indirect calorimetry was assessed using the Comprehensive Lab Animal Monitoring System (CLAMS),No version and no repository URL (confidence < 0.9 — unidentifiable)
AlphaTrak 2,computational_tools,PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AlphaTrak 2,Analysis Software,,,,,,,,,,,,,,,,"Serial blood glucose measurements were made every 10 minutes for 120 minutes using a glucometer (AlphaTrak 2, Zoetis, Parsippany, NJ)",No version and no repository URL (confidence < 0.9 — unidentifiable)
A1C Now Diabetes Management HbA1C test kit,computational_tools,PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,A1C Now Diabetes Management HbA1C test kit,Analysis Software,,,,,,,,,,,,,,,,"For Hemoglobin A1c measurements, blood samples were immediately measured using the A1C Now Diabetes Management HbA1C test kit (PTS Diagnostic, Indianapolis, IN)",No version and no repository URL (confidence < 0.9 — unidentifiable)
LDX Cholestech cartridges,computational_tools,PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LDX Cholestech cartridges,Analysis Software,,,,,,,,,,,,,,,,"For lipoprotein, triglyceride, and cholesterol measurements, fresh serum was assayed using LDX Cholestech cartridges (Abbott, Chicago, IL)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Pro-diabetes multiplex assay,computational_tools,PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Pro-diabetes multiplex assay,Analysis Software,,,,,,,,,,,,,,,,"stored at −80°C until analysis using a Pro-diabetes multiplex assay from Bio-Rad (Bio-Rad, Hercules, CA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Image Pro Plus,computational_tools,PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Image Pro Plus,Analysis Software,,,,,,,,,,,,,,,,Image Pro Plus was used to quantify the area of lipid accumulation (Oil Red-O stained) in each section from the liver and skeletal muscle,No version and no repository URL (confidence < 0.9 — unidentifiable)
GraphPad Prism version 6.0h,computational_tools,PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 6.0h,Analysis Software,6.0h,,,,,,,,,,,,,,,"Analysis was performed using GraphPad Prism version 6.0h (La Jolla, CA, USA)",Generic tool (versioned): GraphPad Prism version 6.0h
MATLAB,computational_tools,PMID:41545416,10.1038/s41540-026-00647-w,Asthma-mediated control of optic glioma growth via T cell-microglia interactions: A mathematical model.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MATLAB,Analysis Software,,,,,,,,,,,,,,,,All simulations in this study were conducted using MATLAB (MathWorks) with the ode15s solver,Publication title lacks NF-specific terms: Asthma-mediated control of optic glioma growth via T cell-microglia interactions
ode15s solver,computational_tools,PMID:41545416,10.1038/s41540-026-00647-w,Asthma-mediated control of optic glioma growth via T cell-microglia interactions: A mathematical model.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ode15s solver,Analysis Software,,,,,,,,,,,,,,,,"conducted using MATLAB (MathWorks) with the ode15s solver, which employs variable-step, variable-order numerical schemes",Publication title lacks NF-specific terms: Asthma-mediated control of optic glioma growth via T cell-microglia interactions
"ImageJ software (version 1.48; National Institutes of Health, Behesda, MD, USA)",computational_tools,PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"ImageJ software (version 1.48; National Institutes of Health, Behesda, MD, USA)",Analysis Software,1.48,,,,,,,,,,,,,,,"More than 200 cells were counted for each drug concentration using ImageJ software (version 1.48; National Institutes of Health, Behesda, MD, USA)","Generic tool (versioned): ImageJ software (version 1.48; National Institutes of Health, Behesda, MD, USA)"
ImageJ (v1.53a),computational_tools,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,ImageJ (v1.53a),Analysis Software,v1.53a,,,,,,,,,,,,,,,Fiber diameter and angle were measured using ImageJ (v1.53a) with at least 200 fibers per fiber type,Publication title lacks NF-specific terms: Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon na
NIH ImageJ (version 1.53a),computational_tools,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,NIH ImageJ (version 1.53a),Analysis Software,version 1.53a,,,,,,,,,,,,,,,"The images were analyzed using NIH ImageJ (version 1.53a) software. Aspect ratio, which is the longest length of the cell divided by the shortest length",Publication title lacks NF-specific terms: Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon na
Thermo Scientific Multiskan GO,computational_tools,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Thermo Scientific Multiskan GO,Analysis Software,,,,,,,,,,,,,,,,"transferred into a 96-well plate, and read using Thermo Scientific Multiskan GO at 570 and 600nm to obtain the absorption gradient",Publication title lacks NF-specific terms: Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon na
Rigol oscilloscope,computational_tools,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Rigol oscilloscope,Analysis Software,,,,,,,,,,,,,,,,stimulus after it passed through the stimulation chamber (Voltage Out) were captured from Channel 1 and Channel 2 of an oscilloscope (Rigol),Publication title lacks NF-specific terms: Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon na
Raspberry Pi Python script,computational_tools,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Raspberry Pi Python script,Analysis Software,,,,,,,,,,,,,,,,connected to a Raspberry Pi running a Python script to store the data in near real time through the USB port connection,Publication title lacks NF-specific terms: Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon na
DNA Engine Peltier Thermal cycler (PTC-200),computational_tools,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DNA Engine Peltier Thermal cycler (PTC-200),Other,,,,,,,,,,,,,,,,"in a DNA Engine Peltier Thermal cycler (PTC-200; MJ Research, Watertown, MA) at 42°C for 1 minute",Software name not in publication title — likely generic usage: DNA Engine Peltier Thermal cycler (PTC-200)
"ABI Prism 7,000 Sequence Detection System",computational_tools,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.95,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"ABI Prism 7,000 Sequence Detection System",Analysis Software,,,,,,,,,,,,,,,,"An ABI Prism 7,000 Sequence Detection System was used for all reactions with the following cycling parameters","Software name not in publication title — likely generic usage: ABI Prism 7,000 Sequence Detection System"
Microsoft Excel program designed for Q-PCR quantitation,computational_tools,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Microsoft Excel program designed for Q-PCR quantitation,Analysis Software,,,,,,,,,,,,,,,,Results were analyzed using a Microsoft Excel program designed for Q-PCR quantitation based on internal control mRNA levels,No version and no repository URL (confidence < 0.9 — unidentifiable)
Simpleware ScanIP,computational_tools,PMID:39966622,10.1038/s41598-025-88589-x,The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas.,,0.95,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Simpleware ScanIP,Analysis Software,,,,,,,,,,,,,,,,"To create the tumor models for the ground truth dataset, an image processing software (Simpleware ScanIP, Synopsys) was used.",Software name not in publication title — likely generic usage: Simpleware ScanIP
DPP V1.0,computational_tools,PMID:39966622,10.1038/s41598-025-88589-x,The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas.,,0.9,Development,True,1.00,High,,,,,,,,,,,,,,,DPP V1.0,Analysis Software,V1.0,,,,,,,,,,,,,,,The helper (DPP V1.0) was trained using proprietary AI- and ML-based algorithms and information.,Software name not in publication title — likely generic usage: DPP V1.0
Simpleware,computational_tools,PMID:39966622,10.1038/s41598-025-88589-x,The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas.,,0.95,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Simpleware,Analysis Software,,,,,,,,,,,,,,,,"To create the tumor models an image processing software (Simpleware, Synopsys, Mountain View, CA) was used.",Software name not in publication title — likely generic usage: Simpleware
Phoenix WinNonlin (Version 8.1),computational_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Phoenix WinNonlin (Version 8.1),Analysis Software,8.1,,,,,,,,,,,,,,,"A noncompartmental analysis was performed to estimate area under the concentration-time curve from time 0 to 12 hours (AUC 0-12h) after a single dose of mirdametinib using Phoenix WinNonlin (Version 8.1; Certara, Princeton, NJ).",Software name not in publication title — likely generic usage: Phoenix WinNonlin (Version 8.1)
NONMEM (version 7.2),computational_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,NONMEM (version 7.2),Analysis Software,7.2,,,,,,,,,,,,,,,"A population pharmacokinetics (PK) analysis was also performed using nonlinear mixed effect modeling with NONMEM (version 7.2; ICON, Ellicott City, MD) with Perl speaks NONMEM version 3.6.2 and Pirana version 2.7.1 (Certara).",Software name not in publication title — likely generic usage: NONMEM (version 7.2)
Perl speaks NONMEM version 3.6.2,computational_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Perl speaks NONMEM version 3.6.2,Package/Library,3.6.2,,,,,,,,,,,,,,,"A population pharmacokinetics (PK) analysis was also performed using nonlinear mixed effect modeling with NONMEM (version 7.2; ICON, Ellicott City, MD) with Perl speaks NONMEM version 3.6.2 and Pirana version 2.7.1 (Certara).",Software name not in publication title — likely generic usage: Perl speaks NONMEM version 3.6.2
Pirana version 2.7.1,computational_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Pirana version 2.7.1,Analysis Software,2.7.1,,,,,,,,,,,,,,,"A population pharmacokinetics (PK) analysis was also performed using nonlinear mixed effect modeling with NONMEM (version 7.2; ICON, Ellicott City, MD) with Perl speaks NONMEM version 3.6.2 and Pirana version 2.7.1 (Certara).",Software name not in publication title — likely generic usage: Pirana version 2.7.1
SAS version 9.4,computational_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SAS version 9.4,Analysis Software,9.4,,,,,,,,,,,,,,,"The pain and QOL data were summarized with descriptive statistics (means, standard deviation [SD]) via SAS version 9.4 (Cary, NC).",Generic tool (versioned): SAS version 9.4
Castor EDC,computational_tools,PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Castor EDC,Web Application,,,,,,,,,,,,,,,,A digital version of the cNF-Skindex was administered to the participants using the data capture system Castor EDC,No version and no repository URL (confidence < 0.9 — unidentifiable)
SPSS version 28.0,computational_tools,PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS version 28.0,Analysis Software,28.0,,,,,,,,,,,,,,,Statistical analyses were performed using SPSS version 28.0,Software name not in publication title — likely generic usage: SPSS version 28.0
REDCap,computational_tools,PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,REDCap,Web Application,,,,,,,,,,,,,,,,"Assessments were completed at baseline, after treatment, and at 6- and 12-month follow-up via REDCap",No version and no repository URL (confidence < 0.9 — unidentifiable)
"SAS, version 9.4",computational_tools,PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"SAS, version 9.4",Analysis Software,9.4,,,,,,,,,,,,,,,"We used SAS, version 9.4 (SAS Institute Inc), for analyses","Generic tool (versioned): SAS, version 9.4"
www.synapse.org/SynodosNF2,computational_tools,PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,0.9,Development,True,1.00,High,,,,,,,,,,,,,,,www.synapse.org/SynodosNF2,Database,,www.synapse.org/SynodosNF2,,,,,,,,,,,,,,This work has created an openly accessible resource (www.synapse.org/SynodosNF2) of fully characterized isogenic schwannoma and meningioma cell systems,Software name not in publication title — likely generic usage: www.synapse.org/SynodosNF2
"LabVIEW (National Instruments, cat. no. 784503–35)",computational_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"LabVIEW (National Instruments, cat. no. 784503–35)",Analysis Software,,,,,,,,,,,,,,,,"LabVIEW (National Instruments, cat. no. 784503–35)",No version and no repository URL (confidence < 0.9 — unidentifiable)
FastQC (version 0.11.2),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,FastQC (version 0.11.2),Analysis Software,0.11.2,,,,,,,,,,,,,,,All sequencing datasets were evaluated using FastQC (version 0.11.2) to ensure high quality,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
Bowtie (version 1.0.0),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Bowtie (version 1.0.0),Analysis Software,1.0.0,,,,,,,,,,,,,,,We first built an index using all sgRNAs in each sample and then used Bowtie (version 1.0.0) to map the sgRNA sequences,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
BWA version 0.7.5,computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,BWA version 0.7.5,Analysis Software,0.7.5,,,,,,,,,,,,,,,We mapped the reads to the reference genomic sequence using BWA version 0.7.5 and SAMtools,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
SAMtools (version 0.1.19),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SAMtools (version 0.1.19),Analysis Software,0.1.19,,,,,,,,,,,,,,,We mapped the reads to the reference genomic sequence using BWA version 0.7.5 and SAMtools (version 0.1.19),Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
VarScan2 (version 2.3),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,VarScan2 (version 2.3),Analysis Software,2.3,,,,,,,,,,,,,,,We then used VarScan2 (version 2.3) to identify insertions and deletions with the 'pileup2indel' mode,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
STAR (version 2.3.0e),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,STAR (version 2.3.0e),Analysis Software,2.3.0e,,,,,,,,,,,,,,,We aligned RNA-seq reads to the mm10 genome using STAR (version 2.3.0e) with default parameters,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
DESeq (version 1.18.0),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,DESeq (version 1.18.0),Package/Library,1.18.0,,,,,,,,,,,,,,,We then determined differential expression using DESeq (version 1.18.0) and accounted for possible batch effects,Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
synapser,computational_tools,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,synapser,Package/Library,,,,,,,,,,,,,,,,"Key packages used include synapser [ 24 ], tidyverse [ 25 ], dplyr [ 26 ], WGCNA [ 27 ]",No version and no repository URL (confidence < 0.9 — unidentifiable)
tidyverse,computational_tools,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,tidyverse,Package/Library,,,,,,,,,,,,,,,,"Key packages used include synapser [ 24 ], tidyverse [ 25 ], dplyr [ 26 ], WGCNA [ 27 ]",No version and no repository URL (confidence < 0.9 — unidentifiable)
dplyr,computational_tools,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,dplyr,Package/Library,,,,,,,,,,,,,,,,"Key packages used include synapser [ 24 ], tidyverse [ 25 ], dplyr [ 26 ], WGCNA [ 27 ]",No version and no repository URL (confidence < 0.9 — unidentifiable)
WGCNA,computational_tools,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,WGCNA,Package/Library,,,,,,,,,,,,,,,,"Key packages used include synapser [ 24 ], tidyverse [ 25 ], dplyr [ 26 ], WGCNA [ 27 ]",Software name not in publication title — likely generic usage: WGCNA
ggplot2,computational_tools,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ggplot2,Package/Library,,,,,,,,,,,,,,,,"Key packages used include synapser [ 24 ], tidyverse [ 25 ], dplyr [ 26 ], WGCNA [ 27 ], ggplot2 [ 28 ]",Generic bioinformatics/stats tool: ggplot2
enrichplot,computational_tools,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,enrichplot,Package/Library,,,,,,,,,,,,,,,,"Key packages used include synapser [ 24 ], tidyverse [ 25 ], dplyr [ 26 ], WGCNA [ 27 ], ggplot2 [ 28 ], enrichplot [ 29 ]",No version and no repository URL (confidence < 0.9 — unidentifiable)
ConsensusClusterPlus,computational_tools,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ConsensusClusterPlus,Package/Library,,,,,,,,,,,,,,,,"Key packages used include synapser [ 24 ], tidyverse [ 25 ], dplyr [ 26 ], WGCNA [ 27 ], ggplot2 [ 28 ], enrichplot [ 29 ], and ConsensusClusterPlus [ 30 ]",Software name not in publication title — likely generic usage: ConsensusClusterPlus
Mechanism Interrogation PlatE (MIPE 4.0) library,computational_tools,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Mechanism Interrogation PlatE (MIPE 4.0) library,Database,,,,,,,,,,,,,,,,The drug screening data were contributed by Ferrer et al. using the Mechanism Interrogation PlatE (MIPE 4.0) library [ 6 ],Software name not in publication title — likely generic usage: Mechanism Interrogation PlatE (MIPE 4.0) library
ChEMBL database,computational_tools,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ChEMBL database,Database,,,,,,,,,,,,,,,,"We queried drug information from the ChEMBL database, a manually curated database of bioactive molecules maintained by the European Bioinformatics Institute",No version and no repository URL (confidence < 0.9 — unidentifiable)
IDAPredict.2drug function package,computational_tools,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,IDAPredict.2drug function package,Package/Library,,,,,,,,,,,,,,,,IDAPredict.2drug function package was used to predict the drug combination between DrugCluster pairs [ 23 ],Software name not in publication title — likely generic usage: IDAPredict.2drug function package
SkinAid cloud software,computational_tools,PMID:41598414,10.3390/jcm15020475,Dermoscopy-Guided High-Frequency Ultrasound Imaging of Subcentimeter Cutaneous and Subcutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SkinAid cloud software,Analysis Software,,,,,,,,,,,,,,,,"Recorded images were analyzed in SkinAid cloud software, stored under patient ID with demographic and lesion details",No version and no repository URL (confidence < 0.9 — unidentifiable)
Zeiss LSM 410,computational_tools,PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Zeiss LSM 410,Other,,,,,,,,,,,,,,,,Confocal images were taken on either a Zeiss LSM 410 or LSM 510 microscope,No version and no repository URL (confidence < 0.9 — unidentifiable)
Zeiss LSM 510,computational_tools,PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Zeiss LSM 510,Other,,,,,,,,,,,,,,,,Confocal images were taken on either a Zeiss LSM 410 or LSM 510 microscope,No version and no repository URL (confidence < 0.9 — unidentifiable)
Zeiss Axioplan 2ie compound microscope,computational_tools,PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Zeiss Axioplan 2ie compound microscope,Other,,,,,,,,,,,,,,,,Wings were imaged under brightfield optics on a Zeiss Axioplan 2ie compound microscope,No version and no repository URL (confidence < 0.9 — unidentifiable)
LightCycler FastStart SYBR green system,computational_tools,PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LightCycler FastStart SYBR green system,Other,,,,,,,,,,,,,,,,quantitative PCR performed using the LightCycler FastStart SYBR green system (Roche),No version and no repository URL (confidence < 0.9 — unidentifiable)
Barocycler NEP 2320,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Barocycler NEP 2320,Other,,,,,,,,,,,,,,,,"...Pressure-based cell lysis was performed for 60 cycles of 50 s at 30 °C and 310 MPa using the Barocycler NEP 2320 instrument (Pressure BioSciences, Easton, MA, USA)...",Software name not in publication title — likely generic usage: Barocycler NEP 2320
Easy-nLC 1200,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Easy-nLC 1200,Other,,,,,,,,,,,,,,,,"...A nanoflow high-performance liquid chromatography system Easy-nLC 1200 coupled to the Q Exactive HF mass spectrometer (Thermo Fisher Scientific, Bremen, Germany)...",Software name not in publication title — likely generic usage: Easy-nLC 1200
Q Exactive HF mass spectrometer,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Q Exactive HF mass spectrometer,Other,,,,,,,,,,,,,,,,"...Easy-nLC 1200 coupled to the Q Exactive HF mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) equipped with a nano-electrospray ionization source...",Software name not in publication title — likely generic usage: Q Exactive HF mass spectrometer
Thermo Xcalibur 4.1,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Thermo Xcalibur 4.1,Analysis Software,4.1,,,,,,,,,,,,,,,...The data were acquired automatically using Thermo Xcalibur 4.1 software (Thermo Fisher Scientific) and processed with the Spectronaut Pulsar software...,Software name not in publication title — likely generic usage: Thermo Xcalibur 4.1
Spectronaut Pulsar,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Spectronaut Pulsar,Analysis Software,,,,,,,,,,,,,,,,"...processed with the Spectronaut Pulsar software (Biognosys, Schlieren, Switzerland). Pulsar is a search engine, integrated into Spectronaut for spectral library generation...",Software name not in publication title — likely generic usage: Spectronaut Pulsar
BenchMark Ultra system,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BenchMark Ultra system,Other,,,,,,,,,,,,,,,,...The Ki67 immunohistochemistry was performed using the BenchMark Ultra system (Roche)...,Software name not in publication title — likely generic usage: BenchMark Ultra system
NanoZoomer S60 digital slide scanner,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NanoZoomer S60 digital slide scanner,Other,,,,,,,,,,,,,,,,"...imaged using the NanoZoomer S60 digital slide scanner (Hamamatsu, Hamamatsu City, Japan)...",Software name not in publication title — likely generic usage: NanoZoomer S60 digital slide scanner
Pannoramic Midi FL slide scanner,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Pannoramic Midi FL slide scanner,Other,,,,,,,,,,,,,,,,"...and Pannoramic Midi FL slide scanner (3DHistech Ltd, Budapest, Hungary)...",Software name not in publication title — likely generic usage: Pannoramic Midi FL slide scanner
R software version 4.0.0,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R software version 4.0.0,Analysis Software,4.0.0,,,,,,,,,,,,,,,"...All analyses were performed using the R software for statistical computing, version 4.0.0, and package lmerTest, version 3.1-2...",Software name not in publication title — likely generic usage: R software version 4.0.0
lmerTest package version 3.1-2,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,lmerTest package version 3.1-2,Package/Library,3.1-2,,,,,,,,,,,,,,,"...using the R software for statistical computing, version 4.0.0, and package lmerTest, version 3.1-2...",Software name not in publication title — likely generic usage: lmerTest package version 3.1-2
ABI PRISM 7900 Cycler,computational_tools,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,ABI PRISM 7900 Cycler,Analysis Software,,,,,,,,,,,,,,,,TaqMan Universal PCR Master Mix was then performed on an ABI PRISM 7900 Cycler (Applied Biosystems),No version and no repository URL (confidence < 0.9 — unidentifiable)
AxioVision 4.1 software,computational_tools,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,AxioVision 4.1 software,Analysis Software,4.1,,,,,,,,,,,,,,,"Images were collected using a DMR HC microscope...and evaluated using AxioVision 4.1 software (Zeiss, Jena, Germany)",Software name not in publication title — likely generic usage: AxioVision 4.1 software
analySIS 5.0 software,computational_tools,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,analySIS 5.0 software,Analysis Software,5.0,,,,,,,,,,,,,,,"Stained sections were analyzed using the BX51 microscope...and analySIS 5.0 software (Soft imaging system GmbH, Münster, Germany)",Software name not in publication title — likely generic usage: analySIS 5.0 software
Affymetrix Mouse Genome 430 2.0 GeneChip,computational_tools,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Affymetrix Mouse Genome 430 2.0 GeneChip,Analysis Software,,,,,,,,,,,,,,,,Target preparation and microarray hybridization were performed by the Siteman Cancer Center Multiplex Gene Analysis Core Facility using Affymetrix Mouse Genome 430 2.0 GeneChip microarrays,No version and no repository URL (confidence < 0.9 — unidentifiable)
Spotfire DecisionSite for Functional Genomics,computational_tools,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Spotfire DecisionSite for Functional Genomics,Analysis Software,,,,,,,,,,,,,,,,"Statistical significance was determined with Student's t test using Spotfire DecisionSite for Functional Genomics (TIBCO Spotfire, Somerville, MA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
MetaMorph,computational_tools,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MetaMorph,Analysis Software,,,,,,,,,,,,,,,,"For NG2 immunofluorescence staining, the pixel intensity was determined using image analysis software MetaMorph (Molecular Devices, Downingtown, PA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Gel-Pro Analyzer 4.0,computational_tools,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Gel-Pro Analyzer 4.0,Analysis Software,4.0,,,,,,,,,,,,,,,"α-tubulin (Sigma, St. Louis, MO) was employed for normalization and densitometric analysis using Gel-Pro Analyzer 4.0 (Media Cybernetics, Bethesda, MD)",Software name not in publication title — likely generic usage: Gel-Pro Analyzer 4.0
GraphPad Prism 4.0,computational_tools,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism 4.0,Analysis Software,4.0,,,,,,,,,,,,,,,"Statistical analyses were performed using GraphPad Prism 4.0 software (GraphPad, La Jolla, CA)",Generic tool (versioned): GraphPad Prism 4.0
MiSeq sequencing platform,computational_tools,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MiSeq sequencing platform,Analysis Software,,,,,,,,,,,,,,,,"Target sequencing was performed using the Haloplex custom target enrichment system (Agilent Technologies, CA, USA) on the MiSeq sequencing platform",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
NextGENe software v.2.3.4.1,computational_tools,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,NextGENe software v.2.3.4.1,Analysis Software,v.2.3.4.1,,,,,,,,,,,,,,,"The data were analysed using NextGENe software v.2.3.4.1 (Softgenetics, PA, USA) with the default settings",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
ImageJ software,computational_tools,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ software,Analysis Software,,,,,,,,,,,,,,,,The width and length of the cranio-cartilage were measured using ImageJ software,Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
g:Profiler,computational_tools,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,g:Profiler,Web Application,,,,,,,,,,,,,,,,GO analysis was performed using g:Profiler,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
BioVenn,computational_tools,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BioVenn,Web Application,,,,,,,,,,,,,,,,Venn diagrams were generated using BioVenn,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
PathVisio software,computational_tools,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PathVisio software,Analysis Software,,,,,,,,,,,,,,,,Proximity maps were generated using PathVisio software,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
"Alamut Visual Plus, version 1.5.1",computational_tools,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"Alamut Visual Plus, version 1.5.1",Analysis Software,1.5.1,,,,,,,,,,,,,,,"Splice site prediction software (Alamut Visual Plus, version 1.5.1; Sophia Genetics) was used to identify variants likely to affect pre-mRNA splicing","Software name not in publication title — likely generic usage: Alamut Visual Plus, version 1.5.1"
"cesium-137 source (J.L. Shepherd & Associates, San Fernando, CA)",computational_tools,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"cesium-137 source (J.L. Shepherd & Associates, San Fernando, CA)",Other,,,,,,,,,,,,,,,,"Mice were placed 16.3 cm from a cesium-137 source (J.L. Shepherd & Associates, San Fernando, CA) and shielded with an iron collimator",No version and no repository URL (confidence < 0.9 — unidentifiable)
Hemavet,computational_tools,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Hemavet,Analysis Software,,,,,,,,,,,,,,,,Complete blood counts were performed on blood samples obtained at the time of sacrifice by cardiac puncture and analyzed immediately on a Hemavet provided by the UCSF Mouse Pathology Core.,No version and no repository URL (confidence < 0.9 — unidentifiable)
"Openlab (Improvision, Waltham, MA)",computational_tools,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"Openlab (Improvision, Waltham, MA)",Analysis Software,,,,,,,,,,,,,,,,"Images were captured and merged using Openlab (Improvision, Waltham, MA).",No version and no repository URL (confidence < 0.9 — unidentifiable)
Peak Scanner software from Applied Biosystems,computational_tools,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Peak Scanner software from Applied Biosystems,Analysis Software,,,,,,,,,,,,,,,,PCR fragment analyses were performed by the UCSF Genome Core using Peak Scanner software from Applied Biosystems.,No version and no repository URL (confidence < 0.9 — unidentifiable)
Zeiss LSM 510 Meta confocal microscope,computational_tools,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Zeiss LSM 510 Meta confocal microscope,Other,,,,,,,,,,,,,,,,"Coverslips were mounted using Vectashield with DAPI (Vector Laboratories), and visualized with a Zeiss LSM 510 Meta confocal microscope.",No version and no repository URL (confidence < 0.9 — unidentifiable)
R 2.7.0,computational_tools,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R 2.7.0,Analysis Software,2.7.0,,,,,,,,,,,,,,,All analyses were performed on R 2.7.0.,Software name not in publication title — likely generic usage: R 2.7.0
Stepone Plus Real-Time PCR System,computational_tools,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Stepone Plus Real-Time PCR System,Analysis Software,,,,,,,,,,,,,,,,Amplifications were run in a Stepone Plus Real-Time PCR System (Applied Biosystems),No version and no repository URL (confidence < 0.9 — unidentifiable)
Axio Vision Rel. 4.8 software,computational_tools,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Axio Vision Rel. 4.8 software,Analysis Software,4.8,,,,,,,,,,,,,,,Images were captured and analyzed using Axio Vision Rel. 4.8 software (Carl Zeiss MicroImaging),Software name not in publication title — likely generic usage: Axio Vision Rel. 4.8 software
Graphpad Prism 6,computational_tools,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Graphpad Prism 6,Analysis Software,6,,,,,,,,,,,,,,,Statistical significance was determined by ANOVA followed by Bonferroni's posthoc test for multiple comparisons and student's t-test for two groups using Graphpad Prism 6 software,Generic tool (versioned): Graphpad Prism 6
piXarray 100 DSR System,computational_tools,PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,piXarray 100 DSR System,Analysis Software,1.0.6,,,,,,,,,,,,,,,"X-rays were taken using a piXarray 100 DSR System with Biopix Software (Version No: 1.0.6., Bioptics, Inc. Tucson, AZ)",Software name not in publication title — likely generic usage: piXarray 100 DSR System
PIXImus II,computational_tools,PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PIXImus II,Analysis Software,,,,,,,,,,,,,,,,"bone mineral density (BMD) of the axial bone was evaluated in vivo using pDEXA (PIXImus II; GE-Lunar Corp., Madison, WI)",No version and no repository URL (confidence < 0.9 — unidentifiable)
XCT Research SA + peripheral quantitative computed tomography (pQCT) scanner,computational_tools,PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,XCT Research SA + peripheral quantitative computed tomography (pQCT) scanner,Analysis Software,5.50,,,,,,,,,,,,,,,"Whole axial bone was placed in the gantry of a XCT Research SA + peripheral quantitative computed tomography (pQCT) scanner (Stratec Medizintechnik GmbH, Pforzheim, Germany) with Software Version 5.50",Software name not in publication title — likely generic usage: XCT Research SA + peripheral quantitative computed tomography (pQCT) scanner
MtestwR software,computational_tools,PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,MtestwR software,Analysis Software,R 1.4.2,,,,,,,,,,,,,,,"biomechanical testing was conducted utilizing Testresouse R systems with MtestwR software version: R 1.4.2 (TestResources Inc. Shakopee, MN)",Software name not in publication title — likely generic usage: MtestwR software
FMRIB software library (FSL),computational_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FMRIB software library (FSL),Analysis Software,5.0,,,,,,,,,,,,,,,"fMRI data analyses were performed using tools from the FMRIB software library ( www.fmrib.ox.ac.uk/fsl ), version 5.0",Software name not in publication title — likely generic usage: FMRIB software library (FSL)
MATLAB,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MATLAB,Analysis Software,2016b,,,,,,,,,,,,,,,"using in-house software running in MATLAB (MathWorks, Natick, MA, version 2016b)",Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
Burrows–Wheeler Aligner,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Burrows–Wheeler Aligner,Analysis Software,0.7.8,,,,,,,,,,,,,,,Burrows–Wheeler Aligner (version 0.7.8) was utilized to map the paired-end clean reads,Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
SAMtools,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SAMtools,Analysis Software,1.0,,,,,,,,,,,,,,,SAMtools (version 1.0) is used for sorting the BAM file,Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
GATK,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GATK,Analysis Software,3.8,,,,,,,,,,,,,,,Single-nucleotide variant is then identified using GATK (version 3.8),Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
ANNOVAR,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ANNOVAR,Analysis Software,2015Dec,,,,,,,,,,,,,,,subsequently annotated using ANNOVAR (version 2015Dec),Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
control-FREEC,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,control-FREEC,Analysis Software,9.9,,,,,,,,,,,,,,,CNV is detected by control-FREEC (version 9.9),Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
FlowJo,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FlowJo,Analysis Software,,,,,,,,,,,,,,,,acquired using BD FACS Canto II and further analyzed by FlowJo software,Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
ImageJ,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,chromosome number was counted using ImageJ software,Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
RStudio,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,RStudio,Analysis Software,1.2.5033,,,,,,,,,,,,,,,We developed R codes and used RStudio (version 1.2.5033),Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
APE,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,APE,Package/Library,5.2,,,,,,,,,,,,,,,"R package ""Analyses of Phylogenetics and Evolution"" (APE, version 5.2)",Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
MEGAX,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MEGAX,Analysis Software,0.1,,,,,,,,,,,,,,,"MEGAX (version 0.1, for MAC) to generate SKY-based phylogenetic trees",Publication title lacks NF-specific terms: Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor
ImageJ,computational_tools,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ,Analysis Software,1.51j8,,,,,,,,,,,,,,,organoid sizes were measured (12 organoids per line) using ImageJ software (version 1.51j8),Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
DESeq2,computational_tools,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DESeq2,Package/Library,v1.18.0,,,,,,,,,,,,,,,DESeq2 (v1.18.0) package was used to normalize count data and for differential gene expression analysis,Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
GSEA,computational_tools,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GSEA,Analysis Software,v3.0 beta2,,,,,,,,,,,,,,,Gene set enrichment analysis (GSEA) was performed using GSEA software v3.0 beta2,Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
XenoBase version 3.5,computational_tools,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,XenoBase version 3.5,Analysis Software,3.5,,,,,,,,,,,,,,,Heat maps were generated using XenoBase® version 3.5 from Affymetrix array data using MAS 5.0 normalization,Software name not in publication title — likely generic usage: XenoBase version 3.5
Affymetrix Expression Console MAS 5.0,computational_tools,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Affymetrix Expression Console MAS 5.0,Analysis Software,MAS 5.0,,,,,,,,,,,,,,,Microarray data was analyzed using Affymetrix expression console MAS 5.0 method,Software name not in publication title — likely generic usage: Affymetrix Expression Console MAS 5.0
StepOne Software v2.3,computational_tools,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,StepOne Software v2.3,Analysis Software,v2.3,,,,,,,,,,,,,,,using StepOne Software v2.3 (Applied Biosystems) standard parameters,Software name not in publication title — likely generic usage: StepOne Software v2.3
Gene Targeted Therapy Map,computational_tools,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Gene Targeted Therapy Map,Database,,,,,,,,,,,,,,,,gene list with significant expression deviation from the reference set are supplied directly to the Gene Targeted Therapy Map,No version and no repository URL (confidence < 0.9 — unidentifiable)
PGSEA,computational_tools,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PGSEA,Analysis Software,,,,,,,,,,,,,,,,"Z-score expression values were also supplied to two drug response pattern evaluation methods, PGSEA and CMAP",No version and no repository URL (confidence < 0.9 — unidentifiable)
CMAP,computational_tools,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CMAP,Analysis Software,,,,,,,,,,,,,,,,"Z-score expression values were also supplied to two drug response pattern evaluation methods, PGSEA and CMAP",No version and no repository URL (confidence < 0.9 — unidentifiable)
FSL version 5.0.7,computational_tools,PMID:32642741,10.1093/noajnl/vdaa037,Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FSL version 5.0.7,Analysis Software,5.0.7,,,,,,,,,,,,,,,"Postprocessing DTI analysis was performed using a previously described method for automated probabilistic tractography of the optic radiations. Briefly, using FSL version 5.0.7 (FMRIB)",Software name not in publication title — likely generic usage: FSL version 5.0.7
PROBTRACKX,computational_tools,PMID:32642741,10.1093/noajnl/vdaa037,Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PROBTRACKX,Analysis Software,,,,,,,,,,,,,,,,Probabilistic streamline fiber tracking (PROBTRACKX) was used with 1000 starting points seeded in each voxel of the lateral geniculate nucleus,No version and no repository URL (confidence < 0.9 — unidentifiable)
Tract-Based Spatial Statistics (TBSS),computational_tools,PMID:32642741,10.1093/noajnl/vdaa037,Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Tract-Based Spatial Statistics (TBSS),Analysis Software,,,,,,,,,,,,,,,,Voxelwise statistical analysis of FA data was accomplished using Tract-Based Spatial Statistics (TBSS) in all participants adjusting for the natural logarithm of age,No version and no repository URL (confidence < 0.9 — unidentifiable)
Montreal Neurologic Institute 152 T1 map,computational_tools,PMID:32642741,10.1093/noajnl/vdaa037,Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Montreal Neurologic Institute 152 T1 map,Database,,,,,,,,,,,,,,,,b = 0 maps were registered to a standard space (Montreal Neurologic Institute 152 T1 map with 2 mm slice thickness),No version and no repository URL (confidence < 0.9 — unidentifiable)
"iPlan Net software (Brainlab, Feldkirchen, Germany)",computational_tools,PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"iPlan Net software (Brainlab, Feldkirchen, Germany)",Analysis Software,,,,,,,,,,,,,,,,"postcontrast thin-sliced (≤ 3 mm) T1-weighted magnetic resonance (MR) sequences were uploaded into the iPlan Net software (Brainlab, Feldkirchen, Germany), and volumes were measured manually or in combination with semiautomated segmentation","Software name not in publication title — likely generic usage: iPlan Net software (Brainlab, Feldkirchen, Germany)"
"Statistical Package for Social Studies (SPSS 10.0 for Windows, SPSS Inc.)",computational_tools,PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,"Statistical Package for Social Studies (SPSS 10.0 for Windows, SPSS Inc.)",Analysis Software,10.0,,,,,,,,,,,,,,,"Statistical evaluation was performed using the Statistical Package for Social Studies (SPSS 10.0 for Windows, SPSS Inc.)","Software name not in publication title — likely generic usage: Statistical Package for Social Studies (SPSS 10.0 for Windows, SPSS Inc.)"
Abi Prism 3700,computational_tools,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Abi Prism 3700,Analysis Software,,,,,,,,,,,,,,,,"directly sequenced through Sanger (Abi Prism 3700, ThermoFisher Scientific, Watham, MA, USA)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
MiniSeq apparatus,computational_tools,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MiniSeq apparatus,Analysis Software,,,,,,,,,,,,,,,,"libraries were run on a MiniSeq apparatus (Illumina, San Diego, CA, USA)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
Human Splicing Finder (HSF) Version 2.4.1,computational_tools,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Human Splicing Finder (HSF) Version 2.4.1,Web Application,2.4.1,,,,,,,,,,,,,,,Human Splicing Finder (HSF) Version 2.4.1 ( http://www.umd.be/HSF/ Assessing on 21 December 2020),Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
Mutation taster,computational_tools,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Mutation taster,Web Application,,,,,,,,,,,,,,,,Mutation taster ( http://www.mutationtaster.org/ Assessing on 21 December 2020),Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
Combined Annotation Dependent Depletion (CADD) v1.6,computational_tools,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Combined Annotation Dependent Depletion (CADD) v1.6,Web Application,v1.6,,,,,,,,,,,,,,,Combined Annotation Dependent Depletion (CADD) v1.6 ( https://cadd.gs.washington.edu/ Assessing on 21 December 2020),Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
Multalin,computational_tools,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Multalin,Web Application,,,,,,,,,,,,,,,,Protein sequence alignments were performed using Multalin ( http://multalin.toulouse.inra.fr/multalin/ Assessing on 28 December 2020),Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
ImageJ,computational_tools,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,Densitometric analyses were performed using the ImageJ (Image Processing and analysis in Java) software,Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
CRISPOR,computational_tools,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CRISPOR,Web Application,,,,,,,,,,,,,,,,"Target sites within the genes of interest were selected using Massachusetts Institute of Technology's CRISPR design tool (now unavailable, previously: crispr.mit.edu, ), or later, CRISPOR",Software name not in publication title — likely generic usage: CRISPOR
CRISPResso,computational_tools,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CRISPResso,Analysis Software,,,,,,,,,,,,,,,,Sequencing data were demultiplexed and analyzed using CRISPResso or CRISPResso2,No version and no repository URL (confidence < 0.9 — unidentifiable)
CRISPResso2,computational_tools,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CRISPResso2,Analysis Software,,,,,,,,,,,,,,,,Sequencing data were demultiplexed and analyzed using CRISPResso or CRISPResso2,No version and no repository URL (confidence < 0.9 — unidentifiable)
JMP Pro 15.0.0,computational_tools,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,JMP Pro 15.0.0,Analysis Software,15.0.0,,,,,,,,,,,,,,,"Logistic regressions were performed in JMP (JMP Pro 15.0.0, SAS Institute Inc., Cary, NC)",Software name not in publication title — likely generic usage: JMP Pro 15.0.0
CRISPRscan,computational_tools,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CRISPRscan,Analysis Software,,,,,,,,,,,,,,,,we used CRISPRscan to identify 3–6 gRNAs that target the gene of interest,Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
Cell Ranger,computational_tools,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Cell Ranger,Analysis Software,,,,,,,,,,,,,,,,the authors used Cell Ranger from 10x Genomics to map zebrafish reads from scRNAseq to the genome,Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
Seurat,computational_tools,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Seurat,Package/Library,,,,,,,,,,,,,,,,Variable genes were identified and clustered with K-nearest neighbors and shared nearest neighbor modularity optimization through Seurat,Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
UN-SCAN-IT gel 6.1,computational_tools,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,UN-SCAN-IT gel 6.1,Analysis Software,6.1,,,,,,,,,,,,,,,band intensities were quantified using UN-SCAN-IT gel 6.1 software,Software name not in publication title — likely generic usage: UN-SCAN-IT gel 6.1
Olympus CellSens dimension,computational_tools,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Olympus CellSens dimension,Analysis Software,,,,,,,,,,,,,,,,"The software used was Olympus CellSens dimension, which is able to do deconvolution on captured z stacks",No version and no repository URL (confidence < 0.9 — unidentifiable)
EasyRatioPro imaging software,computational_tools,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,EasyRatioPro imaging software,Analysis Software,,,,,,,,,,,,,,,,"imaged using a 40X/1.4 NA objective and EasyRatioPro imaging software (PTI, NJ, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
STAR,computational_tools,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR,Analysis Software,v. 2.5.2a,,,,,,,,,,,,,,,"Sequence reads were aligned to human reference genome Ensembl GRCh37 (v.75), using STAR (v. 2.5.2a)",Generic bioinformatics/stats tool: STAR
edgeR,computational_tools,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,edgeR,Package/Library,v. 3.18.1,,,,,,,,,,,,,,,Differentially expressed genes in pair-wise comparisons were identified by edgeR's quasi-likelihood F test (v. 3.18.1),Generic bioinformatics/stats tool: edgeR
fastQC,computational_tools,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,fastQC,Analysis Software,v.0.10.1,,,,,,,,,,,,,,,Quality checking of sequence reads was assessed by fastQC (v.0.10.1),Generic bioinformatics/stats tool: fastQC
SynergyFinder,computational_tools,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SynergyFinder,Web Application,,https://synergyfinder.fimm.fi/,,,,,,,,,,,,,,Synergy scores were generated using the web-based SynergyFinder application (https://synergyfinder.fimm.fi/),Software name not in publication title — likely generic usage: SynergyFinder
GraphPad Prism 8,computational_tools,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism 8,Analysis Software,8,,,,,,,,,,,,,,,Column scatter plots were generated using Graphpad Prism 8,Generic bioinformatics/stats tool: GraphPad Prism 8
QuantStudio 3 Real-Time PCR System,computational_tools,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,QuantStudio 3 Real-Time PCR System,Analysis Software,,,,,,,,,,,,,,,,reactions were performed using the QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific),No version and no repository URL (confidence < 0.9 — unidentifiable)
ImageJ Cell Counter extension,computational_tools,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ Cell Counter extension,Plugin,,,,,,,,,,,,,,,,The target cell type was counted using the ImageJ Cell Counter extension (NIH),Generic tool (versioned): ImageJ Cell Counter extension
GraphPad Prism 7,computational_tools,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism 7,Analysis Software,7,,,,,,,,,,,,,,,Statistical analysis was performed using GraphPad Prism 7 and R version 3.5.1.,Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
R version 3.5.1,computational_tools,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R version 3.5.1,Analysis Software,3.5.1,,,,,,,,,,,,,,,Statistical analysis was performed using GraphPad Prism 7 and R version 3.5.1.,Publication title lacks NF-specific terms: Disruption of a self-amplifying catecholamine loop reduces cytokine release synd
SAS version 9.4,computational_tools,PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SAS version 9.4,Analysis Software,9.4,,,,,,,,,,,,,,,"Statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and R version 3.5.0",Generic tool (versioned): SAS version 9.4
R version 3.5.0,computational_tools,PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R version 3.5.0,Analysis Software,3.5.0,,,,,,,,,,,,,,,"Statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and R version 3.5.0",Generic tool (versioned): R version 3.5.0
ImageJ,computational_tools,PMID:34945792,10.3390/jpm11121320,Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,The images were then subject to densitometric analysis using ImageJ software.,Generic bioinformatics/stats tool: ImageJ
GraphPad Prism,computational_tools,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism,Analysis Software,9.0,,,,,,,,,,,,,,,IC50 values were calculated by nonlinear regression analysis using GraphPad Prism 9.0 software (RRID: SCR_002798),Generic bioinformatics/stats tool: GraphPad Prism
Combenefit platform,computational_tools,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Combenefit platform,Analysis Software,,,,,,,,,,,,,,,,The Bliss synergy scores were calculated using the Combenefit platform as previously described,No version and no repository URL (confidence < 0.9 — unidentifiable)
Image Studio Lite software,computational_tools,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Image Studio Lite software,Analysis Software,,,,,,,,,,,,,,,,Band intensity quantifications were done using Image Studio Lite software (RRID: SCR_013715),Software name not in publication title — likely generic usage: Image Studio Lite software
NCBI Primer-BLAST tool,computational_tools,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NCBI Primer-BLAST tool,Web Application,,,,,,,,,,,,,,,,Primers were designed using the online NCBI Primer-BLAST tool (RRID: SCR_003095),No version and no repository URL (confidence < 0.9 — unidentifiable)
3D U-Net,computational_tools,PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,3D U-Net,Analysis Software,,,,,,,,,,,,,,,,The structure of DINs follows the encoder-decoder scheme with skip connection like 3D U-Net. But 3D U-Net is originally evaluated to segment organs with fixed size and balance pixel spacing,No version and no repository URL (confidence < 0.9 — unidentifiable)
nnU-Net,computational_tools,PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,nnU-Net,Analysis Software,,,,,,,,,,,,,,,,DINs outperform automated methods by 44%–63% and outperform 'nnU-Net + Dim output 1' by 29%. The comparison between 'nnU-Net + Dim output 1' and 'DINs (DIM output 1)' indicates,No version and no repository URL (confidence < 0.9 — unidentifiable)
3DQI software,computational_tools,PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,3DQI software,Analysis Software,,,,,,,,,,,,,,,,Cai et al. perform volume measurements on the LRMRI data set using 3DQI software at Massachusetts General Hospital (MGH) and National Cancer Institute (NCI),Software name not in publication title — likely generic usage: 3DQI software
MEDx software,computational_tools,PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MEDx software,Analysis Software,,,,,,,,,,,,,,,,Cai et al. perform volume measurements on the LRMRI data set using 3DQI software at Massachusetts General Hospital (MGH) and National Cancer Institute (NCI) and MEDx software at NCI,Software name not in publication title — likely generic usage: MEDx software
Random Walk (RW),computational_tools,PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Random Walk (RW),Analysis Software,,,,,,,,,,,,,,,,"We compare DINs with some conventional interactive segmentation methods, including Random Walk (RW), Graph Cut (GC) and Active Contour (AC)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Graph Cut (GC),computational_tools,PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Graph Cut (GC),Analysis Software,,,,,,,,,,,,,,,,"We compare DINs with some conventional interactive segmentation methods, including Random Walk (RW), Graph Cut (GC) and Active Contour (AC)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Active Contour (AC),computational_tools,PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Active Contour (AC),Analysis Software,,,,,,,,,,,,,,,,"We compare DINs with some conventional interactive segmentation methods, including Random Walk (RW), Graph Cut (GC) and Active Contour (AC)",No version and no repository URL (confidence < 0.9 — unidentifiable)
CellTiter‐Glo assay (Promega; G7570),computational_tools,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CellTiter‐Glo assay (Promega; G7570),Other,,,,,,,,,,,,,,,,The CellTiter‐Glo assay (Promega; G7570) is a luminescent viability assay,No version and no repository URL (confidence < 0.9 — unidentifiable)
autophagy assay kit (Abcam; ab139484),computational_tools,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,autophagy assay kit (Abcam; ab139484),Other,,,,,,,,,,,,,,,,An autophagy assay kit (Abcam; ab139484) was used to measure autophagic vacuoles,No version and no repository URL (confidence < 0.9 — unidentifiable)
Annexin V‐FITC apoptosis kit (Abcam; ab14085),computational_tools,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Annexin V‐FITC apoptosis kit (Abcam; ab14085),Other,,,,,,,,,,,,,,,,The Annexin V‐FITC apoptosis kit (Abcam; ab14085) was used to detect apoptosis,No version and no repository URL (confidence < 0.9 — unidentifiable)
generic caspase activity assay kit (Abcam; ab112130),computational_tools,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,generic caspase activity assay kit (Abcam; ab112130),Other,,,,,,,,,,,,,,,,Caspase activity was assessed using the generic caspase activity assay kit (Abcam; ab112130),No version and no repository URL (confidence < 0.9 — unidentifiable)
Olympus BX61 upright light microscope,computational_tools,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Olympus BX61 upright light microscope,Analysis Software,,,,,,,,,,,,,,,,Sections were viewed and imaged using an Olympus BX61 upright light microscope and Q imaging Retiga Exi camera with InVivo 3.2.0 software,No version and no repository URL (confidence < 0.9 — unidentifiable)
Q imaging Retiga Exi camera,computational_tools,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Q imaging Retiga Exi camera,Analysis Software,,,,,,,,,,,,,,,,Sections were viewed and imaged using an Olympus BX61 upright light microscope and Q imaging Retiga Exi camera with InVivo 3.2.0 software,No version and no repository URL (confidence < 0.9 — unidentifiable)
InVivo 3.2.0 software,computational_tools,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,InVivo 3.2.0 software,Analysis Software,3.2.0,,,,,,,,,,,,,,,Sections were viewed and imaged using an Olympus BX61 upright light microscope and Q imaging Retiga Exi camera with InVivo 3.2.0 software (Media Cybernetics),Software name not in publication title — likely generic usage: InVivo 3.2.0 software
Image-Pro Plus software,computational_tools,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Image-Pro Plus software,Analysis Software,,,,,,,,,,,,,,,,Computerized quantitative morphometric analysis was performed using Image-Pro Plus software (Media Cybernetics),Software name not in publication title — likely generic usage: Image-Pro Plus software
"Image J1.45s, version 1.44p",computational_tools,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"Image J1.45s, version 1.44p",Analysis Software,1.44p,,,,,,,,,,,,,,,"The width and equatorial length of the testes were measured on testicular histological images using Image J1.45s, version 1.44p (NIH, Bethesda, MD)","Generic tool (versioned): Image J1.45s, version 1.44p"
GraphPad 5 Prism software,computational_tools,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad 5 Prism software,Analysis Software,5,,,,,,,,,,,,,,,"Differences between Nf1+/- and Nf1+/+ groups were analyzed by 2-tailed Student's t tests and were graphed using GraphPad 5 Prism software (San Diego, Calif., USA)",Software name not in publication title — likely generic usage: GraphPad 5 Prism software
REDCap,computational_tools,PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,REDCap,Web Application,,,,,,,,,,,,,,,,"Surveys were created in REDCap, a secure web-based data capture tool",Software name not in publication title — likely generic usage: REDCap
Weighted Kappa statistic,computational_tools,PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Weighted Kappa statistic,Analysis Software,,,,,,,,,,,,,,,,Weighted Kappa statistic was used to measure the agreement of adolescents and caregiver responses,No version and no repository URL (confidence < 0.9 — unidentifiable)
"IBM SPSS for Windows, version 28",computational_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"IBM SPSS for Windows, version 28",Analysis Software,version 28,,,,,,,,,,,,,,,"The data were analyzed using IBM SPSS for Windows, version 28","Software name not in publication title — likely generic usage: IBM SPSS for Windows, version 28"
GPower 3.1,computational_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GPower 3.1,Analysis Software,3.1,,,,,,,,,,,,,,,A post-hoc power analysis was conducted using GPower 3.1 (n = 19),Software name not in publication title — likely generic usage: GPower 3.1
Burrows-Wheeler Aligner,computational_tools,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Burrows-Wheeler Aligner,Analysis Software,,,,,,,,,,,,,,,,Burrows-Wheeler Aligner was used to map the paired-end clean reads to the human reference genome (GRCh37/hg19),No version and no repository URL (confidence < 0.9 — unidentifiable)
SAMtools,computational_tools,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SAMtools,Analysis Software,,,,,,,,,,,,,,,,After sorting with SAMtools and marking duplicates with the Broad Picard,Generic bioinformatics/stats tool: SAMtools
GATK,computational_tools,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GATK,Analysis Software,,,,,,,,,,,,,,,,Aligned reads were further processed using GATK to remove low mapping quality reads,Generic bioinformatics/stats tool: GATK
VarScan2,computational_tools,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VarScan2,Analysis Software,,,,,,,,,,,,,,,,Somatic SNVs and indels were identified in tumors with matched normal samples by integrating the results from five algorithms for variant calling: VarScan2,Generic bioinformatics/stats tool: VarScan2
Freebayes,computational_tools,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Freebayes,Analysis Software,,,,,,,,,,,,,,,,"integrating the results from five algorithms for variant calling: VarScan2, Freebayes, Strelka, MuTect, and VarDict",No version and no repository URL (confidence < 0.9 — unidentifiable)
Strelka,computational_tools,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Strelka,Analysis Software,,,,,,,,,,,,,,,,"integrating the results from five algorithms for variant calling: VarScan2, Freebayes, Strelka, MuTect, and VarDict",Generic bioinformatics/stats tool: Strelka
MuTect,computational_tools,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MuTect,Analysis Software,,,,,,,,,,,,,,,,"integrating the results from five algorithms for variant calling: VarScan2, Freebayes, Strelka, MuTect, and VarDict",Generic bioinformatics/stats tool: MuTect
VarDict,computational_tools,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VarDict,Analysis Software,,,,,,,,,,,,,,,,"integrating the results from five algorithms for variant calling: VarScan2, Freebayes, Strelka, MuTect, and VarDict",No version and no repository URL (confidence < 0.9 — unidentifiable)
AnnoVar,computational_tools,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AnnoVar,Analysis Software,,,,,,,,,,,,,,,,"Somatic variants were annotated using AnnoVar algorithm, which aggregates information from genomic and protein resources",Generic bioinformatics/stats tool: AnnoVar
MutationTaster2,computational_tools,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MutationTaster2,Analysis Software,,,,,,,,,,,,,,,,"MutationTaster2, Polyphen2, Provean, and SIFT were applied to predict the pathogenicity of missense SNVs",No version and no repository URL (confidence < 0.9 — unidentifiable)
Polyphen2,computational_tools,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Polyphen2,Analysis Software,,,,,,,,,,,,,,,,"MutationTaster2, Polyphen2, Provean, and SIFT were applied to predict the pathogenicity of missense SNVs",No version and no repository URL (confidence < 0.9 — unidentifiable)
SIFT,computational_tools,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SIFT,Analysis Software,,,,,,,,,,,,,,,,"MutationTaster2, Polyphen2, Provean, and SIFT were applied to predict the pathogenicity of missense SNVs",No version and no repository URL (confidence < 0.9 — unidentifiable)
STAR,computational_tools,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,STAR,Analysis Software,,,,,,,,,,,,,,,,The reads were aligned to the human reference genome (GRCh37/hg19) using STAR and the expression was quantitated at gene level using featureCounts,Generic bioinformatics/stats tool: STAR
featureCounts,computational_tools,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,featureCounts,Analysis Software,,,,,,,,,,,,,,,,The reads were aligned to the human reference genome (GRCh37/hg19) using STAR and the expression was quantitated at gene level using featureCounts,Generic bioinformatics/stats tool: featureCounts
netMHCpan-4.0,computational_tools,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,netMHCpan-4.0,Analysis Software,4.0,,,,,,,,,,,,,,,Binding affinity of mutant and corresponding wild-type peptides to the patient's germline HLA alleles was predicted using netMHCpan-4.0,Software name not in publication title — likely generic usage: netMHCpan-4.0
CatWalk XT,computational_tools,PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CatWalk XT,Analysis Software,ver. 8,,,,,,,,,,,,,,,"We used the CatWalk XT (ver. 8, Noldus Information Technology, Wageningen, The Netherlands) system to study the functional recovery of the nerve",Software name not in publication title — likely generic usage: CatWalk XT
Grass neurostimulator,computational_tools,PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Grass neurostimulator,Analysis Software,,,,,,,,,,,,,,,,A Grass neurostimulator was used to deliver stimuli starting with ten single electrical pulses followed by trains of pulses from 2 to 10 Hz,No version and no repository URL (confidence < 0.9 — unidentifiable)
Windaq DI-720 hardware with Pro+ software,computational_tools,PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Windaq DI-720 hardware with Pro+ software,Analysis Software,,,,,,,,,,,,,,,,Digital recordings at 50 kHz (using Windaq DI-720 hardware with Pro+ software) were made,No version and no repository URL (confidence < 0.9 — unidentifiable)
Metamorph software,computational_tools,PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Metamorph software,Analysis Software,,,,,,,,,,,,,,,,"images captured with a Leica DMR III microscope and CCD camera running Metamorph software (Molecular Devices, Inc., Sunnyvale, CA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
ImageJ software,computational_tools,PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ software,Analysis Software,,,,,,,,,,,,,,,,"Using ImageJ software (NIH, Bethesda, MD), g-ratios were calculated on the EM micrographs",Generic bioinformatics/stats tool: ImageJ software
SigmaPlot software,computational_tools,PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SigmaPlot software,Analysis Software,,,,,,,,,,,,,,,,"Differences among means for each group were analyzed by using t-tests and one way ANOVA using SigmaPlot software (Systat, San Jose, CA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Nikon Eclipse E800 microscope,computational_tools,PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Nikon Eclipse E800 microscope,Other,,,,,,,,,,,,,,,,Images were acquired using a Nikon Eclipse E800 microscope,No version and no repository URL (confidence < 0.9 — unidentifiable)
non-B DNA Motif Search Tool,computational_tools,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,non-B DNA Motif Search Tool,Web Application,,,,,,,,,,,,,,,,we used the non-B DNA database and the non-B DNA Motif Search Tool under preset search criteria for direct repeats,Publication title lacks NF-specific terms: SVA retrotransposon insertion-associated deletion represents a novel mutational 
MEME suite software,computational_tools,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MEME suite software,Analysis Software,,,,,,,,,,,,,,,,we screened both datasets for the presence of direct and inverted repeats using the MEME suite software,Publication title lacks NF-specific terms: SVA retrotransposon insertion-associated deletion represents a novel mutational 
UCSC Repeat Masker,computational_tools,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,UCSC Repeat Masker,Web Application,,,,,,,,,,,,,,,,Both datasets were also investigated for the presence of retrotransposons by means of the UCSC Repeat Masker track,Publication title lacks NF-specific terms: SVA retrotransposon insertion-associated deletion represents a novel mutational 
BLASTN,computational_tools,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BLASTN,Analysis Software,,,,,,,,,,,,,,,,we performed BLASTN self-alignments of the respective regions,Publication title lacks NF-specific terms: SVA retrotransposon insertion-associated deletion represents a novel mutational 
Aperio XT scanner,computational_tools,PMID:32642737,10.1093/noajnl/vdz050,Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromass.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Aperio XT scanner,Analysis Software,,,,,,,,,,,,,,,,The hematoxylin and eosin (H&E)-stained slides were scanned using an Aperio XT scanner.,No version and no repository URL (confidence < 0.9 — unidentifiable)
REDcap database,computational_tools,PMID:32642737,10.1093/noajnl/vdz050,Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromass.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,REDcap database,Database,,,,,,,,,,,,,,,,who entered free text of up to a 200 word description for each case into a REDcap database,No version and no repository URL (confidence < 0.9 — unidentifiable)
CaloPix viewer,computational_tools,PMID:32642737,10.1093/noajnl/vdz050,Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromass.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CaloPix viewer,Analysis Software,,,,,,,,,,,,,,,,"analyzed using the CaloPix viewer (TRIBVN-HEALTHCARE, Chatillon, France)",No version and no repository URL (confidence < 0.9 — unidentifiable)
PETCHEM module,computational_tools,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PETCHEM module,Other,,,,,,,,,,,,,,,,"L-[18F]FETrp was radiosynthesized in a custom-manufactured module purchased from PETCHEM Solutions Inc. (Pinckney, MI, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Agilent ChemStation software (version C.01.07),computational_tools,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Agilent ChemStation software (version C.01.07),Analysis Software,C.01.07,,,,,,,,,,,,,,,An Agilent ChemStation software (version C.01.07) was used for data analysis,Software name not in publication title — likely generic usage: Agilent ChemStation software (version C.01.07)
PerkinElmer G4 microPET scanner,computational_tools,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PerkinElmer G4 microPET scanner,Other,,,,,,,,,,,,,,,,Static and dynamic PET imaging in wild-type and NF1 tumor mice was performed in a PerkinElmer G4 microPET scanner,No version and no repository URL (confidence < 0.9 — unidentifiable)
VivoQuant software version 4.0,computational_tools,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,VivoQuant software version 4.0,Analysis Software,4.0,,,,,,,,,,,,,,,"ROIs were manually drawn with VivoQuant software version 4.0 (Invicro, Needham, MA, USA)",Software name not in publication title — likely generic usage: VivoQuant software version 4.0
Ultimate 3000 UPLC system,computational_tools,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Ultimate 3000 UPLC system,Analysis Software,,,,,,,,,,,,,,,,"MS was carried out using an Ultimate 3000 UPLC system (Thermo Fisher, Germany) connected to an Orbitrap Velos Pro mass spectrometer",No version and no repository URL (confidence < 0.9 — unidentifiable)
Orbitrap Velos Pro mass spectrometer,computational_tools,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Orbitrap Velos Pro mass spectrometer,Analysis Software,,,,,,,,,,,,,,,,"MS was carried out using an Ultimate 3000 UPLC system (Thermo Fisher, Germany) connected to an Orbitrap Velos Pro mass spectrometer",No version and no repository URL (confidence < 0.9 — unidentifiable)
MaxQuant version 1.3.05,computational_tools,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MaxQuant version 1.3.05,Analysis Software,1.3.05,,,,,,,,,,,,,,,Andromeda search engine integrated in MaxQuant version 1.3.05 programme was used to identify the proteins,Software name not in publication title — likely generic usage: MaxQuant version 1.3.05
Perseus,computational_tools,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Perseus,Analysis Software,,,,,,,,,,,,,,,,"LFQ data generated by Maxquant were processed using Microsoft Excel and specially developed proteomics software, Perseus",Generic bioinformatics/stats tool: Perseus
DAVID software,computational_tools,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DAVID software,Analysis Software,,,,,,,,,,,,,,,,"Functional enrichment analysis was performed using Benjamini-Hochberg multiple correction testing integrated in to the database for annotation, visualization and integrated discovery (DAVID) software",Software name not in publication title — likely generic usage: DAVID software
Leica DMI6000B microscope,computational_tools,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Leica DMI6000B microscope,Analysis Software,,,,,,,,,,,,,,,,Confocal microscopy was performed using a Leica DMI6000B microscope,No version and no repository URL (confidence < 0.9 — unidentifiable)
Bruker 7.0 T scanner,computational_tools,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bruker 7.0 T scanner,Other,,,,,,,,,,,,,,,,This study was conducted on a Bruker 7.0 T scanner (Bruker BioSpin GmbH).,No version and no repository URL (confidence < 0.9 — unidentifiable)
PubMed/MEDLINE,computational_tools,PMID:41168866,10.1186/s13023-025-04093-5,Artificial intelligence-based tools for precision diagnosis and treatment of neurofibromatosis type 1 associated peripheral and central glial tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PubMed/MEDLINE,Database,,,,,,,,,,,,,,,,A comprehensive search strategy was deployed across the databases: PubMed/MEDLINE and Google Scholar.,No version and no repository URL (confidence < 0.9 — unidentifiable)
Google Scholar,computational_tools,PMID:41168866,10.1186/s13023-025-04093-5,Artificial intelligence-based tools for precision diagnosis and treatment of neurofibromatosis type 1 associated peripheral and central glial tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Google Scholar,Database,,,,,,,,,,,,,,,,A comprehensive search strategy was deployed across the databases: PubMed/MEDLINE and Google Scholar.,No version and no repository URL (confidence < 0.9 — unidentifiable)
SYNAPSE,computational_tools,PMID:41168866,10.1186/s13023-025-04093-5,Artificial intelligence-based tools for precision diagnosis and treatment of neurofibromatosis type 1 associated peripheral and central glial tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SYNAPSE,Database,,,,,,,,,,,,,,,,"manual additions from SYNAPSE, the CTF data portal, and BioArchives, to collect technical reports and preprints.",No version and no repository URL (confidence < 0.9 — unidentifiable)
CTF data portal,computational_tools,PMID:41168866,10.1186/s13023-025-04093-5,Artificial intelligence-based tools for precision diagnosis and treatment of neurofibromatosis type 1 associated peripheral and central glial tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CTF data portal,Database,,,,,,,,,,,,,,,,"manual additions from SYNAPSE, the CTF data portal, and BioArchives, to collect technical reports and preprints.",No version and no repository URL (confidence < 0.9 — unidentifiable)
BioArchives,computational_tools,PMID:41168866,10.1186/s13023-025-04093-5,Artificial intelligence-based tools for precision diagnosis and treatment of neurofibromatosis type 1 associated peripheral and central glial tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BioArchives,Database,,,,,,,,,,,,,,,,"manual additions from SYNAPSE, the CTF data portal, and BioArchives, to collect technical reports and preprints.",No version and no repository URL (confidence < 0.9 — unidentifiable)
GraphPad Prism,computational_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GraphPad Prism,Analysis Software,,,,,,,,,,,,,,,,Kaplan-Meier plots were generated in GraphPad Prism and p-values were determined by log-rank Mantel-Cox test.,Generic bioinformatics/stats tool: GraphPad Prism
log-rank Mantel-Cox test,computational_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,log-rank Mantel-Cox test,Analysis Software,,,,,,,,,,,,,,,,Kaplan-Meier plots were generated in GraphPad Prism and p-values were determined by log-rank Mantel-Cox test.,Software name not in publication title — likely generic usage: log-rank Mantel-Cox test
Kaplan-Meier plots,computational_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Kaplan-Meier plots,Analysis Software,,,,,,,,,,,,,,,,Kaplan-Meier plots were generated in GraphPad Prism and p-values were determined by log-rank Mantel-Cox test.,No version and no repository URL (confidence < 0.9 — unidentifiable)
bulk RNA sequencing,computational_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,bulk RNA sequencing,Analysis Software,,,,,,,,,,,,,,,,"For patients in the institutional cohort whose samples underwent bulk RNA sequencing, whole exome sequencing and spatial transcriptomics profiling",Sequencing hardware or generic assay protocol: bulk RNA sequencing
whole exome sequencing,computational_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,whole exome sequencing,Analysis Software,,,,,,,,,,,,,,,,"For patients in the institutional cohort whose samples underwent bulk RNA sequencing, whole exome sequencing and spatial transcriptomics profiling",Sequencing hardware or generic assay protocol: whole exome sequencing
spatial transcriptomics profiling,computational_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,spatial transcriptomics profiling,Analysis Software,,,,,,,,,,,,,,,,"For patients in the institutional cohort whose samples underwent bulk RNA sequencing, whole exome sequencing and spatial transcriptomics profiling",Software name not in publication title — likely generic usage: spatial transcriptomics profiling
MATLAB,computational_tools,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MATLAB,Analysis Software,,,,,,,,,,,,,,,,System control and data collection were performed on a PC laptop using MATLAB (Mathworks) via direct USB connection...,Publication title lacks NF-specific terms: Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse
Arduino,computational_tools,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Arduino,Command-line Tool,,,,,,,,,,,,,,,,An Arduino was used for transistor–transistor logic and pulse-width modulation signals for control of the LD and shutter servos...,Publication title lacks NF-specific terms: Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse
Leica CM1950 Clinical Cryostat,computational_tools,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Leica CM1950 Clinical Cryostat,Other,,,,,,,,,,,,,,,,"sections were cut on a Leica CM1950 Clinical Cryostat, captured on Superfrost™ Plus Microscope Slides...",Publication title lacks NF-specific terms: Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse
JOEL-10 CX electron microscope,computational_tools,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,JOEL-10 CX electron microscope,Other,,,,,,,,,,,,,,,,"photographed on a JOEL-10 CX electron microscope at 1000–50,000 magnification",Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
HumanRef-8_v2 Sentrix BeadChips,computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HumanRef-8_v2 Sentrix BeadChips,Analysis Software,,,,,,,,,,,,,,,,Amplified biotinylated cRNA (1.5 µg) was hybridized to HumanRef-8_v2 Sentrix BeadChips.,Sequencing hardware or generic assay protocol: HumanRef-8_v2 Sentrix BeadChips
Illumina BeadStation 500 scanner,computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina BeadStation 500 scanner,Analysis Software,,,,,,,,,,,,,,,,"dried, and scanned in an Illumina BeadStation 500 scanner.",No version and no repository URL (confidence < 0.9 — unidentifiable)
BeadScan,computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BeadScan,Analysis Software,,,,,,,,,,,,,,,,Image acquisition and initial image analysis were done with Illumina BeadScan and BeadStudio applications.,No version and no repository URL (confidence < 0.9 — unidentifiable)
BeadStudio,computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BeadStudio,Analysis Software,,,,,,,,,,,,,,,,Image acquisition and initial image analysis were done with Illumina BeadScan and BeadStudio applications.,No version and no repository URL (confidence < 0.9 — unidentifiable)
384-well microfluidic cards,computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,384-well microfluidic cards,Analysis Software,,,,,,,,,,,,,,,,Twenty-one select transcripts plus an endogenous control (GAPDH) were interrogated by qPCR in all 79 samples that were analyzed on microarrays on 384-well microfluidic cards,No version and no repository URL (confidence < 0.9 — unidentifiable)
PedCheck,computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PedCheck,Analysis Software,,,,,,,,,,,,,,,,"In those cases in which family data were available, SNVs were checked for Mendelian segregation with PedCheck",No version and no repository URL (confidence < 0.9 — unidentifiable)
PEDSTATS,computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PEDSTATS,Analysis Software,,,,,,,,,,,,,,,,Hardy-Weinberg equilibrium (HWE) proportions were tested with PEDSTATS on 70 unrelated individuals.,No version and no repository URL (confidence < 0.9 — unidentifiable)
TRAP (Tiled Regression Analysis Package),computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,TRAP (Tiled Regression Analysis Package),Analysis Software,,,,,,,,,,,,,,,,"""Tiled Regression"" as implemented in TRAP (Tiled Regression Analysis Package) was used to identify the set of independent significant variants",Software name not in publication title — likely generic usage: TRAP (Tiled Regression Analysis Package)
Illumina Human OmniQuad-1M SNP-arrays,computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina Human OmniQuad-1M SNP-arrays,Analysis Software,,,,,,,,,,,,,,,,"For genotyping DPH2 SNPs rs4660761 and rs7161, we used genotyping calls obtained from Illumina Human OmniQuad-1M SNP-arrays.",No version and no repository URL (confidence < 0.9 — unidentifiable)
GenomeStudio (v. 2010.2),computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GenomeStudio (v. 2010.2),Analysis Software,v. 2010.2,,,,,,,,,,,,,,,SNP-array analysis was done according to the manufacturer's protocol using GenomeStudio (v. 2010.2) software,Software name not in publication title — likely generic usage: GenomeStudio (v. 2010.2)
Ion Ampliseq Designer v3.0,computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Ion Ampliseq Designer v3.0,Analysis Software,v3.0,,,,,,,,,,,,,,,"A targeted, multiplex PCR primer panel was designed using the custom Ion Ampliseq Designer v3.0",Sequencing hardware or generic assay protocol: Ion Ampliseq Designer v3.0
Ion Torrent PGM Sequencer,computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Ion Torrent PGM Sequencer,Analysis Software,,,,,,,,,,,,,,,,"Individual samples were barcoded, pooled, templated, and sequenced on the Ion Torrent PGM Sequencer",No version and no repository URL (confidence < 0.9 — unidentifiable)
HaploReg,computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HaploReg,Web Application,,,,,,,,,,,,,,,,We also used the online tools HaploReg (http://www.broadinstitute.org/mammals/haploreg/haploreg.php) and RegulomeDB,No version and no repository URL (confidence < 0.9 — unidentifiable)
RegulomeDB,computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,RegulomeDB,Web Application,,,,,,,,,,,,,,,,We also used the online tools HaploReg and RegulomeDB (http://regulome.stanford.edu) as a complementary analysis,No version and no repository URL (confidence < 0.9 — unidentifiable)
MaxQuant (version 1.6.10.43),computational_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MaxQuant (version 1.6.10.43),Analysis Software,1.6.10.43,,,,,,,,,,,,,,,Raw files were processed for label-free quantification by MaxQuant (version 1.6.10.43) LFQ using the Uniprot/Swiss-Prot mouse database,Software name not in publication title — likely generic usage: MaxQuant (version 1.6.10.43)
Perseus (version 1.6.10.50),computational_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Perseus (version 1.6.10.50),Analysis Software,1.6.10.50,,,,,,,,,,,,,,,LFQ intensities for kinases with at least two peptides were imported into Perseus (version 1.6.10.50),Software name not in publication title — likely generic usage: Perseus (version 1.6.10.50)
FlowJo Software (version 9.9.6),computational_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FlowJo Software (version 9.9.6),Analysis Software,9.9.6,,,,,,,,,,,,,,,"Data were acquired uncompensated and exported as FCS 3.0 files for analysis using FlowJo Software (version 9.9.6,Tree Star Inc)",Software name not in publication title — likely generic usage: FlowJo Software (version 9.9.6)
ImageJ (version 1.47),computational_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ (version 1.47),Analysis Software,1.47,,,,,,,,,,,,,,,AXL immunohistochemistry was analyzed using the IHC Profiler plugin for ImageJ (version 1.47),Generic tool (versioned): ImageJ (version 1.47)
HALO Image Analysis Software (version 2.3),computational_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HALO Image Analysis Software (version 2.3),Analysis Software,2.3,,,,,,,,,,,,,,,"representative image were generated using HALO Image Analysis Software (version 2.3, Indica Labs)",Software name not in publication title — likely generic usage: HALO Image Analysis Software (version 2.3)
XCELLigence Real Time Cell Analysis System,computational_tools,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,XCELLigence Real Time Cell Analysis System,Analysis Software,,,,,,,,,,,,,,,,"The microelectronic biosensor XCELLigence Real Time Cell Analysis System (RTCA, Roche Diagnostics GmbH",Software name not in publication title — likely generic usage: XCELLigence Real Time Cell Analysis System
ImageJ,computational_tools,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,Measurements were performed on epifluorescent images using Image J (NIH),Generic bioinformatics/stats tool: ImageJ
R,computational_tools,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,R,Analysis Software,,,,,,,,,,,,,,,,Data analysis was done using R [42],Generic bioinformatics/stats tool: R
ImageJ software (NIH),computational_tools,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ software (NIH),Analysis Software,,,,,,,,,,,,,,,,Nuclei were labeled with DAPI (Sigma-Aldrich) and microscopic images acquired with ImageJ software (NIH),Generic tool (versioned): ImageJ software (NIH)
FlowJo software,computational_tools,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FlowJo software,Analysis Software,,,,,,,,,,,,,,,,Flow cytometry was performed on a FACSCanto (Becton Dickinson) and analyzed using FlowJo software,No version and no repository URL (confidence < 0.9 — unidentifiable)
NanoDrop one spectrophotometer,computational_tools,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NanoDrop one spectrophotometer,Analysis Software,,,,,,,,,,,,,,,,The DNA purity was determined using a NanoDrop one spectrophotometer and quantified with a Qubit 2.0 Fluorometer,No version and no repository URL (confidence < 0.9 — unidentifiable)
Qubit 2.0 Fluorometer,computational_tools,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Qubit 2.0 Fluorometer,Analysis Software,,,,,,,,,,,,,,,,The DNA purity was determined using a NanoDrop one spectrophotometer and quantified with a Qubit 2.0 Fluorometer using the Qubit dsDNA HS Assay Kit,No version and no repository URL (confidence < 0.9 — unidentifiable)
Covaris M220,computational_tools,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Covaris M220,Analysis Software,,,,,,,,,,,,,,,,"DNA was cropped into approximately 300-bp fragments using focused ultrasonicators (Covaris M220, United States)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Illumina HiSeq X Ten System,computational_tools,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina HiSeq X Ten System,Analysis Software,,,,,,,,,,,,,,,,"Sequencing was carried out on an Illumina HiSeq X Ten System (Illumina, San Diego, CA, United States)",Sequencing hardware or generic assay protocol: Illumina HiSeq X Ten System
ABI PRISM 3730XL analyzer,computational_tools,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ABI PRISM 3730XL analyzer,Analysis Software,,,,,,,,,,,,,,,,"An ABI PRISM 3730XL analyzer (Applied Biosystems, Foster City, CA, United States) was used for Sanger sequencing",No version and no repository URL (confidence < 0.9 — unidentifiable)
Primer 3.0,computational_tools,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Primer 3.0,Analysis Software,3.0,,,,,,,,,,,,,,,Primers were designed based on the mutation sites found using Primer 3.0,Software name not in publication title — likely generic usage: Primer 3.0
Olympus FV10i confocal microscope,computational_tools,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Olympus FV10i confocal microscope,Analysis Software,,,,,,,,,,,,,,,,images were acquired and analyzed using an Olympus FV10i confocal microscope,No version and no repository URL (confidence < 0.9 — unidentifiable)
Applied Biosystems 7000 series machine,computational_tools,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Applied Biosystems 7000 series machine,Analysis Software,,,,,,,,,,,,,,,,reactions were run in triplicate with an Applied Biosystems 7000 series machine (Invitrogen),No version and no repository URL (confidence < 0.9 — unidentifiable)
Feature Extraction 10.5,computational_tools,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Feature Extraction 10.5,Analysis Software,10.5,,,,,,,,,,,,,,,Copy number estimates were extracted from the microarray image files using Feature Extraction 10.5 (Agilent),Software name not in publication title — likely generic usage: Feature Extraction 10.5
Agilent Genomic Workbench 6.5,computational_tools,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Agilent Genomic Workbench 6.5,Analysis Software,6.5,,,,,,,,,,,,,,,data were analyzed in Agilent Genomic Workbench 6.5 (Agilent),Software name not in publication title — likely generic usage: Agilent Genomic Workbench 6.5
Image J software,computational_tools,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Image J software,Analysis Software,,,,,,,,,,,,,,,,Nuclei area was measured using Image J software,Generic tool (versioned): Image J software
CellQuestPro software,computational_tools,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CellQuestPro software,Analysis Software,,,,,,,,,,,,,,,,analyzed with FACS Calibur and CellQuestPro software (BD Biosciences),No version and no repository URL (confidence < 0.9 — unidentifiable)
Drop-seq tools (version 1.12),computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Drop-seq tools (version 1.12),Analysis Software,1.12,,,,,,,,,,,,,,,"FASTQ sequencing reads were processed, aligned to the mouse genome (mm10), and converted to digital gene expression matrices using the Drop-seq tools (version 1.12)",Software name not in publication title — likely generic usage: Drop-seq tools (version 1.12)
Cellranger v5.0.1,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cellranger v5.0.1,Analysis Software,v5.0.1,,,,,,,,,,,,,,,"For 10X Genomics datasets, we used Cellranger v5.0.1 to align reads to the hg19 human reference sequence",Software name not in publication title — likely generic usage: Cellranger v5.0.1
Seurat (version 3.1.0),computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat (version 3.1.0),Package/Library,3.1.0,,,,,,,,,,,,,,,"For each sample dataset, unsupervised clustering was performed using R package Seurat (version 3.1.0)",Software name not in publication title — likely generic usage: Seurat (version 3.1.0)
scREF,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,scREF,Analysis Software,,https://github.com/jumphone/scRef/archive/master.zip,,,,,,,,,,,,,,scREF is a reference-based toolkit for single-cell analysis for mapping a query RNA-seq dataset onto a reference,Software name not in publication title — likely generic usage: scREF
CIBERSORTx,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CIBERSORTx,Analysis Software,,,,,,,,,,,,,,,,We used CIBERSORTx to perform deconvolution analysis of bulk tumor data against Lats1/2-mut advanced SN tumor cell types,Software name not in publication title — likely generic usage: CIBERSORTx
inferCNV,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,inferCNV,Analysis Software,,,,,,,,,,,,,,,,Malignant cells were identified by inferring large-scale chromosomal CNVs in each single cell based on a moving averaged expression profiles across chromosomal intervals by inferCNV,Software name not in publication title — likely generic usage: inferCNV
VECTOR,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VECTOR,Analysis Software,,,,,,,,,,,,,,,,Cell-state transition directions were inferred by VECTOR based on the observation that quantile polarization of a cell's principal component values,Software name not in publication title — likely generic usage: VECTOR
Slingshot,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Slingshot,Package/Library,,,,,,,,,,,,,,,,Slingshot is a top performer for cellular trajectory from scRNA-seq data. We used Slingshot to model the pseudotime trajectory,Software name not in publication title — likely generic usage: Slingshot
CytoTRACE version 0.3.3,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CytoTRACE version 0.3.3,Package/Library,0.3.3,,,,,,,,,,,,,,,we used the R package CytoTRACE version 0.3.3 to predict differentiation status of SC lineage cells from mouse and human scRNA-seq data,Software name not in publication title — likely generic usage: CytoTRACE version 0.3.3
ArchR,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ArchR,Package/Library,,,,,,,,,,,,,,,,"ArchR was used for all scATAC-seq analyses according to default parameters, including quality control and cell filtering",Software name not in publication title — likely generic usage: ArchR
CellChat,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CellChat,Package/Library,,,,,,,,,,,,,,,,"We used CellChat to infer the intercellular communication from scRNA-seq data for further data exploration, analysis, and visualization",Software name not in publication title — likely generic usage: CellChat
DGIdb (version 3.0.2),computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DGIdb (version 3.0.2),Database,3.0.2,,,,,,,,,,,,,,,"were used to query the Washington University DGIdb (version 3.0.2), with a focus on expert-curated collections of druggable genes",Software name not in publication title — likely generic usage: DGIdb (version 3.0.2)
OmicsNet,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,OmicsNet,Web Application,,,,,,,,,,,,,,,,The same sets of genes were also queried in OmicsNet and visualized for relationships among genes and transcription factors,No version and no repository URL (confidence < 0.9 — unidentifiable)
Trim Galore (version 0.6.10),computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Trim Galore (version 0.6.10),Analysis Software,0.6.10,,,,,,,,,,,,,,,The raw sequence reads were first trimmed using Trim Galore (version 0.6.10) to remove any primer adapter contamination,Software name not in publication title — likely generic usage: Trim Galore (version 0.6.10)
Broad's Genome Analysis ToolKit (version 4.6.0),computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Broad's Genome Analysis ToolKit (version 4.6.0),Analysis Software,4.6.0,,,,,,,,,,,,,,,The trimmed sequence reads were further analyzed using Broad's Genome Analysis ToolKit (version 4.6.0) following their Best Practices Guidelines,Software name not in publication title — likely generic usage: Broad's Genome Analysis ToolKit (version 4.6.0)
BWA (version 0.7.17-r1188),computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BWA (version 0.7.17-r1188),Analysis Software,0.7.17-r1188,,,,,,,,,,,,,,,BWA (version 0.7.17-r1188) was used to align the trimmed sequences to GATKs hg38 genome from their Resource Bundle,Software name not in publication title — likely generic usage: BWA (version 0.7.17-r1188)
Picard tools (version 3.2.0),computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Picard tools (version 3.2.0),Analysis Software,3.2.0,,,,,,,,,,,,,,,Duplicate reads were removed with Picard tools (version 3.2.0) and Base Quality Score Recalibration (BQSR) was then applied,Software name not in publication title — likely generic usage: Picard tools (version 3.2.0)
Delly,computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Delly,Analysis Software,,,,,,,,,,,,,,,,Both Delly and Manta were used to identify structural variants from these alignments to identify any type of off-target effects,Generic bioinformatics/stats tool: Delly
Manta,computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Manta,Analysis Software,,,,,,,,,,,,,,,,Both Delly and Manta were used to identify structural variants from these alignments to identify any type of off-target effects,No version and no repository URL (confidence < 0.9 — unidentifiable)
Thermo Q Exactive HFx mass spectrometer,computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Thermo Q Exactive HFx mass spectrometer,Analysis Software,,,,,,,,,,,,,,,,"For the global proteomics studies this system ran in-line with a Thermo Q Exactive HFx mass spectrometer, equipped with a Nanospray FlexTM ion source",No version and no repository URL (confidence < 0.9 — unidentifiable)
Thermo Velos Pro Orbitrap mass spectrometer,computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Thermo Velos Pro Orbitrap mass spectrometer,Analysis Software,,,,,,,,,,,,,,,,"the same model of HPLC ran in-line with a Thermo Velos Pro Orbitrap mass spectrometer, equipped with a Nanospray ion source",No version and no repository URL (confidence < 0.9 — unidentifiable)
ReAdW v. 3.5.1,computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ReAdW v. 3.5.1,Analysis Software,3.5.1,,,,,,,,,,,,,,,"The XCalibur RAW files were collected in profile mode, centroided and converted to MzXML using ReAdW v. 3.5.1",Software name not in publication title — likely generic usage: ReAdW v. 3.5.1
MzXML2Search (included in TPP v. 3.5),computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MzXML2Search (included in TPP v. 3.5),Analysis Software,3.5,,,,,,,,,,,,,,,The mgf files were then created using MzXML2Search (included in TPP v. 3.5) for all scans,Software name not in publication title — likely generic usage: MzXML2Search (included in TPP v. 3.5)
MASCOT,computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MASCOT,Analysis Software,,,,,,,,,,,,,,,,"The data were searched using MACOT for the global studies, and SEQUEST (Thermo Fisher Scientific) for the PPI studies",No version and no repository URL (confidence < 0.9 — unidentifiable)
SEQUEST,computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SEQUEST,Analysis Software,,,,,,,,,,,,,,,,"The data were searched using MACOT for the global studies, and SEQUEST (Thermo Fisher Scientific) for the PPI studies",No version and no repository URL (confidence < 0.9 — unidentifiable)
"Scaffold (Protein Sciences, Portland Oregon)",computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"Scaffold (Protein Sciences, Portland Oregon)",Analysis Software,,,,,,,,,,,,,,,,"The list of peptide IDs generated based on SEQUEST or MASCOT search results were filtered separately using Scaffold (Protein Sciences, Portland Oregon)","Software name not in publication title — likely generic usage: Scaffold (Protein Sciences, Portland Oregon)"
Human Protein Atlas (proteinatlas.org),computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Human Protein Atlas (proteinatlas.org),Database,23.0,,,,,,,,,,,,,,,Subcellular localization was assessed for the PPI's using the Human Protein Atlas (proteinatlas.org) Subcellular section (Protein Atlas version 23.0),Software name not in publication title — likely generic usage: Human Protein Atlas (proteinatlas.org)
QIAGEN Ingenuity Pathway Analysis (IPA),computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,QIAGEN Ingenuity Pathway Analysis (IPA),Analysis Software,,,,,,,,,,,,,,,,Further Pathway analysis was conducted using QIAGEN Ingenuity Pathway Analysis (IPA),Software name not in publication title — likely generic usage: QIAGEN Ingenuity Pathway Analysis (IPA)
O2K system (Oroboros Instruments),computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,O2K system (Oroboros Instruments),Analysis Software,,,,,,,,,,,,,,,,750 K cells/ml were added into each chamber of an O2K system (Oroboros Instruments). Cells were permeabilized by addition of digitonin,No version and no repository URL (confidence < 0.9 — unidentifiable)
Neon Transfection System,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Neon Transfection System,Other,,,,,,,,,,,,,,,,"0.2 nmol of HDR were pulsed for 20 ms at 1,800 V using the Neon Transfection System (Thermo)",No version and no repository URL (confidence < 0.9 — unidentifiable)
CytoFLEX flow cytometer,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CytoFLEX flow cytometer,Analysis Software,,,,,,,,,,,,,,,,Cells were run through a CytoFLEX flow cytometer (Beckman Coulter) using the Cytexpert software,No version and no repository URL (confidence < 0.9 — unidentifiable)
FlowJo software,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FlowJo software,Analysis Software,,,,,,,,,,,,,,,,FlowJo software was used to determine cell purity,No version and no repository URL (confidence < 0.9 — unidentifiable)
Bio-Rad CFX96 Real-Time System,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bio-Rad CFX96 Real-Time System,Analysis Software,,,,,,,,,,,,,,,,RT-qPCR was performed using the Bio-Rad CFX96 Real-Time System (Bio-Rad) using technical replicates,No version and no repository URL (confidence < 0.9 — unidentifiable)
Illumina NovaSeq 6000,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina NovaSeq 6000,Analysis Software,,,,,,,,,,,,,,,,Samples were sequenced on an Illumina NovaSeq 6000 using a 150 paired end flow cell,Sequencing hardware or generic assay protocol: Illumina NovaSeq 6000
HISAT2,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HISAT2,Analysis Software,36,,,,,,,,,,,,,,,"The RNA sequencing data were mapped to the Ensembl Sus Scrofa genome 11.1, release 103 using HISAT2",Generic bioinformatics/stats tool: HISAT2
StringTie,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,StringTie,Analysis Software,37,,,,,,,,,,,,,,,"mapped to the Ensembl Sus Scrofa genome 11.1, release 103 using HISAT2 and quantified with StringTie",Generic bioinformatics/stats tool: StringTie
R,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R,Analysis Software,38,,,,,,,,,,,,,,,All graphs were generated using R and tidyverse,Generic bioinformatics/stats tool: R
tidyverse,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,tidyverse,Package/Library,,,,,,,,,,,,,,,,All graphs were generated using R and tidyverse,No version and no repository URL (confidence < 0.9 — unidentifiable)
Li-Cor Odyssey Fc Imaging System,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Li-Cor Odyssey Fc Imaging System,Analysis Software,,,,,,,,,,,,,,,,"Bands were imaged using the Li-Cor Odyssey Fc Imaging System, quantified by densitometry",No version and no repository URL (confidence < 0.9 — unidentifiable)
Cytation 5 cell imaging reader,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Cytation 5 cell imaging reader,Analysis Software,,,,,,,,,,,,,,,,Images were acquired using a Cytation 5 cell imaging reader (BioTek),No version and no repository URL (confidence < 0.9 — unidentifiable)
GraphPad Prism V9,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism V9,Analysis Software,V9,,,,,,,,,,,,,,,All graphs and statistical analyses were performed using GraphPad Prism V9,Generic tool (versioned): GraphPad Prism V9
Celeris ERG stimulator (Diagnosys),computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Celeris ERG stimulator (Diagnosys),Analysis Software,,,,,,,,,,,,,,,,PERGs were recorded and analysed at 12 weeks of age using the Celeris ERG stimulator (Diagnosys),No version and no repository URL (confidence < 0.9 — unidentifiable)
Partek Flow software (v.9.0),computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Partek Flow software (v.9.0),Analysis Software,v.9.0,,,,,,,,,,,,,,,"The analysis for this Article was generated using Partek Flow software, v.9.0",Software name not in publication title — likely generic usage: Partek Flow software (v.9.0)
STAR (v.2.7.3a),computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR (v.2.7.3a),Analysis Software,v.2.7.3a,,,,,,,,,,,,,,,RNA-seq reads were aligned to the Ensembl release 100 top-level assembly with STAR v.2.7.3a,Software name not in publication title — likely generic usage: STAR (v.2.7.3a)
DESeq2,computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2,Package/Library,,,,,,,,,,,,,,,,Differentially expressed gene analysis was then performed using DESeq2 method,Generic bioinformatics/stats tool: DESeq2
ImageJ (v.2.0.0),computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ (v.2.0.0),Analysis Software,v.2.0.0,,,,,,,,,,,,,,,Images were taken using a Zeiss Axio Imager M2 and quantified using ImageJ (v.2.0.0),Generic tool (versioned): ImageJ (v.2.0.0)
Cell Profiler (v.3.1.9),computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cell Profiler (v.3.1.9),Analysis Software,v.3.1.9,,,,,,,,,,,,,,,Cell proliferation was determined by dividing the number of EdU+ cells by the number of DAPI+ cells using Cell Profiler (v.3.1.9),Software name not in publication title — likely generic usage: Cell Profiler (v.3.1.9)
Stereo Investigator software (mbfbioscience v2019),computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Stereo Investigator software (mbfbioscience v2019),Analysis Software,v2019,,,,,,,,,,,,,,,Images were taken using a Zeiss Axio Imager M2 and the Stereo Investigator software (mbfbioscience v2019),Software name not in publication title — likely generic usage: Stereo Investigator software (mbfbioscience v2019)
Image Lab software (v.6),computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Image Lab software (v.6),Analysis Software,v.6,,,,,,,,,,,,,,,imaged on a Bio-Rad Gel Doc imager using Image Lab software (v.6),Software name not in publication title — likely generic usage: Image Lab software (v.6)
Image Studio Lite (v.5.0.21),computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Image Studio Lite (v.5.0.21),Analysis Software,v.5.0.21,,,,,,,,,,,,,,,and analysed using Image Studio Lite (v.5.0.21),Software name not in publication title — likely generic usage: Image Studio Lite (v.5.0.21)
EPC 10 Amplifier,computational_tools,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,EPC 10 Amplifier,Analysis Software,,,,,,,,,,,,,,,,"Whole-cell voltage recordings were performed at room temperature on primary cultured hippocampal neurons using an EPC 10 Amplifier (HEKA Electronics, Germany)",No version and no repository URL (confidence < 0.9 — unidentifiable)
P-97 electrode puller,computational_tools,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,P-97 electrode puller,Analysis Software,,,,,,,,,,,,,,,,"Electrodes were pulled from thin-walled borosilicate glass capillaries (Warner Instruments, Hamden, CT) with a P-97 electrode puller (Sutter Instrument, Novato, CA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Fitmaster,computational_tools,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Fitmaster,Analysis Software,,,,,,,,,,,,,,,,"Analysis was performed using Fitmaster and origin8.1 (OriginLab Corporation, MA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
origin8.1,computational_tools,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,origin8.1,Analysis Software,8.1,,,,,,,,,,,,,,,"Analysis was performed using Fitmaster and origin8.1 (OriginLab Corporation, MA)",Software name not in publication title — likely generic usage: origin8.1
Victor 3 V multilabel plate reader,computational_tools,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Victor 3 V multilabel plate reader,Analysis Software,,,,,,,,,,,,,,,,"fluorescence of resorufin was measured in a Victor 3 V multilabel plate reader (Perkin Elmer, Shelton, CT)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Nikon Elements software,computational_tools,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Nikon Elements software,Analysis Software,,,,,,,,,,,,,,,,The morphometric analysis of neurite lengths of transfected green fluorescent cells was performed with Nikon Elements software,Software name not in publication title — likely generic usage: Nikon Elements software
ImageJ,computational_tools,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,Sholl analysis was performed with ImageJ using an automated Sholl analysis plugin,Generic bioinformatics/stats tool: ImageJ
automated Sholl analysis plugin,computational_tools,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,automated Sholl analysis plugin,Plugin,,,,,,,,,,,,,,,,Sholl analysis was performed with ImageJ using an automated Sholl analysis plugin,No version and no repository URL (confidence < 0.9 — unidentifiable)
Illumina Infinium MethylationEPIC BeadChip array,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina Infinium MethylationEPIC BeadChip array,Analysis Software,,,,,,,,,,,,,,,,"Methylation profiling was performed on bisulfite-treated DNA using the Illumina Infinium MethylationEPIC BeadChip array (Illumina, San Diego, USA)",Sequencing hardware or generic assay protocol: Illumina Infinium MethylationEPIC BeadChip array
minfi package,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,minfi package,Package/Library,,,,,,,,,,,,,,,,Generated raw methylation files were imported and preprocessed with the statistical programming language R using the minfi package (Bioconductor),No version and no repository URL (confidence < 0.9 — unidentifiable)
ConsensusClusterPlus package,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ConsensusClusterPlus package,Package/Library,,,,,,,,,,,,,,,,Unsupervised consensus hierarchical clustering was performed with ConsensusClusterPlus package (Bioconductor),No version and no repository URL (confidence < 0.9 — unidentifiable)
limma,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,limma,Package/Library,,,,,,,,,,,,,,,,Differentially methylated probes were identified using limma based modeling approach (Bioconductor),Generic bioinformatics/stats tool: limma
BWA-MEM v 0.7.12,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BWA-MEM v 0.7.12,Command-line Tool,v 0.7.12,,,,,,,,,,,,,,,read pairs were aligned to the hg19 reference genome using BWA-MEM v 0.7.12 with default parameters,Software name not in publication title — likely generic usage: BWA-MEM v 0.7.12
GATK v3.6.0,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GATK v3.6.0,Command-line Tool,v3.6.0,,,,,,,,,,,,,,,"PCR duplicate marking, indel realignment and base quality score recalibration were performed using Picard v1.72 and GATK v3.6.0",Software name not in publication title — likely generic usage: GATK v3.6.0
Mutect V1.1.6,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Mutect V1.1.6,Command-line Tool,V1.1.6,,,,,,,,,,,,,,,We identified somatic mutations using Mutect V1.1.6 and Strelka v1.0.13 for 20 tumors with matched peripheral blood controls,Software name not in publication title — likely generic usage: Mutect V1.1.6
Strelka v1.0.13,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Strelka v1.0.13,Command-line Tool,v1.0.13,,,,,,,,,,,,,,,We identified somatic mutations using Mutect V1.1.6 and Strelka v1.0.13 for 20 tumors with matched peripheral blood controls,Software name not in publication title — likely generic usage: Strelka v1.0.13
STAR aligner (v.2.6.0),computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR aligner (v.2.6.0),Command-line Tool,v.2.6.0,,,,,,,,,,,,,,,Sequence data was processed and aligned to human reference genome (hg38) using STAR aligner (v.2.6.0),Software name not in publication title — likely generic usage: STAR aligner (v.2.6.0)
edgeR,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,edgeR,Package/Library,v.3.22.3,,,,,,,,,,,,,,,Data was normalized by counts-per-million (CPM) and then subjected to trimmed means of M (TMM) using edgeR (v.3.22.3),Generic bioinformatics/stats tool: edgeR
FusionCatcher v1.1.0,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FusionCatcher v1.1.0,Command-line Tool,v1.1.0,,,,,,,,,,,,,,,Fusion genes for cohort of PNSTs were identified using FusionCatcher v1.1.0 with default parameters,Software name not in publication title — likely generic usage: FusionCatcher v1.1.0
CellRanger,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CellRanger,Pipeline,,,,,,,,,,,,,,,,"CellRanger (10× Genomics) analysis pipeline was used for library demultiplexing, read alignment to human genome GRCh38",No version and no repository URL (confidence < 0.9 — unidentifiable)
Seurat version 3.0,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat version 3.0,Package/Library,version 3.0,,,,,,,,,,,,,,,"The raw gene expression matrix was normalized, and variance stabilized by SCTransform in Suerat version 3.0",Software name not in publication title — likely generic usage: Seurat version 3.0
Monocle2,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Monocle2,Package/Library,,,,,,,,,,,,,,,,Pseudotime analysis was performed as previously described using Monocle2,No version and no repository URL (confidence < 0.9 — unidentifiable)
inferCNV (v.1.1.1),computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,inferCNV (v.1.1.1),Package/Library,v.1.1.1,,,,,,,,,,,,,,,CNAs of neoplastic and non-neoplastic cells were inferred from the snRNA-seq data using inferCNV (v.1.1.1),Software name not in publication title — likely generic usage: inferCNV (v.1.1.1)
Affymetrix GeneChip Mouse Genome 430 2.0 Array,computational_tools,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Affymetrix GeneChip Mouse Genome 430 2.0 Array,Analysis Software,,,,,,,,,,,,,,,,"Mouse optic glioma neurospheres, Nf1−/− TVZ NSCs (TVZ_Cre) and wild-type TVZ NSCs (TVZ_LacZ) RNA was subjected to Affymetrix GeneChip Mouse Genome 430 2.0 Array hybridization",Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
Partex Genomics Suite Version 6.6 beta,computational_tools,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Partex Genomics Suite Version 6.6 beta,Analysis Software,6.6 beta,,,,,,,,,,,,,,,the resulting data analyzed using Partex Genomics Suite Version 6.6 beta,Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
ImageJ,computational_tools,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,Densitometry quantification was done using ImageJ software and normalized to GAPDH,"Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
pheatmap package,computational_tools,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,pheatmap package,Package/Library,,http://cran.r-project.org/web/packages/pheatmap/index.html,,,,,,,,,,,,,,The heatmap was generated using CRAN's pheatmap package ( http://cran.r-project.org/web/packages/pheatmap/index.html ),"Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
Limma package,computational_tools,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Limma package,Package/Library,,http://www.bioconductor.org,,,,,,,,,,,,,,Statistical comparisons were done using R/Bioconductor's Limma package ( http://www.bioconductor.org ),"Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
GeneSpring GXv7.3.1,computational_tools,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GeneSpring GXv7.3.1,Analysis Software,v7.3.1,,,,,,,,,,,,,,,Statistical comparisons were done using R/Bioconductor's Limma package ( http://www.bioconductor.org ) and GeneSpring GXv7.3.1 (Agilent Technologies),"Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
CalcuSyn Version 2.1,computational_tools,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,CalcuSyn Version 2.1,Analysis Software,Version 2.1,,,,,,,,,,,,,,,"All data analysis was done using Calcusyn software (CalcuSyn Version 2.1, BioSoft)","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
"Matlab script (Version 9.9.0, Natick, MA)",computational_tools,PMID:38173515,10.1016/j.heliyon.2023.e23445,Development of a semi-automatic segmentation technique based on mean magnetic resonance imaging intensity thresholding for volumetric quantification of plexiform neurofibromas.,,0.85,Development,True,1.00,High,,,,,,,,,,,,,,,"Matlab script (Version 9.9.0, Natick, MA)",Analysis Software,9.9.0,,,,,,,,,,,,,,,"The SSTMean method consisted of 4 main steps that were implemented in a Matlab script (Version 9.9.0, Natick, MA).","Software name not in publication title — likely generic usage: Matlab script (Version 9.9.0, Natick, MA)"
FSLeyes,computational_tools,PMID:38173515,10.1016/j.heliyon.2023.e23445,Development of a semi-automatic segmentation technique based on mean magnetic resonance imaging intensity thresholding for volumetric quantification of plexiform neurofibromas.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FSLeyes,Analysis Software,,,,,,,,,,,,,,,,"For each MRI slice, the tumor was identified by drawing its contour(s) using the pencil tool from FSLeyes",No version and no repository URL (confidence < 0.9 — unidentifiable)
SSTMean,computational_tools,PMID:38173515,10.1016/j.heliyon.2023.e23445,Development of a semi-automatic segmentation technique based on mean magnetic resonance imaging intensity thresholding for volumetric quantification of plexiform neurofibromas.,,0.9,Development,True,0.67,Medium,,,,,,,,,,,,,,,SSTMean,Analysis Software,,,,,,,,,,,,,,,,A semi-automatic segmentation technique based on mean magnetic resonance imaging (MRI) intensity thresholding (SSTMean) was developed,Software name not in publication title — likely generic usage: SSTMean
SSTMini,computational_tools,PMID:38173515,10.1016/j.heliyon.2023.e23445,Development of a semi-automatic segmentation technique based on mean magnetic resonance imaging intensity thresholding for volumetric quantification of plexiform neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SSTMini,Analysis Software,,,,,,,,,,,,,,,,compared to a similar and previously published technique based on minimum image intensity thresholding (SSTMini),No version and no repository URL (confidence < 0.9 — unidentifiable)
ImageJ,computational_tools,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,"After background subtraction, Pearson's co‐localization coefficient was calculated with the ImageJ Co‐localization Analysis plugin",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
fastp v.0.2,computational_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,fastp v.0.2,Analysis Software,v.0.2,,,,,,,,,,,,,,,raw reads were quality filtered using fastp v.0.2,Software name not in publication title — likely generic usage: fastp v.0.2
BWA v.0.7.17,computational_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BWA v.0.7.17,Analysis Software,v.0.7.17,,,,,,,,,,,,,,,Quality-filtered reads were then aligned to the hg19 human genome assembly using BWA v.0.7.17,Software name not in publication title — likely generic usage: BWA v.0.7.17
Samtools v.1.7,computational_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Samtools v.1.7,Analysis Software,v.1.7,,,,,,,,,,,,,,,Aligned reads were deduplicated with Samtools v.1.7,Software name not in publication title — likely generic usage: Samtools v.1.7
MosDepth,computational_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MosDepth,Analysis Software,,,,,,,,,,,,,,,,Genomic coverage was estimated using MosDepth,No version and no repository URL (confidence < 0.9 — unidentifiable)
ichorCNA tool (Broad v.0.2.0),computational_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ichorCNA tool (Broad v.0.2.0),Analysis Software,v.0.2.0,,,,,,,,,,,,,,,copy number–based estimation of tumor fraction were then performed using the ichorCNA tool (Broad v.0.2.0),Software name not in publication title — likely generic usage: ichorCNA tool (Broad v.0.2.0)
deepTools bamPEFragmentSize,computational_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,deepTools bamPEFragmentSize,Analysis Software,,,,,,,,,,,,,,,,read-pair fragment sizes for cfDNA samples were calculated using deepTools bamPEFragmentSize,Software name not in publication title — likely generic usage: deepTools bamPEFragmentSize
ultra-low-pass whole genome sequencing (ULP-WGS),computational_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ultra-low-pass whole genome sequencing (ULP-WGS),Analysis Software,,,,,,,,,,,,,,,,This multi-institutional study used fragment size analysis and ultra-low-pass whole genome sequencing (ULP-WGS) of plasma cell-free DNA,Sequencing hardware or generic assay protocol: ultra-low-pass whole genome sequencing (ULP-WGS)
CRISPOR software,computational_tools,PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CRISPOR software,Web Application,,http://crispor.tefor.net,,,,,,,,,,,,,,Single-guide RNAs (sgRNAs) were designed using CRISPOR software (http://crispor.tefor.net),Software name not in publication title — likely generic usage: CRISPOR software
FlowJo software,computational_tools,PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FlowJo software,Analysis Software,,,,,,,,,,,,,,,,Data were analyzed using FlowJo software (FlowJo LLC),No version and no repository URL (confidence < 0.9 — unidentifiable)
GraphPad Prism 9,computational_tools,PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism 9,Analysis Software,9,,,,,,,,,,,,,,,All data were processed using GraphPad Prism 9,Generic bioinformatics/stats tool: GraphPad Prism 9
AnyMaze software,computational_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AnyMaze software,Analysis Software,,,,,,,,,,,,,,,,The time spent near each wire cup was recorded and scored with the automated AnyMaze software,Software name not in publication title — likely generic usage: AnyMaze software
ImageJ software,computational_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ software,Analysis Software,,,,,,,,,,,,,,,,neurofibromin-immunoreactive (NF1-ir) cells and pERK-immunoreactive (pERK-ir) cells were counted by a blinded observer using ImageJ software (NIH),Generic bioinformatics/stats tool: ImageJ software
GraphPad Prism version 5.0d,computational_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 5.0d,Analysis Software,5.0d,,,,,,,,,,,,,,,Analysis was performed using GraphPad Prism version 5.0d (GraphPad Software),Generic tool (versioned): GraphPad Prism version 5.0d
Biacore T100 biosensor system,computational_tools,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Biacore T100 biosensor system,Analysis Software,,,,,,,,,,,,,,,,SPR measurements were performed with Biacore T100 biosensor system (GE Heathcare Bioscience),Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
ProteON Manager software,computational_tools,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ProteON Manager software,Analysis Software,,,,,,,,,,,,,,,,"fitted using a Langmiur interaction model (ProteON Manager software, Bio-rad Laboratories)",Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
pClamp software suite,computational_tools,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,pClamp software suite,Analysis Software,,,,,,,,,,,,,,,,Data were digitized with a Digidata 1322 A interface and pClamp software suite,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
ImageJ,computational_tools,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,"analyzed using LAS AF (Leica Microsystems, Wetzlar, Germany) and ImageJ ® software",Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
Origin 8,computational_tools,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Origin 8,Analysis Software,8,,,,,,,,,,,,,,,"Statistical significance was determined using Origin ® 8 (OriginLab, Northampton, MA)",Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
Prism 6.0,computational_tools,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Prism 6.0,Analysis Software,6.0,,,,,,,,,,,,,,,Protein quantification and assessment of significance was determined in Prism 6.0,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
Cronbach's alpha,computational_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Cronbach's alpha,Analysis Software,,,,,,,,,,,,,,,,internal consistency reliability was measured with Cronbach's alpha,No version and no repository URL (confidence < 0.9 — unidentifiable)
SPSS 18,computational_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPSS 18,Analysis Software,18,,,,,,,,,,,,,,,"Statistical analyses were done using SPSS 18 version for Windows (SPSS Inc., Chicago IL, USA)",Software name not in publication title — likely generic usage: SPSS 18
SAS 9.3,computational_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SAS 9.3,Analysis Software,9.3,,,,,,,,,,,,,,,"Statistical analyses were done using SPSS 18 version for Windows (SPSS Inc., Chicago IL, USA) and SAS 9.3 version for Windows (SAS Institute Inc., Cary, NC, USA)",Software name not in publication title — likely generic usage: SAS 9.3
UCSF500 NGS Panel,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,UCSF500 NGS Panel,Analysis Software,,,,,,,,,,,,,,,,Targeted next-generation sequencing was performed using the UCSF500 NGS Panel as previously described,Software name not in publication title — likely generic usage: UCSF500 NGS Panel
BWA,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BWA,Analysis Software,,,,,,,,,,,,,,,,Sequence reads were mapped to the reference human genome build GRCh37 (hg19) using the Burrows-Wheeler aligner (BWA),Generic bioinformatics/stats tool: BWA
GATK,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GATK,Analysis Software,,,,,,,,,,,,,,,,Recalibration and deduplication of reads was performed using the Genome Analysis Toolkit (GATK),Generic bioinformatics/stats tool: GATK
FreeBayes,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FreeBayes,Analysis Software,,,,,,,,,,,,,,,,Single nucleotide variant and small insertion/deletion mutation calling was performed with FreeBayes,No version and no repository URL (confidence < 0.9 — unidentifiable)
Unified Genotyper,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Unified Genotyper,Analysis Software,,,,,,,,,,,,,,,,"Single nucleotide variant and small insertion/deletion mutation calling was performed with FreeBayes, Unified Genotyper, and Pindel",No version and no repository URL (confidence < 0.9 — unidentifiable)
Pindel,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Pindel,Analysis Software,,,,,,,,,,,,,,,,"Single nucleotide variant and small insertion/deletion mutation calling was performed with FreeBayes, Unified Genotyper, and Pindel",No version and no repository URL (confidence < 0.9 — unidentifiable)
Delly,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Delly,Analysis Software,,,,,,,,,,,,,,,,Large insertion/deletion and structural alteration calling was performed with Delly,Generic bioinformatics/stats tool: Delly
Annovar,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Annovar,Analysis Software,,,,,,,,,,,,,,,,Variant annotation was performed with Annovar,Generic bioinformatics/stats tool: Annovar
Integrative Genome Viewer,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Integrative Genome Viewer,Analysis Software,,,,,,,,,,,,,,,,"Single nucleotide variants, insertions/deletions, and structural variants were visualized and verified using Integrative Genome Viewer",No version and no repository URL (confidence < 0.9 — unidentifiable)
CNVkit,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CNVkit,Analysis Software,,,,,,,,,,,,,,,,Genome-wide copy number and zygosity analysis was performed by CNVkit,Generic bioinformatics/stats tool: CNVkit
NxClinical,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NxClinical,Analysis Software,,,,,,,,,,,,,,,,Genome-wide copy number and zygosity analysis was performed by CNVkit and visualized using NxClinical (Biodiscovery),No version and no repository URL (confidence < 0.9 — unidentifiable)
minfi,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,minfi,Package/Library,v.1.38.0,,,,,,,,,,,,,,,Methylation data were preprocessed using the combineArrays function within the minfi package (v.1.38.0) in R Bioconductor,Software name not in publication title — likely generic usage: minfi
Rtsne,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Rtsne,Package/Library,v.0.15,,,,,,,,,,,,,,,Dimensionality reduction using t-distributed stochastic neighbor embedding (tSNE) was performed by Rtsne (v.0.15),Software name not in publication title — likely generic usage: Rtsne
ggplot2,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,ggplot2,Package/Library,v.3.3.5,,,,,,,,,,,,,,,The tSNE plot was visualized with ggplot2 (v.3.3.5),Generic bioinformatics/stats tool: ggplot2
Limma,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Limma,Package/Library,v.3.40.6,,,,,,,,,,,,,,,The lmFit function from the Limma package (v.3.40.6) was applied on a log-transformed b value matrix,Generic bioinformatics/stats tool: Limma
ComplexHeatmap,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ComplexHeatmap,Package/Library,v.2.8.0,,,,,,,,,,,,,,,Visualization was performed using the R package ComplexHeatmap (v.2.8.0),Software name not in publication title — likely generic usage: ComplexHeatmap
FACS Calibur,computational_tools,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FACS Calibur,Analysis Software,,,,,,,,,,,,,,,,All flow cytometry was performed on a FACS Calibur (BD),No version and no repository URL (confidence < 0.9 — unidentifiable)
CellQuest Pro software,computational_tools,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CellQuest Pro software,Analysis Software,,,,,,,,,,,,,,,,Acquisition and data analysis was performed using CellQuest Pro software (BD),No version and no repository URL (confidence < 0.9 — unidentifiable)
HemaVet Mascot 800 hematology analyzer,computational_tools,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HemaVet Mascot 800 hematology analyzer,Analysis Software,,,,,,,,,,,,,,,,"Peripheral blood was analyzed using a HemaVet Mascot 800 hematology analyzer (CDC Technologies, Oxford, CT)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Prism 4.0,computational_tools,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Prism 4.0,Analysis Software,4.0,,,,,,,,,,,,,,,"Graphing and statistical analysis was performed with Prism 4.0 (GraphPad Software, La Jolla, CA)",Software name not in publication title — likely generic usage: Prism 4.0
Feature extractionTM software,computational_tools,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Feature extractionTM software,Analysis Software,9.5.1.1,,,,,,,,,,,,,,,"microarray images were automatically analysed using Feature extractionTM software, version 9.5.1.1 (Agilent Technologies)",Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
limma package,computational_tools,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,limma package,Package/Library,,,,,,,,,,,,,,,,The limma package was also used for differential expression and multiple testing was controlled using the false discovery rate,Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
IncuCyte,computational_tools,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,IncuCyte,Analysis Software,,,,,,,,,,,,,,,,"The live-cell imaging system, IncuCyte (Essen BioScience Ltd, Herts., UK) was used to monitor the migration of cells",Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
Filtlong v0.2.0,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Filtlong v0.2.0,Command-line Tool,v0.2.0,https://github.com/rrwick/Filtlong,,,,,,,,,,,,,,ONT reads meeting a minimum Q-value of 10 were size- and chimera-filtered with Filtlong v0.2.0,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
Porechop v0.2.4,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Porechop v0.2.4,Command-line Tool,v0.2.4,https://github.com/rrwick/Porechop,,,,,,,,,,,,,,ONT reads meeting a minimum Q-value of 10 were size- and chimera-filtered with Filtlong v0.2.0 and Porechop v0.2.4,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
Flye v2.5,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Flye v2.5,Analysis Software,v2.5,,,,,,,,,,,,,,,"Filtered reads were assembled with Flye v2.5, enforcing a 10,000 bp overlap minimum","Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
GCpp v1.0.0-1807624,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GCpp v1.0.0-1807624,Analysis Software,v1.0.0-1807624,https://github.com/PacificBiosciences/gcpp,,,,,,,,,,,,,,Approximately 20× PacBio subread coverage was used with GCpp v1.0.0-1807624 to independently error-correct the ONT-based Flye assembly,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
purge_haplotigs,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,purge_haplotigs,Command-line Tool,,https://bitbucket.org/mroachawri/purge_haplotigs/src/master/,,,,,,,,,,,,,,The resulting error-corrected haploid assembly was deduplicated with purge_haplotigs commit be7e44b,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
Juicer v1.6.2,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Juicer v1.6.2,Analysis Software,v1.6.2,https://github.com/aidenlab/juicer,,,,,,,,,,,,,,"Juicer v1.6.2 and 3D-DNA v180114 were used to scaffold the deduplicated, error-corrected assembly with the Hi-C data","Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
3D-DNA v180114,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,3D-DNA v180114,Analysis Software,v180114,https://github.com/aidenlab/3d-dna,,,,,,,,,,,,,,"Juicer v1.6.2 and 3D-DNA v180114 were used to scaffold the deduplicated, error-corrected assembly with the Hi-C data","Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
BUSCO v5.7.0,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BUSCO v5.7.0,Analysis Software,v5.7.0,https://busco.ezlab.org/,,,,,,,,,,,,,,We assessed the quality of our genome assembly using BUSCO v5.7.0 with mammalia_odb10,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
QUASTv5.0.2,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,QUASTv5.0.2,Analysis Software,v5.0.2,https://quast.sourceforge.net/,,,,,,,,,,,,,,We assessed the quality of our genome assembly using BUSCO v5.7.0 with mammalia_odb10 and QUASTv5.0.2,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
Liftoff v1.6.3,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Liftoff v1.6.3,Analysis Software,v1.6.3,https://github.com/agshumate/Liftoff,,,,,,,,,,,,,,Putative genes in the WMSTM draft genome were identified using Liftoff v1.6.3 with default parameters,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
SnapGeneTM Version 7.2.1,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SnapGeneTM Version 7.2.1,Analysis Software,7.2.1,,,,,,,,,,,,,,,aligned it to the S. scrofa reference coding sequence using the align sequences feature in SnapGeneTM Version 7.2.1,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
AlphaFold 3,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AlphaFold 3,Web Application,,,,,,,,,,,,,,,,The WMSTM and human amino acid sequences were then input into AlphaFold 3 for structural predictions,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
PyMOL Version 3.0.5,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,PyMOL Version 3.0.5,Analysis Software,3.0.5,,,,,,,,,,,,,,,"The structural predictions from WMSTM and human proteins were aligned using PyMOL (The PyMOL Molecular Graphics System, Version 3.0.5 Schrödinger, LLC.)","Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
Skewer v0.2.2.b,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Skewer v0.2.2.b,Command-line Tool,v0.2.2.b,,,,,,,,,,,,,,,"Adapters, low-quality bases, and primers were trimmed from reads to obtain a Phred score of 20 via the trimming software Skewer (v0.2.2.b)","Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
Tassel pipeline version 2,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Tassel pipeline version 2,Pipeline,version 2,,,,,,,,,,,,,,,The Tassel pipeline (version 2) was used to process sequence reads to single nucleotide polymorphism (SNP) genotypes,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
Bowtie2,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bowtie2,Command-line Tool,,,,,,,,,,,,,,,,demultiplexed reads were aligned to the WMSTM draft genome using Bowtie2,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
VCFtools v.0.1.16,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,VCFtools v.0.1.16,Command-line Tool,v.0.1.16,,,,,,,,,,,,,,,The population-wide inbreeding coefficient F was calculated with VCFtools (v.0.1.16),"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
Beagle v4.1,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Beagle v4.1,Analysis Software,v4.1,,,,,,,,,,,,,,,Beagle v4.1 was used to perform whole genome phasing and to impute missing data,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
RAxML,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,RAxML,Analysis Software,,,,,,,,,,,,,,,,A mid-point rooted topology was created from the VCF data using RAxML,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
itol v6.9.1,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,itol v6.9.1,Web Application,v6.9.1,https://itol.embl.de/,,,,,,,,,,,,,,A mid-point rooted topology was created from the VCF data using RAxML and visualized with itol v6.9.1,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
FACS Aria Fusion Special Order System (Becton Dickinson),computational_tools,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FACS Aria Fusion Special Order System (Becton Dickinson),Other,,,,,,,,,,,,,,,,Sorting was performed with the FACS Aria Fusion Special Order System (Becton Dickinson),No version and no repository URL (confidence < 0.9 — unidentifiable)
Smart-seq2,computational_tools,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Smart-seq2,Pipeline,,,,,,,,,,,,,,,,"Smart-seq2 whole transcriptome amplification, library construction, and sequencing were performed as previously published",Software name not in publication title — likely generic usage: Smart-seq2
igraph,computational_tools,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,igraph,Package/Library,,,,,,,,,,,,,,,,"We performed Louvain clustering on the centered matrix with the top 7000 genes using the ""igraph"" package with default parameters.",No version and no repository URL (confidence < 0.9 — unidentifiable)
scdDblFinder,computational_tools,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,scdDblFinder,Package/Library,,,,,,,,,,,,,,,,Doublets were identified by combining the results of two methods that were published recently and implemented in R packages—scdDblFinder,Software name not in publication title — likely generic usage: scdDblFinder
scran,computational_tools,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,scran,Package/Library,,,,,,,,,,,,,,,,scdDblFinder and the doubletCells algorithm from scran,Software name not in publication title — likely generic usage: scran
QuPath,computational_tools,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,QuPath,Analysis Software,,,,,,,,,,,,,,,,Quantification of staining intensity was performed in QuPath,Software name not in publication title — likely generic usage: QuPath
ACE (Advanced Cohort Explorer),computational_tools,PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ACE (Advanced Cohort Explorer),Database,,,,,,,,,,,,,,,,Targeted next generation sequencing data from 2745 cancer samples...were collected with ACE (Advanced Cohort Explorer).,Publication title lacks NF-specific terms: Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases
GENIE (Genomics Evidence Neoplasia Information Exchange),computational_tools,PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GENIE (Genomics Evidence Neoplasia Information Exchange),Database,v.7.0,,,,,,,,,,,,,,,cancer genomics databases including GENIE (Genomics Evidence Neoplasia Information Exchange),Publication title lacks NF-specific terms: Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases
cBioPortal,computational_tools,PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,cBioPortal,Web Application,,,,,,,,,,,,,,,,databases in cBioPortal including TCGA (The Cancer Genome Atlas),Publication title lacks NF-specific terms: Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases
TCGA (The Cancer Genome Atlas),computational_tools,PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,TCGA (The Cancer Genome Atlas),Database,,,,,,,,,,,,,,,,databases in cBioPortal including TCGA (The Cancer Genome Atlas),Publication title lacks NF-specific terms: Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases
Catalogue of Somatic Mutations in Cancer,computational_tools,PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Catalogue of Somatic Mutations in Cancer,Database,,,,,,,,,,,,,,,,Variants with less than 2 Catalogue of Somatic Mutations in Cancer counts were excluded as passenger alterations.,Publication title lacks NF-specific terms: Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases
minfi,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,minfi,Package/Library,1.30,,,,,,,,,,,,,,,Data preprocessing and normalization was performed using minfi version 1.30 in R version 3.6.0,Software name not in publication title — likely generic usage: minfi
Seurat,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat,Package/Library,3.0,,,,,,,,,,,,,,,"Data were normalized, and variance stabilized by SCTransform in Seurat version 3.0",Software name not in publication title — likely generic usage: Seurat
Cell Ranger,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cell Ranger,Analysis Software,1.3.1,,,,,,,,,,,,,,,"Library demultiplexing, read alignment to human genome GRCh38, and unique molecular identifier (UMI) quantification was performed in Cell Ranger version 1.3.1",Software name not in publication title — likely generic usage: Cell Ranger
HISAT2,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HISAT2,Analysis Software,2.0.3,,,,,,,,,,,,,,,Reads were aligned to GRCh38 using the splice-aware aligner HISAT2 version 2.0.3,Generic bioinformatics/stats tool: HISAT2
DESeq2,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2,Package/Library,,,,,,,,,,,,,,,,Differential expression analysis was performed using DESeq2 using the Wald test,Generic bioinformatics/stats tool: DESeq2
MaxQuant,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MaxQuant,Analysis Software,,,,,,,,,,,,,,,,Peptide and protein identification searches were performed using the MaxQuant data analysis algorithm,Generic bioinformatics/stats tool: MaxQuant
MSstats,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MSstats,Package/Library,,,,,,,,,,,,,,,,Label-free quantification and statistical testing were performed using the MSstats statistical R-package,No version and no repository URL (confidence < 0.9 — unidentifiable)
Skyline,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Skyline,Analysis Software,4.2.0.19072,,,,,,,,,,,,,,,All PRM data was analyzed by Skyline 4.2.0.19072,Generic bioinformatics/stats tool: Skyline
ChromVAR,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ChromVAR,Package/Library,,,,,,,,,,,,,,,,Transcription factor motif deviations in the setting of genetic or therapeutic perturbations were quantified using the ChromVAR wrapper in Signac,No version and no repository URL (confidence < 0.9 — unidentifiable)
Signac,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Signac,Package/Library,1.8.0,,,,,,,,,,,,,,,Preprocessing of single-nuclei RNA and ATAC data was performed using Signac v1.8.0,Software name not in publication title — likely generic usage: Signac
CONICS,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CONICS,Analysis Software,,,,,,,,,,,,,,,,"To evaluate whether we could identify single nuclei CNVs from prospective schwannomas that demonstrated loss of chromosome 22q based on DNA methylation profiling, we applied CONICS",No version and no repository URL (confidence < 0.9 — unidentifiable)
Enrichr,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Enrichr,Web Application,,,,,,,,,,,,,,,,Gene ontology analysis of probes was performed by extracting the associated gene body annotation from each probe using the Bioconductor package IlluminaHumanMethylationEPICanno.ilm10b2.hg19 and inputting the gene lists grouped based on the results of hierarchical clustering into Enrichr,Generic bioinformatics/stats tool: Enrichr
caret,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,caret,Package/Library,6.0,,,,,,,,,,,,,,,a methylation-based classifier using differentially methylated probes from our discovery cohort of 66 tumors was used to construct a support vector machine (SVM) using caret version 6.0 in R version 3.6.0,Software name not in publication title — likely generic usage: caret
Harmony,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Harmony,Package/Library,,,,,,,,,,,,,,,,UMAP was performed on significant (p < 0.05) principal components (determined by JackStraw analysis) and batch-corrected using Harmony,No version and no repository URL (confidence < 0.9 — unidentifiable)
Aardex MEMS Adherence Software (ElectronReader 0.9.9),computational_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Aardex MEMS Adherence Software (ElectronReader 0.9.9),Analysis Software,0.9.9,,,,,,,,,,,,,,,"diaries and pill bottles (including empty ones) were collected, and MEMS TM cap data were uploaded to Aardex MEMS TM Adherence Software (ElectronReader 0.9.9).",Software name not in publication title — likely generic usage: Aardex MEMS Adherence Software (ElectronReader 0.9.9)
NanoDrop 2000,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NanoDrop 2000,Analysis Software,,,,,,,,,,,,,,,,"Purity of DNA was assessed by spectrophotometry using NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA)",Software name not in publication title — likely generic usage: NanoDrop 2000
Qubit fluorometer,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Qubit fluorometer,Analysis Software,,,,,,,,,,,,,,,,DNA yields were determined using a double stranded DNA (dsDNA) broad range (BR) kit on a Qubit ® fluorometer (Thermo Fisher Scientific),No version and no repository URL (confidence < 0.9 — unidentifiable)
Bioruptor sonicator,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bioruptor sonicator,Analysis Software,,,,,,,,,,,,,,,,"DNA was sheared into 200 bp fragments on a Bioruptor ® sonicator (Diagenode, Denville, NJ, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Ion Torrent Personal Genome Machine—Ion Torrent PGM™,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.95,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Ion Torrent Personal Genome Machine—Ion Torrent PGM™,Analysis Software,,,,,,,,,,,,,,,,NGS was performed on Ion Torrent Personal Genome Machine—Ion Torrent PGM™ (Thermo Fisher Scientific),Software name not in publication title — likely generic usage: Ion Torrent Personal Genome Machine—Ion Torrent PGM™
Torrent Suite software,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Torrent Suite software,Analysis Software,,,,,,,,,,,,,,,,Primary analyses of NGS data were performed using Torrent Suite software on the Ion Torrent Browser,Software name not in publication title — likely generic usage: Torrent Suite software
TMAP,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,TMAP,Analysis Software,,,,,,,,,,,,,,,,reads were aligned to the reference sequence using TMAP (Torrent Mapping Alignment Program),No version and no repository URL (confidence < 0.9 — unidentifiable)
Ingenuity Variant Analysis software,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Ingenuity Variant Analysis software,Analysis Software,,,,,,,,,,,,,,,,"For variant interpretation, Ingenuity ® Variant Analysis™ software (Qiagen) and SNPnexus web server were used",Software name not in publication title — likely generic usage: Ingenuity Variant Analysis software
SNPnexus web server,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SNPnexus web server,Web Application,,,,,,,,,,,,,,,,"For variant interpretation, Ingenuity ® Variant Analysis™ software (Qiagen) and SNPnexus web server were used",No version and no repository URL (confidence < 0.9 — unidentifiable)
Integrative Genomics Viewer,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Integrative Genomics Viewer,Analysis Software,2.3.40,,,,,,,,,,,,,,,"Variants were also viewed manually on Integrative Genomics Viewer (IGV—version 2.3.40; Broad Institute, Cambridge, MA, USA)",Software name not in publication title — likely generic usage: Integrative Genomics Viewer
Alamut Visual,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Alamut Visual,Analysis Software,2.6.1e,,,,,,,,,,,,,,,"on Alamut ® Visual (version 2.6.1e; Interactive Biosoftware, Rouen, France) to eliminate strand bias and reduce false positive calls",Software name not in publication title — likely generic usage: Alamut Visual
PolyPhen2,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PolyPhen2,Analysis Software,,,,,,,,,,,,,,,,"To predict the potential effect of the mutation on the structure and function of the protein codified by the NF1 gene (neurofibromin), PolyPhen2 and SIFT were applied",No version and no repository URL (confidence < 0.9 — unidentifiable)
SIFT,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SIFT,Analysis Software,,,,,,,,,,,,,,,,"To predict the potential effect of the mutation on the structure and function of the protein codified by the NF1 gene (neurofibromin), PolyPhen2 and SIFT were applied",No version and no repository URL (confidence < 0.9 — unidentifiable)
Human Splicing Finder,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Human Splicing Finder,Web Application,,http://www.umd.be/HSF/,,,,,,,,,,,,,,we also used the online Human Splicing Finder ( http://www.umd.be/HSF/ ),Software name not in publication title — likely generic usage: Human Splicing Finder
AB3130 Genetic Analyzer,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AB3130 Genetic Analyzer,Analysis Software,,,,,,,,,,,,,,,,"All variants were confirmed by Sanger sequencing in an AB3130 Genetic Analyzer (Applied Biosystems, Carlsbad, CA, USA)",Software name not in publication title — likely generic usage: AB3130 Genetic Analyzer
NCBI's Primer BLAST tool,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NCBI's Primer BLAST tool,Web Application,,,,,,,,,,,,,,,,Primers were designed using NCBI's Primer BLAST tool,No version and no repository URL (confidence < 0.9 — unidentifiable)
Sequencing Analysis software,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Sequencing Analysis software,Analysis Software,5.4,,,,,,,,,,,,,,,the sequences were analyzed with the Sequencing Analysis software (version 5.4; Applied Biosystems),Software name not in publication title — likely generic usage: Sequencing Analysis software
FACSCanto II (BD Bioscienses),computational_tools,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FACSCanto II (BD Bioscienses),Analysis Software,,,,,,,,,,,,,,,,...Data was acquired using FACSCanto II (BD Bioscienses) flow cytometer and at least 20.000 events were analyzed...,No version and no repository URL (confidence < 0.9 — unidentifiable)
FACSDiva (BD Biosciences),computational_tools,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FACSDiva (BD Biosciences),Analysis Software,,,,,,,,,,,,,,,,"...at least 20.000 events were analyzed with FACSDiva (BD Biosciences) or FlowJo 7.6.5 ( FlowJo.com ; Tree Star, OR, USA) software...",No version and no repository URL (confidence < 0.9 — unidentifiable)
FlowJo 7.6.5,computational_tools,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FlowJo 7.6.5,Analysis Software,7.6.5,,,,,,,,,,,,,,,"...analyzed with FACSDiva (BD Biosciences) or FlowJo 7.6.5 ( FlowJo.com ; Tree Star, OR, USA) software...",Software name not in publication title — likely generic usage: FlowJo 7.6.5
"ImageJ software v.1.49 (NIH, USA)",computational_tools,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"ImageJ software v.1.49 (NIH, USA)",Analysis Software,v.1.49,,,,,,,,,,,,,,,"...Images were analyzed using ImageJ software v.1.49 (NIH, USA), and the percentage of stained area in each picture was obtained...","Generic tool (versioned): ImageJ software v.1.49 (NIH, USA)"
"Countess II FL Automated Cell Counter (ThermoFisher Scientific, MA, USA)",computational_tools,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"Countess II FL Automated Cell Counter (ThermoFisher Scientific, MA, USA)",Analysis Software,,,,,,,,,,,,,,,,"...the cell number was determined using Countess II FL Automated Cell Counter (ThermoFisher Scientific, MA, USA)...",No version and no repository URL (confidence < 0.9 — unidentifiable)
SPSS v. 20.0,computational_tools,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS v. 20.0,Analysis Software,v. 20.0,,,,,,,,,,,,,,,"...Statistical analysis was performed using Statistical Package for Social Sciences software (SPSS v. 20.0; Chicago, IL, USA)...",Software name not in publication title — likely generic usage: SPSS v. 20.0
iScan machine,computational_tools,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,iScan machine,Analysis Software,,,,,,,,,,,,,,,,"hiPSCs were karyotyped using the iScan machine (Illumina, CA, USA)",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
Karyostudio 1.3 software,computational_tools,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Karyostudio 1.3 software,Analysis Software,1.3,,,,,,,,,,,,,,,The analysis was performed using the Karyostudio 1.3 software (Illumina),Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
IncuCyte Zoom live cell analysis system,computational_tools,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,IncuCyte Zoom live cell analysis system,Analysis Software,,,,,,,,,,,,,,,,"Cell motility was assessed using the IncuCyte cell migration kit (Sartorius, Göttingen, Germany) and an Incucyte Zoom live cell analysis system",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
Partek Flow software,computational_tools,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Partek Flow software,Analysis Software,v10.0,,,,,,,,,,,,,,,"RNA sequencing analysis was generated using Partek Flow software, v10.0",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
STAR,computational_tools,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR,Analysis Software,v2.7.8a,,,,,,,,,,,,,,,RNA sequencing reads were aligned to the hg38 Ensembl release 105 assembly with STAR v2.7.8a,Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
DESeq2,computational_tools,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2,Package/Library,,,,,,,,,,,,,,,,"Differential genetic analysis was then performed using DESeq2 (Love et al., 2014)",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
Imaris software,computational_tools,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Imaris software,Analysis Software,9,,,,,,,,,,,,,,,"Images were 3D-rendered using Imaris software (Imaris 9, Oxford Instruments, Abingdon, UK)",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
Illumina EPIC 850K methylation array,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina EPIC 850K methylation array,Analysis Software,,,,,,,,,,,,,,,,We interrogated the methylation profiles of 45 CNFs and 17 PNFs from NF1 subjects with the Illumina EPIC 850K methylation array.,Sequencing hardware or generic assay protocol: Illumina EPIC 850K methylation array
ChAMP,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ChAMP,Package/Library,v2.18.3,,,,,,,,,,,,,,,Data were analyzed using a modified workflow that is similar to the ChAMP methylation array analysis procedure in R (v3.5.1),Software name not in publication title — likely generic usage: ChAMP
glmmTMB,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,glmmTMB,Package/Library,v0.2.2,,,,,,,,,,,,,,,Differentially methylated loci between cutaneous and plexiform neurofibromas were identified using a hierarchical generalized linear mixed model (GLMM) approach with a logit link function as implemented in glmmTMB (v0.2.2),Software name not in publication title — likely generic usage: glmmTMB
DMRcate,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DMRcate,Package/Library,v1.18.0,,,,,,,,,,,,,,,Differentially methylated regions were called using DMRcate (v1.18.0),Software name not in publication title — likely generic usage: DMRcate
compartmap,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,compartmap,Package/Library,v1.65.71,,,,,,,,,,,,,,,Chromatin compartments were computed at 100 kb resolution as previously described and implemented in compartmap (v1.65.71),Software name not in publication title — likely generic usage: compartmap
missMethyl,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,missMethyl,Package/Library,v1.16.0,,,,,,,,,,,,,,,Enrichment of pathways and gene ontology (GO) terms was performed using the gometh function within the missMethyl (v1.16.0) package in R,Software name not in publication title — likely generic usage: missMethyl
PAMES,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,PAMES,Package/Library,v0.2.3,,,,,,,,,,,,,,,Tissue purity was estimated by PAMES (v0.2.3),Software name not in publication title — likely generic usage: PAMES
SeSAMe,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SeSAMe,Package/Library,v1.3.2,,,,,,,,,,,,,,,Copy number alterations were computed using SeSAMe (v1.3.2) with minor modifications for plotting functionality,Software name not in publication title — likely generic usage: SeSAMe
STAR,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR,Analysis Software,v2.7.0f,,,,,,,,,,,,,,,"Sequencing lanes were merged, followed by alignment with STAR (v2.7.0f) to b37",Generic bioinformatics/stats tool: STAR
edgeR,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,edgeR,Package/Library,v3.27.14,,,,,,,,,,,,,,,Reverse-stranded gene counts were read into R (v3.6.1) using edgeR (v3.27.14),Generic bioinformatics/stats tool: edgeR
betareg,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,betareg,Package/Library,v3.1-2,,,,,,,,,,,,,,,Pairwise comparisons of beta-regressions calculated by betareg (v3.1–2),Software name not in publication title — likely generic usage: betareg
emmeans,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,emmeans,Package/Library,v1.4.2,,,,,,,,,,,,,,,Pairwise comparisons of beta-regressions calculated by betareg (v3.1–2) were done using emmeans (v1.4.2),Software name not in publication title — likely generic usage: emmeans
ggplot2,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ggplot2,Package/Library,v3.2.1,,,,,,,,,,,,,,,"For all correlation plots, data were fit by stat_smooth using loess with span = 1 using ggplot2 (v3.2.1)",Generic bioinformatics/stats tool: ggplot2
TopHat,computational_tools,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,TopHat,Analysis Software,,,,,,,,,,,,,,,,All RNA-Seq data were aligned to mm10 using TopHat with default settings,Generic bioinformatics/stats tool: TopHat
Cuff-diff,computational_tools,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Cuff-diff,Analysis Software,,,,,,,,,,,,,,,,We used Cuff-diff to (1) estimate FPKM values for known transcripts and (2) analyze differentially expressed transcripts,No version and no repository URL (confidence < 0.9 — unidentifiable)
GSEA,computational_tools,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GSEA,Analysis Software,,,,,,,,,,,,,,,,"GO-analysis of gene expression changes was performed using Gene Set Enrichment (GSEA, http://www.broadinstitute.org/gsea/index.jsp )",Generic bioinformatics/stats tool: GSEA
ToppCluster,computational_tools,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ToppCluster,Web Application,,,,,,,,,,,,,,,,We used ToppCluster ( https://toppcluster.cchmc.org/ ) to construct the network of genes belonging to over-represented GO-term categories,No version and no repository URL (confidence < 0.9 — unidentifiable)
MACS version 1.4.2,computational_tools,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MACS version 1.4.2,Analysis Software,1.4.2,,,,,,,,,,,,,,,peak calling was performed using Model-based analysis of ChIP-seq (MACS) version 1.4.2 ( http://liulab.dfci.harvard.edu/MACS ) with default parameters,Software name not in publication title — likely generic usage: MACS version 1.4.2
EaSeq,computational_tools,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,EaSeq,Analysis Software,,,,,,,,,,,,,,,,"WIG files were generated with MACS, which were subsequently visualized using EaSeq ( Lerdrup et al., 2016 )",No version and no repository URL (confidence < 0.9 — unidentifiable)
HOMER software,computational_tools,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HOMER software,Analysis Software,,,,,,,,,,,,,,,,Motif discovery was performed by HOMER software,No version and no repository URL (confidence < 0.9 — unidentifiable)
AltAnalyze,computational_tools,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AltAnalyze,Analysis Software,,,,,,,,,,,,,,,,The heatmap in Figure 7J was generated based on log2 [FPKM] by AltAnalyze ( AltAnalyze.org ) with normalization of rows relative to row mean,No version and no repository URL (confidence < 0.9 — unidentifiable)
Wilcoxon signed rank test,computational_tools,PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Wilcoxon signed rank test,Analysis Software,,,,,,,,,,,,,,,,"...Due to the small sample size, the Wilcoxon signed rank test was used to assess changes on the outcome measures from baseline to 3 months",No version and no repository URL (confidence < 0.9 — unidentifiable)
PRISMAfit,computational_tools,PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PRISMAfit,Analysis Software,,,,,,,,,,,,,,,,"All participants underwent imaging of the lumbosacral plexus at the same 3-T scanner (PRISMAfit, Siemens Healthineers, Erlangen, Germany)",No version and no repository URL (confidence < 0.9 — unidentifiable)
MATLAB,computational_tools,PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,MATLAB,Analysis Software,R2024a Update 3,,,,,,,,,,,,,,,"Image postprocessing was performed via MATLAB (The MathWorks, Inc., 2024: MATLAB, version R2024a Update 3, retrieved from https://www.mathworks.com/)",Generic bioinformatics/stats tool: MATLAB
3D Slicer,computational_tools,PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,3D Slicer,Analysis Software,5.6.2,https://www.slicer.org/,,,,,,,,,,,,,,"The two readers independently performed three-dimensional selection of the volume of interest by manual segmentation of the DRG of levels L5 and S1 via 3D Slicer (The Slicer Community 2024: 3D Slicer, version 5.6.2)",Software name not in publication title — likely generic usage: 3D Slicer
R,computational_tools,PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R,Analysis Software,4.4.1,https://www.r-project.org/,,,,,,,,,,,,,,"Statistical analyses and visualisations were performed with R (The R Foundation for Statistical Computing 2024: R: A language for Data Analysis and Graphics, version 4.4.1)",Generic bioinformatics/stats tool: R
GraphPad Prism,computational_tools,PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism,Analysis Software,9.4.0,,,,,,,,,,,,,,,"Statistical analyses and visualisations were performed with R and GraphPad Prism (GraphPad Prism version 9.4.0, GraphPad Software)",Generic bioinformatics/stats tool: GraphPad Prism
ImageJ,computational_tools,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ,Analysis Software,,http://imagej.nih.gov/ij/,,,,,,,,,,,,,,Central vessel dropout area was quantified from the digital images using the ImageJ software (http://imagej.nih.gov/ij/),Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
Swift_NV macro,computational_tools,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Swift_NV macro,Plugin,,,,,,,,,,,,,,,,neovascular area was determined using the Swift_NV macro for ImageJ,Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
GraphPad Prism version 6.0h,computational_tools,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 6.0h,Analysis Software,6.0h,,,,,,,,,,,,,,,"Analysis was performed using GraphPad Prism version 6.0h (La Jolla, CA, USA)",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
EPIC electronic medical record service,computational_tools,PMID:34646065,10.1155/2021/9386823,Survival and ,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,EPIC electronic medical record service,Database,,,,,,,,,,,,,,,,The data were extracted from an EPIC electronic medical record service and from the Enneking/Anspach Research Center database,Publication title lacks NF-specific terms: Survival and
Enneking/Anspach Research Center database,computational_tools,PMID:34646065,10.1155/2021/9386823,Survival and ,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Enneking/Anspach Research Center database,Database,,,,,,,,,,,,,,,,The data were extracted from an EPIC electronic medical record service and from the Enneking/Anspach Research Center database,Publication title lacks NF-specific terms: Survival and
SPSS 25,computational_tools,PMID:34646065,10.1155/2021/9386823,Survival and ,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS 25,Analysis Software,25,,,,,,,,,,,,,,,"All data were analyzed using statistical software (SPSS 25, IBM Co. Armonk, NY)",Publication title lacks NF-specific terms: Survival and
SimNIBS 3.2,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SimNIBS 3.2,Analysis Software,3.2,https://simnibs.github.io/simnibs/build/html/index.html,,,,,,,,,,,,,,SimNIBS 3.2 ( https://simnibs.github.io/simnibs/build/html/index.html ) was used to estimate the electric field induced by tDCS,Software name not in publication title — likely generic usage: SimNIBS 3.2
headreco pipeline,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,headreco pipeline,Pipeline,,,,,,,,,,,,,,,,The headreco pipeline was used to segment the different tissue types and create a finite element mesh,No version and no repository URL (confidence < 0.9 — unidentifiable)
SPM8,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPM8,Analysis Software,8,http://www.fil.ion.ucl.ac.uk/spm/,,,,,,,,,,,,,,"the T1-weighted anatomical images were segmented into gray matter (GM), white matter (WM) and cerebrospinal fluid (CSF) using SPM8",Software name not in publication title — likely generic usage: SPM8
jMRUI5.1,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,jMRUI5.1,Analysis Software,5.1,,,,,,,,,,,,,,,"Quantification was conducted using the Advanced Magnetic Resonance (AMARES) routine in the Java-based magnetic resonance user's interface (jMRUI5.1, EU project)",Software name not in publication title — likely generic usage: jMRUI5.1
SPM12,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPM12,Analysis Software,12,http://www.fil.ion.ucl.ac.uk/spm,,,,,,,,,,,,,,"Image processing and statistical analysis was carried out using SPM12 (Wellcome Department of Imaging Neuroscience, London)",Software name not in publication title — likely generic usage: SPM12
DARTEL,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DARTEL,Package/Library,,,,,,,,,,,,,,,,segmented using the DARTEL (diffeomorphic anatomical registration through an exponentiated lie algebra) toolbox,No version and no repository URL (confidence < 0.9 — unidentifiable)
Marsbar,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Marsbar,Package/Library,,,,,,,,,,,,,,,,"In order to examine the effect of the stimulation on the DLPFC, a region of interest (ROI) analysis was performed using Marsbar",No version and no repository URL (confidence < 0.9 — unidentifiable)
E-Prime,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,E-Prime,Analysis Software,,,,,,,,,,,,,,,,The task was programmed in-house using E-Prime software,No version and no repository URL (confidence < 0.9 — unidentifiable)
Psychology Experiment Building Language (PEBL),computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Psychology Experiment Building Language (PEBL),Analysis Software,,,,,,,,,,,,,,,,participants were asked to complete the computerised Corsi block task on the Psychology Experiment Building Language (PEBL),No version and no repository URL (confidence < 0.9 — unidentifiable)
Psychopy2,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Psychopy2,Analysis Software,2,,,,,,,,,,,,,,,Psychopy2 software was used to display the stimuli and to record responses,Software name not in publication title — likely generic usage: Psychopy2
SPSS version25,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPSS version25,Analysis Software,25,,,,,,,,,,,,,,,Statistical analyses were performed in SPSS version25 and R version 1.2,Software name not in publication title — likely generic usage: SPSS version25
R version 1.2,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R version 1.2,Analysis Software,1.2,,,,,,,,,,,,,,,Statistical analyses were performed in SPSS version25 and R version 1.2,Generic tool (versioned): R version 1.2
nlme package,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,nlme package,Package/Library,,,,,,,,,,,,,,,,"linear mixed modelling was used to estimate the effect group and stimulation on the ROI beta values and for the fMRI task accuracy, RT and IES using the 'nlme' package",No version and no repository URL (confidence < 0.9 — unidentifiable)
MATLAB R2014a,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MATLAB R2014a,Analysis Software,R2014a,,,,,,,,,,,,,,,"Image processing and statistical analysis was carried out using SPM12 (Wellcome Department of Imaging Neuroscience, London; http://www.fil.ion.ucl.ac.uk/spm ) and MATLAB R2014a",Software name not in publication title — likely generic usage: MATLAB R2014a
JMP,computational_tools,PMID:26822862,10.1038/srep20010,Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,JMP,Analysis Software,,,,,,,,,,,,,,,,"The uniform designs were generated and analysed with JMP (SAS Institute Inc., Cary, North Carolina, USA) using a Gaussian process with a Gaussian covariance function.",No version and no repository URL (confidence < 0.9 — unidentifiable)
VSC (Flemish Supercomputer Center),computational_tools,PMID:26822862,10.1038/srep20010,Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VSC (Flemish Supercomputer Center),Other,,,,,,,,,,,,,,,,"Next, the computer simulations were performed with these parameter combinations, utilizing high-performance computational resources provided by the VSC (Flemish Supercomputer Center).",No version and no repository URL (confidence < 0.9 — unidentifiable)
agent-based model of Bentley et al.,computational_tools,PMID:26822862,10.1038/srep20010,Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study.,,0.75,Citation Only,True,0.67,Low,,,,,,,,,,,,,,,agent-based model of Bentley et al.,Other,,,,,,,,,,,,,,,,The sprouting behaviour of the endothelial cells is derived from the agent-based model of Bentley et al. and is captured with eight intracellular variables,No version and no repository URL (confidence < 0.9 — unidentifiable)
Imaris × 64 version 9.6–9.9,computational_tools,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Imaris × 64 version 9.6–9.9,Analysis Software,9.6–9.9,,,,,,,,,,,,,,,"3-dimensional fluorescence images using Imaris × 64 version 9.6–9.9 (Bitplane, Zurich, Switzerland) algorithms",Software name not in publication title — likely generic usage: Imaris × 64 version 9.6–9.9
IGOR Pro 6.37,computational_tools,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,IGOR Pro 6.37,Analysis Software,6.37,,,,,,,,,,,,,,,"IGOR Pro 6.37 (Lake Oswego, USA) was used for data analysis",Software name not in publication title — likely generic usage: IGOR Pro 6.37
MaxQuant version 1.6.10.43,computational_tools,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MaxQuant version 1.6.10.43,Analysis Software,1.6.10.43,,,,,,,,,,,,,,,MaxQuant version 1.6.10.43 [ 12 ] was used whilst enabling TMTpro 16-plex reporter ion quantitation,Software name not in publication title — likely generic usage: MaxQuant version 1.6.10.43
limma R package,computational_tools,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,limma R package,Package/Library,,,,,,,,,,,,,,,,two-sample moderated t-tests were applied (limma R package; [ 56 ],No version and no repository URL (confidence < 0.9 — unidentifiable)
Prism 7,computational_tools,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Prism 7,Analysis Software,7,,,,,,,,,,,,,,,"one-way ANOVA tests with Bonferroni post hoc tests were employed using Prism 7 (GraphPad Software, San Diego, CA, USA)",Software name not in publication title — likely generic usage: Prism 7
Illumina HiSeq2000,computational_tools,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina HiSeq2000,Analysis Software,,,,,,,,,,,,,,,,We performed exome sequencing on five malignant meningiomas on the Illumina HiSeq2000 platform using Agilent SureSelect Human All Exon kits.,Sequencing hardware or generic assay protocol: Illumina HiSeq2000
wANNOVAR web server,computational_tools,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,wANNOVAR web server,Web Application,,,,,,,,,,,,,,,,"We used wANNOVAR web server to annotate and prioritize variants, identified candidate genes with recurrent mutations",Software name not in publication title — likely generic usage: wANNOVAR web server
Covaris E210,computational_tools,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Covaris E210,Analysis Software,,,,,,,,,,,,,,,,2 μg purified genomic DNA was extracted and randomly fragmented using Covaris E210 to generate DNA fragments around 200 to 300 bp,No version and no repository URL (confidence < 0.9 — unidentifiable)
SeqMule,computational_tools,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SeqMule,Pipeline,,http://seqmule.usc.edu/,,,,,,,,,,,,,,We used SeqMule (http://seqmule.usc.edu/) pipeline as our primary variant calling pipeline.,Software name not in publication title — likely generic usage: SeqMule
BWA,computational_tools,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BWA,Analysis Software,,,,,,,,,,,,,,,,"In SeqMule pipeline, BWA (Li and Durbin, 2009) was used for sequence alignment",Generic bioinformatics/stats tool: BWA
GATK,computational_tools,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GATK,Analysis Software,,,,,,,,,,,,,,,,"GATK (McKenna) and SAMtools (et al., 2010 Li) were used to generate variant calls and to identify consensus calls for analysis.",Generic bioinformatics/stats tool: GATK
SAMtools,computational_tools,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SAMtools,Analysis Software,,,,,,,,,,,,,,,,"GATK (McKenna) and SAMtools (et al., 2010 Li) were used to generate variant calls and to identify consensus calls for analysis.",Generic bioinformatics/stats tool: SAMtools
VarScan2,computational_tools,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VarScan2,Analysis Software,,,,,,,,,,,,,,,,we decided to use VarScan2 as our primary variant calling tools for targeted region sequencing data analysis given sufficient sequencing depth.,Generic bioinformatics/stats tool: VarScan2
Codon Code Aligner,computational_tools,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Codon Code Aligner,Analysis Software,,http://www.codoncode.com/aligner/,,,,,,,,,,,,,,The sequencing traces were manually visualized in Codon Code Aligner software (http://www.codoncode.com/aligner/) to confirm the presence of candidate mutations.,Software name not in publication title — likely generic usage: Codon Code Aligner
primer 3 (v. 0.4.0),computational_tools,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,primer 3 (v. 0.4.0),Web Application,v. 0.4.0,http://bioinfo.ut.ee/primer3-0.4.0/,,,,,,,,,,,,,,Twelve pairs of primers were designed using primer 3 (v. 0.4.0) (http://bioinfo.ut.ee/primer3-0.4.0/).,Software name not in publication title — likely generic usage: primer 3 (v. 0.4.0)
Stratagene Mx3005 – MxPro QPCR-Software,computational_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Stratagene Mx3005 – MxPro QPCR-Software,Analysis Software,2007,,,,,,,,,,,,,,,"Genotyping was performed using a real-time PCR system in the allelic discrimination mode (Stratagene Mx3005 – MxPro QPCR-Software, 2007)",Software name not in publication title — likely generic usage: Stratagene Mx3005 – MxPro QPCR-Software
SPSS 20.0,computational_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.75,Experimental Usage,True,1.00,Low,,,,,,,,,,,,,,,SPSS 20.0,Analysis Software,20.0,,,,,,,,,,,,,,,All statistical procedures were performed in SPSS 20.0,Software name not in publication title — likely generic usage: SPSS 20.0
Incucyte S3 Live-Cell Analysis System,computational_tools,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Incucyte S3 Live-Cell Analysis System,Analysis Software,,,,,,,,,,,,,,,,"The total integrated intensity of RFP was monitored over the course of 72 hours, taking measurements every 2 hours with the Incucyte S3 Live-Cell Analysis System (Sartorius, Gottingen, Germany)",Software name not in publication title — likely generic usage: Incucyte S3 Live-Cell Analysis System
synergyfinder,computational_tools,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,synergyfinder,Web Application,,https://synergyfinder.fimm.fi/,,,,,,,,,,,,,,We used the percent viability compared to untreated cells to calculate a synergy score for each of the analyzed combinations (https://synergyfinder.fimm.fi/),Software name not in publication title — likely generic usage: synergyfinder
GraphPad Prism 9,computational_tools,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism 9,Analysis Software,9,,,,,,,,,,,,,,,IC50 and Lethal Dose 50 (LD50) values and 95% confidence intervals were calculated to assess drug sensitivity (GraphPad Prism 9 software),Generic bioinformatics/stats tool: GraphPad Prism 9
"ABI Prism 7000 Sequence Detection System (Applied Biosystems, version 1.1 software)",computational_tools,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"ABI Prism 7000 Sequence Detection System (Applied Biosystems, version 1.1 software)",Analysis Software,1.1,,,,,,,,,,,,,,,"cDNA samples were then subjected to qPCR amplification on an ABI Prism 7000 Sequence Detection System (Applied Biosystems, version 1.1 software)","Software name not in publication title — likely generic usage: ABI Prism 7000 Sequence Detection System (Applied Biosystems, version 1.1 software)"
Olympus FV1000 point scanning confocal microscope,computational_tools,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Olympus FV1000 point scanning confocal microscope,Analysis Software,,,,,,,,,,,,,,,,Images were acquired with an Olympus FV1000 point scanning confocal microscope (UCSD School of Medicine Light Microscopy Facility,No version and no repository URL (confidence < 0.9 — unidentifiable)
FlowJo software,computational_tools,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FlowJo software,Analysis Software,,,,,,,,,,,,,,,,"Samples were analyzed on a FACScan (Becton Dickinson, Franklin Lakes, NJ), and data were analyzed for DNA content using Flowjo software",No version and no repository URL (confidence < 0.9 — unidentifiable)
Risk-Calibrated Superspase Linear Integer Model (Risk-SLIM),computational_tools,PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Risk-Calibrated Superspase Linear Integer Model (Risk-SLIM),Analysis Software,,,,,,,,,,,,,,,,A new modeling method known as the Risk-Calibrated Superspase Linear Integer Model (Risk-SLIM) was created to reduce the variability in risk assessment using machine learning techniques.,No version and no repository URL (confidence < 0.9 — unidentifiable)
Python version 3.10,computational_tools,PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Python version 3.10,Analysis Software,3.10,,,,,,,,,,,,,,,"All statistics and models were conducted in Python version 3.10 (Python Software Foundation, Wilmington, Delaware, US).",Generic tool (versioned): Python version 3.10
SPSS 17.0,computational_tools,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS 17.0,Analysis Software,17.0,,,,,,,,,,,,,,,Statistical analysis was performed using the SPSS 17.0 statistics software,Software name not in publication title — likely generic usage: SPSS 17.0
Imaris software,computational_tools,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Imaris software,Analysis Software,,,,,,,,,,,,,,,,Images were generated using Imaris software (Bitplane AG),No version and no repository URL (confidence < 0.9 — unidentifiable)
SPSS 12.0,computational_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS 12.0,Analysis Software,12.0,,,,,,,,,,,,,,,"All data were analyzed using SPSS 12.0 (SPSS Inc, Chicago, Illinois)",Software name not in publication title — likely generic usage: SPSS 12.0
IVIS 50 system,computational_tools,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,IVIS 50 system,Analysis Software,,,,,,,,,,,,,,,,Bioluminescence signals from the virus-encoded luciferase activity were detected using an IVIS 50 system (Caliper),No version and no repository URL (confidence < 0.9 — unidentifiable)
PubMed,computational_tools,PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PubMed,Database,,,,,,,,,,,,,,,,...78 sequence variants have been found by searching PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez) and Google...,No version and no repository URL (confidence < 0.9 — unidentifiable)
Google,computational_tools,PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Google,Web Application,,,,,,,,,,,,,,,,...78 sequence variants have been found by searching PubMed and Google (http://google.com/)...,No version and no repository URL (confidence < 0.9 — unidentifiable)
Mutalyzer 2.0,computational_tools,PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Mutalyzer 2.0,Web Application,2.0,,,,,,,,,,,,,,,...the online batch position check tool Mutalyzer 2.0 (http://www.mutalyzer.nl/) was used to confirm genomic position of all SPRED1 gene variants...,Software name not in publication title — likely generic usage: Mutalyzer 2.0
MySQL,computational_tools,PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MySQL,Database,,,,,,,,,,,,,,,,"...SQL tables (MySQL, Inc.) were organized to represent SPRED1 mutation status, associated phenotype, literature references...",No version and no repository URL (confidence < 0.9 — unidentifiable)
PHP,computational_tools,PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PHP,Analysis Software,,,,,,,,,,,,,,,,...PHP coding was performed in-house for dynamic HTML display to render pages and display SQL tables...,No version and no repository URL (confidence < 0.9 — unidentifiable)
FusionCharts v3,computational_tools,PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FusionCharts v3,Analysis Software,v3,,,,,,,,,,,,,,,...Graphics were generated using FusionCharts v3 (www.fusioncharts.com)...,Software name not in publication title — likely generic usage: FusionCharts v3
phpmyadmin,computational_tools,PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,phpmyadmin,Web Application,,,,,,,,,,,,,,,,...SPRED1 mutations were added to the database and edited using phpmyadmin (www.phpmyadmin.net)...,No version and no repository URL (confidence < 0.9 — unidentifiable)
Mac OS X Apache server,computational_tools,PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Mac OS X Apache server,Web Application,,,,,,,,,,,,,,,,...Web pages are hosted on a Mac OS X Apache server...,No version and no repository URL (confidence < 0.9 — unidentifiable)
DESeq2 (version 1.12.4),computational_tools,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DESeq2 (version 1.12.4),Package/Library,1.12.4,,,,,,,,,,,,,,,DESeq2 (version 1.12.4) was used to determine differentially expressed genes (DEGs) between two samples,Software name not in publication title — likely generic usage: DESeq2 (version 1.12.4)
HiSeq XTen sequencers,computational_tools,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HiSeq XTen sequencers,Other,,,,,,,,,,,,,,,,"paired-end sequencing of the library was performed on HiSeq XTen sequencers (Illumina, San Diego, CA, USA)",Sequencing hardware or generic assay protocol: HiSeq XTen sequencers
LightCycler 480 II Real-Time PCR System,computational_tools,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LightCycler 480 II Real-Time PCR System,Other,,,,,,,,,,,,,,,,"Real-time quantitative PCR detection was performed...on a LightCycler ® 480 II Real-Time PCR System (Roche, Mannheim, Germany)",No version and no repository URL (confidence < 0.9 — unidentifiable)
PRISM (version 8),computational_tools,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,PRISM (version 8),Analysis Software,8,,,,,,,,,,,,,,,"Statistical analyses were conducted with PRISM (version 8, GraphPad Software, Inc., San Diego, CA, USA)",Software name not in publication title — likely generic usage: PRISM (version 8)
Zeiss LSM 780 confocal microscope,computational_tools,PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Zeiss LSM 780 confocal microscope,Analysis Software,,,,,,,,,,,,,,,,Optical sections spanning the full depth of the 3D structures were acquired from four contiguous fields (2 × 2) using either an upright Zeiss LSM 780 confocal microscope,No version and no repository URL (confidence < 0.9 — unidentifiable)
Leica Stellaris 5 system,computational_tools,PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Leica Stellaris 5 system,Analysis Software,,,,,,,,,,,,,,,,"or an inverted Leica Stellaris 5 system (Leica Microsystems, Deerfield, IL, USA) equipped with a Tokai Hit stage-top incubator",No version and no repository URL (confidence < 0.9 — unidentifiable)
Volocity software (Version 7.0.0),computational_tools,PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Volocity software (Version 7.0.0),Analysis Software,7.0.0,,,,,,,,,,,,,,,"Image stacks were processed and reconstructed in 3D using Volocity software (Version 7.0.0; PerkinElmer, Waltham, MA, USA) for visualization and quantification",Software name not in publication title — likely generic usage: Volocity software (Version 7.0.0)
ImageJ 1.54g software,computational_tools,PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ 1.54g software,Analysis Software,1.54g,,,,,,,,,,,,,,,"Fluorescence intensity of P-glycoprotein was quantified using ImageJ 1.54g software (National Institutes of Health, Bethesda, MD, USA).",Generic tool (versioned): ImageJ 1.54g software
SpectraMax Plus 384 microplate reader,computational_tools,PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SpectraMax Plus 384 microplate reader,Analysis Software,,,,,,,,,,,,,,,,"Absorbance was measured at 570 nm with background correction at 690 nm using a SpectraMax Plus 384 microplate reader (Molecular Devices, San Jose, CA, USA).",No version and no repository URL (confidence < 0.9 — unidentifiable)
Insight Toolkit,computational_tools,PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Insight Toolkit,Package/Library,,www.itk.org/,,,,,,,,,,,,,,The pipeline for PN identification was developed in-house using the Insight Toolkit ( www.itk.org/ ) interfacing with the medical imaging visualization suite,Software name not in publication title — likely generic usage: Insight Toolkit
Slicer,computational_tools,PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Slicer,Analysis Software,,www.slicer.org/,,,,,,,,,,,,,,"using the Insight Toolkit ( www.itk.org/ ) interfacing with the medical imaging visualization suite, Slicer ( www.slicer.org/ )",Software name not in publication title — likely generic usage: Slicer
Law's texture energy measures,computational_tools,PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Law's texture energy measures,Analysis Software,,,,,,,,,,,,,,,,"Image texture was quantified using Law's texture energy measures (LTEM), grey-level run length (GLRL), and neighborhood grey-tone difference matrices",No version and no repository URL (confidence < 0.9 — unidentifiable)
grey-level co-occurrence matrices,computational_tools,PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,grey-level co-occurrence matrices,Analysis Software,,,,,,,,,,,,,,,,"while image texture was quantified using Law's texture energy measures, grey-level co-occurrence matrices, and neighborhood grey-tone difference matrices",No version and no repository URL (confidence < 0.9 — unidentifiable)
neighborhood grey-tone difference matrices,computational_tools,PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,neighborhood grey-tone difference matrices,Analysis Software,,,,,,,,,,,,,,,,"Image texture was quantified using Law's texture energy measures (LTEM), grey-level run length (GLRL), and neighborhood grey-tone difference matrices (NGTM)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Jarque-Bera normality test,computational_tools,PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Jarque-Bera normality test,Analysis Software,,,,,,,,,,,,,,,,Normality of the feature was tested using the Jarque-Bera normality test and the Levene's test was used to test for equal variances,No version and no repository URL (confidence < 0.9 — unidentifiable)
Levene's test,computational_tools,PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Levene's test,Analysis Software,,,,,,,,,,,,,,,,Normality of the feature was tested using the Jarque-Bera normality test and the Levene's test was used to test for equal variances between the sets,No version and no repository URL (confidence < 0.9 — unidentifiable)
k-medoid clustering,computational_tools,PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,k-medoid clustering,Analysis Software,,,,,,,,,,,,,,,,therefore feature reduction was performed using k-medoid clustering to remove statistically significant features were highly inter-correlated,No version and no repository URL (confidence < 0.9 — unidentifiable)
NMRPipe,computational_tools,PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NMRPipe,Analysis Software,,,,,,,,,,,,,,,,Collected data were processed with NMRPipe (Delaglio et al. 1995),No version and no repository URL (confidence < 0.9 — unidentifiable)
CcpNMR,computational_tools,PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CcpNMR,Analysis Software,,,,,,,,,,,,,,,,analyzed by using CcpNMR (Vranken et al. 2005) software,No version and no repository URL (confidence < 0.9 — unidentifiable)
TALOS+,computational_tools,PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,TALOS+,Analysis Software,,,,,,,,,,,,,,,,"A TALOS+ prediction (Shen et al. 2009) was conducted using the HN, N, C', Cα, and Cβ chemical shifts",No version and no repository URL (confidence < 0.9 — unidentifiable)
CalcuSyn Version 2.1,computational_tools,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CalcuSyn Version 2.1,Analysis Software,2.1,,,,,,,,,,,,,,,"All data analysis was done using Calcusyn software (CalcuSyn Version 2.1, BioSoft)",Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
ImageJ,computational_tools,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,Densitometry quantification was done using ImageJ software and normalized to GAPDH,Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
RELION,computational_tools,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,RELION,Analysis Software,,,,,,,,,,,,,,,,Data processing was done using the RELION (32) software package.,Software name not in publication title — likely generic usage: RELION
MotionCorr,computational_tools,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MotionCorr,Analysis Software,,,,,,,,,,,,,,,,Collected movie frames were motion-corrected and dose-weighed using MotionCorr (33),No version and no repository URL (confidence < 0.9 — unidentifiable)
CTFFIND4,computational_tools,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CTFFIND4,Analysis Software,,,,,,,,,,,,,,,,followed by contrast transfer function estimation using CTFFIND4 (34),No version and no repository URL (confidence < 0.9 — unidentifiable)
Chimera,computational_tools,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Chimera,Analysis Software,,,,,,,,,,,,,,,,"Published models of GRD and Sec-PH (PDB: 1nf1 and 2d4q, respectively) were rigid-body fitted in the density using Chimera.",No version and no repository URL (confidence < 0.9 — unidentifiable)
Coot,computational_tools,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Coot,Analysis Software,,,,,,,,,,,,,,,,The core of the NF1 dimer was completely manually modeled in Coot (35),No version and no repository URL (confidence < 0.9 — unidentifiable)
Phenix,computational_tools,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Phenix,Analysis Software,,,,,,,,,,,,,,,,Structure refinement was done in Phenix (37).,No version and no repository URL (confidence < 0.9 — unidentifiable)
Servalcat,computational_tools,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Servalcat,Analysis Software,,,,,,,,,,,,,,,,Iterative manual inspection and rebuilding of the 3D model in Coot relied on real-space difference maps calculated in Servalcat (38).,No version and no repository URL (confidence < 0.9 — unidentifiable)
Image-Studio,computational_tools,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Image-Studio,Analysis Software,,,,,,,,,,,,,,,,Quantification of Western Blot bands was performed using Image-Studio (Li-COR),No version and no repository URL (confidence < 0.9 — unidentifiable)
SerialEM,computational_tools,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SerialEM,Analysis Software,,,,,,,,,,,,,,,,All data collection was performed with SerialEM.,No version and no repository URL (confidence < 0.9 — unidentifiable)
MiSeq-M01450,computational_tools,PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MiSeq-M01450,Other,,,,,,,,,,,,,,,,followed by sequencing using the MiSeq‐M01450 instrument (150‐base paired end mode; Illumina),Sequencing hardware or generic assay protocol: MiSeq-M01450
bwa-mem v0.7.10,computational_tools,PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,bwa-mem v0.7.10,Analysis Software,v0.7.10,,,,,,,,,,,,,,,Sequence reads were aligned to the reference sequence (GRCh37) using bwa‐mem v0.7.10,Software name not in publication title — likely generic usage: bwa-mem v0.7.10
"GATK, version 1.0.4705",computational_tools,PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"GATK, version 1.0.4705",Analysis Software,1.0.4705,,,,,,,,,,,,,,,"followed by variant calling using GATK, version 1.0.4705","Software name not in publication title — likely generic usage: GATK, version 1.0.4705"
VisCap,computational_tools,PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VisCap,Analysis Software,,,,,,,,,,,,,,,,Copy number variants (CNVs) were identified via an NGS‐based detection tool (VisCap),Software name not in publication title — likely generic usage: VisCap
ddPCR,computational_tools,PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ddPCR,Analysis Software,,,,,,,,,,,,,,,,Confirmation of CNVs was done using ddPCR as previously described,No version and no repository URL (confidence < 0.9 — unidentifiable)
MOD Fit LT software,computational_tools,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MOD Fit LT software,Analysis Software,,,,,,,,,,,,,,,,"analyzed using MOD Fit LT software (Verity Software House, Topsham, ME, USA)",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
ImageJ,computational_tools,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,Densitometry quantification was performed using ImageJ (NIH),Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
Trimmomatic v0.39,computational_tools,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Trimmomatic v0.39,Analysis Software,v0.39,,,,,,,,,,,,,,,Whole-exome sequencing FastQ files were trimmed by using Trimmomatic v 0.39,Software name not in publication title — likely generic usage: Trimmomatic v0.39
BWA-MEM,computational_tools,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BWA-MEM,Analysis Software,,,,,,,,,,,,,,,,aligned against reference sequence hg38 via Burrows-Wheeler Aligner–Maximal Exact Match (BWA-MEM),No version and no repository URL (confidence < 0.9 — unidentifiable)
GATK V4.2,computational_tools,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GATK V4.2,Analysis Software,V4.2,,,,,,,,,,,,,,,Genomic analysis toolkit (GATK) V4.2 base quality score recalibration was also used to process BAM files,Software name not in publication title — likely generic usage: GATK V4.2
VarScan2,computational_tools,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VarScan2,Analysis Software,,,,,,,,,,,,,,,,Somatic single-nucleotide variants (SNVs) and small indels were detected using VarScan2,Generic bioinformatics/stats tool: VarScan2
Strelka2,computational_tools,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Strelka2,Analysis Software,,,,,,,,,,,,,,,,"Somatic single-nucleotide variants (SNVs) and small indels were detected using VarScan2, Strelka2",Generic bioinformatics/stats tool: Strelka2
MuTect2,computational_tools,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MuTect2,Analysis Software,,,,,,,,,,,,,,,,"Somatic single-nucleotide variants (SNVs) and small indels were detected using VarScan2, Strelka2, MuTect2",Generic bioinformatics/stats tool: MuTect2
Pindel,computational_tools,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Pindel,Analysis Software,,,,,,,,,,,,,,,,"Somatic single-nucleotide variants (SNVs) and small indels were detected using VarScan2, Strelka2, MuTect2, and Pindel",No version and no repository URL (confidence < 0.9 — unidentifiable)
Salmon algorithm,computational_tools,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Salmon algorithm,Analysis Software,,,,,,,,,,,,,,,,RNA reads were quantified using the Salmon algorithm,No version and no repository URL (confidence < 0.9 — unidentifiable)
DESeq2,computational_tools,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2,Package/Library,,,,,,,,,,,,,,,,"Raw counts were normalized, and the DESeq2 package was used to call the differentially expressed genes",Generic bioinformatics/stats tool: DESeq2
MAGINE,computational_tools,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MAGINE,Package/Library,,,,,,,,,,,,,,,,"Exploratory data analysis, including UpSet plots, Venn Diagram creation, and heatmaps of expression values, were performed using the Python package MAGINE",No version and no repository URL (confidence < 0.9 — unidentifiable)
FlowJo 10.8,computational_tools,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,FlowJo 10.8,Analysis Software,10.8,,,,,,,,,,,,,,,"Data analysis was performed using FlowJo 10.8, and cell cycle distribution was assigned by using the implemented models",Software name not in publication title — likely generic usage: FlowJo 10.8
PhenoCapture 3.3,computational_tools,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,PhenoCapture 3.3,Analysis Software,3.3,,,,,,,,,,,,,,,Images were captured every 15 min using a time-lapse image software (PhenoCapture 3.3),Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
Fiji 2.0,computational_tools,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Fiji 2.0,Analysis Software,2.0,,,,,,,,,,,,,,,Images were captured every 15 min using a time-lapse image software (PhenoCapture 3.3) and analyzed using Fiji 2.0,Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
Sleep and Activity Metabolic Monitor (SAMM) system,computational_tools,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Sleep and Activity Metabolic Monitor (SAMM) system,Analysis Software,,,,,,,,,,,,,,,,Metabolic rate and activity were measured using the Sleep and Activity Metabolic Monitor (SAMM) system (Sable Systems International).,Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
Noah.py,computational_tools,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Noah.py,Analysis Software,,,,,,,,,,,,,,,,Total feeding was measured over 24 h and analyzed by Noah.py,Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
LAS X software,computational_tools,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LAS X software,Analysis Software,,,,,,,,,,,,,,,,Leica TCS SP8 confocal microscope with LAS X software was used to obtain images.,Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
AlphaImager HP system,computational_tools,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AlphaImager HP system,Analysis Software,,,,,,,,,,,,,,,,"After washing, WesternBright Quantum HRP substrate (Advansta) was added to the membranes and images were captured with AlphaImager HP system (ProteinSimple)",Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
TAPDANCE,computational_tools,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,TAPDANCE,Analysis Software,,,,,,,,,,,,,,,,Identification of TAPDANCE CISs and gene centric CISs from sequenced transposon-genomic DNA PCR products,No version and no repository URL (confidence < 0.9 — unidentifiable)
GeneSpring GX v7.3.1,computational_tools,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GeneSpring GX v7.3.1,Analysis Software,v7.3.1,,,,,,,,,,,,,,,Statistical comparisons were done using R/Bioconductor packages and GeneSpring GX v7.3.1 (Agilent Technologies),Software name not in publication title — likely generic usage: GeneSpring GX v7.3.1
GenoCNA,computational_tools,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GenoCNA,Analysis Software,,,,,,,,,,,,,,,,The data were processed with GenoCNA to segment the genome and determine copy number status,No version and no repository URL (confidence < 0.9 — unidentifiable)
ImageJ,computational_tools,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,automated colony counts were done using ImageJ software,Generic bioinformatics/stats tool: ImageJ
AxioVision,computational_tools,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AxioVision,Analysis Software,,,,,,,,,,,,,,,,Images were acquired using AxioVision software,No version and no repository URL (confidence < 0.9 — unidentifiable)
Cell Ranger pipeline v7.1.0,computational_tools,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cell Ranger pipeline v7.1.0,Pipeline,v7.1.0,,,,,,,,,,,,,,,resulting sequencing files were run through the Cell Ranger pipeline v7.1.0,Software name not in publication title — likely generic usage: Cell Ranger pipeline v7.1.0
Seurat v4.3.0–v5,computational_tools,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat v4.3.0–v5,Package/Library,v4.3.0–v5,,,,,,,,,,,,,,,"Data analysis was completed using R (v 4.3.0–v 4.3.1) Seurat [ 24 ,  25 ] (v4.3.0–v5)",Software name not in publication title — likely generic usage: Seurat v4.3.0–v5
Harmony,computational_tools,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Harmony,Package/Library,,,,,,,,,,,,,,,,"To account for technical and sample variation, Harmony batch correction was conducted",No version and no repository URL (confidence < 0.9 — unidentifiable)
Ingenuity Pathway Analysis (IPA),computational_tools,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Ingenuity Pathway Analysis (IPA),Analysis Software,,,,,,,,,,,,,,,,Ingenuity pathway analysis (IPA) was also used to identify pathways that differ on treatment,Software name not in publication title — likely generic usage: Ingenuity Pathway Analysis (IPA)
scanpy,computational_tools,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,scanpy,Package/Library,,,,,,,,,,,,,,,,"By connecting scanpy [ 28 ], palantir, and scFates [ 29 ] packages",No version and no repository URL (confidence < 0.9 — unidentifiable)
palantir,computational_tools,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,palantir,Package/Library,,,,,,,,,,,,,,,,"By connecting scanpy [ 28 ], palantir, and scFates [ 29 ] packages",No version and no repository URL (confidence < 0.9 — unidentifiable)
scFates,computational_tools,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,scFates,Package/Library,,,,,,,,,,,,,,,,"By connecting scanpy [ 28 ], palantir, and scFates [ 29 ] packages",No version and no repository URL (confidence < 0.9 — unidentifiable)
CellChat,computational_tools,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CellChat,Package/Library,,,,,,,,,,,,,,,,"After processing our snRNA-seq dataset in Seurat, downstream analysis in CellChat was conducted",Software name not in publication title — likely generic usage: CellChat
velocyto,computational_tools,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,velocyto,Command-line Tool,,,,,,,,,,,,,,,,samtools and velocyto were used to generate the.loom spliced/unspliced output,No version and no repository URL (confidence < 0.9 — unidentifiable)
scvelo,computational_tools,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,scvelo,Package/Library,,,,,,,,,,,,,,,,the downstream analysis was performed using the scanpy and scvelo [ 31 ] packages,No version and no repository URL (confidence < 0.9 — unidentifiable)
Scriabin,computational_tools,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Scriabin,Package/Library,,,,,,,,,,,,,,,,"Cell communication was assessed by RNA velocity, Scriabin, and CellChat analyses",No version and no repository URL (confidence < 0.9 — unidentifiable)
"Illumina HiSeq 2,500",computational_tools,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"Illumina HiSeq 2,500",Other,,,,,,,,,,,,,,,,"Paired-end sequencing resulting in 100 bases from each end of the fragments was performed using Illumina HiSeq 2,500 (Illumina, San Diego, CA).","Sequencing hardware or generic assay protocol: Illumina HiSeq 2,500"
VariantDx,computational_tools,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VariantDx,Analysis Software,,,,,,,,,,,,,,,,Somatic mutations were identified using VariantDx custom software for identifying mutations in matched tumor and normal samples from whole exome sequencing (WES).,No version and no repository URL (confidence < 0.9 — unidentifiable)
Illumina CASAVA software (v1.8),computational_tools,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Illumina CASAVA software (v1.8),Analysis Software,v1.8,,,,,,,,,,,,,,,"primary processing of sequence data for both tumor and normal samples were performed using Illumina CASAVA software (v1.8), including masking of adapter sequences.",Software name not in publication title — likely generic usage: Illumina CASAVA software (v1.8)
ELAND software,computational_tools,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ELAND software,Analysis Software,,,,,,,,,,,,,,,,Sequence reads were aligned against the human reference genome (version hg19) using ELAND software.,No version and no repository URL (confidence < 0.9 — unidentifiable)
snpEff,computational_tools,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,snpEff,Analysis Software,,,,,,,,,,,,,,,,"Functional consequences were predicted using snpEff and a custom database of CCDS, RefSeq and Ensembl annotations",Generic bioinformatics/stats tool: snpEff
BioRad QX200 droplet digital PCR system,computational_tools,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BioRad QX200 droplet digital PCR system,Other,,,,,,,,,,,,,,,,Extracted cell-free DNA was analyzed with custom designed droplet digital PrimePCR assays using the BioRad QX200 droplet digital PCR system,No version and no repository URL (confidence < 0.9 — unidentifiable)
RealSeqS,computational_tools,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,RealSeqS,Analysis Software,,https://zenodo.org/record/3656943#.YaZZCdDMKUk.32,,,,,,,,,,,,,,"RealSeqS uses a single primer pair to amplify about 750,000 loci scattered throughout the genome",Software name not in publication title — likely generic usage: RealSeqS
BWA version 0.7.15,computational_tools,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BWA version 0.7.15,Command-line Tool,0.7.15,,,,,,,,,,,,,,,"The sequenced reads were mapped to the hg19 by Burrows-Wheeler Aligner (BWA version 0.7.15, default parameters, BWA-MEM algorithm)",Software name not in publication title — likely generic usage: BWA version 0.7.15
GATK MuTect2 (version 4.1),computational_tools,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GATK MuTect2 (version 4.1),Analysis Software,4.1,,,,,,,,,,,,,,,"Mutations were identified via GATK MuTect2 (version 4.1, default parameters)",Software name not in publication title — likely generic usage: GATK MuTect2 (version 4.1)
ANNOVAR (version 2016-02-01),computational_tools,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ANNOVAR (version 2016-02-01),Analysis Software,2016-02-01,,,,,,,,,,,,,,,"Mutations were annotated with software ANNOVAR (version 2016-02-01, default parameters)",Software name not in publication title — likely generic usage: ANNOVAR (version 2016-02-01)
TIDE (Tracking Indels by Decomposition),computational_tools,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,TIDE (Tracking Indels by Decomposition),Analysis Software,,,,,,,,,,,,,,,,The indel frequencies of TGFBR2 and PDCD1 were measured by TIDE (Tracking Indels by Decomposition) analysis,No version and no repository URL (confidence < 0.9 — unidentifiable)
CFX Connect System,computational_tools,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CFX Connect System,Analysis Software,,,,,,,,,,,,,,,,qPCR reactions were performed with the CFX Connect System (Bio-Rad Laboratories),No version and no repository URL (confidence < 0.9 — unidentifiable)
ChemiDoc XRS,computational_tools,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ChemiDoc XRS,Analysis Software,,,,,,,,,,,,,,,,Chemiluminescence was detected using ChemiDoc XRS (Bio-Rad),No version and no repository URL (confidence < 0.9 — unidentifiable)
EVOS Cell Imaging Systems,computational_tools,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,EVOS Cell Imaging Systems,Analysis Software,,,,,,,,,,,,,,,,images were taken with EVOS Cell Imaging Systems (Thermo Fisher Scientific),No version and no repository URL (confidence < 0.9 — unidentifiable)
JMP Pro software,computational_tools,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,JMP Pro software,Analysis Software,,,,,,,,,,,,,,,,All analyses were performed using the JMP Pro software package (SAS Institute Japan Ltd.),No version and no repository URL (confidence < 0.9 — unidentifiable)
BioSpec 70/30 USR,computational_tools,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BioSpec 70/30 USR,Analysis Software,,,,,,,,,,,,,,,,"7 T scanner (BioSpec 70/30 USR; Bruker, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
LP-100 FUS system,computational_tools,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LP-100 FUS system,Analysis Software,,,,,,,,,,,,,,,,"preclinical LP-100 FUS system (FUS Instruments, Canada)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Aedes software,computational_tools,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Aedes software,Analysis Software,,,,,,,,,,,,,,,,MRI images were transferred into MATLAB with Aedes software for manual segmentation,No version and no repository URL (confidence < 0.9 — unidentifiable)
SAS 9.4,computational_tools,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SAS 9.4,Analysis Software,9.4,,,,,,,,,,,,,,,"All statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC)",Software name not in publication title — likely generic usage: SAS 9.4
ParaVision 6.0.1,computational_tools,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ParaVision 6.0.1,Analysis Software,6.0.1,,,,,,,,,,,,,,,"B-GA12S HP gradients running ParaVision 6.0.1, Bruker BioSpin",Software name not in publication title — likely generic usage: ParaVision 6.0.1
Trimmomatic (v0.33),computational_tools,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Trimmomatic (v0.33),Analysis Software,v0.33,,,,,,,,,,,,,,,quality trimming via Trimmomatic (v0.33),Software name not in publication title — likely generic usage: Trimmomatic (v0.33)
HISAT2 (v2.1.0),computational_tools,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HISAT2 (v2.1.0),Analysis Software,v2.1.0,,,,,,,,,,,,,,,alignment via HISAT2 (v2.1.0),Software name not in publication title — likely generic usage: HISAT2 (v2.1.0)
StringTie (v1.3.4d),computational_tools,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,StringTie (v1.3.4d),Analysis Software,v1.3.4d,,,,,,,,,,,,,,,gene count quantification via StringTie (v1.3.4d),Software name not in publication title — likely generic usage: StringTie (v1.3.4d)
DESeq2 (v1.42.0),computational_tools,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DESeq2 (v1.42.0),Package/Library,v1.42.0,,,,,,,,,,,,,,,"Differential expression analysis was performed using R statistical software (v4.3.1), tidyverse (v2.0.0), and DESeq2 (v1.42.0)",Software name not in publication title — likely generic usage: DESeq2 (v1.42.0)
GeneAnalytics(v),computational_tools,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GeneAnalytics(v),Web Application,v,,,,,,,,,,,,,,,Pathway analysis was performed using GeneAnalytics(v),Software name not in publication title — likely generic usage: GeneAnalytics(v)
ImageJ,computational_tools,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,colonies were counted using the cell counter tool of ImageJ (NIH United States 2014),Generic bioinformatics/stats tool: ImageJ
IBM SPSS Statistics Standard,computational_tools,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,IBM SPSS Statistics Standard,Analysis Software,,,,,,,,,,,,,,,,The SPSS program (IBM SPSS Statistics Standard) was applied,No version and no repository URL (confidence < 0.9 — unidentifiable)
Bruker AutoFlex III mass spectrometer,computational_tools,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bruker AutoFlex III mass spectrometer,Analysis Software,,,,,,,,,,,,,,,,"MALDI IMS experiments were performed on a Bruker AutoFlex III mass spectrometer (Bruker Daltonics Billerica, MA, USA)",Software name not in publication title — likely generic usage: Bruker AutoFlex III mass spectrometer
FlexImaging 4.0,computational_tools,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FlexImaging 4.0,Analysis Software,4.0,,,,,,,,,,,,,,,The 2-D IMS data sets were collected using FlexImaging 4.0 (Bruker Daltonics),Software name not in publication title — likely generic usage: FlexImaging 4.0
MATLAB,computational_tools,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MATLAB,Analysis Software,,,,,,,,,,,,,,,,"All 33 individual 2-D IMS data sets were combined into a single 3-D IMS data set in MATLAB (Mathworks Inc., Natick, MA)",Generic bioinformatics/stats tool: MATLAB
Bioinformatics Toolbox,computational_tools,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bioinformatics Toolbox,Package/Library,,,,,,,,,,,,,,,,This was accomplished using the standard functions provided by the Bioinformatics Toolbox in MATLAB,No version and no repository URL (confidence < 0.9 — unidentifiable)
Sliceomatic,computational_tools,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Sliceomatic,Analysis Software,,,,,,,,,,,,,,,,"The 3-D stack visualization of Figure 1e was generated using Sliceomatic by Eric Ludlam (The Mathworks Inc., Natick, MA, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Thermo LTQ Velos Orbitrap mass spectrometer,computational_tools,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Thermo LTQ Velos Orbitrap mass spectrometer,Analysis Software,,,,,,,,,,,,,,,,"LC-MS/MS experiments were performed on a Thermo LTQ Velos Orbitrap mass spectrometer (Thermo Scientific, Waltham, MA, USA)",Software name not in publication title — likely generic usage: Thermo LTQ Velos Orbitrap mass spectrometer
TagIdent,computational_tools,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,TagIdent,Web Application,,http://web.expasy.org/tagident/,,,,,,,,,,,,,,sequence tags of around 4–5 amino acids that were subsequently searched using TagIdent (http://web.expasy.org/tagident/),Software name not in publication title — likely generic usage: TagIdent
protein prospector MS-product,computational_tools,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,protein prospector MS-product,Web Application,,http://prospector.ucsf.edu/prospector/mshome.htm,,,,,,,,,,,,,,Proteins with matching intact molecular weights and containing the sequence observed were processed using protein prospector MS-product (http://prospector.ucsf.edu/prospector/mshome.htm),Software name not in publication title — likely generic usage: protein prospector MS-product
Scaffold,computational_tools,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Scaffold,Analysis Software,,,,,,,,,,,,,,,,"Scaffold (Proteome Software, Portland, Oregon, USA) was used to analyze and validate protein identifications",Generic bioinformatics/stats tool: Scaffold
SEQUEST,computational_tools,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SEQUEST,Analysis Software,,,,,,,,,,,,,,,,"validate protein identifications derived from SEQUEST (Thermo Scientific, Waltham, MA, USA) database searching",No version and no repository URL (confidence < 0.9 — unidentifiable)
Leica LAS EZ image analysis software,computational_tools,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Leica LAS EZ image analysis software,Analysis Software,,,,,,,,,,,,,,,,"Images were subsequently acquired on a Nikon Eclipse E600 microscope equipped with an optical camera (Leica, Buffalo Grove, IL, USA) and Leica LAS EZ image analysis software",No version and no repository URL (confidence < 0.9 — unidentifiable)
GSE108524,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GSE108524,Database,,,,,,,,,,,,,,,,The gene expression profile GSE108524 of the NF2-associated VSs and normal nerve groups was obtained from the NCBI GEO database.,No version and no repository URL (confidence < 0.9 — unidentifiable)
GPL17586 Platform [HTA-2_0] Affymetrix Human Transcriptome Array 2.0,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GPL17586 Platform [HTA-2_0] Affymetrix Human Transcriptome Array 2.0,Analysis Software,,,,,,,,,,,,,,,,These microarray data were based on GPL17586 Platform [HTA-2_0] Affymetrix Human Transcriptome Array 2.0 [transcript (gene) version],Software name not in publication title — likely generic usage: GPL17586 Platform [HTA-2_0] Affymetrix Human Transcriptome Array 2.0
GEO2R,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GEO2R,Web Application,,,,,,,,,,,,,,,,"GEO2R (http://www.ncbi.nlm.nih.gov/geo/geo2r/), a web tool based on the analysis of variance or t-test, was used to identify DEGs",No version and no repository URL (confidence < 0.9 — unidentifiable)
DAVID,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DAVID,Web Application,6.8,,,,,,,,,,,,,,,"The Database for Annotation, Visualization, and Integrated Discovery (DAVID) (Version 6.8, https://david.ncifcrf.gov/) was used to perform GO and KEGG pathway enrichment analysis",Generic bioinformatics/stats tool: DAVID
STRING,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,STRING,Database,,,,,,,,,,,,,,,,"We submitted DEGs in Search Tool for the Retrieval of Interacting Genes database (STRING, http://www.string-db.org/) to screen the PPI pairs",Generic bioinformatics/stats tool: STRING
Cytoscape,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cytoscape,Analysis Software,3.7.0,,,,,,,,,,,,,,,visualized the interaction using Cytoscape software (Version 3.7.0.),Generic bioinformatics/stats tool: Cytoscape
CentiScaPe,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CentiScaPe,Plugin,,,,,,,,,,,,,,,,"Finally, CentiScaPe and Molecular Complex Detection (MCODE), a Cytoscape plugin, were utilized to screen PPI network key genes.",No version and no repository URL (confidence < 0.9 — unidentifiable)
MCODE,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MCODE,Plugin,,,,,,,,,,,,,,,,"CentiScaPe and Molecular Complex Detection (MCODE), a Cytoscape plugin, were utilized to screen PPI network key genes.",No version and no repository URL (confidence < 0.9 — unidentifiable)
DGIdb,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DGIdb,Database,,,,,,,,,,,,,,,,the hub genes were mapped onto the Drug-Gene Interaction database (DGIdb; http://www.dgidb.org) to obtain potential drug target genes,No version and no repository URL (confidence < 0.9 — unidentifiable)
ClinicalTrials.gov,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ClinicalTrials.gov,Database,,,,,,,,,,,,,,,,"In addition, ClinicalTrials.gov (https://clinicaltrials.gov) was used to identify whether drugs have been previously investigated",No version and no repository URL (confidence < 0.9 — unidentifiable)
SPSS 20.0,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS 20.0,Analysis Software,20.0,,,,,,,,,,,,,,,Statistical analysis was conducted by SPSS 20.0 software.,Software name not in publication title — likely generic usage: SPSS 20.0
Human Genome U133 Plus 2.0 Array,computational_tools,PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Human Genome U133 Plus 2.0 Array,Analysis Software,,,,,,,,,,,,,,,,"RNA was extracted and cRNA were hybridized to Human Genome U133 Plus 2.0 Array (Affymetrix) for analysis of over 47,000 transcripts",No version and no repository URL (confidence < 0.9 — unidentifiable)
DNA Engine Opticon 2 Continuous Fluorescence Detection System,computational_tools,PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DNA Engine Opticon 2 Continuous Fluorescence Detection System,Analysis Software,,,,,,,,,,,,,,,,"RT-qPCR was performed in the DNA Engine Opticon 2 Continuous Fluorescence Detection System (Bio-Rad, Hercules, CA, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Bioconductor limma package,computational_tools,PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bioconductor limma package,Package/Library,,,,,,,,,,,,,,,,The Bioconductor limma package [20] was used to preprocess the expression data from Human Genome U133 Plus 2.0 Affymetrix Array,Software name not in publication title — likely generic usage: Bioconductor limma package
NCATS Mechanism Interrogation PlatE (MIPE) library,computational_tools,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NCATS Mechanism Interrogation PlatE (MIPE) library,Database,,,,,,,,,,,,,,,,We screened a collection of compounds from the NCATS Mechanism Interrogation PlatE (MIPE) library,No version and no repository URL (confidence < 0.9 — unidentifiable)
CompuSyn Software,computational_tools,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CompuSyn Software,Analysis Software,,,,,,,,,,,,,,,,"Combination Index values for the combinations were calculated using CompuSyn Software, based on Chou-Talalay calculations",No version and no repository URL (confidence < 0.9 — unidentifiable)
GraphPad Prism Version 6,computational_tools,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism Version 6,Analysis Software,6,,,,,,,,,,,,,,,"The IC50 was calculated using GraphPad Prism Version 6 (La Jolla, CA).",Generic tool (versioned): GraphPad Prism Version 6
Zeiss LSM 780,computational_tools,PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Zeiss LSM 780,Analysis Software,,,,,,,,,,,,,,,,"Optical sections of 9 or 16 contiguous fields, unless otherwise indicated, through the entire depth of the 3D structures were acquired using Zeiss LSM 780",No version and no repository URL (confidence < 0.9 — unidentifiable)
Stellaris 5,computational_tools,PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Stellaris 5,Analysis Software,,,,,,,,,,,,,,,,"acquired using Zeiss LSM 780 (Carl Zeiss Microscopy, Jena, Germany) or Stellaris 5 (Leica Microsystems, Deerfield, IL, USA) confocal microscopes",No version and no repository URL (confidence < 0.9 — unidentifiable)
Volocity software 7.0.0,computational_tools,PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Volocity software 7.0.0,Analysis Software,7.0.0,,,,,,,,,,,,,,,"Images were reconstructed in 3D using Volocity software 7.0.0 (PerkinElmer, Waltham, MA, USA)",Software name not in publication title — likely generic usage: Volocity software 7.0.0
Nanoparticle Tracking Analysis software version 3.3 Dev Build 3.3.104,computational_tools,PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Nanoparticle Tracking Analysis software version 3.3 Dev Build 3.3.104,Analysis Software,3.3 Dev Build 3.3.104,,,,,,,,,,,,,,,"sEV depletion was determined by version 3.3 Dev Build 3.3.104 Nanoparticle Tracking Analysis software (Malvern Panalytical Ltd., Malvern, UK)",Software name not in publication title — likely generic usage: Nanoparticle Tracking Analysis software version 3.3 Dev Build 3.3.104
ImageJ software,computational_tools,PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ software,Analysis Software,,,,,,,,,,,,,,,,"invaded cells were visualized using a Nikon Eclipse Ti-S microscope (Tokyo, Japan) and quantified using ImageJ software (NIH, Bethesda, MD, USA)",Generic bioinformatics/stats tool: ImageJ software
GraphPad Prism version 8.0.1,computational_tools,PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism version 8.0.1,Analysis Software,8.0.1,,,,,,,,,,,,,,,"The significance of differences was evaluated either by one-way ANOVA, followed by Tukey's post hoc test to correct for multiple comparisons, or by Student's t-test for two groups using GraphPad Prism version 8.0.1",Generic tool (versioned): GraphPad Prism version 8.0.1
NanoSight NS300,computational_tools,PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NanoSight NS300,Analysis Software,,,,,,,,,,,,,,,,"Nanoparticle Tracking Analysis software (Malvern Panalytical Ltd., Malvern, UK) installed in NanoSight NS300 (Malvern Panalytical Ltd., Malvern, UK)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Varian Unity/INOVA 4.7 Tesla scanner,computational_tools,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Varian Unity/INOVA 4.7 Tesla scanner,Analysis Software,,,,,,,,,,,,,,,,"imaged in a small animal MRI (Varian Unity/INOVA 4.7 Tesla scanner, Varian Inc., Palo Alto, CA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Image J software,computational_tools,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Image J software,Analysis Software,,,,,,,,,,,,,,,,"surface area of the tumor on each sequential image was determined using the measurement tool on Image J software (NIH, Bethesda, MD)",Generic tool (versioned): Image J software
Simpleware,computational_tools,PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Simpleware,Analysis Software,,,,,,,,,,,,,,,,"Three researchers independently segmented the 17 original tumors using Simpleware (Synopsys, Mountain View, CA) ""Paint by Threshold"" tool",Publication title lacks NF-specific terms: Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis me
R,computational_tools,PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,R,Analysis Software,,,,,,,,,,,,,,,,"All statistical analyses were performed using R (R Core Team), and visualization of volume differences",Publication title lacks NF-specific terms: Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis me
ggplot2,computational_tools,PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ggplot2,Package/Library,,,,,,,,,,,,,,,,"visualization of volume differences, Dice similarity coefficients, and Hausdorff distances was conducted using ggplot2 and tidyverse",Publication title lacks NF-specific terms: Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis me
tidyverse,computational_tools,PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,tidyverse,Package/Library,,,,,,,,,,,,,,,,"visualization of volume differences, Dice similarity coefficients, and Hausdorff distances was conducted using ggplot2 and tidyverse",Publication title lacks NF-specific terms: Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis me
Dice similarity coefficient,computational_tools,PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Dice similarity coefficient,Analysis Software,,,,,,,,,,,,,,,,"effect of voxel size on segmentation precision was quantified through volume measurements, Dice similarity coefficients, and Hausdorff distances",Publication title lacks NF-specific terms: Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis me
Hausdorff distance,computational_tools,PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Hausdorff distance,Analysis Software,,,,,,,,,,,,,,,,"effect of voxel size on segmentation precision was quantified through volume measurements, Dice similarity coefficients, and Hausdorff distances",Publication title lacks NF-specific terms: Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis me
Wilcoxon signed-rank test,computational_tools,PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Wilcoxon signed-rank test,Analysis Software,,,,,,,,,,,,,,,,"Statistical significance was assessed using the Wilcoxon signed-rank test, comparing resampled tumor volumes across different voxel sizes",Publication title lacks NF-specific terms: Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis me
Acumen eX3 laser-scanning fluorescence microplate cytometer,computational_tools,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Acumen eX3 laser-scanning fluorescence microplate cytometer,Analysis Software,,,,,,,,,,,,,,,,Analysis for pS6 staining intensity was performed using the Acumen eX3 laser-scanning fluorescence microplate cytometer,No version and no repository URL (confidence < 0.9 — unidentifiable)
GraphPad Prism 6.0,computational_tools,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism 6.0,Analysis Software,6.0,,,,,,,,,,,,,,,"Growth curves were plotted using GraphPad Prism 6.0 software (San Diego, CA)",Generic tool (versioned): GraphPad Prism 6.0
ABI Prism 7700 Sequence Detection System,computational_tools,PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ABI Prism 7700 Sequence Detection System,Analysis Software,,,,,,,,,,,,,,,,"The increase in fluorescent signal associated with exponential growth of PCR products is detected by the laser detector of the ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems, Foster City, CA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
PE Biosystems analysis software,computational_tools,PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PE Biosystems analysis software,Analysis Software,,,,,,,,,,,,,,,,using PE Biosystems analysis software according to the manufacturer's manuals,No version and no repository URL (confidence < 0.9 — unidentifiable)
Oligo 5.0 computer program,computational_tools,PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Oligo 5.0 computer program,Analysis Software,5.0,,,,,,,,,,,,,,,"Primers for TBP, RPLP0 and the 489 target genes (List in annex; supplementary information) were chosen with the assistance of the Oligo 5.0 computer program (National Biosciences, Plymouth, MN)",Software name not in publication title — likely generic usage: Oligo 5.0 computer program
Qualtrics,computational_tools,PMID:40737523,10.2196/71728,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Qualtrics,Web Application,,,,,,,,,,,,,,,,Surveys were conducted via Qualtrics and included 25 statements organized into eight categories,No version and no repository URL (confidence < 0.9 — unidentifiable)
Zoom's transcription feature,computational_tools,PMID:40737523,10.2196/71728,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Zoom's transcription feature,Web Application,,,,,,,,,,,,,,,,Audio recordings from the FGDs and individual interviews were then transcribed verbatim by Zoom's transcription feature,No version and no repository URL (confidence < 0.9 — unidentifiable)
Dedoose,computational_tools,PMID:40737523,10.2196/71728,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Dedoose,Analysis Software,,,,,,,,,,,,,,,,The codes assigned to each quote were then reviewed for a final time by the first author as part of entering the coded transcripts using Dedoose.,No version and no repository URL (confidence < 0.9 — unidentifiable)
R 4.4.2 software,computational_tools,PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R 4.4.2 software,Analysis Software,4.4.2,,,,,,,,,,,,,,,"Statistical analyses were performed using R 4.4.2 software (R Foundation for Statistical Computing, Vienna, Austria)",Software name not in publication title — likely generic usage: R 4.4.2 software
Sci-kit Learn,computational_tools,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Sci-kit Learn,Package/Library,,,,,,,,,,,,,,,,We used python 3.5.1 and Sci-kit Learn for machine learning implementations,Software name not in publication title — likely generic usage: Sci-kit Learn
python 3.5.1,computational_tools,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,python 3.5.1,Analysis Software,3.5.1,,,,,,,,,,,,,,,We used python 3.5.1 and Sci-kit Learn for machine learning implementations,Software name not in publication title — likely generic usage: python 3.5.1
Li-COR Image Studio Lite 5.0,computational_tools,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Li-COR Image Studio Lite 5.0,Analysis Software,5.0,,,,,,,,,,,,,,,Densitometry was performed using Li-COR Image Studio Lite 5.0,Software name not in publication title — likely generic usage: Li-COR Image Studio Lite 5.0
R version 3.2.3,computational_tools,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R version 3.2.3,Analysis Software,3.2.3,,,,,,,,,,,,,,,We performed all preprocessing steps using R version 3.2.3,Generic tool (versioned): R version 3.2.3
WGCNA,computational_tools,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,WGCNA,Package/Library,,,,,,,,,,,,,,,,We used the 'collapseRows()' function with the 'maxmean' method from the R package WGCNA,Software name not in publication title — likely generic usage: WGCNA
Docker,computational_tools,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Docker,Analysis Software,,,,,,,,,,,,,,,,"Ensuring a stable compute environment, we performed all analyses in a Docker image",No version and no repository URL (confidence < 0.9 — unidentifiable)
nf1_inactivation GitHub repository,computational_tools,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,nf1_inactivation GitHub repository,Pipeline,,https://github.com/greenelab/nf1_inactivation,,,,,,,,,,,,,,"All source code is available under a permissive open source license in the nf1_inactivation GitHub repository, https://github.com/greenelab/nf1_inactivation",Software name not in publication title — likely generic usage: nf1_inactivation GitHub repository
GeneChip Human Transcriptome Array 2.0,computational_tools,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GeneChip Human Transcriptome Array 2.0,Other,,,,,,,,,,,,,,,,"samples were labeled for the GeneChip Human Transcriptome Array 2.0 (HTA 2.0, Affymetrix)",Software name not in publication title — likely generic usage: GeneChip Human Transcriptome Array 2.0
CELLQuest™ software,computational_tools,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CELLQuest™ software,Analysis Software,,,,,,,,,,,,,,,,FACS analysis was performed using CELLQuest™ software (Becton Dickinson),No version and no repository URL (confidence < 0.9 — unidentifiable)
PamChip peptide arrays,computational_tools,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PamChip peptide arrays,Analysis Software,,,,,,,,,,,,,,,,"PamChip peptide arrays (PamGene International BV, 's-Hertogenbosch, the Netherlands) measure the ability of active kinases",No version and no repository URL (confidence < 0.9 — unidentifiable)
BioNavigator software V.6.3,computational_tools,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BioNavigator software V.6.3,Analysis Software,V.6.3,,,,,,,,,,,,,,,software-based image analysis (BioNavigator software V.6.3 from PamGene),Software name not in publication title — likely generic usage: BioNavigator software V.6.3
IBM SPSS Statistics,computational_tools,PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,IBM SPSS Statistics,Analysis Software,27.01,,,,,,,,,,,,,,,Statistical analyses were conducted using IBM SPSS Statistics (version 27.01),Software name not in publication title — likely generic usage: IBM SPSS Statistics
Vectra software,computational_tools,PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Vectra software,Analysis Software,,,,,,,,,,,,,,,,Images from each device were analysed by a single investigator (J.L.) on a dedicated laptop using the recommended software provided by each imaging system manufacturer,No version and no repository URL (confidence < 0.9 — unidentifiable)
LifeViz App software,computational_tools,PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LifeViz App software,Analysis Software,,,,,,,,,,,,,,,,3D model analysis using LifeViz App software,No version and no repository URL (confidence < 0.9 — unidentifiable)
Cherry Imaging Trace software,computational_tools,PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Cherry Imaging Trace software,Analysis Software,,,,,,,,,,,,,,,,3D model analysis using Cherry Imaging Trace software,No version and no repository URL (confidence < 0.9 — unidentifiable)
PERADIGM,computational_tools,PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.95,Development,True,0.67,Medium,,,,,,,,,,,,,,,PERADIGM,Analysis Software,,,,,,,,,,,,,,,,"Here, we introduce PERADIGM ( Phenotype Embedding similarity-based RAre DIsease Gene Mapping), a novel framework that leverages natural language processing techniques",Publication title lacks NF-specific terms: PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.
UK Biobank 200K dataset,computational_tools,PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,UK Biobank 200K dataset,Database,,,,,,,,,,,,,,,,"We utilized the UK Biobank 200K dataset [ 4 , 50 ] in our analysis",Publication title lacks NF-specific terms: PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.
PLINK,computational_tools,PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PLINK,Analysis Software,,,,,,,,,,,,,,,,we implemented stringent quality control (QC) measures on the whole-exome sequencing (WES) data using PLINK [ 51 ],Publication title lacks NF-specific terms: PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.
Word2Vec,computational_tools,PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Word2Vec,Package/Library,,,,,,,,,,,,,,,,We employed the Word2Vec embedding model to obtain static embedding vectors for the phenotypes,Publication title lacks NF-specific terms: PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.
CBOW,computational_tools,PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CBOW,Package/Library,,,,,,,,,,,,,,,,"In our embedding analysis, we applied the CBOW Word2Vec model to embed the ICD-10 phenotype data from the UK Biobank",Publication title lacks NF-specific terms: PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.
skyscan 1172,computational_tools,PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,skyscan 1172,Analysis Software,,,,,,,,,,,,,,,,Bone samples were analyzed with low (6 µm voxel) or high (up to 1 µm voxel) resolution microCT from skyscan 1172,Software name not in publication title — likely generic usage: skyscan 1172
NRecon,computational_tools,PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NRecon,Analysis Software,,,,,,,,,,,,,,,,"Raw data reconstruction occurred with NRecon, with a defined threshold of 0.00 to 0.10",No version and no repository URL (confidence < 0.9 — unidentifiable)
CTan,computational_tools,PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CTan,Analysis Software,,,,,,,,,,,,,,,,Quantitative evaluation was performed with CTan after definition of appropriated regions of interest,No version and no repository URL (confidence < 0.9 — unidentifiable)
AxioVision Software,computational_tools,PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AxioVision Software,Analysis Software,,,,,,,,,,,,,,,,"Histomorphometric analysis was performed with AxioVision Software (Zeiss, Germany)",No version and no repository URL (confidence < 0.9 — unidentifiable)
ImageJ,computational_tools,PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ,Analysis Software,,imagej.nih.gov/ij/,,,,,,,,,,,,,,"Analysis of EDX images was performed with ImageJ (Rasband WS. ImageJ, U.S. National Institutes of Health, Bethesda, Maryland, USA, imagej.nih.gov/ij/, 1997–2012)",Generic bioinformatics/stats tool: ImageJ
Labview 7.0,computational_tools,PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Labview 7.0,Analysis Software,7.0,,,,,,,,,,,,,,,"Both the camera and the tensile tester were controlled by customized software (Labview 7.0, National Instruments)",Software name not in publication title — likely generic usage: Labview 7.0
Covaris S2,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Covaris S2,Other,,,,,,,,,,,,,,,,"DNA was sonicated using a Covaris S2 (Covaris, Woburn, MA, USA)",Publication title lacks NF-specific terms: A comprehensive custom panel design for routine hereditary cancer testing: prese
BWA mem,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BWA mem,Analysis Software,,,,,,,,,,,,,,,,fastq files were mapped against the GRCh37 human genome assembly...using BWA mem,Publication title lacks NF-specific terms: A comprehensive custom panel design for routine hereditary cancer testing: prese
samtools,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,samtools,Analysis Software,,,,,,,,,,,,,,,,a sorted bam file was created with samtools,Publication title lacks NF-specific terms: A comprehensive custom panel design for routine hereditary cancer testing: prese
bedtools,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,bedtools,Analysis Software,,,,,,,,,,,,,,,,Exhaustive coverage metrics were produced using a combination of bedtools and custom R,Publication title lacks NF-specific terms: A comprehensive custom panel design for routine hereditary cancer testing: prese
VarScan2,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VarScan2,Analysis Software,,,,,,,,,,,,,,,,Variants...were called using VarScan2 with the following parameters,Publication title lacks NF-specific terms: A comprehensive custom panel design for routine hereditary cancer testing: prese
annovar,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,annovar,Analysis Software,,,,,,,,,,,,,,,,variants were annotated with a combination of annovar and custom scripts,Publication title lacks NF-specific terms: A comprehensive custom panel design for routine hereditary cancer testing: prese
bam-readcount,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,bam-readcount,Analysis Software,,,,,,,,,,,,,,,,bam-readcount was then used to compute additional quality parameters,Publication title lacks NF-specific terms: A comprehensive custom panel design for routine hereditary cancer testing: prese
regioneR,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,regioneR,Package/Library,,,,,,,,,,,,,,,,Variants were filtered using the regioneR bioconductor package,Publication title lacks NF-specific terms: A comprehensive custom panel design for routine hereditary cancer testing: prese
CLC Genomics Workbench v6,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CLC Genomics Workbench v6,Analysis Software,v6,,,,,,,,,,,,,,,CLC Genomics Workbench v6 (Qiagen) was used to analyze data from I2HCP V1,Publication title lacks NF-specific terms: A comprehensive custom panel design for routine hereditary cancer testing: prese
Genemania algorithm,computational_tools,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Genemania algorithm,Analysis Software,,,,,,,,,,,,,,,,"We used the Genemania algorithm to generate gene-gene association networks (genetic interaction, physical interaction, and pathways)",No version and no repository URL (confidence < 0.9 — unidentifiable)
GS20 Flex pyrosequencing machine,computational_tools,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GS20 Flex pyrosequencing machine,Other,,,,,,,,,,,,,,,,"Amplicon sequencing using the GS20 Flex pyrosequencing machine (Roche, Indianapolis, IN) was performed according to the manufacturer's protocol",No version and no repository URL (confidence < 0.9 — unidentifiable)
SAS mixed procedure,computational_tools,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SAS mixed procedure,Analysis Software,,,,,,,,,,,,,,,,P values were generated with a random effects model analysis on log transformed tumor volume data using the SAS mixed procedure,No version and no repository URL (confidence < 0.9 — unidentifiable)
Research Patient Database Registry,computational_tools,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Research Patient Database Registry,Database,,,,,,,,,,,,,,,,"Medical records review was performed using the Research Patient Database Registry, an internal research tool providing access to demographic information",No version and no repository URL (confidence < 0.9 — unidentifiable)
Seurat V3.0,computational_tools,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat V3.0,Package/Library,V3.0,,,,,,,,,,,,,,,Data were analyzed by the Seurat V3.0 package in the R programming environment,Software name not in publication title — likely generic usage: Seurat V3.0
STAR 2.4.2.8,computational_tools,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR 2.4.2.8,Analysis Software,2.4.2.8,,,,,,,,,,,,,,,The raw transcript counts were aligned to Refseq related to the build GRCh38-mm10 using STAR 2.4.2.8,Software name not in publication title — likely generic usage: STAR 2.4.2.8
DeSeq2,computational_tools,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DeSeq2,Package/Library,,,,,,,,,,,,,,,,Differentially expressed genes between GFP+ and GFP- tumor populations were analyzed by paired experiment design in the DeSeq2 package,Generic bioinformatics/stats tool: DeSeq2
GSVA package,computational_tools,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GSVA package,Package/Library,,,,,,,,,,,,,,,,The ssgesa was calculated by the GSVA package with default settings,Software name not in publication title — likely generic usage: GSVA package
Limma package,computational_tools,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Limma package,Package/Library,,,,,,,,,,,,,,,,Limma package was used for generating the human 621-MPNST signature,Software name not in publication title — likely generic usage: Limma package
gentleMACS Octo Dissociator,computational_tools,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,gentleMACS Octo Dissociator,Other,,,,,,,,,,,,,,,,then dissociated by gentleMACS Octo Dissociator (Miltenyi Biotec) with 1 g/ml collagenase,No version and no repository URL (confidence < 0.9 — unidentifiable)
S3e sorter,computational_tools,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,S3e sorter,Other,,,,,,,,,,,,,,,,GFP+ and GFP- cells from the same tumor were analyzed and sorted by the S3e sorter (BioRad),No version and no repository URL (confidence < 0.9 — unidentifiable)
IVIS Spectrum scanner,computational_tools,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,IVIS Spectrum scanner,Other,,,,,,,,,,,,,,,,Tumor volume was measured by in vivo luminescence using luciferase reporter IVIS Spectrum scanner (PerkinElmer),No version and no repository URL (confidence < 0.9 — unidentifiable)
FACSVantage SE-dual laser flow-cytometer,computational_tools,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FACSVantage SE-dual laser flow-cytometer,Analysis Software,,,,,,,,,,,,,,,,"Flow-cytometry was performed with a FACSVantage SE-dual laser, three-line flow-cytometer (Becton-Dickinson)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Axioplan 2 microscope,computational_tools,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Axioplan 2 microscope,Other,,,,,,,,,,,,,,,,"Slides were examined by using an Axioplan 2 microscope (Carl Zeiss MicroImaging GmbH, Germany)","Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
GraphPad Prism version 5.01,computational_tools,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 5.01,Analysis Software,5.01,,,,,,,,,,,,,,,"AUCs were compared with two-way ANOVA followed by Bonferroni post-tests, using GraphPad Prism version 5.01","Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
STATA 11,computational_tools,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STATA 11,Analysis Software,11,,,,,,,,,,,,,,,"distributions were first checked for normality by using the Shapiro–Wilk's test with STATA 11 (StataCorp, College Station, TX)","Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
Schrödinger software suite release 2017–1,computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Schrödinger software suite release 2017–1,Analysis Software,2017-1,,,,,,,,,,,,,,,"Briefly, the Schrödinger software suite release 2017–1 was used for system setup.",Publication title lacks NF-specific terms: Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics 
Glide,computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Glide,Analysis Software,,,,,,,,,,,,,,,,Flexible ligand docking into TRAP1 allosteric site was performed using Glide with default settings in SP mode.,Publication title lacks NF-specific terms: Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics 
AMBER16,computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,AMBER16,Analysis Software,16,,,,,,,,,,,,,,,Equilibration and production steps were performed using the AMBER16 MD engine,Publication title lacks NF-specific terms: Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics 
VMD (version 1.9.3),computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,VMD (version 1.9.3),Analysis Software,1.9.3,,,,,,,,,,,,,,,Descriptors were generated with in-house scripts using VMD (version 1.9.3) to calculate solvent accessible surface area,Publication title lacks NF-specific terms: Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics 
gromacs (version 4.6),computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,gromacs (version 4.6),Analysis Software,4.6,,,,,,,,,,,,,,,g_mindist tool of gromacs (version 4.6) to get residue–residue contacts,Publication title lacks NF-specific terms: Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics 
MATLAB version 2019b,computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MATLAB version 2019b,Analysis Software,2019b,,,,,,,,,,,,,,,The predictive power of the trained models was internally checked via 5-fold cross validation procedure available in MATLAB version 2019b,Publication title lacks NF-specific terms: Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics 
Classification Learner app,computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Classification Learner app,Plugin,,,,,,,,,,,,,,,,"GNB, KNB and GDF-SVM were trained on the original and extended training sets by using the Classification Learner app available in the Statistics and Machine Learning Toolbox of MATLAB",Publication title lacks NF-specific terms: Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics 
Curve Fitting tool of MATLAB,computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Curve Fitting tool of MATLAB,Plugin,,,,,,,,,,,,,,,,Linear regression models were generated on the predicted vs observed variables with the Curve Fitting tool of MATLAB,Publication title lacks NF-specific terms: Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics 
PredictSNP2,computational_tools,PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,PredictSNP2,Web Application,,https://loschmidt.chemi.muni.cz/predictsnp/,,,,,,,,,,,,,,The effects of mutations on protein functions were analyzed using the PredictSNP2 tool (https://loschmidt.chemi.muni.cz/predictsnp/),Software name not in publication title — likely generic usage: PredictSNP2
iStable,computational_tools,PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,iStable,Web Application,,,,,,,,,,,,,,,,"The iStable-integrated server, accessible at predictor.nchu.edu.tw/iStable, features two machine learning-based tools",Software name not in publication title — likely generic usage: iStable
Align GVGD,computational_tools,PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Align GVGD,Web Application,,http://agvgd.hci.utah.edu/agvgd_input.php,,,,,,,,,,,,,,Align-GVGD (http://agvgd.hci.utah.edu/agvgd_input.php) is another tool that applies the Grantham difference,Software name not in publication title — likely generic usage: Align GVGD
AlphaFold3,computational_tools,PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AlphaFold3,Analysis Software,,,,,,,,,,,,,,,,"we utilized AlphaFold3 to simulate both the wild-type and mutant NF1 structures, revealing the significant effects",Software name not in publication title — likely generic usage: AlphaFold3
SNPeffect 4.0,computational_tools,PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SNPeffect 4.0,Analysis Software,4.0,,,,,,,,,,,,,,,These mutations were subjected to further phenotyping analysis using SNPeffect 4.0,Software name not in publication title — likely generic usage: SNPeffect 4.0
iMutant 2.0,computational_tools,PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,iMutant 2.0,Analysis Software,2.0,,,,,,,,,,,,,,,We selected the iMutant 2.0 and MUpro algorithms to predict the thermodynamic parameter changes,Software name not in publication title — likely generic usage: iMutant 2.0
MUpro,computational_tools,PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MUpro,Analysis Software,,,,,,,,,,,,,,,,We selected the iMutant 2.0 and MUpro algorithms to predict the thermodynamic parameter changes,No version and no repository URL (confidence < 0.9 — unidentifiable)
Gel-Pro Analyzer 4.0 software,computational_tools,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Gel-Pro Analyzer 4.0 software,Analysis Software,4.0,,,,,,,,,,,,,,,"Densitometry analysis was performed with Gel-Pro Analyzer 4.0 software (Media Cybernetics; Silver Spring, MD)",Software name not in publication title — likely generic usage: Gel-Pro Analyzer 4.0 software
R statistical package,computational_tools,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R statistical package,Analysis Software,,http://cran.r-project.org/,,,,,,,,,,,,,,All the analyses were implemented by the comprehensive statistical package R (http://cran.r-project.org/),Software name not in publication title — likely generic usage: R statistical package
Mini Analysis,computational_tools,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Mini Analysis,Analysis Software,,,,,,,,,,,,,,,,analyzed for statistical significance using the Kolmogorov–Smirnov test (Mini Analysis),No version and no repository URL (confidence < 0.9 — unidentifiable)
Prism,computational_tools,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Prism,Analysis Software,,,,,,,,,,,,,,,,"two-sided testing (Prism, GraphPad Software, Inc., La Jolla, CA, USA",Generic bioinformatics/stats tool: Prism
SPSS,computational_tools,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SPSS,Analysis Software,,,,,,,,,,,,,,,,"and SPSS, IBM Corporation, Armonk, NY, USA)",Generic bioinformatics/stats tool: SPSS
SynergyFinder,computational_tools,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SynergyFinder,Web Application,,,,,,,,,,,,,,,,Synergy was calculated using the web-based SynergyFinder to analyze drug combination dose–response matrix data,No version and no repository URL (confidence < 0.9 — unidentifiable)
ImageJ,computational_tools,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,Data were analyzed using ImageJ,Generic bioinformatics/stats tool: ImageJ
FlowJo,computational_tools,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FlowJo,Analysis Software,,,,,,,,,,,,,,,,Results were analyzed using the FlowJo software,No version and no repository URL (confidence < 0.9 — unidentifiable)
Qupath,computational_tools,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Qupath,Analysis Software,,,,,,,,,,,,,,,,Ki-67 quantification and image analysis was performed with Qupath to score Ki-67 in tumor tissue,No version and no repository URL (confidence < 0.9 — unidentifiable)
SPSS version 19.0,computational_tools,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS version 19.0,Analysis Software,19.0,,,,,,,,,,,,,,,"The statistical analyses were undertaken using a licensed version of SPSS (version 19.0, SPSS Inc, Chicago, IL, USA) compatible with Windows",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
CHOPCHOP,computational_tools,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CHOPCHOP,Web Application,,https://chopchop.cbu.uib.no/,,,,,,,,,,,,,,CHOPCHOP (https://chopchop.cbu.uib.no/) was used to identify the sgRNA sequence,Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
DanioVision tracking system,computational_tools,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DanioVision tracking system,Analysis Software,,,,,,,,,,,,,,,,"images recorded with DanioVision tracking system (Noldus Information Technology, Wageningen, The Netherlands)",Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
Ethovision 11,computational_tools,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Ethovision 11,Analysis Software,11,,,,,,,,,,,,,,,"Locomotor activity was analyzed using Ethovision 11 software (Noldus Information Technology, Wageningen, The Netherlands)",Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
ImageJ,computational_tools,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,Muscular birefringence was calculated by dividing the mean intensity by the selected area of the fish using ImageJ software,Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
Vevo 2100 micro-imaging system,computational_tools,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Vevo 2100 micro-imaging system,Analysis Software,,,,,,,,,,,,,,,,"Sonographic measurement was performed using a Vevo 2100 micro-imaging system (VisualSonics, Amsterdam, Netherlands)",Software name not in publication title — likely generic usage: Vevo 2100 micro-imaging system
Vevo software version 5.0.0,computational_tools,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Vevo software version 5.0.0,Analysis Software,5.0.0,,,,,,,,,,,,,,,Three-dimensional images of the xenografts were generated and analyzed using the Vevo software version 5.0.0 to calculate their size in volume,Software name not in publication title — likely generic usage: Vevo software version 5.0.0
Galaxy server,computational_tools,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Galaxy server,Web Application,,,,,,,,,,,,,,,,Alignment and analysis was performed using a Galaxy server and open source Chipster software,No version and no repository URL (confidence < 0.9 — unidentifiable)
Chipster software,computational_tools,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Chipster software,Analysis Software,,http://chipster.csc.fi/,,,,,,,,,,,,,,Alignment and analysis was performed using a Galaxy server and open source Chipster software (http://chipster.csc.fi/),Software name not in publication title — likely generic usage: Chipster software
R bioconductor,computational_tools,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R bioconductor,Package/Library,,http://www.bioconductor.org/,,,,,,,,,,,,,,as well as R bioconductor (http://www.bioconductor.org/) tools for calculating similarity clusters on a Galaxy server,Software name not in publication title — likely generic usage: R bioconductor
Genome Analyzer IIx,computational_tools,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Genome Analyzer IIx,Analysis Software,,,,,,,,,,,,,,,,"Libraries were sequenced on a Genome Analyzer IIx (Illumina, San Diego, CA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
ARACNe-AP algorithm,computational_tools,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ARACNe-AP algorithm,Analysis Software,,,,,,,,,,,,,,,,the network was built using the ARACNe-AP algorithm. The ARACNe-AP algorithm reconstructs gene regulatory networks from large-scale gene expression data,Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
DESeq2 version 1.18.1,computational_tools,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DESeq2 version 1.18.1,Package/Library,1.18.1,,,,,,,,,,,,,,,The differential expression and fold change calculations on the RNA-Seq datasets were performed using the R package DESeq2 version 1.18.1,Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
igraph package in R,computational_tools,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,igraph package in R,Package/Library,,,,,,,,,,,,,,,,Centrality measures were calculated using the igraph package in R,Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
Qubit 2.0 Fluorometer,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Qubit 2.0 Fluorometer,Analysis Software,,,,,,,,,,,,,,,,The concentration of the gDNA was estimated using the Qubit 2.0 Fluorometer (Invitrogen),No version and no repository URL (confidence < 0.9 — unidentifiable)
Covaris LE220,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Covaris LE220,Analysis Software,,,,,,,,,,,,,,,,"The samples were then sonicated on the Covaris LE220 (Covaris Inc, Woburn, MA, USA) to achieve an average target size of 400 bp",No version and no repository URL (confidence < 0.9 — unidentifiable)
Caliper LabChip GX,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Caliper LabChip GX,Analysis Software,,,,,,,,,,,,,,,,"QC analysis of the post-sonicated material was done using Caliper LabChip GX (Perkin Elmer, Hopkinton, MA, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
"Agilent 2,100 Bioanalyzer",computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"Agilent 2,100 Bioanalyzer",Analysis Software,,,,,,,,,,,,,,,,"the library concentration was estimated by utilizing a DNA 1,000 Chip on an Agilent 2,100 Bioanalyzer",No version and no repository URL (confidence < 0.9 — unidentifiable)
Illumina HiSeqX sequencer,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina HiSeqX sequencer,Analysis Software,,,,,,,,,,,,,,,,"Each sample was then sequenced on an individual lane on an Illumina HiSeqX sequencer (Illumina, Inc., San Diego, CA, USA)",Sequencing hardware or generic assay protocol: Illumina HiSeqX sequencer
Dragen program,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Dragen program,Analysis Software,,,,,,,,,,,,,,,,Reads were mapped to the genome and variants identified using the Dragen program with default settings,Software name not in publication title — likely generic usage: Dragen program
GATK pipeline,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GATK pipeline,Pipeline,,,,,,,,,,,,,,,,The resulting VCF files were then sorted and updated to remove errors and analysed using the GATK pipeline,Software name not in publication title — likely generic usage: GATK pipeline
VarDict,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VarDict,Analysis Software,,,,,,,,,,,,,,,,Somatic mutations were called from BAM files exported by the Dragen alignment using the Java version of VarDict in paired mode,Software name not in publication title — likely generic usage: VarDict
GenomeStudio,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GenomeStudio,Analysis Software,,,,,,,,,,,,,,,,Samples were analysed by GenomeStudio and exported to text,No version and no repository URL (confidence < 0.9 — unidentifiable)
Illumina HiSeq2500 sequencer,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina HiSeq2500 sequencer,Analysis Software,,,,,,,,,,,,,,,,"on an Illumina HiSeq2500 sequencer (Illumina, Inc., San Diego, CA, USA)",Sequencing hardware or generic assay protocol: Illumina HiSeq2500 sequencer
HudsonAlpha RNA-seq data analysis pipeline,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HudsonAlpha RNA-seq data analysis pipeline,Pipeline,,,,,,,,,,,,,,,,Post-processing of the sequencing reads from RNA-seq experiments for each sample was performed using HudsonAlpha's unique in-house RNA-seq data analysis pipeline,Software name not in publication title — likely generic usage: HudsonAlpha RNA-seq data analysis pipeline
TopHat v2.0,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,TopHat v2.0,Analysis Software,v2.0,,,,,,,,,,,,,,,Raw reads were mapped to the reference human genome hg19 using TopHat v2.0 with the -p 4 and -r210 arguments,Software name not in publication title — likely generic usage: TopHat v2.0
Cufflinks v0.9.3,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cufflinks v0.9.3,Analysis Software,v0.9.3,,,,,,,,,,,,,,,Reads were quantified by both Cufflinks v0.9.3,Software name not in publication title — likely generic usage: Cufflinks v0.9.3
FeatureCounts,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FeatureCounts,Analysis Software,,,,,,,,,,,,,,,,Reads were quantified by both Cufflinks v0.9.3 and FeatureCounts,Generic bioinformatics/stats tool: FeatureCounts
Cutaneous NF Github repository,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,Cutaneous NF Github repository,Web Application,,http://www.github.com/Sage-Bionetworks/dermalNF,,,,,,,,,,,,,,"All data is currently stored in the synapse web portal, and is accessible using code in the Cutaneous NF Github repository at http://www.github.com/Sage-Bionetworks/dermalNF",Software name not in publication title — likely generic usage: Cutaneous NF Github repository
QuPath (v0.4.3),computational_tools,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,QuPath (v0.4.3),Analysis Software,v0.4.3,,,,,,,,,,,,,,,QuPath (v0.4.3) was used to quantify the percentage of cells with positive or negative immunostaining,Software name not in publication title — likely generic usage: QuPath (v0.4.3)
R (version 4.3.1),computational_tools,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R (version 4.3.1),Analysis Software,4.3.1,,,,,,,,,,,,,,,"All statistical analyses were performed in R (version 4.3.1) using the 'survival', 'survminer', and 'stats' packages",Software name not in publication title — likely generic usage: R (version 4.3.1)
cBioportal,computational_tools,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,cBioportal,Web Application,,,,,,,,,,,,,,,,The cBioportal website (cbioportal.org) was used to analyze The Cancer Genome Atlas (TCGA)—Firehose Legacy,Software name not in publication title — likely generic usage: cBioportal
REDCap,computational_tools,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,REDCap,Database,,,,,,,,,,,,,,,,A REDCap database was constructed from 542 patients with histologically-confirmed IDH-wild type GBM,No version and no repository URL (confidence < 0.9 — unidentifiable)
ImageJ,computational_tools,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ,Analysis Software,,https://imagej.nih.gov/ij/,,,,,,,,,,,,,,protein bands were quantified using the ImageJ software (https://imagej.nih.gov/ij/),Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
National COVID Cohort Collaborative (N3C),computational_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,National COVID Cohort Collaborative (N3C),Database,,,,,,,,,,,,,,,,"We investigated the proportions of people with NF1, NF2, or SWN in the National COVID Cohort Collaborative (N3C) electronic health record data set",No version and no repository URL (confidence < 0.9 — unidentifiable)
N3C Data Enclave,computational_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,N3C Data Enclave,Web Application,,,,,,,,,,,,,,,,All cohorts were generated using custom SQL queries and subsequently analyzed in the N3C Data Enclave,No version and no repository URL (confidence < 0.9 — unidentifiable)
Shapiro-Wilk test,computational_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Shapiro-Wilk test,Analysis Software,,,,,,,,,,,,,,,,"A Shapiro-Wilk test (base R v3.6.3, shapiro.test function) was used to test the normality of the distributions",No version and no repository URL (confidence < 0.9 — unidentifiable)
R v3.6.3,computational_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R v3.6.3,Analysis Software,v3.6.3,,,,,,,,,,,,,,,"A Shapiro-Wilk test (base R v3.6.3, shapiro.test function) was used to test the normality",Software name not in publication title — likely generic usage: R v3.6.3
BSDA v1.2.0,computational_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BSDA v1.2.0,Package/Library,v1.2.0,,,,,,,,,,,,,,,"compared to estimate the P value of the real observations (real P value) (using BSDA v1.2.0, z.test function)",Software name not in publication title — likely generic usage: BSDA v1.2.0
gdata v2.18.0,computational_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,gdata v2.18.0,Package/Library,v2.18.0,,,,,,,,,,,,,,,"resampled 10,000 times to produce 10,000 possible combinations of age-adjusted proportions (using gdata v2.18.0, resample function)",Software name not in publication title — likely generic usage: gdata v2.18.0
ggplot2 v3.3.2,computational_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ggplot2 v3.3.2,Package/Library,v3.3.2,,,,,,,,,,,,,,,The distributions of bootstrapped P values were visualized using R (ggplot2 v3.3.2),Software name not in publication title — likely generic usage: ggplot2 v3.3.2
Wilcoxon rank-sum test,computational_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Wilcoxon rank-sum test,Analysis Software,,,,,,,,,,,,,,,,"a nonparametric Wilcoxon rank-sum test (base R v3.6.3, wilcox.test function) was used to estimate the real P value",No version and no repository URL (confidence < 0.9 — unidentifiable)
Benjamini-Hochberg (BH) method,computational_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Benjamini-Hochberg (BH) method,Analysis Software,,,,,,,,,,,,,,,,All real P values were adjusted to correct for the number of overlapping comparisons for each disease using the Benjamini-Hochberg (BH) method,No version and no repository URL (confidence < 0.9 — unidentifiable)
FACSCanto (Becton–Dickinson),computational_tools,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FACSCanto (Becton–Dickinson),Analysis Software,,,,,,,,,,,,,,,,We acquired cell suspensions in a dual-laser (Argon 488 and dye laser 630 or HeNe 633) FACSCanto (Becton–Dickinson),No version and no repository URL (confidence < 0.9 — unidentifiable)
Affymetrix Mouse Gene 2.0 ST array,computational_tools,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Affymetrix Mouse Gene 2.0 ST array,Analysis Software,,,,,,,,,,,,,,,,All the probe sets on Affymetrix Mouse Gene 2.0 ST array (Mogene-2_0-st-v1.na33.2.mm10),Software name not in publication title — likely generic usage: Affymetrix Mouse Gene 2.0 ST array
ComBat method,computational_tools,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ComBat method,Package/Library,,,,,,,,,,,,,,,,their batch effects were corrected using ComBat method implemented in Bioconductor's sva package,No version and no repository URL (confidence < 0.9 — unidentifiable)
limma package,computational_tools,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,limma package,Package/Library,,,,,,,,,,,,,,,,The Bioconductor/R limma package was used to define DEGs between two groups,Software name not in publication title — likely generic usage: limma package
WebGestalt webserver,computational_tools,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,WebGestalt webserver,Web Application,,http://bioinfo.vanderbilt.edu/webgestalt/,,,,,,,,,,,,,,Gene set enrichment analysis was performed using the WebGestalt webserver (http://bioinfo.vanderbilt.edu/webgestalt/),Software name not in publication title — likely generic usage: WebGestalt webserver
NetWalk algorithm,computational_tools,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NetWalk algorithm,Analysis Software,,,,,,,,,,,,,,,,A modified version of NetWalk algorithm was used to handle bi-cellular interaction,No version and no repository URL (confidence < 0.9 — unidentifiable)
Discovery VCT,computational_tools,PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Discovery VCT,Other,,,,,,,,,,,,,,,,"18F-FDG PET/CT scans were all acquired to the same protocol in the same institution on one of two scanners (Discovery VCT or DST, GE Healthcare, Chicago, IL, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
DST,computational_tools,PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DST,Other,,,,,,,,,,,,,,,,"18F-FDG PET/CT scans were all acquired to the same protocol in the same institution on one of two scanners (Discovery VCT or DST, GE Healthcare, Chicago, IL, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
MATLAB,computational_tools,PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MATLAB,Analysis Software,Release 2016a,,,,,,,,,,,,,,,"The reconstructed PET datasets were imported into in-house texture analysis software implemented in MATLAB (Release 2016a, The MathWorks, Inc., Natick, MA, USA)",Generic bioinformatics/stats tool: MATLAB
SPSS,computational_tools,PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPSS,Analysis Software,v22,,,,,,,,,,,,,,,"Statistical analysis was performed using SPSS (v22, Chicago, IL, USA) and MedCalc (v16.8.4, Ostend, Belgium) software",Generic bioinformatics/stats tool: SPSS
MedCalc,computational_tools,PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MedCalc,Analysis Software,v16.8.4,,,,,,,,,,,,,,,"Statistical analysis was performed using SPSS (v22, Chicago, IL, USA) and MedCalc (v16.8.4, Ostend, Belgium) software",Software name not in publication title — likely generic usage: MedCalc
Stata 15,computational_tools,PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Stata 15,Analysis Software,15,,,,,,,,,,,,,,,"...All analyses were performed using Stata 15 (StataCorp, College Station, TX, USA)...",Software name not in publication title — likely generic usage: Stata 15
ichorCNA,computational_tools,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ichorCNA,Analysis Software,v.0.2.0,,,,,,,,,,,,,,,copy-number–based estimation of tumor fraction were then performed using the ichorCNA tool (Broad v.0.2.0),Publication title lacks NF-specific terms: Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell
samtools,computational_tools,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,samtools,Command-line Tool,v1.17,,,,,,,,,,,,,,,Downsampling was repeated using seed values 0 to 4 in samtools v1.17,Publication title lacks NF-specific terms: Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell
Picard,computational_tools,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Picard,Command-line Tool,v.4.0.1.2,,,,,,,,,,,,,,,"Fragment lengths, extracted from bam files using Picard (v.4.0.1.2)",Publication title lacks NF-specific terms: Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell
Python sklearn,computational_tools,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Python sklearn,Package/Library,v.1.3.2,,,,,,,,,,,,,,,We then used the Python sklearn library (v.1.3.2) decomposition module incorporating up to 20 components,Publication title lacks NF-specific terms: Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell
ComplexHeatmap,computational_tools,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ComplexHeatmap,Package/Library,v.2.14.0,,,,,,,,,,,,,,,were represented by heatmaps using ComplexHeatmap (v.2.14.0) with supervised clustering,Publication title lacks NF-specific terms: Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell
Zeiss LSM 900 confocal microscope,computational_tools,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Zeiss LSM 900 confocal microscope,Other,,,,,,,,,,,,,,,,Images were captured with a Zeiss LSM 900 confocal microscope equipped with a 20X objective,No version and no repository URL (confidence < 0.9 — unidentifiable)
Image J software,computational_tools,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Image J software,Analysis Software,,,,,,,,,,,,,,,,Image processing and analysis were performed using Image J software,Generic tool (versioned): Image J software
GraphPad Prism 10,computational_tools,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism 10,Analysis Software,10,,,,,,,,,,,,,,,Results were processed in GraphPad Prism 10 software and presented as mean +/- SEM,Generic bioinformatics/stats tool: GraphPad Prism 10
10x Genomics Cell Ranger 7.0.1,computational_tools,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,10x Genomics Cell Ranger 7.0.1,Analysis Software,7.0.1,,,,,,,,,,,,,,,BCL files were processed using 10x Genomics Cell Ranger 7.0.1,Software name not in publication title — likely generic usage: 10x Genomics Cell Ranger 7.0.1
Nextflow,computational_tools,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Nextflow,Workflow,,,,,,,,,,,,,,,,we designed two pipelines using Nextflow [10] and Singularity containerization [17],No version and no repository URL (confidence < 0.9 — unidentifiable)
Singularity,computational_tools,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Singularity,Other,,,,,,,,,,,,,,,,we designed two pipelines using Nextflow [10] and Singularity containerization [17],No version and no repository URL (confidence < 0.9 — unidentifiable)
Seurat V3 package,computational_tools,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat V3 package,Package/Library,V3,,,,,,,,,,,,,,,Each data set was analyzed individually from its raw count matrix using the Seurat V3 package [29],Software name not in publication title — likely generic usage: Seurat V3 package
scDblFinder,computational_tools,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,scDblFinder,Package/Library,,,,,,,,,,,,,,,,Doublet cells were removed using the scDblFinder tool and scds in hybrid mode,No version and no repository URL (confidence < 0.9 — unidentifiable)
harmony package,computational_tools,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,harmony package,Package/Library,,,,,,,,,,,,,,,,"Sampling effect was removed on the PCA using the RunHarmony function from the harmony package [15, 16]",No version and no repository URL (confidence < 0.9 — unidentifiable)
SAS software Version 9.4,computational_tools,PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SAS software Version 9.4,Analysis Software,9.4,,,,,,,,,,,,,,,"The data were analyzed using SAS software Version 9.4 (SAS Institute, Cary, NC, USA), with the significance level set at 0.05",Software name not in publication title — likely generic usage: SAS software Version 9.4
PROC CALIS procedure,computational_tools,PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PROC CALIS procedure,Analysis Software,,,,,,,,,,,,,,,,"Higher order factor confirmatory analysis was performed to confirm that the dimensions created could be combined into one single score. PROC CALIS procedure, SAS 9.4, was employed",No version and no repository URL (confidence < 0.9 — unidentifiable)
SPSS version 25,computational_tools,PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPSS version 25,Analysis Software,25,,,,,,,,,,,,,,,"Data were analyzed in SPSS version 25 (SPSS Inc., Chicago, USA)",Publication title lacks NF-specific terms: Autism Spectrum Disorder Symptom Profile Across the RASopathies.
Analyze 12.0,computational_tools,PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Analyze 12.0,Analysis Software,12.0,,,,,,,,,,,,,,,"Using the multispectral neural network (MSNN) modeling tool available in Analyze 12.0 (AnalyzeDirect, Overland Park, KS)",Software name not in publication title — likely generic usage: Analyze 12.0
MIM Encore 6.9.3,computational_tools,PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MIM Encore 6.9.3,Analysis Software,6.9.3,,,,,,,,,,,,,,,"Measurements were made on a commercially available image analysis software (MIM Encore 6.9.3, MIM Software INC, Cleveland, OH)",Software name not in publication title — likely generic usage: MIM Encore 6.9.3
eLucidate,computational_tools,PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,eLucidate,Analysis Software,,,,,,,,,,,,,,,,"Calculation of IVIM parameters were performed on a molecular kinetic modeling software (eLucidate, Paul R. Territo, Ph.D, Indiana University, Indianapolis, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
multispectral neural network (MSNN),computational_tools,PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,multispectral neural network (MSNN),Analysis Software,,,,,,,,,,,,,,,,Using the multispectral neural network (MSNN) modeling tool available in Analyze 12.0,No version and no repository URL (confidence < 0.9 — unidentifiable)
Clinical Trials Processor,computational_tools,PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Clinical Trials Processor,Analysis Software,,,,,,,,,,,,,,,,DWI MRI image series from baseline and follow up scans are imported into the Clinical Trials Processor for de-identification,No version and no repository URL (confidence < 0.9 — unidentifiable)
Affymetrix GeneChip HU133 Plus 2.0,computational_tools,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Affymetrix GeneChip HU133 Plus 2.0,Analysis Software,,,,,,,,,,,,,,,,for hybridization to the whole-genome Affymetrix GeneChip HU133 Plus 2.0 using the Affymetrix protocol,No version and no repository URL (confidence < 0.9 — unidentifiable)
Genome TraFac 3,computational_tools,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Genome TraFac 3,Analysis Software,,,,,,,,,,,,,,,,We used Genome TraFac 3 for genome-wide detection of compositionally similar cis-clusters in gene orthologues,No version and no repository URL (confidence < 0.9 — unidentifiable)
ImageJ,computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,Western blot band intensities were quantitated with ImageJ software,Generic bioinformatics/stats tool: ImageJ
Genome Analysis Toolkit (GATK),computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Genome Analysis Toolkit (GATK),Analysis Software,,https://gatk.broadinstitute.org,,,,,,,,,,,,,,Variant calling of the germline samples was performed using The Genome Analysis Toolkit (https://gatk.broadinstitute.org),Software name not in publication title — likely generic usage: Genome Analysis Toolkit (GATK)
MuTect,computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MuTect,Analysis Software,,https://github.com/broadinstitute/mutect,,,,,,,,,,,,,,somatic variant calling was performed using either MuTect (https://github.com/broadinstitute/mutect),Generic bioinformatics/stats tool: MuTect
AutoGVP,computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AutoGVP,Analysis Software,,,,,,,,,,,,,,,,Germline variant pathogenicity classification was performed by AutoGVP,No version and no repository URL (confidence < 0.9 — unidentifiable)
cBioPortal,computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,cBioPortal,Web Application,,https://www.cbioportal.org/,,,,,,,,,,,,,,Somatic variants were queried in cBioPortal (https://www.cbioportal.org/),Software name not in publication title — likely generic usage: cBioPortal
nf-core sarek pipeline (v2.7.1),computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,nf-core sarek pipeline (v2.7.1),Pipeline,v2.7.1,,,,,,,,,,,,,,,WES and WGS data processing was performed with a modified version of the Nextflow nf-core 'sarek' data processing pipeline (v2.7.1),Software name not in publication title — likely generic usage: nf-core sarek pipeline (v2.7.1)
DeepVariant,computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DeepVariant,Analysis Software,,,,,,,,,,,,,,,,The pipeline was modified to add DeepVariant as an additional variant-calling method,Software name not in publication title — likely generic usage: DeepVariant
FreeBayes,computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FreeBayes,Analysis Software,,,,,,,,,,,,,,,,Whole exome variant calling was performed with FreeBayes,No version and no repository URL (confidence < 0.9 — unidentifiable)
Strelka2,computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Strelka2,Analysis Software,,,,,,,,,,,,,,,,"Whole exome variant calling was performed with FreeBayes, Mutect2, Strelka2",Generic bioinformatics/stats tool: Strelka2
Control-FREEC,computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Control-FREEC,Analysis Software,,,,,,,,,,,,,,,,copy-number alterations were determined using Control-FREEC (whole genome data only),No version and no repository URL (confidence < 0.9 — unidentifiable)
maftools R package,computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,maftools R package,Package/Library,,,,,,,,,,,,,,,,NF1 variants were extracted from the annotated maf files from the WES data and plotted using the 'maftools' R package,No version and no repository URL (confidence < 0.9 — unidentifiable)
nf-core rnaseq pipeline (v3.5),computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,nf-core rnaseq pipeline (v3.5),Pipeline,v3.5,,,,,,,,,,,,,,,Transcriptomic data processing was performed using the nf-core 'rnaseq' data processing pipeline (v3.5),Software name not in publication title — likely generic usage: nf-core rnaseq pipeline (v3.5)
XF24 Extracellular Flux Analyzer,computational_tools,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,XF24 Extracellular Flux Analyzer,Analysis Software,,,,,,,,,,,,,,,,"OCR was assessed in real-time with the XF24 Extracellular Flux Analyzer (Agilent, North Billerica, MA, USA)",Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
LC-MS/MS (Quattro Premier),computational_tools,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LC-MS/MS (Quattro Premier),Analysis Software,,,,,,,,,,,,,,,,"Mass spectrometry analysis was carried out with an LC-MS/MS (Quattro Premier interfaced with an Acquity UPLC system, Waters)",Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
FACSCanto II flow cytometer,computational_tools,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FACSCanto II flow cytometer,Analysis Software,,,,,,,,,,,,,,,,"Samples were analyzed on a FACSCanto II flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA)",Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
FACSDiva software,computational_tools,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FACSDiva software,Analysis Software,,,,,,,,,,,,,,,,Data acquisition and analysis were performed using FACSDiva software,Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
ImageJ software,computational_tools,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ software,Analysis Software,,,,,,,,,,,,,,,,colonies were stained with Crystal Violet 0.005% and analyzed with ImageJ software,Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
Origin® 8,computational_tools,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Origin® 8,Analysis Software,8,,,,,,,,,,,,,,,"Statistical significance was determined using Origin® 8 (OriginLab, Northampton, MA)",Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
U-Net convolutional neural network,computational_tools,PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,U-Net convolutional neural network,Analysis Software,,,,,,,,,,,,,,,,"Based on a convolutional neural network (U-Net), the mean raw Raman spectra (n = 8,200) were processed and refined",No version and no repository URL (confidence < 0.9 — unidentifiable)
Shifted-Excitation Raman Spectroscopy,computational_tools,PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Shifted-Excitation Raman Spectroscopy,Analysis Software,,,,,,,,,,,,,,,,"Here, we introduce Shifted-Excitation Raman Spectroscopy in combination with deep neural networks for the future perspective",No version and no repository URL (confidence < 0.9 — unidentifiable)
Ventana-785-Raman spectrometer,computational_tools,PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Ventana-785-Raman spectrometer,Analysis Software,,,,,,,,,,,,,,,,"guiding the signals from the Raman probe to the spectrometer (Ventana-785-Raman, Ocean Optics, Rochester, New York, USA)",Software name not in publication title — likely generic usage: Ventana-785-Raman spectrometer
Principal component analysis (PCA),computational_tools,PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Principal component analysis (PCA),Analysis Software,,,,,,,,,,,,,,,,"As a first step, principal component analysis (PCA) was utilized to reduce the number of spectral parameters",No version and no repository URL (confidence < 0.9 — unidentifiable)
linear discriminant analysis (LDA),computational_tools,PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,linear discriminant analysis (LDA),Analysis Software,,,,,,,,,,,,,,,,we employed a multiclass linear discriminant analysis (LDA),No version and no repository URL (confidence < 0.9 — unidentifiable)
SERDS,computational_tools,PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SERDS,Analysis Software,,,,,,,,,,,,,,,,Extraction of the pure Raman spectra from the mean raw spectra...was performed using the SERDS and U-Net deep neural network data processing methods,No version and no repository URL (confidence < 0.9 — unidentifiable)
FMRIB software library (FSL),computational_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FMRIB software library (FSL),Analysis Software,5.0,,,,,,,,,,,,,,,"FMRI data analyses were performed using the FMRIB software library (www.fmrib.ox.ac.uk/fsl), version 5.0",Software name not in publication title — likely generic usage: FMRIB software library (FSL)
SPSS software v. 21,computational_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS software v. 21,Analysis Software,21,,,,,,,,,,,,,,,Analyses of neuropsychological and clinical data were performed using SPSS software v. 21 (IBM),Software name not in publication title — likely generic usage: SPSS software v. 21
FMRIB's Local Analysis of Mixed Effects (FLAME),computational_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FMRIB's Local Analysis of Mixed Effects (FLAME),Analysis Software,,,,,,,,,,,,,,,,The output from the subject-specific analyses was analyzed using a mixed-effects model with FMRIB's Local Analysis of Mixed Effects (FLAME),No version and no repository URL (confidence < 0.9 — unidentifiable)
generalized psychophysiological interaction (gPPI) method,computational_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,generalized psychophysiological interaction (gPPI) method,Analysis Software,,,,,,,,,,,,,,,,We used the generalized psychophysiological interaction (gPPI) method described in McLaren et al. (2012),No version and no repository URL (confidence < 0.9 — unidentifiable)
FSL motion outlier tool,computational_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FSL motion outlier tool,Analysis Software,,,,,,,,,,,,,,,,all subjects' SCAP scans were run through the FSL motion outlier tool (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSLMotionOutliers),No version and no repository URL (confidence < 0.9 — unidentifiable)
Harvard-Oxford cortical and subcortical probabilistic atlases,computational_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Harvard-Oxford cortical and subcortical probabilistic atlases,Database,,,,,,,,,,,,,,,,Brain regions were identified using the Harvard-Oxford cortical and subcortical probabilistic atlases,No version and no repository URL (confidence < 0.9 — unidentifiable)
Light-Cycler 480 Real-Time PCR System,computational_tools,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Light-Cycler 480 Real-Time PCR System,Analysis Software,,,,,,,,,,,,,,,,cDNA was submitted to qPCR in a Light-Cycler 480 Real-Time PCR System,No version and no repository URL (confidence < 0.9 — unidentifiable)
Odyssey Imaging System (LI-COR),computational_tools,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Odyssey Imaging System (LI-COR),Analysis Software,,,,,,,,,,,,,,,,scanned using the Odyssey Imaging System (LI-COR),No version and no repository URL (confidence < 0.9 — unidentifiable)
BD FACSAria II,computational_tools,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BD FACSAria II,Analysis Software,,,,,,,,,,,,,,,,"sorted, after 3 days, using the BD FACSAria II",No version and no repository URL (confidence < 0.9 — unidentifiable)
Countess Automated Cell Counter (Life Technologies),computational_tools,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Countess Automated Cell Counter (Life Technologies),Analysis Software,,,,,,,,,,,,,,,,cells were counted with the Countess Automated Cell Counter (Life Technologies),No version and no repository URL (confidence < 0.9 — unidentifiable)
BD LSRFortessa SORP cytometer,computational_tools,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BD LSRFortessa SORP cytometer,Analysis Software,,,,,,,,,,,,,,,,A BD LSRFortessa SORP cytometer was used to measure,No version and no repository URL (confidence < 0.9 — unidentifiable)
Spectramax M5,computational_tools,PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Spectramax M5,Analysis Software,,,,,,,,,,,,,,,,"A multi-mode microplate reader (Spectramax ® M5: Molecular Devices, California, USA) was used to measure the UV-VIS absorbance.",Publication title lacks NF-specific terms: Spectrophotometric and computational characterization of charge transfer complex
SoftMax Pro Enterprise software,computational_tools,PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SoftMax Pro Enterprise software,Analysis Software,,,,,,,,,,,,,,,,"The SpectraMax M5 reader is controlled and operated by using the SoftMax ® Pro Enterprise software, a leading data acquisition and analysis software",Publication title lacks NF-specific terms: Spectrophotometric and computational characterization of charge transfer complex
GAMESS software,computational_tools,PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GAMESS software,Analysis Software,,,,,,,,,,,,,,,,Quantum mechanics/molecular mechanics (QM/MM) computations...were performed using the General Atomic and Molecular Electronic Structure System (GAMESS software),Publication title lacks NF-specific terms: Spectrophotometric and computational characterization of charge transfer complex
Mutiwfn 3.7,computational_tools,PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Mutiwfn 3.7,Analysis Software,3.7,,,,,,,,,,,,,,,"Mutiwfn 3.7, VMD, and the GAMESS-optimized SEL-DDQ complex were used in the hirshfeld surface HS study",Publication title lacks NF-specific terms: Spectrophotometric and computational characterization of charge transfer complex
VMD,computational_tools,PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VMD,Analysis Software,,,,,,,,,,,,,,,,"Mutiwfn 3.7, VMD, and the GAMESS-optimized SEL-DDQ complex were used in the hirshfeld surface HS study",Publication title lacks NF-specific terms: Spectrophotometric and computational characterization of charge transfer complex
DynaPro NanoStar,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DynaPro NanoStar,Analysis Software,,,,,,,,,,,,,,,,The light scattering measurements were performed using DynaPro NanoStar (Wyatt Technology Corporation),No version and no repository URL (confidence < 0.9 — unidentifiable)
DYNAMIC software,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DYNAMIC software,Analysis Software,V7.1.4,,,,,,,,,,,,,,,"DYNAMIC software (V7.1.4) was used to obtain the normalized time autocorrelation function, polydispersity, and the absolute molecular mass",Software name not in publication title — likely generic usage: DYNAMIC software
J-180 JASCO circular dichroism spectropolarimeter,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,J-180 JASCO circular dichroism spectropolarimeter,Analysis Software,,,,,,,,,,,,,,,,CD experiments were performed on a J-180 JASCO circular dichroism spectropolarimeter equipped with a temperature controlled cell holder,No version and no repository URL (confidence < 0.9 — unidentifiable)
Spectra Manager,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Spectra Manager,Analysis Software,V1.17.00,,,,,,,,,,,,,,,using the Spectra Manager control (V1. 17.00) and application (V1.3.00) software package (JASCO),Software name not in publication title — likely generic usage: Spectra Manager
DichroWeb,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DichroWeb,Web Application,,,,,,,,,,,,,,,,Data deconvolution and normalization were carried out using DichroWeb,No version and no repository URL (confidence < 0.9 — unidentifiable)
Biacore X100,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Biacore X100,Analysis Software,,,,,,,,,,,,,,,,"Surface plasmon resonance (SRP) experiments were performed on a Biacore X100 (GE Life Sciences, NJ) at 25.0 °C",No version and no repository URL (confidence < 0.9 — unidentifiable)
MicroCal™ Auto-iTC 200,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MicroCal™ Auto-iTC 200,Analysis Software,,,,,,,,,,,,,,,,ITC experiments were run in a MicroCal™ Auto-iTC 200 system at 25 °C,No version and no repository URL (confidence < 0.9 — unidentifiable)
Bindworks,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Bindworks,Analysis Software,version 3.1.5,,,,,,,,,,,,,,,"The data were analyzed using the manufacturer provided software Bindworks (version 3.1.5, Calorimetry Sciences Corp. Lindon, UT)",Software name not in publication title — likely generic usage: Bindworks
MantidPlot,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MantidPlot,Analysis Software,,http://www.mantidproject.org/,,,,,,,,,,,,,,Data reduction followed standard procedures that are implemented in MantidPlot (http://www.mantidproject.org/),Software name not in publication title — likely generic usage: MantidPlot
GNOM,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GNOM,Analysis Software,,,,,,,,,,,,,,,,"The length distribution function P(r), radius of gyration Rg, the forward scattering intensity I(0), and the maximum dimension Dmax were calculated from the scattering data using the program GNOM",No version and no repository URL (confidence < 0.9 — unidentifiable)
DAMMIN,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DAMMIN,Analysis Software,,,,,,,,,,,,,,,,The 3-D 'dummy bead' coordinates were generated using the program DAMMIN. Multiple calculations were performed using DAMMIN,No version and no repository URL (confidence < 0.9 — unidentifiable)
DAMAVER,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DAMAVER,Analysis Software,,,,,,,,,,,,,,,,the generated 10 structures were averaged and filtered using the program DAMAVER and DAMFILT,No version and no repository URL (confidence < 0.9 — unidentifiable)
DAMFILT,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DAMFILT,Analysis Software,,,,,,,,,,,,,,,,the generated 10 structures were averaged and filtered using the program DAMAVER and DAMFILT,No version and no repository URL (confidence < 0.9 — unidentifiable)
Situs,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Situs,Analysis Software,,,,,,,,,,,,,,,,The 3-D density map was generated from the averaged coordinates using the program Situs. The fitting and docking of the high-resolution structure to the density map were performed using Situs,No version and no repository URL (confidence < 0.9 — unidentifiable)
UCS Chimera,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,UCS Chimera,Analysis Software,,,,,,,,,,,,,,,,The fitting and docking of the high-resolution structure to the density map were performed using Situs or UCS Chimera,No version and no repository URL (confidence < 0.9 — unidentifiable)
Biospec 4.7 Tesla microimaging system,computational_tools,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Biospec 4.7 Tesla microimaging system,Analysis Software,,,,,,,,,,,,,,,,"MR study was performed on a 4.7 Tesla microimaging system (Biospec, Bruker BioSpin MRI, Inc., Ertlingen, Germany)",No version and no repository URL (confidence < 0.9 — unidentifiable)
LKB8801 ultramicrotome,computational_tools,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.7,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,LKB8801 ultramicrotome,Other,,,,,,,,,,,,,,,,"Thin sections were cut with an LKB8801 ultramicrotome and diamond knife, stained with Sato's lead",No version and no repository URL (confidence < 0.9 — unidentifiable)
Phillips 301 transmission electron microscope,computational_tools,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.7,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Phillips 301 transmission electron microscope,Other,,,,,,,,,,,,,,,,"stained with Sato's lead, and examined in a Phillips 301 transmission electron microscope",No version and no repository URL (confidence < 0.9 — unidentifiable)
"ActiveTwo system (BioSemi, Amsterdam, Netherlands)",computational_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"ActiveTwo system (BioSemi, Amsterdam, Netherlands)",Analysis Software,,,,,,,,,,,,,,,,"EEG data were recorded using an ActiveTwo system (BioSemi, Amsterdam, Netherlands) with 64 EEG channels in standard 10–10 system locations",No version and no repository URL (confidence < 0.9 — unidentifiable)
MATLAB (2019a),computational_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MATLAB (2019a),Analysis Software,2019a,,,,,,,,,,,,,,,MATLAB (2019a) and SPM12 (version 7771) were used to conduct data analyses,Software name not in publication title — likely generic usage: MATLAB (2019a)
SPM12 (version 7771),computational_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPM12 (version 7771),Analysis Software,7771,,,,,,,,,,,,,,,MATLAB (2019a) and SPM12 (version 7771) were used to conduct data analyses,Software name not in publication title — likely generic usage: SPM12 (version 7771)
EEGLAB (version 13.6.5b),computational_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,EEGLAB (version 13.6.5b),Package/Library,13.6.5b,,,,,,,,,,,,,,,Custom functions calling several functions from EEGLAB (version 13.6.5b) and FieldTrip (embedded in SPM release) were used,Software name not in publication title — likely generic usage: EEGLAB (version 13.6.5b)
FieldTrip,computational_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FieldTrip,Package/Library,,,,,,,,,,,,,,,,Custom functions calling several functions from EEGLAB (version 13.6.5b) and FieldTrip (embedded in SPM release) were used,No version and no repository URL (confidence < 0.9 — unidentifiable)
G*Power,computational_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,G*Power,Analysis Software,,,,,,,,,,,,,,,,Post hoc analysis of Ribeiro et al.'s resting state theta effect in NF1 using G*Power suggests that n = 17 participants per group would result in 79% power,No version and no repository URL (confidence < 0.9 — unidentifiable)
laplacian_perrinX function,computational_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,laplacian_perrinX function,Command-line Tool,,,,,,,,,,,,,,,,"spatially filtered using the Surface Laplacian, implemented using the laplacian_perrinX function in MATLAB",No version and no repository URL (confidence < 0.9 — unidentifiable)
SPSS (Version 25),computational_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPSS (Version 25),Analysis Software,25,,,,,,,,,,,,,,,Statistical analyses were conducted using SPSS (Version 25),Software name not in publication title — likely generic usage: SPSS (Version 25)
Qualtrics,computational_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Qualtrics,Web Application,,,,,,,,,,,,,,,,completed an online screening survey administered via Qualtrics ( www.qualtrics.com ),No version and no repository URL (confidence < 0.9 — unidentifiable)
ATLAS.ti (Version 9),computational_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ATLAS.ti (Version 9),Analysis Software,Version 9,,,,,,,,,,,,,,,"The coded transcripts were entered into ATLAS.ti (Version 9; Kansas City, MO)",Software name not in publication title — likely generic usage: ATLAS.ti (Version 9)
Weighted Gene Co-expression Network Analysis (WGCNA),computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Weighted Gene Co-expression Network Analysis (WGCNA),Package/Library,,,,,,,,,,,,,,,,"Weighted Gene Co-expression Network Analysis, WGCNA ( 15 , 17 ) was applied to explore gene expression as an undirected co-expression network",No version and no repository URL (confidence < 0.9 — unidentifiable)
Affymetrix Genotyping Console,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Affymetrix Genotyping Console,Analysis Software,,,,,,,,,,,,,,,,analyzed the Affymetrix Genotyping Console software ( Affymetrix ),No version and no repository URL (confidence < 0.9 — unidentifiable)
R,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,R,Analysis Software,,,,,,,,,,,,,,,,analyzed in GSE16581 R ( 21 ),Generic bioinformatics/stats tool: R
affy package,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,affy package,Package/Library,,,,,,,,,,,,,,,,using functions of the affy package ( 22 ),No version and no repository URL (confidence < 0.9 — unidentifiable)
arrayQualityMetrics package,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,arrayQualityMetrics package,Package/Library,,,,,,,,,,,,,,,,Array quality was determined with the arrayQualityMetrics package ( 23 ),No version and no repository URL (confidence < 0.9 — unidentifiable)
Cytoscape,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Cytoscape,Analysis Software,,,,,,,,,,,,,,,,Cytoscape ( 26 ) was used to create a graphic representation of the pink-module,Generic bioinformatics/stats tool: Cytoscape
CentiScape plug-in,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CentiScape plug-in,Plugin,,,,,,,,,,,,,,,,"Using the CentiScape plug-in ( 27 ), we analyzed several network parameters",No version and no repository URL (confidence < 0.9 — unidentifiable)
ClueGO plug-in,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ClueGO plug-in,Plugin,,,,,,,,,,,,,,,,The ClueGO plug-in ( 28 ) was utilized to create pathway and Gene Ontology ( 29 ) enrichment networks,No version and no repository URL (confidence < 0.9 — unidentifiable)
DAVID web tool,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DAVID web tool,Web Application,,,,,,,,,,,,,,,,"Gene ontology analysis for hub genes was performed with DAVID web tool ( 33 , 34 )",No version and no repository URL (confidence < 0.9 — unidentifiable)
snpStats package,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,snpStats package,Package/Library,,,,,,,,,,,,,,,,with the function spn.lhs.tests implemented in the package snpStats ( 35 ),No version and no repository URL (confidence < 0.9 — unidentifiable)
HaploReg v2,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HaploReg v2,Web Application,v2,,,,,,,,,,,,,,,mQTL putative genes were obtained from the HaploReg v2 web browser ( 36 ),Software name not in publication title — likely generic usage: HaploReg v2
oPPOSUM Single Site Analysis tool,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,oPPOSUM Single Site Analysis tool,Analysis Software,,,,,,,,,,,,,,,,mQTL enrichment in TFBS was studied using oPPOSUM Single Site Analysis tool ( 37 ),No version and no repository URL (confidence < 0.9 — unidentifiable)
STRING,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,STRING,Database,,,,,,,,,,,,,,,,The PPI database STRING ( 39 ) was used to test for known interactions among the proteins,Generic bioinformatics/stats tool: STRING
ComBat function,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ComBat function,Package/Library,,,,,,,,,,,,,,,,batches were removed with the ComBat function implemented in the package sva ( 42 ),No version and no repository URL (confidence < 0.9 — unidentifiable)
limma package,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,limma package,Package/Library,,,,,,,,,,,,,,,,Linear models of the limma package ( 43 ) were applied to determine differential gene expression,No version and no repository URL (confidence < 0.9 — unidentifiable)
GenABEL package,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GenABEL package,Package/Library,,,,,,,,,,,,,,,,"rntransform , package GenABEL ( 45 )] was applied to the dependent variables",No version and no repository URL (confidence < 0.9 — unidentifiable)
matrixStats package,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,matrixStats package,Package/Library,,,,,,,,,,,,,,,,"Gene-expression standard deviation was determined with the function rowSds , part of the package matrixStats ( 25 )",No version and no repository URL (confidence < 0.9 — unidentifiable)
fmsb package,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,fmsb package,Package/Library,,,,,,,,,,,,,,,,Variance inflation factors (VIFs) for lineal models were calculated with the VIF function implemented in the package fmsb ( 46 ),No version and no repository URL (confidence < 0.9 — unidentifiable)
impute package,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,impute package,Package/Library,,,,,,,,,,,,,,,,Expression missing values were imputed with functions of the package impute ( 47 ),No version and no repository URL (confidence < 0.9 — unidentifiable)
E-Prime software,computational_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,E-Prime software,Analysis Software,,,,,,,,,,,,,,,,The task was programmed in-house using E-Prime software.,No version and no repository URL (confidence < 0.9 — unidentifiable)
Psychology Experiment Building Language (PEBL),computational_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Psychology Experiment Building Language (PEBL),Analysis Software,,,,,,,,,,,,,,,,Memory span was assessed using a computerized Corsi block task on the Psychology Experiment Building Language (PEBL; Mueller and Piper 2014).,No version and no repository URL (confidence < 0.9 — unidentifiable)
SPM12 v7771,computational_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPM12 v7771,Analysis Software,v7771,,,,,,,,,,,,,,,"Images were segmented using SPM12 v7771 (Wellcome Trust Centre for Neuroimaging, University College London, United Kingdom)",Software name not in publication title — likely generic usage: SPM12 v7771
MATLAB vR2020b,computational_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,MATLAB vR2020b,Analysis Software,vR2020b,,,,,,,,,,,,,,,"Images were segmented using SPM12 v7771 (Wellcome Trust Centre for Neuroimaging, University College London, United Kingdom) through MATLAB vR2020b",Software name not in publication title — likely generic usage: MATLAB vR2020b
MRIcroGL,computational_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MRIcroGL,Analysis Software,,https://www.nitrc.org/projects/mricrogl,,,,,,,,,,,,,,"For visualization purposes, all thresholded SPM maps were imported into MRIcroGL (https://www.nitrc.org/projects/mricrogl)",Software name not in publication title — likely generic usage: MRIcroGL
marsbar,computational_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,marsbar,Package/Library,,,,,,,,,,,,,,,,We then used marsbar (Brett et al. 2002) to extract gray matter volumes within this region,No version and no repository URL (confidence < 0.9 — unidentifiable)
Cell Ranger 5.0.1,computational_tools,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cell Ranger 5.0.1,Analysis Software,5.0.1,,,,,,,,,,,,,,,"Cell Ranger 5.0.1 (10x Genomics, https://www.10xgenomics.com/) was used to process the raw sequencing data.",Software name not in publication title — likely generic usage: Cell Ranger 5.0.1
Seurat R package,computational_tools,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat R package,Package/Library,v4.0.2,,,,,,,,,,,,,,,The gene expression matrix from Cell Ranger was used as input to the Seurat R package (v4.0.2) for downstream analysis (53).,Software name not in publication title — likely generic usage: Seurat R package
Proteome Discoverer 2.4,computational_tools,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Proteome Discoverer 2.4,Analysis Software,2.4,,,,,,,,,,,,,,,Data were acquired by the facility core and analyzed using Proteome Discoverer 2.4 (Thermo Fisher Scientific)...,Software name not in publication title — likely generic usage: Proteome Discoverer 2.4
Chromium Single Cell Gene Expression,computational_tools,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Chromium Single Cell Gene Expression,Workflow,,,,,,,,,,,,,,,,Cells were processed in the Chromium Single Cell Gene Expression (10x Genomics) to build the 3′ transcriptome libraries...,No version and no repository URL (confidence < 0.9 — unidentifiable)
SPSS version 28.0,computational_tools,PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPSS version 28.0,Analysis Software,28.0,,,,,,,,,,,,,,,The statistical analyses were conducted using SPSS version 28.0,Software name not in publication title — likely generic usage: SPSS version 28.0
randomizr package,computational_tools,PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,randomizr package,Package/Library,,,,,,,,,,,,,,,,Mice were randomized into treatment groups using the randomizr package that arranges animals to achieve the best-case distribution,No version and no repository URL (confidence < 0.9 — unidentifiable)
I2HCP NGS custom panel,computational_tools,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,I2HCP NGS custom panel,Analysis Software,,,,,,,,,,,,,,,,NF1 germline and somatic mutations were detected by NF1 gDNA sequencing using the I2HCP NGS custom panel,No version and no repository URL (confidence < 0.9 — unidentifiable)
bwa mem,computational_tools,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,bwa mem,Analysis Software,,,,,,,,,,,,,,,,Sequencing reads were then mapped with bwa mem against GRCh38,No version and no repository URL (confidence < 0.9 — unidentifiable)
strelka2,computational_tools,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,strelka2,Analysis Software,,,,,,,,,,,,,,,,We called variants with strelka2 and annotated them with annovar,Generic bioinformatics/stats tool: strelka2
annovar,computational_tools,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,annovar,Analysis Software,,,,,,,,,,,,,,,,We called variants with strelka2 and annotated them with annovar,Generic bioinformatics/stats tool: annovar
Salmon v1.8.0,computational_tools,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Salmon v1.8.0,Analysis Software,v1.8.0,,,,,,,,,,,,,,,RNA-Seq data from real and in silico mixed samples was aligned with Salmon v1.8.0,Software name not in publication title — likely generic usage: Salmon v1.8.0
tximport,computational_tools,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,tximport,Package/Library,,,,,,,,,,,,,,,,We imported transcript-level estimates into R and summarized them to gene level using tximport,No version and no repository URL (confidence < 0.9 — unidentifiable)
DESeq2,computational_tools,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2,Package/Library,,,,,,,,,,,,,,,,used DESeq2 to perform differential expression analysis,Generic bioinformatics/stats tool: DESeq2
clusterProfiler,computational_tools,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,clusterProfiler,Package/Library,,,,,,,,,,,,,,,,We finally used clusterProfiler to determine Gene Ontology and KEGG pathway enrichment,Generic bioinformatics/stats tool: clusterProfiler
nCounter Sprint Profiler,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,nCounter Sprint Profiler,Analysis Software,,,,,,,,,,,,,,,,"Gene expression analysis was conducted on the nCounter Sprint Profiler (NanoString Technologies, Inc.)",Software name not in publication title — likely generic usage: nCounter Sprint Profiler
nSolver Advanced Analysis Software version 4.0,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,nSolver Advanced Analysis Software version 4.0,Analysis Software,4.0,,,,,,,,,,,,,,,"Quality control, normalization, differential expression and pathway analysis were performed using nSolver Advanced Analysis Software (version 4.0)",Software name not in publication title — likely generic usage: nSolver Advanced Analysis Software version 4.0
Omics Playground v2.7.18,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Omics Playground v2.7.18,Analysis Software,v2.7.18,,,,,,,,,,,,,,,Raw count matrices with sample metadata deposited on GEO were reanalyzed using the Omics Playground v2.7.18 Platform,Software name not in publication title — likely generic usage: Omics Playground v2.7.18
UCSC Xena browser,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,UCSC Xena browser,Web Application,,,,,,,,,,,,,,,,Publicly available RNA sequencing data was also obtained from the TARGET TCGA GTEx database using the UCSC Xena browser (RRID:SCR_018938),Software name not in publication title — likely generic usage: UCSC Xena browser
IDEP.92,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,IDEP.92,Web Application,0.92,,,,,,,,,,,,,,,"Principal Component Analysis (PCA) was conducted in IDEP.92 using log2 transformed, normalized counts as input",Software name not in publication title — likely generic usage: IDEP.92
Morpheus,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Morpheus,Web Application,,,,,,,,,,,,,,,,Heatmaps in Figure 5B and C were generated using Morpheus,No version and no repository URL (confidence < 0.9 — unidentifiable)
ComplexHeatmap R/Bioconductor package,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ComplexHeatmap R/Bioconductor package,Package/Library,,,,,,,,,,,,,,,,were generated using the ComplexHeatmap R/Bioconductor package (RRID:SCR_017270),Software name not in publication title — likely generic usage: ComplexHeatmap R/Bioconductor package
Scanpy,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Scanpy,Package/Library,,,,,,,,,,,,,,,,Data preprocessing and visualization was performed using Scanpy (RRID:SCR_018139) in Python,Software name not in publication title — likely generic usage: Scanpy
scVI model,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,scVI model,Package/Library,,,,,,,,,,,,,,,,An scVI model was trained on the raw counts with sample and quality metrics,No version and no repository URL (confidence < 0.9 — unidentifiable)
decoupler package,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,decoupler package,Package/Library,,,,,,,,,,,,,,,,the decoupler package was used to perform over-representation analysis (ORA) of cell type markers,No version and no repository URL (confidence < 0.9 — unidentifiable)
infercnvpy package,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,infercnvpy package,Package/Library,,https://github.com/icbi-lab/infercnvpy,,,,,,,,,,,,,,the infercnvpy package (https://github.com/icbi-lab/infercnvpy) was used to detect copy number variations,Software name not in publication title — likely generic usage: infercnvpy package
HALO Image Analysis software version 2.0.5,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HALO Image Analysis software version 2.0.5,Analysis Software,2.0.5,,,,,,,,,,,,,,,Quantitative immunohistochemical analysis for BIRC5 and CENPF was conducted using the Cytonuclear IHC module of HALO Image Analysis software (version 2.0.5),Software name not in publication title — likely generic usage: HALO Image Analysis software version 2.0.5
Illumina Infinium HumanMethylationEPIC (EPIC) array,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina Infinium HumanMethylationEPIC (EPIC) array,Analysis Software,,,,,,,,,,,,,,,,Bisulfite-treated DNA from all tumor samples was then processed for methylation profiling using the Illumina Infinium HumanMethylationEPIC (EPIC) array,Sequencing hardware or generic assay protocol: Illumina Infinium HumanMethylationEPIC (EPIC) array
minfi,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,minfi,Package/Library,3.3,,,,,,,,,,,,,,,Raw IDAT data files were processed using the minfi Bioconductor package (version 3.3),Software name not in publication title — likely generic usage: minfi
ConsensusClusterPlus,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ConsensusClusterPlus,Package/Library,,,,,,,,,,,,,,,,Subgroups were identified using ConsensusClusterPlus Bioconductor package,Software name not in publication title — likely generic usage: ConsensusClusterPlus
limma,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,limma,Package/Library,,,,,,,,,,,,,,,,We performed supervised analysis of methylation data using limma based modeling approach (Bioconductor),Generic bioinformatics/stats tool: limma
Rtsne,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Rtsne,Package/Library,,,,,,,,,,,,,,,,"We used Rtsne package in Bioconductor to generate tSNE plots based on the top 10,000 most variably methylated CpG sites",Software name not in publication title — likely generic usage: Rtsne
conumee,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,conumee,Package/Library,,,,,,,,,,,,,,,,"To generate compound CNV plots using the DNA methylation data, we used the conumee package in Bioconductor",Software name not in publication title — likely generic usage: conumee
Haplotype Caller,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Haplotype Caller,Analysis Software,,,,,,,,,,,,,,,,"Haplotype Caller, MuTect1 v1.1.7 and Strelka v1.0.13 were run to create raw variant call files (VCFs)",Software name not in publication title — likely generic usage: Haplotype Caller
MuTect1,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MuTect1,Analysis Software,v1.1.7,,,,,,,,,,,,,,,"Haplotype Caller, MuTect1 v1.1.7 and Strelka v1.0.13 were run to create raw variant call files",Software name not in publication title — likely generic usage: MuTect1
Strelka,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Strelka,Analysis Software,v1.0.13,,,,,,,,,,,,,,,"Haplotype Caller, MuTect1 v1.1.7 and Strelka v1.0.13 were run to create raw variant call files",Generic bioinformatics/stats tool: Strelka
Variant Effect Predictor,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Variant Effect Predictor,Analysis Software,v92,,,,,,,,,,,,,,,Raw VCF files were annotated with Variant Effect Predictor v92,Software name not in publication title — likely generic usage: Variant Effect Predictor
Sequenza,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Sequenza,Analysis Software,v 2.1.2,,,,,,,,,,,,,,,"Additional analysis was applied to detect allele specific copy number profiles, loss of heterozygosity, and to estimate ploidy/cellularity using Sequenza for matched tumor/normal pairs",Software name not in publication title — likely generic usage: Sequenza
BwaMem,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BwaMem,Analysis Software,v0.7.12,,,,,,,,,,,,,,,WGS data were aligned against hg19 using BwaMem v0.7.12,Software name not in publication title — likely generic usage: BwaMem
Delly,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Delly,Analysis Software,0.8.1,,,,,,,,,,,,,,,Structural variant (SV) prediction for tumor and matched normal pairs was carried out using Delly (version 0.8.1),Generic bioinformatics/stats tool: Delly
MAVIS,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MAVIS,Analysis Software,2.2.6,,,,,,,,,,,,,,,SVs were validated and visualized using MAVIS (version 2.2.6),Software name not in publication title — likely generic usage: MAVIS
FusionCatcher,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FusionCatcher,Analysis Software,,,,,,,,,,,,,,,,We used FusionCatcher to detect novel gene fusions,Software name not in publication title — likely generic usage: FusionCatcher
FastQC,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FastQC,Analysis Software,0.11.5,,,,,,,,,,,,,,,The quality assessment of the raw reads was carried out using the FastQC tool (version 0.11.5),Generic bioinformatics/stats tool: FastQC
STAR aligner,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR aligner,Analysis Software,2.4.2a,,,,,,,,,,,,,,,"The reads were aligned to the human reference genome, hg38 using the star aligner (version 2.4.2a)",Software name not in publication title — likely generic usage: STAR aligner
HtSeq,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HtSeq,Analysis Software,0.11.0,,,,,,,,,,,,,,,The RNASeq reads were counted over gene exons using HtSeq (version 0.11.0),Generic bioinformatics/stats tool: HtSeq
DESeq2,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DESeq2,Package/Library,1.26.0,,,,,,,,,,,,,,,DEseq2 (DESeq2_1.26.0) was used to normalize and difference in library preparation methods was corrected by limma,Generic bioinformatics/stats tool: DESeq2
edgeR,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,edgeR,Package/Library,,,,,,,,,,,,,,,,Differential gene expression analysis was performed using the R package edgeR in BioConductor,Generic bioinformatics/stats tool: edgeR
GSEA,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GSEA,Analysis Software,3.0,,,,,,,,,,,,,,,Pathways analysis was performed using DEG from indicated pairwise analysis by the Gene Set Enrichment Analysis (GSEA) software from the Broad Institute (version 3.0),Generic bioinformatics/stats tool: GSEA
AutoAnnotate,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,AutoAnnotate,Plugin,1.2,,,,,,,,,,,,,,,Highly related pathways were grouped into a theme and labeled by AutoAnnotate (version 1.2) in Cytoscape,Software name not in publication title — likely generic usage: AutoAnnotate
Cytoscape,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cytoscape,Analysis Software,3.7.2,,,,,,,,,,,,,,,labeled by AutoAnnotate (version 1.2) in Cytoscape (Version 3.7.2),Generic bioinformatics/stats tool: Cytoscape
Enrichment Map,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Enrichment Map,Plugin,3.1,,,,,,,,,,,,,,,GSEA results were visualized using the Enrichment Map app (Version 3.1) in Cytoscape,Software name not in publication title — likely generic usage: Enrichment Map
CIBERSORT,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CIBERSORT,Package/Library,,,,,,,,,,,,,,,,We used CIBERSORT Bioconductor package to perform deconvolution and estimate the abundances of cell types,Software name not in publication title — likely generic usage: CIBERSORT
SureDesign,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SureDesign,Analysis Software,,,,,,,,,,,,,,,,"Using SureDesign (Agilent Technologies Inc.), probes were generated to cover the exons and the UTR regions",No version and no repository URL (confidence < 0.9 — unidentifiable)
BWA MEM,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BWA MEM,Analysis Software,,,,,,,,,,,,,,,,Amplicon reads were aligned against the human reference genome hg19 with BWA MEM,Software name not in publication title — likely generic usage: BWA MEM
GeneMapper software,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GeneMapper software,Analysis Software,,,,,,,,,,,,,,,,electrophoresis data were analyzed using GeneMapper software (Life Technologies),Software name not in publication title — likely generic usage: GeneMapper software
Agilent 1200 HPLC,computational_tools,PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Agilent 1200 HPLC,Analysis Software,,,,,,,,,,,,,,,,Ketotifen was quantified in plasma and nerve tissue samples from ketotifen-treated Nf1;flox/flox PostnCre+ mice (n = 3) by HPLC-MS/MS (Agilent 1200 HPLC and ABI 3200 MS/MS),Software name not in publication title — likely generic usage: Agilent 1200 HPLC
ABI 3200 MS/MS,computational_tools,PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ABI 3200 MS/MS,Analysis Software,,,,,,,,,,,,,,,,Ketotifen was quantified in plasma and nerve tissue samples from ketotifen-treated Nf1;flox/flox PostnCre+ mice (n = 3) by HPLC-MS/MS (Agilent 1200 HPLC and ABI 3200 MS/MS),Software name not in publication title — likely generic usage: ABI 3200 MS/MS
GraphPad Prism 5.0,computational_tools,PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism 5.0,Analysis Software,5.0,,,,,,,,,,,,,,,"GraphPad Prism 5.0 and 6.0 was used to perform all statistical analyses. Comparison of the means for nerve root volume, tumor number, KI-67 proliferation index",Generic tool (versioned): GraphPad Prism 5.0
GraphPad Prism 6.0,computational_tools,PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism 6.0,Analysis Software,6.0,,,,,,,,,,,,,,,"GraphPad Prism 5.0 and 6.0 was used to perform all statistical analyses. Comparison of the means for nerve root volume, tumor number, KI-67 proliferation index",Generic tool (versioned): GraphPad Prism 6.0
FastQC (RRID:SCR_014583),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,FastQC (RRID:SCR_014583),Analysis Software,,https://www.bioinformatics.babraham.ac.uk/projects/fastqc/,,,,,,,,,,,,,,All resulting FASTQ files passed quality control by FastQC (RRID:SCR_014583; https://www.bioinformatics.babraham.ac.uk/projects/fastqc/),Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
Cutadapt (RRID:SCR_011841),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Cutadapt (RRID:SCR_011841),Analysis Software,,,,,,,,,,,,,,,,Sequencing reads were trimmed with Cutadapt (RRID:SCR_011841; ref. 70) to keep only 22-mer shRNA guide sequences,Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
bowtie2 (RRID:SCR_016368),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,bowtie2 (RRID:SCR_016368),Analysis Software,,,,,,,,,,,,,,,,that were subsequently mapped to the shRNA library guide sequence reference file using bowtie2 (RRID:SCR_016368; ref. 71),Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
edgeR (RRID:SCR_012802),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,edgeR (RRID:SCR_012802),Package/Library,,,,,,,,,,,,,,,,shRNA read counts were quantified by edgeR (RRID:SCR_012802; ref. 72),Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
HiTSelect,computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HiTSelect,Analysis Software,,,,,,,,,,,,,,,,Ranking of each set of five shRNAs per gene in the library was done for depletion with HiTSelect (20),Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
"GraphPad (Prism, RRID:SCR_002798)",computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"GraphPad (Prism, RRID:SCR_002798)",Analysis Software,,,,,,,,,,,,,,,,"All data are plotted with GraphPad (Prism, RRID:SCR_002798)",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
TrimGalore (RRID:SCR_011847),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,TrimGalore (RRID:SCR_011847),Analysis Software,0.4.5,https://www.bioinformatics.babraham.ac.uk/projects/trim_galore,,,,,,,,,,,,,,"RNA sequencing reads were 3′ trimmed for base quality 15 and adapter sequences using version 0.4.5 of TrimGalore (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore, RRID:SCR_011847)",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
STAR v2.6 (RRID:SCR_004463),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,STAR v2.6 (RRID:SCR_004463),Analysis Software,v2.6,,,,,,,,,,,,,,,and then aligned to human genome assembly hg19 with STAR v2.6 (RRID:SCR_004463) using default parameters,Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
TPMCalculator,computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,TPMCalculator,Analysis Software,,,,,,,,,,,,,,,,Transcripts per million (TPM) data were generated via TPMCalculator (78) using default parameters,Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
HTSeq v0.9.1 (RRID:SCR_005514),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,HTSeq v0.9.1 (RRID:SCR_005514),Analysis Software,v0.9.1,,,,,,,,,,,,,,,Read count tables were generated with HTSeq v0.9.1 (RRID:SCR_005514),Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
DESeq2 (RRID:SCR_000154),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2 (RRID:SCR_000154),Package/Library,,,,,,,,,,,,,,,,Normalization and expression dynamics were evaluated with DESeq2 (RRID:SCR_000154) using library size factor normalization,Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
deepTools v3.1 (RRID:SCR_016366),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,deepTools v3.1 (RRID:SCR_016366),Analysis Software,v3.1,,,,,,,,,,,,,,,These library size factors were also used with deepTools v3.1 (RRID:SCR_016366) to create normalized bigwigs using bamCoverage,Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
Homer v4.5 (RRID:SCR_010881),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Homer v4.5 (RRID:SCR_010881),Analysis Software,v4.5,http://homer.ucsd.edu,,,,,,,,,,,,,,"Pathway enrichment (gene sets and GO) was performed on each cluster using Homer v4.5 (http://homer.ucsd.edu, RRID:SCR_010881)",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
RepeatMasker (RRID:SCR_012954),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,RepeatMasker (RRID:SCR_012954),Analysis Software,,,,,,,,,,,,,,,,"we extracted LTRs, SINEs, and LINEs from the repetitive elements annotated by the RepeatMasker (RRID:SCR_012954)",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
"featureCounts (v1.5.0-p1, RRID:SCR_012919)",computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,"featureCounts (v1.5.0-p1, RRID:SCR_012919)",Analysis Software,v1.5.0-p1,,,,,,,,,,,,,,,"and used featureCounts (v1.5.0-p1, RRID:SCR_012919; ref. 79) to count RNA-seq fragments mapped to them",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
"pheatmap (v.1.0.12, RRID:SCR_016418)",computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,"pheatmap (v.1.0.12, RRID:SCR_016418)",Package/Library,v.1.0.12,,,,,,,,,,,,,,,"were subject to k-means clustering via pheatmap (v.1.0.12, RRID:SCR_016418), separately for the three classes of REs",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
methylKit (RRID:SCR_005177),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,methylKit (RRID:SCR_005177),Package/Library,,,,,,,,,,,,,,,,The methylKit (RRID:SCR_005177; ref. 81) R package was used to filter all samples for CpGs with 10 to 400× coverage,Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
annotatr,computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,annotatr,Package/Library,,,,,,,,,,,,,,,,DMRs were annotated via the annotatr (82) R package,Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
BEDTools suite (RRID:SCR_006646),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BEDTools suite (RRID:SCR_006646),Analysis Software,,,,,,,,,,,,,,,,"For intergenic DMRs, the nearest gene was identified by the closest function in BEDTools suite (RRID:SCR_006646; ref. 83)",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
Genomation (RRID:SCR_003435),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Genomation (RRID:SCR_003435),Package/Library,,,,,,,,,,,,,,,,Genomation (84) R package (RRID:SCR_003435) was used to annotate CpGs and tiles (regions) with their location,Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
ggplot2 (RRID:SCR_014601),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ggplot2 (RRID:SCR_014601),Package/Library,,,,,,,,,,,,,,,,and then plotted as violin plots via ggplot2 (RRID:SCR_014601; ref. 85) package in R,Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
"Partek Genomics Suite (v 7.0, RRID:SCR_011860)",computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,"Partek Genomics Suite (v 7.0, RRID:SCR_011860)",Analysis Software,v 7.0,,,,,,,,,,,,,,,"PCA of methylation data at all tiles (regions) was generated in Partek Genomics Suite (v 7.0, RRID:SCR_011860)",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
Integrative Genomics Viewer,computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Integrative Genomics Viewer,Analysis Software,,,,,,,,,,,,,,,,and subsequent ChIP-seq profiles were visualized either by Integrative Genomics Viewer (87) software,Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
"FCS Express 7 Research Edition (De Novo Software, Inc.; RRID:SCR_016431)",computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,"FCS Express 7 Research Edition (De Novo Software, Inc.; RRID:SCR_016431)",Analysis Software,7 Research Edition,,,,,,,,,,,,,,,"All data were processed and analyzed with FCS Express 7 Research Edition (De Novo Software, Inc.; RRID:SCR_016431)",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
"GIMP (GNU Image Manipulation Program, RRID:SCR_003182)",computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"GIMP (GNU Image Manipulation Program, RRID:SCR_003182)",Analysis Software,,,,,,,,,,,,,,,,"Resulting data were processed and cropped with GIMP (GNU Image Manipulation Program, RRID:SCR_003182) open-source software",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
MSK-IMPACT,computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MSK-IMPACT,Analysis Software,,,,,,,,,,,,,,,,MSK-IMPACT (66) was used to evaluate mutations for 341 cancer genes in human MPNST cell lines and tumors,Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
SigmaPlot,computational_tools,PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SigmaPlot,Analysis Software,,,,,,,,,,,,,,,,"...response data (dat0–dat10) and concentration (C0–C10, in μM) were downloaded and analyzed using a 4-parameter fit in SigmaPlot...",No version and no repository URL (confidence < 0.9 — unidentifiable)
DREA web tool,computational_tools,PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.85,Development,True,0.67,Medium,,,,,,,,,,,,,,,DREA web tool,Web Application,,,,,,,,,,,,,,,,...analyzed using a 4-parameter fit in SigmaPlot and with the DREA web tool (see Supplemental Materials). The DREA web tool recreates our final compound rankings...,No version and no repository URL (confidence < 0.9 — unidentifiable)
Synapse,computational_tools,PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Synapse,Database,,https://doi.org/10.7303/syn4939906,,,,,,,,,,,,,,...Primary files [15] were accessed from Single Agent Screens through Synapse https://doi.org/10.7303/syn4939906...,Software name not in publication title — likely generic usage: Synapse
ClinVar,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ClinVar,Database,,,,,,,,,,,,,,,,ClinVar data for NF1 variants were extracted from the ClinVar version 2024-07-03 available at: https://ftp.ncbi.nlm.nih.gov/pub/clinvar/,Software name not in publication title — likely generic usage: ClinVar
Ion Torrent,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Ion Torrent,Analysis Software,,,,,,,,,,,,,,,,"Constitutional NF1 variants were determined by standard techniques using targeted NGS panel including NF1, NF2, SPRED1, SMARCB1 and LZTR1 genes on Ion Torrent",No version and no repository URL (confidence < 0.9 — unidentifiable)
MLPA,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MLPA,Analysis Software,,,,,,,,,,,,,,,,"Together with NGS, MLPA method was performed to rule out large deletions/duplications in NF1 gene",No version and no repository URL (confidence < 0.9 — unidentifiable)
Mutation Taster,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Mutation Taster,Web Application,,,,,,,,,,,,,,,,The effects on genes and proteins of the variants identified were predicted based on the Mutation Taster (http://www.mutationtaster.org),Software name not in publication title — likely generic usage: Mutation Taster
HGMD,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HGMD,Database,,,,,,,,,,,,,,,,"HGMD (Human Genome Mutation Database—Institute of Medical Genetics, Cardiff, Wales, UK; http://www.hgmd.cf.ac.uk/ac/index.php",Software name not in publication title — likely generic usage: HGMD
LOVD,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LOVD,Database,,,,,,,,,,,,,,,,LOVD. (Leiden Open Variation Database; http://www.LOVD.nl.NF1),Software name not in publication title — likely generic usage: LOVD
PolyPhen-2,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PolyPhen-2,Web Application,,,,,,,,,,,,,,,,Novel variants with amino acid changes were further examined for their disease causing. potential using PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/bgi.shtml),Software name not in publication title — likely generic usage: PolyPhen-2
Human Splicing Finder,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Human Splicing Finder,Web Application,,,,,,,,,,,,,,,,with the Human Splicing Finder (HSF; http://www.umd.be/HSF/),Software name not in publication title — likely generic usage: Human Splicing Finder
ESE Finder,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ESE Finder,Web Application,,,,,,,,,,,,,,,,and the ESE Finder (http://rulai.cshl.edu/cgibin/tools/ESE3/esefinder.cgi?process=home) tools,Software name not in publication title — likely generic usage: ESE Finder
ANNOVAR,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ANNOVAR,Analysis Software,,,,,,,,,,,,,,,,predicted the functional consequence of missense variants using ANNOVAR which included prediction scores from 20 prediction algorithms,Generic bioinformatics/stats tool: ANNOVAR
GnomAD,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GnomAD,Database,v.2.1.1,,,,,,,,,,,,,,,the GnomAD v.2.1.1 (https://gnomad.broadinstitute.org) and 1000 genomes databases were used,Software name not in publication title — likely generic usage: GnomAD
1000 Genomes,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,1000 Genomes,Database,2015 aug,,,,,,,,,,,,,,,"1000 genomes (https://www.internationalgenome.org, release 2015 aug) databases were used",Software name not in publication title — likely generic usage: 1000 Genomes
cutpointR,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,cutpointR,Package/Library,1.1.2,,,,,,,,,,,,,,,"For threshold optimization, we used cutpointR version 1.1.2, maximizing the 'accuracy' metric",Software name not in publication title — likely generic usage: cutpointR
BioSpec 94/20 USR MRI,computational_tools,PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BioSpec 94/20 USR MRI,Analysis Software,,,,,,,,,,,,,,,,Imaging was performed with a 9.4-T BioSpec 94/20 USR MRI (Bruker BioSpin MRI),Publication title lacks NF-specific terms: Brain-wide structural and functional disruption in mice with oligodendrocyte-spe
ExplorDTI,computational_tools,PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ExplorDTI,Analysis Software,,,,,,,,,,,,,,,,Diffusion-weighted images were preprocessed using ExplorDTI (68),Publication title lacks NF-specific terms: Brain-wide structural and functional disruption in mice with oligodendrocyte-spe
Advanced Normalization Tools (ANTs),computational_tools,PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Advanced Normalization Tools (ANTs),Analysis Software,,,,,,,,,,,,,,,,"template, B0, for both controls and Plp-Nf1 fl/+ animals was created using Advanced Normalization Tools (ANTs) (70)",Publication title lacks NF-specific terms: Brain-wide structural and functional disruption in mice with oligodendrocyte-spe
Allen Brain Atlas,computational_tools,PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Allen Brain Atlas,Database,,,,,,,,,,,,,,,,The control template was registered to the Allen Brain Atlas (71),Publication title lacks NF-specific terms: Brain-wide structural and functional disruption in mice with oligodendrocyte-spe
NF Research Tools Database,computational_tools,PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,NF Research Tools Database,Database,,https://tools.nf.synapse.org/,,,,,,,,,,,,,,"...the NF Research Tools Database, is an open-access database that enables the exploration and discovery of information about NF type 1-relevant animal models, cell lines, antibodies...",Generic bioinformatics/stats tool: NF Research Tools Database
schematic Python library,computational_tools,PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,schematic Python library,Package/Library,,,,,,,,,,,,,,,,...This schema was processed with the 'schematic' Python library to generate a MySQL database as well as data intake spreadsheets...,No version and no repository URL (confidence < 0.9 — unidentifiable)
React JavaScript library,computational_tools,PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,React JavaScript library,Package/Library,,,,,,,,,,,,,,,,...We then built the application using the React JavaScript library and the Synapse React Client...,No version and no repository URL (confidence < 0.9 — unidentifiable)
Synapse React Client,computational_tools,PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Synapse React Client,Package/Library,,,,,,,,,,,,,,,,...We then built the application using the React JavaScript library and the Synapse React Client...,No version and no repository URL (confidence < 0.9 — unidentifiable)
MySQL database,computational_tools,PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MySQL database,Database,,,,,,,,,,,,,,,,...This schema was processed with the 'schematic' Python library to generate a MySQL database as well as data intake spreadsheets...,No version and no repository URL (confidence < 0.9 — unidentifiable)
JSON-LD schema,computational_tools,PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.85,Development,True,1.00,High,,,,,,,,,,,,,,,JSON-LD schema,Other,2.0.0,https://github.com/nf-osi/nf-research-tools-schema,,,,,,,,,,,,,,...We constructed a JSON-LD schema from the data model to make it machine-readable (version 2.0.0 at the time of writing...,Software name not in publication title — likely generic usage: JSON-LD schema
Synapse collaborative science platform,computational_tools,PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Synapse collaborative science platform,Web Application,,,,,,,,,,,,,,,,...but all database tables and a variety of 'joined' tables are available for anyone to access on the Synapse collaborative science platform...,Software name not in publication title — likely generic usage: Synapse collaborative science platform
Salmon v1.4,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Salmon v1.4,Analysis Software,v1.4,,,,,,,,,,,,,,,Raw FASTQ files were analyzed using the Salmon v1.4 alignment tool,Software name not in publication title — likely generic usage: Salmon v1.4
BWA-MEM2 v2.1,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BWA-MEM2 v2.1,Analysis Software,v2.1,,,,,,,,,,,,,,,Reads were aligned to hg38 using BWA-MEM2 v2.1,Software name not in publication title — likely generic usage: BWA-MEM2 v2.1
GATK v4.1.9.0,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GATK v4.1.9.0,Analysis Software,v4.1.9.0,,,,,,,,,,,,,,,Base quality score recalibration (BQSR) was performed with GATK v4.1.9.0 BaseRecalibrator,Software name not in publication title — likely generic usage: GATK v4.1.9.0
MCP-Counter,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MCP-Counter,Analysis Software,,,,,,,,,,,,,,,,To assess the cell type of origin in the organoid models we used the tumor deconvolution algorithm MCP-Counter,Software name not in publication title — likely generic usage: MCP-Counter
BSBolt,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BSBolt,Analysis Software,,,,,,,,,,,,,,,,raw fastq files obtained by RRBS were analyzed using BSBolt,Software name not in publication title — likely generic usage: BSBolt
metilene v0.2-8,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,metilene v0.2-8,Analysis Software,v0.2-8,,,,,,,,,,,,,,,Differentially methylated regions were detected using metilene v0.2-8,Software name not in publication title — likely generic usage: metilene v0.2-8
DELLY v1.1.3,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DELLY v1.1.3,Analysis Software,v1.1.3,,,,,,,,,,,,,,,Structural variants and copy number variation were called using DELLY v1.1.3,Software name not in publication title — likely generic usage: DELLY v1.1.3
InterVar,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,InterVar,Analysis Software,update-2021-08-version,,,,,,,,,,,,,,,Germline variants are annotated using InterVar (update-2021-08-version),Software name not in publication title — likely generic usage: InterVar
rare disease workflows,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,rare disease workflows,Workflow,,https://github.com/Sage-Bionetworks/rare-disease-workflows/tree/main/rna-seq-workflow,,,,,,,,,,,,,,Our RNAseq analyses leverage the rare disease workflows at https://github.com/Sage-Bionetworks/rare-disease-workflows/tree/main/rna-seq-workflow,Software name not in publication title — likely generic usage: rare disease workflows
cNFOrganoidAnalysis,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Development,True,1.00,High,,,,,,,,,,,,,,,cNFOrganoidAnalysis,Analysis Software,,https://github.com/PNNL-CompBio/cNFOrganoidAnalysis,,,,,,,,,,,,,,All computational tools used to generate Figures 4 and 5 for this manuscript are available on https://github.com/PNNL-CompBio/cNFOrganoidAnalysis,Software name not in publication title — likely generic usage: cNFOrganoidAnalysis
TissueLyser II (QIAGEN),computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,TissueLyser II (QIAGEN),Other,,,,,,,,,,,,,,,,All tumor or tissue samples were mechanically lysed using a TissueLyser II (QIAGEN) with stainless steel beads at 30 Hz for 90 seconds,No version and no repository URL (confidence < 0.9 — unidentifiable)
BioAnalyzer 2100,computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BioAnalyzer 2100,Other,,,,,,,,,,,,,,,,RNA quality was assessed by chip-based electrophoresis on a BioAnalyzer 2100 using the RNA 6000 Nano Kit,No version and no repository URL (confidence < 0.9 — unidentifiable)
minfi,computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,minfi,Package/Library,,,,,,,,,,,,,,,,Preprocessing and normalization were performed in R using the minfi Bioconductor package,No version and no repository URL (confidence < 0.9 — unidentifiable)
ConsensusClusterPlus,computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ConsensusClusterPlus,Package/Library,v3.10,,,,,,,,,,,,,,,"To identify DNA methylation groups, ConsensusClusterPlus (Bioconductor v3.10) was used",Software name not in publication title — likely generic usage: ConsensusClusterPlus
Bowtie2,computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bowtie2,Analysis Software,,,,,,,,,,,,,,,,Raw FASTQ files were aligned to the reference genome with Bowtie2,Generic bioinformatics/stats tool: Bowtie2
Genome Analysis Toolkit (GATK),computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Genome Analysis Toolkit (GATK),Analysis Software,,,,,,,,,,,,,,,,Whole exome data were analyzed following Genome Analysis Toolkit (GATK) best practices,No version and no repository URL (confidence < 0.9 — unidentifiable)
Mutect2,computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Mutect2,Analysis Software,,,,,,,,,,,,,,,,"Somatic variants (point mutations, small indels) were identified from matched tumor-normal samples and using a panel of normal (PoN) samples with Mutect2",Generic bioinformatics/stats tool: Mutect2
Snpeff,computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Snpeff,Analysis Software,,,,,,,,,,,,,,,,Variants were annotated using Snpeff,Generic bioinformatics/stats tool: Snpeff
HISAT2,computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HISAT2,Analysis Software,,,,,,,,,,,,,,,,Reads were mapped to the appropriate reference genome (hg19) using HISAT2 with default parameters,Generic bioinformatics/stats tool: HISAT2
DESeq2,computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2,Package/Library,,,,,,,,,,,,,,,,Transcript abundance estimation in transcripts per million (TPM) and differential expression analysis were performed using DESeq2,Generic bioinformatics/stats tool: DESeq2
CellRanger,computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CellRanger,Analysis Software,,,,,,,,,,,,,,,,the resulting FASTQ files were processed using the CellRanger analysis suite for alignment to the hg38 reference genome,No version and no repository URL (confidence < 0.9 — unidentifiable)
Seurat,computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Seurat,Package/Library,,,,,,,,,,,,,,,,All downstream analyses were performed in Seurat using the default pipeline,No version and no repository URL (confidence < 0.9 — unidentifiable)
Harmony,computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Harmony,Package/Library,,,,,,,,,,,,,,,,Harmony was used to perform data integration across datasets within a given experiment,No version and no repository URL (confidence < 0.9 — unidentifiable)
Clustree,computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Clustree,Package/Library,,https://github.com/lazappi/clustree,,,,,,,,,,,,,,cluster number optimization was performed by comparing multiple cluster resolutions using Clustree,Software name not in publication title — likely generic usage: Clustree
InferCNV,computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,InferCNV,Package/Library,,,,,,,,,,,,,,,,InferCNV was used in an attempt to delineate tumor from non-tumor cells based on single-nuclear CNVs,No version and no repository URL (confidence < 0.9 — unidentifiable)
GraphPad Prism 8,computational_tools,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism 8,Analysis Software,8,,,,,,,,,,,,,,,Statistical analysis was performed using GraphPad Prism 8,Generic bioinformatics/stats tool: GraphPad Prism 8
ImageJ,computational_tools,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,quantified by densitometry and normalized to glyceraldehyde-3-phosphatase dehydrogenase (GAPDH) or vinculin loading controls using ImageJ,Generic bioinformatics/stats tool: ImageJ
Statistical Parametric Mapping toolbox (SPM8),computational_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Statistical Parametric Mapping toolbox (SPM8),Analysis Software,SPM8,,,,,,,,,,,,,,,"PET images were spatially processed using the Statistical Parametric Mapping toolbox (SPM8, Wellcome Trust Centre for Neuroimaging, 2008)",Software name not in publication title — likely generic usage: Statistical Parametric Mapping toolbox (SPM8)
Matlab 7.12.0,computational_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Matlab 7.12.0,Analysis Software,7.12.0,,,,,,,,,,,,,,,"implemented within Matlab 7.12.0 (MathWorks, Natick, MA, USA)",Software name not in publication title — likely generic usage: Matlab 7.12.0
kernlab R library,computational_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,kernlab R library,Package/Library,,,,,,,,,,,,,,,,we used the Gaussian Process regression (GPR) implementation available within kernlab R library,Software name not in publication title — likely generic usage: kernlab R library
tidyverse,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,tidyverse,Package/Library,,,,,,,,,,,,,,,,"Key packages used include ""tidyverse"" [33], ""PLIER"" [26], ""synapser"" [34], ""tximport"" [35], ""immundeconv"" [35], and ""viper"" [32].",No version and no repository URL (confidence < 0.9 — unidentifiable)
PLIER,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PLIER,Package/Library,,,,,,,,,,,,,,,,"Key packages used include ""tidyverse"" [33], ""PLIER"" [26], ""synapser"" [34], ""tximport"" [35], ""immundeconv"" [35], and ""viper"" [32].",Software name not in publication title — likely generic usage: PLIER
synapser,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,synapser,Package/Library,,,,,,,,,,,,,,,,"Key packages used include ""tidyverse"" [33], ""PLIER"" [26], ""synapser"" [34], ""tximport"" [35], ""immundeconv"" [35], and ""viper"" [32].",No version and no repository URL (confidence < 0.9 — unidentifiable)
tximport,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,tximport,Package/Library,,,,,,,,,,,,,,,,"Key packages used include ""tidyverse"" [33], ""PLIER"" [26], ""synapser"" [34], ""tximport"" [35], ""immundeconv"" [35], and ""viper"" [32].",No version and no repository URL (confidence < 0.9 — unidentifiable)
immunedeconv,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,immunedeconv,Package/Library,,,,,,,,,,,,,,,,"Key packages used include ""tidyverse"" [33], ""PLIER"" [26], ""synapser"" [34], ""tximport"" [35], ""immundeconv"" [35], and ""viper"" [32].",No version and no repository URL (confidence < 0.9 — unidentifiable)
viper,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,viper,Package/Library,,,,,,,,,,,,,,,,"Key packages used include ""tidyverse"" [33], ""PLIER"" [26], ""synapser"" [34], ""tximport"" [35], ""immundeconv"" [35], and ""viper"" [32].",No version and no repository URL (confidence < 0.9 — unidentifiable)
Salmon,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Salmon,Analysis Software,,,,,,,,,,,,,,,,raw fastq files were downloaded from Synapse and transcripts were quantified using the Salmon pseudo-alignment tool [36] with Gencode V29 transcriptome.,Generic bioinformatics/stats tool: Salmon
vcf2maf,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,vcf2maf,Command-line Tool,,https://github.com/mskcc/vcf2maf,,,,,,,,,,,,,,"Variant call format (VCF) files were processed using ""vcf2maf"" (https://github.com/mskcc/vcf2maf)",Software name not in publication title — likely generic usage: vcf2maf
org.Hs.eg.db,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,org.Hs.eg.db,Package/Library,,,,,,,,,,,,,,,,"Salmon output files (quant.sf) files were imported into an R session and converted to HUGO gene names using the ""tximport"" [35] and ""org.Hs.eg.db"" [40] packages.",No version and no repository URL (confidence < 0.9 — unidentifiable)
MultiPLIER,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MultiPLIER,Analysis Software,,https://github.com/greenelab/multi-plier,,,,,,,,,,,,,,"We analyzed transcriptomic data from NF in the context of latent variables from MultiPLIER, a machine learning resource designed to aid in rare disease analyses [27].",Software name not in publication title — likely generic usage: MultiPLIER
caret,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,caret,Package/Library,,,,,,,,,,,,,,,,"The main algorithm was implemented using the ""caret"" and ""randomforest"" packages in R [44, 45].",No version and no repository URL (confidence < 0.9 — unidentifiable)
randomforest,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,randomforest,Package/Library,,,,,,,,,,,,,,,,"The main algorithm was implemented using the ""caret"" and ""randomforest"" packages in R [44, 45].",No version and no repository URL (confidence < 0.9 — unidentifiable)
CIBERSORT,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CIBERSORT,Analysis Software,,,,,,,,,,,,,,,,"we used two tumor deconvolution methods: CIBERSORT and MCP-counter, as implemented through the ""immunedeconv"" R package [29, 30, 31].",Software name not in publication title — likely generic usage: CIBERSORT
MCP-counter,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MCP-counter,Analysis Software,,,,,,,,,,,,,,,,"we used two tumor deconvolution methods: CIBERSORT and MCP-counter, as implemented through the ""immunedeconv"" R package [29, 30, 31].",Software name not in publication title — likely generic usage: MCP-counter
metaVIPER,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,metaVIPER,Analysis Software,,,,,,,,,,,,,,,,We applied the metaVIPER algorithm [32] to infer protein regulatory activity based on the tissue gene expression profiles.,Software name not in publication title — likely generic usage: metaVIPER
pheatmap,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,pheatmap,Package/Library,,,,,,,,,,,,,,,,"A heatmap and subclusters of latent variables that had similar VIPER protein predictions were generated using the ""pheatmap"" R package [47].",No version and no repository URL (confidence < 0.9 — unidentifiable)
clusterProfiler,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,clusterProfiler,Package/Library,,,,,,,,,,,,,,,,"Then, we used gene set enrichment analysis (via the ""clusterProfiler"" R package [48]) to assess whether drug targets were enriched",Generic bioinformatics/stats tool: clusterProfiler
ggplot,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ggplot,Package/Library,,,,,,,,,,,,,,,,"Results were plotted using ""ggplot"" and ""enrichplot"" packages [33, 50].",No version and no repository URL (confidence < 0.9 — unidentifiable)
enrichplot,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,enrichplot,Package/Library,,,,,,,,,,,,,,,,"Results were plotted using ""ggplot"" and ""enrichplot"" packages [33, 50].",No version and no repository URL (confidence < 0.9 — unidentifiable)
NF Data Portal,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NF Data Portal,Database,,,,,,,,,,,,,,,,All data analyzed in this article are stored on the NF Data Portal [24] (http://nfdataportal.org),Software name not in publication title — likely generic usage: NF Data Portal
Drug Target Explorer database,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Drug Target Explorer database,Database,,,,,,,,,,,,,,,,Drug-wise target lists were obtained from the Drug Target Explorer database [49].,No version and no repository URL (confidence < 0.9 — unidentifiable)
GSE108524,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GSE108524,Database,,,,,,,,,,,,,,,,"GSE108524, compiled using the GPL17586 platform of the Affymetrix GeneChip Human Genome HTA_2_0 Array, contains 31 human samples",No version and no repository URL (confidence < 0.9 — unidentifiable)
GSE141801,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GSE141801,Database,,,,,,,,,,,,,,,,"GSE141801, compiled using the GPL13667 Affymetrix Human Genome U219 Array, contains samples from 9 recurrent irradiated VSs",No version and no repository URL (confidence < 0.9 — unidentifiable)
R 4.0.3,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R 4.0.3,Analysis Software,4.0.3,,,,,,,,,,,,,,,Data standardization was performed using the R 4.0.3,Software name not in publication title — likely generic usage: R 4.0.3
WGCNA,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.95,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,WGCNA,Package/Library,,,,,,,,,,,,,,,,"WGCNA, an R package, was used to conduct WGCNA",Software name not in publication title — likely generic usage: WGCNA
pickSoftThreshold,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,pickSoftThreshold,Command-line Tool,,,,,,,,,,,,,,,,The pickSoftThreshold tool was employed for the soft-thresholding power measurement,No version and no repository URL (confidence < 0.9 — unidentifiable)
clusterProfiler,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,clusterProfiler,Package/Library,,,,,,,,,,,,,,,,we performed FEA of the strongly associated modules using the clusterProfiler package of the R software,Generic bioinformatics/stats tool: clusterProfiler
STRING,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STRING,Database,,https://string-db.org/,,,,,,,,,,,,,,The key module genes were uploaded to STRING (https://string-db.org/) to generate the PPI axis,Generic bioinformatics/stats tool: STRING
Cytoscape,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cytoscape,Analysis Software,v3.8.2,,,,,,,,,,,,,,,the results were visualized using the Cytoscape (v3.8.2) software,Generic bioinformatics/stats tool: Cytoscape
miRTarBase,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,miRTarBase,Database,,,,,,,,,,,,,,,,"we retrieved miRNA information from the miRTarBase database, including, over 50,000 experimentally validated miRNA-target associations",Software name not in publication title — likely generic usage: miRTarBase
limma,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,limma,Package/Library,,,,,,,,,,,,,,,,DEGs were identified between NF2-Vs and normal nerves using the R package limma,Generic bioinformatics/stats tool: limma
connectivity map (CMap),computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,connectivity map (CMap),Database,,,,,,,,,,,,,,,,we uploaded our list of up- and down-regulated genes into the connectivity map (CMap) database,Software name not in publication title — likely generic usage: connectivity map (CMap)
SPSS V.23,computational_tools,PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS V.23,Analysis Software,V.23,,,,,,,,,,,,,,,Statistical analyses were undertaken using SPSS V.23,Software name not in publication title — likely generic usage: SPSS V.23
CLC-workbench,computational_tools,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CLC-workbench,Analysis Software,,,,,,,,,,,,,,,,"Variants were validated by Sanger sequencing and analyzed using CLC-workbench (Qiagen, Hilden, Germany)",Software name not in publication title — likely generic usage: CLC-workbench
PredictProtein,computational_tools,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,PredictProtein,Web Application,,https://www.PredictProtein.org,,,,,,,,,,,,,,Analyses of in silico protein modifications by the exon skipping were performed using the web-server version of PredictProtein,Software name not in publication title — likely generic usage: PredictProtein
GraphPad Prism software v7,computational_tools,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism software v7,Analysis Software,v7,,,,,,,,,,,,,,,Statistical analysis was carried out using GraphPad Prism software v7,Generic tool (versioned): GraphPad Prism software v7
SP5 Leica confocal microscope,computational_tools,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SP5 Leica confocal microscope,Analysis Software,,,,,,,,,,,,,,,,Ganglia were imaged on a SP5 Leica confocal microscope and the number of EdU-positive nuclei was quantified,No version and no repository URL (confidence < 0.9 — unidentifiable)
Amira software,computational_tools,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Amira software,Analysis Software,,,,,,,,,,,,,,,,measure the ganglia volume using confocal stacks and the Amira software as previously described,No version and no repository URL (confidence < 0.9 — unidentifiable)
MetaMorph software package,computational_tools,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MetaMorph software package,Analysis Software,,,,,,,,,,,,,,,,counted by 20× microscopic fields using the cell counting feature of MetaMorph software package,No version and no repository URL (confidence < 0.9 — unidentifiable)
FACScalibur instrument,computational_tools,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FACScalibur instrument,Analysis Software,,,,,,,,,,,,,,,,"DNA content was analyzed using a FACScalibur instrument (BD Biosciences, San Jose, CA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
MODFIT,computational_tools,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MODFIT,Analysis Software,,,,,,,,,,,,,,,,"A minimum of 10^4 cells/sample were analyzed to determine the percentage of apoptotic cells and cells in G1, S, and G2/M phase (MODFIT; Variety Software, Topsham, ME)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Axiovert 200M fluorescence microscope,computational_tools,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Axiovert 200M fluorescence microscope,Analysis Software,,,,,,,,,,,,,,,,Images were immediately acquired with an Axiovert 200M fluorescence microscope (Carl Zeiss),No version and no repository URL (confidence < 0.9 — unidentifiable)
CRISPRscan,computational_tools,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CRISPRscan,Web Application,,https://www.crisprscan.org/,,,,,,,,,,,,,,CRISPRscan (https://www.crisprscan.org/) was used to identify gRNA target sequences in exon 1 of the tgfb3 gene,Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
"MATLAB (R2008a, MathWorks, Natick, MA, USA)",computational_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"MATLAB (R2008a, MathWorks, Natick, MA, USA)",Analysis Software,R2008a,,,,,,,,,,,,,,,"Stimuli were generated with MATLAB (R2008a, MathWorks, Natick, MA, USA) and presented with the stimulation software STIM 2","Software name not in publication title — likely generic usage: MATLAB (R2008a, MathWorks, Natick, MA, USA)"
"STIM 2 (Neuroscan, Charlotte, NC, USA)",computational_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"STIM 2 (Neuroscan, Charlotte, NC, USA)",Analysis Software,2,,,,,,,,,,,,,,,"presented with the stimulation software STIM 2 (Neuroscan, Charlotte, NC, USA) with a display resolution of 1,280 × 1,024 × 32","Software name not in publication title — likely generic usage: STIM 2 (Neuroscan, Charlotte, NC, USA)"
Scan 4.5 (Neuroscan),computational_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Scan 4.5 (Neuroscan),Analysis Software,4.5,,,,,,,,,,,,,,,Data analysis was performed with Scan 4.5 (Neuroscan). We started the analysis by correcting the eye blinking artifacts,Software name not in publication title — likely generic usage: Scan 4.5 (Neuroscan)
"IBM SPSS Statistics, version 19",computational_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"IBM SPSS Statistics, version 19",Analysis Software,19,,,,,,,,,,,,,,,"All statistical analyses were performed with IBM SPSS Statistics, version 19, software (IBM Corporation, Armonk, NY, USA)","Software name not in publication title — likely generic usage: IBM SPSS Statistics, version 19"
MACSQuant flow cytometer,computational_tools,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MACSQuant flow cytometer,Analysis Software,,,,,,,,,,,,,,,,"The phenotype of C6 cells was analyzed using flow cytometry with the MACSQuant flow cytometer (Miltenyi, San Diego, CA, USA)",Publication title lacks NF-specific terms: C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of
MACSQuantify software,computational_tools,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MACSQuantify software,Analysis Software,,,,,,,,,,,,,,,,The results were analyzed using the MACSQuantify software (https://www.miltenyibiotec.com),Publication title lacks NF-specific terms: C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of
MATLAB software,computational_tools,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,MATLAB software,Analysis Software,R2019a,,,,,,,,,,,,,,,"Electronic image files were processed using MATLAB software (MathWorks Inc., R2019a, USA)",Publication title lacks NF-specific terms: C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of
GraphPad software,computational_tools,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,GraphPad software,Analysis Software,,,,,,,,,,,,,,,,Results and values are represented in all figures with mean ± standard error using GraphPad software,Publication title lacks NF-specific terms: C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of
WGCNA package v1.69,computational_tools,PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,WGCNA package v1.69,Package/Library,v1.69,,,,,,,,,,,,,,,The conserved gene regulation networks and the correlation between drug responses and the gene network were determined using the WGCNA package v1.69,Software name not in publication title — likely generic usage: WGCNA package v1.69
IDACombo package,computational_tools,PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,IDACombo package,Package/Library,,,,,,,,,,,,,,,,The IDACombo package was used to predict the combination efficacy using the drug screen data with the default settings,No version and no repository URL (confidence < 0.9 — unidentifiable)
SynergyFinder,computational_tools,PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SynergyFinder,Web Application,,https://synergyfinder.org/,,,,,,,,,,,,,,Drug synergy was evaluated using the Bliss independence model via the SynergyFinder online platform (https://synergyfinder.org/),Software name not in publication title — likely generic usage: SynergyFinder
STAR aligner,computational_tools,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,STAR aligner,Analysis Software,,,,,,,,,,,,,,,,"Mouse and human sequences were mapped to the mm10 and hg38 genomes, respectively, with STAR aligner.",Publication title lacks NF-specific terms: A genetic mouse model with postnatal
RSEM,computational_tools,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,RSEM,Analysis Software,,,,,,,,,,,,,,,,Gene-level quantification was determined using RSEM and based on GENCODE M22 gene annotation.,Publication title lacks NF-specific terms: A genetic mouse model with postnatal
limma R package,computational_tools,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,limma R package,Package/Library,,,,,,,,,,,,,,,,Differential expression was modeled using the voom method in the limma R package.,Publication title lacks NF-specific terms: A genetic mouse model with postnatal
ComBat,computational_tools,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ComBat,Analysis Software,,,,,,,,,,,,,,,,ComBat was used to correct for batch and species differences.,Publication title lacks NF-specific terms: A genetic mouse model with postnatal
UMAP,computational_tools,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,UMAP,Analysis Software,,,,,,,,,,,,,,,,we used uniform manifold approximation and projection (UMAP) based on Pearson's distance,Publication title lacks NF-specific terms: A genetic mouse model with postnatal
Leiden Open Variation Database (LOVD),computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Leiden Open Variation Database (LOVD),Database,,www.lovd.nl,,,,,,,,,,,,,,The publically accessible variant databases included were Leiden Open Variation Database (LOVD) ( www.lovd.nl ),Software name not in publication title — likely generic usage: Leiden Open Variation Database (LOVD)
ClinVar NCBI,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ClinVar NCBI,Database,,www.ncbi.nlm.nih.gov/clinvar,,,,,,,,,,,,,,ClinVar NCBI ( www.ncbi.nlm.nih.gov/clinvar ),Software name not in publication title — likely generic usage: ClinVar NCBI
Human Gene Mutation Database (HGMD),computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Human Gene Mutation Database (HGMD),Database,,www.hgmd.cf.ac.uk/ac/all.php,,,,,,,,,,,,,,the Human Gene Mutation Database (HGMD) ( www.hgmd.cf.ac.uk/ac/all.php ),Software name not in publication title — likely generic usage: Human Gene Mutation Database (HGMD)
Clinical Interpretation of Variants in Cancer (CIViC),computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Clinical Interpretation of Variants in Cancer (CIViC),Database,,https://civicdb.org/home,,,,,,,,,,,,,,Clinical Interpretation of Variants in Cancer (CIViC) ( https://civicdb.org/home ),Software name not in publication title — likely generic usage: Clinical Interpretation of Variants in Cancer (CIViC)
Mastermind Genomic Search Engine,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Mastermind Genomic Search Engine,Web Application,,https://www.genomenon.com/mastermind,,,,,,,,,,,,,,Mastermind Genomic Search Engine ( https://www.genomenon.com/mastermind ),Software name not in publication title — likely generic usage: Mastermind Genomic Search Engine
LitVar,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LitVar,Web Application,,,,,,,,,,,,,,,,An extra literature mining step was conducted using LitVar to capture any missing variants,No version and no repository URL (confidence < 0.9 — unidentifiable)
Alamut Visual version 2.15,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Alamut Visual version 2.15,Analysis Software,2.15,,,,,,,,,,,,,,,Variants were imported into the clinical prediction software Alamut Visual version 2.15 (SOPHiA GENETICS),Software name not in publication title — likely generic usage: Alamut Visual version 2.15
Align-GVGD,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Align-GVGD,Analysis Software,,,,,,,,,,,,,,,,Results from the following tools were exported from Alamut and factored into classification analysis: Align‐GVGD,No version and no repository URL (confidence < 0.9 — unidentifiable)
SIFT,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SIFT,Analysis Software,,,,,,,,,,,,,,,,"Results from the following tools were exported from Alamut and factored into classification analysis: Align‐GVGD (Mathe et al., 2006 ), SIFT",No version and no repository URL (confidence < 0.9 — unidentifiable)
PolyPhen-2,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PolyPhen-2,Analysis Software,,,,,,,,,,,,,,,,"SIFT (Kumar et al., 2009 ), PolyPhen‐2",No version and no repository URL (confidence < 0.9 — unidentifiable)
MutationTaster2,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MutationTaster2,Analysis Software,,,,,,,,,,,,,,,,"PolyPhen‐2 (Adzhubei et al., 2010 ), MutationTaster2",No version and no repository URL (confidence < 0.9 — unidentifiable)
SpliceSiteFinder-like tool,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SpliceSiteFinder-like tool,Analysis Software,,,,,,,,,,,,,,,,"MutationTaster2 (Schwarz et al., 2014 ), SpliceSiteFinder‐like tool",No version and no repository URL (confidence < 0.9 — unidentifiable)
MaxEntScan,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MaxEntScan,Analysis Software,,,,,,,,,,,,,,,,"SpliceSiteFinder‐like tool (Zhang, 1998 ), MaxEntScan",No version and no repository URL (confidence < 0.9 — unidentifiable)
gnomAD v2.1.1,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,gnomAD v2.1.1,Database,v2.1.1,gnomad.broadinstitute.org,,,,,,,,,,,,,,Variant frequencies and ExAC constraint metrics were obtained from gnomAD v2.1.1 ( gnomad.broadinstitute.org ),Software name not in publication title — likely generic usage: gnomAD v2.1.1
UCSC LiftOver tool,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,UCSC LiftOver tool,Web Application,,genome.ucsc.edu/cgi-bin/hgLiftOver,,,,,,,,,,,,,,UCSC LiftOver tool was used for any genomic co‐ordinate conversions between genome builds GRCh37/hg19 and GRCh38/hg38,Software name not in publication title — likely generic usage: UCSC LiftOver tool
alleleFrequencyApp,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,alleleFrequencyApp,Web Application,,cardiodb.org/allelefrequencyapp,,,,,,,,,,,,,,Maximum credible population allele frequency was determined using the alleleFrequencyApp ( cardiodb.org/allelefrequencyapp ),Software name not in publication title — likely generic usage: alleleFrequencyApp
DECIPHER database,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DECIPHER database,Database,,,,,,,,,,,,,,,,"The DECIPHER database (Firth et al., 2009 ) was used to investigate possible mutational hotspots or identify regional constraint",No version and no repository URL (confidence < 0.9 — unidentifiable)
REVEL (Rare Exome Variant Ensemble Learner),computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,REVEL (Rare Exome Variant Ensemble Learner),Analysis Software,,,,,,,,,,,,,,,,meta‐predictor REVEL (Rare Exome Variant Ensemble Learner) was used as the deciding score for evidence use (PP3 and BP4),No version and no repository URL (confidence < 0.9 — unidentifiable)
ClinPred,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ClinPred,Analysis Software,,,,,,,,,,,,,,,,"ClinPred (Alirezaie et al., 2018 ) meta‐predictor scores were also produced for variants",No version and no repository URL (confidence < 0.9 — unidentifiable)
COSMIC,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,COSMIC,Database,,www.cancer.sanger.ac.uk,,,,,,,,,,,,,,"COSMIC ( www.cancer.sanger.ac.uk ) (Tate et al., 2019 ) was used in the investigation of variants that were observed in somatic samples",Software name not in publication title — likely generic usage: COSMIC
CanVar-UK cancer predisposition gene variant database,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CanVar-UK cancer predisposition gene variant database,Database,,www.canvaruk.org,,,,,,,,,,,,,,CanVar‐UK cancer predisposition gene variant database ( www.canvaruk.org ) was used in the search for further variant information,Software name not in publication title — likely generic usage: CanVar-UK cancer predisposition gene variant database
Beta Imager 2000Z Digital Beta Imaging System,computational_tools,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Beta Imager 2000Z Digital Beta Imaging System,Analysis Software,,,,,,,,,,,,,,,,"Quantitation was performed using the Beta Imager 2000Z Digital Beta Imaging System (Biospace, France)",Software name not in publication title — likely generic usage: Beta Imager 2000Z Digital Beta Imaging System
Beta-Vision Plus program,computational_tools,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Beta-Vision Plus program,Analysis Software,,,,,,,,,,,,,,,,"Beta Imager 2000Z Digital Beta Imaging System (Biospace, France) and the Beta-Vision Plus program",No version and no repository URL (confidence < 0.9 — unidentifiable)
Siemens Focus F220,computational_tools,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Siemens Focus F220,Analysis Software,,,,,,,,,,,,,,,,data acquired as 1h dynamic scans using the Siemens Focus F220 and Inveon scanners,Software name not in publication title — likely generic usage: Siemens Focus F220
ASIPro VM,computational_tools,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ASIPro VM,Analysis Software,,,,,,,,,,,,,,,,Acquisition Sinogram Image PROcessing using IDL's Virtual Machine™ (ASIPro VM™),No version and no repository URL (confidence < 0.9 — unidentifiable)
Illumina HiSeq 2500 platform,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina HiSeq 2500 platform,Analysis Software,,,,,,,,,,,,,,,,Sequencing of libraries was achieved to an average unique read depth of greater than 500X using Sequencing by Synthesis (SBS) 2 × 100 base pairs (bp) paired-end cluster generation on the Illumina HiSeq 2500 plataform,Sequencing hardware or generic assay protocol: Illumina HiSeq 2500 platform
Illumina bcl2fastq v1.8.4 software,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Illumina bcl2fastq v1.8.4 software,Analysis Software,v1.8.4,,,,,,,,,,,,,,,FASTQ files were generated from Binary Cluster Files (.bcl) using the Illumina bcl2fastq v1.8.4 software with parameters set as per vendor's specifications,Software name not in publication title — likely generic usage: Illumina bcl2fastq v1.8.4 software
Burrows-Wheeler Aligner v0.7.10,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Burrows-Wheeler Aligner v0.7.10,Analysis Software,v0.7.10,,,,,,,,,,,,,,,FASTQ files were aligned to the human genome reference hg19 (GRCh37) using the Burrows-Wheeler Aligner v0.7.10 algorithm with default settings,Software name not in publication title — likely generic usage: Burrows-Wheeler Aligner v0.7.10
Picard Tools v1.119,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Picard Tools v1.119,Analysis Software,v1.119,,,,,,,,,,,,,,,BAM files (.bam) were generated using Picard Tools v1.119,Software name not in publication title — likely generic usage: Picard Tools v1.119
MDLVC v5.0,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MDLVC v5.0,Analysis Software,v5.0,,,,,,,,,,,,,,,variant calling was performed using in-house variant caller algorithm (MDLVC v5.0),Software name not in publication title — likely generic usage: MDLVC v5.0
HaplotypeCaller (Genome Analysis Tool Kit 3.3),computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HaplotypeCaller (Genome Analysis Tool Kit 3.3),Analysis Software,3.3,,,,,,,,,,,,,,,cross referenced with HaplotypeCaller (Genome Analysis Tool Kit 3.3) under discovery mode,Software name not in publication title — likely generic usage: HaplotypeCaller (Genome Analysis Tool Kit 3.3)
Integrated Genomics Viewer v2.3.4 (IGV),computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Integrated Genomics Viewer v2.3.4 (IGV),Analysis Software,v2.3.4,,,,,,,,,,,,,,,"All variant calls were inspected using Integrated Genomics Viewer v2.3.4 (IGV; Broad Institute, MIT Harvard, Cambridge, MA)",Software name not in publication title — likely generic usage: Integrated Genomics Viewer v2.3.4 (IGV)
GraphPad Prism version 8.0,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 8.0,Analysis Software,8.0,,,,,,,,,,,,,,,"Statistical analyses were performed using GraphPad Prism version 8.0 (San Diego, CA)",Generic tool (versioned): GraphPad Prism version 8.0
SAS version 9.4,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SAS version 9.4,Analysis Software,9.4,,,,,,,,,,,,,,,"Statistical analyses were performed using GraphPad Prism version 8.0 (San Diego, CA), SAS version 9.4 (Cary, NC)",Generic tool (versioned): SAS version 9.4
R version 3.3.2,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R version 3.3.2,Analysis Software,3.3.2,,,,,,,,,,,,,,,"Statistical analyses were performed using GraphPad Prism version 8.0 (San Diego, CA), SAS version 9.4 (Cary, NC), and R version 3.3.2",Generic tool (versioned): R version 3.3.2
FMRIPrep,computational_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FMRIPrep,Pipeline,,,,,,,,,,,,,,,,pass registration procedures as defined by FMRIPrep,Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
melodic v3.15,computational_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,melodic v3.15,Analysis Software,v3.15,,,,,,,,,,,,,,,we ran group-based ICA using melodic v3.15,Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
FSLCC,computational_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FSLCC,Analysis Software,,,,,,,,,,,,,,,,We then compared each component to canonical RSNs using spatial correlation (FSLCC),Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
randomise,computational_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,randomise,Analysis Software,,,,,,,,,,,,,,,,group differences were estimated using the randomise tool with threshold-free cluster enhancement,Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
FSLeyes,computational_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FSLeyes,Analysis Software,,,,,,,,,,,,,,,,using the Harvard-Oxford subcortical atlas in FSLeyes,Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
fMRI Expert Analysis Tool (FEAT),computational_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,fMRI Expert Analysis Tool (FEAT),Analysis Software,,,,,,,,,,,,,,,,We used fMRI Expert Analysis Tool (FEAT) to model extracted time series,Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
prcomp,computational_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,prcomp,Package/Library,,,,,,,,,,,,,,,,using the prcomp function in R,Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
Multiple Imputation by Chained Equations (MICE),computational_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Multiple Imputation by Chained Equations (MICE),Package/Library,,,,,,,,,,,,,,,,using a predictive mean matching for mixed types and the Multiple Imputation by Chained Equations (MICE) package in R,Publication title lacks NF-specific terms: Altered canonical and striatal-frontal resting state functional connectivity in 
Burrow-Wheeler aligner,computational_tools,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Burrow-Wheeler aligner,Analysis Software,,,,,,,,,,,,,,,,Sequence reads were mapped using the Burrow-Wheeler aligner,No version and no repository URL (confidence < 0.9 — unidentifiable)
Genome Analysis Toolkit,computational_tools,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Genome Analysis Toolkit,Analysis Software,,,,,,,,,,,,,,,,final alignments generated after multiple quality controls steps applied using the Genome Analysis Toolkit,No version and no repository URL (confidence < 0.9 — unidentifiable)
Samtools,computational_tools,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Samtools,Analysis Software,,,,,,,,,,,,,,,,"quality controls steps applied using the Genome Analysis Toolkit, Samtools and Picard",Generic bioinformatics/stats tool: Samtools
Picard,computational_tools,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Picard,Analysis Software,,,,,,,,,,,,,,,,"quality controls steps applied using the Genome Analysis Toolkit, Samtools and Picard",Generic bioinformatics/stats tool: Picard
TopHat,computational_tools,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,TopHat,Analysis Software,,,,,,,,,,,,,,,,Sequence reads were mapped to the human reference genome (b37) using TopHat,Generic bioinformatics/stats tool: TopHat
BEDtools software,computational_tools,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BEDtools software,Analysis Software,,,,,,,,,,,,,,,,Gene expression levels were calculated using BEDtools software,No version and no repository URL (confidence < 0.9 — unidentifiable)
EdgeR software,computational_tools,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,EdgeR software,Package/Library,,,,,,,,,,,,,,,,Differential expression analysis was performed using EdgeR software implemented in the R statistical framework,No version and no repository URL (confidence < 0.9 — unidentifiable)
Partek Genomics Suite software,computational_tools,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Partek Genomics Suite software,Analysis Software,,,,,,,,,,,,,,,,"Gene Ontology and Pathway enrichment were performed using Partek Genomics Suite software (Partek, St. Louis, MO)",No version and no repository URL (confidence < 0.9 — unidentifiable)
INFLUX cell sorter,computational_tools,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,INFLUX cell sorter,Other,,,,,,,,,,,,,,,,"Flow cytometry was performed using an INFLUX cell sorter (BD Biosciences, CA, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
NVivo software,computational_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NVivo software,Analysis Software,,,,,,,,,,,,,,,,"Qualitative concept elicitation data from transcripts were coded, analyzed using NVivo software, and thematic analysis was conducted",No version and no repository URL (confidence < 0.9 — unidentifiable)
CADvue software,computational_tools,PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CADvue software,Analysis Software,,,,,,,,,,,,,,,,"Post-processing was performed using CADvue software (iCAD, Inc. Nashua, NH) employing the Tofts pharmacokinetic model to quantify vascular permeability as K trans...",No version and no repository URL (confidence < 0.9 — unidentifiable)
CHOP-CHOP,computational_tools,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CHOP-CHOP,Web Application,,,,,,,,,,,,,,,,gRNAs for zebrafish nf2a and nf2b (Table S1) were designed using CHOP-CHOP,Software name not in publication title — likely generic usage: CHOP-CHOP
CRISPResso2,computational_tools,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CRISPResso2,Analysis Software,,,,,,,,,,,,,,,,"At least 10,000 high-quality reads were analyzed for each sample using CRISPResso2 (Clement et al., 2019)",Software name not in publication title — likely generic usage: CRISPResso2
ImageJ,computational_tools,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,"Quantifications for meningeal proliferation (Fig. 4H), Schwann cell hyperplasia (Fig. 5J,K), and nf2b HCR signal in cranial neural crest cells and pLLn SCs (Fig. S1L, M) were performed using ImageJ cell counter feature",Generic bioinformatics/stats tool: ImageJ
Zeiss Axio Observer,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Zeiss Axio Observer,Analysis Software,,,,,,,,,,,,,,,,cell viability was the endpoint as assessed by Zeiss Axio Observer,No version and no repository URL (confidence < 0.9 — unidentifiable)
Cellpose,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Cellpose,Analysis Software,,,,,,,,,,,,,,,,"images were further analyzed using Cellpose (Stringer et al., 2021) and ImageJ",Software name not in publication title — likely generic usage: Cellpose
ImageJ,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,"images were further analyzed using Cellpose (Stringer et al., 2021) and ImageJ (NIH)",Generic bioinformatics/stats tool: ImageJ
Trimmomatic v 0.39,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Trimmomatic v 0.39,Analysis Software,v 0.39,,,,,,,,,,,,,,,WES sequencing FASTQ files were trimmed using Trimmomatic v 0.39,Software name not in publication title — likely generic usage: Trimmomatic v 0.39
BWA-MEM,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BWA-MEM,Analysis Software,,,,,,,,,,,,,,,,aligned against reference sequence hg38 via BWA-MEM,No version and no repository URL (confidence < 0.9 — unidentifiable)
GATK V4.2,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GATK V4.2,Analysis Software,V4.2,,,,,,,,,,,,,,,GATK V4.2 base quality score recalibration (BQSR) was used to process BAM files,Software name not in publication title — likely generic usage: GATK V4.2
Xenosplit,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Xenosplit,Analysis Software,,,,,,,,,,,,,,,,"For PDX sequence data, Xenosplit was used to filter mouse-derived reads",Software name not in publication title — likely generic usage: Xenosplit
VarScan2,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VarScan2,Analysis Software,,,,,,,,,,,,,,,,Somatic single nucleotide variants (SNVs) and small insertions or deletions (indels) were detected using VarScan2,Generic bioinformatics/stats tool: VarScan2
Strelka2,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Strelka2,Analysis Software,,,,,,,,,,,,,,,,"detected using VarScan2, Strelka2, MuTect2, and Pindel",Generic bioinformatics/stats tool: Strelka2
MuTect2,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MuTect2,Analysis Software,,,,,,,,,,,,,,,,"detected using VarScan2, Strelka2, MuTect2, and Pindel",Generic bioinformatics/stats tool: MuTect2
Pindel,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Pindel,Analysis Software,,,,,,,,,,,,,,,,"detected using VarScan2, Strelka2, MuTect2, and Pindel",No version and no repository URL (confidence < 0.9 — unidentifiable)
Variant Effect Predictor (VEP),computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Variant Effect Predictor (VEP),Analysis Software,,,,,,,,,,,,,,,,Variant filtering and annotation were done using Variant Effect Predictor (VEP),Software name not in publication title — likely generic usage: Variant Effect Predictor (VEP)
maftools v2.10.0,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,maftools v2.10.0,Package/Library,v2.10.0,,,,,,,,,,,,,,,Somatic variant plots were created with maftools v2.10.0,Software name not in publication title — likely generic usage: maftools v2.10.0
CNVkit V2.0,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CNVkit V2.0,Analysis Software,V2.0,,,,,,,,,,,,,,,CNVkit V2.0 was used to infer and visualize copy number,Software name not in publication title — likely generic usage: CNVkit V2.0
Salmon algorithm,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Salmon algorithm,Analysis Software,,,,,,,,,,,,,,,,which includes quantitation with the Salmon algorithm,No version and no repository URL (confidence < 0.9 — unidentifiable)
DESeq2 package,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2 package,Package/Library,,,,,,,,,,,,,,,,Gene counts and transcript counts were normalized by using the DESeq2 package,Software name not in publication title — likely generic usage: DESeq2 package
Ventana BenchMark ULTRA,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Ventana BenchMark ULTRA,Analysis Software,,,,,,,,,,,,,,,,Immunohistochemical staining for FAP was performed on a Ventana BenchMark ULTRA platform using the iVIEW DAB detection system,Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
iVIEW DAB detection system,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,iVIEW DAB detection system,Analysis Software,,,,,,,,,,,,,,,,"performed on a Ventana BenchMark ULTRA platform using the iVIEW DAB detection system (Roche, Mannheim, Germany)",Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
TruSight RNA Pan-Cancer Panel,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,TruSight RNA Pan-Cancer Panel,Analysis Software,,,,,,,,,,,,,,,,"RNA fusion profiling was performed using the TruSight RNA Pan-Cancer Panel (Illumina, San Diego, CA, US)",Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
Illumina EPIC DNA methylation profiling,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina EPIC DNA methylation profiling,Analysis Software,,,,,,,,,,,,,,,,"Furthermore, Illumina EPIC DNA methylation profiling was performed with application of the Heidelberg sarcoma classifier",Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
Heidelberg sarcoma classifier,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Heidelberg sarcoma classifier,Analysis Software,,,,,,,,,,,,,,,,Illumina EPIC DNA methylation profiling was performed with application of the Heidelberg sarcoma classifier,Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
GEOquery,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GEOquery,Package/Library,,,,,,,,,,,,,,,,Expression matrices and corresponding phenotype metadata were processed using the GEOquery and Biobase R packages,Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
Biobase,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Biobase,Package/Library,,,,,,,,,,,,,,,,Expression matrices and corresponding phenotype metadata were processed using the GEOquery and Biobase R packages,Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
Seurat,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat,Package/Library,5.3.0,https://satijalab.org/seurat/,,,,,,,,,,,,,,"We processed the data using Seurat (Version: 5.3.0, https://satijalab.org/seurat/) in R (Version: 4.4.0)",Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
Slingshot,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Slingshot,Package/Library,2.12.0,,,,,,,,,,,,,,,"To explore differentiation trajectories among tumor clusters, we applied Slingshot (Version: 2.12.0)",Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
Read10X,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Read10X,Package/Library,,,,,,,,,,,,,,,,"Raw UMI count matrices were loaded via Read10X, filtered to remove cells",Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
Biograph mCT 40,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Biograph mCT 40,Analysis Software,,,,,,,,,,,,,,,,"Scans were obtained on a dedicated PET/CT scanner (Biograph mCT 40; Siemens Healthineers, Erlangen, Germany)",Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
R statistical software version 3.5.1,computational_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R statistical software version 3.5.1,Analysis Software,3.5.1,,,,,,,,,,,,,,,All analyses were done with R statistical software version 3.5.1,Software name not in publication title — likely generic usage: R statistical software version 3.5.1
10x Genomics Chromium 3' gene expression,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,10x Genomics Chromium 3' gene expression,Analysis Software,,,,,,,,,,,,,,,,Single nuclei generated from PN were analyzed using 10 × Genomics Chromium 3′ gene expression,No version and no repository URL (confidence < 0.9 — unidentifiable)
CellRanger,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CellRanger,Analysis Software,,,,,,,,,,,,,,,,Raw sequencing reads were processed using CellRanger (10 × Genomics),Software name not in publication title — likely generic usage: CellRanger
Seurat 3.1.0,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat 3.1.0,Package/Library,3.1.0,,,,,,,,,,,,,,,Raw sequencing reads were processed using CellRanger (10 × Genomics) and Seurat 3.1.0,Software name not in publication title — likely generic usage: Seurat 3.1.0
Harmony,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Harmony,Package/Library,,,,,,,,,,,,,,,,Cells from individual subpopulations were reanalyzed separately using Harmony alignment,No version and no repository URL (confidence < 0.9 — unidentifiable)
Presto,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Presto,Package/Library,,,,,,,,,,,,,,,,Presto was used for determining differential expression and marker gene identification,No version and no repository URL (confidence < 0.9 — unidentifiable)
CellChatDB,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CellChatDB,Database,1.5.0,,,,,,,,,,,,,,,CellChatDB (version 1.5.0) was used to infer ligand–receptor interactions between and within individual subpopulations,Software name not in publication title — likely generic usage: CellChatDB
Space Ranger,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Space Ranger,Analysis Software,v1.2.1,,,,,,,,,,,,,,,"Sequencing data were processed with Space Ranger (10 × genomics, v1.2.1)",Software name not in publication title — likely generic usage: Space Ranger
Seurat v4.0.1,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat v4.0.1,Package/Library,v4.0.1,,,,,,,,,,,,,,,followed by analysis in R using the Seurat (v4.0.1) tool suite,Software name not in publication title — likely generic usage: Seurat v4.0.1
Clustree,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Clustree,Package/Library,,,,,,,,,,,,,,,,"Clustree packages were utilized to cluster, process, filter and integrate newly generated ST data",No version and no repository URL (confidence < 0.9 — unidentifiable)
DAVID,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DAVID,Web Application,6.8,,,,,,,,,,,,,,,"ontological analysis using DAVID (Database for Annotation, Visualization, and Integrated Discovery: https://david.ncifcrf.gov ; version 6.8)",Generic bioinformatics/stats tool: DAVID
Loupe Browser,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Loupe Browser,Analysis Software,,,,,,,,,,,,,,,,ST cluster overlays on H&E image were produced in the Loupe Browser (10 × Genomics),No version and no repository URL (confidence < 0.9 — unidentifiable)
Visium spatial transcriptomics,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Visium spatial transcriptomics,Analysis Software,,,,,,,,,,,,,,,,"mounted on spatial transcriptomic capture slides (Visium, 10 × Genomics)",No version and no repository URL (confidence < 0.9 — unidentifiable)
R Studio PKNCA package (version 0.9.3),computational_tools,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R Studio PKNCA package (version 0.9.3),Package/Library,0.9.3,,,,,,,,,,,,,,,Selumetinib plasma concentration–time data were analyzed using noncompartmental methods implemented in R (version 3.6) R Studio PKNCA package (version 0.9.3),Software name not in publication title — likely generic usage: R Studio PKNCA package (version 0.9.3)
Wes system (ProteinSimple 004–600),computational_tools,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Wes system (ProteinSimple 004–600),Analysis Software,,,,,,,,,,,,,,,,A capillary western blot assay was performed on a Wes system (ProteinSimple 004–600) according to the manufacturer's instructions,No version and no repository URL (confidence < 0.9 — unidentifiable)
Fluidigm platform,computational_tools,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Fluidigm platform,Analysis Software,,,,,,,,,,,,,,,,"Analysis of transcript biomarkers of MEK inhibition was performed using the Fluidigm platform by Reverse Transcription, preamplification with pooled primers and Real Time-PCR",No version and no repository URL (confidence < 0.9 — unidentifiable)
GraphPad Prism 8,computational_tools,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism 8,Analysis Software,8,,,,,,,,,,,,,,,Statistical analyses were performed using GraphPad Prism 8,Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
MOSFLM,computational_tools,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MOSFLM,Analysis Software,,,,,,,,,,,,,,,,Data were processed and scaled using MOSFLM and SCALA in the CCP4 package,Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
SCALA,computational_tools,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SCALA,Analysis Software,,,,,,,,,,,,,,,,Data were processed and scaled using MOSFLM and SCALA in the CCP4 package,Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
CCP4 package,computational_tools,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CCP4 package,Package/Library,,,,,,,,,,,,,,,,Data were processed and scaled using MOSFLM and SCALA in the CCP4 package,Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
GraphPad PRISM,computational_tools,PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad PRISM,Analysis Software,v6.0a,,,,,,,,,,,,,,,"Statistical analysis was performed using GraphPad PRISM (v6.0a, La Jolla, CA)",Generic bioinformatics/stats tool: GraphPad PRISM
Matlab algorithms,computational_tools,PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Matlab algorithms,Analysis Software,,,,,,,,,,,,,,,,Structural properties were extracted from force-displacement curves by custom Matlab algorithms,No version and no repository URL (confidence < 0.9 — unidentifiable)
Reliable Change Index,computational_tools,PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Reliable Change Index,Analysis Software,,,,,,,,,,,,,,,,"individual-level analyses (Reliable Change Index, RCI) were used...using a Reliable Change Index (RCI) methodology",No version and no repository URL (confidence < 0.9 — unidentifiable)
ABI Prism 7900 Sequence Detection System,computational_tools,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ABI Prism 7900 Sequence Detection System,Analysis Software,,,,,,,,,,,,,,,,"mRNA expression of murine Met, miR34a and Ppib were measured using TaqMan technology and an ABI Prism 7900 Sequence Detection System",No version and no repository URL (confidence < 0.9 — unidentifiable)
FlowJo analysis software,computational_tools,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FlowJo analysis software,Analysis Software,,,,,,,,,,,,,,,,The percentage of CD24-staining cells was determined using a FACscan Flow Cytometer (Becton Dickinson) and quantitated using FlowJo analysis software,No version and no repository URL (confidence < 0.9 — unidentifiable)
NuGEN SPET for RNA,computational_tools,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NuGEN SPET for RNA,Analysis Software,,,,,,,,,,,,,,,,These validation samples were enriched for NF1 RNA using NuGEN SPET for RNA,No version and no repository URL (confidence < 0.9 — unidentifiable)
Agilent SureSelect RNA Target Enrichment,computational_tools,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Agilent SureSelect RNA Target Enrichment,Analysis Software,,,,,,,,,,,,,,,,enriched for NF1/SPRED1 using Agilent SureSelect RNA Target Enrichment,No version and no repository URL (confidence < 0.9 — unidentifiable)
NextSeq500 instrument (Illumina),computational_tools,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NextSeq500 instrument (Illumina),Analysis Software,,,,,,,,,,,,,,,,Paired-end sequencing (2x150bp) was performed on a NextSeq500 instrument (Illumina),Sequencing hardware or generic assay protocol: NextSeq500 instrument (Illumina)
STAR mapper (Version 2.4.1d),computational_tools,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR mapper (Version 2.4.1d),Analysis Software,2.4.1d,,,,,,,,,,,,,,,RNAseq reads were mapped with the STAR mapper (Version 2.4.1d),Software name not in publication title — likely generic usage: STAR mapper (Version 2.4.1d)
Picard tools,computational_tools,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Picard tools,Analysis Software,,https://github.com/broadinstitute/picard,,,,,,,,,,,,,,Duplicate read pair detection was carried out with Picard tools,Software name not in publication title — likely generic usage: Picard tools
QURNAs,computational_tools,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,QURNAs,Pipeline,,https://dataverse.nl/dataset.xhtml?persistentId=hdl:10411/LY8ZQ4,,,,,,,,,,,,,,an in-house developed tool (QURNAs) was used to calculate the enrichment score (ERS) for each splicing event,Software name not in publication title — likely generic usage: QURNAs
Alamut v2.15 (Interactive Biosoftware),computational_tools,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Alamut v2.15 (Interactive Biosoftware),Analysis Software,v2.15,,,,,,,,,,,,,,,Alamut v2.15 (Interactive Biosoftware) was used to identify true splice-donor and acceptor sites,Software name not in publication title — likely generic usage: Alamut v2.15 (Interactive Biosoftware)
IGV,computational_tools,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,IGV,Analysis Software,,,,,,,,,,,,,,,,further inspected in the BAM file in a genome browser (IGV and Alamut),No version and no repository URL (confidence < 0.9 — unidentifiable)
exome hidden Markov model (XHMM),computational_tools,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,exome hidden Markov model (XHMM),Analysis Software,,,,,,,,,,,,,,,,The CNV analysis tool exome hidden Markov model (XHMM) was used for exon CNV calling.,Publication title lacks NF-specific terms: Next-generation variant exon screening: Moving forward in routine genetic diseas
Burrows-Wheeler Aligner (bwa-0.7.15),computational_tools,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Burrows-Wheeler Aligner (bwa-0.7.15),Command-line Tool,0.7.15,,,,,,,,,,,,,,,FASTQ files were first aligned to the human reference genome (hg19) by the Burrows-Wheeler Aligner (bwa-0.7.15),Publication title lacks NF-specific terms: Next-generation variant exon screening: Moving forward in routine genetic diseas
Sambamba (v0.6.6),computational_tools,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Sambamba (v0.6.6),Command-line Tool,v0.6.6,https://github.com/biod/sambamba,,,,,,,,,,,,,,PCR duplications that cause bias in copy-number analysis were filtered out using Sambamba (v0.6.6),Publication title lacks NF-specific terms: Next-generation variant exon screening: Moving forward in routine genetic diseas
Genome Analysis Toolkit (GATK),computational_tools,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Genome Analysis Toolkit (GATK),Analysis Software,3.8,,,,,,,,,,,,,,,SNVs/indel variants and SNPs were called using version 3.8 of the Genome Analysis Toolkit (GATK).,Publication title lacks NF-specific terms: Next-generation variant exon screening: Moving forward in routine genetic diseas
CASAVA v1.82,computational_tools,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,CASAVA v1.82,Analysis Software,v1.82,,,,,,,,,,,,,,,Raw image files were processed using CASAVA v1.82 for base calling and generating the raw sequencing data.,Publication title lacks NF-specific terms: Next-generation variant exon screening: Moving forward in routine genetic diseas
Leiden Open Variation Database (LOVD),computational_tools,PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Leiden Open Variation Database (LOVD),Database,,,,,,,,,,,,,,,,Pathogenic variants were collected from the Leiden Open Variation Database (LOVD) database,Publication title lacks NF-specific terms: Exhaustive non-synonymous variants functionality prediction enables high resolut
1000 Genomes Project,computational_tools,PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,1000 Genomes Project,Database,,,,,,,,,,,,,,,,each variant's allele frequency in three different databases of healthy populations: The 1000 Genomes Project,Publication title lacks NF-specific terms: Exhaustive non-synonymous variants functionality prediction enables high resolut
Exome Aggregation Consortium (ExAC),computational_tools,PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Exome Aggregation Consortium (ExAC),Database,,,,,,,,,,,,,,,,"The 1000 Genomes Project, The Exome Aggregation Consortium (ExAC) and the Genome Aggregation Database",Publication title lacks NF-specific terms: Exhaustive non-synonymous variants functionality prediction enables high resolut
Genome Aggregation Database (gnomAD),computational_tools,PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Genome Aggregation Database (gnomAD),Database,,,,,,,,,,,,,,,,The Exome Aggregation Consortium (ExAC) and the Genome Aggregation Database (gnomAD),Publication title lacks NF-specific terms: Exhaustive non-synonymous variants functionality prediction enables high resolut
SnpEff,computational_tools,PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SnpEff,Analysis Software,,,,,,,,,,,,,,,,Variant annotation was performed using SnpEff and included annotations gathered in dbNSFP,Publication title lacks NF-specific terms: Exhaustive non-synonymous variants functionality prediction enables high resolut
dbNSFP,computational_tools,PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,dbNSFP,Database,,,,,,,,,,,,,,,,Variant annotation was performed using SnpEff and included annotations gathered in dbNSFP,Publication title lacks NF-specific terms: Exhaustive non-synonymous variants functionality prediction enables high resolut
Interpro,computational_tools,PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Interpro,Database,,,,,,,,,,,,,,,,NF1 protein domain annotation was performed using Interpro and Nextprot,Publication title lacks NF-specific terms: Exhaustive non-synonymous variants functionality prediction enables high resolut
Nextprot,computational_tools,PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Nextprot,Database,,,,,,,,,,,,,,,,NF1 protein domain annotation was performed using Interpro and Nextprot,Publication title lacks NF-specific terms: Exhaustive non-synonymous variants functionality prediction enables high resolut
H2O R package,computational_tools,PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,H2O R package,Package/Library,,,,,,,,,,,,,,,,Models were trained and validated using the H2O R package,Publication title lacks NF-specific terms: Exhaustive non-synonymous variants functionality prediction enables high resolut
shiny web application framework,computational_tools,PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.8,Development,True,0.67,Medium,,,,,,,,,,,,,,,shiny web application framework,Package/Library,,,,,,,,,,,,,,,,The webserver was developed using the shiny web application framework,Publication title lacks NF-specific terms: Exhaustive non-synonymous variants functionality prediction enables high resolut
shinyapps.io,computational_tools,PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.75,Development,True,0.67,Low,,,,,,,,,,,,,,,shinyapps.io,Web Application,,,,,,,,,,,,,,,,"published on shinyapps.io, a cloud-service platform used to publish applications developed using shiny",Publication title lacks NF-specific terms: Exhaustive non-synonymous variants functionality prediction enables high resolut
Illumina Infinium HumanOmni-1Quad bead-chips,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina Infinium HumanOmni-1Quad bead-chips,Other,,,,,,,,,,,,,,,,Genotyping for the CALM1 samples was performed on Illumina Infinium HumanOmni‐1Quad bead‐chips.,Sequencing hardware or generic assay protocol: Illumina Infinium HumanOmni-1Quad bead-chips
Illumina Infinium Omni2.5 bead-chips,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina Infinium Omni2.5 bead-chips,Other,,,,,,,,,,,,,,,,Genotyping for the replication cohort CALM2 samples was performed on Illumina Infinium Omni2.5 bead‐chips.,Sequencing hardware or generic assay protocol: Illumina Infinium Omni2.5 bead-chips
PLINK,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PLINK,Analysis Software,,,,,,,,,,,,,,,,"multidimensional scaling (MDS) analysis estimating pairwise identity by descent (IBD) for all pairs of founders using independent SNPs in PLINK (Purcell et al., 2007)",Software name not in publication title — likely generic usage: PLINK
LitfOver,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LitfOver,Analysis Software,,,,,,,,,,,,,,,,"LitfOver (Hinrichs et al., 2006) was used to convert genome positions in the CALM1 cohort (NCBI build 36, UCSC hg18) to corresponding positions in the CALM2 cohort",No version and no repository URL (confidence < 0.9 — unidentifiable)
AmpliSeq/IonTorrent platform,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AmpliSeq/IonTorrent platform,Other,,,,,,,,,,,,,,,,Targeted sequencing of candidate loci was carried out in 171 European–American samples using the AmpliSeq/IonTorrent platform,Sequencing hardware or generic assay protocol: AmpliSeq/IonTorrent platform
SNP & Variation Suite v8.3.4,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SNP & Variation Suite v8.3.4,Analysis Software,v8.3.4,,,,,,,,,,,,,,,Quality control for targeted gene sequencing data was done using SNP & Variation Suite v8.3.4 (http://goldenhelix.com/products/SNP_Variation/index.html),Software name not in publication title — likely generic usage: SNP & Variation Suite v8.3.4
EMMAX,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,EMMAX,Analysis Software,,,,,,,,,,,,,,,,"tests of association between each SNP and log‐transformed CALM number, adjusted for age, sex, and body surface area, were performed with EMMAX (Kang et al., 2010)",Software name not in publication title — likely generic usage: EMMAX
METAL,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,METAL,Analysis Software,,,,,,,,,,,,,,,,"Meta‐analyses between the CALM1 and CALM2 cohort studies were performed with METAL (Willer, Li, & Abecasis, 2010)",Software name not in publication title — likely generic usage: METAL
ComPaSS-GWAS,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ComPaSS-GWAS,Analysis Software,,,,,,,,,,,,,,,,"The second approach for corroboration of SNP associations used ComPaSS‐GWAS (Sabourin et al., 2018), a method based on complementary pairs stability selection",Software name not in publication title — likely generic usage: ComPaSS-GWAS
Haploview 4.2,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Haploview 4.2,Analysis Software,4.2,,,,,,,,,,,,,,,"Haploview 4.2 (Barrett, Fry, Maller, & Daly, 2005) was used to generate LD plots across the genome based on D' and r2 values",Software name not in publication title — likely generic usage: Haploview 4.2
UCSC Genome browser,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,UCSC Genome browser,Web Application,,,,,,,,,,,,,,,,Custom tracks on the UCSC Genome browser (http://genome.ucsc.edu) were used to screen NIH Roadmap Epigenomics and ENCODE experimental data,No version and no repository URL (confidence < 0.9 — unidentifiable)
HaploReg,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HaploReg,Web Application,,,,,,,,,,,,,,,,The online tools HaploReg (http://www.broadinstitute.org/mammals/haploreg/haploreg.php) and RegulomeDB were used as complementary analyses,No version and no repository URL (confidence < 0.9 — unidentifiable)
RegulomeDB,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,RegulomeDB,Web Application,,,,,,,,,,,,,,,,The online tools HaploReg and RegulomeDB (http://regulome.stanford.edu) were used as complementary analyses,No version and no repository URL (confidence < 0.9 — unidentifiable)
GTEx,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GTEx,Database,V7,,,,,,,,,,,,,,,"eQTL results for all CALM‐associated SNPs and collated genes based on 749 normal skin tissues were then extracted from GTEx (V7, dbGaP Accession phs000424.v7.p2)",Software name not in publication title — likely generic usage: GTEx
Metabolomics GWAS,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Metabolomics GWAS,Database,,,,,,,,,,,,,,,,the influence of a SNP on metabolite levels in blood was evaluated by extraction of association results for each SNP and metabolites in blood from the Metabolomics GWAS,No version and no repository URL (confidence < 0.9 — unidentifiable)
BIAcore 1000 system,computational_tools,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BIAcore 1000 system,Analysis Software,,,,,,,,,,,,,,,,"Protein-protein interactions were quantified using the BIAcore 1000 system (Pharmacia Biacore AB, Uppsala, Sweden/GE Healthcare)",No version and no repository URL (confidence < 0.9 — unidentifiable)
"cesium-137 source (J.L. Shepherd & Associates, San Fernando, CA) animal irradiator",computational_tools,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"cesium-137 source (J.L. Shepherd & Associates, San Fernando, CA) animal irradiator",Other,,,,,,,,,,,,,,,,"Mice were placed in a cesium-137 source (J.L. Shepherd & Associates, San Fernando, CA) animal irradiator and shielded with an iron collimator",No version and no repository URL (confidence < 0.9 — unidentifiable)
Olympus BX41 microscope,computational_tools,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Olympus BX41 microscope,Other,,,,,,,,,,,,,,,,"Photographs of histology were taken with an Olympus BX41 microscope, using Olympus UplanFl 10X/0.3 and 20X/0.5 objectives",No version and no repository URL (confidence < 0.9 — unidentifiable)
Olympus DP72 camera,computational_tools,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Olympus DP72 camera,Other,,,,,,,,,,,,,,,,An attached Olympus DP72 camera and Adobe Photoshop CS2 were used to capture the images,No version and no repository URL (confidence < 0.9 — unidentifiable)
Adobe Photoshop CS2,computational_tools,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Adobe Photoshop CS2,Analysis Software,CS2,,,,,,,,,,,,,,,An attached Olympus DP72 camera and Adobe Photoshop CS2 were used to capture the images,Software name not in publication title — likely generic usage: Adobe Photoshop CS2
Hemavet,computational_tools,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Hemavet,Analysis Software,,,,,,,,,,,,,,,,Complete blood counts were performed on blood samples obtained at the time of sacrifice by cardiac puncture and analyzed immediately on a Hemavet provided by the UCSF Mouse Pathology Core,No version and no repository URL (confidence < 0.9 — unidentifiable)
Peak Scanner software from Applied Biosystems,computational_tools,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Peak Scanner software from Applied Biosystems,Analysis Software,,,,,,,,,,,,,,,,The UCSF Genome Core using Peak Scanner software from Applied Biosystems performed PCR fragment analyses,Software name not in publication title — likely generic usage: Peak Scanner software from Applied Biosystems
"7900 HT Fast Real-Time PCR system (Applied Biosystems, USA)",computational_tools,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"7900 HT Fast Real-Time PCR system (Applied Biosystems, USA)",Analysis Software,,,,,,,,,,,,,,,,"Assay C2557613_10 was used to genotype using the Taq amplification method in a 7900 HT Fast Real-Time PCR system (Applied Biosystems, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
SDS3.0,computational_tools,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SDS3.0,Analysis Software,3.0,,,,,,,,,,,,,,,"Allelic discrimination plots generated by SDS3.0, an Applied Biosystems program used to make genotyping calls",Software name not in publication title — likely generic usage: SDS3.0
COSMIC Database,computational_tools,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,COSMIC Database,Database,,www.sanger.ac.uk/genetics/CGP/cosmic,,,,,,,,,,,,,,"The Catalogue of Somatic Mutations in Cancer Database (COSMIC, www.sanger.ac.uk/genetics/CGP/cosmic, Wellcome Trust Sanger Institute, United Kingdom) was used to search for references",Software name not in publication title — likely generic usage: COSMIC Database
Prizm v.4 (GraphPad),computational_tools,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Prizm v.4 (GraphPad),Analysis Software,v.4,,,,,,,,,,,,,,,All analyses were performed using Prizm v.4 (GraphPad),Software name not in publication title — likely generic usage: Prizm v.4 (GraphPad)
nf-core/rnaseq (v3.11.2),computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,nf-core/rnaseq (v3.11.2),Pipeline,v3.11.2,,,,,,,,,,,,,,,Raw fastq files were processed using nf-core/rnaseq (v3.11.2),Software name not in publication title — likely generic usage: nf-core/rnaseq (v3.11.2)
salmon (v1.10.1),computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,salmon (v1.10.1),Analysis Software,v1.10.1,,,,,,,,,,,,,,,quantified using salmon: v1.10.1,Software name not in publication title — likely generic usage: salmon (v1.10.1)
sva R package (v3.42.0),computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,sva R package (v3.42.0),Package/Library,v3.42.0,,,,,,,,,,,,,,,ComBat from sva R package (v3.42.0) was used for batch correction,Software name not in publication title — likely generic usage: sva R package (v3.42.0)
immunedeconv (v2.1.0),computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,immunedeconv (v2.1.0),Package/Library,v2.1.0,,,,,,,,,,,,,,,The batch corrected data was then analyzed using the immunedeconv (v2.1.0) package,Software name not in publication title — likely generic usage: immunedeconv (v2.1.0)
quanTIseq algorithm,computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,quanTIseq algorithm,Analysis Software,,,,,,,,,,,,,,,,The quanTIseq algorithm ( 37 ) was used for assessing fractions of specific immune cell types from bulk RNA sequencing data,Sequencing hardware or generic assay protocol: quanTIseq algorithm
ggplot2 (v3.4.4),computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ggplot2 (v3.4.4),Package/Library,v3.4.4,,,,,,,,,,,,,,,The analysis results were visualized using ggplot2 (v3.4.4) and ggridges (v0.5.5) libraries,Software name not in publication title — likely generic usage: ggplot2 (v3.4.4)
ggridges (v0.5.5),computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ggridges (v0.5.5),Package/Library,v0.5.5,,,,,,,,,,,,,,,The analysis results were visualized using ggplot2 (v3.4.4) and ggridges (v0.5.5) libraries,Software name not in publication title — likely generic usage: ggridges (v0.5.5)
HALO imaging analysis software,computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HALO imaging analysis software,Analysis Software,,,,,,,,,,,,,,,,"analyzed with the HALO imaging analysis software (Indica Labs, Corrales, NM)",Software name not in publication title — likely generic usage: HALO imaging analysis software
BDdiva,computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BDdiva,Analysis Software,,,,,,,,,,,,,,,,Data were analyzed using BDdiva and FCS Express Software,No version and no repository URL (confidence < 0.9 — unidentifiable)
FCS Express Software,computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FCS Express Software,Analysis Software,,,,,,,,,,,,,,,,Data were analyzed using BDdiva and FCS Express Software,No version and no repository URL (confidence < 0.9 — unidentifiable)
FreeSurfer,computational_tools,PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FreeSurfer,Analysis Software,"5.3, 7.2.0",,,,,,,,,,,,,,,the data were processed using Freesurfer (https://surfer.nmr.mgh.harvard.edu version 5.3)...processed using Freesurfer (version 7.2.0),Publication title lacks NF-specific terms: Influences of RASopathies on Neuroanatomical Variation in Children.
ComBat harmonization,computational_tools,PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ComBat harmonization,Analysis Software,,,,,,,,,,,,,,,,"we used ComBat harmonization, which corrects for between-scanner and multi-site collection of imaging data",Publication title lacks NF-specific terms: Influences of RASopathies on Neuroanatomical Variation in Children.
mri_glmfit,computational_tools,PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,mri_glmfit,Analysis Software,,,,,,,,,,,,,,,,"We used Freesurfer's, statistical modeling tool, mri_glmfit (http://surfer.nmr.mgh.harvard.edu/fswiki/mri_glmfit)",Publication title lacks NF-specific terms: Influences of RASopathies on Neuroanatomical Variation in Children.
mri_glmfit-sim,computational_tools,PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,mri_glmfit-sim,Analysis Software,,,,,,,,,,,,,,,,"To control for multiple comparisons, we used Freesurfer's tool mri_glmfit-sim, which generates cluster-corrected regions",Publication title lacks NF-specific terms: Influences of RASopathies on Neuroanatomical Variation in Children.
Desikan ROI parcellation,computational_tools,PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Desikan ROI parcellation,Analysis Software,,,,,,,,,,,,,,,,"For all subcortical analyses, we used Desikan ROI parcellation and conducted univariate regressions",Publication title lacks NF-specific terms: Influences of RASopathies on Neuroanatomical Variation in Children.
RStudio,computational_tools,PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,RStudio,Analysis Software,,,,,,,,,,,,,,,,"we calculated Cohen's d effect size between groups (NS vs. TD, and NF1 vs. TD) for each ROI of SA and CT in RStudio",Publication title lacks NF-specific terms: Influences of RASopathies on Neuroanatomical Variation in Children.
GraphPad Prism 8,computational_tools,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism 8,Analysis Software,8,,,,,,,,,,,,,,,"All statistical analyses were performed using GraphPad Prism 8 software (GraphPad Software, Inc., USA)",Generic bioinformatics/stats tool: GraphPad Prism 8
Metamorph analysis software,computational_tools,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Metamorph analysis software,Analysis Software,,,,,,,,,,,,,,,,"size (diameter/cell growth) and number (clonogenic expansion) of the resulting secondary neurospheres was determined using Metamorph analysis software (Molecular Devices, Sunnyvale CA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
GraphPad Prism 5.0,computational_tools,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism 5.0,Analysis Software,5.0,,,,,,,,,,,,,,,Statistical significance (p<0.05) was determined using the appropriate test as described in figure legends using GraphPad Prism 5.0 software,Generic tool (versioned): GraphPad Prism 5.0
ImageJ,computational_tools,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,"Lengths, areas and the number of cells were quantified using the ImageJ software package",Generic bioinformatics/stats tool: ImageJ
FACSDiva v6.1,computational_tools,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FACSDiva v6.1,Analysis Software,v6.1,,,,,,,,,,,,,,,FACSDiva v6.1 and FlowJo software v10.0.8 (BD Biosciences) were used to collect and analyze data,Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
FlowJo software v10.0.8,computational_tools,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FlowJo software v10.0.8,Analysis Software,v10.0.8,,,,,,,,,,,,,,,FACSDiva v6.1 and FlowJo software v10.0.8 (BD Biosciences) were used to collect and analyze data,Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
GraphPad Prism v8.3,computational_tools,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism v8.3,Analysis Software,v8.3,,,,,,,,,,,,,,,The IC50s for each of the cell lines were determined using GraphPad Prism v8.3 (nonlinear regression and dose–response curve fitting),Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
HALO image analysis software v3.2,computational_tools,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HALO image analysis software v3.2,Analysis Software,v3.2,,,,,,,,,,,,,,,Tissues were scored for extent and intensity of staining using the HALO image analysis software v3.2,Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
ZEN imaging software v2.3,computational_tools,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ZEN imaging software v2.3,Analysis Software,v2.3,,,,,,,,,,,,,,,"Image acquisition was performed using a Zeiss LSM 880 with Airyscan confocal microscope (Zeiss, Oberkochen, Germany) and analyses performed with ZEN imaging software v2.3",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
CLC Genomics Workbench 22,computational_tools,PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CLC Genomics Workbench 22,Analysis Software,22,,,,,,,,,,,,,,,"Resulting FASTQ files were analyzed with CLC Genomics Workbench 22 (QIAGEN, Hilden, Germany)",Software name not in publication title — likely generic usage: CLC Genomics Workbench 22
CosinorPy Python package,computational_tools,PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CosinorPy Python package,Package/Library,,,,,,,,,,,,,,,,numerical and graphical analysis was done using the CosinorPy Python package,Software name not in publication title — likely generic usage: CosinorPy Python package
MultiClamp 700B,computational_tools,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MultiClamp 700B,Analysis Software,,,,,,,,,,,,,,,,A MultiClamp 700B patch-clamp amplifier and pCLAMP 9.2 software (MDS Analytical Technologies) were used to acquire data,No version and no repository URL (confidence < 0.9 — unidentifiable)
pCLAMP 9.2,computational_tools,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,pCLAMP 9.2,Analysis Software,9.2,,,,,,,,,,,,,,,A MultiClamp 700B patch-clamp amplifier and pCLAMP 9.2 software (MDS Analytical Technologies) were used to acquire data,Software name not in publication title — likely generic usage: pCLAMP 9.2
MATLAB,computational_tools,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,MATLAB,Analysis Software,R2008a,,,,,,,,,,,,,,,A 2-noise-burst stimulation protocol was designed in MATLAB (Version R2008a),Generic bioinformatics/stats tool: MATLAB
LSM 700,computational_tools,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LSM 700,Analysis Software,,,,,,,,,,,,,,,,"To acquire high resolution z-stack images of the calyces, a laser scanning confocal microscope (LSM 700; Zeiss)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Volocity 4.2,computational_tools,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Volocity 4.2,Analysis Software,4.2,,,,,,,,,,,,,,,The number of swellings per calyx was counted on 3D-rendered (Volocity 4.2; Improvision) images of calyces,Software name not in publication title — likely generic usage: Volocity 4.2
ImageJ 1.46,computational_tools,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ 1.46,Analysis Software,1.46,,,,,,,,,,,,,,,images of calyx terminals were binary thresholded using the built-in thresholding function of ImageJ 1.46 (isodata algorithm),Generic tool (versioned): ImageJ 1.46
Igor 6.22A,computational_tools,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Igor 6.22A,Analysis Software,6.22A,,,,,,,,,,,,,,,Electrophysiological data was analyzed with a custom written program in Igor 6.22A (WaveMetrics),Software name not in publication title — likely generic usage: Igor 6.22A
NeuroMatic,computational_tools,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,NeuroMatic,Package/Library,2.00,,,,,,,,,,,,,,,"Electrophysiological data was analyzed with a custom written program in Igor 6.22A (WaveMetrics) NeuroMatic (version 2.00, kindly provided by Dr. J. Rothman)",Software name not in publication title — likely generic usage: NeuroMatic
Trim Galore,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Trim Galore,Analysis Software,,https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/,,,,,,,,,,,,,,All WES/WGS/RNA-seq samples were trimmed and quality controlled via Trim Galore (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/),Generic bioinformatics/stats tool: Trim Galore
BWA-MEM,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BWA-MEM,Analysis Software,,,,,,,,,,,,,,,,WES and WGS data were aligned against reference sequence hg38 via BWA-MEM,No version and no repository URL (confidence < 0.9 — unidentifiable)
Disambiguate v1.0,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Disambiguate v1.0,Analysis Software,v1.0,,,,,,,,,,,,,,,"For PDX sequence data, Disambiguate v1.0 was used to filter out mouse-derived reads",Software name not in publication title — likely generic usage: Disambiguate v1.0
Manta,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Manta,Analysis Software,,,,,,,,,,,,,,,,Structural variants (SVs) and large indels were detected using Manta,No version and no repository URL (confidence < 0.9 — unidentifiable)
VarScan2,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VarScan2,Analysis Software,,,,,,,,,,,,,,,,SNVs and small indels were detected using VarScan2,Generic bioinformatics/stats tool: VarScan2
Strelka2,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Strelka2,Analysis Software,,,,,,,,,,,,,,,,"SNVs and small indels were detected using VarScan2, Strelka2",Generic bioinformatics/stats tool: Strelka2
MuTect2,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MuTect2,Analysis Software,,,,,,,,,,,,,,,,"SNVs and small indels were detected using VarScan2, Strelka2, MuTect2",Generic bioinformatics/stats tool: MuTect2
Pindel,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Pindel,Analysis Software,,,,,,,,,,,,,,,,"SNVs and small indels were detected using VarScan2, Strelka2, MuTect2, and Pindel",No version and no repository URL (confidence < 0.9 — unidentifiable)
Variant Effect Predictor (VEP),computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Variant Effect Predictor (VEP),Analysis Software,version 95,,,,,,,,,,,,,,,includes best-practices variant filtering and annotation with Variant Effect Predictor (VEP; version 95),Software name not in publication title — likely generic usage: Variant Effect Predictor (VEP)
GenVisR,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GenVisR,Analysis Software,,,,,,,,,,,,,,,,Waterfall somatic variant plots were created with GenVisR,No version and no repository URL (confidence < 0.9 — unidentifiable)
Xenosplit,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Xenosplit,Analysis Software,,,,,,,,,,,,,,,,Mouse-derived reads were filtered using Xenosplit,No version and no repository URL (confidence < 0.9 — unidentifiable)
PartekFlow,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PartekFlow,Analysis Software,,,,,,,,,,,,,,,,RNA reads were quantified by using the expectation-maximization (EM) quantification on PartekFlow,No version and no repository URL (confidence < 0.9 — unidentifiable)
DESeq2,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2,Package/Library,,,,,,,,,,,,,,,,Gene counts and transcript counts were normalized by using the DESeq2 package,Generic bioinformatics/stats tool: DESeq2
CNVkit,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CNVkit,Analysis Software,,,,,,,,,,,,,,,,CNVkit was used to infer and visualize copy number from high-throughput WGS data,Generic bioinformatics/stats tool: CNVkit
Cell Ranger,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cell Ranger,Pipeline,version 3.1.0,,,,,,,,,,,,,,,The standard 10X Genomics Cell Ranger (version 3.1.0) pipeline was used to extract FASTQ files,Software name not in publication title — likely generic usage: Cell Ranger
Seurat,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat,Package/Library,version 3.0,,,,,,,,,,,,,,,filtered_feature_bc_matrix was imported using the Read10X function in Seurat (version 3.0),Software name not in publication title — likely generic usage: Seurat
inferCNV,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,inferCNV,Package/Library,,https://github.com/broadinstitute/infercnv,,,,,,,,,,,,,,Copy number variations of each PDX were inferred from scRNA-seq using the R package inferCNV,Software name not in publication title — likely generic usage: inferCNV
UPhyloplot2,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,UPhyloplot2,Analysis Software,,https://github.com/harbourlab/UPhyloplot2,,,,,,,,,,,,,,The Uphyloplot2 (https://github.com/harbourlab/UPhyloplot2) was used to visualize the clonality,Software name not in publication title — likely generic usage: UPhyloplot2
HISAT2 version 2.2.1,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HISAT2 version 2.2.1,Analysis Software,2.2.1,,,,,,,,,,,,,,,"To align the reads, we employed HISAT2 version 2.2.1 against the GRCh38 human genome",Software name not in publication title — likely generic usage: HISAT2 version 2.2.1
StringTie version 2.2.1,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,StringTie version 2.2.1,Analysis Software,2.2.1,,,,,,,,,,,,,,,Read counts were normalized by StringTie version 2.2.1,Software name not in publication title — likely generic usage: StringTie version 2.2.1
DEGseq version 1.48.0,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DEGseq version 1.48.0,Package/Library,1.48.0,,,,,,,,,,,,,,,Differential expression analysis was analyzed by DEGseq version 1.48.0,Software name not in publication title — likely generic usage: DEGseq version 1.48.0
ClusterProfiler version 4.2.2,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ClusterProfiler version 4.2.2,Package/Library,4.2.2,,,,,,,,,,,,,,,the GSEA KEGG method with ClusterProfiler version 4.2.2 was applied,Software name not in publication title — likely generic usage: ClusterProfiler version 4.2.2
STRING version 11.5,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STRING version 11.5,Web Application,11.5,https://string-db.org/,,,,,,,,,,,,,,protein–protein interaction analysis using STRING version 11.5,Generic tool (versioned): STRING version 11.5
FlowJo™ software v10.8,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FlowJo™ software v10.8,Analysis Software,10.8,,,,,,,,,,,,,,,The data were analyzed by v10.8 of FlowJo™ software,Software name not in publication title — likely generic usage: FlowJo™ software v10.8
Seahorse Wave Pro software,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Seahorse Wave Pro software,Analysis Software,,,,,,,,,,,,,,,,"The analysis was performed with Seahorse Wave Pro software (Agilent Technologies, Santa Clara, CA, USA)",Software name not in publication title — likely generic usage: Seahorse Wave Pro software
GraphPad Prism version 9,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 9,Analysis Software,9,,,,,,,,,,,,,,,The analysis was performed using GraphPad Prism version 9,Generic tool (versioned): GraphPad Prism version 9
FASTQC,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FASTQC,Analysis Software,,,,,,,,,,,,,,,,"RNA sequencing was carried out on a NovaSeq 6000 system, and the read quality was checked with FASTQC",Generic bioinformatics/stats tool: FASTQC
Agilent Tapestation 4200,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Agilent Tapestation 4200,Analysis Software,,,,,,,,,,,,,,,,Fragmented gDNAs were tested for size distribution and concentration using an Agilent Tapestation 4200 and Qubit dsDNA High Sensitivity kit.,Software name not in publication title — likely generic usage: Agilent Tapestation 4200
Illumina NextSeq550Dx,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina NextSeq550Dx,Analysis Software,,,,,,,,,,,,,,,,"The samples were then sequenced on an Illumina NextSeq550Dx, which generated paired-end reads of 151 bp.",Sequencing hardware or generic assay protocol: Illumina NextSeq550Dx
Varsome Clinical Software v.12.3.2,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Varsome Clinical Software v.12.3.2,Analysis Software,v.12.3.2,,,,,,,,,,,,,,,"Candidate somatic variants, consisting of point mutations, insertions, and deletions were sorted out with Varsome Clinical Software v.12.3.2 (Saphetor, Lausanne, Switzerland).",Software name not in publication title — likely generic usage: Varsome Clinical Software v.12.3.2
Plotly v4.9.3,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Plotly v4.9.3,Package/Library,v4.9.3,https://plotly-r.com,,,,,,,,,,,,,,The VAF plot was generated using Plotly v4.9.3 in the R environment (available from https://plotly-r.com).,Software name not in publication title — likely generic usage: Plotly v4.9.3
CNVKit version 0.9.11,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CNVKit version 0.9.11,Analysis Software,0.9.11,,,,,,,,,,,,,,,"Finally, to determine the profiles of the alterations in the number of copies, the CNV calling was also performed using the CNVKit version 0.9.11.",Software name not in publication title — likely generic usage: CNVKit version 0.9.11
ggplot2 v3.5.1,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ggplot2 v3.5.1,Package/Library,v3.5.1,https://ggplot2.tidyverse.org,,,,,,,,,,,,,,The output was then visualized using ggplot2 v3.5.1 (https://ggplot2.tidyverse.org).,Software name not in publication title — likely generic usage: ggplot2 v3.5.1
GEPIA,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GEPIA,Web Application,,http://gepia.cancer-pku.cn/,,,,,,,,,,,,,,"Kaplan–Meier survival curves were generated using GEPIA (http://gepia.cancer-pku.cn/) on the TCGA-SARC, TCGA-LUAD and TCGA-LUSC RNA-seq expression dataset.",Software name not in publication title — likely generic usage: GEPIA
Cluster Profiler v.4.0,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cluster Profiler v.4.0,Package/Library,v.4.0,,,,,,,,,,,,,,,"Gene Ontology (GO) and pathway enrichment analysis was performed using Cluster Profiler v.4.0, selecting statistically significant terms and pathways.",Software name not in publication title — likely generic usage: Cluster Profiler v.4.0
UpSetR Version 1.4.0,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,UpSetR Version 1.4.0,Package/Library,1.4.0,,,,,,,,,,,,,,,Visualization of intersecting sets was performed with UpSetR Version 1.4.0 (R package).,Generic tool (versioned): UpSetR Version 1.4.0
XGBoost,computational_tools,PMID:39845289,10.1093/jamiaopen/ooae157,Evaluating dimensionality reduction of comorbidities for predictive modeling in individuals with neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,XGBoost,Analysis Software,,,,,,,,,,,,,,,,"We compared the performance of logistic regression, XGBoost, and random forest models utilizing each feature set.",No version and no repository URL (confidence < 0.9 — unidentifiable)
Yellowbrick,computational_tools,PMID:39845289,10.1093/jamiaopen/ooae157,Evaluating dimensionality reduction of comorbidities for predictive modeling in individuals with neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Yellowbrick,Package/Library,,,,,,,,,,,,,,,,"Yellowbrick, a ML visualization library, was used for this purpose.",No version and no repository URL (confidence < 0.9 — unidentifiable)
HoloViews,computational_tools,PMID:39845289,10.1093/jamiaopen/ooae157,Evaluating dimensionality reduction of comorbidities for predictive modeling in individuals with neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HoloViews,Package/Library,,,,,,,,,,,,,,,,"HoloViews, a data analysis and visualization library, was used to generate the shared feature plots.",No version and no repository URL (confidence < 0.9 — unidentifiable)
Clinical Classifications Software Refined,computational_tools,PMID:39845289,10.1093/jamiaopen/ooae157,Evaluating dimensionality reduction of comorbidities for predictive modeling in individuals with neurofibromatosis type 1.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Clinical Classifications Software Refined,Analysis Software,,,,,,,,,,,,,,,,"We used Phecode and CCSR, aggregation and reduction methods that group ICD-10 codes into standardized, clinically meaningful concepts",No version and no repository URL (confidence < 0.9 — unidentifiable)
Phecode,computational_tools,PMID:39845289,10.1093/jamiaopen/ooae157,Evaluating dimensionality reduction of comorbidities for predictive modeling in individuals with neurofibromatosis type 1.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Phecode,Analysis Software,,,,,,,,,,,,,,,,"We used Phecode and CCSR, aggregation and reduction methods that group ICD-10 codes into standardized, clinically meaningful concepts",No version and no repository URL (confidence < 0.9 — unidentifiable)
CellTiter-Blue® assay,computational_tools,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CellTiter-Blue® assay,Analysis Software,,,,,,,,,,,,,,,,"Viability of MPNST cell lines S462, NSF1, and T265 in response to increasing doses (0-120 μM) of 3-BrPA was analyzed by CellTiter-Blue® assay",No version and no repository URL (confidence < 0.9 — unidentifiable)
MATLAB® version R2007a,computational_tools,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,MATLAB® version R2007a,Analysis Software,R2007a,,,,,,,,,,,,,,,"statistical hypothesis testing were performed by the software package MATLAB®, version R2007a (The MathWorks, Inc., Natick, MA, USA)",Software name not in publication title — likely generic usage: MATLAB® version R2007a
pathoZoom®,computational_tools,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,pathoZoom®,Analysis Software,,,,,,,,,,,,,,,,"Ki67 labelling was analysed conventionally as well as using analysis software pathoZoom® (smart in media, Köln, Germany)",No version and no repository URL (confidence < 0.9 — unidentifiable)
DAKO Autostainer Link 48,computational_tools,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,DAKO Autostainer Link 48,Other,,,,,,,,,,,,,,,,Analyses were performed using standard protocols according to the manufacturer's instructions on an autostainer (DAKO Autostainer Link 48),No version and no repository URL (confidence < 0.9 — unidentifiable)
SynergyFinder,computational_tools,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SynergyFinder,Analysis Software,,,,,,,,,,,,,,,,data analyzed using SynergyFinder (RRID: SCR-019318),Software name not in publication title — likely generic usage: SynergyFinder
ImageJ,computational_tools,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ,Analysis Software,,,,,,,,,,,,,,,,Densitometry quantification was performed using ImageJ (RRID: SCR_003070),Generic bioinformatics/stats tool: ImageJ
FlowJo v10,computational_tools,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FlowJo v10,Analysis Software,v10,,,,,,,,,,,,,,,"data analyzed using FlowJo v10 (Becton Dickinson, RRID: SCR_008520)",Software name not in publication title — likely generic usage: FlowJo v10
salmon,computational_tools,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,salmon,Analysis Software,1.4.0,,,,,,,,,,,,,,,quantified reads to the GENCODE M19 transcriptome using 'salmon' (1.4.0) aligner (RRID: SCR_017036),Generic bioinformatics/stats tool: salmon
DESeq2,computational_tools,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DESeq2,Analysis Software,1.24.0,,,,,,,,,,,,,,,Differential gene expression analysis was then conducted with DESeq2 (1.24.0) (RRID: SCR_015687),Generic bioinformatics/stats tool: DESeq2
CIBERSORT,computational_tools,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CIBERSORT,Analysis Software,,,,,,,,,,,,,,,,DEGs were mapped to their human orthologs and were further analyzed using CIBERSORT (RRID: SCR_016955),Software name not in publication title — likely generic usage: CIBERSORT
iPathwayGuide,computational_tools,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,iPathwayGuide,Analysis Software,,,,,,,,,,,,,,,,DEGs were analyzed using 'iPathwayGuide' software (Advaita Bioinformatics),No version and no repository URL (confidence < 0.9 — unidentifiable)
ImageJ (v1.48),computational_tools,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ (v1.48),Analysis Software,v1.48,,,,,,,,,,,,,,,The volume of tumour spheroids was measured using ImageJ (v1.48) software,Generic tool (versioned): ImageJ (v1.48)
HALO (Indica Labs),computational_tools,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HALO (Indica Labs),Analysis Software,,,,,,,,,,,,,,,,"HALO (Indica Labs) or Aperio (Leica Biosystems, Wetzlar, Germany) Image Analysis software was used",Software name not in publication title — likely generic usage: HALO (Indica Labs)
Aperio Image Analysis (Leica Biosystems),computational_tools,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Aperio Image Analysis (Leica Biosystems),Analysis Software,,,,,,,,,,,,,,,,"HALO (Indica Labs) or Aperio (Leica Biosystems, Wetzlar, Germany) Image Analysis software was used",Software name not in publication title — likely generic usage: Aperio Image Analysis (Leica Biosystems)
Incucyte system (Essen Bioscience),computational_tools,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Incucyte system (Essen Bioscience),Analysis Software,,,,,,,,,,,,,,,,"then the cells were allowed to recover for 2 h prior to beginning imaging with the Incucyte system (Essen Bioscience, Ann Arbor, MI, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Studylog system software (Pacifica),computational_tools,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Studylog system software (Pacifica),Analysis Software,,,,,,,,,,,,,,,,"The animals were then randomised based on tumour size using matched distribution analysis from Studylog system software (Pacifica, CA, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
RUMM2030,computational_tools,PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,RUMM2030,Analysis Software,,,,,,,,,,,,,,,,"Rasch analysis was conducted using the RUMM2030 programme (Andrich et al., 2010)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Children's Tumor Foundation Patient Registry,computational_tools,PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Children's Tumor Foundation Patient Registry,Database,,,,,,,,,,,,,,,,patients were recruited through the Children's Tumor Foundation Patient Registry (https://nfregistry.patientcrossroads.org),No version and no repository URL (confidence < 0.9 — unidentifiable)
XF96 Extracellular Flux Analyzer (Agilent Technologies),computational_tools,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,XF96 Extracellular Flux Analyzer (Agilent Technologies),Analysis Software,,,,,,,,,,,,,,,,Oxygen consumption rate (OCR) was measured in schwannoma and normal Schwann cells 24 h post protein delivery using an XF96 Extracellular Flux Analyzer,Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
LSM780 NLO confocal microscope (Carl Zeiss AG),computational_tools,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LSM780 NLO confocal microscope (Carl Zeiss AG),Analysis Software,,,,,,,,,,,,,,,,"Fluorescence images were collected using an inverted confocal microscope (Cat. no. LSM780 NLO, Carl Zeiss AG, Dublin, CA, USA)",Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
"Cytation 5 instrument equipped with Gen5 software (Biotek, Agilent)",computational_tools,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"Cytation 5 instrument equipped with Gen5 software (Biotek, Agilent)",Analysis Software,,,,,,,,,,,,,,,,"All nuclei per well were imaged and counted using a Cytation 5 instrument equipped with Gen5 software (Biotek, Agilent)",Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
Image J software,computational_tools,PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Image J software,Analysis Software,,,,,,,,,,,,,,,,LacZ positive cell number and bone perimeter were quantified with the multipoint tool and segmented line measurement function of Image J software,Publication title lacks NF-specific terms: Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone
FACSCanto,computational_tools,PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FACSCanto,Analysis Software,,,,,,,,,,,,,,,,Cells were analyzed on a FACSCanto (BD Biosciences) instrument,Publication title lacks NF-specific terms: Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone
eXplore Locus SP,computational_tools,PMID:25639352,10.1002/jbmr.2447,Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,eXplore Locus SP,Analysis Software,,,,,,,,,,,,,,,,analyzed by microcomputed tomography using an eXplore Locus SP (GE Healthcare Pre-Clinical Imaging),Publication title lacks NF-specific terms: Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone
R Studio version 2022.02.3,computational_tools,PMID:36604703,10.1186/s13023-022-02607-z,The German version of the neurofibromatosis 2 impact on quality of life questionnaire correlates with severity of depression and physician-reported disease severity.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R Studio version 2022.02.3,Analysis Software,2022.02.3,,,,,,,,,,,,,,,"R Studio version 2022.02.3 was utilised for descriptive statistics, Cronbach's α and Pearson's correlation analyses",Software name not in publication title — likely generic usage: R Studio version 2022.02.3
lordif,computational_tools,PMID:38170419,10.1007/s11136-023-03574-z,Development of the PROMIS pediatric stigma and extension to the PROMIS pediatric stigma: skin item banks.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,lordif,Package/Library,,,,,,,,,,,,,,,,"DIF was conducted using lordif, a hybrid logistic ordinal regression/IRT ability score framework",Publication title lacks NF-specific terms: Development of the PROMIS pediatric stigma and extension to the PROMIS pediatric
Assay-by-Design,computational_tools,PMID:18188004,10.4161/epi.3.1.5469,Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows balanced expression from the maternal and paternal chromosomes and strain-specific variation in expression levels.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Assay-by-Design,Analysis Software,,,,,,,,,,,,,,,,We designed Taqman assays for these SNPs using Assay-by-Design or Primer-Express software,Publication title lacks NF-specific terms: Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows
Primer-Express,computational_tools,PMID:18188004,10.4161/epi.3.1.5469,Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows balanced expression from the maternal and paternal chromosomes and strain-specific variation in expression levels.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Primer-Express,Analysis Software,,,,,,,,,,,,,,,,We designed Taqman assays for these SNPs using Assay-by-Design or Primer-Express software,Publication title lacks NF-specific terms: Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows
GraphPad Prism 4.0a,computational_tools,PMID:18188004,10.4161/epi.3.1.5469,Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows balanced expression from the maternal and paternal chromosomes and strain-specific variation in expression levels.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism 4.0a,Analysis Software,4.0a,,,,,,,,,,,,,,,using the LINEST function in Excel or regression analysis in GraphPad Prism 4.0a,Publication title lacks NF-specific terms: Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows
"ABI Prism 7700 sequence detection system (Applied Biosystems, Foster City, Calif, USA)",computational_tools,PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"ABI Prism 7700 sequence detection system (Applied Biosystems, Foster City, Calif, USA)",Analysis Software,,,,,,,,,,,,,,,,"real-time quantitative RT-PCR using the ABI Prism 7700 sequence detection system (Applied Biosystems, Foster City, Calif, USA) have been described in detail elsewhere","Software name not in publication title — likely generic usage: ABI Prism 7700 sequence detection system (Applied Biosystems, Foster City, Calif, USA)"
HYBrite instrument,computational_tools,PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HYBrite instrument,Analysis Software,,,,,,,,,,,,,,,,The DNA probes and the sections of tissues were denatured at 85°C for 5 minutes using a HYBrite instrument.,No version and no repository URL (confidence < 0.9 — unidentifiable)
"SAS 8.2 software package (SAS Institute Inc, Cary, NC, USA)",computational_tools,PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"SAS 8.2 software package (SAS Institute Inc, Cary, NC, USA)",Analysis Software,8.2,,,,,,,,,,,,,,,"Statistical analyses were performed with the SAS 8.2 software package (SAS Institute Inc, Cary, NC, USA).","Software name not in publication title — likely generic usage: SAS 8.2 software package (SAS Institute Inc, Cary, NC, USA)"
SpliceAI,computational_tools,PMID:34573290,10.3390/genes12091308,Performance Evaluation of SpliceAI for the Prediction of Splicing of ,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SpliceAI,Web Application,,https://spliceailookup.broadinstitute.org/#,,,,,,,,,,,,,,"SpliceAI, a web-based interface (https://spliceailookup.broadinstitute.org/#, accessed on 1 July 2021), was used for splicing prediction.",Publication title lacks NF-specific terms: Performance Evaluation of SpliceAI for the Prediction of Splicing of
gnomAD,computational_tools,PMID:34573290,10.3390/genes12091308,Performance Evaluation of SpliceAI for the Prediction of Splicing of ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,gnomAD,Database,v2.1.1,https://gnomad.broadinstitute.org/,,,,,,,,,,,,,,"allele frequencies were reviewed using gnomAD (v2.1.1, https://gnomad.broadinstitute.org/, accessed on 1 July 2021)",Publication title lacks NF-specific terms: Performance Evaluation of SpliceAI for the Prediction of Splicing of
Human Genome Variation Database (HGMD),computational_tools,PMID:34573290,10.3390/genes12091308,Performance Evaluation of SpliceAI for the Prediction of Splicing of ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Human Genome Variation Database (HGMD),Database,Professional release 2021.2,,,,,,,,,,,,,,,Previous reports of NF1 variants were reviewed using Human Genome Variation Database (HGMD® Professional release 2021.2),Publication title lacks NF-specific terms: Performance Evaluation of SpliceAI for the Prediction of Splicing of
ClinVar,computational_tools,PMID:34573290,10.3390/genes12091308,Performance Evaluation of SpliceAI for the Prediction of Splicing of ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ClinVar,Database,,https://www.ncbi.nlm.nih.gov/clinvar/,,,,,,,,,,,,,,"Previous reports of NF1 variants were reviewed using...ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/, accessed on 1 July 2021)",Publication title lacks NF-specific terms: Performance Evaluation of SpliceAI for the Prediction of Splicing of
Leiden Open Variation Database (LOVD),computational_tools,PMID:34573290,10.3390/genes12091308,Performance Evaluation of SpliceAI for the Prediction of Splicing of ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Leiden Open Variation Database (LOVD),Database,,https://databases.lovd.nl/shared/variants/NF1,,,,,,,,,,,,,,Previous reports of NF1 variants were reviewed using...Leiden Open Variation Database (LOVD; https://databases.lovd.nl/shared/variants/NF1),Publication title lacks NF-specific terms: Performance Evaluation of SpliceAI for the Prediction of Splicing of
NanoDrop,computational_tools,PMID:34573290,10.3390/genes12091308,Performance Evaluation of SpliceAI for the Prediction of Splicing of ,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NanoDrop,Analysis Software,,,,,,,,,,,,,,,,"The concentration and purity of the DNA were measured using NanoDrop (Thermo Fisher Scientific, Waltham, MA, USA)",Publication title lacks NF-specific terms: Performance Evaluation of SpliceAI for the Prediction of Splicing of
GeneAmp PCR System 9700 Thermal Cycler,computational_tools,PMID:34573290,10.3390/genes12091308,Performance Evaluation of SpliceAI for the Prediction of Splicing of ,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GeneAmp PCR System 9700 Thermal Cycler,Analysis Software,,,,,,,,,,,,,,,,Amplification of NF1 cDNA was performed through 24 overlapping fragments using the GeneAmp PCR System 9700 Thermal Cycler (Applied Biosystems),Publication title lacks NF-specific terms: Performance Evaluation of SpliceAI for the Prediction of Splicing of
ABI 3730xl DNA Analyzer,computational_tools,PMID:34573290,10.3390/genes12091308,Performance Evaluation of SpliceAI for the Prediction of Splicing of ,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ABI 3730xl DNA Analyzer,Analysis Software,,,,,,,,,,,,,,,,sequence traces were obtained on an ABI 3730xl DNA Analyzer (Applied Biosystems),Publication title lacks NF-specific terms: Performance Evaluation of SpliceAI for the Prediction of Splicing of
Sequencher software,computational_tools,PMID:34573290,10.3390/genes12091308,Performance Evaluation of SpliceAI for the Prediction of Splicing of ,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Sequencher software,Analysis Software,,,,,,,,,,,,,,,,"Sequence variations were detected through Sequencher software (Gene Codes, Ann Arbor, MI, USA)",Publication title lacks NF-specific terms: Performance Evaluation of SpliceAI for the Prediction of Splicing of
MES,computational_tools,PMID:34573290,10.3390/genes12091308,Performance Evaluation of SpliceAI for the Prediction of Splicing of ,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MES,Analysis Software,,,,,,,,,,,,,,,,"For the comparison of the performance of the SpliceAI with other in silico splicing prediction tools, MES [16] and SSF [17], two commonly used algorithms",Publication title lacks NF-specific terms: Performance Evaluation of SpliceAI for the Prediction of Splicing of
SSF,computational_tools,PMID:34573290,10.3390/genes12091308,Performance Evaluation of SpliceAI for the Prediction of Splicing of ,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SSF,Analysis Software,,,,,,,,,,,,,,,,"For the comparison of the performance of the SpliceAI with other in silico splicing prediction tools, MES [16] and SSF [17], two commonly used algorithms",Publication title lacks NF-specific terms: Performance Evaluation of SpliceAI for the Prediction of Splicing of
Alamut Visual v.2.15 software,computational_tools,PMID:34573290,10.3390/genes12091308,Performance Evaluation of SpliceAI for the Prediction of Splicing of ,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Alamut Visual v.2.15 software,Analysis Software,v.2.15,,,,,,,,,,,,,,,"MES [16] and SSF [17], two commonly used algorithms, were conducted using Alamut® Visual v.2.15 software (SOPHiA GENETICS)",Publication title lacks NF-specific terms: Performance Evaluation of SpliceAI for the Prediction of Splicing of
MedCalc Statistical Software,computational_tools,PMID:34573290,10.3390/genes12091308,Performance Evaluation of SpliceAI for the Prediction of Splicing of ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MedCalc Statistical Software,Analysis Software,version 19.0.5,,,,,,,,,,,,,,,"Statistical analyses were performed using MedCalc Statistical Software version 19.0.5 (MedCalc Software, Ostend, Belgium)",Publication title lacks NF-specific terms: Performance Evaluation of SpliceAI for the Prediction of Splicing of
GeneSpring GX v7.3.1 (Agilent Technologies),computational_tools,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GeneSpring GX v7.3.1 (Agilent Technologies),Analysis Software,v7.3.1,,,,,,,,,,,,,,,All statistical comparisons and data visualization were performed using GeneSpring GX v7.3.1 (Agilent Technologies),Software name not in publication title — likely generic usage: GeneSpring GX v7.3.1 (Agilent Technologies)
GenomeStudio (Ilumina),computational_tools,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GenomeStudio (Ilumina),Analysis Software,,,,,,,,,,,,,,,,raw data from Illumina's cnv370-duo and h660w-quad SNP array chips were processed using GenomeStudio (Ilumina),No version and no repository URL (confidence < 0.9 — unidentifiable)
GeneGo's MetaCore,computational_tools,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GeneGo's MetaCore,Analysis Software,,,,,,,,,,,,,,,,We used GeneGo's MetaCore to construct a gene interaction network using the direct interactions network building algorithm,No version and no repository URL (confidence < 0.9 — unidentifiable)
E-CRISP,computational_tools,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,E-CRISP,Web Application,,,,,,,,,,,,,,,,Brd4 sgRNA was designed using E-CRISP software (http://www.e-crisp.org/E-CRISP),No version and no repository URL (confidence < 0.9 — unidentifiable)
BLAST,computational_tools,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BLAST,Web Application,,,,,,,,,,,,,,,,Sequence similarity was assessed using the Basic Local Alignment Search Tool (BLAST) provided by the NCBI,No version and no repository URL (confidence < 0.9 — unidentifiable)
Cytobank,computational_tools,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Cytobank,Analysis Software,,,,,,,,,,,,,,,,Cytobank and FlowJo software (Tree Star) were utilized for data visualization and analyses,No version and no repository URL (confidence < 0.9 — unidentifiable)
FlowJo,computational_tools,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FlowJo,Analysis Software,,,,,,,,,,,,,,,,Cytobank and FlowJo software (Tree Star) were utilized for data visualization and analyses,No version and no repository URL (confidence < 0.9 — unidentifiable)
Illumina Human HT-12 microarray,computational_tools,PMID:26657314,10.1371/journal.pone.0144620,Immortalized Human Schwann Cell Lines Derived From Tumors of Schwannomatosis Patients.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Illumina Human HT-12 microarray,Analysis Software,Unknown,Unknown,,,,,,,,,,,,,,"RNA from SWN tumor samples, SWN cell lines, and normal primary Human Schwann cells were analyzed using the Illumina Human HT-12 microarray covering more than 47,000 transcripts",Software name not in publication title — likely generic usage: Illumina Human HT-12 microarray
Ingenuity iReport software,computational_tools,PMID:26657314,10.1371/journal.pone.0144620,Immortalized Human Schwann Cell Lines Derived From Tumors of Schwannomatosis Patients.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Ingenuity iReport software,Analysis Software,Unknown,Unknown,,,,,,,,,,,,,,"Differences in expression between the two groups were identified using the Ingenuity iReport software, and Nexus Gene expression software.",Software name not in publication title — likely generic usage: Ingenuity iReport software
Nexus Gene expression software,computational_tools,PMID:26657314,10.1371/journal.pone.0144620,Immortalized Human Schwann Cell Lines Derived From Tumors of Schwannomatosis Patients.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Nexus Gene expression software,Analysis Software,Unknown,Unknown,,,,,,,,,,,,,,"Differences in expression between the two groups were identified using the Ingenuity iReport software, and Nexus Gene expression software.",Software name not in publication title — likely generic usage: Nexus Gene expression software
DAVID gene ontology software,computational_tools,PMID:26657314,10.1371/journal.pone.0144620,Immortalized Human Schwann Cell Lines Derived From Tumors of Schwannomatosis Patients.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DAVID gene ontology software,Web Application,Unknown,www.david.abcc.ncifcrf.gov,,,,,,,,,,,,,,Functional gene groupings were complied using DAVID gene ontology software www.david.abcc.ncifcrf.gov,Software name not in publication title — likely generic usage: DAVID gene ontology software
Osirix software (Pixmeo SARL; v10.0.0),computational_tools,PMID:34604751,10.1093/noajnl/vdab116,Feasibility of magnetic resonance-guided high-intensity focused ultrasound treatment targeting distinct nodular lesions in neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Osirix software (Pixmeo SARL; v10.0.0),Analysis Software,v10.0.0,,,,,,,,,,,,,,,"Osirix software (Pixmeo SARL; v10.0.0) was used for all evaluations and measurements. Whole-body MRIs were closely examined, identifying all lesions meeting criteria for DNL.",Software name not in publication title — likely generic usage: Osirix software (Pixmeo SARL; v10.0.0)
Siemens SOMATOM Force CT scanner,computational_tools,PMID:32193437,10.1038/s41598-020-61251-4,Longitudinal phenotype development in a minipig model of neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Siemens SOMATOM Force CT scanner,Analysis Software,,,,,,,,,,,,,,,,"A non-contrast enhanced, full body screening CT was acquired at TP1 and TP3 using a Siemens SOMATOM Force CT scanner (Siemens Healthcare, Forcheim, Germany)",No version and no repository URL (confidence < 0.9 — unidentifiable)
GE Discovery MI PET/CT,computational_tools,PMID:32193437,10.1038/s41598-020-61251-4,Longitudinal phenotype development in a minipig model of neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GE Discovery MI PET/CT,Analysis Software,,,,,,,,,,,,,,,,"using a Siemens SOMATOM Force CT scanner (Siemens Healthcare, Forcheim, Germany) or a GE Discovery MI PET/CT (GE Healthcare, Waukesha, WI)",No version and no repository URL (confidence < 0.9 — unidentifiable)
General Electric Discovery MR750w,computational_tools,PMID:32193437,10.1038/s41598-020-61251-4,Longitudinal phenotype development in a minipig model of neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,General Electric Discovery MR750w,Analysis Software,,,,,,,,,,,,,,,,MR imaging was performed at all timepoints using a 3.0 T General Electric Discovery MR750w,No version and no repository URL (confidence < 0.9 — unidentifiable)
3D Slicer,computational_tools,PMID:32193437,10.1038/s41598-020-61251-4,Longitudinal phenotype development in a minipig model of neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,3D Slicer,Analysis Software,,https://www.slicer.org/,,,,,,,,,,,,,,skeletal measurements were taken with tools available in 3D Slicer (https://www.slicer.org/) to identify any developmental abnormalities,Software name not in publication title — likely generic usage: 3D Slicer
Primer SP MRI-Compatible Veterinary Anesthesia Ventilator,computational_tools,PMID:32193437,10.1038/s41598-020-61251-4,Longitudinal phenotype development in a minipig model of neurofibromatosis type 1.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Primer SP MRI-Compatible Veterinary Anesthesia Ventilator,Other,,,,,,,,,,,,,,,,mechanically ventilated using a Primer SP MRI-Compatible Veterinary Anesthesia Ventilator (DRE Veterinary),No version and no repository URL (confidence < 0.9 — unidentifiable)
PIXImus II,computational_tools,PMID:21980365,10.1371/journal.pone.0024917,The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PIXImus II,Analysis Software,,,,,,,,,,,,,,,,"bone mineral density (BMD) of the tibial diaphysis was evaluated in vivo using pDEXA (PIXImus II; GE-Lunar Corp., Madison, WI)",No version and no repository URL (confidence < 0.9 — unidentifiable)
μCT-20,computational_tools,PMID:21980365,10.1371/journal.pone.0024917,The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,μCT-20,Analysis Software,,,,,,,,,,,,,,,,"high-resolution desktop microcomputed tomography imaging system (μCT-20; Scanco Medical AG, Basserdorf, Switzerland)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Image Pro Plus version 4.1,computational_tools,PMID:21980365,10.1371/journal.pone.0024917,The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Image Pro Plus version 4.1,Analysis Software,4.1,,,,,,,,,,,,,,,"using Image Pro Plus version 4.1 software (Media Cybernetics, Silver Spring, MD)",Software name not in publication title — likely generic usage: Image Pro Plus version 4.1
ABI 3130 xl Genetic Analyzer,computational_tools,PMID:22916147,10.1371/journal.pone.0042682,Applying microsatellite multiplex PCR analysis (MMPA) for determining allele copy-number status and percentage of normal cells within tumors.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ABI 3130 xl Genetic Analyzer,Analysis Software,,,,,,,,,,,,,,,,PCR fragments were separated by capillary electrophoresis on an ABI 3130 xl Genetic Analyzer,Publication title lacks NF-specific terms: Applying microsatellite multiplex PCR analysis (MMPA) for determining allele cop
Peak Scanner software (Applied Biosystems),computational_tools,PMID:22916147,10.1371/journal.pone.0042682,Applying microsatellite multiplex PCR analysis (MMPA) for determining allele copy-number status and percentage of normal cells within tumors.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Peak Scanner software (Applied Biosystems),Analysis Software,,,,,,,,,,,,,,,,Peak height values for each microsatellite allele were extracted using Peak Scanner software (Applied Biosystems),Publication title lacks NF-specific terms: Applying microsatellite multiplex PCR analysis (MMPA) for determining allele cop
mmpa.rb,computational_tools,PMID:22916147,10.1371/journal.pone.0042682,Applying microsatellite multiplex PCR analysis (MMPA) for determining allele copy-number status and percentage of normal cells within tumors.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,mmpa.rb,Command-line Tool,,http://www.imppc.org/research-activities/genetic-variation-and-cancer/mmpa.html,,,,,,,,,,,,,,This automated analysis has been implemented using the Ruby programming language in a script named mmpa.rb,Publication title lacks NF-specific terms: Applying microsatellite multiplex PCR analysis (MMPA) for determining allele cop
Global Parameter Hidden Markov Model (GPHMM) algorithm,computational_tools,PMID:22916147,10.1371/journal.pone.0042682,Applying microsatellite multiplex PCR analysis (MMPA) for determining allele copy-number status and percentage of normal cells within tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Global Parameter Hidden Markov Model (GPHMM) algorithm,Analysis Software,,,,,,,,,,,,,,,,by applying a Global Parameter Hidden Markov Model (GPHMM) algorithm that quantitatively models signal baseline shift,Publication title lacks NF-specific terms: Applying microsatellite multiplex PCR analysis (MMPA) for determining allele cop
Slidebook (v5.0),computational_tools,PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Slidebook (v5.0),Analysis Software,v5.0,,,,,,,,,,,,,,,"images were acquired with a monochrome camera (Hamamatsu, OrcaER) using Slidebook (v5.0) software",Software name not in publication title — likely generic usage: Slidebook (v5.0)
ViCell XR,computational_tools,PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ViCell XR,Analysis Software,,,,,,,,,,,,,,,,viable total cell number determined by ViCell XR (Beckman),No version and no repository URL (confidence < 0.9 — unidentifiable)
Kaplan-Meier Plotter version 2013,computational_tools,PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Kaplan-Meier Plotter version 2013,Web Application,2013,,,,,,,,,,,,,,,Expression array data was evaluated using the Kaplan-Meier Plotter version 2013 ( http://www.kmplot.com/ovar ),Software name not in publication title — likely generic usage: Kaplan-Meier Plotter version 2013
GraphPad Prism Software (v5.0d),computational_tools,PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism Software (v5.0d),Analysis Software,v5.0d,,,,,,,,,,,,,,,"Differences between pairs of data were determined using an unpaired two-tailed student's t test (GraphPad Prism Software, v5.0d)",Generic tool (versioned): GraphPad Prism Software (v5.0d)
Secreted Protein Database,computational_tools,PMID:20739432,10.1158/1078-0432.CCR-10-0613,Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Secreted Protein Database,Database,,,,,,,,,,,,,,,,"We generated a list of candidate secreted NF1 biomarkers by intersecting genes statistically differentially expressed between cultured normal human Schwann cells (NHSC), Schwann cells derived from neurofibroma, and MPNST cell lines with proteins cataloged in the Secreted Protein Database",No version and no repository URL (confidence < 0.9 — unidentifiable)
GSE14038,computational_tools,PMID:20739432,10.1158/1078-0432.CCR-10-0613,Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GSE14038,Database,,,,,,,,,,,,,,,,The data underlying this analysis can be accessed in Gene Expression Omnibus (accession number GSE14038 at http://www.ncbi.nlm.nih.gov ),Software name not in publication title — likely generic usage: GSE14038
GeneSpring GX v7.3.1,computational_tools,PMID:20739432,10.1158/1078-0432.CCR-10-0613,Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GeneSpring GX v7.3.1,Analysis Software,v7.3.1,,,,,,,,,,,,,,,All statistical comparisons and data visualizations were done using GeneSpring GX v7.3.1 (Agilent Technologies),Software name not in publication title — likely generic usage: GeneSpring GX v7.3.1
Primer3 software,computational_tools,PMID:20739432,10.1158/1078-0432.CCR-10-0613,Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Primer3 software,Web Application,,http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi,,,,,,,,,,,,,,We obtained primer sequences using Primer3 software ( http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi ),Software name not in publication title — likely generic usage: Primer3 software
ABI 7500 Sequence Detection System,computational_tools,PMID:20739432,10.1158/1078-0432.CCR-10-0613,Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ABI 7500 Sequence Detection System,Analysis Software,,,,,,,,,,,,,,,,Relative levels of RNA were measured by quantitative real-time PCR (qPCR) using the ABI 7500 Sequence Detection System default settings,No version and no repository URL (confidence < 0.9 — unidentifiable)
ImageJ software,computational_tools,PMID:20739432,10.1158/1078-0432.CCR-10-0613,Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ software,Analysis Software,,,,,,,,,,,,,,,,The area of tube formation was then quantified using ImageJ software,Generic bioinformatics/stats tool: ImageJ software
Paint®,computational_tools,PMID:25475340,10.1186/s13023-014-0202-9,Validity and interexaminer reliability of a new method to quantify skin neurofibromas of neurofibromatosis 1 using paper frames.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Paint®,Analysis Software,,,,,,,,,,,,,,,,"All the pictures were analyzed using the software Paint® (Microsoft Corporation, Redmond, WA, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
SPSS,computational_tools,PMID:25475340,10.1186/s13023-014-0202-9,Validity and interexaminer reliability of a new method to quantify skin neurofibromas of neurofibromatosis 1 using paper frames.,,0.75,Experimental Usage,True,1.00,Low,,,,,,,,,,,,,,,SPSS,Analysis Software,v. 20.0,,,,,,,,,,,,,,,"For statistical analysis, we used the SPSS software (IBM® SPSS®, v. 20.0, Armonk, NY, USA)",Generic bioinformatics/stats tool: SPSS
Excel 2011,computational_tools,PMID:25475340,10.1186/s13023-014-0202-9,Validity and interexaminer reliability of a new method to quantify skin neurofibromas of neurofibromatosis 1 using paper frames.,,0.75,Experimental Usage,True,1.00,Low,,,,,,,,,,,,,,,Excel 2011,Analysis Software,2011,,,,,,,,,,,,,,,"For statistical analysis, we used the SPSS software (IBM® SPSS®, v. 20.0, Armonk, NY, USA) and Excel 2011 (Microsoft Corporation, Redmond, WA, USA)",Software name not in publication title — likely generic usage: Excel 2011
Scanco μCT 40 system,computational_tools,PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Scanco μCT 40 system,Analysis Software,,,,,,,,,,,,,,,,"μCT analyses were performed using a Scanco μCT 40 system (Scanco Medical, Bassersdorf, Switzerland)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Bioquant Analysis System,computational_tools,PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bioquant Analysis System,Analysis Software,,,,,,,,,,,,,,,,"using the Bioquant Analysis System (Nashville, TN, USA) on 5 μm undecalcified methymethacrylate sections",No version and no repository URL (confidence < 0.9 — unidentifiable)
GraphPad PRISM (v6.0a),computational_tools,PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad PRISM (v6.0a),Analysis Software,v6.0a,,,,,,,,,,,,,,,"Statistical analysis was performed using GraphPad PRISM (v6.0a, La Jolla, CA)",Generic tool (versioned): GraphPad PRISM (v6.0a)
STAR 2.4.2a,computational_tools,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR 2.4.2a,Analysis Software,2.4.2a,,,,,,,,,,,,,,,FastQC-passed reads were aligned to the mouse reference genome (mm10) using STAR 2.4.2a (RRID:SCR_004463),Software name not in publication title — likely generic usage: STAR 2.4.2a
Salmon 0.60,computational_tools,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Salmon 0.60,Analysis Software,0.60,,,,,,,,,,,,,,,reads were translated to transcriptome coordinates using Salmon 0.60,Software name not in publication title — likely generic usage: Salmon 0.60
biomaRt,computational_tools,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,biomaRt,Package/Library,,,,,,,,,,,,,,,,Isoform data were collated to single gene IDs using the R package biomaRt (RRID:SCR_019214),No version and no repository URL (confidence < 0.9 — unidentifiable)
Morpheus,computational_tools,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Morpheus,Web Application,,https://software.broadinstitute.org/morpheus/,,,,,,,,,,,,,,"used for unsupervised hierarchical clustering (complete linkage) in Morpheus (https://software.broadinstitute.org/morpheus/, RRID:SCR_017386)",Software name not in publication title — likely generic usage: Morpheus
DESeq2,computational_tools,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2,Package/Library,,,,,,,,,,,,,,,,Abundance values for genes were used as input for DESeq2 (RRID:SCR_000154) to identify differentially expressed genes,Generic bioinformatics/stats tool: DESeq2
ComplexHeatmap,computational_tools,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ComplexHeatmap,Package/Library,,,,,,,,,,,,,,,,Heatmaps were generated using the R package ComplexHeatmap,No version and no repository URL (confidence < 0.9 — unidentifiable)
BioVenn,computational_tools,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BioVenn,Web Application,,,,,,,,,,,,,,,,Venn diagrams were generated with BioVenn (biovenn.nl),No version and no repository URL (confidence < 0.9 — unidentifiable)
MaxQuant LFQ,computational_tools,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MaxQuant LFQ,Analysis Software,,,,,,,,,,,,,,,,Raw files were processed for label-free quantification by MaxQuant LFQ using the Uniprot/Swiss-Prot mouse database,Software name not in publication title — likely generic usage: MaxQuant LFQ
Perseus,computational_tools,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Perseus,Analysis Software,,,,,,,,,,,,,,,,LFQ intensities for kinases with at least two peptides were imported into Perseus,Generic bioinformatics/stats tool: Perseus
Coral,computational_tools,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Coral,Analysis Software,,,,,,,,,,,,,,,,Tree plots of the kinome were generated in Coral,No version and no repository URL (confidence < 0.9 — unidentifiable)
SynergyFinder,computational_tools,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SynergyFinder,Analysis Software,,,,,,,,,,,,,,,,"Synergy graphs and ZIP, Bliss, Loewe, and HSA synergy scores were computed using SynergyFinder",Software name not in publication title — likely generic usage: SynergyFinder
HALO Image Analysis software,computational_tools,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HALO Image Analysis software,Analysis Software,2.0.5,,,,,,,,,,,,,,,Quantitative immunohistochemical analysis was conducted using the Cytonuclear IHC module for HALO Image Analysis software (version 2.0.5),Software name not in publication title — likely generic usage: HALO Image Analysis software
Imaris,computational_tools,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Imaris,Analysis Software,,,,,,,,,,,,,,,,"Images were processed using Imaris (Bitplane, RRID:SCR_007370)",Generic bioinformatics/stats tool: Imaris
PK Solver,computational_tools,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PK Solver,Plugin,,,,,,,,,,,,,,,,Non-compartmental analysis of the data was performed using PK Solver add-ins in Excel,No version and no repository URL (confidence < 0.9 — unidentifiable)
KwikQuant Image Analyzer 5.9,computational_tools,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,KwikQuant Image Analyzer 5.9,Analysis Software,5.9,,,,,,,,,,,,,,,Densitometry analysis for western blots was performed using KwikQuant Image Analyzer 5.9,Software name not in publication title — likely generic usage: KwikQuant Image Analyzer 5.9
NovaSeq 6000,computational_tools,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NovaSeq 6000,Other,,,,,,,,,,,,,,,,Sequencing was performed on a NovaSeq 6000 (Illumina) generating approximately 20 million reads/sample,Sequencing hardware or generic assay protocol: NovaSeq 6000
Trimmomatic,computational_tools,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Trimmomatic,Analysis Software,,,,,,,,,,,,,,,,RNA-seq data was trimmed and aligned with Trimmomatic and HISAT2 to the human genome (hg38),Generic bioinformatics/stats tool: Trimmomatic
HISAT2,computational_tools,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HISAT2,Analysis Software,,,,,,,,,,,,,,,,RNA-seq data was trimmed and aligned with Trimmomatic and HISAT2 to the human genome (hg38),Generic bioinformatics/stats tool: HISAT2
featureCounts,computational_tools,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,featureCounts,Analysis Software,,,,,,,,,,,,,,,,Reads were counted using featureCounts,Generic bioinformatics/stats tool: featureCounts
DESeq2,computational_tools,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2,Package/Library,,,,,,,,,,,,,,,,Differentially expressed genes were identified using DESeq2,Generic bioinformatics/stats tool: DESeq2
EnrichR,computational_tools,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,EnrichR,Web Application,,,,,,,,,,,,,,,,Pathway analysis was performed using EnrichR and gene set enrichment analysis (GSEA),Generic bioinformatics/stats tool: EnrichR
clusterProfiler,computational_tools,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,clusterProfiler,Package/Library,,,,,,,,,,,,,,,,"gene set enrichment analysis (GSEA) as previously described with the R package, clusterProfiler",Generic bioinformatics/stats tool: clusterProfiler
limma,computational_tools,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,limma,Package/Library,,,,,,,,,,,,,,,,Differential methylation of probes was identified with limma,Generic bioinformatics/stats tool: limma
minfi,computational_tools,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,minfi,Package/Library,,,,,,,,,,,,,,,,Filtering and normalization were performed using minfi,No version and no repository URL (confidence < 0.9 — unidentifiable)
Spectrum Mill MS Proteomics Workbench,computational_tools,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Spectrum Mill MS Proteomics Workbench,Analysis Software,,,,,,,,,,,,,,,,Data were analyzed with Spectrum Mill MS Proteomics Workbench,No version and no repository URL (confidence < 0.9 — unidentifiable)
Synthego's Inference of CRISPR Edits analysis tool,computational_tools,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Synthego's Inference of CRISPR Edits analysis tool,Web Application,,https://ice.synthego.com,,,,,,,,,,,,,,Single-cell clones were validated using Western blotting and Synthego's Inference of CRISPR Edits analysis tool (https://ice.synthego.com),Software name not in publication title — likely generic usage: Synthego's Inference of CRISPR Edits analysis tool
CalcuSyn software,computational_tools,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CalcuSyn software,Analysis Software,,,,,,,,,,,,,,,,Combination index values were determined with the median-effect principle using CalcuSyn software (Biosoft),No version and no repository URL (confidence < 0.9 — unidentifiable)
FlowJo,computational_tools,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FlowJo,Analysis Software,,,,,,,,,,,,,,,,Data were analyzed using FlowJo,No version and no repository URL (confidence < 0.9 — unidentifiable)
COMET,computational_tools,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,COMET,Analysis Software,,,,,,,,,,,,,,,,Raw data were searched using COMET against a target-decoy version of the human (Homo sapiens) proteome sequence database,No version and no repository URL (confidence < 0.9 — unidentifiable)
Fiji,computational_tools,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Fiji,Analysis Software,,,,,,,,,,,,,,,,"Image processing was performed with Fiji, built on ImageJ2",Generic bioinformatics/stats tool: Fiji
ImageJ2,computational_tools,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ2,Analysis Software,,,,,,,,,,,,,,,,"Image processing was performed with Fiji, built on ImageJ2",Generic tool (versioned): ImageJ2
R statistical programming language,computational_tools,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R statistical programming language,Analysis Software,,http://www.R-project.org,,,,,,,,,,,,,,TPP-TR analyses were performed using the R statistical programming language (http://www.R-project.org),Software name not in publication title — likely generic usage: R statistical programming language
STAR,computational_tools,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR,Analysis Software,2.3,,,,,,,,,,,,,,,"mapped to the human reference genome (hg19) or mouse reference genome (mm9) using STAR, version 2.3",Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
GSEA,computational_tools,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GSEA,Analysis Software,2.0,,,,,,,,,,,,,,,GSEA was performed using the JAVA GSEA 2.0 program,Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
HOMER,computational_tools,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HOMER,Analysis Software,4.5,,,,,,,,,,,,,,,"Motif signatures were obtained using HOMER, version 4.5",Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
Bowtie2,computational_tools,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Bowtie2,Analysis Software,2.3.5,,,,,,,,,,,,,,,"aligned to the human genome (hg19) using Bowtie2 alignment software, version 2.3.5",Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
MACS2,computational_tools,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MACS2,Analysis Software,2.1.1,,,,,,,,,,,,,,,"Peak calling for H3K27ac was performed using MACS2 software, version 2.1.1",Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
ROSE R package,computational_tools,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ROSE R package,Package/Library,,,,,,,,,,,,,,,,used for SE analysis using the ROSE R package (option: –t 2500),Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
DESeq2,computational_tools,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2,Package/Library,,,,,,,,,,,,,,,,used by DESeq2 software to identify peaks with differential modifications,Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
Image J,computational_tools,PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Image J,Analysis Software,,http://rsbweb.nih.gov/ij/,,,,,,,,,,,,,,"Image J image analysis software ( http://rsbweb.nih.gov/ij/ ; Wayne Rasband, National Institute of Mental Health, Bethesda, MD)",Generic bioinformatics/stats tool: Image J
FlowJo,computational_tools,PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FlowJo,Analysis Software,,,,,,,,,,,,,,,,"data were subsequently analyzed using FlowJo (Tree Star, Inc., Ashland, OR)",Software name not in publication title — likely generic usage: FlowJo
Bio-Rad CFX Manager software,computational_tools,PMID:21157378,10.1097/NEN.0b013e3182032d37,Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bio-Rad CFX Manager software,Analysis Software,,,,,,,,,,,,,,,,Bio-Rad CFX Manager software was used to convert the fluorescent data into cycle threshold (CT) measurements,Software name not in publication title — likely generic usage: Bio-Rad CFX Manager software
AmiGO,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AmiGO,Database,,,,,,,,,,,,,,,,The complete list of NF1 gene ontologies (GO) and phenotype ontologies were obtained in the AmiGO and Human Phenotype Ontology (HPO) databases,No version and no repository URL (confidence < 0.9 — unidentifiable)
Human Phenotype Ontology (HPO),computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Human Phenotype Ontology (HPO),Database,,,,,,,,,,,,,,,,The complete list of NF1 gene ontologies (GO) and phenotype ontologies were obtained in the AmiGO and Human Phenotype Ontology (HPO) databases,No version and no repository URL (confidence < 0.9 — unidentifiable)
STRING database v.11,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STRING database v.11,Database,v.11,,,,,,,,,,,,,,,"Networks were generated using STRING database v.11, comprising protein–protein interactions (PPI) for Homo sapiens",Software name not in publication title — likely generic usage: STRING database v.11
Cytoscape v.3.7.2,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cytoscape v.3.7.2,Analysis Software,v.3.7.2,,,,,,,,,,,,,,,"The assembled networks were transferred to Cytoscape v.3.7.2 software, with which the network statistics was obtained",Software name not in publication title — likely generic usage: Cytoscape v.3.7.2
DyNet application,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DyNet application,Plugin,,,,,,,,,,,,,,,,Comparison between networks was performed with DyNet application for Cytoscape v.3.7.2,No version and no repository URL (confidence < 0.9 — unidentifiable)
PhenomeScape app,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PhenomeScape app,Plugin,,,,,,,,,,,,,,,,"Complex networks comprising HPO selected phenotypes, gene expression, and PPI networks were assembled using the PhenomeScape app, also in Cytoscape v.3.7.2",No version and no repository URL (confidence < 0.9 — unidentifiable)
Gene Expression Omnibus (GEO),computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Gene Expression Omnibus (GEO),Database,,,,,,,,,,,,,,,,RNA-seq and microarray secondary analysis were performed using studies selected in Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases,No version and no repository URL (confidence < 0.9 — unidentifiable)
The Cancer Genome Atlas (TCGA),computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,The Cancer Genome Atlas (TCGA),Database,,,,,,,,,,,,,,,,RNA-seq and microarray secondary analysis were performed using studies selected in Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases,No version and no repository URL (confidence < 0.9 — unidentifiable)
oligo R package,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,oligo R package,Package/Library,,,,,,,,,,,,,,,,the robust multiarray averaging (RMA) normalization was applied using oligo or affy R packages (R v.3.6.2),No version and no repository URL (confidence < 0.9 — unidentifiable)
affy R package,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,affy R package,Package/Library,,,,,,,,,,,,,,,,the robust multiarray averaging (RMA) normalization was applied using oligo or affy R packages (R v.3.6.2),No version and no repository URL (confidence < 0.9 — unidentifiable)
limma package,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,limma package,Package/Library,,,,,,,,,,,,,,,,The differentially expressed genes were obtained using the limma package (R v.3.6.2),No version and no repository URL (confidence < 0.9 — unidentifiable)
TCGAbiolinks package,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,TCGAbiolinks package,Package/Library,,,,,,,,,,,,,,,,The gene expression analysis for TCGA data was performed by extracting the data with TCGAbiolinks package,No version and no repository URL (confidence < 0.9 — unidentifiable)
edgeR package,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,edgeR package,Package/Library,,,,,,,,,,,,,,,,evaluating differential gene expression with edgeR package. All analyses were performed in R v.3.6.2,No version and no repository URL (confidence < 0.9 — unidentifiable)
RandomWalkRestartMH package,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,RandomWalkRestartMH package,Package/Library,,,,,,,,,,,,,,,,"The heterogeneous networks comprising both the genes and phenotypes selected were assembled in the RandomWalkRestartMH package, in R v.3.6.2",No version and no repository URL (confidence < 0.9 — unidentifiable)
BioGrid,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BioGrid,Database,,,,,,,,,,,,,,,,"Other databases consulted to obtain data for the potential NF1 phenotype-modifier genes were: (1) BioGrid, for curated protein interactions",No version and no repository URL (confidence < 0.9 — unidentifiable)
PINOT tool,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PINOT tool,Analysis Software,,,,,,,,,,,,,,,,"(2) PINOT tool, for literature data on curated protein interactions",No version and no repository URL (confidence < 0.9 — unidentifiable)
The Human Reference Protein Interactome (HuRI),computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,The Human Reference Protein Interactome (HuRI),Database,,,,,,,,,,,,,,,,"(4) The Human Reference Protein Interactome (HuRI), for the binary protein–protein interactions",No version and no repository URL (confidence < 0.9 — unidentifiable)
The Genome Aggregation Database (gnomAD) v 2.1.1,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,The Genome Aggregation Database (gnomAD) v 2.1.1,Database,v 2.1.1,,,,,,,,,,,,,,,we consulted The Genome Aggregation Database (gnomAD) v 2.1.1 and the ClinVar archive,Software name not in publication title — likely generic usage: The Genome Aggregation Database (gnomAD) v 2.1.1
ClinVar archive,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ClinVar archive,Database,,,,,,,,,,,,,,,,we consulted The Genome Aggregation Database (gnomAD) v 2.1.1 and the ClinVar archive,No version and no repository URL (confidence < 0.9 — unidentifiable)
AACR Project GENIE,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AACR Project GENIE,Database,,,,,,,,,,,,,,,,"an additional analysis was performed consulting the 79,720 tumor samples made available by the AACR Project GENIE",No version and no repository URL (confidence < 0.9 — unidentifiable)
cBioPortal for Cancer Genomics,computational_tools,PMID:32858845,10.3390/cancers12092416,Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,cBioPortal for Cancer Genomics,Web Application,,,,,,,,,,,,,,,,using the cBioPortal for Cancer Genomics. Samples were filtered according to their mutational status,No version and no repository URL (confidence < 0.9 — unidentifiable)
SAS 9.4,computational_tools,PMID:29415745,10.1186/s13023-018-0772-z,Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SAS 9.4,Analysis Software,9.4,,,,,,,,,,,,,,,"All the analysis was conducted using SAS 9.4 (Cary, NC).",Software name not in publication title — likely generic usage: SAS 9.4
Vitrea2,computational_tools,PMID:19430883,10.1007/s11060-009-9867-7,Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Vitrea2,Analysis Software,,,,,,,,,,,,,,,,"Tumor volumetry will typically be performed centrally in multicenter trials, and should be performed using post-contrast images through the internal auditory canal with the Vitrea2 (Vital Images, Minnetonka, MN) semi-automated segmentation software",Software name not in publication title — likely generic usage: Vitrea2
Storm 860 phosphorimager system,computational_tools,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Storm 860 phosphorimager system,Analysis Software,,,,,,,,,,,,,,,,"Blots were quantitated using ECL + and the Storm 860 phosphorimager system (Molecular Dynamics, Sunnyvale, CA)",Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
Zeiss LSM 510 confocal laser-scanning microscope,computational_tools,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Zeiss LSM 510 confocal laser-scanning microscope,Analysis Software,,,,,,,,,,,,,,,,Sections were analyzed with a Zeiss LSM 510 confocal laser-scanning microscope using a 40× numerical aperture objective,Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
Axopatch 200B amplifier,computational_tools,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Axopatch 200B amplifier,Analysis Software,,,,,,,,,,,,,,,,"Whole-cell voltage-clamp recordings using an Axopatch 200B amplifier (Axon Instruments, Foster City, CA)",Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
3900A Integrating Patch Clamp Amplifier,computational_tools,PMID:18984165,10.1016/j.cell.2008.09.060,Neurofibromin regulation of ERK signaling modulates GABA release and learning.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,3900A Integrating Patch Clamp Amplifier,Analysis Software,,,,,,,,,,,,,,,,"or a 3900A Integrating Patch Clamp Amplifier (Dagan, Minneapolis, MN)",Publication title lacks NF-specific terms: Neurofibromin regulation of ERK signaling modulates GABA release and learning.
Incucyte Live Cell Imaging System,computational_tools,PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Incucyte Live Cell Imaging System,Analysis Software,,,,,,,,,,,,,,,,"Proliferation was monitored using the Incucyte Live Cell Imaging System (Essen Bioscience, Michigan).",No version and no repository URL (confidence < 0.9 — unidentifiable)
ImageJ (versions 1.45 s and 1.8.0_172),computational_tools,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ (versions 1.45 s and 1.8.0_172),Analysis Software,1.45s and 1.8.0_172,,,,,,,,,,,,,,,Neurite extension was measured by determining the length of at least 10–20 neurites per field using the ImageJ (versions 1.45 s and 1.8.0_172),Generic tool (versioned): ImageJ (versions 1.45 s and 1.8.0_172)
NeuronJ,computational_tools,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NeuronJ,Plugin,,,,,,,,,,,,,,,,using the ImageJ (versions 1.45 s and 1.8.0_172; https://imagej.nih.gov/ij/download.html) plugin NeuronJ,Software name not in publication title — likely generic usage: NeuronJ
SpliceAid 2,computational_tools,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SpliceAid 2,Web Application,,,,,,,,,,,,,,,,was analyzed using the online tool SpliceAid 2 to determine RNA sequences predicted to be bound by splicing proteins,Software name not in publication title — likely generic usage: SpliceAid 2
Trimmomatic v0.3,computational_tools,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Trimmomatic v0.3,Analysis Software,v0.3,,,,,,,,,,,,,,,Sequencing data was quality trimmed with Trimmomatic v0.3 then processed with TopHat v 2.0.9,Software name not in publication title — likely generic usage: Trimmomatic v0.3
TopHat v 2.0.9,computational_tools,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,TopHat v 2.0.9,Analysis Software,v 2.0.9,,,,,,,,,,,,,,,Sequencing data was quality trimmed with Trimmomatic v0.3 then processed with TopHat v 2.0.9,Software name not in publication title — likely generic usage: TopHat v 2.0.9
Bowtie2,computational_tools,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bowtie2,Analysis Software,,,,,,,,,,,,,,,,"processed with TopHat v 2.0.9, mapping with Bowtie2 against the Rattus norvergicus reference genome",Generic bioinformatics/stats tool: Bowtie2
gplots R package,computational_tools,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,gplots R package,Package/Library,,,,,,,,,,,,,,,,Heat map plots were generated with the gplots R package,No version and no repository URL (confidence < 0.9 — unidentifiable)
human U133v2 gene chips (Affymetrix),computational_tools,PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,human U133v2 gene chips (Affymetrix),Analysis Software,,,,,,,,,,,,,,,,"To compare gene expression profiles, we used human U133v2 gene chips (Affymetrix) and the probes derived from three independently transduced",Publication title lacks NF-specific terms: Merlin is a potent inhibitor of glioma growth.
ArrayAssist Lite version 3.4 (Stratagene),computational_tools,PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ArrayAssist Lite version 3.4 (Stratagene),Analysis Software,3.4,,,,,,,,,,,,,,,"Probe intensity data were imported to ArrayAssist Lite version 3.4 (Stratagene), and expression values for the probe sets were calculated using GCRMA",Publication title lacks NF-specific terms: Merlin is a potent inhibitor of glioma growth.
GeneSpringGX version 7.3.1 (Agilent),computational_tools,PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GeneSpringGX version 7.3.1 (Agilent),Analysis Software,7.3.1,,,,,,,,,,,,,,,The data were then imported back to GeneSpringGX version 7.3.1 (Agilent) and filtered based on P in at least two of six samples,Publication title lacks NF-specific terms: Merlin is a potent inhibitor of glioma growth.
SAM version 2.2.1 (Stanford University),computational_tools,PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SAM version 2.2.1 (Stanford University),Analysis Software,2.2.1,,,,,,,,,,,,,,,"Finally, SAM version 2.2.1 (Stanford University) was applied using a two-class unpaired analysis, and differentially expressed genes were identified",Publication title lacks NF-specific terms: Merlin is a potent inhibitor of glioma growth.
IVIS-200 imaging system (Xenogen),computational_tools,PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,IVIS-200 imaging system (Xenogen),Analysis Software,,,,,,,,,,,,,,,,bioluminescence images of the intracranial tumors were acquired by using IVIS-200 imaging system (Xenogen) at In vivo Molecular Imaging Shared Facility,Publication title lacks NF-specific terms: Merlin is a potent inhibitor of glioma growth.
Cell Ranger Single Cell Software Suite,computational_tools,PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Cell Ranger Single Cell Software Suite,Analysis Software,,,,,,,,,,,,,,,,Experiment data were demultiplexed using the Cell Ranger Single Cell Software Suite,Software name not in publication title — likely generic usage: Cell Ranger Single Cell Software Suite
R Statistical Software (v4.1.3),computational_tools,PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R Statistical Software (v4.1.3),Analysis Software,v4.1.3,,,,,,,,,,,,,,,Analysis was performed with R Statistical Software (v4.1.3),Software name not in publication title — likely generic usage: R Statistical Software (v4.1.3)
Seurat (v4.2.0),computational_tools,PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat (v4.2.0),Package/Library,v4.2.0,,,,,,,,,,,,,,,Analysis was performed with R Statistical Software (v4.1.3) and Seurat (v4.2.0),Software name not in publication title — likely generic usage: Seurat (v4.2.0)
SCTransform,computational_tools,PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SCTransform,Package/Library,,,,,,,,,,,,,,,,Seurat objects for each dataset were merged then split to create lists that can be transformed and normalized using SCTransform,Software name not in publication title — likely generic usage: SCTransform
ScType,computational_tools,PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ScType,Package/Library,,,,,,,,,,,,,,,,which were automatically identified with ScType using a modified marker list,Software name not in publication title — likely generic usage: ScType
fgsea,computational_tools,PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,fgsea,Package/Library,,,,,,,,,,,,,,,,The Fast Gene Set Enrichment Analysis (fgsea) package was used to analyze enriched pathways,Software name not in publication title — likely generic usage: fgsea
FlowJo software,computational_tools,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FlowJo software,Analysis Software,,,,,,,,,,,,,,,,Data were acquired using Muse flow cytometer (Millipore) and analyzed with FlowJo software,Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
GraphPad,computational_tools,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GraphPad,Analysis Software,,,,,,,,,,,,,,,,"Survival was assessed with Kaplan–Meier curves and statistical analyses made using standard software and statistical packages (GraphPad, San Diego, CA, USA)",Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
R/BioConductor,computational_tools,PMID:28542306,10.1371/journal.pone.0178316,Gene signature associated with benign neurofibroma transformation to malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,R/BioConductor,Analysis Software,,,,,,,,,,,,,,,,Each microarray was preprocessed and evaluated independently using the R/BioConductor software environment,No version and no repository URL (confidence < 0.9 — unidentifiable)
MEDIPS R package,computational_tools,PMID:28542306,10.1371/journal.pone.0178316,Gene signature associated with benign neurofibroma transformation to malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MEDIPS R package,Package/Library,,,,,,,,,,,,,,,,"Methylation data were downloaded from GEO, and inspected and analyzed using the MEDIPS R package",Software name not in publication title — likely generic usage: MEDIPS R package
PANTHER v.10,computational_tools,PMID:28542306,10.1371/journal.pone.0178316,Gene signature associated with benign neurofibroma transformation to malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,PANTHER v.10,Web Application,v.10,,,,,,,,,,,,,,,The over-representation test for GO terms...was performed through PANTHER v.10 (release 20160715),Software name not in publication title — likely generic usage: PANTHER v.10
EnrichNet tool,computational_tools,PMID:28542306,10.1371/journal.pone.0178316,Gene signature associated with benign neurofibroma transformation to malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,EnrichNet tool,Web Application,,,,,,,,,,,,,,,,"The EnrichNet tool was used to inspect KEGG, BioCarta, Wiki Pathways and Reactome databases",No version and no repository URL (confidence < 0.9 — unidentifiable)
SOTA,computational_tools,PMID:28542306,10.1371/journal.pone.0178316,Gene signature associated with benign neurofibroma transformation to malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SOTA,Analysis Software,,,,,,,,,,,,,,,,Genes were grouped using SOTA implemented in the analysis and visualization tool MultiexperimentViewer MeV v. 4.9,No version and no repository URL (confidence < 0.9 — unidentifiable)
MultiexperimentViewer MeV v. 4.9,computational_tools,PMID:28542306,10.1371/journal.pone.0178316,Gene signature associated with benign neurofibroma transformation to malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MultiexperimentViewer MeV v. 4.9,Analysis Software,v. 4.9,,,,,,,,,,,,,,,Genes were grouped using SOTA implemented in the analysis and visualization tool MultiexperimentViewer MeV v. 4.9,Software name not in publication title — likely generic usage: MultiexperimentViewer MeV v. 4.9
NFFinder,computational_tools,PMID:28542306,10.1371/journal.pone.0178316,Gene signature associated with benign neurofibroma transformation to malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NFFinder,Analysis Software,,,,,,,,,,,,,,,,The search for opposite and similar gene signatures in CMap-DrugMatrix and GEO databases in NFFinder was performed,No version and no repository URL (confidence < 0.9 — unidentifiable)
GSE66743,computational_tools,PMID:28542306,10.1371/journal.pone.0178316,Gene signature associated with benign neurofibroma transformation to malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GSE66743,Database,,,,,,,,,,,,,,,,"In an example illustrating the factors involved in gene score computation, S13 Table shows values for the differentially expressed genes obtained by comparing MPNST vs. NF from the GSE66743 study",No version and no repository URL (confidence < 0.9 — unidentifiable)
RectLabel,computational_tools,PMID:39863790,10.1038/s41746-025-01454-z,A multicenter study of neurofibromatosis type 1 utilizing deep learning for whole body tumor identification.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,RectLabel,Analysis Software,,,,,,,,,,,,,,,,"Ground truth for the ROI region was manually established in all selected images. This task was completed by two experienced radiologists (Y.T. and C.Y.) and one doctor (C.W.) with expertise in NF1, using RectLabel (Ryo Kawamura, San Francisco, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Colabeler,computational_tools,PMID:39863790,10.1038/s41746-025-01454-z,A multicenter study of neurofibromatosis type 1 utilizing deep learning for whole body tumor identification.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Colabeler,Analysis Software,,,,,,,,,,,,,,,,"Ground truth for the ROI region was manually established in all selected images. This task was completed by two experienced radiologists (Y.T. and C.Y.) and one doctor (C.W.) with expertise in NF1, using RectLabel (Ryo Kawamura, San Francisco, USA) and Colabeler (Kuaiyi Technology Co., Ltd, Hangzhou, China)",No version and no repository URL (confidence < 0.9 — unidentifiable)
U-Net,computational_tools,PMID:39863790,10.1038/s41746-025-01454-z,A multicenter study of neurofibromatosis type 1 utilizing deep learning for whole body tumor identification.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,U-Net,Analysis Software,,,,,,,,,,,,,,,,"U-Net, a convolutional neural network (CNN), was utilized to perform automatic segmentation. The runtime environment for our model was on Python 3.7.1",Software name not in publication title — likely generic usage: U-Net
ResNet 18,computational_tools,PMID:39863790,10.1038/s41746-025-01454-z,A multicenter study of neurofibromatosis type 1 utilizing deep learning for whole body tumor identification.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ResNet 18,Analysis Software,,,,,,,,,,,,,,,,"ResNet 18, an 18-layer deep CNN model, was employed for our differential diagnosis model (the model structure is shown in Fig. 3). The model was developed using PyTorch.",Software name not in publication title — likely generic usage: ResNet 18
PyTorch,computational_tools,PMID:39863790,10.1038/s41746-025-01454-z,A multicenter study of neurofibromatosis type 1 utilizing deep learning for whole body tumor identification.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PyTorch,Package/Library,,,,,,,,,,,,,,,,"ResNet 18, an 18-layer deep CNN model, was employed for our differential diagnosis model (the model structure is shown in Fig. 3). The model was developed using PyTorch.",No version and no repository URL (confidence < 0.9 — unidentifiable)
You Only Look Once-v5 (YOLO-v5),computational_tools,PMID:39863790,10.1038/s41746-025-01454-z,A multicenter study of neurofibromatosis type 1 utilizing deep learning for whole body tumor identification.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,You Only Look Once-v5 (YOLO-v5),Analysis Software,,,,,,,,,,,,,,,,"Another deep learning algorithm, You Only Look Once-v5 (YOLO-v5), was adopted and improved to establish a PNF/MPNST detection and diagnosis system.",Software name not in publication title — likely generic usage: You Only Look Once-v5 (YOLO-v5)
Gradient-weighted Class Activation Mapping,computational_tools,PMID:39863790,10.1038/s41746-025-01454-z,A multicenter study of neurofibromatosis type 1 utilizing deep learning for whole body tumor identification.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Gradient-weighted Class Activation Mapping,Analysis Software,,,,,,,,,,,,,,,,"The Gradient-weighted Class Activation Mapping can visualize the predictive basis of CNN-based deep learning models by generating saliency maps, which was normally adopted as a method to visually explain these models",No version and no repository URL (confidence < 0.9 — unidentifiable)
Python 3.7.1,computational_tools,PMID:39863790,10.1038/s41746-025-01454-z,A multicenter study of neurofibromatosis type 1 utilizing deep learning for whole body tumor identification.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Python 3.7.1,Analysis Software,3.7.1,,,,,,,,,,,,,,,"The runtime environment for our model was on Python 3.7.1, and the model structure is illustrated in Fig. 3",Software name not in publication title — likely generic usage: Python 3.7.1
Affymetrix Mouse Genome chip (Murine 430 2.0),computational_tools,PMID:16524466,10.1186/1471-2202-7-22,Cognitive dysfunction in NF1 knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Affymetrix Mouse Genome chip (Murine 430 2.0),Analysis Software,,,,,,,,,,,,,,,,Gene expression analysis was performed for hippocampal samples...utilizing the Affymetrix Mouse Genome chip (Murine 430 2.0),Software name not in publication title — likely generic usage: Affymetrix Mouse Genome chip (Murine 430 2.0)
Affymetrix Microarray Suite version 5.1,computational_tools,PMID:16524466,10.1186/1471-2202-7-22,Cognitive dysfunction in NF1 knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Affymetrix Microarray Suite version 5.1,Analysis Software,5.1,,,,,,,,,,,,,,,Data was extracted from the array images using Affymetrix Microarray Suite version 5.1 software (MAS5.0),Software name not in publication title — likely generic usage: Affymetrix Microarray Suite version 5.1
GeneSpring v 5.0,computational_tools,PMID:16524466,10.1186/1471-2202-7-22,Cognitive dysfunction in NF1 knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GeneSpring v 5.0,Analysis Software,5.0,,,,,,,,,,,,,,,The modified gene expression data for each individual array was imported into GeneSpring v 5.0 (Agilent Technologies),Software name not in publication title — likely generic usage: GeneSpring v 5.0
GeneGo network building algorithms,computational_tools,PMID:16524466,10.1186/1471-2202-7-22,Cognitive dysfunction in NF1 knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GeneGo network building algorithms,Analysis Software,,,,,,,,,,,,,,,,"The GeneGo network building algorithms (GeneGo, Inc) were used in an iterative fashion to build gene/protein interaction pathways",No version and no repository URL (confidence < 0.9 — unidentifiable)
Chromo4 Four-Color Real-Time System,computational_tools,PMID:16524466,10.1186/1471-2202-7-22,Cognitive dysfunction in NF1 knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Chromo4 Four-Color Real-Time System,Analysis Software,,,,,,,,,,,,,,,,Resulting cDNA was amplified on the Chromo4 Four-Color Real-Time System (MJ Research),No version and no repository URL (confidence < 0.9 — unidentifiable)
FluorS-Multi-Imager,computational_tools,PMID:26549023,10.1038/onc.2015.404,"The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.",,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,FluorS-Multi-Imager,Analysis Software,,,,,,,,,,,,,,,,Band densities were quantified using FluorS-Multi-Imager and Quantity One.,"Publication title lacks NF-specific terms: The scaffold protein KSR1, a novel therapeutic target for the treatment of Merli"
Quantity One,computational_tools,PMID:26549023,10.1038/onc.2015.404,"The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.",,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,Quantity One,Analysis Software,,,,,,,,,,,,,,,,Band densities were quantified using FluorS-Multi-Imager and Quantity One.,"Publication title lacks NF-specific terms: The scaffold protein KSR1, a novel therapeutic target for the treatment of Merli"
Qiagen IPA,computational_tools,PMID:26549023,10.1038/onc.2015.404,"The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Qiagen IPA,Analysis Software,,,,,,,,,,,,,,,,Detailed methods of LC-MS/MS and Qiagen IPA data analysis are described in the supplementary information.,"Publication title lacks NF-specific terms: The scaffold protein KSR1, a novel therapeutic target for the treatment of Merli"
"high-resolution research tomograph (HRRT, Siemens)",computational_tools,PMID:31033921,10.1097/MAO.0000000000002272,[18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"high-resolution research tomograph (HRRT, Siemens)",Analysis Software,,,,,,,,,,,,,,,,"were scanned with FLT and FDG using a high-resolution research tomograph (HRRT, Siemens) and a Siemens Biograph TrueV PET-CT",No version and no repository URL (confidence < 0.9 — unidentifiable)
Siemens Biograph TrueV PET-CT,computational_tools,PMID:31033921,10.1097/MAO.0000000000002272,[18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Siemens Biograph TrueV PET-CT,Analysis Software,,,,,,,,,,,,,,,,"were scanned with FLT and FDG using a high-resolution research tomograph (HRRT, Siemens) and a Siemens Biograph TrueV PET-CT",No version and no repository URL (confidence < 0.9 — unidentifiable)
Brainlab iPlan software,computational_tools,PMID:31033921,10.1097/MAO.0000000000002272,[18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Brainlab iPlan software,Analysis Software,,,,,,,,,,,,,,,,Volumetric measurements were made on T1-weighted (T1W) postcontrast imaging using the semiautomatic segmentation tool within the Brainlab iPlan software,Software name not in publication title — likely generic usage: Brainlab iPlan software
e7_tools,computational_tools,PMID:31033921,10.1097/MAO.0000000000002272,[18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,e7_tools,Analysis Software,,,,,,,,,,,,,,,,"For the TrueV scanner, the Siemens offline reconstruction package ""e7_tools"" was used with an image zoom of two",No version and no repository URL (confidence < 0.9 — unidentifiable)
HRRT user community software,computational_tools,PMID:31033921,10.1097/MAO.0000000000002272,[18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HRRT user community software,Analysis Software,,,,,,,,,,,,,,,,HRRT data was reconstructed using HRRT user community software generating images consisting of 256 × 256 × 207 voxels,No version and no repository URL (confidence < 0.9 — unidentifiable)
Analyze version 11,computational_tools,PMID:31033921,10.1097/MAO.0000000000002272,[18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Analyze version 11,Analysis Software,11,,,,,,,,,,,,,,,All manual outlining was done using Analyze version 11 and was performed under the supervision of AJ and ID,Software name not in publication title — likely generic usage: Analyze version 11
SPM 8,computational_tools,PMID:31033921,10.1097/MAO.0000000000002272,[18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPM 8,Analysis Software,8,http://www.fil.ion.ucl.ac.uk/spm,,,,,,,,,,,,,,"Using SPM 8 (http://www.fil.ion.ucl.ac.uk/spm), contrast enhanced T1W MRIs were coregistered to the 30 minutes motion corrected PET images",Software name not in publication title — likely generic usage: SPM 8
SPSS version 23,computational_tools,PMID:31033921,10.1097/MAO.0000000000002272,[18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPSS version 23,Analysis Software,23,,,,,,,,,,,,,,,SPSS version 23 was used for all statistical analyses,Software name not in publication title — likely generic usage: SPSS version 23
Bio-Rad FX96,computational_tools,PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bio-Rad FX96,Other,,,,,,,,,,,,,,,,qPCR was performed on a Bio-Rad FX96 apparatus,Software name not in publication title — likely generic usage: Bio-Rad FX96
10X Genomics Chromium controller,computational_tools,PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,10X Genomics Chromium controller,Other,,,,,,,,,,,,,,,,"single cell suspension of ~ 10,000 cells per sample was loaded into a 10X Genomics Chromium controller",Software name not in publication title — likely generic usage: 10X Genomics Chromium controller
Illumina HiSeq sequencer,computational_tools,PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina HiSeq sequencer,Other,,,,,,,,,,,,,,,,transcript barcoding and sequenced on an Illumina HiSeq sequencer,Sequencing hardware or generic assay protocol: Illumina HiSeq sequencer
Cell Ranger version 3.0.0,computational_tools,PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cell Ranger version 3.0.0,Analysis Software,3.0.0,,,,,,,,,,,,,,,Cell Ranger version 3.0.0 (10× Genomics) was used to process the raw sequencing data,Software name not in publication title — likely generic usage: Cell Ranger version 3.0.0
Seurat version 3.0.0,computational_tools,PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat version 3.0.0,Package/Library,3.0.0,,,,,,,,,,,,,,,The gene x cell expression matrices were loaded to the R package Seurat version 3.0.0,Software name not in publication title — likely generic usage: Seurat version 3.0.0
GSE163028,computational_tools,PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GSE163028,Database,,,,,,,,,,,,,,,,The expression data has been deposited in NCBI's Gene Expression Omnibus (GEO) and is accessible through GEP series accession number GSE163028,Software name not in publication title — likely generic usage: GSE163028
REDCap,computational_tools,PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,REDCap,Web Application,,,,,,,,,,,,,,,,"All enrolled participants completed assessment measures at baseline, post-intervention, and at 6- and 12-month follow-up via REDCap, a secure online data collection and management system.",No version and no repository URL (confidence < 0.9 — unidentifiable)
SAS version 9.8,computational_tools,PMID:37440099,10.1007/s11060-023-04389-1,The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SAS version 9.8,Analysis Software,9.8,,,,,,,,,,,,,,,We conducted the analysis using SAS version 9.8.,Generic tool (versioned): SAS version 9.8
Matlab,computational_tools,PMID:31416081,10.1159/000501696,Magnetic Resonance Fingerprinting to Characterize Childhood and Young Adult Brain Tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Matlab,Analysis Software,,,,,,,,,,,,,,,,"All data processing was performed in Matlab (MathWorks, Natick, MA, USA).",Publication title lacks NF-specific terms: Magnetic Resonance Fingerprinting to Characterize Childhood and Young Adult Brai
STATA,computational_tools,PMID:31416081,10.1159/000501696,Magnetic Resonance Fingerprinting to Characterize Childhood and Young Adult Brain Tumors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,STATA,Analysis Software,Version 11.2,,,,,,,,,,,,,,,"All statistical analyses were performed using STATA (Version 11.2, College Station, TX, USA)",Publication title lacks NF-specific terms: Magnetic Resonance Fingerprinting to Characterize Childhood and Young Adult Brai
R,computational_tools,PMID:31416081,10.1159/000501696,Magnetic Resonance Fingerprinting to Characterize Childhood and Young Adult Brain Tumors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R,Analysis Software,version 3.2.4,,,,,,,,,,,,,,,"except Firth's logistic regression which was performed using R (version 3.2.4, Vienna, Austria).",Publication title lacks NF-specific terms: Magnetic Resonance Fingerprinting to Characterize Childhood and Young Adult Brai
ImageJ software,computational_tools,PMID:25433207,10.1016/j.ydbio.2014.11.017,Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ software,Analysis Software,,,,,,,,,,,,,,,,Cell counting was performed using the ImageJ software,Generic bioinformatics/stats tool: ImageJ software
SH800 sorter (Sony),computational_tools,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SH800 sorter (Sony),Analysis Software,,,,,,,,,,,,,,,,selected by flow cytometry using a SH800 sorter (Sony),"Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
HISAT2,computational_tools,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HISAT2,Analysis Software,,,,,,,,,,,,,,,,Reads were mapped to the appropriate reference genome (hg19) using HISAT2 with default parameters,"Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
DESeq2,computational_tools,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2,Package/Library,,,,,,,,,,,,,,,,Transcript abundance estimation in transcripts per million (TPM) and differential expression analysis were performed using DESeq2,"Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
Fragpipe (v22),computational_tools,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Fragpipe (v22),Analysis Software,v22,,,,,,,,,,,,,,,Raw mass spectrometry data were searched using Fragpipe (v22),"Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
PhosphoLFQ,computational_tools,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PhosphoLFQ,Workflow,,,,,,,,,,,,,,,,using PhosphoLFQ label-free quantification workflow,"Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
MSstats (v4.8.7),computational_tools,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MSstats (v4.8.7),Package/Library,v4.8.7,,,,,,,,,,,,,,,Statistical analysis was performed using MSstats (v4.8.7),"Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
artMS (v1.18.0),computational_tools,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,artMS (v1.18.0),Package/Library,v1.18.0,,,,,,,,,,,,,,,from the artMS (v1.18.0) R package,"Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
RoKAI Differential Expression analysis,computational_tools,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,RoKAI Differential Expression analysis,Analysis Software,,,,,,,,,,,,,,,,Kinase enrichment analysis was performed using RoKAI Differential Expression analysis,"Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
Spectronaut (version 18.4.231017.55695),computational_tools,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Spectronaut (version 18.4.231017.55695),Analysis Software,18.4.231017.55695,,,,,,,,,,,,,,,Raw mass spectrometry files were analyzed using Spectronaut (version 18.4.231017.55695),"Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
ImageJ (NIH),computational_tools,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ (NIH),Analysis Software,,,,,,,,,,,,,,,,Quantification was performed in ImageJ (NIH) using the relative densitometry,"Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
eQUISTA,computational_tools,PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,eQUISTA,Analysis Software,,,,,,,,,,,,,,,,"QST statistical analysis was performed using ""eQUISTA"" (Casquar GmbH, Bochum, Germany)",No version and no repository URL (confidence < 0.9 — unidentifiable)
BrainVision Recorder,computational_tools,PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BrainVision Recorder,Analysis Software,,,,,,,,,,,,,,,,"EEG was recorded with nose-reference using 64 active channels (EASY CAP) and BrainVision Recorder-software (Brain Products GmbH, Gilching, Germany)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Fieldtrip,computational_tools,PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Fieldtrip,Analysis Software,,www.ru.nl/fcdonders/fieldtrip,,,,,,,,,,,,,,"The data were analyzed offline using Fieldtrip software (Donders Centre for Cognitive Neuroimaging, AH Nijmegen, The Netherlands, www.ru.nl/fcdonders/fieldtrip)",Software name not in publication title — likely generic usage: Fieldtrip
IncuCyte Zoom Live-Cell Analysis System,computational_tools,PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,IncuCyte Zoom Live-Cell Analysis System,Analysis Software,,,,,,,,,,,,,,,,cells were imaged every 1 to 2 hours by IncuCyte Zoom Live-Cell Analysis System (Essen Bioscience),No version and no repository URL (confidence < 0.9 — unidentifiable)
WES automated Western system,computational_tools,PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,WES automated Western system,Analysis Software,,,,,,,,,,,,,,,,validation of protein changes with the WES automated Western system,No version and no repository URL (confidence < 0.9 — unidentifiable)
SynergyFinder 2.0,computational_tools,PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SynergyFinder 2.0,Analysis Software,2.0,,,,,,,,,,,,,,,analyzed using SynergyFinder 2.0 software (RRID:SCR_019318) and the HSA model,Software name not in publication title — likely generic usage: SynergyFinder 2.0
DESeq2 package,computational_tools,PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2 package,Package/Library,,,,,,,,,,,,,,,,Differential expression analysis was performed with the DESeq2 package (R Bioconductor software; RRID:SCR_015687),Software name not in publication title — likely generic usage: DESeq2 package
GraphPad Prism version 9,computational_tools,PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism version 9,Analysis Software,version 9,,,,,,,,,,,,,,,Data were analyzed and graphed in GraphPad Prism version 9 (RRID:SCR_002798),Generic tool (versioned): GraphPad Prism version 9
ICCB Known Bioactives library,computational_tools,PMID:28065690,10.1016/j.biochi.2017.01.001,Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ICCB Known Bioactives library,Database,,,,,,,,,,,,,,,,"The ICCB Known Bioactives library (Enzo Life Sciences, USA, BML-2840-0100) was used for the screening",No version and no repository URL (confidence < 0.9 — unidentifiable)
Calcusyn,computational_tools,PMID:28065690,10.1016/j.biochi.2017.01.001,Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Calcusyn,Analysis Software,,,,,,,,,,,,,,,,"The values of IC50, the drug concentration required for 50% growth inhibition, were calculated using software package Calcusyn (Biosoft)",Software name not in publication title — likely generic usage: Calcusyn
Nano-Drop spectrophotometer,computational_tools,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Nano-Drop spectrophotometer,Analysis Software,,,,,,,,,,,,,,,,"The quality of the DNA was estimated using the Nano-Drop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).",No version and no repository URL (confidence < 0.9 — unidentifiable)
Ion Personal Genome Machine® (PGM™) Sequencer,computational_tools,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Ion Personal Genome Machine® (PGM™) Sequencer,Analysis Software,,,,,,,,,,,,,,,,"In this study, we took the advantage of this gene panel for the germline mutation analysis of NF1 using the Ion Personal Genome Machine® (PGM™) Sequencer (Life technology).",Software name not in publication title — likely generic usage: Ion Personal Genome Machine® (PGM™) Sequencer
Agilent Bioanalyzer,computational_tools,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Agilent Bioanalyzer,Analysis Software,,,,,,,,,,,,,,,,the size distribution of the DNA fragments was analyzed on the Agilent Bioanalyzer using High-Sensitivity DNA chip,No version and no repository URL (confidence < 0.9 — unidentifiable)
Qubit 2.0 Fluorometer,computational_tools,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Qubit 2.0 Fluorometer,Analysis Software,,,,,,,,,,,,,,,,the quality checking of ion sphere particles for the prepared library was performed using Qubit 2.0 Fluorometer (Life Technologies).,No version and no repository URL (confidence < 0.9 — unidentifiable)
Torrent Suite,computational_tools,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Torrent Suite,Pipeline,4.2,,,,,,,,,,,,,,,"We used IT platform-specific pipeline software Torrent Suite, version 4.2, with the plug-in ""variant caller"" program",Software name not in publication title — likely generic usage: Torrent Suite
Integrative Genome Viewer (IGV),computational_tools,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Integrative Genome Viewer (IGV),Analysis Software,,http://software.broadinstitute.org/software/igv/,,,,,,,,,,,,,,The Integrative Genome Viewer (IGV) (http://software.broadinstitute.org/software/igv/) was used for visualizing the status of each read alignment.,Software name not in publication title — likely generic usage: Integrative Genome Viewer (IGV)
Sorting Tolerant From Intolerant (SIFT),computational_tools,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Sorting Tolerant From Intolerant (SIFT),Analysis Software,,,,,,,,,,,,,,,,Variants with amino acid changes were further examined for whether the changes were potentially damaging alterations using Sorting Tolerant From Intolerant (SIFT),Software name not in publication title — likely generic usage: Sorting Tolerant From Intolerant (SIFT)
Polymorphism Phenotyping v2 (PolyPhen2),computational_tools,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Polymorphism Phenotyping v2 (PolyPhen2),Analysis Software,v2,,,,,,,,,,,,,,,using Sorting Tolerant From Intolerant (SIFT) and Polymorphism Phenotyping v2 (PolyPhen2) softwares,Software name not in publication title — likely generic usage: Polymorphism Phenotyping v2 (PolyPhen2)
Applied Biosystems 3730 Genetic Analyzer,computational_tools,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Applied Biosystems 3730 Genetic Analyzer,Analysis Software,,,,,,,,,,,,,,,,"We performed Sanger validation for all putatively pathogenic SNVs and indels variants on each detected patient (and their family members, if available) by PCR amplification and sequenced with Applied Biosystems 3730 Genetic Analyzer.",No version and no repository URL (confidence < 0.9 — unidentifiable)
Applied Biosystems 3730xl Automated Sequencer Genetic Analyzer,computational_tools,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Applied Biosystems 3730xl Automated Sequencer Genetic Analyzer,Analysis Software,,,,,,,,,,,,,,,,analyzed on an Applied Biosystems 3730xl Automated Sequencer Genetic Analyzer (Life Technologies).,No version and no repository URL (confidence < 0.9 — unidentifiable)
Autoassembler computer program,computational_tools,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Autoassembler computer program,Analysis Software,,,,,,,,,,,,,,,,Sequence alignments and analysis were further performed using the Autoassembler computer program (Life Technologies).,No version and no repository URL (confidence < 0.9 — unidentifiable)
Genetic Analyzer 3730 capillary electrophoresis system,computational_tools,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Genetic Analyzer 3730 capillary electrophoresis system,Analysis Software,,,,,,,,,,,,,,,,the PCR products were analyzed on a Genetic Analyzer 3730 capillary electrophoresis system and interpreted using Genotyper version 2.0,No version and no repository URL (confidence < 0.9 — unidentifiable)
Genotyper,computational_tools,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Genotyper,Analysis Software,2.0,,,,,,,,,,,,,,,"interpreted using Genotyper version 2.0 (Applied Biosystems, CA, USA).",Software name not in publication title — likely generic usage: Genotyper
Coffalyser program,computational_tools,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Coffalyser program,Analysis Software,3.5,,,,,,,,,,,,,,,"In this study, we used the Coffalyser program (version 3.5) for peak area normalization and gene dosage calculation.",Software name not in publication title — likely generic usage: Coffalyser program
Prism 6,computational_tools,PMID:24848258,10.1126/scitranslmed.3008639,Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Prism 6,Analysis Software,6,,,,,,,,,,,,,,,Statistical analysis was performed using Prism 6 software,Publication title lacks NF-specific terms: Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relatio
CHOPCHOP,computational_tools,PMID:33279959,10.1093/brain/awaa404,"Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish.",,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,CHOPCHOP,Web Application,,http://chopchop.cbu.uib.no/,,,,,,,,,,,,,,Guide RNAs (gRNAs) were designed using the CHOPCHOP website (http://chopchop.cbu.uib.no/),Software name not in publication title — likely generic usage: CHOPCHOP
DanioVision software,computational_tools,PMID:33279959,10.1093/brain/awaa404,"Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DanioVision software,Analysis Software,,,,,,,,,,,,,,,,the travelling distance of each larva was analysed using DanioVision software (Noldus),No version and no repository URL (confidence < 0.9 — unidentifiable)
Image-Pro Plus software,computational_tools,PMID:33279959,10.1093/brain/awaa404,"Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Image-Pro Plus software,Analysis Software,,,,,,,,,,,,,,,,the staining was evaluated with Image-Pro Plus software (Media Cybernetics Inc.),No version and no repository URL (confidence < 0.9 — unidentifiable)
GeneMaths software,computational_tools,PMID:33279959,10.1093/brain/awaa404,"Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GeneMaths software,Analysis Software,,,,,,,,,,,,,,,,"The analysis was performed using GeneMaths software (Applied Maths, Inc., Austin, TX) with Pearson correlation",No version and no repository URL (confidence < 0.9 — unidentifiable)
GSEA,computational_tools,PMID:33279959,10.1093/brain/awaa404,"Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GSEA,Analysis Software,,,,,,,,,,,,,,,,The enrichment of signature genes in the tumour subgroups identified by UHC in our models was assessed by gene set enrichment analysis (GSEA),Generic bioinformatics/stats tool: GSEA
Noldus behavioural tracking system,computational_tools,PMID:33279959,10.1093/brain/awaa404,"Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Noldus behavioural tracking system,Analysis Software,,,,,,,,,,,,,,,,The motor capabilities of the larvae in different groups were evaluated using a behavioural tracking system (Noldus),No version and no repository URL (confidence < 0.9 — unidentifiable)
Openlab software,computational_tools,PMID:23099891,10.1007/s00401-012-1056-7,Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Openlab software,Analysis Software,,,,,,,,,,,,,,,,...We acquired microscopic images with Openlab software suites on a Zeiss Axiovert 200...,No version and no repository URL (confidence < 0.9 — unidentifiable)
qBase,computational_tools,PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,qBase,Analysis Software,,,,,,,,,,,,,,,,Relative expression was calculated using qBase,No version and no repository URL (confidence < 0.9 — unidentifiable)
Psychophysics Toolbox 3,computational_tools,PMID:29566645,10.1186/s11689-018-9230-4,"Oscillatory motor patterning is impaired in neurofibromatosis type 1: a behavioural, EEG and fMRI study.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Psychophysics Toolbox 3,Package/Library,,,,,,,,,,,,,,,,"The paradigm was designed and presented using the Psychophysics Toolbox 3 [32, 33], running on Matlab R2013b",No version and no repository URL (confidence < 0.9 — unidentifiable)
Matlab R2013b,computational_tools,PMID:29566645,10.1186/s11689-018-9230-4,"Oscillatory motor patterning is impaired in neurofibromatosis type 1: a behavioural, EEG and fMRI study.",,0.75,Experimental Usage,True,1.00,Low,,,,,,,,,,,,,,,Matlab R2013b,Analysis Software,R2013b,,,,,,,,,,,,,,,"running on Matlab R2013b (MathWorks, Natick, MA, USA)",Software name not in publication title — likely generic usage: Matlab R2013b
BrainVoyager QX 2.8.2,computational_tools,PMID:29566645,10.1186/s11689-018-9230-4,"Oscillatory motor patterning is impaired in neurofibromatosis type 1: a behavioural, EEG and fMRI study.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BrainVoyager QX 2.8.2,Analysis Software,2.8.2,,,,,,,,,,,,,,,"The complete processing pipeline and analysis of the functional data was done using BrainVoyager QX 2.8.2 (Brain Innovation, Maastricht, The Netherlands)",Software name not in publication title — likely generic usage: BrainVoyager QX 2.8.2
EEGlab toolbox,computational_tools,PMID:29566645,10.1186/s11689-018-9230-4,"Oscillatory motor patterning is impaired in neurofibromatosis type 1: a behavioural, EEG and fMRI study.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,EEGlab toolbox,Package/Library,,,,,,,,,,,,,,,,"The processing was performed using the EEGlab toolbox [34] for Matlab (MathWorks, Natick, MA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Scan 4.5,computational_tools,PMID:29566645,10.1186/s11689-018-9230-4,"Oscillatory motor patterning is impaired in neurofibromatosis type 1: a behavioural, EEG and fMRI study.",,0.75,Experimental Usage,True,1.00,Low,,,,,,,,,,,,,,,Scan 4.5,Analysis Software,4.5,,,,,,,,,,,,,,,"Data were acquired using Scan 4.5 (NeuroScan, Compumedics, Charlotte, NC)",Software name not in publication title — likely generic usage: Scan 4.5
Pixcell II LCM system,computational_tools,PMID:32245042,10.3390/genes11030331,Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Pixcell II LCM system,Analysis Software,,,,,,,,,,,,,,,,"an average of 15,000 tumor cells was isolated from the surrounding microenvironment using a Pixcell II LCM system (Arcturus, Mountain View, CA, USA)",Software name not in publication title — likely generic usage: Pixcell II LCM system
Aushon 2470 arrayer,computational_tools,PMID:32245042,10.3390/genes11030331,Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Aushon 2470 arrayer,Analysis Software,,,,,,,,,,,,,,,,"Using an Aushon 2470 arrayer (Aushon BioSystems, Billerica, MA, USA) equipped with 185 μm pins",No version and no repository URL (confidence < 0.9 — unidentifiable)
MicroVigene software version 5.1,computational_tools,PMID:32245042,10.3390/genes11030331,Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MicroVigene software version 5.1,Analysis Software,5.1,,,,,,,,,,,,,,,"Acquired images were analysed using the MicroVigene software version 5.1 (Vigene Tech, Carlisle, MA, USA)",Software name not in publication title — likely generic usage: MicroVigene software version 5.1
R v3.2.2,computational_tools,PMID:32245042,10.3390/genes11030331,Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R v3.2.2,Analysis Software,3.2.2,https://cran.r-project.org/,,,,,,,,,,,,,,All analyses were conducted using R v3.2.2 (https://cran.r-project.org/),Software name not in publication title — likely generic usage: R v3.2.2
R v3.6.1,computational_tools,PMID:32245042,10.3390/genes11030331,Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R v3.6.1,Analysis Software,3.6.1,,,,,,,,,,,,,,,Plots were generated using R v3.6.1,Software name not in publication title — likely generic usage: R v3.6.1
ggplot2 (v3.2.1),computational_tools,PMID:32245042,10.3390/genes11030331,Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ggplot2 (v3.2.1),Package/Library,3.2.1,,,,,,,,,,,,,,,data were fit by stat_smooth using loess with span = 1 using ggplot2 (v3.2.1),Software name not in publication title — likely generic usage: ggplot2 (v3.2.1)
R (v3.6.2),computational_tools,PMID:32245042,10.3390/genes11030331,Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R (v3.6.2),Analysis Software,3.6.2,,,,,,,,,,,,,,,All analyses were done using R (v3.6.2),Software name not in publication title — likely generic usage: R (v3.6.2)
reverse phase phosphoproteome array (RPPA),computational_tools,PMID:32245042,10.3390/genes11030331,Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,reverse phase phosphoproteome array (RPPA),Analysis Software,,,,,,,,,,,,,,,,quantify the impact of both the genomic context and targeted therapy on MPNST resistance using reverse phase phosphoproteome array (RPPA) analysis,No version and no repository URL (confidence < 0.9 — unidentifiable)
GeneSpring GX v7.3.1,computational_tools,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GeneSpring GX v7.3.1,Analysis Software,v7.3.1,,,,,,,,,,,,,,,Data were processed using GeneSpring GX v7.3.1 (Agilent Technologies) with background correction and Robust Multi-array Average (RMA) normalization,Software name not in publication title — likely generic usage: GeneSpring GX v7.3.1
Bioconductor/limma package,computational_tools,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bioconductor/limma package,Package/Library,,,,,,,,,,,,,,,,Differential gene expression was predicted using Bioconductor/ limma package,Software name not in publication title — likely generic usage: Bioconductor/limma package
BD FACSDiVa software version 4.0,computational_tools,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BD FACSDiVa software version 4.0,Analysis Software,4.0,,,,,,,,,,,,,,,analyzed on a BD FACS LSR II using BD FACSDiVa software version 4.0 (BD Biosciences),Software name not in publication title — likely generic usage: BD FACSDiVa software version 4.0
FlowJo version 7.6.5,computational_tools,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FlowJo version 7.6.5,Analysis Software,7.6.5,,,,,,,,,,,,,,,Flow cytometry data analysis was performed using FlowJo version 7.6.5 (Tree Star),Software name not in publication title — likely generic usage: FlowJo version 7.6.5
GraphPad Prism 7,computational_tools,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism 7,Analysis Software,7,,,,,,,,,,,,,,,"using the two-step method of Benjamini, Krieger, and Yekutieli to control for a false discovery rate of 0.05 using GraphPad Prism 7 software",Generic bioinformatics/stats tool: GraphPad Prism 7
BRB-Array Tools Version 4.2.1,computational_tools,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BRB-Array Tools Version 4.2.1,Analysis Software,4.2.1,,,,,,,,,,,,,,,Analyses were performed using BRB-Array Tools Version 4.2.1. BRB-ArrayTools is an integrated software package for the analysis of DNA microarray data,Software name not in publication title — likely generic usage: BRB-Array Tools Version 4.2.1
Cluster/Treeview,computational_tools,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Cluster/Treeview,Analysis Software,,,,,,,,,,,,,,,,Hierarchical clustering was employed to generate heat maps for subsets of significant genes using the open source software Cluster/Treeview written by Michael Eisen,No version and no repository URL (confidence < 0.9 — unidentifiable)
Fiji,computational_tools,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Fiji,Analysis Software,,,,,,,,,,,,,,,,"Image processing was performed with Fiji, built on ImageJ2",Generic bioinformatics/stats tool: Fiji
ImageJ2,computational_tools,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ2,Analysis Software,,,,,,,,,,,,,,,,"Image processing was performed with Fiji, built on ImageJ2",Generic tool (versioned): ImageJ2
Seahorse Wave 2.2/2.3,computational_tools,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seahorse Wave 2.2/2.3,Analysis Software,2.2/2.3,,,,,,,,,,,,,,,The analysis was performed with Seahorse Wave 2.2/2.3,Software name not in publication title — likely generic usage: Seahorse Wave 2.2/2.3
FlowJo,computational_tools,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FlowJo,Analysis Software,,,,,,,,,,,,,,,,Histograms were generated using the FlowJo or FlowLogic flow cytometry analysis software packages,No version and no repository URL (confidence < 0.9 — unidentifiable)
FlowLogic,computational_tools,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FlowLogic,Analysis Software,,,,,,,,,,,,,,,,Histograms were generated using the FlowJo or FlowLogic flow cytometry analysis software packages,No version and no repository URL (confidence < 0.9 — unidentifiable)
Illumina MiSeq,computational_tools,PMID:26066488,10.1371/journal.pone.0129099,A Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina MiSeq,Analysis Software,,,,,,,,,,,,,,,,"All sample libraries were equimolarly pooled and sequenced on the Illumina MiSeq Sequencer (Illumina, San Diego, CA, USA) with MiSeq Reagent Kit v2",Sequencing hardware or generic assay protocol: Illumina MiSeq
BWA MEM,computational_tools,PMID:26066488,10.1371/journal.pone.0129099,A Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BWA MEM,Analysis Software,,,,,,,,,,,,,,,,Amplicon reads were aligned against the human reference genome hg19 with BWA MEM,No version and no repository URL (confidence < 0.9 — unidentifiable)
GATK version 2.5.2,computational_tools,PMID:26066488,10.1371/journal.pone.0129099,A Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GATK version 2.5.2,Analysis Software,2.5.2,,,,,,,,,,,,,,,GATK version 2.5.2 was used to recalibrate base qualities and realign aligned reads around indels,Software name not in publication title — likely generic usage: GATK version 2.5.2
MuTect version 1.1.4,computational_tools,PMID:26066488,10.1371/journal.pone.0129099,A Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MuTect version 1.1.4,Analysis Software,1.1.4,,,,,,,,,,,,,,,SNVs were identified using MuTect version 1.1.4 with standard parameters,Software name not in publication title — likely generic usage: MuTect version 1.1.4
GATK IndelGenotyperV2,computational_tools,PMID:26066488,10.1371/journal.pone.0129099,A Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GATK IndelGenotyperV2,Analysis Software,,,,,,,,,,,,,,,,GATK IndelGenotyperV2 (with minFraction = 0.001 and minCnt = 3) was used to detect InDels,No version and no repository URL (confidence < 0.9 — unidentifiable)
Annovar,computational_tools,PMID:26066488,10.1371/journal.pone.0129099,A Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Annovar,Analysis Software,,,,,,,,,,,,,,,,Genomic and functional annotation of detected variants was made by Annovar,Generic bioinformatics/stats tool: Annovar
Illumina DesignStudio,computational_tools,PMID:26066488,10.1371/journal.pone.0129099,A Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina DesignStudio,Web Application,,,,,,,,,,,,,,,,Amplicons were designed by Illumina DesignStudio (http://www.illumina.com),No version and no repository URL (confidence < 0.9 — unidentifiable)
GeneMapper software,computational_tools,PMID:26066488,10.1371/journal.pone.0129099,A Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GeneMapper software,Analysis Software,,,,,,,,,,,,,,,,"Electrophoresis data were analyzed by GeneMapper software (Life Technologies, Carlsbad, CA, USA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Rotor Gene 6000 Instrument,computational_tools,PMID:26066488,10.1371/journal.pone.0129099,A Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Rotor Gene 6000 Instrument,Analysis Software,,,,,,,,,,,,,,,,"HRM analysis was performed on the Rotor Gene 6000 Instrument (Corbett Research, Sydney, Australia)",No version and no repository URL (confidence < 0.9 — unidentifiable)
AB/SCIEX 6500 QTRAP,computational_tools,PMID:37616542,10.1158/1535-7163.MCT-23-0258,"Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AB/SCIEX 6500 QTRAP,Analysis Software,,,,,,,,,,,,,,,,5 μL was injected onto an AB/SCIEX 6500 QTRAP hybrid triple quadrupole mass spectrometer,No version and no repository URL (confidence < 0.9 — unidentifiable)
MultiQuant 3.0,computational_tools,PMID:37616542,10.1158/1535-7163.MCT-23-0258,"Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MultiQuant 3.0,Analysis Software,3.0,,,,,,,,,,,,,,,Data were integrated using MultiQuant 3.0 software to generate peak area intensities,Software name not in publication title — likely generic usage: MultiQuant 3.0
Metaboanalyst,computational_tools,PMID:37616542,10.1158/1535-7163.MCT-23-0258,"Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Metaboanalyst,Web Application,,,,,,,,,,,,,,,,Peak intensities were normalized to vehicle-treated samples and analyzed further using Metaboanalyst,No version and no repository URL (confidence < 0.9 — unidentifiable)
GraphPad Prism,computational_tools,PMID:37616542,10.1158/1535-7163.MCT-23-0258,"Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GraphPad Prism,Analysis Software,,,,,,,,,,,,,,,,plotted in GraphPad Prism (RRID:SCR_002798) and analyzed by ordinary one-way ANOVA,Generic bioinformatics/stats tool: GraphPad Prism
Aperio Imagescope,computational_tools,PMID:37616542,10.1158/1535-7163.MCT-23-0258,"Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.",,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Aperio Imagescope,Analysis Software,,,,,,,,,,,,,,,,analyzed by a trained blinded investigator using Aperio Imagescope software,No version and no repository URL (confidence < 0.9 — unidentifiable)
Image Pro Plus (version 4.1),computational_tools,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Image Pro Plus (version 4.1),Analysis Software,4.1,,,,,,,,,,,,,,,The number of cells in each photographed field were counted using Image Pro Plus (version 4.1) software,Software name not in publication title — likely generic usage: Image Pro Plus (version 4.1)
StereoInvestigator software,computational_tools,PMID:19306381,10.1002/glia.20866,Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,StereoInvestigator software,Analysis Software,,,,,,,,,,,,,,,,"controlled by a computer equipped with StereoInvestigator software (MBF Bioscience, Inc.; Williston, VT)",No version and no repository URL (confidence < 0.9 — unidentifiable)
R subread package,computational_tools,PMID:33816648,10.1016/j.omtm.2021.03.004,Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,R subread package,Package/Library,,,,,,,,,,,,,,,,RNA-seq analysis was performed using the Source Forge R subread package,Publication title lacks NF-specific terms: Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and gl
EdgeR software,computational_tools,PMID:33816648,10.1016/j.omtm.2021.03.004,Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,EdgeR software,Package/Library,,,,,,,,,,,,,,,,Further analysis was performed using EdgeR software,Publication title lacks NF-specific terms: Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and gl
FlowJo software,computational_tools,PMID:33816648,10.1016/j.omtm.2021.03.004,Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FlowJo software,Analysis Software,,,,,,,,,,,,,,,,Flow cytometry was performed on a BD LSR II analyzer and obtained data were gated within FlowJo software,Publication title lacks NF-specific terms: Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and gl
FSL 6.0.5,computational_tools,PMID:39665502,10.1002/hbm.70087,Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Application of Advanced Diffusion-Weighted Imaging in Children With Rasopathies.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FSL 6.0.5,Analysis Software,6.0.5,,,,,,,,,,,,,,,"DWI data were preprocessed (author MR) using FSL 6.0.5 (FMRIB Analysis Group, Oxford, UK), with topup susceptibility‐induced distortion correction",Publication title lacks NF-specific terms: Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Applica
topup,computational_tools,PMID:39665502,10.1002/hbm.70087,Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Application of Advanced Diffusion-Weighted Imaging in Children With Rasopathies.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,topup,Command-line Tool,,,,,,,,,,,,,,,,"using FSL 6.0.5 (FMRIB Analysis Group, Oxford, UK), with topup susceptibility‐induced distortion correction and eddy for correction",Publication title lacks NF-specific terms: Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Applica
eddy,computational_tools,PMID:39665502,10.1002/hbm.70087,Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Application of Advanced Diffusion-Weighted Imaging in Children With Rasopathies.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,eddy,Command-line Tool,,,,,,,,,,,,,,,,with topup susceptibility‐induced distortion correction and eddy for correction of eddy currents‐induced distortions and subject movements,Publication title lacks NF-specific terms: Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Applica
NODDI Matlab Toolbox v. 1.05,computational_tools,PMID:39665502,10.1002/hbm.70087,Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Application of Advanced Diffusion-Weighted Imaging in Children With Rasopathies.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,NODDI Matlab Toolbox v. 1.05,Package/Library,v. 1.05,,,,,,,,,,,,,,,"The NODDI maps were generated using the NODDI Matlab Toolbox v. 1.05 (UCL, UK) through fitting to the preprocessed diffusion data",Publication title lacks NF-specific terms: Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Applica
MATLAB R2023b,computational_tools,PMID:39665502,10.1002/hbm.70087,Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Application of Advanced Diffusion-Weighted Imaging in Children With Rasopathies.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MATLAB R2023b,Analysis Software,R2023b,,,,,,,,,,,,,,,"through fitting to the preprocessed diffusion data in MATLAB R2023b (Mathworks, Natick, MA)",Publication title lacks NF-specific terms: Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Applica
dtifit,computational_tools,PMID:39665502,10.1002/hbm.70087,Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Application of Advanced Diffusion-Weighted Imaging in Children With Rasopathies.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,dtifit,Command-line Tool,,,,,,,,,,,,,,,,The DKI maps for MK were generated using the dtifit command in FSL by including the kurtdir argument for multi‐shell data,Publication title lacks NF-specific terms: Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Applica
TRACULA,computational_tools,PMID:39665502,10.1002/hbm.70087,Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Application of Advanced Diffusion-Weighted Imaging in Children With Rasopathies.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,TRACULA,Analysis Software,,,,,,,,,,,,,,,,TRActs Constrained by UnderLying Anatomy (TRACULA) delineated 42 major white matter tracts using probabilistic tractography,Publication title lacks NF-specific terms: Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Applica
R 4.3.1,computational_tools,PMID:39665502,10.1002/hbm.70087,Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Application of Advanced Diffusion-Weighted Imaging in Children With Rasopathies.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R 4.3.1,Analysis Software,4.3.1,,,,,,,,,,,,,,,"Statistical analysis was completed by JP in R 4.3.1 (R Core Team, 2023)",Publication title lacks NF-specific terms: Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Applica
MICE package,computational_tools,PMID:39665502,10.1002/hbm.70087,Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Application of Advanced Diffusion-Weighted Imaging in Children With Rasopathies.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MICE package,Package/Library,,,,,,,,,,,,,,,,missing data were imputed using a predictive mean matching algorithm performed by the Multiple Imputation by Chained Equations (MICE) package in R,Publication title lacks NF-specific terms: Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Applica
prcomp function,computational_tools,PMID:39665502,10.1002/hbm.70087,Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Application of Advanced Diffusion-Weighted Imaging in Children With Rasopathies.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,prcomp function,Package/Library,,,,,,,,,,,,,,,,"PCA was conducted using the prcomp function in R, which performs PCA using the singular value decomposition approach",Publication title lacks NF-specific terms: Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Applica
MASS package,computational_tools,PMID:39665502,10.1002/hbm.70087,Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Application of Advanced Diffusion-Weighted Imaging in Children With Rasopathies.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MASS package,Package/Library,,,,,,,,,,,,,,,,linear discriminant analysis was then conducted using the lda function within the MASS package in R,Publication title lacks NF-specific terms: Elucidating Microstructural Alterations in Neurodevelopmental Disorders: Applica
R Statistical Environment V 3.2.4,computational_tools,PMID:28644838,10.1371/journal.pone.0178639,"Characterization and utilization of an international neurofibromatosis web-based, patient-entered registry: An observational study.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R Statistical Environment V 3.2.4,Analysis Software,3.2.4,,,,,,,,,,,,,,,...imported into the R Statistical Environment V 3.2.4. Tabulations were performed using the stat.table function...,Software name not in publication title — likely generic usage: R Statistical Environment V 3.2.4
Epi package,computational_tools,PMID:28644838,10.1371/journal.pone.0178639,"Characterization and utilization of an international neurofibromatosis web-based, patient-entered registry: An observational study.",,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Epi package,Package/Library,,,,,,,,,,,,,,,,...Tabulations were performed using the stat.table function of the Epi package...,No version and no repository URL (confidence < 0.9 — unidentifiable)
MySQL Server,computational_tools,PMID:28644838,10.1371/journal.pone.0178639,"Characterization and utilization of an international neurofibromatosis web-based, patient-entered registry: An observational study.",,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,MySQL Server,Database,,,,,,,,,,,,,,,,...Invitae uses MySQL Server as the back-end relational database...,No version and no repository URL (confidence < 0.9 — unidentifiable)
Agilent-026437 Zebrafish GX v3 4 × 44K,computational_tools,PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Agilent-026437 Zebrafish GX v3 4 × 44K,Database,v3,,,,,,,,,,,,,,,"Microarray was performed using Agilent-026437 (Agilent, Santa Clara, CA, USA), Zebrafish GX v3 4 × 44K",Publication title lacks NF-specific terms: Activation of Sonic hedgehog signaling in neural progenitor cells promotes gliom
Agilent Feature Extraction software,computational_tools,PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Agilent Feature Extraction software,Analysis Software,v.10.5.1.1,,,,,,,,,,,,,,,data were extracted by Agilent Feature Extraction software (v.10.5.1.1) using GE1_105_Jan09 protocol,Publication title lacks NF-specific terms: Activation of Sonic hedgehog signaling in neural progenitor cells promotes gliom
Nikon NIS Elements,computational_tools,PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Nikon NIS Elements,Analysis Software,,,,,,,,,,,,,,,,OT from the midline to the left and right edges was measured and analyzed using Nikon NIS Elements,Publication title lacks NF-specific terms: Activation of Sonic hedgehog signaling in neural progenitor cells promotes gliom
IVIS 2.50 cooled charged-coupled device camera,computational_tools,PMID:18931645,10.1097/MAO.0b013e31818b6cea,Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,IVIS 2.50 cooled charged-coupled device camera,Analysis Software,2.50,,,,,,,,,,,,,,,"Ten minutes after luciferin injection, mice were imaged with an IVIS 2.50 cooled charged-coupled device camera (Xenogen 200 series).",Software name not in publication title — likely generic usage: IVIS 2.50 cooled charged-coupled device camera
Living Image software,computational_tools,PMID:18931645,10.1097/MAO.0b013e31818b6cea,Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Living Image software,Analysis Software,,,,,,,,,,,,,,,,"For BLI analysis, an intracranial area of signal was defined using Living Image software",No version and no repository URL (confidence < 0.9 — unidentifiable)
small animal stereotactic frame,computational_tools,PMID:18931645,10.1097/MAO.0b013e31818b6cea,Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice.,,0.75,Experimental Usage,True,0.67,Low,,,,,,,,,,,,,,,small animal stereotactic frame,Other,,,,,,,,,,,,,,,,"With the aide of a small animal stereotactic frame (ASI Instruments, Houston, TX, USA), cells were injected",No version and no repository URL (confidence < 0.9 — unidentifiable)
Tucker-Davis Technologies BioSigRZ system,computational_tools,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Tucker-Davis Technologies BioSigRZ system,Analysis Software,,,,,,,,,,,,,,,,"The Tucker-Davis Technologies (TDT) BioSigRZ system, with an RZ6 digital/analog converter (TDT), was used to produce and record responses",No version and no repository URL (confidence < 0.9 — unidentifiable)
HALO AI DenseNet module,computational_tools,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HALO AI DenseNet module,Analysis Software,4.0,,,,,,,,,,,,,,,"Abnormal tissue and nuclear quantifications were performed using H&E-stained slides and a custom or pretrained HALO AI DenseNet module, respectively (Indica Labs, version 4.0, RRID:SCR_018350)",Software name not in publication title — likely generic usage: HALO AI DenseNet module
Seurat,computational_tools,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat,Package/Library,4.0.2,,,,,,,,,,,,,,,"The filtered_bc_matrix.h5 files were read into R using the Read10X_h5 function in Seurat (version 4.0.2, RRID:SCR_016341)",Software name not in publication title — likely generic usage: Seurat
CellChat,computational_tools,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CellChat,Package/Library,2.1.2,,,,,,,,,,,,,,,"CellChat (version 2.1.2, RRID:SCR_021946) was used to assess cell-cell communication within human VS",Software name not in publication title — likely generic usage: CellChat
SynergyFinder,computational_tools,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SynergyFinder,Package/Library,3.2,,,,,,,,,,,,,,,"Synergy graphs and Zero Interaction Potency score (ZIP), Loewe, and Bliss synergy scores were computed using the SynergyFinder package (version 3.2, RRID:SCR_019318) in R",Software name not in publication title — likely generic usage: SynergyFinder
iDEP.96,computational_tools,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,iDEP.96,Web Application,,,,,,,,,,,,,,,,Log 2 [counts per million (CPM) + 4] normalization of raw counts was performed using iDEP.96,No version and no repository URL (confidence < 0.9 — unidentifiable)
Omics Playground,computational_tools,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Omics Playground,Analysis Software,2.7.18,,,,,,,,,,,,,,,Plots for gene set enrichment (Figs. 2 and 3) and cell type mapping (reference dataset: LM22) were generated in Omics Playground software v2.7.18,Software name not in publication title — likely generic usage: Omics Playground
Imaris,computational_tools,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Imaris,Analysis Software,,,,,,,,,,,,,,,,"Images were processed using Imaris (Bitplane, RRID:SCR_007370)",Generic bioinformatics/stats tool: Imaris
ImageJ,computational_tools,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ,Analysis Software,1.53,,,,,,,,,,,,,,,"Arbitrary densitometry units were calculated and quantified using the ImageJ software [National Institutes of Health (NIH), version 1.53]",Generic bioinformatics/stats tool: ImageJ
ImageJ software,computational_tools,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ software,Analysis Software,,,,,,,,,,,,,,,,All images were analyzed with ImageJ software.,Generic bioinformatics/stats tool: ImageJ software
Drosophila Activity Monitoring System (Trikinetics),computational_tools,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Drosophila Activity Monitoring System (Trikinetics),Analysis Software,,,,,,,,,,,,,,,,"Sleep was monitored with the single-beam Drosophila Activity Monitoring System (Trikinetics, Waltham, MA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
Clocklab software (Actimetrics),computational_tools,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Clocklab software (Actimetrics),Analysis Software,,,,,,,,,,,,,,,,"Locomotor activity during days 1–7 in constant darkness was analyzed with Clocklab software (Actimetrics, Wilmette, IL).",No version and no repository URL (confidence < 0.9 — unidentifiable)
Meta-cycle R program,computational_tools,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Meta-cycle R program,Package/Library,,,,,,,,,,,,,,,,the calcium data were subjected to Jonckheere-Terpstra-Kendall (JTK)_CYCLE and Lomb-Scargle (LS) analysis using the Meta-cycle R program,No version and no repository URL (confidence < 0.9 — unidentifiable)
GeneNetwork,computational_tools,PMID:17216419,10.1007/s10048-006-0078-5,Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GeneNetwork,Web Application,,http://www.genenetwork.org/search.html,,,,,,,,,,,,,,The GeneNetwork (http://www.genenetwork.org/search.html) was searched for Nf1 in mouse B×D datasets from the brain,Software name not in publication title — likely generic usage: GeneNetwork
WebQTL,computational_tools,PMID:17216419,10.1007/s10048-006-0078-5,Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,WebQTL,Analysis Software,,,,,,,,,,,,,,,,WebQTL interval mapping was used to determine regions of the genome responsible for variation in Nf1 expression levels,No version and no repository URL (confidence < 0.9 — unidentifiable)
UCSC Genome Browser,computational_tools,PMID:17216419,10.1007/s10048-006-0078-5,Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,UCSC Genome Browser,Web Application,,,,,,,,,,,,,,,,using a blast-like alignment tool (BLAT) search in the UCSC Genome Browser that is linked to GeneNetwork,No version and no repository URL (confidence < 0.9 — unidentifiable)
MX4000 (Stratagene),computational_tools,PMID:17216419,10.1007/s10048-006-0078-5,Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MX4000 (Stratagene),Analysis Software,,,,,,,,,,,,,,,,"PCR products were analyzed for the number of cycles required to reach the threshold using a quantitative real-time PCR machine, the MX4000 (Stratagene)",No version and no repository URL (confidence < 0.9 — unidentifiable)
"MPlus, version 7.3",computational_tools,PMID:27760236,10.1001/jamapsychiatry.2016.2600,Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT).,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"MPlus, version 7.3",Analysis Software,7.3,,,,,,,,,,,,,,,"a series of mixture models (MPlus, version 7.3) were used to investigate the presence of latent classes","Software name not in publication title — likely generic usage: MPlus, version 7.3"
"SPSS, version 23",computational_tools,PMID:27760236,10.1001/jamapsychiatry.2016.2600,Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT).,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,"SPSS, version 23",Analysis Software,23,,,,,,,,,,,,,,,"Data were analyzed in SPSS, version 23 (IBM Corp)","Software name not in publication title — likely generic usage: SPSS, version 23"
FACScalibur,computational_tools,PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FACScalibur,Analysis Software,,,,,,,,,,,,,,,,"DNA analyses were made with a FACScalibur instrument (BD Biosciences, San Jose, CA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
MODFIT,computational_tools,PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MODFIT,Analysis Software,,,,,,,,,,,,,,,,"Percentages of cells in the G0/G1, S, and G2/M stages of the cell cycle were determined with a DNA histogram-fitting program (MODFIT; Verity Software, Topsham, ME)",Software name not in publication title — likely generic usage: MODFIT
ImageQuant software,computational_tools,PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageQuant software,Analysis Software,,,,,,,,,,,,,,,,"ImageQuant software (GE Healthcare, Piscataway, NJ) was used for densitometry and quantification of immunoblot signals",No version and no repository URL (confidence < 0.9 — unidentifiable)
ADOBE Photoshop software,computational_tools,PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ADOBE Photoshop software,Analysis Software,,,,,,,,,,,,,,,,"brightness and contrast levels of scanned immunoblot images were uniformly adjusted using ADOBE Photoshop software (Adobe Systems, San Jose, CA)",No version and no repository URL (confidence < 0.9 — unidentifiable)
GraphPad Prism Version 7.03,computational_tools,PMID:29796169,10.18632/oncotarget.25195,Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism Version 7.03,Analysis Software,7.03,,,,,,,,,,,,,,,ATRX protein expression was compared between histology by Fisher's Exact Test using Graphpad Prism Version 7.03.,Generic tool (versioned): GraphPad Prism Version 7.03
SAS version 9.4,computational_tools,PMID:29796169,10.18632/oncotarget.25195,Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SAS version 9.4,Analysis Software,9.4,,,,,,,,,,,,,,,"Statistical analyses were performed with SAS (version 9.4; SAS Institute, Cary, NC) unless otherwise noted.",Generic tool (versioned): SAS version 9.4
vivaCT40 scanner,computational_tools,PMID:18671844,10.1186/1741-7015-6-21,Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,vivaCT40 scanner,Analysis Software,,,,,,,,,,,,,,,,Methacrylate embedded tibiae were scanned in plastic blocks using a vivaCT40 scanner from ScancoMedical,No version and no repository URL (confidence < 0.9 — unidentifiable)
Scanco evaluation software,computational_tools,PMID:18671844,10.1186/1741-7015-6-21,Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin.,,0.85,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Scanco evaluation software,Analysis Software,,,,,,,,,,,,,,,,All VOIs were analysed under identical settings with the Scanco evaluation software,No version and no repository URL (confidence < 0.9 — unidentifiable)
Kaplan-Meier method,computational_tools,PMID:18984156,10.1016/j.cell.2008.08.041,Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Kaplan-Meier method,Analysis Software,,,,,,,,,,,,,,,,Analysis of survival outcomes was performed using the Kaplan-Meier method.,No version and no repository URL (confidence < 0.9 — unidentifiable)
Student's t test,computational_tools,PMID:18984156,10.1016/j.cell.2008.08.041,Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.,,0.8,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Student's t test,Analysis Software,,,,,,,,,,,,,,,,"Comparison of the mean size of tumors, differences in cellularity and apoptosis in the experimental groups was performed using Student's t test or analysis of variance.",No version and no repository URL (confidence < 0.9 — unidentifiable)
dLight1.2,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,dLight1.2,Viral,AAV,hSyn,,,,,,,,,,,,,,,,,,pAAV-hSyn-dLight1.2 Addgene Plasmid#: 111068 RRID: Addgene_111068 Gift on Lin Tian; produced by UC Davis Vector Core,Insert does not reference a core NF disease gene: dLight1.2
hChR2(H134R)-EYFP,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,hChR2(H134R)-EYFP,Viral,AAV,hSyn,,,,,,,,,,,,,,,,,,pAAV-hSyn-hChR2(H134R)-EYFP Addgene Plasmid#: 26973 RRID: Addgene_26973 Gift of Karl Deisseroth,Insert does not reference a core NF disease gene: hChR2(H134R)-EYFP
Cre,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,AAV9,Th,,,,,,,,,,,,,,,,,,AAV9-Th-PI-Cre-SV40 Addgene Plasmid#: 107788 RRID: Addgene_107788 Addgene viral prep#: 107788-AAV9,Insert does not reference a core NF disease gene: Cre
eNpHR3.0-eYFP,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,eNpHR3.0-eYFP,Viral,AAV-DJ,Ef1α,,,,,,,,,,,,,,,,,,pAAV-DJ-Ef1α-DO-eNpHR3.0-eYFP-WPRE-pA Addgene Plasmid#: 37087 RRID: Addgene_37087 Gift of Bernardo Sabatini,Insert does not reference a core NF disease gene: eNpHR3.0-eYFP
mCherry,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mCherry,Viral,AAV-DJ,Ef1α,,,,,,,,,,,,,,,,,,pAAV-DJ-Ef1α-DO-mCherry-WPRE-pA Addgene Plasmid#: 37119 RRID: Addgene_37119 Gift of Bernardo Sabatini,Generic reagent (fluorescent label / control / probe): mCherry
tTA,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,tTA,Viral,AAV,ihSyn1,,,,,,,,,,,,,,,,,,pAAV-ihSyn1-tTA-WPRE Addgene Plasmid#: 99120 RRID: Addgene_99120,Insert does not reference a core NF disease gene: tTA
tTA,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,tTA,Viral,AAV,Th,,,,,,,,,,,,,,,,,,pAAV-Th-tTA-WPRE Addgene Plasmid#: 133268 RRID: Addgene_133268,Insert does not reference a core NF disease gene: tTA
mRuby,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mRuby,Viral,AAV,TRE,,,,,,,,,,,,,,,,,,pAAV-TRE-mRuby-WPRE Addgene Plasmid#: 99114 RRID: Addgene_99114,Generic reagent (fluorescent label / control / probe): mRuby
mTurquoise,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mTurquoise,Viral,AAV,TRE,,,,,,,,,,,,,,,,,,pAAV-TRE-mTurquoise-WPRE Addgene Plasmid#: 99113 RRID: Addgene_99113,Generic reagent (fluorescent label / control / probe): mTurquoise
GFP,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Viral,AAV,Th,,,,,,,,,,,,,,,,,,pAAV-Th-GFP-WPRE Addgene Plasmid#: 99128 RRID: Addgene_99128,Generic reagent (fluorescent label / control / probe): GFP
iCAP-PHP.eB,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,iCAP-PHP.eB,Plasmid,pUCmini,,,,,,,,,,,,,,,,,,,pUCmini-iCAP-PHP.eB Addgene Plasmid#: 103005 RRID: Addgene_103005,Insert does not reference a core NF disease gene: iCAP-PHP.eB
dLight1,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,dLight1,Viral,,,,,,,,,,,,,,,,,,,,We employed the genetically encoded optical dopamine sensor dLight1 to monitor dopaminergic neurotransmission in the ventral striatum of NF1 mice,Insert does not reference a core NF disease gene: dLight1
DNA extraction kit,genetic_reagents,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction kit,Other,,,,,,,,,,,,,,,,,,,,Genomic DNA (gDNA) was extracted from blood or frozen tissue using Qiagen DNeasy Blood & Tissue kit (Qiagen Ca#69506),Non-genetic lab reagent/kit/consumable: DNA extraction kit
Human exome capture,genetic_reagents,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human exome capture,Other,,,,,,,,,,,,,,,,,,,,"subjected to exome enrichment using SureSelectXT Human All Exon version 5 (Agilent Technologies, Wilmington, DE, catalog# 5190-6210)",Non-genetic lab reagent/kit/consumable: Human exome capture
LacZ,genetic_reagents,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,LacZ,Viral,,,,,,,,,,,,,,,,,,,,Cells were transduced with either lentiviral control shLacZ (Genome Institute at Washington University),Insert does not reference a core NF disease gene: LacZ
Trim23,genetic_reagents,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Trim23,Viral,,,,,,,,,,,,,,,,,,,,"separate lentiviral shRNAs targeting Trim23 (Sigma; TRCN0000308323, TRCN0000308321, TRCN0000308320)",Insert does not reference a core NF disease gene: Trim23
Cre,genetic_reagents,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,,CMV,,,,,,,,,,,,,,,,,,"DRG-NSCs were isolated from E13.5 embryo DRG/nerve roots, and were infected with Ad-CMV-Cre",Insert does not reference a core NF disease gene: Cre
shCOL1A2,genetic_reagents,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shCOL1A2,Viral,,,,,,,,,,,,,,,,,,,,Human sh COL1A2 and mouse sh Col1a2 lentiviral particles (TRCN0000090043; TRCN0000090045; TRCN0000335210),Insert does not reference a core NF disease gene: shCOL1A2
TRIzol LS,genetic_reagents,PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TRIzol LS,Other,,,,,,,,,,,,,,,,,,,,RNA was isolated from fresh blood leukocytes from two normal individuals using TRIzol LS Reagent (Invitrogen) according to the manufacturer's instructions.,Non-genetic lab reagent/kit/consumable: TRIzol LS
SuperScript II,genetic_reagents,PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SuperScript II,Other,,,,,,,,,,,,,,,,,,,,Total RNA (2 μg) was reverse transcribed using SuperScript II Reverse transcriptase (Invitrogen) and random hexamers (Amersham Biosciences).,Non-genetic lab reagent/kit/consumable: SuperScript II
pCR2.1-TOPO,genetic_reagents,PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pCR2.1-TOPO,Plasmid,pCR2.1,,,,,,,,,,,,,,,,,,,The PCR products were cloned in the pCR2.1-TOPO-vector (Invitrogen) and transformed into TOP-10F' cells.,Generic reagent (fluorescent label / control / probe): pCR2.1-TOPO
Thermo Sequenase,genetic_reagents,PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Thermo Sequenase,Other,,,,,,,,,,,,,,,,,,,,All transcripts with a different restriction pattern were sequenced (primer sequences available upon request) using the Thermo Sequenase fluorescent labelled primer cycle sequencing kit (Amersham Biosciences),Non-genetic lab reagent/kit/consumable: Thermo Sequenase
dispase grade II,genetic_reagents,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,dispase grade II,Other,,,,,,,,,,,,,,,,,,,,"enzymatically digested with dispase grade II (1.25 U/mL, Roche, Basel, Switzerland)",Non-genetic lab reagent/kit/consumable: dispase grade II
collagenase type I,genetic_reagents,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,collagenase type I,Other,,,,,,,,,,,,,,,,,,,,"collagenase type I (160 U/mL, Sigma, St. Louis, MO, USA)",Non-genetic lab reagent/kit/consumable: collagenase type I
CCK8,genetic_reagents,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CCK8,Other,,,,,,,,,,,,,,,,,,,,"Cell viability was evaluated using the Cell Counting Kit-8 (CCK8, Dojindo Laboratories, Kumamoto, Japan)",Non-genetic lab reagent/kit/consumable: CCK8
Cre,genetic_reagents,PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,Ad5,CMV,,,,,,,,,,,,,,,,,,infection with adenovirus Ad5-CMV-Cre or Ad5-CMV-eGFP (2500 viral particles per cell; Vector Development Lab),Insert does not reference a core NF disease gene: Cre
eGFP,genetic_reagents,PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,eGFP,Viral,Ad5,CMV,,,,,,,,,,,,,,,,,,infection with adenovirus Ad5-CMV-Cre or Ad5-CMV-eGFP (2500 viral particles per cell; Vector Development Lab),Generic reagent (fluorescent label / control / probe): eGFP
Gateway entry vector,genetic_reagents,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Gateway entry vector,Plasmid,,,,,,,,,,,,,,,,,,,,PCR amplicons were cloned into pDonr255 and fully sequence-verified,Generic reagent (fluorescent label / control / probe): Gateway entry vector
baculovirus expression vector,genetic_reagents,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,baculovirus expression vector,Plasmid,pFastBac1,,,,,,,,,,,,,,,,,,,Gateway LR recombination was used to generate final expression clones in baculovirus Destination vectors pDest-635 (pFastBac1 with N-terminal His 6 tag),Generic reagent (fluorescent label / control / probe): baculovirus expression vector
baculovirus expression vector,genetic_reagents,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,baculovirus expression vector,Plasmid,pFastBac1,,,,,,,,,,,,,,,,,,,pDest-636 (pFastBac1 with N-terminal His 6 -MBP tag),Generic reagent (fluorescent label / control / probe): baculovirus expression vector
E. coli expression vector,genetic_reagents,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,E. coli expression vector,Plasmid,,,,,,,,,,,,,,,,,,,,"E. coli Destination vector pDest-566 (N-terminal His6-MBP tag, Addgene catalog no. 11517)",Generic reagent (fluorescent label / control / probe): E. coli expression vector
exome capture,genetic_reagents,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,exome capture,Other,,,,,,,,,,,,,,,,,,,,"Exome libraries were captured with an IDT exome reagent, then pooled with a WGS library for sequencing",Non-genetic lab reagent/kit/consumable: exome capture
RNA library preparation,genetic_reagents,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA library preparation,Other,,,,,,,,,,,,,,,,,,,,"RNA was prepared with a TrueSeq stranded total RNA library kit, then sequenced on an Illumina HISeq4000",Non-genetic lab reagent/kit/consumable: RNA library preparation
TruSeq DNA PCR Free 350bp,genetic_reagents,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSeq DNA PCR Free 350bp,Other,,,,,,,,,,,,,,,,,,,,Between 350 and 500 ng of tumor DNA were used to prepare DNA sequencing libraries using the TruSeq DNA PCR Free 350bp kit,Non-genetic lab reagent/kit/consumable: TruSeq DNA PCR Free 350bp
truXTRAC FFPE DNA,genetic_reagents,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,truXTRAC FFPE DNA,Other,,,,,,,,,,,,,,,,,,,,DNA extraction from FFPE tissue samples was performed using the Covaris truXTRAC FFPE DNA kit with the E220 Evolution-focused ultrasonicator system,Insert does not reference a core NF disease gene: truXTRAC FFPE DNA
Kapa HyperPlus,genetic_reagents,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Kapa HyperPlus,Other,,,,,,,,,,,,,,,,,,,,"Exome libraries were prepared using the Roche Kapa HyperPlus kit, captured using the HyperExome kit Roche",Insert does not reference a core NF disease gene: Kapa HyperPlus
HumanMethylationEPIC,genetic_reagents,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HumanMethylationEPIC,Other,,,,,,,,,,,,,,,,,,,,Tumor DNA derived from fresh-frozen tumors and paired normal nerve samples was used for whole-genome DNA methylation array profiling using the HumanMethylationEPIC beadchip platform,Insert does not reference a core NF disease gene: HumanMethylationEPIC
EZ DNA methylation Gold,genetic_reagents,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,EZ DNA methylation Gold,Other,,,,,,,,,,,,,,,,,,,,350 ng of DNA were bisulfite converted using the Zymo EZ DNA methylation Gold kit (Zymo Research Corp.),Insert does not reference a core NF disease gene: EZ DNA methylation Gold
RNA extraction reagent,genetic_reagents,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"total RNA was extracted from VS and control nerve samples using the Trizol reagent (Gibco Invitrogen, Carlsbad, CA)",Non-genetic lab reagent/kit/consumable: RNA extraction reagent
oligo-dT,genetic_reagents,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,oligo-dT,Other,,,,,,,,,,,,,,,,,,,,"mRNA was selected by running total RNA over oligo-dT columns (Invitrogen, Carlsbad, CA)",Generic reagent (fluorescent label / control / probe): oligo-dT
reverse transcription kit,genetic_reagents,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,reverse transcription kit,Other,,,,,,,,,,,,,,,,,,,,"mRNA (5 μg per 50 μL sample) was reverse transcribed using the Gene AMP kit (Perkin-Elmer; Waltham, MA)",Non-genetic lab reagent/kit/consumable: reverse transcription kit
PCR master mix,genetic_reagents,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PCR master mix,Other,,,,,,,,,,,,,,,,,,,,"Taqman Universal PCR Master Mix (2× buffer containing polymerase; Applied Biosystems, Foster City, CA)",Insert does not reference a core NF disease gene: PCR master mix
gene expression assay,genetic_reagents,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,gene expression assay,Other,,,,,,,,,,,,,,,,,,,,"20× solution of primers and fluorophor-labeled probe (Taqman Gene Expression Assays; Applied Biosystems, Foster City, CA)",Non-genetic lab reagent/kit/consumable: gene expression assay
GSK2126458,genetic_reagents,PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,GSK2126458,,,,,,,,,,,,,,,,,,,,,"Cell viability results showed that three agents (GSK2126458, Panobinostat, CUDC-907) had the greatest activity across schwannoma and meningioma cell systems",Drug compound: GSK2126458
Panobinostat,genetic_reagents,PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Panobinostat,,,,,,,,,,,,,,,,,,,,,"Cell viability results showed that three agents (GSK2126458, Panobinostat, CUDC-907) had the greatest activity across schwannoma and meningioma cell systems",Drug compound (class suffix): Panobinostat
CUDC-907,genetic_reagents,PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,CUDC-907,,,,,,,,,,,,,,,,,,,,,"Cell viability results showed that three agents (GSK2126458, Panobinostat, CUDC-907) had the greatest activity across schwannoma and meningioma cell systems",Drug compound: CUDC-907
GLuc,genetic_reagents,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GLuc,Viral,,,,,,,,,,,,,,,,,,,,"NF2 −/− cells should be transduced before use so they express the GLuc reporter gene, which is a secreted reporter that can be detected in the blood of tumor-bearing animals.",Insert does not reference a core NF disease gene: GLuc
GLuc,genetic_reagents,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GLuc,Viral,,,,,,,,,,,,,,,,,,,,"GLuc vector and assay kits are commercially available from various biotech companies, such as Thermo Fisher Scientific (cat. no. 16146) and New England BioLabs (cat. no. N8084S).",Insert does not reference a core NF disease gene: GLuc
GLuc,genetic_reagents,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GLuc,Viral,,,,,,,,,,,,,,,,,,,,"GLuc vector and assay kits are commercially available from various biotech companies, such as Thermo Fisher Scientific (cat. no. 16146) and New England BioLabs (cat. no. N8084S).",Insert does not reference a core NF disease gene: GLuc
mGeCKOa sgRNA library,genetic_reagents,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mGeCKOa sgRNA library,Viral,,,,,,,,,,,,,,,,,,,,"We infected p53−/−; Myc; Cas9 hepatocytes with the mGeCKOa lentiviral library of 67,000 single-guide RNAs (sgRNAs), targeting 20,611 mouse genes",Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
Cas9/sgRNA,genetic_reagents,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9/sgRNA,Plasmid,pX330,,,,,,,,,,,,,,,,,,,sgRNA oligos (IDT) were annealed and cloned into the pX330 vector (addgene 42230),Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
sgRNA,genetic_reagents,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,sgRNA,Viral,lentiV2,,,,,,,,,,,,,,,,,,,sgRNA oligos (IDT) were annealed and cloned into the pX330 vector (addgene 42230) or lentiV2 (addgene 52961),Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
Myc,genetic_reagents,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Myc,Plasmid,pT3,EF1α,,,,,,,,,,,,,,,,,,"pX330.sgNf1 (20 μg), pT3-EF1α-Myc (5 μg), and CMV-SB10 transposase (1 μg) plasmids were delivered",Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
SB10 transposase,genetic_reagents,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SB10 transposase,Plasmid,,CMV,,,,,,,,,,,,,,,,,,"pX330.sgNf1 (20 μg), pT3-EF1α-Myc (5 μg), and CMV-SB10 transposase (1 μg) plasmids were delivered",Publication title lacks NF-specific terms: Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kin
apterous-Gal4,genetic_reagents,PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,apterous-Gal4,Other,,,,,,,,,,,,,,,,,,,,ectopic expression of the NF2 isoforms under the control of the apterous-Gal4 driver,Insert does not reference a core NF disease gene: apterous-Gal4
Complete Mini protease inhibitors,genetic_reagents,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Complete Mini protease inhibitors,Other,,,,,,,,,,,,,,,,,,,,"...sonicated for five cycles of 30 s on, 30 s off in 50 µL of 100 mM triethylammonium bicarbonate buffer supplemented with Complete Mini protease inhibitors (Roche, Basel, Switzerland)...",Non-genetic lab reagent/kit/consumable: Complete Mini protease inhibitors
S-Trap micro spin columns,genetic_reagents,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,S-Trap micro spin columns,Other,,,,,,,,,,,,,,,,,,,,"...After acidification with phosphoric acid and addition of the S-Trap binding buffer, the samples were applied to S-Trap micro spin columns (ProtiFi, Farmingdale, NY, USA)...",Non-genetic lab reagent/kit/consumable: S-Trap micro spin columns
UltraView Universal DAB detection kit,genetic_reagents,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,UltraView Universal DAB detection kit,Other,,,,,,,,,,,,,,,,,,,,...and detection with the UltraView Universal DAB detection kit (Roche)...,Non-genetic lab reagent/kit/consumable: UltraView Universal DAB detection kit
Dako EnVision kit,genetic_reagents,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Dako EnVision kit,Other,,,,,,,,,,,,,,,,,,,,"...The labeling was carried out using the peroxidase-based Dako EnVision kit (Agilent Dako, Santa Clara, CA, USA)...",Non-genetic lab reagent/kit/consumable: Dako EnVision kit
pan-T-cell isolation,genetic_reagents,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,pan-T-cell isolation,,,,,,,,,,,,,,,,,,,,,"CD3+ T cells were purified from the lymph nodes using pan-T-cell isolation kit (Miltenyi Biotec, Auburn, CA)",Generic reagent (fluorescent label / control / probe): pan-T-cell isolation
7-aminoactinomycin D,genetic_reagents,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,7-aminoactinomycin D,,,,,,,,,,,,,,,,,,,,,Live cells were isolated from dead cells by staining with 7-aminoactinomycin D (Biolegend; 420403; 1:100),Non-genetic lab reagent/kit/consumable: 7-aminoactinomycin D
Vecta Stain Elite ABC,genetic_reagents,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Vecta Stain Elite ABC,,,,,,,,,,,,,,,,,,,,,"the Vecta Stain Elite ABC kit (Vectorlabs, PK-6100) was used according to the manufacturer's protocol",Non-genetic lab reagent/kit/consumable: Vecta Stain Elite ABC
RNA extraction reagent,genetic_reagents,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"RNA was isolated from the knee cartilage...using peqGOLD TriFast (PeqLab Biotechnologie GmbH, Erlangen, Germany)",Non-genetic lab reagent/kit/consumable: RNA extraction reagent
Reverse Transcriptase,genetic_reagents,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Reverse Transcriptase,Other,,,,,,,,,,,,,,,,,,,,"cDNA was synthesized from 1 μg of total RNA with MuLV Reverse Transcriptase (Applied Biosystems, Carlsbad, CA, USA)",Non-genetic lab reagent/kit/consumable: Reverse Transcriptase
PCR Master Mix,genetic_reagents,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PCR Master Mix,Other,,,,,,,,,,,,,,,,,,,,TaqMan Universal PCR Master Mix was then performed on an ABI PRISM 7900 Cycler (Applied Biosystems),Insert does not reference a core NF disease gene: PCR Master Mix
Cre,genetic_reagents,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,Ad5,,,,,,,,,,,,,,,,,,,The Nf1 gene was inactivated in passage 1 Nf1flox/flox astrocytes by infection with adenovirus (Ad5) containing Cre recombinase,Insert does not reference a core NF disease gene: Cre
LacZ,genetic_reagents,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,LacZ,Viral,Ad5,,,,,,,,,,,,,,,,,,,Control Nf1flox/flox astrocytes (wild-type) were treated identically with an adenovirus encoding LacZ,Insert does not reference a core NF disease gene: LacZ
RASopathy gene panel,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RASopathy gene panel,Other,,,,,,,,,,,,,,,,,,,,"Target sequencing was performed using the Haloplex custom target enrichment system (Agilent Technologies, CA, USA) on the MiSeq sequencing platform",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
Site-directed mutagenesis reagents,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Site-directed mutagenesis reagents,Other,,,,,,,,,,,,,,,,,,,,"We introduced a single-base substitution into the corresponding expression vector using Q5® Site-Directed Mutagenesis Kit (NEB, UK)",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
Luciferase reporter,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Luciferase reporter,Plasmid,,Gal4,,,,,,,,,,,,,,,,,,"We introduced pGal-LUC (Clontech), pGal-ELK1 and the expression plasmids into HEK-293T cells",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
ELK1,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ELK1,Plasmid,,Gal4,,,,,,,,,,,,,,,,,,"We introduced pGal-LUC (Clontech), pGal-ELK1 and the expression plasmids into HEK-293T cells",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
Dual luciferase reporter,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Dual luciferase reporter,Other,,,,,,,,,,,,,,,,,,,,"The luciferase activity was measured using a Dual-Luciferase® Reporter assay system (Promega, WI, USA)",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
Renilla luciferase,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Renilla luciferase,Plasmid,,SV40,,,,,,,,,,,,,,,,,,"Transfection efficiencies were normalised to the control plasmid, which was pSV-RLuc (Promega, WI, USA) expressing Renilla luciferase",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
GFP fusion vector,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP fusion vector,Plasmid,pCMV6-AC-GFP,CMV,,,,,,,,,,,,,,,,,,"the in-frame coding sequence of RAF1, A2ML1 and RIT1 were subcloned into the pCMV6-AC-GFP vector such that the GFP coding sequence was fused in-frame",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
T7 transcription reagents,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,T7 transcription reagents,Other,,,,,,,,,,,,,,,,,,,,"GFP-tagged RNA transcripts were synthesised using the mMESSAGE mMACHINE T7 Transcription Kit (Thermo Fisher Scientific, MA, USA)",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
cmlc1 probe,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,cmlc1 probe,Other,,,,,,,,,,,,,,,,,,,,"PFA fixed embryos were probed with digoxigenin-labelled cmlc1, which is a cardiac development marker for zebrafish, by in situ hybridization",Publication title lacks NF-specific terms: Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pip
mApple,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mApple,Plasmid,,,,,,,,,,,,,,,,,,,,mApple-N1 (Addgene plasmid no. 54567) was a gift from M. Davidson,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
ZO-1,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ZO-1,Plasmid,,,,,,,,,,,,,,,,,,,,pSK ZO-1 (Addgene plasmid no. 30316) was a gift from J. Anderson and A. Fanning,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
GFP-NMHC II-B,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP-NMHC II-B,Plasmid,,CMV,,,,,,,,,,,,,,,,,,CMV-GFP-NMHC II-B (Addgene plasmid no. 11348) was a gift from R. Adelstein,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
GFP-vinculin,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP-vinculin,Plasmid,,,,,,,,,,,,,,,,,,,,pGFP(C3)-vinculin (Addgene plasmid no. 30312) was a gift from K. Hahn,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
venus-Scrib,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,venus-Scrib,Plasmid,,,,,,,,,,,,,,,,,,,,pKvenus-Scrib (Addgene plasmid no. 58738) was a gift from I. Macara,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
EGFP-hYAP1,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,EGFP-hYAP1,Plasmid,,,,,,,,,,,,,,,,,,,,"pEGFP-C3-hYAP1 and pEGFP C3-Lats1 (Addgene plasmid nos. 19053 and 17843, respectively) were gifts from M. Sudol",Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
EGFP-Lats1,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,EGFP-Lats1,Plasmid,,,,,,,,,,,,,,,,,,,,"pEGFP-C3-hYAP1 and pEGFP C3-Lats1 (Addgene plasmid nos. 19053 and 17843, respectively) were gifts from M. Sudol",Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
HA-AMOT p130,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HA-AMOT p130,Plasmid,,,,,,,,,,,,,,,,,,,,HA-AMOT p130 (Addgene plasmid no. 32821) was a gift from K. Guan,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
NLuc,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NLuc,Plasmid,pcDNA3.1,,,,,,,,,,,,,,,,,,,pcDNA3.1-ccdB-NLuc (Addgene plasmid no. 87067) was a gift from M. Taipale,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
4XBS2WT-Luc,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,4XBS2WT-Luc,Plasmid,,,,,,,,,,,,,,,,,,,,p4XBS2WT-Luc (Addgene plasmid no. 16593) was a gift from B. Vogelstein,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
8xGTIIC-luciferase,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,8xGTIIC-luciferase,Plasmid,,,,,,,,,,,,,,,,,,,,p8xGTIIC-luciferase (Addgene plasmid no. 34615) was a gift from S. Piccolo,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
p53 WT,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,p53 WT,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,pcDNA3 p53 WT (Addgene plasmid no. 69003) was a gift from D. Meek,Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
ZsGreen,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ZsGreen,Plasmid,pTRE3G-BI,,,,,,,,,,,,,,,,,,,"The Tet-inducible plasmids, pTRE3G-BI-ZsGreen and pCMV-Tet3G, were purchased from Tanaka Holdings",Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
Tet3G,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tet3G,Plasmid,,CMV,,,,,,,,,,,,,,,,,,"The Tet-inducible plasmids, pTRE3G-BI-ZsGreen and pCMV-Tet3G, were purchased from Tanaka Holdings",Publication title lacks NF-specific terms: Proximity biotinylation identifies a set of conformation-specific interactions b
H-RAS,genetic_reagents,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,H-RAS,Plasmid,,,,,,,,,,,,,,,,,,,,HA-H-RAS was expressed together with either wild-type (WT) or variant NF in COS-7 or HEK 293 T cells,Insert does not reference a core NF disease gene: H-RAS
RAF-RBD,genetic_reagents,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RAF-RBD,Other,,,,,,,,,,,,,,,,,,,,GTP-bound RAS was subsequently isolated using glutathione-agarose beads coated with recombinant GST-RAF-RBD,Insert does not reference a core NF disease gene: RAF-RBD
AT101,genetic_reagents,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,AT101,,,,,,,,,,,,,,,,,,,,,"AT101 was provided by Ascenta Therapeutics (Malvern, PA)",Drug compound: AT101
BNIP3,genetic_reagents,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,BNIP3,Other,,,,,,,,,,,,,,,,,,,,BNIP3 and HIF-1α siRNA (siGENOME SMARTPool) was purchased from Thermo Scientific,Insert does not reference a core NF disease gene: BNIP3
HIF-1α,genetic_reagents,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HIF-1α,Other,,,,,,,,,,,,,,,,,,,,BNIP3 and HIF-1α siRNA (siGENOME SMARTPool) was purchased from Thermo Scientific,Insert does not reference a core NF disease gene: HIF-1α
Trp53,genetic_reagents,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Trp53,Other,,,,,,,,,,,,,,,,,,,,"Trp53 Exon 3, F AAGTCACAGCACATGACGG",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
Brca1,genetic_reagents,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Brca1,Other,,,,,,,,,,,,,,,,,,,,"Brca1 Exon 6, F GCGTCGATCATCCAGAGCGT",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
Nf1,genetic_reagents,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,Nf1,Other,,,,,,,,,,,,,,,,,,,,"Nf1 Exon 8, F CCAGGACATCTCCAAGGATG",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
Pten,genetic_reagents,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Pten,Other,,,,,,,,,,,,,,,,,,,,"Pten Exon 6, R ATATACATAGCGCCTCTGAC",Publication title lacks NF-specific terms: Assessing the origin of high-grade serous ovarian cancer using CRISPR-modificati
PAXgene,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PAXgene,Other,,,,,,,,,,,,,,,,,,,,"blood was collected in PAXgene whole blood samples (Becton Dickinson, Franklin Lakes, NJ, USA)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
PAXgene Blood RNA System,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PAXgene Blood RNA System,Other,,,,,,,,,,,,,,,,,,,,"extraction was carried out with the PAXgene™ Blood RNA System (Qiagen, Hilden, Germany)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
Haloplex HS,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Haloplex HS,Other,,,,,,,,,,,,,,,,,,,,"library preparation with a Haloplex HS or SureSelect kits (Agilent Technologies, Santa Clara, CA, USA)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
SureSelect,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SureSelect,Other,,,,,,,,,,,,,,,,,,,,"library preparation with a Haloplex HS or SureSelect kits (Agilent Technologies, Santa Clara, CA, USA)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
SALSA MLPA P081/P082,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SALSA MLPA P081/P082,Other,,,,,,,,,,,,,,,,,,,,"using the SALSA MLPA kits P081/P082 (MRC Holland, Amsterdam, The Netherlands)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
Gentra Puregene,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Gentra Puregene,Other,,,,,,,,,,,,,,,,,,,,"using the Gentra Puregene kit (Puregene Cell and Tissue kit plus Qiagen GmbH, Hilden, Germany)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
beta-globin,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,beta-globin,Plasmid,,,,,,,,,,,,,,,,,,,,"cloned into the beta-globin vector, as previously described",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
Lipofectamine 2000,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Lipofectamine 2000,Other,,,,,,,,,,,,,,,,,,,,"transfected with 1 µg of the wild type or the mutated minigene using Lipofectamine 2000 (ThermoFisher Scientific, Watham, MA, USA)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
TRIzol,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TRIzol,Other,,,,,,,,,,,,,,,,,,,,"total RNA was extracted with TRIzolTM (ThermoFisher Scientific, Watham, MA, USA)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
SuperScript II,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SuperScript II,Other,,,,,,,,,,,,,,,,,,,,"retrotranscribed using SuperScript II reverse transcriptase (ThermoFisher Scientific, Watham, MA, USA)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
TOPO TA,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TOPO TA,Plasmid,,,,,,,,,,,,,,,,,,,,"purified bands were subcloned using the TOPO TA Cloning kit (ThermoFisher Scientific, Watham, MA, USA)",Publication title lacks NF-specific terms: Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles 
Phusion polymerase,genetic_reagents,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Phusion polymerase,,,,,,,,,,,,,,,,,,,,,"we used Phusion polymerase (M0530S; New England Biolabs, Inc., Ipswitch, MA) to synthesize a gRNA in vitro transcription template",Non-genetic lab reagent/kit/consumable: Phusion polymerase
T7 transcription,genetic_reagents,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,T7 transcription,,,,,,,,,,,,,,,,,,,,,used for in vitro transcription of gRNA according to the manufacturer instructions (MEGAshortscript T7 Transcription Kit (AM1354); ThermoFisher Scientific,Non-genetic lab reagent/kit/consumable: T7 transcription
Cas9,genetic_reagents,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Other,,,,,,,,,,,,,,,,,,,,1.95μm Cas9 (Cas9 Nuclease V3; IDT),Generic reagent (fluorescent label / control / probe): Cas9
Q5 DNA polymerase,genetic_reagents,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Q5 DNA polymerase,,,,,,,,,,,,,,,,,,,,,"PCR was performed using Q5® Hot Start High-Fidelity DNA Polymerase (New England Biolabs, Inc.) according to manufacturer's suggestions",Non-genetic lab reagent/kit/consumable: Q5 DNA polymerase
PrimeSTAR GXL,genetic_reagents,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,PrimeSTAR GXL,,,,,,,,,,,,,,,,,,,,,"the targeted region was PCR amplified with the hotstart PrimeSTAR GXL DNA polymerase (Takara Bio Inc., Mountain View, CA)",Insert does not reference a core NF disease gene: PrimeSTAR GXL
Cas9,genetic_reagents,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Other,,,,,,,,,,,,,,,,,,,,"The injection solution contained gRNAs, S. pyogenes Cas9 mRNA (PNA Bio Inc., Thousand Oaks, CA or Millipore Sigma, Burlington, MA)",Generic reagent (fluorescent label / control / probe): Cas9
dll4,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,dll4,,,hsp70,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
dlb,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,dlb,,,hsp70,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
hey1,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,hey1,,,hsp70,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
id2b,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,id2b,,,hsp70,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
Cas9,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,Cas9,,,ubi,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
dll4-gRNAs,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,dll4-gRNAs,,,u6,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
n3-gRNAs,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,n3-gRNAs,,,u6,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
hey1,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,hey1,,pXP1,,,,,,,,,,,,,,,,,,,A 3kb region upstream of the hey1 gene's transcription start site was amplified by PCR and cloned into Xho1/Kpn1 sites of the pXP1 plasmid to create 3kb-hey1:luciferase,Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
dlb,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,dlb,,pCS2,,,,,,,,,,,,,,,,,,,"we generated pCS2+dlb-EGFP, pCS2+n3-EGFP and pCS2+id2b-EGFP constructs",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
n3,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,n3,,pCS2,,,,,,,,,,,,,,,,,,,"we generated pCS2+dlb-EGFP, pCS2+n3-EGFP and pCS2+id2b-EGFP constructs",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
id2b,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,id2b,,pCS2,,,,,,,,,,,,,,,,,,,"we generated pCS2+dlb-EGFP, pCS2+n3-EGFP and pCS2+id2b-EGFP constructs",Publication title lacks NF-specific terms: Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response 
NHE1,genetic_reagents,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NHE1,Other,,,,,,,,,,,,,,,,,,,,"NHE1 siRNA: ON-TARGET SMART pool (Thermo Scientific); NBCn1 siRNA (SASI_Hs01_00030755, Sigma-Aldrich)",Insert does not reference a core NF disease gene: NHE1
V-CSCW2,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,V-CSCW2,Viral,CSCW2,,,,,,,,,,,,,,,,,,,Ben-Men-1 cells were transduced with either NF2-CSCW2 or V-CSCW2,Insert does not reference a core NF disease gene: V-CSCW2
INK128,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,INK128,,,,,,,,,,,,,,,,,,,,,"inhibitor drugs lapatinib, erlotinib, INK128/TAK-228, and BMS-754807 (Selleck Chemicals)",Drug compound: INK128
TAK-228,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,TAK-228,,,,,,,,,,,,,,,,,,,,,"inhibitor drugs lapatinib, erlotinib, INK128/TAK-228, and BMS-754807 (Selleck Chemicals)",Drug compound: TAK-228
BMS-754807,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,BMS-754807,,,,,,,,,,,,,,,,,,,,,"inhibitor drugs lapatinib, erlotinib, INK128/TAK-228, and BMS-754807 (Selleck Chemicals)",Drug compound: BMS-754807
lapatinib,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,lapatinib,,,,,,,,,,,,,,,,,,,,,"inhibitor drugs lapatinib, erlotinib, INK128/TAK-228, and BMS-754807 (Selleck Chemicals)",Drug compound (class suffix): lapatinib
erlotinib,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,erlotinib,,,,,,,,,,,,,,,,,,,,,"inhibitor drugs lapatinib, erlotinib, INK128/TAK-228, and BMS-754807 (Selleck Chemicals)",Drug compound (class suffix): erlotinib
rapamycin,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,rapamycin,,,,,,,,,,,,,,,,,,,,,rapamycin (EMD Millipore),Drug compound (class suffix): rapamycin
AZD2014,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,AZD2014,,,,,,,,,,,,,,,,,,,,,AZD2014 (obtained from AstraZeneca),Drug compound: AZD2014
MM-121,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,MM-121,,,,,,,,,,,,,,,,,,,,,MM-121 (generously provided by Merrimack Pharmaceuticals),Insert does not reference a core NF disease gene: MM-121
CellTiter-Glo cell viability kit,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,CellTiter-Glo cell viability kit,,,,,,,,,,,,,,,,,,,,,Drug screening assays for all cell lines were carried out in a 384-well format using the CellTiter-Glo cell viability kit (Promega),Non-genetic lab reagent/kit/consumable: CellTiter-Glo cell viability kit
ADU-S100,genetic_reagents,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,ADU-S100,,,,,,,,,,,,,,,,,,,,,"50 μg of the STING agonist ADU-S100 (HY-12885B, MedChemExpress)",Non-genetic lab reagent/kit/consumable: ADU-S100
SA3,genetic_reagents,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,SA3,,,,,,,,,,,,,,,,,,,,,"mice that were treated with the STING agonist SA3 (HY-103665, MedChemExpress)",Insert does not reference a core NF disease gene: SA3
GRDC24,genetic_reagents,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,GRDC24,Viral,AAV,CBh,,,,,,,,,,,,,,,,,,pscAAV-GFP and pscAAV-GRDC24 (2163 bp between ITRs) were used to generate AAV-GFP and AAV-GRDC24,Insert does not reference a core NF disease gene: GRDC24
NF-targeting capsid,genetic_reagents,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,NF-targeting capsid,Viral,AAV,,,,,,,,,,,,,,,,,,,"This tailored vector, AAV-NF, exhibits greatly reduced liver uptake, enhanced tumor targeting across various NF1-related MPNST",Insert does not reference a core NF disease gene: NF-targeting capsid
M1 morpholino,genetic_reagents,PMID:34945792,10.3390/jpm11121320,Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,M1 morpholino,Other,,,,,,,,,,,,,,,,,,,,Morpholino sequences include: M1: TGGACAAGAGAAGATACTTACAGCT,Insert does not reference a core NF disease gene: M1 morpholino
M2 morpholino,genetic_reagents,PMID:34945792,10.3390/jpm11121320,Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,M2 morpholino,Other,,,,,,,,,,,,,,,,,,,,M2: GACAAGAGAAGATACTTACAGCTTC,Insert does not reference a core NF disease gene: M2 morpholino
Control morpholino,genetic_reagents,PMID:34945792,10.3390/jpm11121320,Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Control morpholino,Other,,,,,,,,,,,,,,,,,,,,Control (Ctrl): CCTCTTACCTCAGTTACAATTTATA,Insert does not reference a core NF disease gene: Control morpholino
Human Phospho-RTK Array,genetic_reagents,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human Phospho-RTK Array,Other,,,,,,,,,,,,,,,,,,,,"MPNST cells were seeded in 15-cm dishes, allowed cell attachment overnight, treated the next day with the desired drug concentrations, harvested at the experiment endpoint, and lysed using the lysis buffer provided by Human Phospho-RTK Array Kit (R&D)",Insert does not reference a core NF disease gene: Human Phospho-RTK Array
CRISPR-Cas9,genetic_reagents,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CRISPR-Cas9,Viral,LentiCRISPR-v2,,,,,,,,,,,,,,,,,,,"The LentiCRISPR-v2 (RRID: Addgene_52961), LentiGuide-Puro (RRID: Addgene_52963), and LentiCas9-Blast (RRID: Addgene_52962) vectors were purchased from Addgene",Generic reagent (fluorescent label / control / probe): CRISPR-Cas9
Guide RNA,genetic_reagents,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Guide RNA,Viral,LentiGuide-Puro,,,,,,,,,,,,,,,,,,,"The LentiCRISPR-v2 (RRID: Addgene_52961), LentiGuide-Puro (RRID: Addgene_52963), and LentiCas9-Blast (RRID: Addgene_52962) vectors were purchased from Addgene",Generic reagent (fluorescent label / control / probe): Guide RNA
Cas9,genetic_reagents,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Viral,LentiCas9-Blast,,,,,,,,,,,,,,,,,,,"The LentiCRISPR-v2 (RRID: Addgene_52961), LentiGuide-Puro (RRID: Addgene_52963), and LentiCas9-Blast (RRID: Addgene_52962) vectors were purchased from Addgene",Generic reagent (fluorescent label / control / probe): Cas9
Cas9,genetic_reagents,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Plasmid,,,,,,,,,,,,,,,,,,,,WT S2R+ cells were co‐transfected with the pl018 plasmid to express Cas9,Generic reagent (fluorescent label / control / probe): Cas9
GFP,genetic_reagents,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Plasmid,,Actin,,,,,,,,,,,,,,,,,,co‐transfected with the pl018 plasmid to express Cas9 and the sgRNA (CGCTTCTCCCTTGTCATATC) and pAct‐GFP plasmid,Generic reagent (fluorescent label / control / probe): GFP
CRISPR-Cas9,genetic_reagents,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CRISPR-Cas9,Plasmid,,,,,,,,,,,,,,,,,,,,"NF1‐sg2 (ACACTGGAAAAATGTCTTGC), a sgRNA targeting human NF1 exon 3 in the lentiCRISPR v1 plasmid",Generic reagent (fluorescent label / control / probe): CRISPR-Cas9
Human All Exon capture probes,genetic_reagents,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human All Exon capture probes,Other,,,,,,,,,,,,,,,,,,,,"Sequencing libraries were generated from 1 μg genomic DNA using Agilent SureSelect Human All Exon kit (Agilent Technologies, California, USA)",Generic reagent (fluorescent label / control / probe): Human All Exon capture probes
Fluc and mCherry,genetic_reagents,PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Fluc and mCherry,Viral,,,,,,,,,,,,,,,,,,,,These cell lines have been transduced with lentivirus expressing Fluc and mCherry genes as described previously,Generic reagent (fluorescent label / control / probe): Fluc and mCherry
NF1-area probes,genetic_reagents,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1-area probes,Other,,,,,,,,,,,,,,,,,,,,"The deletions analyzed in this study were identified by MLPA analysis (P122-C1 NF1-area kit, MRC-Holland, The Netherlands)",Publication title lacks NF-specific terms: SVA retrotransposon insertion-associated deletion represents a novel mutational 
Long Template PCR enzymes,genetic_reagents,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Long Template PCR enzymes,Other,,,,,,,,,,,,,,,,,,,,"Breakpoint-spanning PCRs were performed using the Expand Long Template PCR system (Roche, Mannheim, Germany)",Publication title lacks NF-specific terms: SVA retrotransposon insertion-associated deletion represents a novel mutational 
BigDye Terminator,genetic_reagents,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,BigDye Terminator,Other,,,,,,,,,,,,,,,,,,,,"sequenced with the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies, Darmstadt, Germany)",Publication title lacks NF-specific terms: SVA retrotransposon insertion-associated deletion represents a novel mutational 
GenomeWalker adaptors,genetic_reagents,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GenomeWalker adaptors,Other,,,,,,,,,,,,,,,,,,,,"To perform GenomeWalker™ analysis (Clontech, Saint-Germain-en-Laye, France), genomic DNA (2.5 μg per experiment) was restriction digested",Publication title lacks NF-specific terms: SVA retrotransposon insertion-associated deletion represents a novel mutational 
Advantage 2 PCR enzymes,genetic_reagents,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Advantage 2 PCR enzymes,Other,,,,,,,,,,,,,,,,,,,,PCRs were performed with the Advantage® 2 PCR Kit (Clontech),Publication title lacks NF-specific terms: SVA retrotransposon insertion-associated deletion represents a novel mutational 
L-[18F]FETrp,genetic_reagents,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,L-[18F]FETrp,,,,,,,,,,,,,,,,,,,,,"We studied a fluorine-18 labeled tryptophan positron emission tomography (PET) radiotracer, 1-(2-[18F]FETrp",Insert does not reference a core NF disease gene: L-[18F]FETrp
phospho-protein purification kit from Qiagen®,genetic_reagents,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,phospho-protein purification kit from Qiagen®,,,,,,,,,,,,,,,,,,,,,Phospho-proteins were isolated from cell lysates using the commercially available phospho-protein purification kit from Qiagen®,Non-genetic lab reagent/kit/consumable: phospho-protein purification kit from Qiagen®
PDLIM2 shRNA,genetic_reagents,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PDLIM2 shRNA,Plasmid,pLKO.1-puro,,,,,,,,,,,,,,,,,,,Five different shRNA clones were tested... cloned into the plasmid pLKO.1-puro,Insert does not reference a core NF disease gene: PDLIM2 shRNA
λ-phosphatase,genetic_reagents,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,λ-phosphatase,,,,,,,,,,,,,,,,,,,,,Protein dephosphorylation was achieved by treating 20 μg of protein lysate with λ-phosphatase (New England Biolabs),Insert does not reference a core NF disease gene: λ-phosphatase
cytoplasmic and nuclear extraction assay (Thermo Scientific),genetic_reagents,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,cytoplasmic and nuclear extraction assay (Thermo Scientific),,,,,,,,,,,,,,,,,,,,,"To ascertain the cellular location of PDLIM2, a cytoplasmic and nuclear extraction assay (Thermo Scientific) was performed",Non-genetic lab reagent/kit/consumable: cytoplasmic and nuclear extraction assay (Thermo Scientific)
Cre and gRNAs,genetic_reagents,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,Cre and gRNAs,Viral,pLenti,CMV,,,,,,,,,,,,,,,,,,"We then prepared lentivirus vector pLentiCre/gRNA, which could express the elements blocking the function of four genes: Nf2, P15",Insert does not reference a core NF disease gene: Cre and gRNAs
Cre and gRNAs,genetic_reagents,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,Cre and gRNAs,Viral,AAV,pEFS,,,,,,,,,,,,,,,,,,"we constructed an AAV vector of pAAVCre/gRNA, which could import Cre and the four gRNAs",Insert does not reference a core NF disease gene: Cre and gRNAs
Taq polymerase,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Taq polymerase,,,,,,,,,,,,,,,,,,,,,"0.25 units of Taq polymerase (Perkin-Elmer Cetus) and a mixture of dATP, dCTP, dGTP and dTTP",Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
NeoTkp,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,NeoTkp,,,,,,,,,,,,,,,,,,,,,"200 ng of each oligonucleotide primer (NeoTkp, NF31a, NF31b)",Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
NF31a,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,NF31a,,,,,,,,,,,,,,,,,,,,,"200 ng of each oligonucleotide primer (NeoTkp, NF31a, NF31b)",Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
NF31b,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,NF31b,,,,,,,,,,,,,,,,,,,,,"200 ng of each oligonucleotide primer (NeoTkp, NF31a, NF31b)",Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
Leibovitz's L15 medium,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,Leibovitz's L15 medium,,,,,,,,,,,,,,,,,,,,,Embryos were decapitated in Leibovitz's L15 medium (Gibco),Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
DMEM,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,DMEM,,,,,,,,,,,,,,,,,,,,,"transferred to approximately 10 ml of Dulbecco's Modified Eagle Medium (DMEM, Gibco)",Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
2.5S NGF,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,2.5S NGF,,,,,,,,,,,,,,,,,,,,,"50 ng/ml nerve growth factor [2.5S NGF, Harlan Bio-products]",Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
rhGGF2,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,rhGGF2,,,,,,,,,,,,,,,,,,,,,"amplified for 1 week in recombinant human glial growth factor (rhGGF2, Cambridge Neuroscience)",Publication title lacks NF-specific terms: Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.
empty vector,genetic_reagents,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,empty vector,Plasmid,pcDNA3.1,,,,,,,,,,,,,,,,,,,An empty vector pcDNA3.1 was used as a control,Generic reagent (fluorescent label / control / probe): empty vector
GFP,genetic_reagents,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Viral,Adenovirus,,,,,,,,,,,,,,,,,,,"MPNST cells were infected with purified Ad-NF1-GRD or control Ad-GFP, in triplicate",Generic reagent (fluorescent label / control / probe): GFP
MAF,genetic_reagents,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MAF,Viral,Lentivirus,,,,,,,,,,,,,,,,,,,"Constitutive expression used mCherry tagged MAF (EX-Y2046-Lv111, GeneCopoeia) and mCherry control lentivirus",Insert does not reference a core NF disease gene: MAF
MAF ORF,genetic_reagents,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MAF ORF,Viral,pLVX-Tight-Puro,,,,,,,,,,,,,,,,,,,Inducible expression used lentiviral vectors containing the MAF ORF or empty pLVX-Tight-Puro vector (GeneCopoeia),Insert does not reference a core NF disease gene: MAF ORF
Tet-On,genetic_reagents,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tet-On,Viral,pLVX,Tet-inducible,,,,,,,,,,,,,,,,,,in a modified pTight backbone (Clonetech) with pLVX-Tet-On doxycycline inducible vector (Clonetech),Generic reagent (fluorescent label / control / probe): Tet-On
AP-1 luciferase,genetic_reagents,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,AP-1 luciferase,Plasmid,,AP-1,,,,,,,,,,,,,,,,,,Cells were transfected using FuGENE HD (Roche) with 100ng per well of an AP-1 luciferase (Stratagene) reporter vector,Generic reagent (fluorescent label / control / probe): AP-1 luciferase
DNA extraction reagent,genetic_reagents,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"Genomic DNA was extracted from the peripheral blood, skin lesions, hair, oral mucosa, and tumor tissues separately using the AxyPrep Blood Genomic DNA Miniprep Kit (Axygen, Corning, Jiangsu, China)",Non-genetic lab reagent/kit/consumable: DNA extraction reagent
DNA extraction reagent,genetic_reagents,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"Genomic DNA was extracted from the peripheral blood, skin lesions, hair, oral mucosa, and tumor tissues separately using the AxyPrep Blood Genomic DNA Miniprep Kit (Axygen, Corning, Jiangsu, China) and DNeasy Blood & Tissue Kit (Qiagen, Germany)",Non-genetic lab reagent/kit/consumable: DNA extraction reagent
DNA quantification reagent,genetic_reagents,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA quantification reagent,Other,,,,,,,,,,,,,,,,,,,,"quantified with a Qubit 2.0 Fluorometer using the Qubit dsDNA HS Assay Kit (Life Technologies, Thermo Fisher Scientific, Inc.)",Non-genetic lab reagent/kit/consumable: DNA quantification reagent
capture probe library,genetic_reagents,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,capture probe library,Other,,,,,,,,,,,,,,,,,,,,the capture probe from the Roche NimbleGen Sequence Capture SeqCap EZ Library was used to capture a total of 569 genes associated with hereditary dermatosis,Non-genetic lab reagent/kit/consumable: capture probe library
MLN8237,genetic_reagents,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,MLN8237,,,,,,,,,,,,,,,,,,,,,AURKA specific inhibitor MLN8237 (Selleck Chemicals). Mice were treated by gavage once daily with 30mg/kg MLN8237,Drug compound: MLN8237
C1368,genetic_reagents,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,C1368,,,,,,,,,,,,,,,,,,,,,Small-molecule AKIs were dissolved and diluted in DMSO/DMEM and included the pan-aurora inhibitors C1368 (Sigma),Drug compound: C1368
VX680,genetic_reagents,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,VX680,,,,,,,,,,,,,,,,,,,,,pan-aurora inhibitors C1368 (Sigma) and VX680 (Selleck Chemicals),Drug compound: VX680
pLKO.1,genetic_reagents,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pLKO.1,Plasmid,pLKO.1,,,,,,,,,,,,,,,,,,,"Lentivirus packaging, envelope and control non-hairpin (NHP) pLKO.1 plasmids (Addgene)",Generic reagent (fluorescent label / control / probe): pLKO.1
shRHAMM,genetic_reagents,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRHAMM,Viral,,,,,,,,,,,,,,,,,,,,shRNA against RHAMM and TPX2 (Sigma),Insert does not reference a core NF disease gene: shRHAMM
shTPX2,genetic_reagents,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shTPX2,Viral,,,,,,,,,,,,,,,,,,,,shRNA against RHAMM and TPX2 (Sigma),Insert does not reference a core NF disease gene: shTPX2
ZEB1,genetic_reagents,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ZEB1,Other,,,,,,,,,,,,,,,,,,,,"For siRNA knockdown targeting ZEB1 (Sigma-Aldrich, SASI_Hs02_00330526, SASI_Hs02_00330527, SASI_Hs02_00330530)",Insert does not reference a core NF disease gene: ZEB1
ALDH1A1,genetic_reagents,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ALDH1A1,Other,,,,,,,,,,,,,,,,,,,,"ALDH1A1 (Sigma-Aldrich, SASI_Hs01_00244055, SASI_Hs01_00244056, SASI_Hs02_00303091) in MPNST cell lines",Insert does not reference a core NF disease gene: ALDH1A1
ZEB1,genetic_reagents,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ZEB1,Viral,,,,,,,,,,,,,,,,,,,,"T265, was infected by nontarget control or lentiviral vectors carrying ZEB1 shRNA lentivirus for 48 hours",Insert does not reference a core NF disease gene: ZEB1
Cas9,genetic_reagents,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Other,,,,,,,,,,,,,,,,,,,,we utilized CRISPR Cas9 targeting of NF1 exon 2 to create inactivating indels in NF1 on both alleles,Generic reagent (fluorescent label / control / probe): Cas9
StrepII tag,genetic_reagents,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,StrepII tag,Other,,,,,,,,,,,,,,,,,,,,"We utilized a StepTactin XT System from IBA Lifesciences (Gottingen, Germany). Whole cell lysates were generated by collecting cells and lysing them",Insert does not reference a core NF disease gene: StrepII tag
M-PER,genetic_reagents,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,M-PER,Other,,,,,,,,,,,,,,,,,,,,"Global protein extracts were attained using M-PER™ Mammalian Protein Extraction Reagent (Thermo Fisher Scientific, Cat.# 78501)",Insert does not reference a core NF disease gene: M-PER
BCA,genetic_reagents,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,BCA,Other,,,,,,,,,,,,,,,,,,,,"and quantified using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Cat.# PI23225)",Insert does not reference a core NF disease gene: BCA
DNA extraction kit,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,DNA extraction kit,,,,,,,,,,,,,,,,,,,,,DNA was isolated from harvested tissues using DNeasy blood and tissue kit (Qiagen) according to the manufacturer's protocol,Non-genetic lab reagent/kit/consumable: DNA extraction kit
RNA extraction kit,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA extraction kit,,,,,,,,,,,,,,,,,,,,,Total RNA was extracted from cells and tissues using the RNeasy mini kit (Qiagen) following manufacturer's instructions,Non-genetic lab reagent/kit/consumable: RNA extraction kit
alamarBlue,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,alamarBlue,,,,,,,,,,,,,,,,,,,,,Proliferation was evaluated by the alamarBlue TM cell viability assay (Invitrogen) after indicated days in culture,Non-genetic lab reagent/kit/consumable: alamarBlue
Gentamicin,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,Gentamicin,,,,,,,,,,,,,,,,,,,,,Gentamicin (Sigma) and G418 (Corning) were reconstituted in sterile deionized water to a stock concentration of 50 mg/mL,Insert does not reference a core NF disease gene: Gentamicin
G418,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,G418,,,,,,,,,,,,,,,,,,,,,Gentamicin (Sigma) and G418 (Corning) were reconstituted in sterile deionized water,Drug compound: G418
Ataluren,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,Ataluren,,,,,,,,,,,,,,,,,,,,,Ataluren (MedChem Express) was reconstituted in sterile dimethyl sulfoxide (DMSO) to a stock concentration of 10 mM,Drug compound: Ataluren
PBSB,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PBSB,Transposon,,,,,,,,,,,,,,,,,,,,we used Gateway cloning to transfer the DLR insert to a hygromycin-resistant PiggyBac Sleeping Beauty (PBSB) transposon vector,Insert does not reference a core NF disease gene: PBSB
UPF1,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,UPF1,Other,,,,,,,,,,,,,,,,,,,,"cells were transfected with 50 nm of siRNA targeting UPF1. In a pilot experiment, three custom and non-overlapping UPF1 duplexes were tested",Insert does not reference a core NF disease gene: UPF1
EdU,genetic_reagents,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,EdU,,,,,,,,,,,,,,,,,,,,,EdU proliferation assay was performed using the Click-iT EdU Alexa Fluor 594 imaging kit (Thermo Fisher Scientific C10339),Insert does not reference a core NF disease gene: EdU
Amplex Red glutamic acid/glutamate oxidase assay,genetic_reagents,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,Amplex Red glutamic acid/glutamate oxidase assay,,,,,,,,,,,,,,,,,,,,,Glutamate released from wild-type and Nf1 cortical neurons was measured using the Amplex Red glutamic acid/glutsamate oxidase assay kit (Invitrogen),Non-genetic lab reagent/kit/consumable: Amplex Red glutamic acid/glutamate oxidase assay
EGFP,genetic_reagents,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,EGFP,,,,,,,,,,,,,,,,,,,,,Neurite outgrowth was determined from low-density hippocampal neurons transfected with EGFP using Lipofectamine,Generic reagent (fluorescent label / control / probe): EGFP
Lipofectamine,genetic_reagents,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Lipofectamine,Other,,,,,,,,,,,,,,,,,,,,Neurite outgrowth was determined from low-density hippocampal neurons transfected with EGFP using Lipofectamine,Insert does not reference a core NF disease gene: Lipofectamine
DNA extraction reagent,genetic_reagents,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"DNA was extracted from fresh-frozen tumor tissue and normal tissue using the DNeasy Blood and Tissue Kit (Qiagen, USA)",Non-genetic lab reagent/kit/consumable: DNA extraction reagent
RNA extraction reagent,genetic_reagents,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"Total RNA was isolated from tumor using the RNeasy Mini Kit (Qiagen, USA)",Non-genetic lab reagent/kit/consumable: RNA extraction reagent
Cas9,genetic_reagents,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Plasmid,pX330,,,,,,,,,,,,,,,,,,,"To generate CRISPR/Cas9-modified ipNF06.2A cell lines, sequences were subcloned into pX330",Generic reagent (fluorescent label / control / probe): Cas9
LacZ,genetic_reagents,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,LacZ,Viral,Ad5,,,,,,,,,,,,,,,,,,,Wild-type and Nf1 −/− NSCs were generated from Nf1 flox/flox mouse brains following infection with Ad5-LacZ and Ad5-Cre adenovirus,Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
Cre,genetic_reagents,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,Ad5,,,,,,,,,,,,,,,,,,,Wild-type and Nf1 −/− NSCs were generated from Nf1 flox/flox mouse brains following infection with Ad5-LacZ and Ad5-Cre adenovirus,Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
Abcg1,genetic_reagents,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Abcg1,Plasmid,pLKO.1,,,,,,,,,,,,,,,,,,,"Abcg1 shRNA or control shGFP-containing pLKO.1 plasmid was co-transfected with pMDLg/pRRE, pRSV-REV and pCMV-VSV-G",Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
shRNA,genetic_reagents,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNA,Plasmid,pLKO.1,,,,,,,,,,,,,,,,,,,Abcg1 shRNA or control shGFP-containing pLKO.1 plasmid was co-transfected,Publication title lacks NF-specific terms: Mouse low-grade gliomas contain cancer stem cells with unique molecular and func
GSK3B,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GSK3B,Viral,,,,,,,,,,,,,,,,,,,,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
AXIN1,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,AXIN1,Viral,,,,,,,,,,,,,,,,,,,,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
CTNNB1,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CTNNB1,Viral,,,,,,,,,,,,,,,,,,,,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
TNKS,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TNKS,Viral,,,,,,,,,,,,,,,,,,,,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
RSPO2,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RSPO2,Viral,,,,,,,,,,,,,,,,,,,,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems","Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
CTNNB1 S33Y,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CTNNB1 S33Y,Viral,,CAGGS,,,,,,,,,,,,,,,,,,A dsRed control and CTNNB1 S33Y were cloned into a vector containing a CAGGS promoter to drive cDNA expression followed by an IRES-GFP,"Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
GSK3B,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GSK3B,Plasmid,,CAGGS,,,,,,,,,,,,,,,,,,GSK3B and Luciferase cDNA (Invitrogen) were each cloned into a vector containing a CAGGS promoter to drive cDNA expression followed by an IRES-GFP,"Publication title lacks NF-specific terms: Canonical Wnt/β-catenin signaling drives human schwann cell transformation, prog"
hGFAP-cre,genetic_reagents,PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,hGFAP-cre,Other,,,,,,,,,,,,,,,,,,,,The control mice used in this study are a pool of phenotypically indistinguishable mice with genotypes of hGFAP-cre-; Nf1 flox/flox,Insert does not reference a core NF disease gene: hGFAP-cre
Nestin-cre ER,genetic_reagents,PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,Nestin-cre ER,,,,,,,,,,,,,,,,,,,,,"For inducible experiments, Nestin-cre ER +; Nf1 flox/+  (tamoxifen+) mice were used as controls while Nestin-cre ER +; Nf1 flox/flox",Insert does not reference a core NF disease gene: Nestin-cre ER
R26 LacZR,genetic_reagents,PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,R26 LacZR,,,,,,,,,,,,,,,,,,,,,Both of inducible strains carry R26 LacZR  allele as a reporter.,Insert does not reference a core NF disease gene: R26 LacZR
PD0325901,genetic_reagents,PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,PD0325901,,,,,,,,,,,,,,,,,,,,,"MEK inhibitor (PD0325901, Sigma) was dissolved in DMSO at a concentration of 25mg/ml",Drug compound: PD0325901
HK2,genetic_reagents,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,HK2,,,,,,,,,,,,,,,,,,,,,"Human HK2 recombinant protein (0.5 μg; HXK0703, ATGEN) or total cell lysate",Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
D4ER,genetic_reagents,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,D4ER,,,,,,,,,,,,,,,,,,,,,cells were transfected with the ER‐targeted D4ER Ca2+ probe,Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
GCAMP6f,genetic_reagents,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,GCAMP6f,,,,,,,,,,,,,,,,,,,,,cells were transfected with a cDNA encoding mitochondrial and nuclear GCAMP6f,Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
mit-Aeqmut,genetic_reagents,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,mit-Aeqmut,,,,,,,,,,,,,,,,,,,,,cells were transfected with a plasmid encoding low‐affinity mitochondrial matrix aequorin (mit‐Aeqmut),Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
GFP-PHD,genetic_reagents,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,GFP-PHD,,,,,,,,,,,,,,,,,,,,,cells were transfected with a plasmid encoding the GFP‐tagged pleckstrin homology (PH) domain of PLC‐δ1 (GFP‐PHD),Publication title lacks NF-specific terms: Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca
cfDNA extraction reagent,genetic_reagents,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,cfDNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"cfDNA was extracted from 2 to 8 mL of plasma using the QIAamp Circulating Nucleic Acid kit (Qiagen, Hilden, Germany)",Non-genetic lab reagent/kit/consumable: cfDNA extraction reagent
DNA extraction reagent,genetic_reagents,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"germline DNA extraction using the DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany)",Non-genetic lab reagent/kit/consumable: DNA extraction reagent
DNA extraction reagent,genetic_reagents,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"germline DNA from PBMCs was collected in and extracted using PAXgene Blood DNA tubes and kit (PreAnalytix, Germantown, Maryland)",Non-genetic lab reagent/kit/consumable: DNA extraction reagent
DNA/RNA extraction reagent,genetic_reagents,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA/RNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"Nucleic acids were isolated from tumor FFPE samples using the manufacturer's protocol with the AllPrep DNA/RNA FFPE kit (Qiagen, Hilden, Germany)",Non-genetic lab reagent/kit/consumable: DNA/RNA extraction reagent
library preparation reagent,genetic_reagents,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,library preparation reagent,Other,,,,,,,,,,,,,,,,,,,,"Sequencing libraries were constructed from cfDNA using commercial kits per the manufacturers' instructions: TruSeq Nano (Illumina, San Diego, California)",Non-genetic lab reagent/kit/consumable: library preparation reagent
library preparation reagent,genetic_reagents,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,library preparation reagent,Other,,,,,,,,,,,,,,,,,,,,"Sequencing libraries were constructed using commercial kits: Kapa HyperPrep (Roche, Basel, Switzerland) for WUSTL samples",Non-genetic lab reagent/kit/consumable: library preparation reagent
human FBXW11,genetic_reagents,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,human FBXW11,Plasmid,,,,,,,,,,,,,,,,,,,,"Myc-DDK–tagged human FBXW11 transcript variant 3 cDNA (RC218905, Origene)",Insert does not reference a core NF disease gene: human FBXW11
GFP,genetic_reagents,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Viral,AAV5,CMV,,,,,,,,,,,,,,,,,,"control (GFP; AAV5-CMV-GFP, UNC) or Cre-recombinase fused to GFP (CRE; AAV5-CMV-Cre-GFP, UNC)",Generic reagent (fluorescent label / control / probe): GFP
Cre-GFP,genetic_reagents,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre-GFP,Viral,AAV5,CMV,,,,,,,,,,,,,,,,,,"control (GFP; AAV5-CMV-GFP, UNC) or Cre-recombinase fused to GFP (CRE; AAV5-CMV-Cre-GFP, UNC)",Insert does not reference a core NF disease gene: Cre-GFP
CRISPRv2,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CRISPRv2,Viral,lentiCRISPRv2,,,,,,,,,,,,,,,,,,,TRAP1 and CyPD expression were knocked out using the lenti CRISPRv2 system,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
lentiCRISPRv2,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,lentiCRISPRv2,Plasmid,lentiCRISPRv2,,,,,,,,,,,,,,,,,,,"cloned into the transfer plasmid lentiCRISPRv2 (Addgene, https://www.addgene.org/52961/)",Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
Cyclophilin D,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cyclophilin D,Plasmid,pSUMO,,,,,,,,,,,,,,,,,,,The human CypD expression system was constructed by building the pSUMO-Cyclophilin D plasmid,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
mito-GFP1-9,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mito-GFP1-9,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,co-transfected with a combination of plasmids pcDNA3 mito-GFP1-9,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
TRAP1-GFP10,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TRAP1-GFP10,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,pcDNA3-TRAP1-GFP10,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
CyPD-GFP11,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CyPD-GFP11,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,pcDNA3CyPD-GFP11,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
ATP50-GFP11,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ATP50-GFP11,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,pcDNA3ATP50-GFP11,Publication title lacks NF-specific terms: The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.
trametinib,genetic_reagents,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,trametinib,,,,,,,,,,,,,,,,,,,,,An FDA-approved small molecule MEK inhibitor (either trametinib or selumetinib) was used off-label to treat nine patients,Drug compound (class suffix): trametinib
selumetinib,genetic_reagents,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,selumetinib,,,,,,,,,,,,,,,,,,,,,An FDA-approved small molecule MEK inhibitor (either trametinib or selumetinib) was used off-label to treat nine patients,Drug compound (class suffix): selumetinib
miRNAeasy kit,genetic_reagents,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,miRNAeasy kit,,,,,,,,,,,,,,,,,,,,,"Total RNA, including miRNA was extracted using the miRNAeasy kit (Qiagen Ltd, Crawley, West Sussex, UK)",Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
Agilent Human miRNA Microarray V2,genetic_reagents,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,Experimental Usage,False,0.50,Low,,,,,,,,,,,Agilent Human miRNA Microarray V2,,,,,,,,,,,,,,,,,,,,,Hundred nanogram of total RNA per sample was labelled and hybridised to the Agilent Human miRNA microarray V2,Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
TaqMan miRNA assays,genetic_reagents,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,TaqMan miRNA assays,,,,,,,,,,,,,,,,,,,,,"MicroRNA expression in each sample, and the cell line, was measured using TaqMan miRNA assays technology (Applied Biosystems Inc.)",Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
miR-29c,genetic_reagents,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,miR-29c,,,,,,,,,,,,,,,,,,,,,"sNF96.2, was transfected in six-well plates using oligofectamine (Invitrogen) giving a final concentration of 100 nM of miRNA mimics (Dharmacon Inc.)",Publication title lacks NF-specific terms: MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tu
DNA extraction reagent,genetic_reagents,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,High molecular weight (HMW) DNA (25 µg) was extracted from leukocytes using the Circulomics Nanobind CBB Big DNA kit,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
sequencing library preparation,genetic_reagents,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,sequencing library preparation,Other,,,,,,,,,,,,,,,,,,,,Sequencing libraries were prepared from 3 µg of input DNA using the SQK-LSK109 ligation sequencing kit,"Publication title lacks NF-specific terms: The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical resea"
papain,genetic_reagents,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,papain,Other,,,,,,,,,,,,,,,,,,,,Tumors were mechanically and enzymatically dissociated using a papain-based tumor dissociation kit (Miltenyi Biotec).,Non-genetic lab reagent/kit/consumable: papain
calcein AM,genetic_reagents,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,calcein AM,,,,,,,,,,,,,,,,,,,,,re-suspended in 1 mL of BSA/HBSS containing 1 mM calcein AM (Life Technologies) and 0.33 mM TO-PRO-3 iodide,Non-genetic lab reagent/kit/consumable: calcein AM
TO-PRO-3 iodide,genetic_reagents,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,TO-PRO-3 iodide,,,,,,,,,,,,,,,,,,,,,re-suspended in 1 mL of BSA/HBSS containing 1 mM calcein AM (Life Technologies) and 0.33 mM TO-PRO-3 iodide (Life Technologies),Non-genetic lab reagent/kit/consumable: TO-PRO-3 iodide
DNA extraction reagent,genetic_reagents,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"Extraction of DNA from leukocytes and purification were performed with QIAamp DNA Blood Mini kit (Qiagen, Valencia, CA, USA)",Non-genetic lab reagent/kit/consumable: DNA extraction reagent
Mycoplasma detection reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Mycoplasma detection reagents,,,,,,,,,,,,,,,,,,,,,"cells were tested for mycoplasma using the Promokine Mycoplasma Test Kit I/C (Minerva Biolabs, Berlin, Germany)",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
STR analysis reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,STR analysis reagents,,,,,,,,,,,,,,,,,,,,,Cell line identity (short tandem repeat analysis) was performed using the GenePrint 10 System (Promega),Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
Hematopoietic differentiation factors,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Hematopoietic differentiation factors,,,,,,,,,,,,,,,,,,,,,HPCs were generated using the STEMdiff hematopoietic kit (STEMCELL Technologies),Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
RNA extraction reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA extraction reagents,,,,,,,,,,,,,,,,,,,,,"cells were harvested and RNA was isolated with the ReliaPrep RNA tissue kit (Promega, Fitchburg, USA)",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
Reverse transcription reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Reverse transcription reagents,,,,,,,,,,,,,,,,,,,,,"RNA was reverse transcribed into cDNA using the PrimeScript RT reagent kit (Takara Bio, Kusatsu, Japan)",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
Cell migration assay reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Cell migration assay reagents,,,,,,,,,,,,,,,,,,,,,"Cell motility was assessed using the IncuCyte cell migration kit (Sartorius, Göttingen, Germany)",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
cAMP detection reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,cAMP detection reagents,,,,,,,,,,,,,,,,,,,,,"cAMP levels in hiMGL cells were determined using the cAMP ELISA kit (Cayman Chemical, Ann Arbor, MI, USA)",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
Cytokine detection reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Cytokine detection reagents,,,,,,,,,,,,,,,,,,,,,"The MILLIPLEX MAP human cytokine/chemokine/growth factor panel A – immunology multiplex assay (HCYTA-60K, Merck) was used",Publication title lacks NF-specific terms: Neurofibromin 1 mutations impair the function of human induced pluripotent stem 
DNA methylation conversion reagent,genetic_reagents,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA methylation conversion reagent,Other,,,,,,,,,,,,,,,,,,,,"500 ng of DNA from each sample was bisulfite converted using the Zymo EZ DNA Methylation Kit (Zymo Research, Irvine, CA USA)",Non-genetic lab reagent/kit/consumable: DNA methylation conversion reagent
verteporfin,genetic_reagents,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,verteporfin,,,,,,,,,,,,,,,,,,,,,"verteporfin (S1786, Selleckchem) and sorafenib p-Toluenesulfonate salt (S-8502, LC Laboratories) were dissolved in DMSO",Drug compound: verteporfin
sorafenib p-Toluenesulfonate salt,genetic_reagents,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,sorafenib p-Toluenesulfonate salt,,,,,,,,,,,,,,,,,,,,,"verteporfin (S1786, Selleckchem) and sorafenib p-Toluenesulfonate salt (S-8502, LC Laboratories) were dissolved in DMSO",Non-genetic lab reagent/kit/consumable: sorafenib p-Toluenesulfonate salt
imatinib mesylate,genetic_reagents,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,imatinib mesylate,,,,,,,,,,,,,,,,,,,,,"Dobutamine hydrochloride (D0676, Sigma Aldrich) and imatinib mesylate (I-5508, LC Laboratories) were dissolved in distilled water",Non-genetic lab reagent/kit/consumable: imatinib mesylate
NF1 shRNA,genetic_reagents,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1 shRNA,Viral,,,,,,,,,,,,,,,,,,,,"Lentiviral vectors expressing NF1 small hairpin (sh) RNA and shCtr were purchased from Sigma (CAT# TRCN000023878, TRCN0000039713, and SHC202)",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
NF1 shRNA,genetic_reagents,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1 shRNA,Viral,,,,,,,,,,,,,,,,,,,,"Lentiviral vectors expressing NF1 small hairpin (sh) RNA and shCtr were purchased from Sigma (CAT# TRCN000023878, TRCN0000039713, and SHC202)",Publication title lacks NF-specific terms: Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neov
NF1,genetic_reagents,PMID:34646065,10.1155/2021/9386823,Survival and ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1,Other,,,,,,,,,,,,,,,,,,,,"all samples were screened for large deletions using four TaqMan NF1 copy-number assays across the gene (ThermoFisher; Hs05477010, Hs06413401, Hs05512625, and Hs03960106)",Publication title lacks NF-specific terms: Survival and
Human All Exon,genetic_reagents,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human All Exon,Other,,,,,,,,,,,,,,,,,,,,We performed exome sequencing on five malignant meningiomas on the Illumina HiSeq2000 platform using Agilent SureSelect Human All Exon kits.,Generic reagent (fluorescent label / control / probe): Human All Exon
targeted region arrays,genetic_reagents,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,targeted region arrays,Other,,,,,,,,,,,,,,,,,,,,"We next designed custom NimbleGen targeted region arrays on five candidate genes, and sequenced four additional malignant meningiomas.",Insert does not reference a core NF disease gene: targeted region arrays
DNA FFPE extraction,genetic_reagents,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA FFPE extraction,Other,,,,,,,,,,,,,,,,,,,,"DNA samples were extracted from the tumor FFPE slides from these patients using QIAamp DNA FFPE kit (Qiagen, Valencia, CA, USA)",Non-genetic lab reagent/kit/consumable: DNA FFPE extraction
AMpure XP,genetic_reagents,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,AMpure XP,Other,,,,,,,,,,,,,,,,,,,,"Next, we purified DNA fragments using AMpure XP beads (Beckman, Brea, CA, USA).",Non-genetic lab reagent/kit/consumable: AMpure XP
AccuPrime Taq High Fidelity,genetic_reagents,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,AccuPrime Taq High Fidelity,Other,,,,,,,,,,,,,,,,,,,,"The PCR mixture contained 5 μl of 10X AccuPrime™ PCR Buffer, 0.3 μl of AccuPrime™ Taq High Fidelit",Non-genetic lab reagent/kit/consumable: AccuPrime Taq High Fidelity
COMT val158met probe,genetic_reagents,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,COMT val158met probe,Other,,,,,,,,,,,,,,,,,,,,"Genotyping was performed using a real-time PCR system in the allelic discrimination mode...using the TaqMan Genotyping Master Mix (Applied Biosystems, Foster City, CA, USA)",Insert does not reference a core NF disease gene: COMT val158met probe
nuclear RFP,genetic_reagents,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,nuclear RFP,Viral,,EF1α,,,,,,,,,,,,,,,,,,"Cell lines were transduced with Incucyte Nuclight Red Lentivirus (Sartorius, Gottingen, Germany) such that they will produce an EF1α promoter driven nuclear restricted red fluorescent label",Generic reagent (fluorescent label / control / probe): nuclear RFP
non-targeting control,genetic_reagents,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,non-targeting control,Other,,,,,,,,,,,,,,,,,,,,"Transfection with a non-targeting, random sequence siRNA (Dharmacon) or Lipofectamine ™ 2000 alone served as separate negative controls.",Generic reagent (fluorescent label / control / probe): non-targeting control
RNA extraction kit,genetic_reagents,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA extraction kit,Other,,,,,,,,,,,,,,,,,,,,"total RNA was harvested with the RNeasy Mini Kit according to manufacturer's instructions (Qiagen Sciences, Germantown, MD)",Non-genetic lab reagent/kit/consumable: RNA extraction kit
reverse transcription reagents,genetic_reagents,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,reverse transcription reagents,Other,,,,,,,,,,,,,,,,,,,,"2 μg of RNA was converted to the more stable complimentary deoxyribonucleic acid (cDNA) strands with TaqMan reverse transcription reagents (Applied Biosystems, Foster city, CA)",Non-genetic lab reagent/kit/consumable: reverse transcription reagents
BrdU staining reagents,genetic_reagents,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,BrdU staining reagents,Other,,,,,,,,,,,,,,,,,,,,Cells were then treated with Zymed ® BrdU Staining Kit (Invitrogen),Non-genetic lab reagent/kit/consumable: BrdU staining reagents
Annexin V-FITC,genetic_reagents,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Annexin V-FITC,Other,,,,,,,,,,,,,,,,,,,,"The Annexin V-FITC Apoptosis Detection kit (Calbiochem, San Diego, Cat # PF032) was used following the manufacturer's instructions.",Non-genetic lab reagent/kit/consumable: Annexin V-FITC
Ras Binding Domain,genetic_reagents,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Ras Binding Domain,Other,,,,,,,,,,,,,,,,,,,,"To determine the activity of Ras the EZ-Detect Ras Activation Kit (cat. 89855 from Pierce, Rockford, IL) was used",Insert does not reference a core NF disease gene: Ras Binding Domain
CCK8,genetic_reagents,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,CCK8,,,,,,,,,,,,,,,,,,,,,Viability was assessed using the Cell Counting Kit 8 (CCK8) from Dojindo Molecular Technologies,Non-genetic lab reagent/kit/consumable: CCK8
B-Raf,genetic_reagents,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,B-Raf,Other,,,,,,,,,,,,,,,,,,,,"siRNA for either B-Raf: AAAGAATTGGATCTGGATCAT, and C-Raf: TGTGCGAAATGGAATGAGCTT, both from Dharmacon",Insert does not reference a core NF disease gene: B-Raf
C-Raf,genetic_reagents,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,C-Raf,Other,,,,,,,,,,,,,,,,,,,,"siRNA for either B-Raf: AAAGAATTGGATCTGGATCAT, and C-Raf: TGTGCGAAATGGAATGAGCTT, both from Dharmacon",Insert does not reference a core NF disease gene: C-Raf
Nutlin-3,genetic_reagents,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Nutlin-3,Other,,,,,,,,,,,,,,,,,,,,"Nutlin-3 (# S1778, Beyotime, Shanghai, China), MG-132 (# S1748, Beyotime) and Pifithrin (PFT)-α",Drug compound: Nutlin-3
MG-132,genetic_reagents,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MG-132,Other,,,,,,,,,,,,,,,,,,,,"Nutlin-3 (# S1778, Beyotime, Shanghai, China), MG-132 (# S1748, Beyotime) and Pifithrin (PFT)-α",Drug compound: MG-132
P53 shRNA,genetic_reagents,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,P53 shRNA,Viral,Lentiviral,,,,,,,,,,,,,,,,,,,P53 (5′-GA CTCCA GTGGT AA TCT A C-3′),Insert does not reference a core NF disease gene: P53 shRNA
P53,genetic_reagents,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,P53,Plasmid,,,,,,,,,,,,,,,,,,,,Flag-tagged P53 (Addgene; #10838),Insert does not reference a core NF disease gene: P53
CCK-8,genetic_reagents,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,CCK-8,Other,,,,,,,,,,,,,,,,,,,,"Cell viability was determined by Cell Counting Kit-8 (CCK-8) from Dojindo (Kumamoto, Japan)",Insert does not reference a core NF disease gene: CCK-8
CXCL12,genetic_reagents,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CXCL12,Viral,,,,,,,,,,,,,,,,,,,,Murine CXCL12 cDNA was subcloned into the lentiviral vector,Insert does not reference a core NF disease gene: CXCL12
firefly luciferase-GFP fusion,genetic_reagents,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,firefly luciferase-GFP fusion,Viral,,human ubiquitin-C,,,,,,,,,,,,,,,,,,A second packaging vector (FUW-FLG) encoding a fusion of firefly luciferase and enhanced green fluorescent protein,Generic reagent (fluorescent label / control / probe): firefly luciferase-GFP fusion
Everolimus,genetic_reagents,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Everolimus,,,,,,,,,,,,,,,,,,,,,Everolimus (RAD001) inhibits the mTOR and is currently FDA approved for several types of solid tumors,Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
PD-0325901,genetic_reagents,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,PD-0325901,,,,,,,,,,,,,,,,,,,,,"PD-0325901 (PD-901) inhibits MEK, a component of the MAPK pathway, and is currently in clinical trials",Publication title lacks NF-specific terms: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered m
FLAG,genetic_reagents,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,FLAG,Plasmid,,,,,,,,,,,,,,,,,,,,"Gateway LR recombination according to the manufacturer's protocol to insert NF1, SPRED1, and RAS entry clones into transient mammalian expression vectors pCAN-FLAG-DEST",Insert does not reference a core NF disease gene: FLAG
HA,genetic_reagents,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HA,Plasmid,,,,,,,,,,,,,,,,,,,,"Gateway LR recombination according to the manufacturer's protocol to insert NF1, SPRED1, and RAS entry clones into transient mammalian expression vectors pCAN-FLAG-DEST and pCAN-HA-DEST",Insert does not reference a core NF disease gene: HA
Tet-inducible,genetic_reagents,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tet-inducible,Viral,pLIX403,TRE3G,,,,,,,,,,,,,,,,,,the lentiviral attR1-attR2 Gateway destination vector pLIX403 (Addgene 41395) was modified to attR4-attR2 by Gibson assembly,Generic reagent (fluorescent label / control / probe): Tet-inducible
packaging,genetic_reagents,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,packaging,Plasmid,psPAX2,,,,,,,,,,,,,,,,,,,Lentiviral particles were then generated by equimolar cotransfection of these NF1 expression vectors with psPAX2 (Addgene 12260),Generic reagent (fluorescent label / control / probe): packaging
envelope,genetic_reagents,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,envelope,Plasmid,pMD2.G,,,,,,,,,,,,,,,,,,,Lentiviral particles were then generated by equimolar cotransfection of these NF1 expression vectors with psPAX2 (Addgene 12260) and pMD2.G (Addgene 12259) packaging plasmids,Generic reagent (fluorescent label / control / probe): envelope
DNA extraction kit,genetic_reagents,PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction kit,Other,,,,,,,,,,,,,,,,,,,,DNA was extracted from peripheral blood samples using PureGene Blood Core Kit B (Qiagen),Non-genetic lab reagent/kit/consumable: DNA extraction kit
DNA capture system,genetic_reagents,PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA capture system,Other,,,,,,,,,,,,,,,,,,,,NGS was performed by oligonucleotide hybridization‐based DNA capture (SureSelect; Agilent),Generic reagent (fluorescent label / control / probe): DNA capture system
RABL6A shRNA,genetic_reagents,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RABL6A shRNA,Viral,pLKO.1,,,,,,,,,,,,,,,,,,,"Human RABL6A and RB1 shRNAs in the pLKO.1 lentiviral vector (Open Biosystems, Huntsville, AL, USA)",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
RB1 shRNA,genetic_reagents,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RB1 shRNA,Viral,pLKO.1,,,,,,,,,,,,,,,,,,,"Human RABL6A and RB1 shRNAs in the pLKO.1 lentiviral vector (Open Biosystems, Huntsville, AL, USA)",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
β-Galactosidase,genetic_reagents,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,β-Galactosidase,,,,,,,,,,,,,,,,,,,,,"stained using the Senescence β-Galactosidase Staining Kit (Cell Signaling Technology #9860, Danvers, MA, USA)",Publication title lacks NF-specific terms: RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
Tet-pLKO-puro,genetic_reagents,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tet-pLKO-puro,Plasmid,pLKO,,,,,,,,,,,,,,,,,,,"shRNAs targeting PTPN11 #5003 and #818 were subcloned into Tet-pLKO-puro vector (Addgene, no. 21915)",Insert does not reference a core NF disease gene: Tet-pLKO-puro
TTIGFP-MLUEX,genetic_reagents,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TTIGFP-MLUEX,Plasmid,,Tet-regulated promoter,,,,,,,,,,,,,,,,,,The human NF1-GRD was amplified using the genomic deoxyribonucleic acid (gDNA) from HEK293T as polymerase chain reaction template and subcloned into TTIGFP-MLUEX vector,Insert does not reference a core NF disease gene: TTIGFP-MLUEX
shPTPN11,genetic_reagents,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shPTPN11,Plasmid,pLKO,Tet-regulated,,,,,,,,,,,,,,,,,,shRNAs targeting PTPN11 #5003 and #818 were subcloned into Tet-pLKO-puro vector,Insert does not reference a core NF disease gene: shPTPN11
shPTPN11,genetic_reagents,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shPTPN11,Plasmid,pLKO,Tet-regulated,,,,,,,,,,,,,,,,,,shRNAs targeting PTPN11 #5003 and #818 were subcloned into Tet-pLKO-puro vector,Insert does not reference a core NF disease gene: shPTPN11
Nf1-eGFP,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Development,True,1.00,High,,,,,,,,,,,Nf1-eGFP,Plasmid,pUAST-attB,,,,,,,,,,,,,,,,,,,UAS-Nf1-eGFP transgenes were generated using an Nf1 mini-gene (full-length Nf1 cDNA corresponding to the RF isoform with addition of introns 9 and 10).,Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
Q5 Site-Directed Mutagenesis Kit,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Q5 Site-Directed Mutagenesis Kit,,,,,,,,,,,,,,,,,,,,,The R1320P mutation was created in a wild-type cDNA using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs).,Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
Nf1 RNAi,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,Nf1 RNAi,Other,,,,,,,,,,,,,,,,,,,,The Nf1 RNAi line was obtained from the Vienna Drosophila RNAi Center (VDRC #109637),Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
rl Sem,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,rl Sem,,,,,,,,,,,,,,,,,,,,,ERK was activated via expression of ERK with the gain-of-function mutation ERK 56 Sem (UAS-rl Sem).,Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
nSyb,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,nSyb,,,,,,,,,,,,,,,,,,,,,The following lines were obtained from the Bloomington Drosophila Stock Center (BDSC): nSyb (BDSC #51635),Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
R57C10,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,R57C10,,,,,,,,,,,,,,,,,,,,,"The following lines were obtained from the Bloomington Drosophila Stock Center (BDSC): nSyb (BDSC #51635), R57C10 (39171)",Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
tsh-Gal4,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,tsh-Gal4,,,,,,,,,,,,,,,,,,,,,"The following lines were obtained from the Bloomington Drosophila Stock Center (BDSC): nSyb (BDSC #51635), R57C10 (39171), 69B (1774), tsh-Gal4 (3040)",Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
Oct-TyrR-Gal4,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Oct-TyrR-Gal4,,,,,,,,,,,,,,,,,,,,,"The following lines were obtained from the Bloomington Drosophila Stock Center (BDSC): nSyb (BDSC #51635), R57C10 (39171), 69B (1774), tsh-Gal4 (3040), and Oct-TyrR-Gal4 (36494).",Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
PCB-Gal4,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,PCB-Gal4,,,,,,,,,,,,,,,,,,,,,PCB-Gal4 (fatbody-Gal4) was previously generated by Ronald Kühnlein,Publication title lacks NF-specific terms: Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.
SB11,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SB11,Other,,,,,,,,,,,,,,,,,,,,a conditionally expressed SB transposase enzyme (R26-lsl-SB11),Insert does not reference a core NF disease gene: SB11
Cre,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Cre,,,CNP,,,,,,,,,,,,,,,,,,a Schwann cell specific Cre-recombinase controlled by the CNP promoter (Cnp-Cre),Insert does not reference a core NF disease gene: Cre
T2/Onc15,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,T2/Onc15,Transposon,,,,,,,,,,,,,,,,,,,,a concatomer of oncogenic transposons (T2/Onc15),Insert does not reference a core NF disease gene: T2/Onc15
EGFR,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,EGFR,,,CNP,,,,,,,,,,,,,,,,,,"MPNST predisposing alleles, Cnp-EGFR and conditional Trp53 alleles",Insert does not reference a core NF disease gene: EGFR
shRNA,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNA,Viral,GIPZ,,,,,,,,,,,,,,,,,,,shRNA GIPZ lentiviral constructs were purchased from Openbiosystems,Generic reagent (fluorescent label / control / probe): shRNA
FOXR2,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,FOXR2,Transposon,piggyBac,,,,,,,,,,,,,,,,,,,FOXR2 cDNA (Open Biosystems) was cloned into the Gateway Vector System (Invitrogen) and subcloned into a piggyBac (PB) transposon vector,Insert does not reference a core NF disease gene: FOXR2
FOXR2,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,FOXR2,Other,,,,,,,,,,,,,,,,,,,,TALENs targeting FOXR2 were designed using TALE-NT and constructed,Insert does not reference a core NF disease gene: FOXR2
HPRT,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HPRT,Other,,,,,,,,,,,,,,,,,,,,An HPRT TALEN pair served as a control,Insert does not reference a core NF disease gene: HPRT
KCNMA1,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KCNMA1,Other,,,,,,,,,,,,,,,,,,,,QuantiTech Qiagen primers:  KCNMA1  (cat# QT00024157),Insert does not reference a core NF disease gene: KCNMA1
PRKCE,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PRKCE,Other,,,,,,,,,,,,,,,,,,,,PRKCE  (cat# QT00016352),Insert does not reference a core NF disease gene: PRKCE
OPCML,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,OPCML,Other,,,,,,,,,,,,,,,,,,,,OPCML  (cat# QT01005361),Insert does not reference a core NF disease gene: OPCML
GRIK2,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GRIK2,Other,,,,,,,,,,,,,,,,,,,,GRIK2  (cat# QT00016597),Insert does not reference a core NF disease gene: GRIK2
CADM2,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CADM2,Other,,,,,,,,,,,,,,,,,,,,CADM2  (cat# QT00048888),Insert does not reference a core NF disease gene: CADM2
CREB5,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CREB5,Other,,,,,,,,,,,,,,,,,,,,CREB5  (cat# QT00054488),Insert does not reference a core NF disease gene: CREB5
CAMK1D,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CAMK1D,Other,,,,,,,,,,,,,,,,,,,,CAMK1D  (cat# QT00036344),Insert does not reference a core NF disease gene: CAMK1D
ITGB8,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ITGB8,Other,,,,,,,,,,,,,,,,,,,,ITGB8  (cat# QT00038507),Insert does not reference a core NF disease gene: ITGB8
TruSeq library construction kit,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSeq library construction kit,Other,,,,,,,,,,,,,,,,,,,,"Genomic DNA from tumor and normal samples were fragmented and used for Illumina TruSeq library construction (Illumina, San Diego, CA) according to the manufacturer's instructions.",Non-genetic lab reagent/kit/consumable: TruSeq library construction kit
AMPure XP beads,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,AMPure XP beads,Other,,,,,,,,,,,,,,,,,,,,"DNA was purified using Agencourt AMPure XP beads (Beckman Coulter, IN) in a ratio of 1.0–0.9 of PCR product to beads.",Non-genetic lab reagent/kit/consumable: AMPure XP beads
End Repair Enzyme Mix,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,End Repair Enzyme Mix,Other,,,,,,,,,,,,,,,,,,,,"5 µl of End Repair Enzyme Mix (cat# E6050, NEB, Ipswich, MA). The 100 µl end-repair mixture was incubated at 20°C for 30 min",Non-genetic lab reagent/kit/consumable: End Repair Enzyme Mix
Klenow (exo-),genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Klenow (exo-),Other,,,,,,,,,,,,,,,,,,,,"42 µl of end-repaired DNA was mixed with 5 µl of 10 X dA Tailing Reaction Buffer and 3 µl of Klenow (exo-)(cat# E6053, NEB, Ipswich, MA).",Insert does not reference a core NF disease gene: Klenow (exo-)
Quick T4 DNA ligase,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Quick T4 DNA ligase,Other,,,,,,,,,,,,,,,,,,,,"10 µl of 5 X Ligation buffer and 5 µl of Quick T4 DNA ligase (cat# E6056, NEB, Ipswich, MA). The ligation mixture was incubated at 20°C for 15 min",Non-genetic lab reagent/kit/consumable: Quick T4 DNA ligase
SureSelect v.4,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SureSelect v.4,Other,,,,,,,,,,,,,,,,,,,,"Exonic regions were captured in solution using the Agilent SureSelect v.4 kit (Agilent, Santa Clara, CA).",Non-genetic lab reagent/kit/consumable: SureSelect v.4
cfDNA Extraction Kit,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,cfDNA Extraction Kit,Other,,,,,,,,,,,,,,,,,,,,"cfDNA from each of the plasma samples was purified using a BioChain cfDNA Extraction Kit (BioChain, cat #K5011610) using the manufacturer's recommended protocol.",Non-genetic lab reagent/kit/consumable: cfDNA Extraction Kit
circulating nucleic acid kit,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,circulating nucleic acid kit,Other,,,,,,,,,,,,,,,,,,,,Cell-free DNA was extracted using the QIAGEN circulating nucleic acid kit (Catalog# 55114).,Non-genetic lab reagent/kit/consumable: circulating nucleic acid kit
anti-HER1 CAR 806,genetic_reagents,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,anti-HER1 CAR 806,Viral,,,,,,,,,,,,,,,,,,,,"To target HER1, we constructed CARs using three distinct scFvs (806, E2 and NEC)",Insert does not reference a core NF disease gene: anti-HER1 CAR 806
anti-HER1 CAR E2,genetic_reagents,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,anti-HER1 CAR E2,Viral,,,,,,,,,,,,,,,,,,,,"To target HER1, we constructed CARs using three distinct scFvs (806, E2 and NEC)",Insert does not reference a core NF disease gene: anti-HER1 CAR E2
anti-HER1 CAR NEC,genetic_reagents,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,anti-HER1 CAR NEC,Viral,,,,,,,,,,,,,,,,,,,,"To target HER1, we constructed CARs using three distinct scFvs (806, E2 and NEC)",Insert does not reference a core NF disease gene: anti-HER1 CAR NEC
AHR,genetic_reagents,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,AHR,Other,,,,,,,,,,,,,,,,,,,,siRNA targeting...AHR (s1200),Insert does not reference a core NF disease gene: AHR
bevacizumab,genetic_reagents,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,bevacizumab,,,,,,,,,,,,,,,,,,,,,"bevacizumab 5 mg/kg b.w., Avastin® 100 mg/25 ml, Roche, Basel, Switzerland",Drug compound (class suffix): bevacizumab
bevacizumab,genetic_reagents,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,bevacizumab,,,,,,,,,,,,,,,,,,,,,"murine bevacizumab 5 mg/kg b.w. (B20-4.1.1, 100 mg/25 ml, Roche, Basel, Switzerland)",Drug compound (class suffix): bevacizumab
gadolinium contrast,genetic_reagents,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,gadolinium contrast,,,,,,,,,,,,,,,,,,,,,"IV gadolinium contrast injection (0.1 ml/kg, Gadovist, Bayer Inc.)",Non-genetic lab reagent/kit/consumable: gadolinium contrast
microbubbles,genetic_reagents,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,microbubbles,,,,,,,,,,,,,,,,,,,,,"IV microbubble administration (0.02 ml/kg, Definity, Lantheus Medical Imaging, USA)",Non-genetic lab reagent/kit/consumable: microbubbles
gRNA,genetic_reagents,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,gRNA,Plasmid,,U6,,,,,,,,,,,,,,,,,,U6-gRNA vectors were produced as previously described and introduced into iHSCs that are proficient for NF1,Generic reagent (fluorescent label / control / probe): gRNA
Cas9,genetic_reagents,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Cas9,,,,,,,,,,,,,,,,,,,,,One million cells were electroporated (1 pulse of 1400V for 30 ms) with 2 µg Flag-hCas9,Generic reagent (fluorescent label / control / probe): Cas9
Luciferase-IRES-GFP,genetic_reagents,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Luciferase-IRES-GFP,Transposon,,CAGG,,,,,,,,,,,,,,,,,,co-transposition was performed using 500 ng of the piggyBac (PB) transposon PB-CAGG-Luciferase-IRES-GFP-PGK-PuroR,Generic reagent (fluorescent label / control / probe): Luciferase-IRES-GFP
PB7 transposase,genetic_reagents,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,PB7 transposase,,,CMV,,,,,,,,,,,,,,,,,,500 ng of CMV-PB7 transposase,Insert does not reference a core NF disease gene: PB7 transposase
PD0325901,genetic_reagents,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,PD0325901,,,,,,,,,,,,,,,,,,,,,MEK inhibitor PD0325901...Ten mice were treated with ATRA (15 mg/kg) or PD0325901 (10 mg/kg),Drug compound: PD0325901
ATRA,genetic_reagents,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,ATRA,,,,,,,,,,,,,,,,,,,,,all-trans retinoic acid (ATRA)...Ten mice were treated with ATRA (15 mg/kg) or PD0325901 (10 mg/kg),Drug compound: ATRA
SYBR premix EX Taq,genetic_reagents,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,SYBR premix EX Taq,,,,,,,,,,,,,,,,,,,,,"Reverse transcription was carried out using SYBR premix EX Taq (Takara, Japan)",Non-genetic lab reagent/kit/consumable: SYBR premix EX Taq
SYBR Premix Ex Taq II,genetic_reagents,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,SYBR Premix Ex Taq II,,,,,,,,,,,,,,,,,,,,,and SYBR Premix Ex Taq II (Takara) was used for qPCR,Non-genetic lab reagent/kit/consumable: SYBR Premix Ex Taq II
Human Universal Reference RNA,genetic_reagents,PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,Human Universal Reference RNA,,,,,,,,,,,,,,,,,,,,,"Sample RNA was processed in triplicate with serial dilutions of Human Universal Reference RNA (Stratagene, La Jolla, CA, USA)",Insert does not reference a core NF disease gene: Human Universal Reference RNA
trastuzumab,genetic_reagents,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,trastuzumab,,,,,,,,,,,,,,,,,,,,,"trastuzumab (25 mg/kg in 0.25 ml normal saline i.p., Genentech, South San Francisco, CA)",Drug compound (class suffix): trastuzumab
erlotinib,genetic_reagents,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,erlotinib,,,,,,,,,,,,,,,,,,,,,"erlotinib (50 mg/kg, Genentech, South San Francisco, CA), five days a week",Drug compound (class suffix): erlotinib
AZD2014,genetic_reagents,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,AZD2014,,,,,,,,,,,,,,,,,,,,,"AZD2014 (provided by AstraZeneca; Wilmington, DE)",Drug compound: AZD2014
FRAX597,genetic_reagents,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,FRAX597,,,,,,,,,,,,,,,,,,,,,"FRAX597 (generously given by Dr. Joseph Kissil, The Scripps Research Institute, Jupiter, FL)",Drug compound: FRAX597
shRNA,genetic_reagents,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNA,Plasmid,pLKO,,,,,,,,,,,,,,,,,,,"6,091 shRNAs, cloned into the pLKO-puromycin system",Generic reagent (fluorescent label / control / probe): shRNA
SGK1,genetic_reagents,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SGK1,Plasmid,pLKO,,,,,,,,,,,,,,,,,,,pLKO-puro-based shRNAs targeting human SGK1 (TRCN0000194957),Insert does not reference a core NF disease gene: SGK1
PAK1,genetic_reagents,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PAK1,Plasmid,pLKO,,,,,,,,,,,,,,,,,,,human PAK1 (TRCN0000197238),Insert does not reference a core NF disease gene: PAK1
RHEB,genetic_reagents,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RHEB,Plasmid,pLKO,,,,,,,,,,,,,,,,,,,human RHEB (TRCN0000010424),Insert does not reference a core NF disease gene: RHEB
TaqMan PCR Core REAGENTS Kit,genetic_reagents,PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TaqMan PCR Core REAGENTS Kit,Other,,,,,,,,,,,,,,,,,,,,All PCR reactions were performed using an ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems) and either the TaqMan ® PCR Core REAGENTS Kit,Non-genetic lab reagent/kit/consumable: TaqMan PCR Core REAGENTS Kit
SYBR Green PCR Core Reagents kit,genetic_reagents,PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SYBR Green PCR Core Reagents kit,Other,,,,,,,,,,,,,,,,,,,,or the SYBR ® Green PCR Core Reagents kit (Perkin-Elmer Applied Biosystems),Non-genetic lab reagent/kit/consumable: SYBR Green PCR Core Reagents kit
RNasin RNase inhibitor,genetic_reagents,PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNasin RNase inhibitor,Other,,,,,,,,,,,,,,,,,,,,"20 units of RNasin RNase inhibitor (Promega, Madison, WI)",Non-genetic lab reagent/kit/consumable: RNasin RNase inhibitor
Superscript II RNase H-reverse transcriptase,genetic_reagents,PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Superscript II RNase H-reverse transcriptase,Other,,,,,,,,,,,,,,,,,,,,"100 units of Superscript II RNase H-reverse transcriptase (Invitrogen, Cergy Pontoise, France)",Non-genetic lab reagent/kit/consumable: Superscript II RNase H-reverse transcriptase
NE-PER Nuclear and Cytoplasmic Extraction Reagents,genetic_reagents,PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,NE-PER Nuclear and Cytoplasmic Extraction Reagents,,,,,,,,,,,,,,,,,,,,,Nuclear and non-nuclear fractions were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents following manufacturer's instructions (Thermo Fisher Scientific).,Non-genetic lab reagent/kit/consumable: NE-PER Nuclear and Cytoplasmic Extraction Reagents
Ultra Low Cluster Plates,genetic_reagents,PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,Ultra Low Cluster Plates,,,,,,,,,,,,,,,,,,,,,plated in 0.34% low melting temperature agarose (FMC Bioproducts) in complete medium at 2×10 4 (Meso-33 cells) or 1.2×10 4 (FC-1801 cells) per well in 24-well Ultra Low Cluster Plates (Costar).,Insert does not reference a core NF disease gene: Ultra Low Cluster Plates
GFP,genetic_reagents,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Viral,,,,,,,,,,,,,,,,,,,,subcloned as a Bgl II/Xho I fragment into the retroviral expression vector pBMN-I-GFP,Generic reagent (fluorescent label / control / probe): GFP
GST-PID,genetic_reagents,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GST-PID,Plasmid,,,,,,,,,,,,,,,,,,,,A GST-PID (Pak1 amino acids 83–149) or Gst-PID L107F cDNA was subcloned,Insert does not reference a core NF disease gene: GST-PID
Gst-PID L107F,genetic_reagents,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Gst-PID L107F,Plasmid,,,,,,,,,,,,,,,,,,,,A GST-PID (Pak1 amino acids 83–149) or Gst-PID L107F cDNA was subcloned,Insert does not reference a core NF disease gene: Gst-PID L107F
Non-targeting control,genetic_reagents,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Non-targeting control,Other,,,,,,,,,,,,,,,,,,,,"RNAi was performed using ON-TARGETplus Non-targeting Pool (#D-001810–10-05, Dharmacon)",Generic reagent (fluorescent label / control / probe): Non-targeting control
PTPN11,genetic_reagents,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PTPN11,Other,,,,,,,,,,,,,,,,,,,,"SMARTPool ON-TARGETplus Human PTPN11 siRNA (#L-003947–00-0005, Dharmacon) to knockdown (KD) the expression of non-targeting control (NTC) and SHP2",Insert does not reference a core NF disease gene: PTPN11
I2HCP panel,genetic_reagents,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Development,False,1.00,Medium,,,,,,,,,,,I2HCP panel,Other,,,,,,,,,,,,,,,,,,,,"we developed the I2HCP panel, a custom bait library covering 122 hereditary cancer genes",Publication title lacks NF-specific terms: A comprehensive custom panel design for routine hereditary cancer testing: prese
SureSelect bait library V1,genetic_reagents,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SureSelect bait library V1,Other,,,,,,,,,,,,,,,,,,,,"We used Agilent eArray to design our SureSelect bait library V1 (Agilent, California, USA), covering 106 genes",Publication title lacks NF-specific terms: A comprehensive custom panel design for routine hereditary cancer testing: prese
SureSelect bait library V2,genetic_reagents,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SureSelect bait library V2,Other,,,,,,,,,,,,,,,,,,,,The bait library V2 included 122 genes responsible for most of the cancer predisposition syndromes,Publication title lacks NF-specific terms: A comprehensive custom panel design for routine hereditary cancer testing: prese
shRNAs,genetic_reagents,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNAs,Viral,,,,,,,,,,,,,,,,,,,,"We infected secondary Nf1 neurofibroma spheres or fl/fl;DhhCre Stat3 DRG/neurofibroma spheres with shRNAs and non-target control (Sigma, St Louis, MO, USA)",Generic reagent (fluorescent label / control / probe): shRNAs
β-catenin ΔN90,genetic_reagents,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,β-catenin ΔN90,Viral,,,,,,,,,,,,,,,,,,,,"β-catenin overexpression lentivirus ΔN90 (Addgene, Cambridge MA)",Insert does not reference a core NF disease gene: β-catenin ΔN90
D22S193,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,D22S193,Other,,,,,,,,,,,,,,,,,,,,checked for loss of heterozygosity in tumor DNA at markers D22S193 (centromeric to NF2),Insert does not reference a core NF disease gene: D22S193
D22S929,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,D22S929,Other,,,,,,,,,,,,,,,,,,,,"NF2 TET and D22S929 (intragenic), and D22S268 and D22S430",Insert does not reference a core NF disease gene: D22S929
D22S268,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,D22S268,Other,,,,,,,,,,,,,,,,,,,,"D22S929 (intragenic), and D22S268 and D22S430 (telomeric to NF2)",Insert does not reference a core NF disease gene: D22S268
D22S430,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,D22S430,Other,,,,,,,,,,,,,,,,,,,,and D22S268 and D22S430 (telomeric to NF2),Insert does not reference a core NF disease gene: D22S430
BstUI,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,BstUI,Other,,,,,,,,,,,,,,,,,,,,"PCR products were then digested using the endonuclease BstUI in 30 μl volumes according to the manufacturer's specifications (New England Biolabs, Beverly, MA)",Insert does not reference a core NF disease gene: BstUI
Taq polymerase,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Taq polymerase,Other,,,,,,,,,,,,,,,,,,,,"1 μl of 10X buffer, and 0.25 U of Taq polymerase (Qiagen, Valencia, CA)",Non-genetic lab reagent/kit/consumable: Taq polymerase
EdU,genetic_reagents,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,EdU,,,,,,,,,,,,,,,,,,,,,"The incorporated EdU were stained on top of BrdU staining with Click-iT™ EdU Cell Proliferation Kit for Imaging (ThemoFisher, Cat# C10337)",Insert does not reference a core NF disease gene: EdU
StemSep,genetic_reagents,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,StemSep,Other,,,,,,,,,,,,,,,,,,,,Lineage-marker-negative (Lin-) cells were purified through a 0.3-in StemSep negative selection column as per the manufacturer's instructions,"Publication title lacks NF-specific terms: Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metab"
Rapamycin,genetic_reagents,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,Rapamycin,,,,,,,,,,,,,,,,,,,,,"Rapamycin (LC Laboratories, catalog number R-5000; Supplementary Fig. S1A)",Drug compound (class suffix): Rapamycin
NVP-BEZ235,genetic_reagents,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,NVP-BEZ235,,,,,,,,,,,,,,,,,,,,,"NVP-BEZ235 (LC Laboratories, catalog number 915019-65-7; Supplementary Fig. S1B)",Drug compound: NVP-BEZ235
LY294002,genetic_reagents,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,LY294002,,,,,,,,,,,,,,,,,,,,,"and LY294002 (Calbiochem, San Diego CA) were purchased from commercial sources",Drug compound: LY294002
lamotrigine,genetic_reagents,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,lamotrigine,,,,,,,,,,,,,,,,,,,,,the HCN channel agonist lamotrigine rescued the electrophysiological and cognitive deficits,Drug compound: lamotrigine
biocytin,genetic_reagents,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,biocytin,,,,,,,,,,,,,,,,,,,,,0.2% biocytin was included in the intracellular pipette solution for later morphological identification,Insert does not reference a core NF disease gene: biocytin
mirdametinib,genetic_reagents,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,Experimental Usage,False,0.50,Low,,,,,,,,,,,mirdametinib,,,,,,,,,,,,,,,,,,,,,"Mirdametinib (also known as PD0325901) has the chemical structure of N-[(2R)-2,3 dihydroxypropoxyl]-3,4-difluro-2-[(2-fluoro-4-iodophenyl) amino] benzamide",Drug compound (class suffix): mirdametinib
NucLight red,genetic_reagents,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NucLight red,Viral,,,,,,,,,,,,,,,,,,,,Cell lines were infected with NucLight red lentivirus and stably selected in puromycin,Generic reagent (fluorescent label / control / probe): NucLight red
WT1-AS,genetic_reagents,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,WT1-AS,Plasmid,pcDNA,,,,,,,,,,,,,,,,,,,The human lncRNA WT1-AS were cloned into plasmid cloning DNA (pcDNA) vector,Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
RNA extraction reagent,genetic_reagents,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,RNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,Total cellular RNA was extracted from glioma tissues and cultured cells using the commercially procured TRIzol reagent (Invitrogen),Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
cDNA synthesis,genetic_reagents,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,cDNA synthesis,Other,,,,,,,,,,,,,,,,,,,,RNA was reverse transcribed in to complementary DNA (cDNA) using the commercial Transcriptor First strand cDNA synthesis kit (Roche Diagnostics),Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
WT1-AS,genetic_reagents,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,WT1-AS,Plasmid,pmirGLO,,,,,,,,,,,,,,,,,,,"The WT1-AS sequence including the putative binding sites of miR-494-3p was subcloned and then inserted into the pmirGLO vector (Promega, Madison, Wisconsin)",Publication title lacks NF-specific terms: Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.
psPAX,genetic_reagents,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,psPAX,Plasmid,,,,,,,,,,,,,,,,,,,,co-transfected with the packaging plasmids psPAX (Addgene #12260),Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
pMD2.G,genetic_reagents,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pMD2.G,Plasmid,,,,,,,,,,,,,,,,,,,,"and pMD2.G (Addgene, #12259)",Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
UAS:eGFP-KRAS G12D,genetic_reagents,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,UAS:eGFP-KRAS G12D,Transposon,Tol2,UAS,,,,,,,,,,,,,,,,,,injected with Tol2(UAS:eGFP-KRAS G12D) plasmid,Publication title lacks NF-specific terms: HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioener
CytoTox 96,genetic_reagents,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,CytoTox 96,,,,,,,,,,,,,,,,,,,,,"Cytotoxic efficacy of the non-adherent spleen cells was assessed by adding them as effector cells to PNF-derived Schwann cells as target cells at a ratio of 1∶10 for 4 h using the CytoTox 96 Non-Radioactive Cytotoxicity assay (Promega, Fitchburg, WI)",Non-genetic lab reagent/kit/consumable: CytoTox 96
TruSeq Stranded Total RNA,genetic_reagents,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,TruSeq Stranded Total RNA,,,,,,,,,,,,,,,,,,,,,"Sequencing libraries were prepared using TruSeq Stranded Total RNA Sample Preparation kit (Illumina, San Diego, CA)",Non-genetic lab reagent/kit/consumable: TruSeq Stranded Total RNA
SuperScript III,genetic_reagents,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,SuperScript III,,,,,,,,,,,,,,,,,,,,,"mRNA was reverse transcribed using SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsabd, CA)",Non-genetic lab reagent/kit/consumable: SuperScript III
RNA isolation kit,genetic_reagents,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA isolation kit,,,,,,,,,,,,,,,,,,,,,RNA from primary astrocytes was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol,Publication title lacks NF-specific terms: Graph complexity analysis identifies an ETV5 tumor-specific network in human and
DNeasy mini kit,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNeasy mini kit,Other,,,,,,,,,,,,,,,,,,,,"Genomic DNA (gDNA) was extracted from both frozen tumour and blood tissues using the DNeasy mini kit (Qiagen, Valencia, CA, USA)",Non-genetic lab reagent/kit/consumable: DNeasy mini kit
NEBNext DNA Library Prep Reagent Set,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NEBNext DNA Library Prep Reagent Set,Other,,,,,,,,,,,,,,,,,,,,"Standard whole genome library prep was done using the NEBNext DNA Library Prep Reagent Set for Illumina (New England BioLabs Inc., Ipswich, MA, USA)",Non-genetic lab reagent/kit/consumable: NEBNext DNA Library Prep Reagent Set
KAPA Library Quantification Kit,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KAPA Library Quantification Kit,Other,,,,,,,,,,,,,,,,,,,,Accurate quantification for sequencing applications was determined using the qPCR-based KAPA Biosystems Library Quantification Kit,Non-genetic lab reagent/kit/consumable: KAPA Library Quantification Kit
HumanOmni2.5-8,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HumanOmni2.5-8,Other,,,,,,,,,,,,,,,,,,,,"SNP array sample prep was done using the HumanOmni2.5–8 (Illumina, Inc., San Diego, CA, USA)",Insert does not reference a core NF disease gene: HumanOmni2.5-8
miRNeasy mini kit,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,miRNeasy mini kit,Other,,,,,,,,,,,,,,,,,,,,"Total RNA containing both mRNA as well as microRNA fractions was extracted from the tissues using the miRNeasy mini kit (Qiagen, Valencia, CA, USA)",Non-genetic lab reagent/kit/consumable: miRNeasy mini kit
NEBNext Magnetic Oligo d(T)25 Beads,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NEBNext Magnetic Oligo d(T)25 Beads,Other,,,,,,,,,,,,,,,,,,,,Poly-adenylated RNAs were isolated using NEBNext Magnetic Oligo d(T)25 Beads,Non-genetic lab reagent/kit/consumable: NEBNext Magnetic Oligo d(T)25 Beads
NEBNext mRNA Library Prep Reagent Set,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NEBNext mRNA Library Prep Reagent Set,Other,,,,,,,,,,,,,,,,,,,,"The NEBNext mRNA Library Prep Reagent Set for Illumina (New England BioLabs Inc., Ipswich, MA, USA) was then used to prepare individually bar-coded",Non-genetic lab reagent/kit/consumable: NEBNext mRNA Library Prep Reagent Set
TruSeq SBS HS v4 Kit,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSeq SBS HS v4 Kit,Other,,,,,,,,,,,,,,,,,,,,"Paired-end sequencing (25 million, 50-bp, paired-end reads) was performed using a 200 Cycle TruSeq SBS HS v4 Kit",Non-genetic lab reagent/kit/consumable: TruSeq SBS HS v4 Kit
NF1,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1,Plasmid,pFastBacHta,,,,,,,,,,,,,,,,,,,synthetic gene (GeneArt) encoding the human full-length NF1 (synNF1) was cloned into the pFastBacHta (Life Technology) vector,Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
NF1,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.9,Experimental Usage,True,0.50,Medium,,,,,,,,,,,NF1,,,,,,,,,,,,,,,,,,,,,synthetic gene (GeneArt) encoding the human full-length NF1 (synNF1),Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
NF1-eGFP,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.9,Experimental Usage,True,0.50,Medium,,,,,,,,,,,NF1-eGFP,,,,,,,,,,,,,,,,,,,,,full-length human neurofibromin with C-terminal eGFP tag (synNF1eGFP),Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
EndoPorter,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,EndoPorter,Other,,,,,,,,,,,,,,,,,,,,"SynNF1 was transduced into fibroblasts using the transduction reagent EndoPorter (GeneTools, LLC)",Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
NF1 siRNA,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1 siRNA,Other,,,,,,,,,,,,,,,,,,,,"transfected with 4 siRNAs (FlexiTube, Qiagen, Hilden; Supplementary Table 2) designed for silencing the NF1 message",Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
Control siRNA,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Control siRNA,Other,,,,,,,,,,,,,,,,,,,,As a control the Allstar Negative Control siRNA (Qiagen) was used,Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
Lipofectamine RNAiMAX,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Lipofectamine RNAiMAX,Other,,,,,,,,,,,,,,,,,,,,using the Lipofectamine RNAiMAX transfection reagent (Life Technologies),Publication title lacks NF-specific terms: Restoring functional neurofibromin by protein transduction.
RNA extraction kit,genetic_reagents,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA extraction kit,Other,,,,,,,,,,,,,,,,,,,,"RNAs were isolated using RNeasy mini kit (QIAGEN, Valencia, CA)",Non-genetic lab reagent/kit/consumable: RNA extraction kit
interferon alpha-2b,genetic_reagents,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,interferon alpha-2b,Other,,,,,,,,,,,,,,,,,,,,PEGylated interferon alpha-2b was purchased at the Cincinnati Children's Hospital (National Drug Code 00085132302) pharmacy,Insert does not reference a core NF disease gene: interferon alpha-2b
QIAamp Circulating Nucleic Acid kit,genetic_reagents,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,QIAamp Circulating Nucleic Acid kit,Other,,,,,,,,,,,,,,,,,,,,cfDNA was extracted from 2 to 8 mL of plasma using the QIAamp Circulating Nucleic Acid kit (Qiagen),Publication title lacks NF-specific terms: Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell
Qubit dsDNA High-Sensitivity Assay kit,genetic_reagents,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Qubit dsDNA High-Sensitivity Assay kit,Other,,,,,,,,,,,,,,,,,,,,Extracted DNA concentration was measured using the Qubit dsDNA High-Sensitivity Assay kit (Thermo-Fisher),Publication title lacks NF-specific terms: Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell
KAPA HyperPrep kit,genetic_reagents,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KAPA HyperPrep kit,Other,,,,,,,,,,,,,,,,,,,,cfDNA sequencing libraries were constructed from 10 to 60 ng of isolated DNA using the KAPA HyperPrep kit (Roche),Publication title lacks NF-specific terms: Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell
xGen UDI-UMI Adapters,genetic_reagents,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,xGen UDI-UMI Adapters,Other,,,,,,,,,,,,,,,,,,,,cfDNA sequencing libraries were constructed from 10 to 60 ng of isolated DNA using the KAPA HyperPrep kit (Roche) and xGen UDI-UMI Adapters (IDT),Publication title lacks NF-specific terms: Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell
TruSight Oncology 500,genetic_reagents,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSight Oncology 500,Other,,,,,,,,,,,,,,,,,,,,Tissue genomic profiling was performed by Clinical Laboratory Improvement Amendments–certified molecular laboratories using TruSight Oncology 500 (Illumina),Publication title lacks NF-specific terms: Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell
EdU,genetic_reagents,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,EdU,,,,,,,,,,,,,,,,,,,,,EdU detection was performed on 14 μm-thick cryosections using the Click-IT Plus EdU Alexa Fluor 488 Imaging Kit (Thermo Fisher Scientific),Insert does not reference a core NF disease gene: EdU
RNA isolation reagent,genetic_reagents,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA isolation reagent,Other,,,,,,,,,,,,,,,,,,,,We isolated total RNA from frozen tissue and cells using the RNeasy kit (Qiagen),Non-genetic lab reagent/kit/consumable: RNA isolation reagent
shSOX9,genetic_reagents,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shSOX9,Viral,,,,,,,,,,,,,,,,,,,,we infected MPNST cells at 70–90% confluence with lentiviral particles containing shRNAs targeting SOX9 (Open Biosystems; TRC library),Insert does not reference a core NF disease gene: shSOX9
GFP,genetic_reagents,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Viral,,,,,,,,,,,,,,,,,,,,lentiviral particles containing shRNAs targeting SOX9 (Open Biosystems; TRC library) or GFP (Addgene),Generic reagent (fluorescent label / control / probe): GFP
MTS assay reagent,genetic_reagents,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MTS assay reagent,Other,,,,,,,,,,,,,,,,,,,,We conducted MTS assays for viable cell number on days 3–7 post-infection using the CellTiter 96® Aqueous One Solution Cell Proliferation Assay (Promega),Non-genetic lab reagent/kit/consumable: MTS assay reagent
TUNEL assay reagent,genetic_reagents,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TUNEL assay reagent,Other,,,,,,,,,,,,,,,,,,,,"we fixed cells in 4% paraformaldehyde for the detection of nuclear DNA fragmentation with the DeadEnd Fluorometric TUNEL System (Promega; Madison, WI)",Non-genetic lab reagent/kit/consumable: TUNEL assay reagent
hTERT and mCdk4,genetic_reagents,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,hTERT and mCdk4,Viral,pTYcPPT,EF1α,,,,,,,,,,,,,,,,,,"The vector pTYcPPT, containing the elongation factor 1 alpha promoter, was used to separately clone hTERT and mCdk4",Insert does not reference a core NF disease gene: hTERT and mCdk4
hTERT,genetic_reagents,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,hTERT,Viral,,,,,,,,,,,,,,,,,,,,full length human telomerase reverse transcriptase cDNA,Insert does not reference a core NF disease gene: hTERT
mCdk4,genetic_reagents,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mCdk4,Viral,,,,,,,,,,,,,,,,,,,,murine Cdk4 full-length cDNA,Insert does not reference a core NF disease gene: mCdk4
CRISPR-Cas9,genetic_reagents,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CRISPR-Cas9,Plasmid,lentiCRISPRv2,,,,,,,,,,,,,,,,,,,"Oligonucleotide pairs were annealed and cloned into the transfer plasmid lentiCRISPRv2 (Addgene, Watertown, MA, USA, #52961)",Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
NF1-GRD,genetic_reagents,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1-GRD,Viral,pMSCV,,,,,,,,,,,,,,,,,,,NF1-GRD sequence was introduced in Nf1−/− MEFs using the pMSCV-GRD vector,Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
pBABE vectors,genetic_reagents,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pBABE vectors,Viral,pBABE,,,,,,,,,,,,,,,,,,,pBABE vectors were used for expression of constitutively active (CA: S217E/S221E) and dominant negative (DN: S217A) MEK1 and hyperactive RAS (G12D mutant),Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
NAD+/NADH assay,genetic_reagents,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,NAD+/NADH assay,,,,,,,,,,,,,,,,,,,,,"The NAD+/NADH ratio was measured using the NAD+/NADH colorimetric assay kit (Abcam, Waltham, MA, USA)",Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
SuperScript III,genetic_reagents,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,SuperScript III,,,,,,,,,,,,,,,,,,,,,2 µg of total RNA was used to synthesize cDNA with the SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific),Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
MitoSOX,genetic_reagents,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,MitoSOX,,,,,,,,,,,,,,,,,,,,,Measurements of mitochondrial ROS were performed by MitoSOX (Thermo Fisher Scientific) staining,Publication title lacks NF-specific terms: Tumor growth of neurofibromin-deficient cells is driven by decreased respiration
Hematoxylin & Eosin,genetic_reagents,PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Hematoxylin & Eosin,Other,,,,,,,,,,,,,,,,,,,,Four standard 10-μm-thick sections were stained with Hematoxylin & Eosin for each specimen,Non-genetic lab reagent/kit/consumable: Hematoxylin & Eosin
KIF15/KIF23 siRNA,genetic_reagents,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KIF15/KIF23 siRNA,Other,,,,,,,,,,,,,,,,,,,,"siRNA pool targeting KIF15, KIF23, or a non-targeting control (NTC; siGENOME SMARTpool, Dharmacon)",Insert does not reference a core NF disease gene: KIF15/KIF23 siRNA
Cas9,genetic_reagents,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Plasmid,pX330,U6,,,,,,,,,,,,,,,,,,pX330-U6-Chimeric_BB-CBh-HSpCas0 (Addgene),Generic reagent (fluorescent label / control / probe): Cas9
RGS2,genetic_reagents,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RGS2,Plasmid,,,,,,,,,,,,,,,,,,,,pRGS2 surrogate reporter (Labomics),Insert does not reference a core NF disease gene: RGS2
ispinesib,genetic_reagents,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,ispinesib,,,,,,,,,,,,,,,,,,,,,"ispinesib (Selleckchem) or ARRY-520 (MedChemExpress), which selectively inhibit KIF11",Insert does not reference a core NF disease gene: ispinesib
ARRY-520,genetic_reagents,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,ARRY-520,,,,,,,,,,,,,,,,,,,,,"ispinesib (Selleckchem) or ARRY-520 (MedChemExpress), which selectively inhibit KIF11",Drug compound: ARRY-520
HiTrap Chelating Sepharose™ High Performance,genetic_reagents,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,HiTrap Chelating Sepharose™ High Performance,Other,,,,,,,,,,,,,,,,,,,,The supernatant ran through a 5 ml HiTrap Chelating Sepharose™ High Performance (GE healthcare) and washed extensively,Insert does not reference a core NF disease gene: HiTrap Chelating Sepharose™ High Performance
Superdex 200 10/300 GL column,genetic_reagents,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,Superdex 200 10/300 GL column,Other,,,,,,,,,,,,,,,,,,,,Further purification followed by gel filtration chromatography using a Superdex 200 10/300 GL column (GE Healthcare),Insert does not reference a core NF disease gene: Superdex 200 10/300 GL column
Cre,genetic_reagents,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,,,,,,,,,,,,,,,,,,,,Cre recombinase was targeted to the mouse leptomeninges by direct injection of 3 µL (1 × 10 8 plaque‐forming units) of adCre suspension,Insert does not reference a core NF disease gene: Cre
Gd-DTPA,genetic_reagents,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,Gd-DTPA,,,,,,,,,,,,,,,,,,,,,"all animals were intraperitoneally injected (1) a MR contrast agent, Gd-DTPA (Magnevist ®, Schering, Leverkusen, Germany) at a dose of 0.8 mL/kg",Insert does not reference a core NF disease gene: Gd-DTPA
Human Mapping 100K Set,genetic_reagents,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human Mapping 100K Set,Other,,,,,,,,,,,,,,,,,,,,Tumor genotyping was performed with the Human Mapping 100K Set platform ( Affymetrix ),Insert does not reference a core NF disease gene: Human Mapping 100K Set
GeneChip Human Genome U133 Plus 2.0 Arrays,genetic_reagents,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GeneChip Human Genome U133 Plus 2.0 Arrays,Other,,,,,,,,,,,,,,,,,,,,gene-expression data were obtained using GeneChip Human Genome U133 Plus 2.0 Arrays ( Affymetrix ),Insert does not reference a core NF disease gene: GeneChip Human Genome U133 Plus 2.0 Arrays
PD0325901,genetic_reagents,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,PD0325901,,,,,,,,,,,,,,,,,,,,,"For MEKi treatment, 1 μg/mL PD0325901 (Selleckchem, S1036) was added to cell culture for 72 hours.",Drug compound: PD0325901
CNMCS Compartmental Protein Extraction Kit,genetic_reagents,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,CNMCS Compartmental Protein Extraction Kit,,,,,,,,,,,,,,,,,,,,,"Mouse tissues were collected and lysed with the CNMCS Compartmental Protein Extraction Kit (Millipore, 2145)...",Non-genetic lab reagent/kit/consumable: CNMCS Compartmental Protein Extraction Kit
PDE4A1,genetic_reagents,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,PDE4A1,Viral,,,,,,,,,,,,,,,,,,,,Full-length murine PDE4A1 or catalytically inactive PDE4A1-H229Q was cloned into a lentiviral packaging vector that also encodes mCherry fluorescent protein,Insert does not reference a core NF disease gene: PDE4A1
PDE4A1-H229Q,genetic_reagents,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,PDE4A1-H229Q,Viral,,,,,,,,,,,,,,,,,,,,Full-length murine PDE4A1 or catalytically inactive PDE4A1-H229Q was cloned into a lentiviral packaging vector that also encodes mCherry fluorescent protein,Insert does not reference a core NF disease gene: PDE4A1-H229Q
firefly luciferase-eGFP fusion,genetic_reagents,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,firefly luciferase-eGFP fusion,Viral,FUW,human ubiquitin C,,,,,,,,,,,,,,,,,,A second packaging vector (FUW-FLG) encoding a fusion of firefly luciferase and enhanced green fluorescent protein driven by the human ubiquitin C promoter,Generic reagent (fluorescent label / control / probe): firefly luciferase-eGFP fusion
luciferase,genetic_reagents,PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,luciferase,Viral,lentivirus,,,,,,,,,,,,,,,,,,,GL261-luc cells were generated by infection of lentivirus carrying luciferase as described.,Publication title lacks NF-specific terms: Neutrophil depletion enhanced the
CAS9,genetic_reagents,PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CAS9,Other,,,,,,,,,,,,,,,,,,,,"Conditional gene expression, CRISPR-CAS9, and shRNA-mediated knockdown were used to perform gain/loss-of-function experiments",Generic reagent (fluorescent label / control / probe): CAS9
shRNA,genetic_reagents,PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNA,Other,,,,,,,,,,,,,,,,,,,,"CRISPR-CAS9, and shRNA-mediated knockdown were used to perform gain/loss-of-function experiments to explore the effect of reconstituting the GTPase-activating protein-related domain of NF1",Generic reagent (fluorescent label / control / probe): shRNA
selumetinib,genetic_reagents,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,selumetinib,,,,,,,,,,,,,,,,,,,,,"selumetinib (Tocris, catalog 6815), ogerin (Tocris, catalog 5722)",Drug compound (class suffix): selumetinib
ogerin,genetic_reagents,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,ogerin,,,,,,,,,,,,,,,,,,,,,"selumetinib (Tocris, catalog 6815), ogerin (Tocris, catalog 5722)",Drug compound: ogerin
GANT61,genetic_reagents,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,GANT61,,,,,,,,,,,,,,,,,,,,,"GANT61 (Tocris, catalog 3191), LGK-974 (Selleckchem, catalog S7143)",Drug compound: GANT61
LGK-974,genetic_reagents,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,LGK-974,,,,,,,,,,,,,,,,,,,,,"GANT61 (Tocris, catalog 3191), LGK-974 (Selleckchem, catalog S7143)",Drug compound: LGK-974
PAM71,genetic_reagents,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,PAM71,,,,,,,,,,,,,,,,,,,,,"PAM71 (MedChemExpress, catalog HY-134494), 8-(4-Chlorophenylthio)adenosine",Insert does not reference a core NF disease gene: PAM71
8CPT cAMP,genetic_reagents,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,8CPT cAMP,,,,,,,,,,,,,,,,,,,,,"8-(4-Chlorophenylthio)adenosine 3′,5′-cyclic monophosphate (8CPT cAMP) (Abcam, catalog ab120424)",Non-genetic lab reagent/kit/consumable: 8CPT cAMP
Forskolin,genetic_reagents,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,Forskolin,,,,,,,,,,,,,,,,,,,,,"Forskolin (MilliporeSigma, catalog F6886). They were prepared as indicated by the manufacturers",Drug compound: Forskolin
Cre,genetic_reagents,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,,CMV,,,,,,,,,,,,,,,,,,"Cre recombinase expressing adenovirus (Ad5CMVCre-GFP High Titer, University of Iowa Viral Vector Core)",Insert does not reference a core NF disease gene: Cre
DNA extraction reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,DNA was purified using the Qiagen DNeasy Extraction kit and 0.5 µg was subjected to bisulfite treatment,Non-genetic lab reagent/kit/consumable: DNA extraction reagent
Bisulfite treatment reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Bisulfite treatment reagent,Other,,,,,,,,,,,,,,,,,,,,"0.5 µg was subjected to bisulfite treatment (Qiagen, EpiTect plus)",Non-genetic lab reagent/kit/consumable: Bisulfite treatment reagent
Exome capture reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Exome capture reagent,Other,,,,,,,,,,,,,,,,,,,,Libraries were constructed from > 200 ng starting genomic DNA using the Agilent SureSelect Human All Exon V5 + UTRs kit,Non-genetic lab reagent/kit/consumable: Exome capture reagent
Library preparation reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Library preparation reagent,Other,,,,,,,,,,,,,,,,,,,,Genomic DNA (0.5–1 µg) libraries were generated using the Illumina TruSeq PCR-free DNA library preparation kit,Non-genetic lab reagent/kit/consumable: Library preparation reagent
RNA library preparation reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA library preparation reagent,Other,,,,,,,,,,,,,,,,,,,,"Tumor RNA libraries were prepared from 200 ng of RNA and the Illumina TruSeq mStranded Total RNA (N = 18, RIN > 8)",Non-genetic lab reagent/kit/consumable: RNA library preparation reagent
RNA depletion reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA depletion reagent,Other,,,,,,,,,,,,,,,,,,,,"Illumina TruSeq mStranded Total RNA (N = 18, RIN > 8) and Ribo-Zero Gold (N = 6, RIN < 8) kits",Non-genetic lab reagent/kit/consumable: RNA depletion reagent
Reverse transcription reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Reverse transcription reagent,Other,,,,,,,,,,,,,,,,,,,,"To validate fusions, purified RNAs were reverse-transcribed using SuperScript VILO kit",Non-genetic lab reagent/kit/consumable: Reverse transcription reagent
PCR purification reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PCR purification reagent,Other,,,,,,,,,,,,,,,,,,,,PCR products were purified using the Qiagen MinElute PCR purification kit and run on a 1.2% agarose gel,Non-genetic lab reagent/kit/consumable: PCR purification reagent
Target enrichment reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Target enrichment reagent,Other,,,,,,,,,,,,,,,,,,,,Library preparation for NGS was accomplished using the HaloPlex PCR target enrichment system (Agilent Technologies Inc.),Non-genetic lab reagent/kit/consumable: Target enrichment reagent
Sequencing reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Sequencing reagent,Other,,,,,,,,,,,,,,,,,,,,"Sequencing was performed using MiSeq reagent kit version 2, 300 cycles, on the MiSeq instrument",Non-genetic lab reagent/kit/consumable: Sequencing reagent
Microsatellite markers,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Microsatellite markers,Other,,,,,,,,,,,,,,,,,,,,"Loss of heterozygosity (LOH) in 22q was investigated using microsatellites D22S420, D22S539, D22S1174, D22S315, D22S1154, D22S1163, D22S280, D22S277, D22S283, D22S423, D22S274, and D22S1169 from the ABI PRISM Linkage Mapping set version 2.5",Generic reagent (fluorescent label / control / probe): Microsatellite markers
MLPA probe set,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MLPA probe set,Other,,,,,,,,,,,,,,,,,,,,"SMARCB1, NF2 and 22q11 MLPA test kits (MRC-Holland, P044_B1, P258_C1 and P324_A2) were used",Insert does not reference a core NF disease gene: MLPA probe set
MLPA probe set,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MLPA probe set,Other,,,,,,,,,,,,,,,,,,,,"SMARCB1, NF2 and 22q11 MLPA test kits (MRC-Holland, P044_B1, P258_C1 and P324_A2) were used",Insert does not reference a core NF disease gene: MLPA probe set
MLPA probe set,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MLPA probe set,Other,,,,,,,,,,,,,,,,,,,,"SMARCB1, NF2 and 22q11 MLPA test kits (MRC-Holland, P044_B1, P258_C1 and P324_A2) were used",Insert does not reference a core NF disease gene: MLPA probe set
tamoxifen,genetic_reagents,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,tamoxifen,,,,,,,,,,,,,,,,,,,,,"Timed-pregnant FMPrC dams (gestational day 14–16) underwent oral gavage with 1mg tamoxifen (Sigma-Aldrich, St. Louis, MO)",Drug compound: tamoxifen
progesterone,genetic_reagents,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,progesterone,,,,,,,,,,,,,,,,,,,,,"1mg tamoxifen (Sigma-Aldrich, St. Louis, MO) and 1 mg progesterone (Sigma-Aldrich, St. Louis, MO)",Drug compound: progesterone
DAPI,genetic_reagents,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,DAPI,,,,,,,,,,,,,,,,,,,,,"followed by either Alexa-Fluor-tagged secondary antibodies (Invitrogen, Grand Island, NY) and DAPI counterstaining",Non-genetic lab reagent/kit/consumable: DAPI
Vectastain Elite ABC,genetic_reagents,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Vectastain Elite ABC,,,,,,,,,,,,,,,,,,,,,or biotinylated secondary antibodies and Vectastain Elite ABC development,Non-genetic lab reagent/kit/consumable: Vectastain Elite ABC
Ketotifen fumarate,genetic_reagents,PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Ketotifen fumarate,,,,,,,,,,,,,,,,,,,,,"Ketotifen fumarate was purchased from Sigma-Aldrich. In the prevention and intervention therapeutic studies, ketotifen 1 mg/mL was prepared in ddH2O and administered via oral gavage at 10 mg/kg once daily",Drug compound: Ketotifen fumarate
Kit Ligand,genetic_reagents,PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Kit Ligand,,,,,,,,,,,,,,,,,,,,,"To determine if ketotifen had an in vivo effect on mast cell infiltration and degranulation, four-month old Nf1 mice were administered subcutaneous Kit Ligand as previously described",Insert does not reference a core NF disease gene: Kit Ligand
psPAX2,genetic_reagents,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,psPAX2,Plasmid,psPAX2,,,,,,,,,,,,,,,,,,,"Lentiviral transfer plasmid plus packaging plasmids psPAX2 (gift from Didier Trono, Addgene Plasmid #12260, RRID:Addgene_12260) and pCMV-VSV-G",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
VSV-G,genetic_reagents,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,VSV-G,Plasmid,pCMV-VSV-G,CMV,,,,,,,,,,,,,,,,,,"pCMV-VSV-G (gift from Bob Weinberg, Addgene Plasmid #8454, RRID:Addgene_8454) were cotransfected intro HEK-293T cells",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
shRNA library,genetic_reagents,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNA library,Viral,LT3GEPIR mir-E,,,,,,,,,,,,,,,,,,,A doxycycline-inducible pooled human epigenome-focused lentiviral shRNA plasmid library in the LT3GEPIR mir-E backbone,Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
shRNA,genetic_reagents,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNA,Plasmid,LT3GEPIR,,,,,,,,,,,,,,,,,,,"Control (sh Ren.713), DNMT1, DNMT3A, and DNMT3B shRNAs were cloned into Tet-ON all-in-one plasmids LT3GEPIR (gift from Johannes Zuber, RRID:Addgene_111177)",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
sgRNA,genetic_reagents,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,sgRNA,Plasmid,pL-CRISPR.EFS.Blast,EFS,,,,,,,,,,,,,,,,,,Control and SUZ12 sgRNA targeting the VEFS functional domain were cloned into pL-CRISPR.EFS.Blast (plasmid was generated by replacing tagRFP in Addgene Plasmid #57819),Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
SUZ12,genetic_reagents,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SUZ12,Plasmid,pLV-EF1α-IRES-Puro,EF1α,,,,,,,,,,,,,,,,,,"Human SUZ12 cDNA was cloned into pLV-EF1α-IRES-Puro (gift from Tobias Meyer, RRID:Addgene_85132)",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
MIPE 4.0,genetic_reagents,PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MIPE 4.0,Other,,,,,,,,,,,,,,,,,,,,"...screen a panel of 1912 small molecules (the MIPE 4.0 library [17]) against immortalized NF1 −/−, NF1 +/−, and NF1 +/+ cell lines...",Drug compound: MIPE 4.0
ATP detection reagent,genetic_reagents,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,ATP detection reagent,,,,,,,,,,,,,,,,,,,,,CellTiter-Glo 3D Reagent Promega CAT#G968B,Non-genetic lab reagent/kit/consumable: ATP detection reagent
All-Prep Universal Kit,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,All-Prep Universal Kit,Other,,,,,,,,,,,,,,,,,,,,"DNA and RNA were isolated from cell lines, human samples, or mouse allografts using the All-Prep Universal Kit (#80224, QIAGEN)",Non-genetic lab reagent/kit/consumable: All-Prep Universal Kit
Illumina Methylation EPIC Beadchip,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Illumina Methylation EPIC Beadchip,Other,,,,,,,,,,,,,,,,,,,,"Genomic DNA from human tumors were processed for methylation analysis using the Illumina Methylation EPIC Beadchip (#WG-317-1003, Illumina)",Non-genetic lab reagent/kit/consumable: Illumina Methylation EPIC Beadchip
Kapa Hyper Prep Kit,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Kapa Hyper Prep Kit,Other,,,,,,,,,,,,,,,,,,,,"Sequencing libraries were prepared using the Kapa Hyper Prep Kit (#07962312001, Roche)",Non-genetic lab reagent/kit/consumable: Kapa Hyper Prep Kit
Nimblegen SeqCap EZ Human Exome Kit,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Nimblegen SeqCap EZ Human Exome Kit,Other,,,,,,,,,,,,,,,,,,,,exome capture was performed using the Nimblegen SeqCap EZ Human Exome Kit v3.0 (Roche),Non-genetic lab reagent/kit/consumable: Nimblegen SeqCap EZ Human Exome Kit
TruSeq RNA Library Prep Kit v2,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSeq RNA Library Prep Kit v2,Other,,,,,,,,,,,,,,,,,,,,"Library preparation was performed using the TruSeq RNA Library Prep Kit v2 (#RS-122-2001, Illumina)",Non-genetic lab reagent/kit/consumable: TruSeq RNA Library Prep Kit v2
Chromium Single Cell 3′ Library & Gel Bead Kit v3.1,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Chromium Single Cell 3′ Library & Gel Bead Kit v3.1,Other,,,,,,,,,,,,,,,,,,,,Single-nuclei or single-cell RNA sequencing was performed using the Chromium Single Cell 3′ Library & Gel Bead Kit v3.1 on a 10× Chromium controller,Non-genetic lab reagent/kit/consumable: Chromium Single Cell 3′ Library & Gel Bead Kit v3.1
CellTiter 96 Non-Radioactive Cell Proliferation Assay,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CellTiter 96 Non-Radioactive Cell Proliferation Assay,Other,,,,,,,,,,,,,,,,,,,,"Viability assays were carried out with the CellTiter 96 Non-Radioactive Cell Proliferation Assay (#G410, Promega)",Non-genetic lab reagent/kit/consumable: CellTiter 96 Non-Radioactive Cell Proliferation Assay
RNeasy Mini Kit,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNeasy Mini Kit,Other,,,,,,,,,,,,,,,,,,,,"RNA was extracted from cell lines using the RNeasy Mini Kit (#74106, QIAGEN)",Non-genetic lab reagent/kit/consumable: RNeasy Mini Kit
iScript cDNA Synthesis kit,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,iScript cDNA Synthesis kit,Other,,,,,,,,,,,,,,,,,,,,"cDNA was synthesized from RNA using iScript cDNA Synthesis kit (#1708891, Bio-Rad)",Non-genetic lab reagent/kit/consumable: iScript cDNA Synthesis kit
PowerUp SYBR Green Master Mix,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PowerUp SYBR Green Master Mix,Other,,,,,,,,,,,,,,,,,,,,"Real-time QPCR was performed using PowerUp SYBR Green Master Mix (#A25918, Thermo Fisher Scientific)",Non-genetic lab reagent/kit/consumable: PowerUp SYBR Green Master Mix
dCas9-BFP-KRAB,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,dCas9-BFP-KRAB,Plasmid,pMH0001,SFFV,,,,,,,,,,,,,,,,,,"Lentivirus containing pMH0001 (UCOE-SFFV-dCas9-BFP-KRAB, #85969, Addgene) was produced",Insert does not reference a core NF disease gene: dCas9-BFP-KRAB
sgRNA,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,sgRNA,Plasmid,pCRISPRia-v2,,,,,,,,,,,,,,,,,,,"Subsequent gene specific knockdowns were achieved by individually cloning single-guide RNA (sgRNA) protospacer sequences into the pCRISPRia-v2 vector (#84832, Addgene)",Generic reagent (fluorescent label / control / probe): sgRNA
ALDH1A1,genetic_reagents,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ALDH1A1,Plasmid,pLKO.1-puro,,,,,,,,,,,,,,,,,,,ALDH1A1 (TRCN0000026415)—5′-GCCAAATCATTCCTTGGAATTT-3′,Insert does not reference a core NF disease gene: ALDH1A1
TAZ,genetic_reagents,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TAZ,Plasmid,pLKO.1-puro,,,,,,,,,,,,,,,,,,,TAZ (TRCN0000307197)—5′-CGGACTTCATTCAAGAGGAAT-3′,Insert does not reference a core NF disease gene: TAZ
YAP,genetic_reagents,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,YAP,Plasmid,pLKO.1-puro,,,,,,,,,,,,,,,,,,,YAP (TRCN0000107266)—5′-GCCACCAAGCTAGATAAAGAA-3′,Insert does not reference a core NF disease gene: YAP
Scramble,genetic_reagents,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Scramble,Plasmid,pLKO.1-puro,,,,,,,,,,,,,,,,,,,Scramble (TRC1/1.5; SHC002)—5′-CAACAAGATGAAGAGCACCAA-3′,Generic reagent (fluorescent label / control / probe): Scramble
IPA-3,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,IPA-3,,,,,,,,,,,,,,,,,,,,,Cells were treated with IPA-3 (Sigma-Aldrich) a PAK group1 inhibitor (PAK1/2/3),Insert does not reference a core NF disease gene: IPA-3
Q-proteome cell compartment kit,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Q-proteome cell compartment kit,,,,,,,,,,,,,,,,,,,,,were fractionated using the Q-proteome cell compartment kit (Qiagen) following manufacturer's instructions,Non-genetic lab reagent/kit/consumable: Q-proteome cell compartment kit
Co-IP kit,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Co-IP kit,,,,,,,,,,,,,,,,,,,,,Co-IP experiments were performed without deviation from Co-IP kit protocol (Thermo Scientific),Non-genetic lab reagent/kit/consumable: Co-IP kit
Rneasy Mini Kit,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Rneasy Mini Kit,,,,,,,,,,,,,,,,,,,,,"Total RNA of cultured cells was extracted using the Rneasy Mini Kit (Qiagen, Germantown, MD)",Non-genetic lab reagent/kit/consumable: Rneasy Mini Kit
SuperScript III first-strand synthesis system,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,SuperScript III first-strand synthesis system,,,,,,,,,,,,,,,,,,,,,500ng of RNA were reverse-transcribed using the SuperScript™ III first-strand synthesis system for RT-PCR (Life Technologies),Non-genetic lab reagent/kit/consumable: SuperScript III first-strand synthesis system
Power SYBR Green PCR master mix,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Power SYBR Green PCR master mix,,,,,,,,,,,,,,,,,,,,,quantitative real-time PCR (Q-PCR) using Power SYBR Green PCR master mix (Life Technologies),Non-genetic lab reagent/kit/consumable: Power SYBR Green PCR master mix
Vybrant MTT cell proliferation assay kit,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Vybrant MTT cell proliferation assay kit,,,,,,,,,,,,,,,,,,,,,The Vybrant ® MTT cell proliferation assay kit quick protocol (Life Technologies) was employed,Non-genetic lab reagent/kit/consumable: Vybrant MTT cell proliferation assay kit
I2HCP panel,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,I2HCP panel,Other,,,,,,,,,,,,,,,,,,,,Genetic testing was performed using the customized I2HCP panel in blood or tissue when available.,Insert does not reference a core NF disease gene: I2HCP panel
PMOs,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PMOs,Other,,,,,,,,,,,,,,,,,,,,"The 25-mer-specific PMOs for four patients with splicing variants, and a pair of PMOs to induce exon skipping of exons 4, 8, and 11 of the NF2 gene were designed",Insert does not reference a core NF disease gene: PMOs
Endo-Porter,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Endo-Porter,Other,,,,,,,,,,,,,,,,,,,,Endo-Porter (Gene Tools) was used as vehicle to deliver PMOs into cells at 6 μM,Insert does not reference a core NF disease gene: Endo-Porter
Click-iT EdU Alexa Fluor 488,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Click-iT EdU Alexa Fluor 488,Other,,,,,,,,,,,,,,,,,,,,"AClick-iT EdU Alexa Fluor 488 Flow Cytometry Assay Kit (Molecular Probes, Invitrogen) was used, according to the manufacturer's protocol, to determine cell proliferation",Non-genetic lab reagent/kit/consumable: Click-iT EdU Alexa Fluor 488
RealTime-Glo MT,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RealTime-Glo MT,Other,,,,,,,,,,,,,,,,,,,,Cell viability was assessed using RealTime-Glo MT Cell Viability Assay (Promega) following the manufacturer's instructions,Non-genetic lab reagent/kit/consumable: RealTime-Glo MT
Gateway Gene Cloning system,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Gateway Gene Cloning system,Other,,,,,,,,,,,,,,,,,,,,The NF2 gene was cloned using the Gateway Gene Cloning system (Invitrogen) after treatment to induce the exon-skipping to an FLAG Tag Expression Vector,Insert does not reference a core NF disease gene: Gateway Gene Cloning system
FLAG Tag,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,FLAG Tag,Plasmid,,,,,,,,,,,,,,,,,,,,The NF2 gene was cloned using the Gateway Gene Cloning system (Invitrogen) after treatment to induce the exon-skipping to an FLAG Tag Expression Vector,Insert does not reference a core NF disease gene: FLAG Tag
Lipofectamine LTX,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Lipofectamine LTX,Other,,,,,,,,,,,,,,,,,,,,"The expression vector was transfected into HeLa cells (Lipofectamine LTX with Plus Reagent, Invitrogen)",Insert does not reference a core NF disease gene: Lipofectamine LTX
NeuroD1,genetic_reagents,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NeuroD1,Viral,,CMV,,,,,,,,,,,,,,,,,,"AdCMVNeuroD1 at 2 × 109 pfu/mL, or AdCMVNeuroD1 at 5 × 109 pfu/mL (ViraQuest, Inc.) were applied to the culture medium",Insert does not reference a core NF disease gene: NeuroD1
empty vector,genetic_reagents,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,empty vector,Viral,,CMV,,,,,,,,,,,,,,,,,,"Adenovirus (Ad) CMVempty vector (EV) at 5 × 109 pfu/mL, AdCMVNeuroD1 at 2 × 109 pfu/mL",Generic reagent (fluorescent label / control / probe): empty vector
EdU detection,genetic_reagents,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,EdU detection,,,,,,,,,,,,,,,,,,,,,EdU was detected in whole ganglion using the Click-It EdU kit per manufacturer's instructions (Life Technologies),Non-genetic lab reagent/kit/consumable: EdU detection
EdU detection,genetic_reagents,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,EdU detection,,,,,,,,,,,,,,,,,,,,,Edu staining was performed using Click-it EdU Alexa Fluor 633 Image Kit (ThermoFisher C10340),Non-genetic lab reagent/kit/consumable: EdU detection
Tgfb3,genetic_reagents,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tgfb3,Other,,,,,,,,,,,,,,,,,,,,"Sequence-based reagent Tgfb3-MO Gene Tools, LLC Lissamine-tagged, tgfb3-targeting Morpholino",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
Tgfb1b,genetic_reagents,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tgfb1b,Other,,,,,,,,,,,,,,,,,,,,"Sequence-based reagent Tgfb1b-MO Gene Tools, LLC Lissamine-tagged, tgfb1b-targeting Morpholino",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
tgfb3-EGFP,genetic_reagents,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,tgfb3-EGFP,Plasmid,pCS2+,,,,,,,,,,,,,,,,,,,Recombinant DNA reagent pCS2+ tgfb3-EGFP This paper; Figure 3—figure supplement 1B Vector for generating RNA,Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
nCas9n-nanos3'UTR,genetic_reagents,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,nCas9n-nanos3'UTR,Plasmid,pCS2,,,,,,,,,,,,,,,,,,,"Recombinant DNA reagent pCS2-nCas9n-nanos3'UTR Addgene, Plasmid #62542",Publication title lacks NF-specific terms: Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina rege
CellTiter-Glo,genetic_reagents,PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,CellTiter-Glo,,,,,,,,,,,,,,,,,,,,,"Cell viability was assessed using the CellTiter-Glo Luminescent Cell Viability Assay (Cat# G755B/G756B; Promega, Madison, WI, USA)",Non-genetic lab reagent/kit/consumable: CellTiter-Glo
RNA isolation kit,genetic_reagents,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA isolation kit,,,,,,,,,,,,,,,,,,,,,Total RNA was isolated using the Direct-zol RNA Miniprep Kit (Zymo).,Publication title lacks NF-specific terms: A genetic mouse model with postnatal
RNA library preparation kit,genetic_reagents,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA library preparation kit,,,,,,,,,,,,,,,,,,,,,Libraries were prepared using the TruSeq Stranded Total RNA Library Prep Kit (Illumina),Publication title lacks NF-specific terms: A genetic mouse model with postnatal
SCH23390,genetic_reagents,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,SCH23390,,,,,,,,,,,,,,,,,,,,,"[3H]-SCH23390, [3H]-raclopride, [3H]-Win 35428 (PerkinElmer Life and Analytical Sciences; Shelton, CT)",Drug compound: SCH23390
raclopride,genetic_reagents,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,raclopride,,,,,,,,,,,,,,,,,,,,,"[3H]-SCH23390, [3H]-raclopride, [3H]-Win 35428 (PerkinElmer Life and Analytical Sciences; Shelton, CT)",Drug compound: raclopride
Win 35428,genetic_reagents,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Win 35428,,,,,,,,,,,,,,,,,,,,,"[3H]-SCH23390, [3H]-raclopride, [3H]-Win 35428 (PerkinElmer Life and Analytical Sciences; Shelton, CT)",Drug compound: Win 35428
WC-10,genetic_reagents,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,WC-10,,,,,,,,,,,,,,,,,,,,,"[3H]-WC-10, and [3H]-a-Dihydrotetrabenazine ([3H]-DTBZ; American Radiolabeled Chemicals; St. Louis, MO)",Insert does not reference a core NF disease gene: WC-10
DTBZ,genetic_reagents,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,DTBZ,,,,,,,,,,,,,,,,,,,,,"[3H]-a-Dihydrotetrabenazine ([3H]-DTBZ; American Radiolabeled Chemicals; St. Louis, MO)",Drug compound: DTBZ
raclopride,genetic_reagents,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,raclopride,,,,,,,,,,,,,,,,,,,,,Mice were injected with ~200μCi of [11C]-raclopride (~2500 Ci/mmol specific activity) via the tail vein,Drug compound: raclopride
telomere repeat sequence probe,genetic_reagents,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,telomere repeat sequence probe,,,,,,,,,,,,,,,,,,,,,hybridization with a Cy3-labeled peptide nucleic acid (PNA) probe complementary to the mammalian telomere repeat sequence [(N-terminus to C-terminus) CCCTAACCCTAACCCTAA],Insert does not reference a core NF disease gene: telomere repeat sequence probe
centromeric DNA repeats probe,genetic_reagents,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,centromeric DNA repeats probe,,,,,,,,,,,,,,,,,,,,,an Alexa Fluor-488–labeled PNA probe specific to human centromeric DNA repeats was also included as a control to assess the validity of the hybridization,Insert does not reference a core NF disease gene: centromeric DNA repeats probe
Agilent SureSelect-XT reagents,genetic_reagents,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Agilent SureSelect-XT reagents,Other,,,,,,,,,,,,,,,,,,,,"DNA libraries were prepared using Agilent SureSelect-XT reagents (Agilent Technologies, Inc., Santa Clara, CA)",Non-genetic lab reagent/kit/consumable: Agilent SureSelect-XT reagents
644 cancer gene panel,genetic_reagents,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,644 cancer gene panel,Other,,,,,,,,,,,,,,,,,,,,Genomic regions of interest were captured using an Agilent custom-designed bait set covering the full coding regions of 644 cancer associated genes,Insert does not reference a core NF disease gene: 644 cancer gene panel
Human Exome,genetic_reagents,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human Exome,Other,,,,,,,,,,,,,,,,,,,,"Whole-exome capture was performed using either the SeqCap EZ Human Exome Library (Nimblegen, Basel, Switzerland)",Generic reagent (fluorescent label / control / probe): Human Exome
Human Exome,genetic_reagents,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human Exome,Other,,,,,,,,,,,,,,,,,,,,"Whole-exome capture was performed using either the SeqCap EZ Human Exome Library (Nimblegen, Basel, Switzerland) or TruSeq Exome kit (Illumina, San Diego, CA)",Generic reagent (fluorescent label / control / probe): Human Exome
pcDNA3.1,genetic_reagents,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pcDNA3.1,Plasmid,pcDNA3.1,,,,,,,,,,,,,,,,,,,"PCR amplicons were cloned into pcDNA3.1 vector (Life Technologies, CA, USA)",Generic reagent (fluorescent label / control / probe): pcDNA3.1
MEM Alpha,genetic_reagents,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,MEM Alpha,Other,,,,,,,,,,,,,,,,,,,,"Cells were pelleted and re-suspended in Minimum Essential Medium (MEM) Alpha (Life Technologies, CA, USA)",Non-genetic lab reagent/kit/consumable: MEM Alpha
sgRNA,genetic_reagents,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,sgRNA,Plasmid,pU6(x),U6,,,,,,,,,,,,,,,,,,gRNAs targeting zebrafish nf2a/b were validated and cloned in the pU6(x):sgRNA#(x) vectors,Generic reagent (fluorescent label / control / probe): sgRNA
LNTH-1363S,genetic_reagents,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,LNTH-1363S,Other,,,,,,,,,,,,,,,,,,,,"After administration of 179 MBq [68Ga]Ga-LNTH-1363S, (FAP-directed radiotracer; mass dose, 90 ug)",Publication title lacks NF-specific terms: FAP expression as a marker of malignant transformation enabling in vivo characte
DUSP6,genetic_reagents,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,DUSP6,,,,,,,,,,,,,,,,,,,,,using the following pig TaqMan primers ( DUSP6 -Ss06941845_m1;  FOS  -Ss03390402_m1; normalized to the average of pig housekeeping genes,Insert does not reference a core NF disease gene: DUSP6
FOS,genetic_reagents,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,FOS,,,,,,,,,,,,,,,,,,,,,using the following pig TaqMan primers ( DUSP6 -Ss06941845_m1;  FOS  -Ss03390402_m1; normalized to the average of pig housekeeping genes,Insert does not reference a core NF disease gene: FOS
pCW57.1,genetic_reagents,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pCW57.1,Plasmid,pCW57.1,,,,,,,,,,,,,,,,,,,The plasmids pCW57.1 (Addgene plasmid 41393),Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
KRAS WT,genetic_reagents,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KRAS WT,Plasmid,pDONR223,,,,,,,,,,,,,,,,,,,pDONR223 KRAS WT (Addgene plasmid 81751),Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
KRAS G12D,genetic_reagents,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KRAS G12D,Plasmid,pDONR223,,,,,,,,,,,,,,,,,,,pDONR223 KRAS G12D (Addgene plasmid 81651),Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
Active RAS Pull-Down Kit,genetic_reagents,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Active RAS Pull-Down Kit,,,,,,,,,,,,,,,,,,,,,Ras-GTP assays were performed with the Active RAS Pull-Down Kit (Thermo Fisher),Publication title lacks NF-specific terms: Structural and functional analyses of a germline KRAS T50I mutation provide insi
GFP,genetic_reagents,PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Viral,Ad5,CMV,,,,,,,,,,,,,,,,,,"containing either Ad5-CMV-GFP or Ad5-CMV-cre (Vector development lab, Baylor College of Medicine)",Generic reagent (fluorescent label / control / probe): GFP
Cre,genetic_reagents,PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,Ad5,CMV,,,,,,,,,,,,,,,,,,"containing either Ad5-CMV-GFP or Ad5-CMV-cre (Vector development lab, Baylor College of Medicine)",Insert does not reference a core NF disease gene: Cre
Trametinib,genetic_reagents,PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Trametinib,,,,,,,,,,,,,,,,,,,,,Trametinib (a MEK inhibitor) and BMP2 released locally at the fracture site,Drug compound (class suffix): Trametinib
SU-11274,genetic_reagents,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,SU-11274,,,,,,,,,,,,,,,,,,,,,MM cells in log growth phase were treated with vehicle control or c-Met inhibitors SU-11274 (5 μM),Drug compound: SU-11274
SGX2943,genetic_reagents,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,SGX2943,,,,,,,,,,,,,,,,,,,,,or SGX2943 (5 μM Calbiochem) for 24 h before harvesting for protein extraction,Drug compound: SGX2943
Tp53,genetic_reagents,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tp53,Other,,,,,,,,,,,,,,,,,,,,Cells were nucleofected with siRNA against Tp53 or miR34a (Dharmacon),Insert does not reference a core NF disease gene: Tp53
miR34a,genetic_reagents,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,miR34a,Other,,,,,,,,,,,,,,,,,,,,Cells were nucleofected with siRNA against Tp53 or miR34a (Dharmacon),Insert does not reference a core NF disease gene: miR34a
ficoll,genetic_reagents,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ficoll,Other,,,,,,,,,,,,,,,,,,,,White blood cells were isolated using ficoll (Sigma-Aldrich) from fresh whole blood,Non-genetic lab reagent/kit/consumable: ficoll
RPMI 1640,genetic_reagents,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,RPMI 1640,Other,,,,,,,,,,,,,,,,,,,,complete medium consisting of RPMI 1640 supplemented with 12.5% FCS,Non-genetic lab reagent/kit/consumable: RPMI 1640
PHA,genetic_reagents,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PHA,Other,,,,,,,,,,,,,,,,,,,,Lymphocyte growth was stimulated with 50 µl/ml PHA (Gibco),Insert does not reference a core NF disease gene: PHA
IL-2,genetic_reagents,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,IL-2,Other,,,,,,,,,,,,,,,,,,,,stimulated with 50 µl/ml PHA (Gibco) and 10 units/ml of IL-2 (Roche),Insert does not reference a core NF disease gene: IL-2
puromycin,genetic_reagents,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,puromycin,Other,,,,,,,,,,,,,,,,,,,,one part was treated with 200 µg/ml of puromycin (Sigma-Aldrich) as an inhibitor of nonsense mediated RNA decay,Drug compound (class suffix): puromycin
RNeasy Plus micro columns,genetic_reagents,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNeasy Plus micro columns,Other,,,,,,,,,,,,,,,,,,,,Total RNA was purified and DNAseI treated using RNeasy Plus micro columns (Qiagen),Non-genetic lab reagent/kit/consumable: RNeasy Plus micro columns
IGT-T192V1 Plus panel,genetic_reagents,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,IGT-T192V1 Plus panel,Other,,,,,,,,,,,,,,,,,,,,ES was performed by standard procedures using the IGT-T192V1 Plus panel (Integrated DNA Technologies) to capture selected targets.,Publication title lacks NF-specific terms: Next-generation variant exon screening: Moving forward in routine genetic diseas
Qiagen DNA Blood Midi/Mini kit,genetic_reagents,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,Qiagen DNA Blood Midi/Mini kit,Other,,,,,,,,,,,,,,,,,,,,"A total of 50 ng of genomic DNA purified from peripheral blood (Qiagen DNA Blood Midi/Mini kit, Qiagen GmbH)",Publication title lacks NF-specific terms: Next-generation variant exon screening: Moving forward in routine genetic diseas
Fast DNA Library Prep Set CW3045M,genetic_reagents,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,Fast DNA Library Prep Set CW3045M,Other,,,,,,,,,,,,,,,,,,,,"The modified fragments were then ligated with barcoded adapters (Fast DNA Library Prep Set CW3045M, CWBIO Inc).",Publication title lacks NF-specific terms: Next-generation variant exon screening: Moving forward in routine genetic diseas
MBP fusion,genetic_reagents,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MBP fusion,Plasmid,pMAL-c2X,,,,,,,,,,,,,,,,,,,The cDNA fragments were cloned in pMAL-c2X vector (New England Biolabs) for the expression of recombinant proteins as MBP fusions,Insert does not reference a core NF disease gene: MBP fusion
His-p55,genetic_reagents,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,His-p55,Other,,,,,,,,,,,,,,,,,,,,Bacterially expressed His-p55 was immobilized on the CM5 sensor chip,Insert does not reference a core NF disease gene: His-p55
REPLI-g FFPE,genetic_reagents,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,REPLI-g FFPE,,,,,,,,,,,,,,,,,,,,,genomic DNA was isolated and subjected to whole genome amplification according to manufacturers instructions using the REPLI-g FFPE kit (Qiagen),Insert does not reference a core NF disease gene: REPLI-g FFPE
Bond Polymer Refine Kit,genetic_reagents,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Bond Polymer Refine Kit,Other,,,,,,,,,,,,,,,,,,,,"Detection was performed using the Bond Polymer Refine Kit (DS9800, Leica Biosystems)",Non-genetic lab reagent/kit/consumable: Bond Polymer Refine Kit
FOXP3/Transcription Factor Fixation/Permeabilization kit,genetic_reagents,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,FOXP3/Transcription Factor Fixation/Permeabilization kit,Other,,,,,,,,,,,,,,,,,,,,"cells first underwent fixation and permeabilization using the eBioscience ™ FOXP3/Transcription Factor Fixation/Permeabilization kit (Thermo Fisher Scientific, #00552100,)",Non-genetic lab reagent/kit/consumable: FOXP3/Transcription Factor Fixation/Permeabilization kit
KAPA RiboErase HMR,genetic_reagents,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KAPA RiboErase HMR,Other,,,,,,,,,,,,,,,,,,,,"depletion was performed with KAPA RiboErase HMR (Roche, #07962274001)",Non-genetic lab reagent/kit/consumable: KAPA RiboErase HMR
TruSeq Stranded Total RNA Library Prep Gold kit,genetic_reagents,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSeq Stranded Total RNA Library Prep Gold kit,Other,,,,,,,,,,,,,,,,,,,,"samples were prepared with TruSeq ® Stranded Total RNA Library Prep Gold kit (Illumina, #20020599)",Non-genetic lab reagent/kit/consumable: TruSeq Stranded Total RNA Library Prep Gold kit
reprogramming factors,genetic_reagents,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,reprogramming factors,Viral,,,,,,,,,,,,,,,,,,,,"The first vectors used to generate iPSCs were gamma retroviruses, specifically murine leukemia retroviruses, chosen for their favorable long-term transgene expression",Insert does not reference a core NF disease gene: reprogramming factors
reprogramming factors,genetic_reagents,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,reprogramming factors,Viral,,,,,,,,,,,,,,,,,,,,"The first vectors used to generate iPSCs were gamma retroviruses, specifically murine leukemia retroviruses, chosen for their favorable long-term transgene expression",Insert does not reference a core NF disease gene: reprogramming factors
reprogramming factors,genetic_reagents,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,reprogramming factors,Viral,,,,,,,,,,,,,,,,,,,,"Lentiviral vectors, a retroviral subclass, can transduce both non-dividing and rapidly-dividing cells with efficiencies comparable to other retroviruses",Insert does not reference a core NF disease gene: reprogramming factors
Cre,genetic_reagents,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Other,,,,,,,,,,,,,,,,,,,,excisable lentiviral vectors have been developed using Cre/loxP technology,Insert does not reference a core NF disease gene: Cre
reprogramming factors,genetic_reagents,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,reprogramming factors,Viral,,,,,,,,,,,,,,,,,,,,Adenoviral vectors are considered a non-integrative option for reprogramming factor delivery,Insert does not reference a core NF disease gene: reprogramming factors
reprogramming factors,genetic_reagents,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,reprogramming factors,Viral,,,,,,,,,,,,,,,,,,,,Sendai viral vectors are another non-integrative reprogramming alternative,Insert does not reference a core NF disease gene: reprogramming factors
"OCT4, SOX2, MYC, KLF4, NANOG, LIN28",genetic_reagents,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,"OCT4, SOX2, MYC, KLF4, NANOG, LIN28",Plasmid,oriP/EBNA1,,,,,,,,,,,,,,,,,,,"human fibroblasts have been successfully reprogrammed after a single transfection with oriP/EBNA1 (Epstein-Barr nuclear antigen-1)-based episomal vectors expressing OCT4, SOX2, MYC, KLF4, NANOG, LIN28","Insert does not reference a core NF disease gene: OCT4, SOX2, MYC, KLF4, NANOG, LIN28"
pac,genetic_reagents,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pac,Viral,MSCV,,,,,,,,,,,,,,,,,,,a virus expressing the selectable marker gene alone (MSCV-pac),Insert does not reference a core NF disease gene: pac
c-abl siRNA,genetic_reagents,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,c-abl siRNA,Other,,,,,,,,,,,,,,,,,,,,"c-abl siRNA oligonucleotides (Cat. no. sc-29844) were purchased from Santa Cruz Biotechnology, Inc.",Insert does not reference a core NF disease gene: c-abl siRNA
Scrambled siRNA,genetic_reagents,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Scrambled siRNA,Other,,,,,,,,,,,,,,,,,,,,Scrambled oligonucleotides (Cat. no. sc-36869) or vehicle only was used as controls,Generic reagent (fluorescent label / control / probe): Scrambled siRNA
p21 ras activation assay,genetic_reagents,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,p21 ras activation assay,Other,,,,,,,,,,,,,,,,,,,,"p21 ras activation was subsequently determined using a p21 ras activation pulldown assay kit (Upstate Biotechnology, Lake Placid, NY, USA)",Non-genetic lab reagent/kit/consumable: p21 ras activation assay
NF-1,genetic_reagents,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NF-1,Viral,lentiviral,,,,,,,,,,,,,,,,,,,"cells were transfected with the control lentivirus (LV-vector), NF-1 sgRNA-CAS9 lentivirus (LV-NF-1), Rictor sgRNA-CAS9 lentivirus (LV-Rictor)",Insert does not reference a core NF disease gene: NF-1
Rictor,genetic_reagents,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Rictor,Viral,lentiviral,,,,,,,,,,,,,,,,,,,"cells were transfected with the control lentivirus (LV-vector), NF-1 sgRNA-CAS9 lentivirus (LV-NF-1), Rictor sgRNA-CAS9 lentivirus (LV-Rictor)",Insert does not reference a core NF disease gene: Rictor
TUNEL,genetic_reagents,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TUNEL,Other,,,,,,,,,,,,,,,,,,,,"The TUNEL assay was conducted by using the TUNEL kit (Roche, Reinach, Switzerland)",Insert does not reference a core NF disease gene: TUNEL
NSC23766,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,NSC23766,,,,,,,,,,,,,,,,,,,,,"Pharmacologic inhibitor experiments used 104 cells per well (NSC23766, 10 µM; AG825, 10 µM; Sigma, St. Louis MO)",Drug compound: NSC23766
AG825,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,AG825,,,,,,,,,,,,,,,,,,,,,"Pharmacologic inhibitor experiments used 104 cells per well (NSC23766, 10 µM; AG825, 10 µM; Sigma, St. Louis MO)",Non-genetic lab reagent/kit/consumable: AG825
MSCV,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MSCV,Viral,,,,,,,,,,,,,,,,,,,,Murine stem cell virus (MSCV) infection was employed to express human WT or mutant (L64P patient mutation) merlin,Generic reagent (fluorescent label / control / probe): MSCV
Rac1 N17,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Rac1 N17,,,,,,,,,,,,,,,,,,,,,dominant-negative Rac1 (Rac1 N17) as previously described [15],Insert does not reference a core NF disease gene: Rac1 N17
PLKO,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PLKO,Viral,,,,,,,,,,,,,,,,,,,,PLKO virus was used as an empty vector control,Generic reagent (fluorescent label / control / probe): PLKO
Rac1 activation Assay Kit,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Rac1 activation Assay Kit,,,,,,,,,,,,,,,,,,,,,"Active Rac1 (Rac1-GTP) was determined by PAK1-PBD affinity chromatography (Rac1 activation Assay Kit, Millipore, Bedford MA)",Non-genetic lab reagent/kit/consumable: Rac1 activation Assay Kit
PD0325901,genetic_reagents,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PD0325901,Other,,,,,,,,,,,,,,,,,,,,"MEK inhibitor (MEKi, PD0325901, Sigma-Aldrich, St. Louis, MO) was dissolved in DMSO at a concentration of 25 mg/ml",Drug compound: PD0325901
pGEX 4T-1,genetic_reagents,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pGEX 4T-1,Plasmid,pGEX,,,,,,,,,,,,,,,,,,,"Human MCL-1-glutathione-S-transferase (GST) and BCL-XL-GST fusion proteins were cloned into the pGEX 4T-1 expression plasmid (available from Addgene, Watertown, MA, USA)",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
SpCas9,genetic_reagents,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SpCas9,Plasmid,,CMV,,,,,,,,,,,,,,,,,,"MCF7 cells (1 × 10 6 ) were transfected with 1 µg of a 12:1 DNA ratio of the pCMV-T7-(FZ) SpCas9-BPNLS(SV40)-3xFLAG-P2A-Puro-R plasmid (modified from RTW3027, Addgene #139987)",Publication title lacks NF-specific terms: Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Inte
Custom gene panel,genetic_reagents,PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Custom gene panel,Other,,,,,,,,,,,,,,,,,,,,Transcript level of the following genes were analyzed using an Illumina custom panel,Insert does not reference a core NF disease gene: Custom gene panel
Alexa Fluor 594-labeled dextrans,genetic_reagents,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,Alexa Fluor 594-labeled dextrans,,,,,,,,,,,,,,,,,,,,,"we electroporated the afferent fibers to the calyx of Held with Alexa Fluor 594-labeled dextrans (10,000 MW; Invitrogen)",Insert does not reference a core NF disease gene: Alexa Fluor 594-labeled dextrans
CEP 8 (D8Z2),genetic_reagents,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CEP 8 (D8Z2),Other,,,,,,,,,,,,,,,,,,,,Probes used were a centromeric-enumerating probe Vysis CEP 8 (D8Z2) SpectrumGreen combined with locus-specific probe,Insert does not reference a core NF disease gene: CEP 8 (D8Z2)
LSI MYC,genetic_reagents,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,LSI MYC,Other,,,,,,,,,,,,,,,,,,,,combined with locus-specific probe Vysis LSI MYC SpectrumOrange (Abbott Molecular),Insert does not reference a core NF disease gene: LSI MYC
DNA extraction reagent,genetic_reagents,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"The gDNA was purified starting from formalin-fixed paraffin-embedded (FFPE) samples obtained at surgical resection, using the Magcore DNA FFPE One-Step Kit (Code 405).",Non-genetic lab reagent/kit/consumable: DNA extraction reagent
DNA quantification reagent,genetic_reagents,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA quantification reagent,Other,,,,,,,,,,,,,,,,,,,,Fragmented gDNAs were tested for size distribution and concentration using an Agilent Tapestation 4200 and Qubit dsDNA High Sensitivity kit.,Non-genetic lab reagent/kit/consumable: DNA quantification reagent
exome capture reagent,genetic_reagents,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,exome capture reagent,Other,,,,,,,,,,,,,,,,,,,,"The NGS library was executed using the Agilent Sure Select XT HS2 all exon v8 kit (Agilent, Santa Clara, CA, USA), following the manufacturer's instructions.",Non-genetic lab reagent/kit/consumable: exome capture reagent
PSME3,genetic_reagents,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PSME3,Plasmid,pSG5,SV40,,,,,,,,,,,,,,,,,,stably transfected with plasmid pSG5 vector and encoding PSME3 cDNA harbor PA28у cDNA under a constitutive SV40 promotor,Insert does not reference a core NF disease gene: PSME3
APX3330,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,APX3330,,,,,,,,,,,,,,,,,,,,,"Small-molecule Ref-1 inhibitors APX3330, APX2009 and APX2014 (Apexian Pharmaceuticals, Indianapolis, IN, USA)",Drug compound: APX3330
APX2009,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,APX2009,,,,,,,,,,,,,,,,,,,,,"Small-molecule Ref-1 inhibitors APX3330, APX2009 and APX2014 (Apexian Pharmaceuticals, Indianapolis, IN, USA)",Drug compound: APX2009
APX2014,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,APX2014,,,,,,,,,,,,,,,,,,,,,"Small-molecule Ref-1 inhibitors APX3330, APX2009 and APX2014 (Apexian Pharmaceuticals, Indianapolis, IN, USA)",Drug compound: APX2014
Napabucasin,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Napabucasin,,,,,,,,,,,,,,,,,,,,,"STAT3 inhibitor Napabucasin (SelleckChem, Houston, TX, USA) was dissolved in 100% DMSO",Drug compound: Napabucasin
Ruxolitinib,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Ruxolitinib,,,,,,,,,,,,,,,,,,,,,JAK1/2 kinase inhibitor Ruxolitinib (SelleckChem) was dissolved in 100% DMSO,Drug compound (class suffix): Ruxolitinib
Ref-1,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Ref-1,Other,,,,,,,,,,,,,,,,,,,,MPNST cells were transfected with Ref-1 #1 siRNA (sequence previously reported),Insert does not reference a core NF disease gene: Ref-1
Ref-1,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Ref-1,Other,,,,,,,,,,,,,,,,,,,,"LifeTech validated Ref-1 siRNA (s1447, Santa Cruz, Dallas, TX, USA)",Insert does not reference a core NF disease gene: Ref-1
STAT3,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,STAT3,Other,,,,,,,,,,,,,,,,,,,,"validated STAT3 siRNAs (sc-44275, sc-29493) and scrambled control",Insert does not reference a core NF disease gene: STAT3
Mycoplasma detection primers,genetic_reagents,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Mycoplasma detection primers,,,,,,,,,,,,,,,,,,,,,"All cultures were routinely tested for mycoplasma contamination (LookOut Mycoplasma PCR detection kit, Sigma-Aldrich, St. Louis, MO, USA)",Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
Hsp90β,genetic_reagents,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Hsp90β,Plasmid,pBad,,,,,,,,,,,,,,,,,,,"the human Hsp90β sequence was optimized and cloned into a pBad/Myc-Hisx6 vector (Invitrogen, Thermo Fisher Scientific)",Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
Ni-NTA resin,genetic_reagents,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Ni-NTA resin,,,,,,,,,,,,,,,,,,,,,Recombinant wild-type Hsp90β was purified from the bacterial culture using a Ni-NTA purification system (Invitrogen),Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
Chariot protein delivery reagent,genetic_reagents,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Chariot protein delivery reagent,,,,,,,,,,,,,,,,,,,,,"4 μL of the lipophilic cell permeation agent Chariot (Active Motif, Carlsbad, CA, USA) in 100 μL ddH2O",Publication title lacks NF-specific terms: Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell pro
Trizol Reagent,genetic_reagents,PMID:18188004,10.4161/epi.3.1.5469,Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows balanced expression from the maternal and paternal chromosomes and strain-specific variation in expression levels.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Trizol Reagent,,,,,,,,,,,,,,,,,,,,,"The tissue was weighed and 100 mg was homogenized in Trizol Reagent (Invitrogen, Carlsbad, CA)",Publication title lacks NF-specific terms: Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows
DNAfree,genetic_reagents,PMID:18188004,10.4161/epi.3.1.5469,Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows balanced expression from the maternal and paternal chromosomes and strain-specific variation in expression levels.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,DNAfree,,,,,,,,,,,,,,,,,,,,,"Prior to cDNA synthesis the total RNA was DNased-treated with DNAfree (Ambion, Austin, TX)",Publication title lacks NF-specific terms: Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows
Superscript II First-Strand Synthesis System,genetic_reagents,PMID:18188004,10.4161/epi.3.1.5469,Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows balanced expression from the maternal and paternal chromosomes and strain-specific variation in expression levels.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Superscript II First-Strand Synthesis System,,,,,,,,,,,,,,,,,,,,,"The cDNA was synthesized using Superscript II First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA).",Publication title lacks NF-specific terms: Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows
LSAB detection system,genetic_reagents,PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,LSAB detection system,Other,,,,,,,,,,,,,,,,,,,,"staining was revealed with LSAB kit (Dako). For anti-Survivin (12C4, Dako, final dilution 1/100) staining was revealed with CSAII (Dako)",Insert does not reference a core NF disease gene: LSAB detection system
CSAII detection system,genetic_reagents,PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CSAII detection system,Other,,,,,,,,,,,,,,,,,,,,"For anti-Survivin (12C4, Dako, final dilution 1/100) staining was revealed with CSAII (Dako), according to manufacturer's instruction.",Insert does not reference a core NF disease gene: CSAII detection system
LSI EGFR,genetic_reagents,PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,LSI EGFR,Other,,,,,,,,,,,,,,,,,,,,"EGFR specific sequence probe (LSI EGFR) and control chromosome enumeration probe 7 (CEP7) were used according to the manufacturers' recommended protocol (Vysis-Abbott Molecular Diagnostics, Baar, Switzerland)",Insert does not reference a core NF disease gene: LSI EGFR
CEP7,genetic_reagents,PMID:18769552,10.1155/2008/849156,Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CEP7,Other,,,,,,,,,,,,,,,,,,,,"EGFR specific sequence probe (LSI EGFR) and control chromosome enumeration probe 7 (CEP7) were used according to the manufacturers' recommended protocol (Vysis-Abbott Molecular Diagnostics, Baar, Switzerland)",Insert does not reference a core NF disease gene: CEP7
DNA purification reagents,genetic_reagents,PMID:34573290,10.3390/genes12091308,Performance Evaluation of SpliceAI for the Prediction of Splicing of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA purification reagents,Other,,,,,,,,,,,,,,,,,,,,"DNA was extracted using a Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA) according to the manufacturer's instructions",Publication title lacks NF-specific terms: Performance Evaluation of SpliceAI for the Prediction of Splicing of
cDNA synthesis reagents,genetic_reagents,PMID:34573290,10.3390/genes12091308,Performance Evaluation of SpliceAI for the Prediction of Splicing of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,cDNA synthesis reagents,Other,,,,,,,,,,,,,,,,,,,,1 µg of samples were reverse transcribed using Thermo Scientific RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific),Publication title lacks NF-specific terms: Performance Evaluation of SpliceAI for the Prediction of Splicing of
sequencing reagents,genetic_reagents,PMID:34573290,10.3390/genes12091308,Performance Evaluation of SpliceAI for the Prediction of Splicing of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,sequencing reagents,Other,,,,,,,,,,,,,,,,,,,,Cyclic sequencing was performed using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems),Publication title lacks NF-specific terms: Performance Evaluation of SpliceAI for the Prediction of Splicing of
shAURKA,genetic_reagents,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shAURKA,Viral,,,,,,,,,,,,,,,,,,,,"MPNST cells at 50 – 60% confluence were infected with lentiviral particles containing shRNAs targeting AURKA, AURKB",Insert does not reference a core NF disease gene: shAURKA
shAURKB,genetic_reagents,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shAURKB,Viral,,,,,,,,,,,,,,,,,,,,"MPNST cells at 50 – 60% confluence were infected with lentiviral particles containing shRNAs targeting AURKA, AURKB",Insert does not reference a core NF disease gene: shAURKB
shNon-targeting,genetic_reagents,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shNon-targeting,Viral,,,,,,,,,,,,,,,,,,,,"infected with lentiviral particles containing shRNAs targeting AURKA, AURKB or shNon-targeting (SigmaAldrich; TRC library)",Insert does not reference a core NF disease gene: shNon-targeting
MLN8237,genetic_reagents,PMID:22811580,10.1158/1078-0432.CCR-12-1072,Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,MLN8237,,,,,,,,,,,,,,,,,,,,,"an AURKA selective inhibitor, MLN8237, stabilized tumor volume and significantly increased survival of mice with MPNST xenografts",Drug compound: MLN8237
Cas9,genetic_reagents,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Viral,pCW,,,,,,,,,,,,,,,,,,,Doxycycline inducible Cas9 cDNA lentiviral vector (Addgene plasmid #50061 = pCW-Cas9),Generic reagent (fluorescent label / control / probe): Cas9
sgRNA,genetic_reagents,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,sgRNA,Viral,pLX,,,,,,,,,,,,,,,,,,,additional lentivector constitutively expressing AAVS1-targeting sgRNA (sgCON) (Addgene plasmid #50662 = pLX-sgRNA),Generic reagent (fluorescent label / control / probe): sgRNA
shRNA,genetic_reagents,PMID:30796033,10.1158/1078-0432.CCR-18-2437,Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNA,Viral,pLKO.1,,,,,,,,,,,,,,,,,,,cloning of the following 21-mer sequences...into the pLKO.1-puro empty backbone lentiviral vector,Generic reagent (fluorescent label / control / probe): shRNA
SV40 large T antigen,genetic_reagents,PMID:26657314,10.1371/journal.pone.0144620,Immortalized Human Schwann Cell Lines Derived From Tumors of Schwannomatosis Patients.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SV40 large T antigen,Viral,pLenti,Unknown,,,,,,,,,,,,,,,,,,Cells were immortalized using pLenti-SV40 from ABM (catalog number G203) according to manufacturer's instructions.,Insert does not reference a core NF disease gene: SV40 large T antigen
MesenCult,genetic_reagents,PMID:21980365,10.1371/journal.pone.0024917,The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,MesenCult,,,,,,,,,,,,,,,,,,,,,cultured in mouse MesenCult basal medium containing MesenCult Supplement (Stem Cell Technologies Inc.),Insert does not reference a core NF disease gene: MesenCult
DNA purification kit,genetic_reagents,PMID:22916147,10.1371/journal.pone.0042682,Applying microsatellite multiplex PCR analysis (MMPA) for determining allele copy-number status and percentage of normal cells within tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA purification kit,Other,,,,,,,,,,,,,,,,,,,,DNA from blood was isolated either by the Wizard Genomic DNA purification kit (Promega) according to the manufacturer's instructions,Publication title lacks NF-specific terms: Applying microsatellite multiplex PCR analysis (MMPA) for determining allele cop
DNA purification kit,genetic_reagents,PMID:22916147,10.1371/journal.pone.0042682,Applying microsatellite multiplex PCR analysis (MMPA) for determining allele copy-number status and percentage of normal cells within tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA purification kit,Other,,,,,,,,,,,,,,,,,,,,DNA from skin or neurofibromas was extracted using the Gentra Puregene Kit (Qiagen) following manufacturer's instructions,Publication title lacks NF-specific terms: Applying microsatellite multiplex PCR analysis (MMPA) for determining allele cop
PicoGreen,genetic_reagents,PMID:22916147,10.1371/journal.pone.0042682,Applying microsatellite multiplex PCR analysis (MMPA) for determining allele copy-number status and percentage of normal cells within tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PicoGreen,Other,,,,,,,,,,,,,,,,,,,,samples were further quantified using Quant-iT PicoGreen reagent (Invitrogen),Publication title lacks NF-specific terms: Applying microsatellite multiplex PCR analysis (MMPA) for determining allele cop
Multiplex PCR Kit,genetic_reagents,PMID:22916147,10.1371/journal.pone.0042682,Applying microsatellite multiplex PCR analysis (MMPA) for determining allele copy-number status and percentage of normal cells within tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Multiplex PCR Kit,Other,,,,,,,,,,,,,,,,,,,,We used a Multiplex PCR Kit (Qiagen) with which we obtained good global microsatellite amplification,Publication title lacks NF-specific terms: Applying microsatellite multiplex PCR analysis (MMPA) for determining allele cop
Human660W-Quad beadchip,genetic_reagents,PMID:22916147,10.1371/journal.pone.0042682,Applying microsatellite multiplex PCR analysis (MMPA) for determining allele copy-number status and percentage of normal cells within tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human660W-Quad beadchip,Other,,,,,,,,,,,,,,,,,,,,"SNP-array data generated in a previous study (Illumina Infinium SNP-array, Human660W-Quad beadchip ∼660000 SNPs)",Publication title lacks NF-specific terms: Applying microsatellite multiplex PCR analysis (MMPA) for determining allele cop
PF-271,genetic_reagents,PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PF-271,Other,,,,,,,,,,,,,,,,,,,,"small molecule FAK inhibitor (PF-271, also termed VS-6062)",Insert does not reference a core NF disease gene: PF-271
non-target shRNA,genetic_reagents,PMID:24786638,10.1016/j.ygyno.2014.04.044,Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,non-target shRNA,Plasmid,pLKO.1,,,,,,,,,,,,,,,,,,,pLKO.1-puro non-target shRNA control plasmid (SHC016) were from Mission-Sigma,Insert does not reference a core NF disease gene: non-target shRNA
sALP-FcD10,genetic_reagents,PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,sALP-FcD10,Other,,,,,,,,,,,,,,,,,,,,"sALP-FcD10 (Asfotase Alfa, Alexion Pharmaceuticals) was described previously. Briefly, mineral-targeting recombinant tissue nonspecific alkaline phosphatase",Insert does not reference a core NF disease gene: sALP-FcD10
GFP,genetic_reagents,PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Viral,Ad5,CMV,,,,,,,,,,,,,,,,,,"cells were incubated in complete culture medium containing either Ad5-CMV-GFP or Ad5-CMV-cre (Vector development lab, Baylor College of Medicine)",Generic reagent (fluorescent label / control / probe): GFP
Cre,genetic_reagents,PMID:24997609,10.1038/nm.3583,"Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,Ad5,CMV,,,,,,,,,,,,,,,,,,"cells were incubated in complete culture medium containing either Ad5-CMV-GFP or Ad5-CMV-cre (Vector development lab, Baylor College of Medicine)",Insert does not reference a core NF disease gene: Cre
Cre,genetic_reagents,PMID:37406085,10.1158/1078-0432.CCR-22-2854,Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,,,,,,,,,,,,,,,,,,,,Adenovirus GFP Cre (University of Iowa) was added to the cell media at a dilution of 1:500,Insert does not reference a core NF disease gene: Cre
RNA extraction reagent,genetic_reagents,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,RNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,RNA was extracted using the RNeasy Mini Kit (Qiagen),Non-genetic lab reagent/kit/consumable: RNA extraction reagent
EZH2 inhibitor,genetic_reagents,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,EZH2 inhibitor,Other,,,,,,,,,,,,,,,,,,,,"350000 iPNF and N0(32) cells were treated with 1 µM EZH2 methyltransferase inhibitor (Selleck Chemicals, GSK126)",Insert does not reference a core NF disease gene: EZH2 inhibitor
gamma-secretase inhibitor,genetic_reagents,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,gamma-secretase inhibitor,Other,,,,,,,,,,,,,,,,,,,,"MPNST cell lines (wild-type and GOF) were treated with γ-secretase inhibitor, nirogacestat (Selleckchem, S8018)",Insert does not reference a core NF disease gene: gamma-secretase inhibitor
MEK inhibitor,genetic_reagents,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MEK inhibitor,Other,,,,,,,,,,,,,,,,,,,,"MPNST cell lines (wild-type and GOF) were treated with γ-secretase inhibitor, nirogacestat (Selleckchem, S8018), and mirdametinib (Selleckchem, S1036)",Insert does not reference a core NF disease gene: MEK inhibitor
cell viability reagent,genetic_reagents,PMID:39620202,10.1093/noajnl/vdae188,Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,cell viability reagent,Other,,,,,,,,,,,,,,,,,,,,The 96-well plate was stained with alamarBlue (Invitrogen) to determine proliferation on day 3,Insert does not reference a core NF disease gene: cell viability reagent
Y102,genetic_reagents,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Y102,Other,,,,,,,,,,,,,,,,,,,,Y102 was originally purchased from Maybridge (NRB04162SC). Subsequent stocks of Y102...were synthesized by Enamine,Insert does not reference a core NF disease gene: Y102
lentiCRISPRv2,genetic_reagents,PMID:39016685,10.1242/jcs.262343,Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,lentiCRISPRv2,Plasmid,lentiCRISPRv2,,,,,,,,,,,,,,,,,,,cells were transfected with lentiCRISPRv2 (# 52961 Addgene) and gRNA at a 3:1 ratio,Insert does not reference a core NF disease gene: lentiCRISPRv2
Cas9-P2A-Blast,genetic_reagents,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9-P2A-Blast,Plasmid,pLCP2B,,,,,,,,,,,,,,,,,,,The pLCP2B plasmid was generated by removing Cas9-P2A-tRFP from pL-CRISPR.EFS.tRFP,Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
CRISPR/Cas9,genetic_reagents,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CRISPR/Cas9,Viral,lentiCRISPR-v2,,,,,,,,,,,,,,,,,,,The lentiCRISPR-v2 vector with puromycin was purchased from Addgene (no. 52961),Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
OVA,genetic_reagents,PMID:35852856,10.1172/JCI153437,Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,OVA,Viral,pMSCV,PGK,,,,,,,,,,,,,,,,,,"The pMSCV-EGFP-PGK-Luc2-2A-USA plasmid, which included OT-I– and OT-II–binding antigens",Publication title lacks NF-specific terms: Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert micro
SV40 large and small T antigen,genetic_reagents,PMID:25877069,10.1007/s11626-015-9885-z,Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SV40 large and small T antigen,Plasmid,pCMV/TO,CMV,,,,,,,,,,,,,,,,,,"The transfer plasmid pCMV/TO SV40 was obtained from Addgene (# 22298). Primary cells were seeded at a density of 10,000 cells/cm2; 24 h post-seeding cells were transfected with lentivirus",Insert does not reference a core NF disease gene: SV40 large and small T antigen
E23a targeting sequences,genetic_reagents,PMID:33574490,10.1038/s41598-021-83152-w,Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,E23a targeting sequences,Other,,,,,,,,,,,,,,,,,,,,"The 25-mer PMOs were designed, synthesized and purified by GeneTools (Philomath, OR, USA)",Insert does not reference a core NF disease gene: E23a targeting sequences
erg6,genetic_reagents,PMID:21697395,10.1158/1535-7163.MCT-11-0309,Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,erg6,Other,,,,,,,,,,,,,,,,,,,,erg6Δ and erg6Δ ira2Δ were generated using standard one-step PCR-based gene deletion methods,Insert does not reference a core NF disease gene: erg6
erg6 ira2,genetic_reagents,PMID:21697395,10.1158/1535-7163.MCT-11-0309,Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,erg6 ira2,Other,,,,,,,,,,,,,,,,,,,,erg6Δ and erg6Δ ira2Δ were generated using standard one-step PCR-based gene deletion methods,Insert does not reference a core NF disease gene: erg6 ira2
NAB3,genetic_reagents,PMID:21697395,10.1158/1535-7163.MCT-11-0309,Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NAB3,Plasmid,YEp13,,,,,,,,,,,,,,,,,,,The YEp13-NAB3 plasmid was generated from a suppressing YEp13 plasmid containing genomic DNA,Insert does not reference a core NF disease gene: NAB3
nab3,genetic_reagents,PMID:21697395,10.1158/1535-7163.MCT-11-0309,Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,nab3,Other,,,,,,,,,,,,,,,,,,,,nab3Δ nab3-3 was obtained from Dr. M. Swanson,Insert does not reference a core NF disease gene: nab3
nab3,genetic_reagents,PMID:21697395,10.1158/1535-7163.MCT-11-0309,Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,nab3,Other,,,,,,,,,,,,,,,,,,,,nab3–11 was a gift from Dr. J. Corden,Insert does not reference a core NF disease gene: nab3
ctk1,genetic_reagents,PMID:21697395,10.1158/1535-7163.MCT-11-0309,Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ctk1,Other,,,,,,,,,,,,,,,,,,,,The ctk1Δ::KANMX allele was backcrossed to the Σ1278b background from the Open Biosystems yeast deletion collection,Insert does not reference a core NF disease gene: ctk1
UC1,genetic_reagents,PMID:21697395,10.1158/1535-7163.MCT-11-0309,Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,UC1,Other,,,,,,,,,,,,,,,,,,,,"we describe UC1, a small molecule that targets NF1(-/-) cell lines and ira2Δ budding yeast",Insert does not reference a core NF disease gene: UC1
merlin,genetic_reagents,PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,merlin,Viral,pQCXIP,,,,,,,,,,,,,,,,,,,Wild-type merlin and the merlin mutants together with their COOH terminal v5-epitope tags were cloned into the retroviral expression vector pQCXIP (BD Bioscience),Publication title lacks NF-specific terms: Merlin is a potent inhibitor of glioma growth.
merlin mutants,genetic_reagents,PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,merlin mutants,Other,,,,,,,,,,,,,,,,,,,,"Full-length merlin isoform I was obtained as described, and the merlin mutants were generated using the QuikChange mutagenesis kits (Stratagene)",Publication title lacks NF-specific terms: Merlin is a potent inhibitor of glioma growth.
β-catenin–responsive luciferase reporter,genetic_reagents,PMID:18632626,10.1158/0008-5472.CAN-08-0190,Merlin is a potent inhibitor of glioma growth.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,β-catenin–responsive luciferase reporter,Plasmid,,TCF/LEF,,,,,,,,,,,,,,,,,,"we used the β-catenin–responsive luciferase reporter construct (TopFlash, Addgene), which contains T-cell factor/lymphocyte enhancer factor (TCF/LEF) binding sites",Publication title lacks NF-specific terms: Merlin is a potent inhibitor of glioma growth.
Tumor Dissociation Kit,genetic_reagents,PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Tumor Dissociation Kit,,,,,,,,,,,,,,,,,,,,,"digested with a Tumor Dissociation Kit (Cat #130-095-929; Miltenyi Biotec, Gaithersburg, MD, USA)",Non-genetic lab reagent/kit/consumable: Tumor Dissociation Kit
Chromium Single Cell 3' Reagent Kit v3.1,genetic_reagents,PMID:37817770,10.3389/fonc.2023.1253659,Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Chromium Single Cell 3' Reagent Kit v3.1,,,,,,,,,,,,,,,,,,,,,"Libraries were constructed according to the Chromium Single Cell 3' Reagent Kit v3.1 user guide (10x Genomics, Pleasanton, CA)",Non-genetic lab reagent/kit/consumable: Chromium Single Cell 3' Reagent Kit v3.1
shATRX,genetic_reagents,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shATRX,Viral,pLKO.1,,,,,,,,,,,,,,,,,,,"Short hairpin RNA target human ATRX (sh11 and sh90), mouse ATRX (sh1 and sh3), and vector control pLKO.1 were obtained from Millipore Sigma",Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
shATRX,genetic_reagents,PMID:35740680,10.3390/cancers14123015,Therapeutic Vulnerability to ATR Inhibition in Concurrent ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shATRX,Viral,pLKO.1,,,,,,,,,,,,,,,,,,,"Short hairpin RNA target human ATRX (sh11 and sh90), mouse ATRX (sh1 and sh3), and vector control pLKO.1 were obtained from Millipore Sigma",Publication title lacks NF-specific terms: Therapeutic Vulnerability to ATR Inhibition in Concurrent
RNA extraction reagent,genetic_reagents,PMID:16524466,10.1186/1471-2202-7-22,Cognitive dysfunction in NF1 knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA extraction reagent,,,,,,,,,,,,,,,,,,,,,Total RNA was isolated from each 40 mg tissue sample using Stratagene RTPCR Mini-prep kit,Non-genetic lab reagent/kit/consumable: RNA extraction reagent
RNA purification reagent,genetic_reagents,PMID:16524466,10.1186/1471-2202-7-22,Cognitive dysfunction in NF1 knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA purification reagent,,,,,,,,,,,,,,,,,,,,,Extracted RNA was subsequently cleaned using the Qiagen Mini kit protocol,Non-genetic lab reagent/kit/consumable: RNA purification reagent
RNA extraction reagent,genetic_reagents,PMID:16524466,10.1186/1471-2202-7-22,Cognitive dysfunction in NF1 knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA extraction reagent,,,,,,,,,,,,,,,,,,,,,Total RNA was extracted from ~20 mg of hippocampus...using the Absolutely RNA Miniprep Kit (Stratagene),Non-genetic lab reagent/kit/consumable: RNA extraction reagent
cDNA synthesis reagent,genetic_reagents,PMID:16524466,10.1186/1471-2202-7-22,Cognitive dysfunction in NF1 knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,cDNA synthesis reagent,,,,,,,,,,,,,,,,,,,,,Reverse transcription reactions were done using...the Super Script III First Strand cDNA synthesis kit (Invitrogen),Non-genetic lab reagent/kit/consumable: cDNA synthesis reagent
qPCR reagent,genetic_reagents,PMID:16524466,10.1186/1471-2202-7-22,Cognitive dysfunction in NF1 knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,qPCR reagent,,,,,,,,,,,,,,,,,,,,,amplified on the Chromo4 Four-Color Real-Time System (MJ Research) using the DyNAmo HS SYBR Green qPCR Kit (Finnzymes),Insert does not reference a core NF disease gene: qPCR reagent
mKSR1,genetic_reagents,PMID:26549023,10.1038/onc.2015.404,"The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mKSR1,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,"Plasmids pcDNA3-pyo-mKSR1 wild-type, S443A and 4xA ( 11 , 22 ), pcDNA3.2-V5-Merlin-S518A/D ( 5 ) were described previously.","Publication title lacks NF-specific terms: The scaffold protein KSR1, a novel therapeutic target for the treatment of Merli"
mKSR1 S443A,genetic_reagents,PMID:26549023,10.1038/onc.2015.404,"The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mKSR1 S443A,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,"Plasmids pcDNA3-pyo-mKSR1 wild-type, S443A and 4xA ( 11 , 22 ), pcDNA3.2-V5-Merlin-S518A/D ( 5 ) were described previously.","Publication title lacks NF-specific terms: The scaffold protein KSR1, a novel therapeutic target for the treatment of Merli"
mKSR1 4xA,genetic_reagents,PMID:26549023,10.1038/onc.2015.404,"The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mKSR1 4xA,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,"Plasmids pcDNA3-pyo-mKSR1 wild-type, S443A and 4xA ( 11 , 22 ), pcDNA3.2-V5-Merlin-S518A/D ( 5 ) were described previously.","Publication title lacks NF-specific terms: The scaffold protein KSR1, a novel therapeutic target for the treatment of Merli"
Merlin-S518A/D,genetic_reagents,PMID:26549023,10.1038/onc.2015.404,"The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,Merlin-S518A/D,Plasmid,pcDNA3.2,,,,,,,,,,,,,,,,,,,"Plasmids pcDNA3-pyo-mKSR1 wild-type, S443A and 4xA ( 11 , 22 ), pcDNA3.2-V5-Merlin-S518A/D ( 5 ) were described previously.","Publication title lacks NF-specific terms: The scaffold protein KSR1, a novel therapeutic target for the treatment of Merli"
Lipofectamine 2000,genetic_reagents,PMID:26549023,10.1038/onc.2015.404,"The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Lipofectamine 2000,Other,,,,,,,,,,,,,,,,,,,,All transfections for schwannoma cells were carried out with Lipofectamine ™ 2000 (Invitrogen).,"Publication title lacks NF-specific terms: The scaffold protein KSR1, a novel therapeutic target for the treatment of Merli"
Fugene 6,genetic_reagents,PMID:26549023,10.1038/onc.2015.404,"The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Fugene 6,Other,,,,,,,,,,,,,,,,,,,,Fugene® 6 (Roche) was used for transfection of HEK293T cells.,"Publication title lacks NF-specific terms: The scaffold protein KSR1, a novel therapeutic target for the treatment of Merli"
shKSR1,genetic_reagents,PMID:26549023,10.1038/onc.2015.404,"The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shKSR1,Plasmid,pLKO.1,U6,,,,,,,,,,,,,,,,,,"A set of pLKO.1-shRNA plasmid encoding a short hairpin RNA (shRNA) with scrambled sequence or sequences targeting human KSR1 ( NM_014238 ), was purchased from Open Biosystems.","Publication title lacks NF-specific terms: The scaffold protein KSR1, a novel therapeutic target for the treatment of Merli"
shKSR1,genetic_reagents,PMID:26549023,10.1038/onc.2015.404,"The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shKSR1,Viral,,,,,,,,,,,,,,,,,,,,"Two shRNA clones, TRCN0000006226 and TRCN0000006229, were chosen for lentivirus production.","Publication title lacks NF-specific terms: The scaffold protein KSR1, a novel therapeutic target for the treatment of Merli"
shKSR1,genetic_reagents,PMID:26549023,10.1038/onc.2015.404,"The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shKSR1,Viral,,,,,,,,,,,,,,,,,,,,"Two shRNA clones, TRCN0000006226 and TRCN0000006229, were chosen for lentivirus production.","Publication title lacks NF-specific terms: The scaffold protein KSR1, a novel therapeutic target for the treatment of Merli"
Caspase-Glo 3/7,genetic_reagents,PMID:26549023,10.1038/onc.2015.404,"The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.",,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,Caspase-Glo 3/7,Other,,,,,,,,,,,,,,,,,,,,Cell apoptosis was determined with the Caspase-Glo ®3/7 Assay kit (Promega) according to the manufacture's instruction.,"Publication title lacks NF-specific terms: The scaffold protein KSR1, a novel therapeutic target for the treatment of Merli"
TRIzol,genetic_reagents,PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TRIzol,Other,,,,,,,,,,,,,,,,,,,,RNA extraction was performed using the TRIzol reagent,Non-genetic lab reagent/kit/consumable: TRIzol
iScript Select,genetic_reagents,PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,iScript Select,Other,,,,,,,,,,,,,,,,,,,,reverse transcription was performed using iScript Select cDNA synthesis kit,Insert does not reference a core NF disease gene: iScript Select
iSCRIPT,genetic_reagents,PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,iSCRIPT,Other,,,,,,,,,,,,,,,,,,,,qPCR was performed on a Bio-Rad FX96 apparatus using Bio-Rad iSCRIPT master mix,Insert does not reference a core NF disease gene: iSCRIPT
Vecta Stain Elite ABC,genetic_reagents,PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Vecta Stain Elite ABC,Other,,,,,,,,,,,,,,,,,,,,incubated with a premixture of avidin and biotin (following Vecta Stain Elite ABC kit procedure),Non-genetic lab reagent/kit/consumable: Vecta Stain Elite ABC
whole skin dissociation kit,genetic_reagents,PMID:33413690,10.1186/s40478-020-01103-4,Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,whole skin dissociation kit,Other,,,,,,,,,,,,,,,,,,,,"Based on the whole skin dissociation kit (Miltenyi Biotec, Cat. No. 130-101-540)",Non-genetic lab reagent/kit/consumable: whole skin dissociation kit
"OCT4, SOX2, KLF4, cMYC",genetic_reagents,PMID:30713041,10.1016/j.stemcr.2019.01.001,Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,"OCT4, SOX2, KLF4, cMYC",Viral,Sendai virus,,,,,,,,,,,,,,,,,,,"For non-integrative reprogramming, a Cytotune-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher Scientific) was used according to the manufacturer's protocol.","Insert does not reference a core NF disease gene: OCT4, SOX2, KLF4, cMYC"
mTESR1 medium,genetic_reagents,PMID:30713041,10.1016/j.stemcr.2019.01.001,Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,mTESR1 medium,,,,,,,,,,,,,,,,,,,,,iPSC established lines were grown on dishes coated with growth factor-reduced Matrigel (BD Biosciences) in mTESR1 medium (STEMCELL Technologies),Insert does not reference a core NF disease gene: mTESR1 medium
CHIR9902,genetic_reagents,PMID:30713041,10.1016/j.stemcr.2019.01.001,Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,CHIR9902,,,,,,,,,,,,,,,,,,,,,neural crest induction/differentiation medium: hESC medium without activin and supplemented with 2 μM CHIR9902 (STEMCELL Technologies),Insert does not reference a core NF disease gene: CHIR9902
SB432542,genetic_reagents,PMID:30713041,10.1016/j.stemcr.2019.01.001,Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,SB432542,,,,,,,,,,,,,,,,,,,,,supplemented with 2 μM CHIR9902 (STEMCELL Technologies) and 20 μM SB432542 (STEMCELL Technologies),Insert does not reference a core NF disease gene: SB432542
dCas9-BFP-KRAB,genetic_reagents,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,dCas9-BFP-KRAB,Plasmid,,SFFV,,,,,,,,,,,,,,,,,,"Lentivirus containing pMH0001 (UCOE-SFFV-dCas9-BFP-KRAB, #85969, Addgene) was produced from transfected HEK293T cells","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
G,genetic_reagents,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,G,Plasmid,pMD2,,,,,,,,,,,,,,,,,,,"transfected HEK293T cells with packaging vectors (pMD2.G #12259, Addgene, and pCMV-dR8.91, Trono Lab)","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
dR8.91,genetic_reagents,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,dR8.91,Plasmid,pCMV,CMV,,,,,,,,,,,,,,,,,,"packaging vectors (pMD2.G #12259, Addgene, and pCMV-dR8.91, Trono Lab)","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
CRISPRia-v2,genetic_reagents,PMID:40587782,10.1073/pnas.2506823122,"A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CRISPRia-v2,Plasmid,pCRISPRia-v2,,,,,,,,,,,,,,,,,,,"individually cloning single-guide RNA protospacer sequences into the pCRISPRia-v2 vector (#84832, Addgene)","Publication title lacks NF-specific terms: A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin"
BigDye Terminator,genetic_reagents,PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,BigDye Terminator,Other,,,,,,,,,,,,,,,,,,,,"Sanger sequencing of the PCR products was performed using the BigDye Terminator Cycle Sequencing Kit (ABI, Life Technologies, Foster City, CA, USA)",Non-genetic lab reagent/kit/consumable: BigDye Terminator
DAB,genetic_reagents,PMID:32443592,10.3390/ijms21103569,C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DAB,Other,,,,,,,,,,,,,,,,,,,,"followed by addition of the chromogen Metal Enhanced DAB Substrate Kit (Thermo Scientific, #34065, Bremen, Germany)",Insert does not reference a core NF disease gene: DAB
TYK2,genetic_reagents,PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TYK2,Other,,,,,,,,,,,,,,,,,,,,"using two gRNAs provided by the Genome Engineering & Stem Cell Center (GESC), against murine TYK2 (GAATCCCCACGGCAGCCGGTNGG; CTTCCCCGACCGGCTGCCGTNGG)",Insert does not reference a core NF disease gene: TYK2
GFP,genetic_reagents,PMID:36799629,10.1158/1078-0432.CCR-22-3722,MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Plasmid,FUW-FLG,,,,,,,,,,,,,,,,,,,JW23.3 cells were cotransfected with TYK2 gRNAs and FUW-FLG GFP plasmid (RRID:CVCL_AU20),Generic reagent (fluorescent label / control / probe): GFP
DNA purification reagent,genetic_reagents,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA purification reagent,Other,,,,,,,,,,,,,,,,,,,,Genomic DNA of each patient was then prepared using the PUREGENE DNA purification kit from GENTRA using standard protein precipitation procedures.,Non-genetic lab reagent/kit/consumable: DNA purification reagent
DNA purification beads,genetic_reagents,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA purification beads,Other,,,,,,,,,,,,,,,,,,,,"Following the purification and size selection using AMPure beads (Beckman Coulter, Brea, CA, USA)",Non-genetic lab reagent/kit/consumable: DNA purification beads
Sequencing reagents,genetic_reagents,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Sequencing reagents,Other,,,,,,,,,,,,,,,,,,,,Enriched ISPs were prepared for sequencing using the Ion PGM 200 Sequencing Kit v2.0,Non-genetic lab reagent/kit/consumable: Sequencing reagents
Sequencing reagents,genetic_reagents,PMID:30290804,10.1186/s12929-018-0474-9,Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Sequencing reagents,Other,,,,,,,,,,,,,,,,,,,,PCR products were sequenced using the Big Dye Terminator cycle sequencing kit (Life Technologies),Non-genetic lab reagent/kit/consumable: Sequencing reagents
VS-4718,genetic_reagents,PMID:24848258,10.1126/scitranslmed.3008639,Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,VS-4718,Other,,,,,,,,,,,,,,,,,,,,"Our data demonstrate that low Merlin expression predicts for increased sensitivity of MPM cells to a FAK inhibitor, VS-4718, in vitro and in tumor xenograft models.",Publication title lacks NF-specific terms: Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relatio
NF2,genetic_reagents,PMID:24848258,10.1126/scitranslmed.3008639,Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,NF2,Viral,pMXs-IRES-GFP,,,,,,,,,,,,,,,,,,,"The pMXs-NF2-IRES-GFP construct was generated by inserting NF2 cDNA (Open Biosystems, MHS1011-202832561) into pMXs-IRES-GFP retroviral vector",Publication title lacks NF-specific terms: Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relatio
PTK2,genetic_reagents,PMID:24848258,10.1126/scitranslmed.3008639,Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PTK2,Other,,,,,,,,,,,,,,,,,,,,"A mix of four individual PTK2 siRNAs (ON-TARGETplus PTK2 siRNA; Dharmacon, Thermo Scientific) was used for depletion of FAK",Publication title lacks NF-specific terms: Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relatio
Non-Targeting,genetic_reagents,PMID:24848258,10.1126/scitranslmed.3008639,Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Non-Targeting,Other,,,,,,,,,,,,,,,,,,,,siGENOME Non-Targeting siRNA #1was used as a negative control,Publication title lacks NF-specific terms: Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relatio
tp53 gRNA,genetic_reagents,PMID:33279959,10.1093/brain/awaa404,"Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish.",,0.9,Development,False,1.00,Medium,,,,,,,,,,,tp53 gRNA,Plasmid,Cas9-T2A-mCherry,gfap,,,,,,,,,,,,,,,,,,"gfap:Cas9-T2A-mCherry,U6:gRNA(nf1a), gfap:Cas9-T2A-mCherry,U6:gRNA(tp53), and gfap:Cas9-T2A-mCherry,U6:gRNA(rb1) vectors",Insert does not reference a core NF disease gene: tp53 gRNA
rb1 gRNA,genetic_reagents,PMID:33279959,10.1093/brain/awaa404,"Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish.",,0.9,Development,False,1.00,Medium,,,,,,,,,,,rb1 gRNA,Plasmid,Cas9-T2A-mCherry,gfap,,,,,,,,,,,,,,,,,,"gfap:Cas9-T2A-mCherry,U6:gRNA(nf1a), gfap:Cas9-T2A-mCherry,U6:gRNA(tp53), and gfap:Cas9-T2A-mCherry,U6:gRNA(rb1) vectors",Insert does not reference a core NF disease gene: rb1 gRNA
Cas9,genetic_reagents,PMID:33279959,10.1093/brain/awaa404,"Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Plasmid,pCS2,,,,,,,,,,,,,,,,,,,"Cas9 mRNA was produced by in vitro transcription from a pCS2 Cas9 vector (Jao et al., 2013)",Generic reagent (fluorescent label / control / probe): Cas9
PLX3397,genetic_reagents,PMID:23099891,10.1007/s00401-012-1056-7,Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,PLX3397,,,,,,,,,,,,,,,,,,,,,"...PLX3397 (fms/kit inhibitor) and vehicle carrier, were provided by Plexxikon Inc. (Berkeley, CA)...",Insert does not reference a core NF disease gene: PLX3397
TUNEL detection kit,genetic_reagents,PMID:23099891,10.1007/s00401-012-1056-7,Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,TUNEL detection kit,,,,,,,,,,,,,,,,,,,,,...TUNEL staining was performed using Roche In Situ Cell Death detection Fluorescein kit (Cat # 11 684 795 910)...,Non-genetic lab reagent/kit/consumable: TUNEL detection kit
erlotinib,genetic_reagents,PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,erlotinib,Other,,,,,,,,,,,,,,,,,,,,"For EGFR inhibition experiments, erlotinib (Genentech; San Francisco, CA), was dissolved in DMSO, added at 3 μM",Drug compound (class suffix): erlotinib
eGFP,genetic_reagents,PMID:19041782,10.1016/j.stem.2008.10.003,Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,eGFP,Viral,,,,,,,,,,,,,,,,,,,,We produced lentivirus particles encoding GFP by transient co-transfection of 293T cells,Generic reagent (fluorescent label / control / probe): eGFP
RNA extraction reagent,genetic_reagents,PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,RNA extracted from FFPE (formalin-fixed paraffin-embedded) histology slides based on the RNeasy FFPE kit (Qiagen; 73504),Non-genetic lab reagent/kit/consumable: RNA extraction reagent
Reverse transcriptase,genetic_reagents,PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Reverse transcriptase,Other,,,,,,,,,,,,,,,,,,,,reverse transcription reaction using Roche Transcriptor™ and N6 random primers,Non-genetic lab reagent/kit/consumable: Reverse transcriptase
Immunohistochemistry detection reagent,genetic_reagents,PMID:38900740,10.1371/journal.pone.0301040,Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,Immunohistochemistry detection reagent,Other,,,,,,,,,,,,,,,,,,,,"For immunohistochemistry, the Vecta Stain Elite ABC kit (Vectorlabs, PK-6100) was used",Non-genetic lab reagent/kit/consumable: Immunohistochemistry detection reagent
capmatinib,genetic_reagents,PMID:32245042,10.3390/genes11030331,Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,capmatinib,,,,,,,,,,,,,,,,,,,,,"capmatinib (30 mg/kg twice daily vial oral gavage), trametinib (1 mg/kg daily via oral gavage), and doxorubicin",Drug compound (class suffix): capmatinib
trametinib,genetic_reagents,PMID:32245042,10.3390/genes11030331,Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,trametinib,,,,,,,,,,,,,,,,,,,,,"capmatinib (30 mg/kg twice daily vial oral gavage), trametinib (1 mg/kg daily via oral gavage), and doxorubicin",Drug compound (class suffix): trametinib
doxorubicin,genetic_reagents,PMID:32245042,10.3390/genes11030331,Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,doxorubicin,,,,,,,,,,,,,,,,,,,,,"trametinib (1 mg/kg daily via oral gavage), and doxorubicin (1 mg/kg once via subcutaneous injection)",Insert does not reference a core NF disease gene: doxorubicin
Mycoplasma detection reagents,genetic_reagents,PMID:29137242,10.18632/oncotarget.18301,Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Mycoplasma detection reagents,,,,,,,,,,,,,,,,,,,,,"All cell lines used in this study were found to be free of mycoplasma using MycoAlert™ Mycoplasma Detection Kit (LT07-318, Lonza Inc. Allendale, NJ)",Non-genetic lab reagent/kit/consumable: Mycoplasma detection reagents
ira2Δ leu2-3 his3-11,genetic_reagents,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ira2Δ leu2-3 his3-11,Other,,,,,,,,,,,,,,,,,,,,"Yeast (MDW320, Table 3) were transformed with 1 μg of the S. cerevisiae AB320 genomic library in YEp13 (ATCC 37323)",Insert does not reference a core NF disease gene: ira2Δ leu2-3 his3-11
RIPK1,genetic_reagents,PMID:29662612,10.18632/oncotarget.19335,Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RIPK1,Other,,,,,,,,,,,,,,,,,,,,"Cells were transfected with siRNA targeting RIPK1 (Sigma, SASI_Hs01_00071803)",Insert does not reference a core NF disease gene: RIPK1
TruSeq Custom Amplicon,genetic_reagents,PMID:26066488,10.1371/journal.pone.0129099,A Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSeq Custom Amplicon,Other,,,,,,,,,,,,,,,,,,,,"Library preparation was performed using the TruSeq Custom Amplicon Library Preparation Kit v1.5 (Illumina, San Diego, CA, USA)",Non-genetic lab reagent/kit/consumable: TruSeq Custom Amplicon
HotStarTaq Plus,genetic_reagents,PMID:26066488,10.1371/journal.pone.0129099,A Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,HotStarTaq Plus,Other,,,,,,,,,,,,,,,,,,,,"0.5U HotStarTaq Plus (Qiagen, Hilden, Germany) and 100 ng of genomic DNA",Non-genetic lab reagent/kit/consumable: HotStarTaq Plus
BigDye Terminator,genetic_reagents,PMID:26066488,10.1371/journal.pone.0129099,A Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,BigDye Terminator,Other,,,,,,,,,,,,,,,,,,,,Sequencing analysis was performed on both strands using the BigDye Terminator v1.1 Cycle Sequencing Kit,Non-genetic lab reagent/kit/consumable: BigDye Terminator
22q11 MLPA,genetic_reagents,PMID:26066488,10.1371/journal.pone.0129099,A Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,22q11 MLPA,Other,,,,,,,,,,,,,,,,,,,,"Copy number changes (deletions or duplications) of NF2 locus and flanking genes were analyzed by Multiplex Ligation-Dependent Probe Amplification (MLPA), using NF2 and/or 22q11 MLPA test kits (MRC-Holland, P044_B1 and P324_A2)",Insert does not reference a core NF disease gene: 22q11 MLPA
mCherry,genetic_reagents,PMID:33816648,10.1016/j.omtm.2021.03.004,Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mCherry,Viral,pCF525,EF1α,,,,,,,,,,,,,,,,,,Lentivirus was assembled from pCF525-EF1a-Hygro-P2A-mCherry-lenti lentiviral vector (AddGene #115796),Publication title lacks NF-specific terms: Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and gl
Matrigel,genetic_reagents,PMID:33816648,10.1016/j.omtm.2021.03.004,Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Matrigel,,,,,,,,,,,,,,,,,,,,,miPSCs/mESCs were maintained in liquid nitrogen storage and thawed for plating on Matrigel (Corning)-coated flasks,Publication title lacks NF-specific terms: Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and gl
Thy1.2,genetic_reagents,PMID:33816648,10.1016/j.omtm.2021.03.004,Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Thy1.2,,,,,,,,,,,,,,,,,,,,,MMBS for Thy1.2+ cells was performed according to the manufacturer protocol using the Dynabeads Mouse Pan T (Thermo Fisher) kit,Publication title lacks NF-specific terms: Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and gl
SMART-seq v4,genetic_reagents,PMID:33816648,10.1016/j.omtm.2021.03.004,Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,SMART-seq v4,,,,,,,,,,,,,,,,,,,,,Sequencing libraries were prepared at Bayer sequencing core facility using the Takara SMART-seq v4 kit,Publication title lacks NF-specific terms: Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and gl
Gal4VP16;14 × UAS-smoa1-EGFP,genetic_reagents,PMID:24686726,10.1038/oncsis.2014.10,Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,Gal4VP16;14 × UAS-smoa1-EGFP,Plasmid,pDestTol2pA2,krt5,,,,,,,,,,,,,,,,,,"to create the construct pKrt5:Gal4VP16;14 × UAS-smoa1-EGFP using the LR Clonase II Plus Enzyme mix (Invitrogen, Carlsbad, CA, USA).",Publication title lacks NF-specific terms: Activation of Sonic hedgehog signaling in neural progenitor cells promotes gliom
luciferase,genetic_reagents,PMID:18931645,10.1097/MAO.0b013e31818b6cea,Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,luciferase,Viral,pHR-SIN-CSGW dlNotI,,,,,,,,,,,,,,,,,,,"Lentiviruses were generated by cotransfection of 293T cells with 3 plasmids: gag-pol, env, and pHR-SIN-CSGW dlNotI-luciferase",Insert does not reference a core NF disease gene: luciferase
DNA extraction kit,genetic_reagents,PMID:18931645,10.1097/MAO.0b013e31818b6cea,Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction kit,Other,,,,,,,,,,,,,,,,,,,,Male mouse whole genomic DNA was extracted from several mouse spleens using the Qiagen DNeasy Blood & Tissue Kit.,Non-genetic lab reagent/kit/consumable: DNA extraction kit
DNA labeling kit,genetic_reagents,PMID:18931645,10.1097/MAO.0b013e31818b6cea,Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA labeling kit,Other,,,,,,,,,,,,,,,,,,,,The extracted DNA was quantified and then labeled using the Nick Translation Kit and Spectrum Green deoxyuridine 5-triphosphate,Non-genetic lab reagent/kit/consumable: DNA labeling kit
VS-4718,genetic_reagents,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,VS-4718,Other,,,,,,,,,,,,,,,,,,,,VS-4718 (PND-1186 and HY-13917) and selumetinib (AZD6244 and HY-50706) were purchased from MedChemExpress,Insert does not reference a core NF disease gene: VS-4718
selumetinib,genetic_reagents,PMID:41616055,10.1126/sciadv.ady8382,Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,selumetinib,Other,,,,,,,,,,,,,,,,,,,,VS-4718 (PND-1186 and HY-13917) and selumetinib (AZD6244 and HY-50706) were purchased from MedChemExpress,Drug compound (class suffix): selumetinib
Nsyb-GS,genetic_reagents,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.85,Development,False,1.00,Medium,,,,,,,,,,,Nsyb-GS,Other,,n-synaptobrevin,,,,,,,,,,,,,,,,,,nsyb-GS construct was generated using Gateway cloning (Invitrogen) and the construct was targeted to the PhiC31-attP2 landing site,Insert does not reference a core NF disease gene: Nsyb-GS
Cal 520 AM,genetic_reagents,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Cal 520 AM,,,,,,,,,,,,,,,,,,,,,4 μM Cal 520 acetoxymethyl ester (AM) (Abcam ab171868) in Hank's balanced salt solution,Insert does not reference a core NF disease gene: Cal 520 AM
β-galactosidase,genetic_reagents,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,β-galactosidase,Viral,adenovirus type 5,,,,,,,,,,,,,,,,,,,infected with adenovirus type 5 containing β-galactosidase (Ad5-LacZ) or Cre recombinase (Ad5-Cre),Insert does not reference a core NF disease gene: β-galactosidase
Cre recombinase,genetic_reagents,PMID:29590612,10.1016/j.celrep.2018.03.014,A Conserved Circadian Function for the Neurofibromatosis 1 Gene.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre recombinase,Viral,adenovirus type 5,,,,,,,,,,,,,,,,,,,infected with adenovirus type 5 containing β-galactosidase (Ad5-LacZ) or Cre recombinase (Ad5-Cre),Insert does not reference a core NF disease gene: Cre recombinase
TRIZOL,genetic_reagents,PMID:17216419,10.1007/s10048-006-0078-5,Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TRIZOL,Other,,,,,,,,,,,,,,,,,,,,Total RNA was extracted with TRIZOL according to manufacturer's instructions,Non-genetic lab reagent/kit/consumable: TRIZOL
DNase,genetic_reagents,PMID:17216419,10.1007/s10048-006-0078-5,Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,DNase,Other,,,,,,,,,,,,,,,,,,,,"10 μg RNA was treated with DNase (DNA-free, Ambion) and repurified",Insert does not reference a core NF disease gene: DNase
RNEasy,genetic_reagents,PMID:17216419,10.1007/s10048-006-0078-5,Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNEasy,Other,,,,,,,,,,,,,,,,,,,,repurified using the Qiagen RNEasy kit,Non-genetic lab reagent/kit/consumable: RNEasy
SuperScript III,genetic_reagents,PMID:17216419,10.1007/s10048-006-0078-5,Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SuperScript III,Other,,,,,,,,,,,,,,,,,,,,reverse transcribed into Cdna using oligo dT primers and the SuperScript III First-strand synthesis system (Invitrogen),Non-genetic lab reagent/kit/consumable: SuperScript III
ThermalAce DNA polymerase,genetic_reagents,PMID:17216419,10.1007/s10048-006-0078-5,Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ThermalAce DNA polymerase,Other,,,,,,,,,,,,,,,,,,,,ThermalAce DNA polymerase (Invitrogen) was used in all standard PCR reactions,Non-genetic lab reagent/kit/consumable: ThermalAce DNA polymerase
SYBR Green,genetic_reagents,PMID:17216419,10.1007/s10048-006-0078-5,Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SYBR Green,Other,,,,,,,,,,,,,,,,,,,,"Brilliant SYBR Green (Stratagene), master mix or core kit, was used for each qPCR reaction",Non-genetic lab reagent/kit/consumable: SYBR Green
hGFAP-cre,genetic_reagents,PMID:16314489,10.1242/dev.02162,Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,hGFAP-cre,Other,,hGFAP,,,,,,,,,,,,,,,,,,"Nf1flox/+; hGFAP-cre+ and Nf1flox/flox; hGFAP-cre+, which have similar phenotypes",Insert does not reference a core NF disease gene: hGFAP-cre
gefitinib,genetic_reagents,PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,gefitinib,,,,,,,,,,,,,,,,,,,,,"Gefitinib (AstraZeneca, Alderly Park, UK) and CI-1033 (Pfizer, Groton, CT) were prepared as stock solutions",Drug compound (class suffix): gefitinib
CI-1033,genetic_reagents,PMID:18927496,10.4161/cbt.7.12.6942,Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,CI-1033,,,,,,,,,,,,,,,,,,,,,"Gefitinib (AstraZeneca, Alderly Park, UK) and CI-1033 (Pfizer, Groton, CT) were prepared as stock solutions",Insert does not reference a core NF disease gene: CI-1033
Technovit 9100,genetic_reagents,PMID:18671844,10.1186/1741-7015-6-21,Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,Technovit 9100,Other,,,,,,,,,,,,,,,,,,,,tissue samples destined for calcified bone histology and micro computed tomography (μCT) analysis were processed according to the Technovit 9100 Kit manual,Insert does not reference a core NF disease gene: Technovit 9100
patient-derived xenograft (PDX),patient_derived_models,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,CB17 SCID,MPNST,,,,,,"For MPNST M3 cell line-derived xenograft and patient-derived xenograft (PDX) studies, 2 × 10^6 and 3 × 10^6 cells, respectively",Vague PDX descriptor — no specific model ID or NF context: patient-derived xenograft (PDX)
patient-derived xenograft models,patient_derived_models,PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,NSG,MPNST,,,,,,efficacy studies in cell-line-derived and patient-derived xenograft models,Vague PDX descriptor — no specific model ID or NF context: patient-derived xenograft models
MPNST PDX-1,patient_derived_models,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,MPNST,CB-17 SCID,MPNST,,,,,,"MPNST PDX-1 tumors in CB-17 SCID mice (Taconic, RRID:IMSR_TAC:cb17sc) were enzymatically dissociated, followed by subcutaneous injection into flanks",Publication title lacks NF-specific terms: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Target
NF1-associated MPNST-PDX,patient_derived_models,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,NRG,MPNST,,,,,,We developed 13 NF1-associated MPNST-PDX and identified mutations,Vague PDX name — no specific model ID (e.g. PDX-1): NF1-associated MPNST-PDX
NF1-MPNST patient-derived xenografts,patient_derived_models,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,NSG,MPNST,,,,,,we developed a collection of NF1-MPNST patient-derived xenografts (PDX). These PDX were compared with the primary tumors,Plural/generic PDX description — re-mine for specific model IDs: NF1-MPNST patient-derived xenografts
Patient-derived xenografts,patient_derived_models,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,MPNST,NRG,MPNST,,,,,,tumor pieces were acquired from MPNST patients at time of surgical resection and implanted subcutaneously,Vague PDX descriptor — no specific model ID or NF context: Patient-derived xenografts
